{"docstore/data": {"27128e1f-79cb-4a66-87f6-31b5d6655697": {"__data__": {"id_": "27128e1f-79cb-4a66-87f6-31b5d6655697", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n30-Oct-2019  \nMcKesson Corp.   (MCK ) \nQ2 2020 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n30-Oct-2019  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e385906f-c0ce-4fa2-b4d2-9c45ca30478e", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9cdb877b99d7a169a068fc815e745604f88e3691b95fcf8acd7823aefb4f8de0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d7366c2-e4e8-4f21-a2c4-49d8d2be4744", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n30-Oct-2019  \nMcKesson Corp.   (MCK ) \nQ2 2020 Earnings Call    ", "original_text": "(MCK ) \nQ2 2020 Earnings Call    "}, "hash": "57bfff19dca8c01b6ba571bba4f275d26dd78d9d7d6a129e05d50c9561893a89", "class_name": "RelatedNodeInfo"}}, "text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n30-Oct-2019  \nMcKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d7366c2-e4e8-4f21-a2c4-49d8d2be4744": {"__data__": {"id_": "2d7366c2-e4e8-4f21-a2c4-49d8d2be4744", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n30-Oct-2019  \nMcKesson Corp.   (MCK ) \nQ2 2020 Earnings Call    ", "original_text": "(MCK ) \nQ2 2020 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e385906f-c0ce-4fa2-b4d2-9c45ca30478e", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9cdb877b99d7a169a068fc815e745604f88e3691b95fcf8acd7823aefb4f8de0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27128e1f-79cb-4a66-87f6-31b5d6655697", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n30-Oct-2019  \nMcKesson Corp.   (MCK ) \nQ2 2020 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n30-Oct-2019  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c72d818fc1b556b3f2f4e738616851b210373f23404cde4e84bb2e6dfbf4a188", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e73dbf6b-a88c-4195-8dc1-7b08ef125561", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  "}, "hash": "ab63a9b9211467904d235879f267f880d6e7d76b1ecc38438eaa6e4cfdc433fe", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2020 Earnings Call    ", "start_char_idx": 165, "end_char_idx": 198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e73dbf6b-a88c-4195-8dc1-7b08ef125561": {"__data__": {"id_": "e73dbf6b-a88c-4195-8dc1-7b08ef125561", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "900e42a9ca1a0211be624e3d7a2925db552bf9ac40a5ed898a6cc83f346d09c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d7366c2-e4e8-4f21-a2c4-49d8d2be4744", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n30-Oct-2019  \nMcKesson Corp.   (MCK ) \nQ2 2020 Earnings Call    ", "original_text": "(MCK ) \nQ2 2020 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41149aa840d2fac7beb149ae57092e8a2a37982dde06aef7a4216d6aea772632", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5acbfab8-3f45-4b0c-9223-d0385f6a56aa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n"}, "hash": "60c5487fbc666e79e514c2457e8f79491cb6525c36a2bc0ac092d82ebf1f88b0", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5acbfab8-3f45-4b0c-9223-d0385f6a56aa": {"__data__": {"id_": "5acbfab8-3f45-4b0c-9223-d0385f6a56aa", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "900e42a9ca1a0211be624e3d7a2925db552bf9ac40a5ed898a6cc83f346d09c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e73dbf6b-a88c-4195-8dc1-7b08ef125561", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "572010c072395194d0633217408bc8687bdaa119668067c3c01394eea5e4d69d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1703f5ac-9284-4867-94a4-0fe3a89d082c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "original_text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "92d8d5ede7766ddaccb73427368623cb781351ddd327ed5b9fc7cfc03add522b", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "start_char_idx": 16, "end_char_idx": 283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1703f5ac-9284-4867-94a4-0fe3a89d082c": {"__data__": {"id_": "1703f5ac-9284-4867-94a4-0fe3a89d082c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "original_text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "900e42a9ca1a0211be624e3d7a2925db552bf9ac40a5ed898a6cc83f346d09c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5acbfab8-3f45-4b0c-9223-d0385f6a56aa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c5437501b1f06ebe677f0ced75d647819e853381a16f5dee06f50ad6b7ead3b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "917c26f1-58d3-4028-b7b8-bf4087e2b002", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Robert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n "}, "hash": "0e7772cc970c317aea2b5c2966d103c4ca8f76ff2cd6bbea2f16e158d8f534f9", "class_name": "RelatedNodeInfo"}}, "text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 283, "end_char_idx": 352, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "917c26f1-58d3-4028-b7b8-bf4087e2b002": {"__data__": {"id_": "917c26f1-58d3-4028-b7b8-bf4087e2b002", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Robert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "900e42a9ca1a0211be624e3d7a2925db552bf9ac40a5ed898a6cc83f346d09c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1703f5ac-9284-4867-94a4-0fe3a89d082c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "original_text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c360d549a3e9a906b630687420922832e9542c131a357cbbe8d7f018601bbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73116bb2-1fce-439d-9eb3-3cea3fb4bb51", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Robert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "2b7f4a13720eff02c8b1c3487ce95987a1ccd7970ad6f483ebc3b0091eb5167b", "class_name": "RelatedNodeInfo"}}, "text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "start_char_idx": 352, "end_char_idx": 442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73116bb2-1fce-439d-9eb3-3cea3fb4bb51": {"__data__": {"id_": "73116bb2-1fce-439d-9eb3-3cea3fb4bb51", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Robert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "900e42a9ca1a0211be624e3d7a2925db552bf9ac40a5ed898a6cc83f346d09c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "917c26f1-58d3-4028-b7b8-bf4087e2b002", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Robert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "89dee3d0a1e2e40d58d312326a0a497461af25396dabccbb64c963cfeb86c642", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3b91612-32f5-4f9e-80a3-961708352f4a", "node_type": "1", "metadata": {"window": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Robert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call.  Today's conference is being recorded. ", "original_text": "LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n"}, "hash": "3103e50f92a1d125e36a59bedf0fa20ea9e043587340bf355ea50cce67eb266c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 442, "end_char_idx": 1008, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3b91612-32f5-4f9e-80a3-961708352f4a": {"__data__": {"id_": "d3b91612-32f5-4f9e-80a3-961708352f4a", "embedding": null, "metadata": {"window": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Robert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call.  Today's conference is being recorded. ", "original_text": "LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "900e42a9ca1a0211be624e3d7a2925db552bf9ac40a5ed898a6cc83f346d09c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73116bb2-1fce-439d-9eb3-3cea3fb4bb51", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Robert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c244859460424f71491755f06d9fc4bae1f85a03341fd9f1be6cb70480476478", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f92643c0-0d5c-4a34-a81c-50a7c7678765", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Robert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call.  Today's conference is being recorded.  At \nthis time, I'd like to turn the conference over to Holly Weiss. ", "original_text": "Robert P. Jones  \nAnalyst, Goldman Sachs & Co. "}, "hash": "4eba85abbb9fc486497a871e8b4c82e2ad265e28c041bce121de769eb2ba3159", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "start_char_idx": 1008, "end_char_idx": 1071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f92643c0-0d5c-4a34-a81c-50a7c7678765": {"__data__": {"id_": "f92643c0-0d5c-4a34-a81c-50a7c7678765", "embedding": null, "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Robert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call.  Today's conference is being recorded.  At \nthis time, I'd like to turn the conference over to Holly Weiss. ", "original_text": "Robert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "900e42a9ca1a0211be624e3d7a2925db552bf9ac40a5ed898a6cc83f346d09c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3b91612-32f5-4f9e-80a3-961708352f4a", "node_type": "1", "metadata": {"window": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Robert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call.  Today's conference is being recorded. ", "original_text": "LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97e846b8366b41b3ec253491ffe640279854b1f7dcbca9997ef7c02ac292570d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac9d0176-0e0f-4ab5-9406-878caca2b5cb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Robert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call.  Today's conference is being recorded.  At \nthis time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n ", "original_text": "LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call. "}, "hash": "ae88ee867e31615118b4aa012f2419e49e48275ad3389f059275523f53001528", "class_name": "RelatedNodeInfo"}}, "text": "Robert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "start_char_idx": 1071, "end_char_idx": 1118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac9d0176-0e0f-4ab5-9406-878caca2b5cb": {"__data__": {"id_": "ac9d0176-0e0f-4ab5-9406-878caca2b5cb", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Robert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call.  Today's conference is being recorded.  At \nthis time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n ", "original_text": "LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call. ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "900e42a9ca1a0211be624e3d7a2925db552bf9ac40a5ed898a6cc83f346d09c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f92643c0-0d5c-4a34-a81c-50a7c7678765", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Robert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call.  Today's conference is being recorded.  At \nthis time, I'd like to turn the conference over to Holly Weiss. ", "original_text": "Robert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "408079dc7b12c440458799bf5169051f67d757be923bebd428ada960d549d02b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52e5ab9d-e0eb-460a-be7a-35947fd0bf20", "node_type": "1", "metadata": {"window": "LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Robert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call.  Today's conference is being recorded.  At \nthis time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "original_text": "Today's conference is being recorded. "}, "hash": "6a5fccec12086e7626166aa8b28763b619599be314acc087826c4fc88656ef4e", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call. ", "start_char_idx": 1118, "end_char_idx": 1530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52e5ab9d-e0eb-460a-be7a-35947fd0bf20": {"__data__": {"id_": "52e5ab9d-e0eb-460a-be7a-35947fd0bf20", "embedding": null, "metadata": {"window": "LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Robert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call.  Today's conference is being recorded.  At \nthis time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "original_text": "Today's conference is being recorded. ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "900e42a9ca1a0211be624e3d7a2925db552bf9ac40a5ed898a6cc83f346d09c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac9d0176-0e0f-4ab5-9406-878caca2b5cb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Charles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Robert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call.  Today's conference is being recorded.  At \nthis time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n ", "original_text": "LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call. ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5a44b51c13a5fbb3840718638ff2fc24fc70929d4680b2adb07b7d8c5eef81d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d1cd378-10dd-4911-9cf1-caa9062a0aef", "node_type": "1", "metadata": {"window": "Robert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call.  Today's conference is being recorded.  At \nthis time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Susanne. ", "original_text": "At \nthis time, I'd like to turn the conference over to Holly Weiss. "}, "hash": "ffbeb5ef8f4e36adc35c4ad126bf4aa414c72d7f569792e5e03f4286b5a6bcd7", "class_name": "RelatedNodeInfo"}}, "text": "Today's conference is being recorded. ", "start_char_idx": 1530, "end_char_idx": 1568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d1cd378-10dd-4911-9cf1-caa9062a0aef": {"__data__": {"id_": "2d1cd378-10dd-4911-9cf1-caa9062a0aef", "embedding": null, "metadata": {"window": "Robert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call.  Today's conference is being recorded.  At \nthis time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Susanne. ", "original_text": "At \nthis time, I'd like to turn the conference over to Holly Weiss. ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "900e42a9ca1a0211be624e3d7a2925db552bf9ac40a5ed898a6cc83f346d09c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52e5ab9d-e0eb-460a-be7a-35947fd0bf20", "node_type": "1", "metadata": {"window": "LLC  \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Robert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call.  Today's conference is being recorded.  At \nthis time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "original_text": "Today's conference is being recorded. ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd1090cfee270f4d14a11f8317d6bc2635a36a573bc847ecd4bd83ef63f442f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5207a613-0e01-431f-8020-b719f1a28dca", "node_type": "1", "metadata": {"window": "LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call.  Today's conference is being recorded.  At \nthis time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Susanne.  Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall. ", "original_text": "Please go ahead.  \n "}, "hash": "010eb54c0fba60c4464702cb2a66e5e8278bcc319f285b3f386a29cd0e798d20", "class_name": "RelatedNodeInfo"}}, "text": "At \nthis time, I'd like to turn the conference over to Holly Weiss. ", "start_char_idx": 1568, "end_char_idx": 1636, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5207a613-0e01-431f-8020-b719f1a28dca": {"__data__": {"id_": "5207a613-0e01-431f-8020-b719f1a28dca", "embedding": null, "metadata": {"window": "LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call.  Today's conference is being recorded.  At \nthis time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Susanne.  Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall. ", "original_text": "Please go ahead.  \n ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "900e42a9ca1a0211be624e3d7a2925db552bf9ac40a5ed898a6cc83f346d09c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d1cd378-10dd-4911-9cf1-caa9062a0aef", "node_type": "1", "metadata": {"window": "Robert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call.  Today's conference is being recorded.  At \nthis time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Susanne. ", "original_text": "At \nthis time, I'd like to turn the conference over to Holly Weiss. ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c868914f80c8db9f70a52a9dc2ae8f2cb8fe8dcc5f5f163b6a2475dd59b402", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b17c625f-c6f2-4a53-b683-91a3a68d89f4", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At \nthis time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Susanne.  Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n"}, "hash": "c585346c2d3981011d648a7adc1bdf16cf477cd066189821268b37979ccf5f27", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1636, "end_char_idx": 1656, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b17c625f-c6f2-4a53-b683-91a3a68d89f4": {"__data__": {"id_": "b17c625f-c6f2-4a53-b683-91a3a68d89f4", "embedding": null, "metadata": {"window": "Today's conference is being recorded.  At \nthis time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Susanne.  Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "900e42a9ca1a0211be624e3d7a2925db552bf9ac40a5ed898a6cc83f346d09c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5207a613-0e01-431f-8020-b719f1a28dca", "node_type": "1", "metadata": {"window": "LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q2 earnings call.  Today's conference is being recorded.  At \nthis time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Susanne.  Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall. ", "original_text": "Please go ahead.  \n ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d98c2fc1873a35f4aa62692dde916f1d30357d340a70f590141642fa8db77b25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a94e57b-90ac-4b26-b61e-ec58ea3e2767", "node_type": "1", "metadata": {"window": "At \nthis time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Susanne.  Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n", "original_text": "Thank you, Susanne. "}, "hash": "29b9942faeb5b1735e9590b669e9c47a9105dcfa18943cbe2639d689da4dcd9d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "start_char_idx": 1656, "end_char_idx": 1987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a94e57b-90ac-4b26-b61e-ec58ea3e2767": {"__data__": {"id_": "3a94e57b-90ac-4b26-b61e-ec58ea3e2767", "embedding": null, "metadata": {"window": "At \nthis time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Susanne.  Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n", "original_text": "Thank you, Susanne. ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "900e42a9ca1a0211be624e3d7a2925db552bf9ac40a5ed898a6cc83f346d09c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b17c625f-c6f2-4a53-b683-91a3a68d89f4", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At \nthis time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Susanne.  Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2aff518886a5d870851d061fb63b7feb2bd278c5b83736876f988d4cce434365", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "743468f6-1d35-4ef2-8d29-e781e6e9b65e", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Susanne.  Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall. "}, "hash": "0368cdd6bb73cad3210e3a25f1892987fc4872e8ded94cd6efc75b7a03cf74e4", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Susanne. ", "start_char_idx": 1987, "end_char_idx": 2007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "743468f6-1d35-4ef2-8d29-e781e6e9b65e": {"__data__": {"id_": "743468f6-1d35-4ef2-8d29-e781e6e9b65e", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Susanne.  Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall. ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "900e42a9ca1a0211be624e3d7a2925db552bf9ac40a5ed898a6cc83f346d09c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a94e57b-90ac-4b26-b61e-ec58ea3e2767", "node_type": "1", "metadata": {"window": "At \nthis time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Susanne.  Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n", "original_text": "Thank you, Susanne. ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f6908f01375f55d367455b5358ec009d26bfc63f8677ea9941ea443473dcee6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0b3ad52-6736-4bf6-8567-25db70a96eca", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Susanne.  Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n"}, "hash": "f829a75ca534b7093d7569faa07ea504fc8dabae9efa7a8813b4af88cbf520bc", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall. ", "start_char_idx": 2007, "end_char_idx": 2101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0b3ad52-6736-4bf6-8567-25db70a96eca": {"__data__": {"id_": "e0b3ad52-6736-4bf6-8567-25db70a96eca", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Susanne.  Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "900e42a9ca1a0211be624e3d7a2925db552bf9ac40a5ed898a6cc83f346d09c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "743468f6-1d35-4ef2-8d29-e781e6e9b65e", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Susanne.  Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall. ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5adf1c9539d5d277f5b59fdb98fb8dbcbf022876fadfb507b1582ad0809f15fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f910ec9e-673f-41a3-85b9-2264b78d5396", "node_type": "1", "metadata": {"window": "Thank you, Susanne.  Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n"}, "hash": "ec7160fb9c4bddd335a421353d99bca330ba305d02e7e252e4e54647e196a298", "class_name": "RelatedNodeInfo"}}, "text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n", "start_char_idx": 2101, "end_char_idx": 2214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f910ec9e-673f-41a3-85b9-2264b78d5396": {"__data__": {"id_": "f910ec9e-673f-41a3-85b9-2264b78d5396", "embedding": null, "metadata": {"window": "Thank you, Susanne.  Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "900e42a9ca1a0211be624e3d7a2925db552bf9ac40a5ed898a6cc83f346d09c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0b3ad52-6736-4bf6-8567-25db70a96eca", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Susanne.  Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d078aa13fd9038eb885d1058d5a6f14f77e76c314edfc70384be0c509770aeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adf465b8-fff7-400d-b8fc-770e7a7a3cbf", "node_type": "1", "metadata": {"window": "Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. "}, "hash": "ef46425037825dfad2a8bb08c3d9c51488e88292d15c0927d92287536dae7ab1", "class_name": "RelatedNodeInfo"}}, "text": "Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n", "start_char_idx": 2214, "end_char_idx": 2314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adf465b8-fff7-400d-b8fc-770e7a7a3cbf": {"__data__": {"id_": "adf465b8-fff7-400d-b8fc-770e7a7a3cbf", "embedding": null, "metadata": {"window": "Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "900e42a9ca1a0211be624e3d7a2925db552bf9ac40a5ed898a6cc83f346d09c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f910ec9e-673f-41a3-85b9-2264b78d5396", "node_type": "1", "metadata": {"window": "Thank you, Susanne.  Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f324539f38624d1957eae41aac44082437df006706f65d84b6a5007b42342556", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fecab0e9-efbb-43ad-9b58-be7b0fc5b771", "node_type": "1", "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n"}, "hash": "c8a58a46bebf11feaf731fb31542135974d8472967aba99f9a3aff24c65bf9f8", "class_name": "RelatedNodeInfo"}}, "text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "start_char_idx": 2314, "end_char_idx": 2441, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fecab0e9-efbb-43ad-9b58-be7b0fc5b771": {"__data__": {"id_": "fecab0e9-efbb-43ad-9b58-be7b0fc5b771", "embedding": null, "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "900e42a9ca1a0211be624e3d7a2925db552bf9ac40a5ed898a6cc83f346d09c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adf465b8-fff7-400d-b8fc-770e7a7a3cbf", "node_type": "1", "metadata": {"window": "Good morning, and welcome, everyone, to McKesson's second quarter fiscal 2020 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca5966926d89f5166eb100f9615ef75f3bd696c1c499ef9d3418b24c0a4ece52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "383602b8-d7d5-46fb-82db-3fc3355a429b", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "During this call, we will discuss non -GAAP financial measures. "}, "hash": "aef194d5ef5174f8e1b0baed509320f81425d4546f9b311ae36fb1e578864ee7", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n", "start_char_idx": 2441, "end_char_idx": 2757, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "383602b8-d7d5-46fb-82db-3fc3355a429b": {"__data__": {"id_": "383602b8-d7d5-46fb-82db-3fc3355a429b", "embedding": null, "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "During this call, we will discuss non -GAAP financial measures. ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "900e42a9ca1a0211be624e3d7a2925db552bf9ac40a5ed898a6cc83f346d09c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fecab0e9-efbb-43ad-9b58-be7b0fc5b771", "node_type": "1", "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Offic er. \n Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a040cdeac6d3e88c798f8a7e1f74470ed9d80fcec166d1fa6f1397b43ffc4355", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a9e9b89-1170-4c5d-bbca-95cb1795c117", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n "}, "hash": "b86725f6d6ee888a3de5c6fc7709c6cab630fbbd2d9dcc05431e29379a7b79dc", "class_name": "RelatedNodeInfo"}}, "text": "During this call, we will discuss non -GAAP financial measures. ", "start_char_idx": 2757, "end_char_idx": 2821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a9e9b89-1170-4c5d-bbca-95cb1795c117": {"__data__": {"id_": "0a9e9b89-1170-4c5d-bbca-95cb1795c117", "embedding": null, "metadata": {"window": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "900e42a9ca1a0211be624e3d7a2925db552bf9ac40a5ed898a6cc83f346d09c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "383602b8-d7d5-46fb-82db-3fc3355a429b", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question and answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "During this call, we will discuss non -GAAP financial measures. ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0cdd8e115b3c4c8b3cda83676a9bf25b9e0fc56135b4080721c83f489e428e4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "816e888a-539e-4c9e-8855-b45b20335340", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly. ", "original_text": "McKesson Corp.  "}, "hash": "132f46cc74a4304ad28a18d0122db0f30cab4cfd193fa9736bd783d563b16702", "class_name": "RelatedNodeInfo"}}, "text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "start_char_idx": 2821, "end_char_idx": 3074, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "816e888a-539e-4c9e-8855-b45b20335340": {"__data__": {"id_": "816e888a-539e-4c9e-8855-b45b20335340", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a9e9b89-1170-4c5d-bbca-95cb1795c117", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary  statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forwar d-looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32022b19d59f37c38ec24c709208c0bee98f00741ee2e1f89c4b29da6fe40c53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "094c2473-8130-45b9-a943-16911ca12ae4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly.  Good morning, everyone. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n "}, "hash": "eee8fa89963ffff52c80c4a165a204bf80b491aa4e0875909b09b974dcef3a05", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "094c2473-8130-45b9-a943-16911ca12ae4": {"__data__": {"id_": "094c2473-8130-45b9-a943-16911ca12ae4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly.  Good morning, everyone. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "816e888a-539e-4c9e-8855-b45b20335340", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1b03bf672c550751b58f4db9e4f49e19f31604732c4a51cec138ae8d7bca3f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "219d5862-3cce-4f14-85da-edb76cd4697b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly.  Good morning, everyone.  Thanks for joining us on  our call today. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "49104a09fc44df856253a4f9422d2e17ecc11bca43c9a0a0f565aa7f8596314f", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n ", "start_char_idx": 16, "end_char_idx": 221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "219d5862-3cce-4f14-85da-edb76cd4697b": {"__data__": {"id_": "219d5862-3cce-4f14-85da-edb76cd4697b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly.  Good morning, everyone.  Thanks for joining us on  our call today. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "094c2473-8130-45b9-a943-16911ca12ae4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly.  Good morning, everyone. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d4453bd85a250611662c1308ff13cb4683a25e53b6fb02b2a4e85f3a492a4b10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ccdc336-55bd-4b4a-9a4c-852db12eac54", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly.  Good morning, everyone.  Thanks for joining us on  our call today.  Today, we reported second \nquarter total company revenues of $57.6 billion. ", "original_text": "Thank you, Holly. "}, "hash": "f8360dd3b21cbac946603d33716a80b09d4af9240c4c56fd24951f2842a2a939", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 221, "end_char_idx": 548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ccdc336-55bd-4b4a-9a4c-852db12eac54": {"__data__": {"id_": "9ccdc336-55bd-4b4a-9a4c-852db12eac54", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly.  Good morning, everyone.  Thanks for joining us on  our call today.  Today, we reported second \nquarter total company revenues of $57.6 billion. ", "original_text": "Thank you, Holly. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "219d5862-3cce-4f14-85da-edb76cd4697b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly.  Good morning, everyone.  Thanks for joining us on  our call today. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a19e5dfabb634af539ff3d28bc886b3288b04f69123caf8e08567a2c514138e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26871d99-772f-4e00-916a-39da73c26b6d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly.  Good morning, everyone.  Thanks for joining us on  our call today.  Today, we reported second \nquarter total company revenues of $57.6 billion.  Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations. ", "original_text": "Good morning, everyone. "}, "hash": "1335f3cf5a1e0557d157d82eaed479c0f1168562ec3ed49725ac98f70ab63611", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Holly. ", "start_char_idx": 548, "end_char_idx": 566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26871d99-772f-4e00-916a-39da73c26b6d": {"__data__": {"id_": "26871d99-772f-4e00-916a-39da73c26b6d", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly.  Good morning, everyone.  Thanks for joining us on  our call today.  Today, we reported second \nquarter total company revenues of $57.6 billion.  Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations. ", "original_text": "Good morning, everyone. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ccdc336-55bd-4b4a-9a4c-852db12eac54", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly.  Good morning, everyone.  Thanks for joining us on  our call today.  Today, we reported second \nquarter total company revenues of $57.6 billion. ", "original_text": "Thank you, Holly. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1da8cd87be806511aa591217fe4ea6bf819847ac7f2619d82cb8e9232f58692e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "107a304a-b224-4b21-a603-49ea6bb88961", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly.  Good morning, everyone.  Thanks for joining us on  our call today.  Today, we reported second \nquarter total company revenues of $57.6 billion.  Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations.  And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n", "original_text": "Thanks for joining us on  our call today. "}, "hash": "2ab151fa0afb699e04ae8613f27c7edb9e9d9b8dba1bb6bb86334272816ae5e6", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, everyone. ", "start_char_idx": 566, "end_char_idx": 590, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "107a304a-b224-4b21-a603-49ea6bb88961": {"__data__": {"id_": "107a304a-b224-4b21-a603-49ea6bb88961", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly.  Good morning, everyone.  Thanks for joining us on  our call today.  Today, we reported second \nquarter total company revenues of $57.6 billion.  Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations.  And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n", "original_text": "Thanks for joining us on  our call today. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26871d99-772f-4e00-916a-39da73c26b6d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly.  Good morning, everyone.  Thanks for joining us on  our call today.  Today, we reported second \nquarter total company revenues of $57.6 billion.  Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations. ", "original_text": "Good morning, everyone. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2c46f1fa0e117b73dd4811c978e5de40dbb39e005d7357bc5c170819dbfd752", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b9d1842-4db9-4c79-8af9-f0bdd38bd22a", "node_type": "1", "metadata": {"window": "Thank you, Holly.  Good morning, everyone.  Thanks for joining us on  our call today.  Today, we reported second \nquarter total company revenues of $57.6 billion.  Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations.  And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share. ", "original_text": "Today, we reported second \nquarter total company revenues of $57.6 billion. "}, "hash": "b21a0a52827d7340acec6e6e2f1f281b075ce7a60836a7644e1c617b77e22469", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for joining us on  our call today. ", "start_char_idx": 590, "end_char_idx": 632, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b9d1842-4db9-4c79-8af9-f0bdd38bd22a": {"__data__": {"id_": "1b9d1842-4db9-4c79-8af9-f0bdd38bd22a", "embedding": null, "metadata": {"window": "Thank you, Holly.  Good morning, everyone.  Thanks for joining us on  our call today.  Today, we reported second \nquarter total company revenues of $57.6 billion.  Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations.  And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share. ", "original_text": "Today, we reported second \nquarter total company revenues of $57.6 billion. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "107a304a-b224-4b21-a603-49ea6bb88961", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly.  Good morning, everyone.  Thanks for joining us on  our call today.  Today, we reported second \nquarter total company revenues of $57.6 billion.  Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations.  And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n", "original_text": "Thanks for joining us on  our call today. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ce314e8897afd19822a4a0e299c959c26492c38c836407f1ab31ba6f17469a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c09dc24b-31ce-465c-82b9-76b3a6fa21af", "node_type": "1", "metadata": {"window": "Good morning, everyone.  Thanks for joining us on  our call today.  Today, we reported second \nquarter total company revenues of $57.6 billion.  Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations.  And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share.  This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n", "original_text": "Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations. "}, "hash": "16db245aa1dfd9d5f58bf324091ccb4b842f5ec922b031de9484453e83a08d2d", "class_name": "RelatedNodeInfo"}}, "text": "Today, we reported second \nquarter total company revenues of $57.6 billion. ", "start_char_idx": 632, "end_char_idx": 708, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c09dc24b-31ce-465c-82b9-76b3a6fa21af": {"__data__": {"id_": "c09dc24b-31ce-465c-82b9-76b3a6fa21af", "embedding": null, "metadata": {"window": "Good morning, everyone.  Thanks for joining us on  our call today.  Today, we reported second \nquarter total company revenues of $57.6 billion.  Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations.  And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share.  This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n", "original_text": "Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b9d1842-4db9-4c79-8af9-f0bdd38bd22a", "node_type": "1", "metadata": {"window": "Thank you, Holly.  Good morning, everyone.  Thanks for joining us on  our call today.  Today, we reported second \nquarter total company revenues of $57.6 billion.  Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations.  And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share. ", "original_text": "Today, we reported second \nquarter total company revenues of $57.6 billion. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82930510fd32f699cecfd8d58c9f5198f79106a5385fc6e40db186de43f177e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26090125-0cf9-4fe2-8094-8cc1342d6248", "node_type": "1", "metadata": {"window": "Thanks for joining us on  our call today.  Today, we reported second \nquarter total company revenues of $57.6 billion.  Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations.  And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share.  This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation. ", "original_text": "And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n"}, "hash": "fe3c849b5e821d0e657abd405d04cadcb52453b9132a755d5e560a233ebb4ea2", "class_name": "RelatedNodeInfo"}}, "text": "Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations. ", "start_char_idx": 708, "end_char_idx": 801, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26090125-0cf9-4fe2-8094-8cc1342d6248": {"__data__": {"id_": "26090125-0cf9-4fe2-8094-8cc1342d6248", "embedding": null, "metadata": {"window": "Thanks for joining us on  our call today.  Today, we reported second \nquarter total company revenues of $57.6 billion.  Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations.  And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share.  This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation. ", "original_text": "And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c09dc24b-31ce-465c-82b9-76b3a6fa21af", "node_type": "1", "metadata": {"window": "Good morning, everyone.  Thanks for joining us on  our call today.  Today, we reported second \nquarter total company revenues of $57.6 billion.  Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations.  And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share.  This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n", "original_text": "Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "62e23c850569243bc71a473bca2fa8077d3f189377b98a73c986a7bba2690520", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95437e0c-6ecb-4de7-83e2-4ffacffab1f4", "node_type": "1", "metadata": {"window": "Today, we reported second \nquarter total company revenues of $57.6 billion.  Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations.  And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share.  This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation.  Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation. ", "original_text": "Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share. "}, "hash": "2cc296653c22ba77f9d4b6e9521648c75d92a9611473fc576157640311acb422", "class_name": "RelatedNodeInfo"}}, "text": "And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n", "start_char_idx": 801, "end_char_idx": 1043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95437e0c-6ecb-4de7-83e2-4ffacffab1f4": {"__data__": {"id_": "95437e0c-6ecb-4de7-83e2-4ffacffab1f4", "embedding": null, "metadata": {"window": "Today, we reported second \nquarter total company revenues of $57.6 billion.  Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations.  And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share.  This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation.  Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation. ", "original_text": "Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26090125-0cf9-4fe2-8094-8cc1342d6248", "node_type": "1", "metadata": {"window": "Thanks for joining us on  our call today.  Today, we reported second \nquarter total company revenues of $57.6 billion.  Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations.  And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share.  This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation. ", "original_text": "And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf88b613de6bd04b2407fd2407bdc016708a6ba915ae969d68852327643420c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2e86462-b473-4905-bc99-afb3817f3252", "node_type": "1", "metadata": {"window": "Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations.  And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share.  This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation.  Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation.  McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results. ", "original_text": "This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n"}, "hash": "c13b25e68f66edb58f3ff138bdeea47045e67ce12247a307adbe23e6b1a38a99", "class_name": "RelatedNodeInfo"}}, "text": "Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share. ", "start_char_idx": 1043, "end_char_idx": 1205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2e86462-b473-4905-bc99-afb3817f3252": {"__data__": {"id_": "c2e86462-b473-4905-bc99-afb3817f3252", "embedding": null, "metadata": {"window": "Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations.  And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share.  This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation.  Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation.  McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results. ", "original_text": "This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95437e0c-6ecb-4de7-83e2-4ffacffab1f4", "node_type": "1", "metadata": {"window": "Today, we reported second \nquarter total company revenues of $57.6 billion.  Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations.  And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share.  This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation.  Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation. ", "original_text": "Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1321bfcafd700e76fae0cb23b5890deefbd32906a9650d1687a3ceba7734d52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd8f4fb2-ca4a-47b0-b864-6c919d388809", "node_type": "1", "metadata": {"window": "And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share.  This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation.  Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation.  McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results.  We strongly dispute the allegations made by these two counties. ", "original_text": "Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation. "}, "hash": "66c60ad464e9b1406040fc5fa24dff4eca89842921e37c70606bef733b1b3627", "class_name": "RelatedNodeInfo"}}, "text": "This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n", "start_char_idx": 1205, "end_char_idx": 1310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd8f4fb2-ca4a-47b0-b864-6c919d388809": {"__data__": {"id_": "bd8f4fb2-ca4a-47b0-b864-6c919d388809", "embedding": null, "metadata": {"window": "And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share.  This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation.  Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation.  McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results.  We strongly dispute the allegations made by these two counties. ", "original_text": "Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2e86462-b473-4905-bc99-afb3817f3252", "node_type": "1", "metadata": {"window": "Our adjusted earnings per diluted share was $3.60, which was in \nline with our expectations.  And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share.  This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation.  Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation.  McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results. ", "original_text": "This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f3237297f77a99a15727ed59483da90e3302a799e3d714b6080b2267329f89d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eaebaba8-9700-47aa-8df5-63037cfe1ad1", "node_type": "1", "metadata": {"window": "Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share.  This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation.  Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation.  McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results.  We strongly dispute the allegations made by these two counties.  However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n", "original_text": "Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation. "}, "hash": "5ec3bfb12c87d59368eeb638d7e09de0ff2733dedcf20b590ba52b32a9b2fe9e", "class_name": "RelatedNodeInfo"}}, "text": "Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation. ", "start_char_idx": 1310, "end_char_idx": 1481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eaebaba8-9700-47aa-8df5-63037cfe1ad1": {"__data__": {"id_": "eaebaba8-9700-47aa-8df5-63037cfe1ad1", "embedding": null, "metadata": {"window": "Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share.  This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation.  Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation.  McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results.  We strongly dispute the allegations made by these two counties.  However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n", "original_text": "Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd8f4fb2-ca4a-47b0-b864-6c919d388809", "node_type": "1", "metadata": {"window": "And, when excluding the $0.33 prior -year benefit from the reversal of a contractual \nliability associated with McKesson's investment in Change Healthcare, second quarter results per diluted share \nincreased more than 10% year over year.  \n \n Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share.  This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation.  Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation.  McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results.  We strongly dispute the allegations made by these two counties. ", "original_text": "Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1889eacc778d8dfcabf7c837ca1e711d06a2f3d95f77bf5570920ef82314e69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a244e964-f321-42ed-9858-efcef3fb46cd", "node_type": "1", "metadata": {"window": "This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation.  Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation.  McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results.  We strongly dispute the allegations made by these two counties.  However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions. ", "original_text": "McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results. "}, "hash": "f07bcc873659b81bb3750b1e8b640edf90f764d410cc1e413ac883d66d72176b", "class_name": "RelatedNodeInfo"}}, "text": "Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation. ", "start_char_idx": 1481, "end_char_idx": 1688, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a244e964-f321-42ed-9858-efcef3fb46cd": {"__data__": {"id_": "a244e964-f321-42ed-9858-efcef3fb46cd", "embedding": null, "metadata": {"window": "This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation.  Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation.  McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results.  We strongly dispute the allegations made by these two counties.  However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions. ", "original_text": "McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eaebaba8-9700-47aa-8df5-63037cfe1ad1", "node_type": "1", "metadata": {"window": "Our first -half fiscal 2020 results give us confidence in our reaffirmed fiscal 2020 full -year outlook of $14 to $14.60 \nof adjusted earnings per diluted share.  This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation.  Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation.  McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results.  We strongly dispute the allegations made by these two counties.  However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n", "original_text": "Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5109a1ca71befd81d5c5f6bdfaaeb111ca6072a8e80bb2d2c483521cf5afa22c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cf3edbe-86f5-4038-8176-c3369629c8af", "node_type": "1", "metadata": {"window": "Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation.  Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation.  McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results.  We strongly dispute the allegations made by these two counties.  However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions.  While we have made good progress, there are many details and variables that \nremain open and still need to be addressed. ", "original_text": "We strongly dispute the allegations made by these two counties. "}, "hash": "6336b3042754dd9906de52ed38ffa40804ae81b8d9ad40e9ec9b336d27ae6e60", "class_name": "RelatedNodeInfo"}}, "text": "McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results. ", "start_char_idx": 1688, "end_char_idx": 1793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cf3edbe-86f5-4038-8176-c3369629c8af": {"__data__": {"id_": "8cf3edbe-86f5-4038-8176-c3369629c8af", "embedding": null, "metadata": {"window": "Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation.  Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation.  McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results.  We strongly dispute the allegations made by these two counties.  However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions.  While we have made good progress, there are many details and variables that \nremain open and still need to be addressed. ", "original_text": "We strongly dispute the allegations made by these two counties. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a244e964-f321-42ed-9858-efcef3fb46cd", "node_type": "1", "metadata": {"window": "This continues to reflect year -over-year adjusted operating profit growth in \neach of our segments.  \n \n Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation.  Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation.  McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results.  We strongly dispute the allegations made by these two counties.  However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions. ", "original_text": "McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9b36ab0a85d16f9f212fc653e75ad6c1f14405f07599ab06d56eb5fbcd42488", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "253fc8ec-dff1-451e-826a-c65a33a0a8ea", "node_type": "1", "metadata": {"window": "Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation.  McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results.  We strongly dispute the allegations made by these two counties.  However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions.  While we have made good progress, there are many details and variables that \nremain open and still need to be addressed.  We're optimistic that a broad resolution can be achieved, and that \nremains our goal. ", "original_text": "However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n"}, "hash": "18697e0dea30e4f1ccf25e031eb6ca3dd5de5f95d883c12ea80650c6ed7e73ad", "class_name": "RelatedNodeInfo"}}, "text": "We strongly dispute the allegations made by these two counties. ", "start_char_idx": 1793, "end_char_idx": 1857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "253fc8ec-dff1-451e-826a-c65a33a0a8ea": {"__data__": {"id_": "253fc8ec-dff1-451e-826a-c65a33a0a8ea", "embedding": null, "metadata": {"window": "Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation.  McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results.  We strongly dispute the allegations made by these two counties.  However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions.  While we have made good progress, there are many details and variables that \nremain open and still need to be addressed.  We're optimistic that a broad resolution can be achieved, and that \nremains our goal. ", "original_text": "However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cf3edbe-86f5-4038-8176-c3369629c8af", "node_type": "1", "metadata": {"window": "Before I go deeper into our second quarter results, I want to take a few minutes to discu ss one topic I know is top \nof mind for everyone, and that is opioid litigation.  Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation.  McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results.  We strongly dispute the allegations made by these two counties.  However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions.  While we have made good progress, there are many details and variables that \nremain open and still need to be addressed. ", "original_text": "We strongly dispute the allegations made by these two counties. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7362ab06ad87d691d0c63398a3298681460370e48dd0447c6c5e1ea3105ace53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81f3847a-f92b-4e05-a9f3-3a82dbdf6d56", "node_type": "1", "metadata": {"window": "McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results.  We strongly dispute the allegations made by these two counties.  However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions.  While we have made good progress, there are many details and variables that \nremain open and still need to be addressed.  We're optimistic that a broad resolution can be achieved, and that \nremains our goal.  All along we've said the goal is to ring -fence the risk. ", "original_text": "Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions. "}, "hash": "73d3af11f6b0d6fa49eefebafe21d20730025abf18c802618b801b16651025fd", "class_name": "RelatedNodeInfo"}}, "text": "However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n", "start_char_idx": 1857, "end_char_idx": 2106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81f3847a-f92b-4e05-a9f3-3a82dbdf6d56": {"__data__": {"id_": "81f3847a-f92b-4e05-a9f3-3a82dbdf6d56", "embedding": null, "metadata": {"window": "McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results.  We strongly dispute the allegations made by these two counties.  However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions.  While we have made good progress, there are many details and variables that \nremain open and still need to be addressed.  We're optimistic that a broad resolution can be achieved, and that \nremains our goal.  All along we've said the goal is to ring -fence the risk. ", "original_text": "Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "253fc8ec-dff1-451e-826a-c65a33a0a8ea", "node_type": "1", "metadata": {"window": "Last week McKesson, along with two other distributors, reached \na collective $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the \nmulti district opioid litigation.  McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results.  We strongly dispute the allegations made by these two counties.  However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions.  While we have made good progress, there are many details and variables that \nremain open and still need to be addressed.  We're optimistic that a broad resolution can be achieved, and that \nremains our goal. ", "original_text": "However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e38f3d82450f6366b4eabb072fe520fc1ac6a1d84aeb2a11a318806738adde8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63d9ae78-8f8e-4abb-a5f2-8316d400e305", "node_type": "1", "metadata": {"window": "We strongly dispute the allegations made by these two counties.  However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions.  While we have made good progress, there are many details and variables that \nremain open and still need to be addressed.  We're optimistic that a broad resolution can be achieved, and that \nremains our goal.  All along we've said the goal is to ring -fence the risk.  However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n", "original_text": "While we have made good progress, there are many details and variables that \nremain open and still need to be addressed. "}, "hash": "183198bee1c31d684b7c134d6e3c247fb8e24390c92a7d7fec4a5a424852335b", "class_name": "RelatedNodeInfo"}}, "text": "Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions. ", "start_char_idx": 2106, "end_char_idx": 2247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63d9ae78-8f8e-4abb-a5f2-8316d400e305": {"__data__": {"id_": "63d9ae78-8f8e-4abb-a5f2-8316d400e305", "embedding": null, "metadata": {"window": "We strongly dispute the allegations made by these two counties.  However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions.  While we have made good progress, there are many details and variables that \nremain open and still need to be addressed.  We're optimistic that a broad resolution can be achieved, and that \nremains our goal.  All along we've said the goal is to ring -fence the risk.  However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n", "original_text": "While we have made good progress, there are many details and variables that \nremain open and still need to be addressed. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81f3847a-f92b-4e05-a9f3-3a82dbdf6d56", "node_type": "1", "metadata": {"window": "McKesson's portion of the settlement was $82 million, which was recorded in our \nsecond quarter results.  We strongly dispute the allegations made by these two counties.  However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions.  While we have made good progress, there are many details and variables that \nremain open and still need to be addressed.  We're optimistic that a broad resolution can be achieved, and that \nremains our goal.  All along we've said the goal is to ring -fence the risk. ", "original_text": "Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f34407e57c01004143e3eebced1181c4e36d15d5538f3a0e849402ca5bd76448", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35a1278a-4a67-48ec-97a1-d4cc1d3155cb", "node_type": "1", "metadata": {"window": "However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions.  While we have made good progress, there are many details and variables that \nremain open and still need to be addressed.  We're optimistic that a broad resolution can be achieved, and that \nremains our goal.  All along we've said the goal is to ring -fence the risk.  However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts. ", "original_text": "We're optimistic that a broad resolution can be achieved, and that \nremains our goal. "}, "hash": "b64444bc72d9b9c828a5198b23273a2f7043bbc13d4d8dd12b9106b4a9d0ff34", "class_name": "RelatedNodeInfo"}}, "text": "While we have made good progress, there are many details and variables that \nremain open and still need to be addressed. ", "start_char_idx": 2247, "end_char_idx": 2368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35a1278a-4a67-48ec-97a1-d4cc1d3155cb": {"__data__": {"id_": "35a1278a-4a67-48ec-97a1-d4cc1d3155cb", "embedding": null, "metadata": {"window": "However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions.  While we have made good progress, there are many details and variables that \nremain open and still need to be addressed.  We're optimistic that a broad resolution can be achieved, and that \nremains our goal.  All along we've said the goal is to ring -fence the risk.  However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts. ", "original_text": "We're optimistic that a broad resolution can be achieved, and that \nremains our goal. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63d9ae78-8f8e-4abb-a5f2-8316d400e305", "node_type": "1", "metadata": {"window": "We strongly dispute the allegations made by these two counties.  However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions.  While we have made good progress, there are many details and variables that \nremain open and still need to be addressed.  We're optimistic that a broad resolution can be achieved, and that \nremains our goal.  All along we've said the goal is to ring -fence the risk.  However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n", "original_text": "While we have made good progress, there are many details and variables that \nremain open and still need to be addressed. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3437eba32302265cfe3386b0e05e8afa57b6cbe4e071d98d2f65b5f424a92ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffcac5a3-cc32-45eb-8fca-18048f7a7a79", "node_type": "1", "metadata": {"window": "Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions.  While we have made good progress, there are many details and variables that \nremain open and still need to be addressed.  We're optimistic that a broad resolution can be achieved, and that \nremains our goal.  All along we've said the goal is to ring -fence the risk.  However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts.  I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis. ", "original_text": "All along we've said the goal is to ring -fence the risk. "}, "hash": "8012d52e9895f77bc9cbe2d0a32ea6b2385a6ca1ba4f1f0622fed14a4fd0dfd4", "class_name": "RelatedNodeInfo"}}, "text": "We're optimistic that a broad resolution can be achieved, and that \nremains our goal. ", "start_char_idx": 2368, "end_char_idx": 2454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffcac5a3-cc32-45eb-8fca-18048f7a7a79": {"__data__": {"id_": "ffcac5a3-cc32-45eb-8fca-18048f7a7a79", "embedding": null, "metadata": {"window": "Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions.  While we have made good progress, there are many details and variables that \nremain open and still need to be addressed.  We're optimistic that a broad resolution can be achieved, and that \nremains our goal.  All along we've said the goal is to ring -fence the risk.  However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts.  I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis. ", "original_text": "All along we've said the goal is to ring -fence the risk. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35a1278a-4a67-48ec-97a1-d4cc1d3155cb", "node_type": "1", "metadata": {"window": "However, settling the \nbellwether trial was in our view an im portant stepping -stone to achieving a broad resolution to opioid litigation and \nto accelerating relief efforts for the people and communities impacted by this public health crisis.  \n \n Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions.  While we have made good progress, there are many details and variables that \nremain open and still need to be addressed.  We're optimistic that a broad resolution can be achieved, and that \nremains our goal.  All along we've said the goal is to ring -fence the risk.  However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts. ", "original_text": "We're optimistic that a broad resolution can be achieved, and that \nremains our goal. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e7fef32146655ce1864ffc975f9cc3311fcbd3c45d37f8c560d71cd166495f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "346ac7ae-b936-4ddb-89de-88e37147c091", "node_type": "1", "metadata": {"window": "While we have made good progress, there are many details and variables that \nremain open and still need to be addressed.  We're optimistic that a broad resolution can be achieved, and that \nremains our goal.  All along we've said the goal is to ring -fence the risk.  However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts.  I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis.  And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say. ", "original_text": "However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n"}, "hash": "29b1bd735a85e3791e6e7e467c51cf9b38a66e7541d9c2ef7530fffcb79a7a5c", "class_name": "RelatedNodeInfo"}}, "text": "All along we've said the goal is to ring -fence the risk. ", "start_char_idx": 2454, "end_char_idx": 2512, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "346ac7ae-b936-4ddb-89de-88e37147c091": {"__data__": {"id_": "346ac7ae-b936-4ddb-89de-88e37147c091", "embedding": null, "metadata": {"window": "While we have made good progress, there are many details and variables that \nremain open and still need to be addressed.  We're optimistic that a broad resolution can be achieved, and that \nremains our goal.  All along we've said the goal is to ring -fence the risk.  However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts.  I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis.  And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say. ", "original_text": "However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffcac5a3-cc32-45eb-8fca-18048f7a7a79", "node_type": "1", "metadata": {"window": "Over the next few months, we'll be working hard with other parties on the settlement framework that includes \nstates and their subdivisions.  While we have made good progress, there are many details and variables that \nremain open and still need to be addressed.  We're optimistic that a broad resolution can be achieved, and that \nremains our goal.  All along we've said the goal is to ring -fence the risk.  However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts.  I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis. ", "original_text": "All along we've said the goal is to ring -fence the risk. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bacd61a8d861b0123de19040238ae0353000ab8786620fec2c71f470ae735517", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d665882f-56e1-4274-8432-56b082d9cade", "node_type": "1", "metadata": {"window": "We're optimistic that a broad resolution can be achieved, and that \nremains our goal.  All along we've said the goal is to ring -fence the risk.  However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts.  I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis.  And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say.  And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n", "original_text": "The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts. "}, "hash": "59f732b6cd5700a3f1d4cb88bf051aec13be4b47ba5764e0d6db36126ce79a3c", "class_name": "RelatedNodeInfo"}}, "text": "However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n", "start_char_idx": 2512, "end_char_idx": 2771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d665882f-56e1-4274-8432-56b082d9cade": {"__data__": {"id_": "d665882f-56e1-4274-8432-56b082d9cade", "embedding": null, "metadata": {"window": "We're optimistic that a broad resolution can be achieved, and that \nremains our goal.  All along we've said the goal is to ring -fence the risk.  However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts.  I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis.  And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say.  And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n", "original_text": "The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "346ac7ae-b936-4ddb-89de-88e37147c091", "node_type": "1", "metadata": {"window": "While we have made good progress, there are many details and variables that \nremain open and still need to be addressed.  We're optimistic that a broad resolution can be achieved, and that \nremains our goal.  All along we've said the goal is to ring -fence the risk.  However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts.  I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis.  And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say. ", "original_text": "However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8db9c18c8221800e5f69db1a74245b90afe084c53ab1df919192c6ed5f5e027d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a93b8f7-2061-426d-9967-8d918a74f637", "node_type": "1", "metadata": {"window": "All along we've said the goal is to ring -fence the risk.  However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts.  I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis.  And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say.  And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n I also want to provide a brief update on our Board of Directors. ", "original_text": "I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis. "}, "hash": "f5273467e84fd2bee48780a9a1eebb76b0e9436bd63c0195d50dce136c1c3806", "class_name": "RelatedNodeInfo"}}, "text": "The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts. ", "start_char_idx": 2771, "end_char_idx": 2938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a93b8f7-2061-426d-9967-8d918a74f637": {"__data__": {"id_": "5a93b8f7-2061-426d-9967-8d918a74f637", "embedding": null, "metadata": {"window": "All along we've said the goal is to ring -fence the risk.  However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts.  I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis.  And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say.  And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n I also want to provide a brief update on our Board of Directors. ", "original_text": "I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d665882f-56e1-4274-8432-56b082d9cade", "node_type": "1", "metadata": {"window": "We're optimistic that a broad resolution can be achieved, and that \nremains our goal.  All along we've said the goal is to ring -fence the risk.  However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts.  I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis.  And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say.  And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n", "original_text": "The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b979403f264ccd17215de750f94aa18165b9cf74ff9d7ebae4a0d8e71cd8d49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c63d36bf-6663-48d6-9fd6-93bf3d9b1101", "node_type": "1", "metadata": {"window": "However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts.  I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis.  And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say.  And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n I also want to provide a brief update on our Board of Directors.  In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director. ", "original_text": "And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say. "}, "hash": "6868fcbfa5485340e217bf36fe0c99625680e60af49aebe16f1ae686b5bf308c", "class_name": "RelatedNodeInfo"}}, "text": "I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis. ", "start_char_idx": 2938, "end_char_idx": 3053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c63d36bf-6663-48d6-9fd6-93bf3d9b1101": {"__data__": {"id_": "c63d36bf-6663-48d6-9fd6-93bf3d9b1101", "embedding": null, "metadata": {"window": "However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts.  I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis.  And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say.  And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n I also want to provide a brief update on our Board of Directors.  In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director. ", "original_text": "And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a93b8f7-2061-426d-9967-8d918a74f637", "node_type": "1", "metadata": {"window": "All along we've said the goal is to ring -fence the risk.  However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts.  I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis.  And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say.  And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n I also want to provide a brief update on our Board of Directors. ", "original_text": "I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "39f2155e8b316e0bfbf9554fa32f293925ba9e826fb918ec6c4c8a1031277b64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c7d14a6-400f-4bc3-9c1e-802d57b7b73e", "node_type": "1", "metadata": {"window": "The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts.  I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis.  And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say.  And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n I also want to provide a brief update on our Board of Directors.  In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director.  Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018. ", "original_text": "And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n"}, "hash": "e30d58704eb9c5cab525a7f85cae9b63204559cf84895870fab8e9eb3a0a4376", "class_name": "RelatedNodeInfo"}}, "text": "And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say. ", "start_char_idx": 3053, "end_char_idx": 3205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c7d14a6-400f-4bc3-9c1e-802d57b7b73e": {"__data__": {"id_": "2c7d14a6-400f-4bc3-9c1e-802d57b7b73e", "embedding": null, "metadata": {"window": "The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts.  I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis.  And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say.  And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n I also want to provide a brief update on our Board of Directors.  In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director.  Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018. ", "original_text": "And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c63d36bf-6663-48d6-9fd6-93bf3d9b1101", "node_type": "1", "metadata": {"window": "However, to the extent the broad \nresolution settlement framework is unsuccessful, McKesson is prepared and continues to be prepared to litigate \nand to vigorously defend the mischaracte rization that our company drove demand for opioids in this country.  \n \n The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts.  I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis.  And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say.  And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n I also want to provide a brief update on our Board of Directors.  In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director. ", "original_text": "And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "47b766d1e8de9ea495bc8967281a3ba6a95d12534c50b361e2df0cafeb8f8403", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c3bbed6-c223-4754-afc7-bda899611901", "node_type": "1", "metadata": {"window": "I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis.  And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say.  And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n I also want to provide a brief update on our Board of Directors.  In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director.  Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018.  She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from. ", "original_text": "I also want to provide a brief update on our Board of Directors. "}, "hash": "efd283ea7ccaf62ed0c9e29499d09220e76d1e31662b0f85d0b9f65e2f2100eb", "class_name": "RelatedNodeInfo"}}, "text": "And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n", "start_char_idx": 3205, "end_char_idx": 3289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c3bbed6-c223-4754-afc7-bda899611901": {"__data__": {"id_": "9c3bbed6-c223-4754-afc7-bda899611901", "embedding": null, "metadata": {"window": "I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis.  And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say.  And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n I also want to provide a brief update on our Board of Directors.  In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director.  Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018.  She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from. ", "original_text": "I also want to provide a brief update on our Board of Directors. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c7d14a6-400f-4bc3-9c1e-802d57b7b73e", "node_type": "1", "metadata": {"window": "The litigation process, if necessary, will be costly and could take many years to conclude, causing a significant \nand substantial delay to crisis mitigation efforts.  I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis.  And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say.  And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n I also want to provide a brief update on our Board of Directors.  In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director.  Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018. ", "original_text": "And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b30ea567d0a44b13889de80d3c3e87c8e11efc6d30e7c5be812fdfbf7b3f75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "587c7861-d872-4dbb-8491-f6d19684775a", "node_type": "1", "metadata": {"window": "And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say.  And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n I also want to provide a brief update on our Board of Directors.  In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director.  Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018.  She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from.  Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n", "original_text": "In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director. "}, "hash": "c24814b852cd0c6084b63423e672b93ab7ee531671b728939383a0f60a239fb5", "class_name": "RelatedNodeInfo"}}, "text": "I also want to provide a brief update on our Board of Directors. ", "start_char_idx": 3289, "end_char_idx": 3354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "587c7861-d872-4dbb-8491-f6d19684775a": {"__data__": {"id_": "587c7861-d872-4dbb-8491-f6d19684775a", "embedding": null, "metadata": {"window": "And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say.  And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n I also want to provide a brief update on our Board of Directors.  In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director.  Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018.  She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from.  Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n", "original_text": "In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c3bbed6-c223-4754-afc7-bda899611901", "node_type": "1", "metadata": {"window": "I've stated this befo re: McKesson remains firmly committed to \nbeing part of the broader solution to this crisis.  And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say.  And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n I also want to provide a brief update on our Board of Directors.  In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director.  Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018.  She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from. ", "original_text": "I also want to provide a brief update on our Board of Directors. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9150d205811440815147ffc68bc79712006e2f735ae7258f9680b148907b593", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "caef3579-4e0e-44ef-bbe0-17c39c969fc6", "node_type": "1", "metadata": {"window": "And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n I also want to provide a brief update on our Board of Directors.  In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director.  Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018.  She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from.  Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare. ", "original_text": "Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018. "}, "hash": "f5f680531db74614a2459bf3f0e8fb2509e161a546437d1f72c1238a866a6d3f", "class_name": "RelatedNodeInfo"}}, "text": "In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director. ", "start_char_idx": 3354, "end_char_idx": 3450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "caef3579-4e0e-44ef-bbe0-17c39c969fc6": {"__data__": {"id_": "caef3579-4e0e-44ef-bbe0-17c39c969fc6", "embedding": null, "metadata": {"window": "And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n I also want to provide a brief update on our Board of Directors.  In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director.  Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018.  She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from.  Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare. ", "original_text": "Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "587c7861-d872-4dbb-8491-f6d19684775a", "node_type": "1", "metadata": {"window": "And while I appreciate there are many, many questions on this \ntopic, given that discussions are ongoing, we'll be somewhat limited in what we can say.  And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n I also want to provide a brief update on our Board of Directors.  In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director.  Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018.  She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from.  Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n", "original_text": "In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec42ad5470b05ce1c235302f1c5f0c35780774dd1629095d00b44c4cb136440f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1903d3fa-ff64-4bba-84a0-499434a17460", "node_type": "1", "metadata": {"window": "I also want to provide a brief update on our Board of Directors.  In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director.  Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018.  She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from.  Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare.  We have an aging \npopulation, as well as increase in chronic conditions. ", "original_text": "She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from. "}, "hash": "f39ad2ece091f222bfa68effb19febb26529e4882d2d328db0b4079075bc3422", "class_name": "RelatedNodeInfo"}}, "text": "Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018. ", "start_char_idx": 3450, "end_char_idx": 3562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1903d3fa-ff64-4bba-84a0-499434a17460": {"__data__": {"id_": "1903d3fa-ff64-4bba-84a0-499434a17460", "embedding": null, "metadata": {"window": "I also want to provide a brief update on our Board of Directors.  In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director.  Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018.  She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from.  Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare.  We have an aging \npopulation, as well as increase in chronic conditions. ", "original_text": "She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "caef3579-4e0e-44ef-bbe0-17c39c969fc6", "node_type": "1", "metadata": {"window": "And I'm sure you can \nappreciate this, and we thank you for your understanding.  \n \n I also want to provide a brief update on our Board of Directors.  In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director.  Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018.  She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from.  Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare. ", "original_text": "Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ae0733a001a1b8b4764b829196accb2cbdbfd917bca04b015fe10070d7e28c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d22bae23-12a8-4cce-855a-a752dc8d7ef2", "node_type": "1", "metadata": {"window": "In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director.  Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018.  She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from.  Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare.  We have an aging \npopulation, as well as increase in chronic conditions.  We're also seeing growth in innovative specialty medicines. \n", "original_text": "Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n"}, "hash": "ff04196520c6e84644fba3e25260a329682a7ba0a1ac2b3daf5aaad04f70461b", "class_name": "RelatedNodeInfo"}}, "text": "She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from. ", "start_char_idx": 3562, "end_char_idx": 3684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d22bae23-12a8-4cce-855a-a752dc8d7ef2": {"__data__": {"id_": "d22bae23-12a8-4cce-855a-a752dc8d7ef2", "embedding": null, "metadata": {"window": "In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director.  Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018.  She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from.  Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare.  We have an aging \npopulation, as well as increase in chronic conditions.  We're also seeing growth in innovative specialty medicines. \n", "original_text": "Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1903d3fa-ff64-4bba-84a0-499434a17460", "node_type": "1", "metadata": {"window": "I also want to provide a brief update on our Board of Directors.  In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director.  Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018.  She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from.  Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare.  We have an aging \npopulation, as well as increase in chronic conditions. ", "original_text": "She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7877cbeea1df1baa2f617f873782f79d6d1aa9342fe5b60d2dbdc389f5e58d6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a89fb811-f9f8-450f-9d18-c75962736164", "node_type": "1", "metadata": {"window": "Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018.  She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from.  Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare.  We have an aging \npopulation, as well as increase in chronic conditions.  We're also seeing growth in innovative specialty medicines. \n The pipeline is rich with suc h medicines, including biosimilars.  \n ", "original_text": "Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare. "}, "hash": "902c243671cf6b691c27d528c0f5de93d18e2de4de64b9aec7daf97239c5f031", "class_name": "RelatedNodeInfo"}}, "text": "Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n", "start_char_idx": 3684, "end_char_idx": 3891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a89fb811-f9f8-450f-9d18-c75962736164": {"__data__": {"id_": "a89fb811-f9f8-450f-9d18-c75962736164", "embedding": null, "metadata": {"window": "Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018.  She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from.  Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare.  We have an aging \npopulation, as well as increase in chronic conditions.  We're also seeing growth in innovative specialty medicines. \n The pipeline is rich with suc h medicines, including biosimilars.  \n ", "original_text": "Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d22bae23-12a8-4cce-855a-a752dc8d7ef2", "node_type": "1", "metadata": {"window": "In mid -October, our Board of Directors welcomed \nMaria Martinez as a new Independent Director.  Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018.  She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from.  Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare.  We have an aging \npopulation, as well as increase in chronic conditions.  We're also seeing growth in innovative specialty medicines. \n", "original_text": "Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "452b67b8e2bf1f56554511583aeeff87bc124fccf7293b3d537361826278d8bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a285595f-c370-452e-b671-5247d520299b", "node_type": "1", "metadata": {"window": "She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from.  Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare.  We have an aging \npopulation, as well as increase in chronic conditions.  We're also seeing growth in innovative specialty medicines. \n The pipeline is rich with suc h medicines, including biosimilars.  \n ", "original_text": "We have an aging \npopulation, as well as increase in chronic conditions. "}, "hash": "0523df7d0a49af7a04ee162998f9c7de2205a226a523b5c52a13dd7ea7290e16", "class_name": "RelatedNodeInfo"}}, "text": "Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare. ", "start_char_idx": 3891, "end_char_idx": 4097, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a285595f-c370-452e-b671-5247d520299b": {"__data__": {"id_": "a285595f-c370-452e-b671-5247d520299b", "embedding": null, "metadata": {"window": "She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from.  Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare.  We have an aging \npopulation, as well as increase in chronic conditions.  We're also seeing growth in innovative specialty medicines. \n The pipeline is rich with suc h medicines, including biosimilars.  \n ", "original_text": "We have an aging \npopulation, as well as increase in chronic conditions. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a89fb811-f9f8-450f-9d18-c75962736164", "node_type": "1", "metadata": {"window": "Maria has served as Executive Vice President and Chief \nCustomer Experience Officer for Cisco since April 2018.  She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from.  Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare.  We have an aging \npopulation, as well as increase in chronic conditions.  We're also seeing growth in innovative specialty medicines. \n The pipeline is rich with suc h medicines, including biosimilars.  \n ", "original_text": "Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4429f42979bf322ad81b800d0340efd19b0c5f22a3bc964ee0a671e49acc3db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42bf4aa0-4acf-44f3-8425-0c8056c2e744", "node_type": "1", "metadata": {"window": "Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare.  We have an aging \npopulation, as well as increase in chronic conditions.  We're also seeing growth in innovative specialty medicines. \n The pipeline is rich with suc h medicines, including biosimilars.  \n ", "original_text": "We're also seeing growth in innovative specialty medicines. \n"}, "hash": "96e759ef7acfc2bd12719870792969125e6139df56517cd5fd850cc484e3c05e", "class_name": "RelatedNodeInfo"}}, "text": "We have an aging \npopulation, as well as increase in chronic conditions. ", "start_char_idx": 4097, "end_char_idx": 4170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42bf4aa0-4acf-44f3-8425-0c8056c2e744": {"__data__": {"id_": "42bf4aa0-4acf-44f3-8425-0c8056c2e744", "embedding": null, "metadata": {"window": "Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare.  We have an aging \npopulation, as well as increase in chronic conditions.  We're also seeing growth in innovative specialty medicines. \n The pipeline is rich with suc h medicines, including biosimilars.  \n ", "original_text": "We're also seeing growth in innovative specialty medicines. \n", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a285595f-c370-452e-b671-5247d520299b", "node_type": "1", "metadata": {"window": "She brings deep experience in customer experience, \ntechnology, and innovation, which we look forward to benefiting from.  Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare.  We have an aging \npopulation, as well as increase in chronic conditions.  We're also seeing growth in innovative specialty medicines. \n The pipeline is rich with suc h medicines, including biosimilars.  \n ", "original_text": "We have an aging \npopulation, as well as increase in chronic conditions. ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5630eb4f6c7f89fc5742412a93c01037aaed3a53ef0d86d14a85b788e6415810", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5bd98a0-4667-492e-86f1-5fbc5a175df0", "node_type": "1", "metadata": {"window": "Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare.  We have an aging \npopulation, as well as increase in chronic conditions.  We're also seeing growth in innovative specialty medicines. \n The pipeline is rich with suc h medicines, including biosimilars.  \n ", "original_text": "The pipeline is rich with suc h medicines, including biosimilars.  \n "}, "hash": "762938472e54b325bd8e4847242990035e5673191c900a2d5c8ec02a6dd0be6b", "class_name": "RelatedNodeInfo"}}, "text": "We're also seeing growth in innovative specialty medicines. \n", "start_char_idx": 4170, "end_char_idx": 4231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5bd98a0-4667-492e-86f1-5fbc5a175df0": {"__data__": {"id_": "c5bd98a0-4667-492e-86f1-5fbc5a175df0", "embedding": null, "metadata": {"window": "Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare.  We have an aging \npopulation, as well as increase in chronic conditions.  We're also seeing growth in innovative specialty medicines. \n The pipeline is rich with suc h medicines, including biosimilars.  \n ", "original_text": "The pipeline is rich with suc h medicines, including biosimilars.  \n ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "982d3d57b83433b797ed0529664f9896ca78a13ebc3d1756008fe4b4b1255451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42bf4aa0-4acf-44f3-8425-0c8056c2e744", "node_type": "1", "metadata": {"window": "Maria's appointment, in addition to Ken \nWashington joi ning our Board of Directors in July, demonstrates our continuing commitment to refresh our Board \nand add valuable expertise and new perspectives.  \n \n Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare.  We have an aging \npopulation, as well as increase in chronic conditions.  We're also seeing growth in innovative specialty medicines. \n The pipeline is rich with suc h medicines, including biosimilars.  \n ", "original_text": "We're also seeing growth in innovative specialty medicines. \n", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4cda0aa1dcdc2dfbdf8d164c83ccaea6f3d97f3814cc39f6eb747af35c1f9583", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ee9de18-edaf-4992-888b-8175276ea5ec", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOur U.S.  Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop.  Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases. ", "original_text": "McKesson Corp.  "}, "hash": "4238c8efbf949946dacf93d31d85d1ce3a63840b65757eca00ed0605782187b5", "class_name": "RelatedNodeInfo"}}, "text": "The pipeline is rich with suc h medicines, including biosimilars.  \n ", "start_char_idx": 4231, "end_char_idx": 4300, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ee9de18-edaf-4992-888b-8175276ea5ec": {"__data__": {"id_": "1ee9de18-edaf-4992-888b-8175276ea5ec", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOur U.S.  Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop.  Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5bd98a0-4667-492e-86f1-5fbc5a175df0", "node_type": "1", "metadata": {"window": "Now let's get to the business results and share why I'm so confident in McKesson's positioning and our outloo k. If \nyou step back from a macro perspective, trends continue to support growth in healthcare.  We have an aging \npopulation, as well as increase in chronic conditions.  We're also seeing growth in innovative specialty medicines. \n The pipeline is rich with suc h medicines, including biosimilars.  \n ", "original_text": "The pipeline is rich with suc h medicines, including biosimilars.  \n ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73c2d0cad350e9ef0a298e034dc30dde60ef3007669450050c26741328209375", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74555ded-8826-4828-8435-46938e102920", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOur U.S.  Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop.  Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases.  For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOur U.S. "}, "hash": "d682c438b3c673a9f1df896868122379e05d4235849351ef6c3bc5770c64bd0a", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74555ded-8826-4828-8435-46938e102920": {"__data__": {"id_": "74555ded-8826-4828-8435-46938e102920", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOur U.S.  Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop.  Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases.  For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOur U.S. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ee9de18-edaf-4992-888b-8175276ea5ec", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOur U.S.  Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop.  Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a02b025d0bf876120ebe0c9e48e1c4414df1b0f15e4641cb7868207a7e27757", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b03d06e7-114f-4189-bdf0-c83ddf800263", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOur U.S.  Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop.  Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases.  For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n", "original_text": "Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop. "}, "hash": "74a522d8541f51a64e910e6e8aa274007203bdc2663b03b04314cf502b6318a9", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOur U.S. ", "start_char_idx": 16, "end_char_idx": 189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b03d06e7-114f-4189-bdf0-c83ddf800263": {"__data__": {"id_": "b03d06e7-114f-4189-bdf0-c83ddf800263", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOur U.S.  Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop.  Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases.  For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n", "original_text": "Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74555ded-8826-4828-8435-46938e102920", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOur U.S.  Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop.  Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases.  For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOur U.S. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66204a34852ff6675041fedc6612e6c76e817c6ad362b63d9a5f39c3ca3eb5ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a04c1f56-522f-4448-b8d4-3d1d1849abcd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOur U.S.  Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop.  Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases.  For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series. ", "original_text": "Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases. "}, "hash": "ff45d63db7b9df009fdb3cafce18321f87e964cfaaa5d9418d04ab2e68890057", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop. ", "start_char_idx": 189, "end_char_idx": 307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a04c1f56-522f-4448-b8d4-3d1d1849abcd": {"__data__": {"id_": "a04c1f56-522f-4448-b8d4-3d1d1849abcd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOur U.S.  Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop.  Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases.  For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series. ", "original_text": "Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b03d06e7-114f-4189-bdf0-c83ddf800263", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOur U.S.  Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop.  Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases.  For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n", "original_text": "Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae96b2aef622b0e785393442246eda8a63b78325291651d594f0911e8ad75f2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2c5a40b-b59f-4476-952e-e972b6dea690", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOur U.S.  Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop.  Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases.  For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series.  RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n", "original_text": "For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n"}, "hash": "822068d43b86e31e93dba03f1fae36c3632144160bbb7799a9efe583a3d29080", "class_name": "RelatedNodeInfo"}}, "text": "Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases. ", "start_char_idx": 307, "end_char_idx": 415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2c5a40b-b59f-4476-952e-e972b6dea690": {"__data__": {"id_": "a2c5a40b-b59f-4476-952e-e972b6dea690", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOur U.S.  Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop.  Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases.  For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series.  RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n", "original_text": "For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a04c1f56-522f-4448-b8d4-3d1d1849abcd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOur U.S.  Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop.  Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases.  For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series. ", "original_text": "Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad61c1c1a35eca7cbda5b732c13aecf7e884e7b3ffc8bcccd3bbb22ce2631622", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "555f7e0d-57dd-477c-a339-433905cddc6a", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop.  Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases.  For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series.  RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies. ", "original_text": "Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n"}, "hash": "92848b2dbd25458c1730d7abfde3eecfd6ff32e4a06edeaaf278243e9628e1c3", "class_name": "RelatedNodeInfo"}}, "text": "For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n", "start_char_idx": 415, "end_char_idx": 589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "555f7e0d-57dd-477c-a339-433905cddc6a": {"__data__": {"id_": "555f7e0d-57dd-477c-a339-433905cddc6a", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop.  Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases.  For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series.  RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies. ", "original_text": "Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2c5a40b-b59f-4476-952e-e972b6dea690", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOur U.S.  Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop.  Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases.  For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series.  RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n", "original_text": "For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3dd2c5680a3de1fd05166862a592fb0b5a904d56f558a98a1fcc2493a1ac8e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac2cbe01-6951-4641-84c9-46b12dce1525", "node_type": "1", "metadata": {"window": "Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases.  For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series.  RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies.  We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n", "original_text": "Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series. "}, "hash": "3e89bb8ae646be7a9d0c0940b1e19a35b3c84a358acde6cbe46b70f6283b8f8b", "class_name": "RelatedNodeInfo"}}, "text": "Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n", "start_char_idx": 589, "end_char_idx": 696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac2cbe01-6951-4641-84c9-46b12dce1525": {"__data__": {"id_": "ac2cbe01-6951-4641-84c9-46b12dce1525", "embedding": null, "metadata": {"window": "Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases.  For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series.  RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies.  We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n", "original_text": "Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "555f7e0d-57dd-477c-a339-433905cddc6a", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop.  Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases.  For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series.  RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies. ", "original_text": "Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ceb243a8d78de0ed4185d453c1ffb6a6e0d5cbeae43c035c0a33c10f4dd929f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c6150fc-8ce1-4b1a-83f0-af3cd0616080", "node_type": "1", "metadata": {"window": "For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series.  RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies.  We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities. ", "original_text": "RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n"}, "hash": "266f777e001a89bde3e0fc4dc338e684a4328b7f20be4bbb5a9107a9b1c3e8ae", "class_name": "RelatedNodeInfo"}}, "text": "Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series. ", "start_char_idx": 696, "end_char_idx": 853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c6150fc-8ce1-4b1a-83f0-af3cd0616080": {"__data__": {"id_": "5c6150fc-8ce1-4b1a-83f0-af3cd0616080", "embedding": null, "metadata": {"window": "For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series.  RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies.  We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities. ", "original_text": "RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac2cbe01-6951-4641-84c9-46b12dce1525", "node_type": "1", "metadata": {"window": "Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases.  For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series.  RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies.  We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n", "original_text": "Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc065e8ddb37393900be959bd6fcfe8d961b86a3f36b12a1bf3266411b10452d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74c0ecac-fc3c-4e3b-bc50-0fffe93700a0", "node_type": "1", "metadata": {"window": "Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series.  RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies.  We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities.  When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n", "original_text": "In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies. "}, "hash": "7a73efe05a77e2a424e0f63391d6b6b23e6a0c7c11f8cae339f3779f1a71803b", "class_name": "RelatedNodeInfo"}}, "text": "RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n", "start_char_idx": 853, "end_char_idx": 1020, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74c0ecac-fc3c-4e3b-bc50-0fffe93700a0": {"__data__": {"id_": "74c0ecac-fc3c-4e3b-bc50-0fffe93700a0", "embedding": null, "metadata": {"window": "Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series.  RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies.  We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities.  When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n", "original_text": "In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c6150fc-8ce1-4b1a-83f0-af3cd0616080", "node_type": "1", "metadata": {"window": "For generics, consistent with prior quarters, our ClarusONE Sourcing venture is performing in line with \nexpectations, and the sell -side remains competitive but stable.  \n \n Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series.  RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies.  We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities. ", "original_text": "RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a64251e316a541ed3a62030d73054ec1d905848230eec4f456bd5aabe18918e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2bdf916-86ef-4e13-84f8-a80894b61da4", "node_type": "1", "metadata": {"window": "Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series.  RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies.  We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities.  When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n These businesses are organized in t hree strategic areas. ", "original_text": "We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n"}, "hash": "8c0f7ec2cd002e3e12e82417e5fe1db2086ce31628bb7e2fc6c3cdc096736f92", "class_name": "RelatedNodeInfo"}}, "text": "In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies. ", "start_char_idx": 1020, "end_char_idx": 1213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2bdf916-86ef-4e13-84f8-a80894b61da4": {"__data__": {"id_": "b2bdf916-86ef-4e13-84f8-a80894b61da4", "embedding": null, "metadata": {"window": "Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series.  RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies.  We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities.  When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n These businesses are organized in t hree strategic areas. ", "original_text": "We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74c0ecac-fc3c-4e3b-bc50-0fffe93700a0", "node_type": "1", "metadata": {"window": "Independent pharmacies continued to demonstrate resiliency and remain an im portant customer of McKesson. \n Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series.  RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies.  We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities.  When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n", "original_text": "In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95ba7ea41ca2bab6dd9099c396dc2012edb27748193b8adeb386f82b17a6656", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40f8af73-563f-4cce-86a7-a147b0fb14e8", "node_type": "1", "metadata": {"window": "RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies.  We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities.  When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n These businesses are organized in t hree strategic areas.  First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers. ", "original_text": "I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities. "}, "hash": "442b9974d7f010cfb67ea12e9bc14372efa625c300369891efe80db9fa0d17ae", "class_name": "RelatedNodeInfo"}}, "text": "We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n", "start_char_idx": 1213, "end_char_idx": 1367, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40f8af73-563f-4cce-86a7-a147b0fb14e8": {"__data__": {"id_": "40f8af73-563f-4cce-86a7-a147b0fb14e8", "embedding": null, "metadata": {"window": "RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies.  We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities.  When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n These businesses are organized in t hree strategic areas.  First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers. ", "original_text": "I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2bdf916-86ef-4e13-84f8-a80894b61da4", "node_type": "1", "metadata": {"window": "Recently, our McKesson RxOwnership team partnered with the National Community Pharmacists Association to \nsponsor its 10th annual Ownership Workshop series.  RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies.  We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities.  When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n These businesses are organized in t hree strategic areas. ", "original_text": "We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cdf7552dd119b45c1dd6443c2a06b56f4b4afc2afeb3181ffbf36ab34208ea0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec510c98-9236-4eb0-b66d-87004d8b947f", "node_type": "1", "metadata": {"window": "In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies.  We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities.  When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n These businesses are organized in t hree strategic areas.  First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers.  Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n", "original_text": "When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n"}, "hash": "f1fb05f2bcd40cc7198c76f0549041627c1d96b9bae8e19da91a7ba8b3ff2f82", "class_name": "RelatedNodeInfo"}}, "text": "I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities. ", "start_char_idx": 1367, "end_char_idx": 1510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec510c98-9236-4eb0-b66d-87004d8b947f": {"__data__": {"id_": "ec510c98-9236-4eb0-b66d-87004d8b947f", "embedding": null, "metadata": {"window": "In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies.  We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities.  When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n These businesses are organized in t hree strategic areas.  First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers.  Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n", "original_text": "When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40f8af73-563f-4cce-86a7-a147b0fb14e8", "node_type": "1", "metadata": {"window": "RxOwnership supports the future of pharmacy ownership by \ngiving pharma cists the knowledge, the support, and the tools required to achieve their ownership goals.  \n \n In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies.  We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities.  When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n These businesses are organized in t hree strategic areas.  First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers. ", "original_text": "I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "62396faa6a22ac07bb08d1026be82900fb70ff1afd4a2136b0e110b501d6c806", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "696ba670-e1a6-494b-8d39-f5e6b70a043c", "node_type": "1", "metadata": {"window": "We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities.  When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n These businesses are organized in t hree strategic areas.  First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers.  Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n Next is the practice management business. ", "original_text": "These businesses are organized in t hree strategic areas. "}, "hash": "bee5b2c18e34d47bb6287fe72ebba36149f902b98176641221c602d90bf197b8", "class_name": "RelatedNodeInfo"}}, "text": "When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n", "start_char_idx": 1510, "end_char_idx": 1933, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "696ba670-e1a6-494b-8d39-f5e6b70a043c": {"__data__": {"id_": "696ba670-e1a6-494b-8d39-f5e6b70a043c", "embedding": null, "metadata": {"window": "We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities.  When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n These businesses are organized in t hree strategic areas.  First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers.  Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n Next is the practice management business. ", "original_text": "These businesses are organized in t hree strategic areas. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec510c98-9236-4eb0-b66d-87004d8b947f", "node_type": "1", "metadata": {"window": "In the past year, RxOwnership assisted more than 725 owners in launching a new pharmacy, and since 2008 our \nteam aided in ownership or transfer process of roughly 6 ,000 community pharmacies.  We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities.  When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n These businesses are organized in t hree strategic areas.  First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers.  Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n", "original_text": "When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74791ebce3c186e0391a33f0d96c6e317d7bf6788d81e62c16cc5be00e7cef3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b175cd96-f60e-46dd-80c5-3989c9e8e885", "node_type": "1", "metadata": {"window": "I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities.  When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n These businesses are organized in t hree strategic areas.  First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers.  Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n Next is the practice management business.  We discuss the U.S. ", "original_text": "First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers. "}, "hash": "4acb1f08cfd91f3404fb17d97810d1707640f30ea3a6cf4a1edd9a3c9813903c", "class_name": "RelatedNodeInfo"}}, "text": "These businesses are organized in t hree strategic areas. ", "start_char_idx": 1933, "end_char_idx": 1991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b175cd96-f60e-46dd-80c5-3989c9e8e885": {"__data__": {"id_": "b175cd96-f60e-46dd-80c5-3989c9e8e885", "embedding": null, "metadata": {"window": "I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities.  When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n These businesses are organized in t hree strategic areas.  First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers.  Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n Next is the practice management business.  We discuss the U.S. ", "original_text": "First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "696ba670-e1a6-494b-8d39-f5e6b70a043c", "node_type": "1", "metadata": {"window": "We are proud of the long -\nterm investments we've made in helping independent pharmacies deliver exceptional care to their patients and \ncommunities.  \n \n I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities.  When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n These businesses are organized in t hree strategic areas.  First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers.  Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n Next is the practice management business. ", "original_text": "These businesses are organized in t hree strategic areas. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1c8fa3cd40bcbc29514419cb987b8be33214892dcbf23e8deb3572af8bd8f0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ff80ff6-a2ec-4472-af84-be231fe815e7", "node_type": "1", "metadata": {"window": "When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n These businesses are organized in t hree strategic areas.  First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers.  Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n Next is the practice management business.  We discuss the U.S.  Oncology Network quite often. ", "original_text": "Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n"}, "hash": "f4d5ba77b1cd44258af2dc92e89af552b58a8190dd53d331acc41ee2f2653ab3", "class_name": "RelatedNodeInfo"}}, "text": "First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers. ", "start_char_idx": 1991, "end_char_idx": 2180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ff80ff6-a2ec-4472-af84-be231fe815e7": {"__data__": {"id_": "1ff80ff6-a2ec-4472-af84-be231fe815e7", "embedding": null, "metadata": {"window": "When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n These businesses are organized in t hree strategic areas.  First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers.  Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n Next is the practice management business.  We discuss the U.S.  Oncology Network quite often. ", "original_text": "Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b175cd96-f60e-46dd-80c5-3989c9e8e885", "node_type": "1", "metadata": {"window": "I'm also pleased with the strength we continue to see from our specialty business es, where we have a broad array \nof assets and capabilities.  When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n These businesses are organized in t hree strategic areas.  First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers.  Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n Next is the practice management business.  We discuss the U.S. ", "original_text": "First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3da6e2f2643ccbc2985dec84b33f2357aa7b57f24a3b3688fa2b054342b1fbe2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9e4ba94-4662-4042-91fe-ec1d864b791a", "node_type": "1", "metadata": {"window": "These businesses are organized in t hree strategic areas.  First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers.  Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n Next is the practice management business.  We discuss the U.S.  Oncology Network quite often.  This organization \nsupports more than 1,400 physicians across  450 sites of service. ", "original_text": "Next is the practice management business. "}, "hash": "40ac52913a492c362a687fd9616a309db59c06353f537675dade419d00eb3bca", "class_name": "RelatedNodeInfo"}}, "text": "Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n", "start_char_idx": 2180, "end_char_idx": 2337, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9e4ba94-4662-4042-91fe-ec1d864b791a": {"__data__": {"id_": "c9e4ba94-4662-4042-91fe-ec1d864b791a", "embedding": null, "metadata": {"window": "These businesses are organized in t hree strategic areas.  First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers.  Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n Next is the practice management business.  We discuss the U.S.  Oncology Network quite often.  This organization \nsupports more than 1,400 physicians across  450 sites of service. ", "original_text": "Next is the practice management business. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ff80ff6-a2ec-4472-af84-be231fe815e7", "node_type": "1", "metadata": {"window": "When I talk about our specialty businesses, I'm largely referring to our provider \nsolutions and practice management businesses that serve the community setting, primarily in oncology but also in \nother \"ologies\" like ophthalmology, rheumatology, and neurology, and our life sciences business, that leverage \nour provider footprint and differentiated services to drive solutions upstream for our manufacturer partners.  \n \n These businesses are organized in t hree strategic areas.  First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers.  Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n Next is the practice management business.  We discuss the U.S.  Oncology Network quite often. ", "original_text": "Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa31070482602bce012897751ae829af22f20977749c4d7f6229b964881a04c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4dccd61-86ff-4a17-b8a3-c15a633a8dbd", "node_type": "1", "metadata": {"window": "First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers.  Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n Next is the practice management business.  We discuss the U.S.  Oncology Network quite often.  This organization \nsupports more than 1,400 physicians across  450 sites of service.  We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively. ", "original_text": "We discuss the U.S. "}, "hash": "2f6bf55dc592d9713207c1fd4a496dff731db537e21b6a91443cda48627e729a", "class_name": "RelatedNodeInfo"}}, "text": "Next is the practice management business. ", "start_char_idx": 2337, "end_char_idx": 2379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4dccd61-86ff-4a17-b8a3-c15a633a8dbd": {"__data__": {"id_": "b4dccd61-86ff-4a17-b8a3-c15a633a8dbd", "embedding": null, "metadata": {"window": "First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers.  Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n Next is the practice management business.  We discuss the U.S.  Oncology Network quite often.  This organization \nsupports more than 1,400 physicians across  450 sites of service.  We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively. ", "original_text": "We discuss the U.S. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9e4ba94-4662-4042-91fe-ec1d864b791a", "node_type": "1", "metadata": {"window": "These businesses are organized in t hree strategic areas.  First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers.  Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n Next is the practice management business.  We discuss the U.S.  Oncology Network quite often.  This organization \nsupports more than 1,400 physicians across  450 sites of service. ", "original_text": "Next is the practice management business. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a69177049723f8deca62d423a88ab518160842db3d46fe6d139494d5038bbb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e1a9184-4fe8-4b0c-b433-ec698ad71d1e", "node_type": "1", "metadata": {"window": "Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n Next is the practice management business.  We discuss the U.S.  Oncology Network quite often.  This organization \nsupports more than 1,400 physicians across  450 sites of service.  We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively.  This allows the physician to focus h is or her time on treating patients. \n", "original_text": "Oncology Network quite often. "}, "hash": "4289a1dbb9dcbf3a40b9c4727945139fbabe7a72e72fca761b4bf10011edc04e", "class_name": "RelatedNodeInfo"}}, "text": "We discuss the U.S. ", "start_char_idx": 2379, "end_char_idx": 2399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e1a9184-4fe8-4b0c-b433-ec698ad71d1e": {"__data__": {"id_": "4e1a9184-4fe8-4b0c-b433-ec698ad71d1e", "embedding": null, "metadata": {"window": "Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n Next is the practice management business.  We discuss the U.S.  Oncology Network quite often.  This organization \nsupports more than 1,400 physicians across  450 sites of service.  We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively.  This allows the physician to focus h is or her time on treating patients. \n", "original_text": "Oncology Network quite often. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4dccd61-86ff-4a17-b8a3-c15a633a8dbd", "node_type": "1", "metadata": {"window": "First, provider solutions, which is the largest of the three \nbusinesses, includes the distribution and GPO services that are core to McKesson and to the needs of our \nphysician customers.  Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n Next is the practice management business.  We discuss the U.S.  Oncology Network quite often.  This organization \nsupports more than 1,400 physicians across  450 sites of service.  We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively. ", "original_text": "We discuss the U.S. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dbfc82877d04671dab3c253e03868a13c03f59a3aa1da06e356a793ff7626207", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d4c9cf1-014b-4c6f-9978-8193dd0f579d", "node_type": "1", "metadata": {"window": "Next is the practice management business.  We discuss the U.S.  Oncology Network quite often.  This organization \nsupports more than 1,400 physicians across  450 sites of service.  We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively.  This allows the physician to focus h is or her time on treating patients. \n McKesson has 15 practices in the U.S. ", "original_text": "This organization \nsupports more than 1,400 physicians across  450 sites of service. "}, "hash": "b267af3b05569b8975643418fe4340139a5f6e2727d87b9f08e4f9d37e83ce7a", "class_name": "RelatedNodeInfo"}}, "text": "Oncology Network quite often. ", "start_char_idx": 2399, "end_char_idx": 2429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d4c9cf1-014b-4c6f-9978-8193dd0f579d": {"__data__": {"id_": "0d4c9cf1-014b-4c6f-9978-8193dd0f579d", "embedding": null, "metadata": {"window": "Next is the practice management business.  We discuss the U.S.  Oncology Network quite often.  This organization \nsupports more than 1,400 physicians across  450 sites of service.  We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively.  This allows the physician to focus h is or her time on treating patients. \n McKesson has 15 practices in the U.S. ", "original_text": "This organization \nsupports more than 1,400 physicians across  450 sites of service. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e1a9184-4fe8-4b0c-b433-ec698ad71d1e", "node_type": "1", "metadata": {"window": "Also in this business, we have technology and t ools that enhance value -based care delivery \nand products and services to help expand practice revenue.  \n \n Next is the practice management business.  We discuss the U.S.  Oncology Network quite often.  This organization \nsupports more than 1,400 physicians across  450 sites of service.  We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively.  This allows the physician to focus h is or her time on treating patients. \n", "original_text": "Oncology Network quite often. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1380f59d421108cf42fcb20bcf37494a99550440e69786a21fe50fbc5592955", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "034b2e7a-7c6f-4b32-a25f-590eb9d0a231", "node_type": "1", "metadata": {"window": "We discuss the U.S.  Oncology Network quite often.  This organization \nsupports more than 1,400 physicians across  450 sites of service.  We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively.  This allows the physician to focus h is or her time on treating patients. \n McKesson has 15 practices in the U.S.  Oncology Network that are participating in the Oncology Care Model, or \nOCM. ", "original_text": "We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively. "}, "hash": "2c819ff96f08ae25c1d6ec48f76bfd7275a8261b062b14a169f5426bc90084f8", "class_name": "RelatedNodeInfo"}}, "text": "This organization \nsupports more than 1,400 physicians across  450 sites of service. ", "start_char_idx": 2429, "end_char_idx": 2514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "034b2e7a-7c6f-4b32-a25f-590eb9d0a231": {"__data__": {"id_": "034b2e7a-7c6f-4b32-a25f-590eb9d0a231", "embedding": null, "metadata": {"window": "We discuss the U.S.  Oncology Network quite often.  This organization \nsupports more than 1,400 physicians across  450 sites of service.  We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively.  This allows the physician to focus h is or her time on treating patients. \n McKesson has 15 practices in the U.S.  Oncology Network that are participating in the Oncology Care Model, or \nOCM. ", "original_text": "We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d4c9cf1-014b-4c6f-9978-8193dd0f579d", "node_type": "1", "metadata": {"window": "Next is the practice management business.  We discuss the U.S.  Oncology Network quite often.  This organization \nsupports more than 1,400 physicians across  450 sites of service.  We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively.  This allows the physician to focus h is or her time on treating patients. \n McKesson has 15 practices in the U.S. ", "original_text": "This organization \nsupports more than 1,400 physicians across  450 sites of service. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1be51032e330a3b1b94473d78ecbaf743790efafeb5660f1caab1f193432c15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8a51797-594f-4032-8893-7d38c50bf06d", "node_type": "1", "metadata": {"window": "Oncology Network quite often.  This organization \nsupports more than 1,400 physicians across  450 sites of service.  We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively.  This allows the physician to focus h is or her time on treating patients. \n McKesson has 15 practices in the U.S.  Oncology Network that are participating in the Oncology Care Model, or \nOCM.  The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM. ", "original_text": "This allows the physician to focus h is or her time on treating patients. \n"}, "hash": "e9db174bcf06cd3b6fce2123860196aa39cbb92662323b2b5554e8ea86a91a33", "class_name": "RelatedNodeInfo"}}, "text": "We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively. ", "start_char_idx": 2514, "end_char_idx": 2713, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8a51797-594f-4032-8893-7d38c50bf06d": {"__data__": {"id_": "e8a51797-594f-4032-8893-7d38c50bf06d", "embedding": null, "metadata": {"window": "Oncology Network quite often.  This organization \nsupports more than 1,400 physicians across  450 sites of service.  We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively.  This allows the physician to focus h is or her time on treating patients. \n McKesson has 15 practices in the U.S.  Oncology Network that are participating in the Oncology Care Model, or \nOCM.  The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM. ", "original_text": "This allows the physician to focus h is or her time on treating patients. \n", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "034b2e7a-7c6f-4b32-a25f-590eb9d0a231", "node_type": "1", "metadata": {"window": "We discuss the U.S.  Oncology Network quite often.  This organization \nsupports more than 1,400 physicians across  450 sites of service.  We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively.  This allows the physician to focus h is or her time on treating patients. \n McKesson has 15 practices in the U.S.  Oncology Network that are participating in the Oncology Care Model, or \nOCM. ", "original_text": "We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "62b4e795ebd48f97b67422419d18c1c4bff670b663c4a7d78a01b17a8d934d81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5a50f5c-5c5c-4615-8208-2ad8a105a564", "node_type": "1", "metadata": {"window": "This organization \nsupports more than 1,400 physicians across  450 sites of service.  We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively.  This allows the physician to focus h is or her time on treating patients. \n McKesson has 15 practices in the U.S.  Oncology Network that are participating in the Oncology Care Model, or \nOCM.  The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM.  I'm pleased to report that all 15 practices earned high marks for quality performance. \n", "original_text": "McKesson has 15 practices in the U.S. "}, "hash": "08b0832e05aaafe3912033ae384b1befe7a3ed61b72187739c91862c683e0e00", "class_name": "RelatedNodeInfo"}}, "text": "This allows the physician to focus h is or her time on treating patients. \n", "start_char_idx": 2713, "end_char_idx": 2788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5a50f5c-5c5c-4615-8208-2ad8a105a564": {"__data__": {"id_": "f5a50f5c-5c5c-4615-8208-2ad8a105a564", "embedding": null, "metadata": {"window": "This organization \nsupports more than 1,400 physicians across  450 sites of service.  We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively.  This allows the physician to focus h is or her time on treating patients. \n McKesson has 15 practices in the U.S.  Oncology Network that are participating in the Oncology Care Model, or \nOCM.  The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM.  I'm pleased to report that all 15 practices earned high marks for quality performance. \n", "original_text": "McKesson has 15 practices in the U.S. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8a51797-594f-4032-8893-7d38c50bf06d", "node_type": "1", "metadata": {"window": "Oncology Network quite often.  This organization \nsupports more than 1,400 physicians across  450 sites of service.  We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively.  This allows the physician to focus h is or her time on treating patients. \n McKesson has 15 practices in the U.S.  Oncology Network that are participating in the Oncology Care Model, or \nOCM.  The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM. ", "original_text": "This allows the physician to focus h is or her time on treating patients. \n", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b8e2842d5f5f25c212358bb54f31d1e48d71a12cea8379678eff3dc73e00bd0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "925f194e-ac29-437f-aae9-cf17ad9644e9", "node_type": "1", "metadata": {"window": "We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively.  This allows the physician to focus h is or her time on treating patients. \n McKesson has 15 practices in the U.S.  Oncology Network that are participating in the Oncology Care Model, or \nOCM.  The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM.  I'm pleased to report that all 15 practices earned high marks for quality performance. \n The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark. ", "original_text": "Oncology Network that are participating in the Oncology Care Model, or \nOCM. "}, "hash": "7f375a269317004c4184732251e0c7049157f383b1ee9392a69e141f257a65da", "class_name": "RelatedNodeInfo"}}, "text": "McKesson has 15 practices in the U.S. ", "start_char_idx": 2788, "end_char_idx": 2826, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "925f194e-ac29-437f-aae9-cf17ad9644e9": {"__data__": {"id_": "925f194e-ac29-437f-aae9-cf17ad9644e9", "embedding": null, "metadata": {"window": "We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively.  This allows the physician to focus h is or her time on treating patients. \n McKesson has 15 practices in the U.S.  Oncology Network that are participating in the Oncology Care Model, or \nOCM.  The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM.  I'm pleased to report that all 15 practices earned high marks for quality performance. \n The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark. ", "original_text": "Oncology Network that are participating in the Oncology Care Model, or \nOCM. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5a50f5c-5c5c-4615-8208-2ad8a105a564", "node_type": "1", "metadata": {"window": "This organization \nsupports more than 1,400 physicians across  450 sites of service.  We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively.  This allows the physician to focus h is or her time on treating patients. \n McKesson has 15 practices in the U.S.  Oncology Network that are participating in the Oncology Care Model, or \nOCM.  The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM.  I'm pleased to report that all 15 practices earned high marks for quality performance. \n", "original_text": "McKesson has 15 practices in the U.S. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a50c4915cb37d33b5d48df3c5f738f815f11c7c795fe77b6e44b74234eaabe9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1a0e04d-ed1f-4c34-9e4c-ad596b15a1fa", "node_type": "1", "metadata": {"window": "This allows the physician to focus h is or her time on treating patients. \n McKesson has 15 practices in the U.S.  Oncology Network that are participating in the Oncology Care Model, or \nOCM.  The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM.  I'm pleased to report that all 15 practices earned high marks for quality performance. \n The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark.  We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n", "original_text": "The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM. "}, "hash": "702e998fef924e81894e81afadf62165bb6c4fea38744205f666d2a3e03b419c", "class_name": "RelatedNodeInfo"}}, "text": "Oncology Network that are participating in the Oncology Care Model, or \nOCM. ", "start_char_idx": 2826, "end_char_idx": 2903, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1a0e04d-ed1f-4c34-9e4c-ad596b15a1fa": {"__data__": {"id_": "b1a0e04d-ed1f-4c34-9e4c-ad596b15a1fa", "embedding": null, "metadata": {"window": "This allows the physician to focus h is or her time on treating patients. \n McKesson has 15 practices in the U.S.  Oncology Network that are participating in the Oncology Care Model, or \nOCM.  The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM.  I'm pleased to report that all 15 practices earned high marks for quality performance. \n The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark.  We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n", "original_text": "The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "925f194e-ac29-437f-aae9-cf17ad9644e9", "node_type": "1", "metadata": {"window": "We provide a unique value proposition, which \nallows the physician to remain independent while utilizing McKesson's services and staff to ensure the practice is \nrunning efficiently and effectively.  This allows the physician to focus h is or her time on treating patients. \n McKesson has 15 practices in the U.S.  Oncology Network that are participating in the Oncology Care Model, or \nOCM.  The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM.  I'm pleased to report that all 15 practices earned high marks for quality performance. \n The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark. ", "original_text": "Oncology Network that are participating in the Oncology Care Model, or \nOCM. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1af6a5bdc5301aa610872aa2ec166bce4f4374b9564656ec3423553fd5a5adf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d7716a6-9813-4729-a19a-49d702ad8cf6", "node_type": "1", "metadata": {"window": "McKesson has 15 practices in the U.S.  Oncology Network that are participating in the Oncology Care Model, or \nOCM.  The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM.  I'm pleased to report that all 15 practices earned high marks for quality performance. \n The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark.  We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n The third business is our McKesson Life Sciences business. ", "original_text": "I'm pleased to report that all 15 practices earned high marks for quality performance. \n"}, "hash": "6dae8cd48b77bcc588a40a4d2d0ba01725e96b5f74e22a16086cf1bce6ba32a9", "class_name": "RelatedNodeInfo"}}, "text": "The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM. ", "start_char_idx": 2903, "end_char_idx": 3033, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d7716a6-9813-4729-a19a-49d702ad8cf6": {"__data__": {"id_": "3d7716a6-9813-4729-a19a-49d702ad8cf6", "embedding": null, "metadata": {"window": "McKesson has 15 practices in the U.S.  Oncology Network that are participating in the Oncology Care Model, or \nOCM.  The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM.  I'm pleased to report that all 15 practices earned high marks for quality performance. \n The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark.  We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n The third business is our McKesson Life Sciences business. ", "original_text": "I'm pleased to report that all 15 practices earned high marks for quality performance. \n", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1a0e04d-ed1f-4c34-9e4c-ad596b15a1fa", "node_type": "1", "metadata": {"window": "This allows the physician to focus h is or her time on treating patients. \n McKesson has 15 practices in the U.S.  Oncology Network that are participating in the Oncology Care Model, or \nOCM.  The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM.  I'm pleased to report that all 15 practices earned high marks for quality performance. \n The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark.  We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n", "original_text": "The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c91184571f31780fc83142526d4e7f8304984980f1795109fb2beb072dc5b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3198a460-a31d-4426-a2de-6bb534e38568", "node_type": "1", "metadata": {"window": "Oncology Network that are participating in the Oncology Care Model, or \nOCM.  The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM.  I'm pleased to report that all 15 practices earned high marks for quality performance. \n The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark.  We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n The third business is our McKesson Life Sciences business.  This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence. ", "original_text": "The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark. "}, "hash": "a4f335d9f0873231c5021dfe221482ad30b092b6bad44b944726225fdb12bc54", "class_name": "RelatedNodeInfo"}}, "text": "I'm pleased to report that all 15 practices earned high marks for quality performance. \n", "start_char_idx": 3033, "end_char_idx": 3121, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3198a460-a31d-4426-a2de-6bb534e38568": {"__data__": {"id_": "3198a460-a31d-4426-a2de-6bb534e38568", "embedding": null, "metadata": {"window": "Oncology Network that are participating in the Oncology Care Model, or \nOCM.  The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM.  I'm pleased to report that all 15 practices earned high marks for quality performance. \n The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark.  We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n The third business is our McKesson Life Sciences business.  This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence. ", "original_text": "The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d7716a6-9813-4729-a19a-49d702ad8cf6", "node_type": "1", "metadata": {"window": "McKesson has 15 practices in the U.S.  Oncology Network that are participating in the Oncology Care Model, or \nOCM.  The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM.  I'm pleased to report that all 15 practices earned high marks for quality performance. \n The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark.  We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n The third business is our McKesson Life Sciences business. ", "original_text": "I'm pleased to report that all 15 practices earned high marks for quality performance. \n", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "382b38a8fac9df93f4bfbfd542cec32d0238ce5c984fbcbb241feb24f269352a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b36d83d-ea1c-4aad-a25b-8ce3024b426a", "node_type": "1", "metadata": {"window": "The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM.  I'm pleased to report that all 15 practices earned high marks for quality performance. \n The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark.  We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n The third business is our McKesson Life Sciences business.  This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence.  These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n", "original_text": "We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n"}, "hash": "ca968c70f25443c674cd68fc98b4cafb95b7f028818fb3dcdc6ae449a79776fb", "class_name": "RelatedNodeInfo"}}, "text": "The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark. ", "start_char_idx": 3121, "end_char_idx": 3316, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b36d83d-ea1c-4aad-a25b-8ce3024b426a": {"__data__": {"id_": "2b36d83d-ea1c-4aad-a25b-8ce3024b426a", "embedding": null, "metadata": {"window": "The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM.  I'm pleased to report that all 15 practices earned high marks for quality performance. \n The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark.  We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n The third business is our McKesson Life Sciences business.  This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence.  These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n", "original_text": "We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3198a460-a31d-4426-a2de-6bb534e38568", "node_type": "1", "metadata": {"window": "Oncology Network that are participating in the Oncology Care Model, or \nOCM.  The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM.  I'm pleased to report that all 15 practices earned high marks for quality performance. \n The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark.  We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n The third business is our McKesson Life Sciences business.  This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence. ", "original_text": "The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f814d3f5235f5df1e22057e9c33beecbe569b045f93416cd006ad6423836fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a43141e5-8514-4598-8c07-e08e3e06dc70", "node_type": "1", "metadata": {"window": "I'm pleased to report that all 15 practices earned high marks for quality performance. \n The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark.  We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n The third business is our McKesson Life Sciences business.  This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence.  These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market. ", "original_text": "The third business is our McKesson Life Sciences business. "}, "hash": "4ca7866c482d89b3756582465648044835da4d0e064315d685df8f2b3d29185f", "class_name": "RelatedNodeInfo"}}, "text": "We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n", "start_char_idx": 3316, "end_char_idx": 3601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a43141e5-8514-4598-8c07-e08e3e06dc70": {"__data__": {"id_": "a43141e5-8514-4598-8c07-e08e3e06dc70", "embedding": null, "metadata": {"window": "I'm pleased to report that all 15 practices earned high marks for quality performance. \n The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark.  We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n The third business is our McKesson Life Sciences business.  This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence.  These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market. ", "original_text": "The third business is our McKesson Life Sciences business. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b36d83d-ea1c-4aad-a25b-8ce3024b426a", "node_type": "1", "metadata": {"window": "The Centers for Medicaid and Medicaid Innovation recently released results for the fourth performance \nperiod related to the OCM.  I'm pleased to report that all 15 practices earned high marks for quality performance. \n The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark.  We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n The third business is our McKesson Life Sciences business.  This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence.  These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n", "original_text": "We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6125b3e9079faf122dbdaf07d59e0156af631faa4f6948774e196c6244549b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "325a2857-c90f-4f52-9b11-1bd035e4c4d8", "node_type": "1", "metadata": {"window": "The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark.  We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n The third business is our McKesson Life Sciences business.  This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence.  These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market.  And McKesson is often the partner of choice throughout the lifecycle of a therapy. ", "original_text": "This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence. "}, "hash": "16c7cc2ba2e2c1031c4596fd60553600232cb6da875b754bae17d5a69f9af36e", "class_name": "RelatedNodeInfo"}}, "text": "The third business is our McKesson Life Sciences business. ", "start_char_idx": 3601, "end_char_idx": 3660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "325a2857-c90f-4f52-9b11-1bd035e4c4d8": {"__data__": {"id_": "325a2857-c90f-4f52-9b11-1bd035e4c4d8", "embedding": null, "metadata": {"window": "The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark.  We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n The third business is our McKesson Life Sciences business.  This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence.  These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market.  And McKesson is often the partner of choice throughout the lifecycle of a therapy. ", "original_text": "This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a43141e5-8514-4598-8c07-e08e3e06dc70", "node_type": "1", "metadata": {"window": "I'm pleased to report that all 15 practices earned high marks for quality performance. \n The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark.  We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n The third business is our McKesson Life Sciences business.  This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence.  These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market. ", "original_text": "The third business is our McKesson Life Sciences business. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "736b5f98c9d1399baa70a69737e4e2e9c098d24f10f903f3963f3dcb17bef48c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d33920bc-f128-4c63-87e2-0cb3eeeda48a", "node_type": "1", "metadata": {"window": "We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n The third business is our McKesson Life Sciences business.  This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence.  These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market.  And McKesson is often the partner of choice throughout the lifecycle of a therapy.  As you can see,  \ntwo of our strategic imperatives, supporting specialty and the manufacturer services value proposition, are ", "original_text": "These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n"}, "hash": "e4717d0cfbb7be846ab12a0e94162babcee9600473fbbbc256380ab447c90eb0", "class_name": "RelatedNodeInfo"}}, "text": "This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence. ", "start_char_idx": 3660, "end_char_idx": 3958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d33920bc-f128-4c63-87e2-0cb3eeeda48a": {"__data__": {"id_": "d33920bc-f128-4c63-87e2-0cb3eeeda48a", "embedding": null, "metadata": {"window": "We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n The third business is our McKesson Life Sciences business.  This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence.  These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market.  And McKesson is often the partner of choice throughout the lifecycle of a therapy.  As you can see,  \ntwo of our strategic imperatives, supporting specialty and the manufacturer services value proposition, are ", "original_text": "These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "325a2857-c90f-4f52-9b11-1bd035e4c4d8", "node_type": "1", "metadata": {"window": "The practices improved care and provided an enhanced patient experience and also saved Medicare \napproximately $35 million during the performance period as compared to the established benchmark.  We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n The third business is our McKesson Life Sciences business.  This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence.  These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market.  And McKesson is often the partner of choice throughout the lifecycle of a therapy. ", "original_text": "This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dda7228b8d8c67a058e50e4161fa1e09b2e33c1d84c23abc9fa376f1f532953e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6255426e-faf8-4bb5-b455-8aeff9917ace", "node_type": "1", "metadata": {"window": "The third business is our McKesson Life Sciences business.  This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence.  These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market.  And McKesson is often the partner of choice throughout the lifecycle of a therapy.  As you can see,  \ntwo of our strategic imperatives, supporting specialty and the manufacturer services value proposition, are ", "original_text": "These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market. "}, "hash": "254fbb1a9ed537338c8423c0be53f0357ee0fd6dc117e99503d6c8f12afefd8d", "class_name": "RelatedNodeInfo"}}, "text": "These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n", "start_char_idx": 3958, "end_char_idx": 4087, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6255426e-faf8-4bb5-b455-8aeff9917ace": {"__data__": {"id_": "6255426e-faf8-4bb5-b455-8aeff9917ace", "embedding": null, "metadata": {"window": "The third business is our McKesson Life Sciences business.  This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence.  These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market.  And McKesson is often the partner of choice throughout the lifecycle of a therapy.  As you can see,  \ntwo of our strategic imperatives, supporting specialty and the manufacturer services value proposition, are ", "original_text": "These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d33920bc-f128-4c63-87e2-0cb3eeeda48a", "node_type": "1", "metadata": {"window": "We are \ncommitted to ensuring that community practices have access to all the resources necessary, including access to \nclinical trials, to successfully accomplish the challenging practice transformation requi red by the OCM and the \nother value -based alternative payment models.  \n \n The third business is our McKesson Life Sciences business.  This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence.  These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market.  And McKesson is often the partner of choice throughout the lifecycle of a therapy.  As you can see,  \ntwo of our strategic imperatives, supporting specialty and the manufacturer services value proposition, are ", "original_text": "These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37108df86f868bc88ad27521906aa1b5c990a66533c8e5de7d0c8856e7c2cbaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3bf17fe-cb14-499a-8645-3a1241e9a013", "node_type": "1", "metadata": {"window": "This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence.  These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market.  And McKesson is often the partner of choice throughout the lifecycle of a therapy.  As you can see,  \ntwo of our strategic imperatives, supporting specialty and the manufacturer services value proposition, are ", "original_text": "And McKesson is often the partner of choice throughout the lifecycle of a therapy. "}, "hash": "35b27e0fc12986a963e66fd8a1ef1e3eb8c458f5da2ca0267aae049c58a51411", "class_name": "RelatedNodeInfo"}}, "text": "These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market. ", "start_char_idx": 4087, "end_char_idx": 4215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3bf17fe-cb14-499a-8645-3a1241e9a013": {"__data__": {"id_": "b3bf17fe-cb14-499a-8645-3a1241e9a013", "embedding": null, "metadata": {"window": "This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence.  These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market.  And McKesson is often the partner of choice throughout the lifecycle of a therapy.  As you can see,  \ntwo of our strategic imperatives, supporting specialty and the manufacturer services value proposition, are ", "original_text": "And McKesson is often the partner of choice throughout the lifecycle of a therapy. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6255426e-faf8-4bb5-b455-8aeff9917ace", "node_type": "1", "metadata": {"window": "The third business is our McKesson Life Sciences business.  This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence.  These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market.  And McKesson is often the partner of choice throughout the lifecycle of a therapy.  As you can see,  \ntwo of our strategic imperatives, supporting specialty and the manufacturer services value proposition, are ", "original_text": "These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "911310b40d42f9bad7c05f4a40a28f84af22c9a9d973d537b2ddaa121831592c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57a44c61-0b7a-4740-842c-54d06dbda987", "node_type": "1", "metadata": {"window": "These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market.  And McKesson is often the partner of choice throughout the lifecycle of a therapy.  As you can see,  \ntwo of our strategic imperatives, supporting specialty and the manufacturer services value proposition, are ", "original_text": "As you can see,  \ntwo of our strategic imperatives, supporting specialty and the manufacturer services value proposition, are "}, "hash": "af8abe52d16a8c8f389e9d754acf3fea18adf4cb8d521a7b9ae7d298b5236540", "class_name": "RelatedNodeInfo"}}, "text": "And McKesson is often the partner of choice throughout the lifecycle of a therapy. ", "start_char_idx": 4215, "end_char_idx": 4298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57a44c61-0b7a-4740-842c-54d06dbda987": {"__data__": {"id_": "57a44c61-0b7a-4740-842c-54d06dbda987", "embedding": null, "metadata": {"window": "These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market.  And McKesson is often the partner of choice throughout the lifecycle of a therapy.  As you can see,  \ntwo of our strategic imperatives, supporting specialty and the manufacturer services value proposition, are ", "original_text": "As you can see,  \ntwo of our strategic imperatives, supporting specialty and the manufacturer services value proposition, are ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5115b185-e381-4dac-955b-4a06264b92a1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8386fc58fae948af8fbe82223edd9755f7efea6d87ac0798b9a08655b508f5d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3bf17fe-cb14-499a-8645-3a1241e9a013", "node_type": "1", "metadata": {"window": "This business includes third -party logistics, specialty \npharmacy solutions for oncology and other rare and orphan products, pat ient access, adherence and affordability \nsolutions, clinical education services, and a suite of data services providing commercial insights and real -world \nevidence.  These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market.  And McKesson is often the partner of choice throughout the lifecycle of a therapy.  As you can see,  \ntwo of our strategic imperatives, supporting specialty and the manufacturer services value proposition, are ", "original_text": "And McKesson is often the partner of choice throughout the lifecycle of a therapy. ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d8ab119fbe1a09767e5a7b8a409066eceb9f6c513cb2b921d9b18ab4408cdf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3860da1-5f5a-42aa-a4e5-cfae38c69db9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nunderpinned by the strong portfolio of our existing offerings.  And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers.  We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services. ", "original_text": "McKesson Corp.  "}, "hash": "d48de145ccafd9ededb5b0bd1054ef293489a4f92a27bcd76e0eb6d7e27b1f06", "class_name": "RelatedNodeInfo"}}, "text": "As you can see,  \ntwo of our strategic imperatives, supporting specialty and the manufacturer services value proposition, are ", "start_char_idx": 4298, "end_char_idx": 4424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3860da1-5f5a-42aa-a4e5-cfae38c69db9": {"__data__": {"id_": "a3860da1-5f5a-42aa-a4e5-cfae38c69db9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nunderpinned by the strong portfolio of our existing offerings.  And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers.  We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57a44c61-0b7a-4740-842c-54d06dbda987", "node_type": "1", "metadata": {"window": "These services help ensure biopharma manufacturers are successful in the post -launch \ncommer cialization of their products.  \n \n These three businesses are well -positioned as innovative specialty products, including biosimilars, are coming to \nthe market.  And McKesson is often the partner of choice throughout the lifecycle of a therapy.  As you can see,  \ntwo of our strategic imperatives, supporting specialty and the manufacturer services value proposition, are ", "original_text": "As you can see,  \ntwo of our strategic imperatives, supporting specialty and the manufacturer services value proposition, are ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3042428fc7b6a6ea25a38721289386774fe44b18d6cd50f495f4c186d8a70d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cf4e140-c222-4ba1-b544-9393cdbd15d7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nunderpinned by the strong portfolio of our existing offerings.  And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers.  We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services.  We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nunderpinned by the strong portfolio of our existing offerings. "}, "hash": "eb9e0f694c9919ba56c9a8b6cd7d09cd44125fea1f7ca98a56008cdc925db740", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cf4e140-c222-4ba1-b544-9393cdbd15d7": {"__data__": {"id_": "8cf4e140-c222-4ba1-b544-9393cdbd15d7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nunderpinned by the strong portfolio of our existing offerings.  And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers.  We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services.  We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nunderpinned by the strong portfolio of our existing offerings. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3860da1-5f5a-42aa-a4e5-cfae38c69db9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nunderpinned by the strong portfolio of our existing offerings.  And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers.  We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5511ea4d2456e053362b0970d2df3d66446436e1baba14a395e081b95978d207", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0362ecd-26b6-422f-9bfa-2b0da6ffb28e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nunderpinned by the strong portfolio of our existing offerings.  And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers.  We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services.  We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n Let me turn now to Europe. ", "original_text": "And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers. "}, "hash": "712de5840e2234323a0067a002f84b4198a5a32af43362f850c54694e161cb69", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nunderpinned by the strong portfolio of our existing offerings. ", "start_char_idx": 16, "end_char_idx": 243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0362ecd-26b6-422f-9bfa-2b0da6ffb28e": {"__data__": {"id_": "b0362ecd-26b6-422f-9bfa-2b0da6ffb28e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nunderpinned by the strong portfolio of our existing offerings.  And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers.  We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services.  We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n Let me turn now to Europe. ", "original_text": "And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cf4e140-c222-4ba1-b544-9393cdbd15d7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nunderpinned by the strong portfolio of our existing offerings.  And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers.  We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services.  We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nunderpinned by the strong portfolio of our existing offerings. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "763074c594ae1d85f58630605c2ac16e62e7bd44f13ac4cc664b72b2775778f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7eafa46d-903a-4d32-a2d6-7b4a243ceb8f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nunderpinned by the strong portfolio of our existing offerings.  And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers.  We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services.  We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n Let me turn now to Europe.  As a reminder, last quarter in our U.K. ", "original_text": "We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services. "}, "hash": "19324c426a383f86ac1a30370cf45f8b7838ad84751b82cfb49ead8baffc922d", "class_name": "RelatedNodeInfo"}}, "text": "And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers. ", "start_char_idx": 243, "end_char_idx": 360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7eafa46d-903a-4d32-a2d6-7b4a243ceb8f": {"__data__": {"id_": "7eafa46d-903a-4d32-a2d6-7b4a243ceb8f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nunderpinned by the strong portfolio of our existing offerings.  And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers.  We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services.  We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n Let me turn now to Europe.  As a reminder, last quarter in our U.K. ", "original_text": "We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0362ecd-26b6-422f-9bfa-2b0da6ffb28e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nunderpinned by the strong portfolio of our existing offerings.  And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers.  We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services.  We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n Let me turn now to Europe. ", "original_text": "And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f4cbee23f5e36c02b7d03899064aa542b96f6291989d691efcd7d2aebaeeaee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "806ffb8a-a211-4041-9251-dde468d14eb8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nunderpinned by the strong portfolio of our existing offerings.  And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers.  We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services.  We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n Let me turn now to Europe.  As a reminder, last quarter in our U.K.  retail business we experienced industry -wide \nunderfunding by the NHS. ", "original_text": "We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n"}, "hash": "413865f4cccefef0f4389cdd062f154beb16d9a3739f1313001a834aadabbe57", "class_name": "RelatedNodeInfo"}}, "text": "We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services. ", "start_char_idx": 360, "end_char_idx": 461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "806ffb8a-a211-4041-9251-dde468d14eb8": {"__data__": {"id_": "806ffb8a-a211-4041-9251-dde468d14eb8", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nunderpinned by the strong portfolio of our existing offerings.  And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers.  We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services.  We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n Let me turn now to Europe.  As a reminder, last quarter in our U.K.  retail business we experienced industry -wide \nunderfunding by the NHS. ", "original_text": "We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7eafa46d-903a-4d32-a2d6-7b4a243ceb8f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nunderpinned by the strong portfolio of our existing offerings.  And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers.  We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services.  We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n Let me turn now to Europe.  As a reminder, last quarter in our U.K. ", "original_text": "We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2cbe2c34cc539bbf4067a9ca65e1bbdf84af2063a822d5e05b8ef756a184970c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f439a4a-4605-455e-bed2-8ffcab97088d", "node_type": "1", "metadata": {"window": "And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers.  We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services.  We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n Let me turn now to Europe.  As a reminder, last quarter in our U.K.  retail business we experienced industry -wide \nunderfunding by the NHS.  Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August. ", "original_text": "Let me turn now to Europe. "}, "hash": "065ce2c1d218aaf2cc573fe553c2a2e29c31f2a1aca3e06030db94146bc5b260", "class_name": "RelatedNodeInfo"}}, "text": "We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n", "start_char_idx": 461, "end_char_idx": 572, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f439a4a-4605-455e-bed2-8ffcab97088d": {"__data__": {"id_": "4f439a4a-4605-455e-bed2-8ffcab97088d", "embedding": null, "metadata": {"window": "And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers.  We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services.  We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n Let me turn now to Europe.  As a reminder, last quarter in our U.K.  retail business we experienced industry -wide \nunderfunding by the NHS.  Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August. ", "original_text": "Let me turn now to Europe. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "806ffb8a-a211-4041-9251-dde468d14eb8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nunderpinned by the strong portfolio of our existing offerings.  And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers.  We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services.  We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n Let me turn now to Europe.  As a reminder, last quarter in our U.K.  retail business we experienced industry -wide \nunderfunding by the NHS. ", "original_text": "We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9906142d4e5a2967d399fde6263a5633dd9304750e9ef0beda83eaea0967ad08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "281b25e5-e7cd-4d26-ba65-1b6824bf99cf", "node_type": "1", "metadata": {"window": "We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services.  We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n Let me turn now to Europe.  As a reminder, last quarter in our U.K.  retail business we experienced industry -wide \nunderfunding by the NHS.  Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August.  And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n", "original_text": "As a reminder, last quarter in our U.K. "}, "hash": "05489290a907864bac099023f594efa50dc6dd628c5cac96e2afbcb21059206f", "class_name": "RelatedNodeInfo"}}, "text": "Let me turn now to Europe. ", "start_char_idx": 572, "end_char_idx": 599, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "281b25e5-e7cd-4d26-ba65-1b6824bf99cf": {"__data__": {"id_": "281b25e5-e7cd-4d26-ba65-1b6824bf99cf", "embedding": null, "metadata": {"window": "We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services.  We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n Let me turn now to Europe.  As a reminder, last quarter in our U.K.  retail business we experienced industry -wide \nunderfunding by the NHS.  Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August.  And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n", "original_text": "As a reminder, last quarter in our U.K. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f439a4a-4605-455e-bed2-8ffcab97088d", "node_type": "1", "metadata": {"window": "And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers.  We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services.  We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n Let me turn now to Europe.  As a reminder, last quarter in our U.K.  retail business we experienced industry -wide \nunderfunding by the NHS.  Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August. ", "original_text": "Let me turn now to Europe. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f66b483a143be1ab2a253ecf65fb665dbafb94ea572d618655cd892fee24f37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07c4e30b-063d-454c-b976-db9b86ab5f79", "node_type": "1", "metadata": {"window": "We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n Let me turn now to Europe.  As a reminder, last quarter in our U.K.  retail business we experienced industry -wide \nunderfunding by the NHS.  Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August.  And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n Outside of the U.K. ", "original_text": "retail business we experienced industry -wide \nunderfunding by the NHS. "}, "hash": "db3194795ace640d5172b459197b5be3f7d10c5bca08f34b85f0fd91753b8e9f", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, last quarter in our U.K. ", "start_char_idx": 599, "end_char_idx": 639, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07c4e30b-063d-454c-b976-db9b86ab5f79": {"__data__": {"id_": "07c4e30b-063d-454c-b976-db9b86ab5f79", "embedding": null, "metadata": {"window": "We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n Let me turn now to Europe.  As a reminder, last quarter in our U.K.  retail business we experienced industry -wide \nunderfunding by the NHS.  Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August.  And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n Outside of the U.K. ", "original_text": "retail business we experienced industry -wide \nunderfunding by the NHS. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "281b25e5-e7cd-4d26-ba65-1b6824bf99cf", "node_type": "1", "metadata": {"window": "We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services.  We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n Let me turn now to Europe.  As a reminder, last quarter in our U.K.  retail business we experienced industry -wide \nunderfunding by the NHS.  Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August.  And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n", "original_text": "As a reminder, last quarter in our U.K. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d363295a47d710a9b788d5bf771db2b2a238289faa55f96802dc7a52341685d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb069e4a-fb33-4580-9013-91b535786003", "node_type": "1", "metadata": {"window": "Let me turn now to Europe.  As a reminder, last quarter in our U.K.  retail business we experienced industry -wide \nunderfunding by the NHS.  Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August.  And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n Outside of the U.K.  in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment. ", "original_text": "Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August. "}, "hash": "6dc8f1869b311f9f943ae0766ac83b2be4d2339c115ca8428794f6b569eace79", "class_name": "RelatedNodeInfo"}}, "text": "retail business we experienced industry -wide \nunderfunding by the NHS. ", "start_char_idx": 639, "end_char_idx": 711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb069e4a-fb33-4580-9013-91b535786003": {"__data__": {"id_": "cb069e4a-fb33-4580-9013-91b535786003", "embedding": null, "metadata": {"window": "Let me turn now to Europe.  As a reminder, last quarter in our U.K.  retail business we experienced industry -wide \nunderfunding by the NHS.  Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August.  And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n Outside of the U.K.  in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment. ", "original_text": "Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07c4e30b-063d-454c-b976-db9b86ab5f79", "node_type": "1", "metadata": {"window": "We're making these investments in order to further \nexpand our capabilities and support our future growth.  \n \n Let me turn now to Europe.  As a reminder, last quarter in our U.K.  retail business we experienced industry -wide \nunderfunding by the NHS.  Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August.  And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n Outside of the U.K. ", "original_text": "retail business we experienced industry -wide \nunderfunding by the NHS. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "194f49dda5305a25ca4ab492be48602426240f9090c10898760792e731c74782", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3087752-1ee9-4a2f-b924-90ae3e083235", "node_type": "1", "metadata": {"window": "As a reminder, last quarter in our U.K.  retail business we experienced industry -wide \nunderfunding by the NHS.  Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August.  And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n Outside of the U.K.  in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment.  Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n", "original_text": "And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n"}, "hash": "33be20aa6346488196ab6e5a138ccc7222d4454ee682e71f914609f051d82c1c", "class_name": "RelatedNodeInfo"}}, "text": "Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August. ", "start_char_idx": 711, "end_char_idx": 815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3087752-1ee9-4a2f-b924-90ae3e083235": {"__data__": {"id_": "d3087752-1ee9-4a2f-b924-90ae3e083235", "embedding": null, "metadata": {"window": "As a reminder, last quarter in our U.K.  retail business we experienced industry -wide \nunderfunding by the NHS.  Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August.  And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n Outside of the U.K.  in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment.  Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n", "original_text": "And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb069e4a-fb33-4580-9013-91b535786003", "node_type": "1", "metadata": {"window": "Let me turn now to Europe.  As a reminder, last quarter in our U.K.  retail business we experienced industry -wide \nunderfunding by the NHS.  Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August.  And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n Outside of the U.K.  in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment. ", "original_text": "Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d10b3b0e96c367ed625999efdcd694d95e47de3302663b415aaa5aebcfca0e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb3e0a63-31a6-400e-be1c-bb1faf57f44d", "node_type": "1", "metadata": {"window": "retail business we experienced industry -wide \nunderfunding by the NHS.  Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August.  And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n Outside of the U.K.  in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment.  Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n A few words on our Medical -Surgical business. ", "original_text": "Outside of the U.K. "}, "hash": "769493e9e49a99968d0da058f9c69512dc59ebcee7dfa31bd00f90aa62fc64d8", "class_name": "RelatedNodeInfo"}}, "text": "And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n", "start_char_idx": 815, "end_char_idx": 989, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb3e0a63-31a6-400e-be1c-bb1faf57f44d": {"__data__": {"id_": "eb3e0a63-31a6-400e-be1c-bb1faf57f44d", "embedding": null, "metadata": {"window": "retail business we experienced industry -wide \nunderfunding by the NHS.  Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August.  And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n Outside of the U.K.  in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment.  Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n A few words on our Medical -Surgical business. ", "original_text": "Outside of the U.K. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3087752-1ee9-4a2f-b924-90ae3e083235", "node_type": "1", "metadata": {"window": "As a reminder, last quarter in our U.K.  retail business we experienced industry -wide \nunderfunding by the NHS.  Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August.  And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n Outside of the U.K.  in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment.  Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n", "original_text": "And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1646811e3b631625ab379026f00e75cc3efa8ee2489b8cfdd9399c2d95905e70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcdba95c-b876-47cf-97ef-067252937dbf", "node_type": "1", "metadata": {"window": "Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August.  And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n Outside of the U.K.  in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment.  Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n A few words on our Medical -Surgical business.  We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care. ", "original_text": "in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment. "}, "hash": "21624b37762814cae1ff40f51a614eceb03b2832d0dce467cbb49f7965a1706c", "class_name": "RelatedNodeInfo"}}, "text": "Outside of the U.K. ", "start_char_idx": 989, "end_char_idx": 1009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcdba95c-b876-47cf-97ef-067252937dbf": {"__data__": {"id_": "dcdba95c-b876-47cf-97ef-067252937dbf", "embedding": null, "metadata": {"window": "Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August.  And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n Outside of the U.K.  in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment.  Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n A few words on our Medical -Surgical business.  We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care. ", "original_text": "in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb3e0a63-31a6-400e-be1c-bb1faf57f44d", "node_type": "1", "metadata": {"window": "retail business we experienced industry -wide \nunderfunding by the NHS.  Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August.  And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n Outside of the U.K.  in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment.  Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n A few words on our Medical -Surgical business. ", "original_text": "Outside of the U.K. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c06a4511e5dcac61282d7ba97c84257a05511ac3c39a84604ee4346920c71e4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f11fef06-7abd-4e91-bf06-5cf930e033da", "node_type": "1", "metadata": {"window": "And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n Outside of the U.K.  in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment.  Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n A few words on our Medical -Surgical business.  We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care.  McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively. ", "original_text": "Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n"}, "hash": "d63a3887cf318c053c526c43e3808b5a8b6a10850d76c77e1511729891b4a98c", "class_name": "RelatedNodeInfo"}}, "text": "in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment. ", "start_char_idx": 1009, "end_char_idx": 1127, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f11fef06-7abd-4e91-bf06-5cf930e033da": {"__data__": {"id_": "f11fef06-7abd-4e91-bf06-5cf930e033da", "embedding": null, "metadata": {"window": "And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n Outside of the U.K.  in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment.  Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n A few words on our Medical -Surgical business.  We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care.  McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively. ", "original_text": "Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcdba95c-b876-47cf-97ef-067252937dbf", "node_type": "1", "metadata": {"window": "Consistent with our expectations in July, we did see a nominal tariff increase in the \nmonth of August.  And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n Outside of the U.K.  in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment.  Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n A few words on our Medical -Surgical business.  We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care. ", "original_text": "in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfece7ebcd31a43cd5cd27405a4a9d1f136d6c052aa429d42c6a2a60d45052de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45f5c8aa-71a9-415f-b643-ce9d621358e7", "node_type": "1", "metadata": {"window": "Outside of the U.K.  in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment.  Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n A few words on our Medical -Surgical business.  We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care.  McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively.  And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S. ", "original_text": "A few words on our Medical -Surgical business. "}, "hash": "a9ddfbe4a0ba3c5d7001ef00e6001fe2cc9f9c23fd78fce87b6f6740ee85a3e1", "class_name": "RelatedNodeInfo"}}, "text": "Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n", "start_char_idx": 1127, "end_char_idx": 1208, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45f5c8aa-71a9-415f-b643-ce9d621358e7": {"__data__": {"id_": "45f5c8aa-71a9-415f-b643-ce9d621358e7", "embedding": null, "metadata": {"window": "Outside of the U.K.  in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment.  Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n A few words on our Medical -Surgical business.  We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care.  McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively.  And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S. ", "original_text": "A few words on our Medical -Surgical business. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f11fef06-7abd-4e91-bf06-5cf930e033da", "node_type": "1", "metadata": {"window": "And we do expect a further upward t ariff revision later this fiscal year, which should result in a \npartial recovery of the underfunding we've experienced year to date.  \n \n Outside of the U.K.  in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment.  Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n A few words on our Medical -Surgical business.  We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care.  McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively. ", "original_text": "Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb3de65bc87a746fa625f486c3336d9511310c5798ccb183f4f5a63497044d4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1d9b1c9-2710-4bd6-8589-83b17fecba45", "node_type": "1", "metadata": {"window": "in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment.  Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n A few words on our Medical -Surgical business.  We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care.  McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively.  And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S.  Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices. ", "original_text": "We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care. "}, "hash": "7624c4ea1e3bdc3f2df97dfc66bc1d2783a7ff9c665c70d280c2dbec09dab80e", "class_name": "RelatedNodeInfo"}}, "text": "A few words on our Medical -Surgical business. ", "start_char_idx": 1208, "end_char_idx": 1255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1d9b1c9-2710-4bd6-8589-83b17fecba45": {"__data__": {"id_": "b1d9b1c9-2710-4bd6-8589-83b17fecba45", "embedding": null, "metadata": {"window": "in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment.  Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n A few words on our Medical -Surgical business.  We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care.  McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively.  And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S.  Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices. ", "original_text": "We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45f5c8aa-71a9-415f-b643-ce9d621358e7", "node_type": "1", "metadata": {"window": "Outside of the U.K.  in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment.  Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n A few words on our Medical -Surgical business.  We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care.  McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively.  And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S. ", "original_text": "A few words on our Medical -Surgical business. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37722c4fc6d153eb3a944d40c11f47dc9559c1e05b96a6c8f70e138f18fb5670", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c81d37d9-2184-4e9f-9db6-4243b5978beb", "node_type": "1", "metadata": {"window": "Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n A few words on our Medical -Surgical business.  We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care.  McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively.  And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S.  Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices.  This continues to be an area of growth for our \nbusiness. ", "original_text": "McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively. "}, "hash": "b937c1780334ca8057cb9a461165b4d185a0ac7802af950b93c7241c4df18a04", "class_name": "RelatedNodeInfo"}}, "text": "We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care. ", "start_char_idx": 1255, "end_char_idx": 1406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c81d37d9-2184-4e9f-9db6-4243b5978beb": {"__data__": {"id_": "c81d37d9-2184-4e9f-9db6-4243b5978beb", "embedding": null, "metadata": {"window": "Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n A few words on our Medical -Surgical business.  We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care.  McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively.  And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S.  Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices.  This continues to be an area of growth for our \nbusiness. ", "original_text": "McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1d9b1c9-2710-4bd6-8589-83b17fecba45", "node_type": "1", "metadata": {"window": "in Europe, we continue to see in aggregate year -to-date performance in line with our \nexpectations for that segment.  Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n A few words on our Medical -Surgical business.  We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care.  McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively.  And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S.  Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices. ", "original_text": "We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c833e58be53f340ae163da66e053f3a00c64207c84c746ae4f1e844547453110", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "addf21ea-785b-4e79-a148-deebc9fc2eb5", "node_type": "1", "metadata": {"window": "A few words on our Medical -Surgical business.  We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care.  McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively.  And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S.  Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices.  This continues to be an area of growth for our \nbusiness.  And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n", "original_text": "And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S. "}, "hash": "c502f4605e880c46f3900eb7a91152365fd2bbd8169e06686790555bce5a6987", "class_name": "RelatedNodeInfo"}}, "text": "McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively. ", "start_char_idx": 1406, "end_char_idx": 1585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "addf21ea-785b-4e79-a148-deebc9fc2eb5": {"__data__": {"id_": "addf21ea-785b-4e79-a148-deebc9fc2eb5", "embedding": null, "metadata": {"window": "A few words on our Medical -Surgical business.  We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care.  McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively.  And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S.  Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices.  This continues to be an area of growth for our \nbusiness.  And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n", "original_text": "And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c81d37d9-2184-4e9f-9db6-4243b5978beb", "node_type": "1", "metadata": {"window": "Britt will discuss our full -year outlook for this segment in a few minutes.  \n \n A few words on our Medical -Surgical business.  We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care.  McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively.  And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S.  Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices.  This continues to be an area of growth for our \nbusiness. ", "original_text": "McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b0c203f59e24230607f8e714615efdaba866df4a3a509bd328cfb7f153881b38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8e4e24a-7dff-4b2c-9298-8df345630a97", "node_type": "1", "metadata": {"window": "We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care.  McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively.  And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S.  Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices.  This continues to be an area of growth for our \nbusiness.  And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare. ", "original_text": "Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices. "}, "hash": "4d6f61515af70b1ca749f53cdc9520285f5ce3ca7d2bf573de70035875b67721", "class_name": "RelatedNodeInfo"}}, "text": "And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S. ", "start_char_idx": 1585, "end_char_idx": 1695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8e4e24a-7dff-4b2c-9298-8df345630a97": {"__data__": {"id_": "b8e4e24a-7dff-4b2c-9298-8df345630a97", "embedding": null, "metadata": {"window": "We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care.  McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively.  And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S.  Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices.  This continues to be an area of growth for our \nbusiness.  And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare. ", "original_text": "Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "addf21ea-785b-4e79-a148-deebc9fc2eb5", "node_type": "1", "metadata": {"window": "A few words on our Medical -Surgical business.  We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care.  McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively.  And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S.  Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices.  This continues to be an area of growth for our \nbusiness.  And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n", "original_text": "And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce138562f7cab953c1d5f9733757b2662952b530d25d89225f8db13551f89b96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbfce098-4bab-4d5f-abd3-ece600e91c4f", "node_type": "1", "metadata": {"window": "McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively.  And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S.  Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices.  This continues to be an area of growth for our \nbusiness.  And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus. ", "original_text": "This continues to be an area of growth for our \nbusiness. "}, "hash": "177f915a39ef1eed4ee77f1850ff00362b6b7f5529281f0ba7e576608e84a527", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices. ", "start_char_idx": 1695, "end_char_idx": 1827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbfce098-4bab-4d5f-abd3-ece600e91c4f": {"__data__": {"id_": "dbfce098-4bab-4d5f-abd3-ece600e91c4f", "embedding": null, "metadata": {"window": "McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively.  And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S.  Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices.  This continues to be an area of growth for our \nbusiness.  And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus. ", "original_text": "This continues to be an area of growth for our \nbusiness. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8e4e24a-7dff-4b2c-9298-8df345630a97", "node_type": "1", "metadata": {"window": "We continue to see above -market growth as we operate in strong \nmarkets and [ph] care (11:12) shifts out of the hospital  to alternate sites of care.  McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively.  And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S.  Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices.  This continues to be an area of growth for our \nbusiness.  And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare. ", "original_text": "Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c813d1148931f8872dcc424e2824bc2a5f1a38fcffaeaf649f3b915ab04b2f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c64be524-0588-4166-a170-d6791e7db736", "node_type": "1", "metadata": {"window": "And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S.  Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices.  This continues to be an area of growth for our \nbusiness.  And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus.  We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada. ", "original_text": "And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n"}, "hash": "a4cbf5a7c4c8fed2a8b0703cc5e1bb9c3db6a8613f47d7b8955e57ab1f63fe9e", "class_name": "RelatedNodeInfo"}}, "text": "This continues to be an area of growth for our \nbusiness. ", "start_char_idx": 1827, "end_char_idx": 1885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c64be524-0588-4166-a170-d6791e7db736": {"__data__": {"id_": "c64be524-0588-4166-a170-d6791e7db736", "embedding": null, "metadata": {"window": "And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S.  Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices.  This continues to be an area of growth for our \nbusiness.  And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus.  We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada. ", "original_text": "And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbfce098-4bab-4d5f-abd3-ece600e91c4f", "node_type": "1", "metadata": {"window": "McKesson has a full range of \nproducts and services for our physician, health system, post -acute, and home care provider customers, so we can \nserve their needs comprehensively.  And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S.  Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices.  This continues to be an area of growth for our \nbusiness.  And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus. ", "original_text": "This continues to be an area of growth for our \nbusiness. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c541dbda2f88464880f729562c1862e52f60680e7efba48d551d4d110135dfa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b29348b3-faae-428a-a760-61d1707e2b4d", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices.  This continues to be an area of growth for our \nbusiness.  And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus.  We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada.  This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients. ", "original_text": "Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare. "}, "hash": "eef93b73064313e395a6b84e84d595265ba5f32489c2914632bfd50f28770ce9", "class_name": "RelatedNodeInfo"}}, "text": "And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n", "start_char_idx": 1885, "end_char_idx": 2084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b29348b3-faae-428a-a760-61d1707e2b4d": {"__data__": {"id_": "b29348b3-faae-428a-a760-61d1707e2b4d", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices.  This continues to be an area of growth for our \nbusiness.  And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus.  We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada.  This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients. ", "original_text": "Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c64be524-0588-4166-a170-d6791e7db736", "node_type": "1", "metadata": {"window": "And our customers benefit from our enterprise mind -set as our Med -Surg \nteam partners closely with our U.S.  Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices.  This continues to be an area of growth for our \nbusiness.  And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus.  We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada. ", "original_text": "And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e0afdedb39f8ec52eeef71d4859061eae4bf7256188ca06e13b24239b85ed8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3598aa8-6046-40e8-aa65-67b415e02a01", "node_type": "1", "metadata": {"window": "This continues to be an area of growth for our \nbusiness.  And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus.  We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada.  This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients.  I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n", "original_text": "As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus. "}, "hash": "c04bab3e5a861a61ebcdc3e518cb993c257ca85fa2a27dcb023c7a376171387b", "class_name": "RelatedNodeInfo"}}, "text": "Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare. ", "start_char_idx": 2084, "end_char_idx": 2247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3598aa8-6046-40e8-aa65-67b415e02a01": {"__data__": {"id_": "a3598aa8-6046-40e8-aa65-67b415e02a01", "embedding": null, "metadata": {"window": "This continues to be an area of growth for our \nbusiness.  And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus.  We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada.  This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients.  I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n", "original_text": "As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b29348b3-faae-428a-a760-61d1707e2b4d", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions business to ensure physicians \nreceive the pharmaceuticals they need to run their practices.  This continues to be an area of growth for our \nbusiness.  And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus.  We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada.  This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients. ", "original_text": "Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79a64c170d09a820a3db18d471b37c1df29d9a5c0e18cfe4d00a90a27bf5b445", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fee208b-bbc0-4b0d-9127-604e03300c2a", "node_type": "1", "metadata": {"window": "And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus.  We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada.  This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients.  I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n Moving on to MRxTS, the business continues to show strong growth in both new and existing products. ", "original_text": "We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada. "}, "hash": "e0fb353f99855c8518915f4c732c83a03dd8207804aeab728613620489f030bb", "class_name": "RelatedNodeInfo"}}, "text": "As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus. ", "start_char_idx": 2247, "end_char_idx": 2445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fee208b-bbc0-4b0d-9127-604e03300c2a": {"__data__": {"id_": "7fee208b-bbc0-4b0d-9127-604e03300c2a", "embedding": null, "metadata": {"window": "And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus.  We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada.  This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients.  I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n Moving on to MRxTS, the business continues to show strong growth in both new and existing products. ", "original_text": "We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3598aa8-6046-40e8-aa65-67b415e02a01", "node_type": "1", "metadata": {"window": "This continues to be an area of growth for our \nbusiness.  And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus.  We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada.  This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients.  I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n", "original_text": "As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74aea2781749f73603d74ab9b5ee10e30c087137bd8152a2c02cbfcb628e6dcc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67270314-9332-486d-8700-7f5ea1cc7b20", "node_type": "1", "metadata": {"window": "Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus.  We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada.  This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients.  I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n Moving on to MRxTS, the business continues to show strong growth in both new and existing products.  In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization. ", "original_text": "This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients. "}, "hash": "6a82aa741f738576aff9a787ca315a931fb2d20e3b71dcabbcda3bdb1ec6100c", "class_name": "RelatedNodeInfo"}}, "text": "We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada. ", "start_char_idx": 2445, "end_char_idx": 2686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67270314-9332-486d-8700-7f5ea1cc7b20": {"__data__": {"id_": "67270314-9332-486d-8700-7f5ea1cc7b20", "embedding": null, "metadata": {"window": "Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus.  We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada.  This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients.  I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n Moving on to MRxTS, the business continues to show strong growth in both new and existing products.  In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization. ", "original_text": "This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fee208b-bbc0-4b0d-9127-604e03300c2a", "node_type": "1", "metadata": {"window": "And the MSD acquisition, which we fully lapped in the first quarter, is on track with its planned \nintegration as we work to consolidate the business and position ourselves to effectively scale.  \n \n Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus.  We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada.  This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients.  I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n Moving on to MRxTS, the business continues to show strong growth in both new and existing products. ", "original_text": "We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad7c6ad0654bcf4112dbe020034c1efa15212bdcae3f9b84489879260ee3d57e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1281a9c4-b649-4315-adad-d5463339ef7a", "node_type": "1", "metadata": {"window": "As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus.  We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada.  This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients.  I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n Moving on to MRxTS, the business continues to show strong growth in both new and existing products.  In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization.  During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications. ", "original_text": "I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n"}, "hash": "22dbac32dab0092a6f0eba1f7fed0cd861dc2bea28f1d3167fec4f514267ceb0", "class_name": "RelatedNodeInfo"}}, "text": "This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients. ", "start_char_idx": 2686, "end_char_idx": 2876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1281a9c4-b649-4315-adad-d5463339ef7a": {"__data__": {"id_": "1281a9c4-b649-4315-adad-d5463339ef7a", "embedding": null, "metadata": {"window": "As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus.  We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada.  This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients.  I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n Moving on to MRxTS, the business continues to show strong growth in both new and existing products.  In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization.  During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications. ", "original_text": "I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67270314-9332-486d-8700-7f5ea1cc7b20", "node_type": "1", "metadata": {"window": "Turning to the Other segment, which primarily consists of Canada, McKesso n Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus.  We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada.  This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients.  I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n Moving on to MRxTS, the business continues to show strong growth in both new and existing products.  In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization. ", "original_text": "This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "90a6ce5f243f5b4e43171171b9cf1b194b79c45ca8281e8113363ec1899b9d32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b8b528a-063a-4b9b-8ff1-25401bb5c272", "node_type": "1", "metadata": {"window": "We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada.  This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients.  I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n Moving on to MRxTS, the business continues to show strong growth in both new and existing products.  In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization.  During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications.  This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n", "original_text": "Moving on to MRxTS, the business continues to show strong growth in both new and existing products. "}, "hash": "4ad4ebd929e731354d8a028016a36935570a8678f6eb45bae39b470064156495", "class_name": "RelatedNodeInfo"}}, "text": "I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n", "start_char_idx": 2876, "end_char_idx": 3009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b8b528a-063a-4b9b-8ff1-25401bb5c272": {"__data__": {"id_": "9b8b528a-063a-4b9b-8ff1-25401bb5c272", "embedding": null, "metadata": {"window": "We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada.  This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients.  I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n Moving on to MRxTS, the business continues to show strong growth in both new and existing products.  In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization.  During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications.  This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n", "original_text": "Moving on to MRxTS, the business continues to show strong growth in both new and existing products. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1281a9c4-b649-4315-adad-d5463339ef7a", "node_type": "1", "metadata": {"window": "As we evaluate ways to further leverage the scale and \nexpertise of our businesses in Canada, we've recently streamlined our leadership team structure into a retail and \nwholesale operations focus.  We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada.  This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients.  I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n Moving on to MRxTS, the business continues to show strong growth in both new and existing products.  In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization.  During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications. ", "original_text": "I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1da3e46d3f4e79bc1f2b8617ff6420d262f4269f6addcdc22e78734da21130c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f9f2496-560e-43f1-95b3-4bd1cd2a2a60", "node_type": "1", "metadata": {"window": "This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients.  I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n Moving on to MRxTS, the business continues to show strong growth in both new and existing products.  In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization.  During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications.  This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly. ", "original_text": "In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization. "}, "hash": "1e5ee53d5af5cc8d676f066cd05fa595f5cfad6564b439cbe7ab22d96250b48a", "class_name": "RelatedNodeInfo"}}, "text": "Moving on to MRxTS, the business continues to show strong growth in both new and existing products. ", "start_char_idx": 3009, "end_char_idx": 3109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f9f2496-560e-43f1-95b3-4bd1cd2a2a60": {"__data__": {"id_": "1f9f2496-560e-43f1-95b3-4bd1cd2a2a60", "embedding": null, "metadata": {"window": "This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients.  I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n Moving on to MRxTS, the business continues to show strong growth in both new and existing products.  In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization.  During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications.  This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly. ", "original_text": "In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b8b528a-063a-4b9b-8ff1-25401bb5c272", "node_type": "1", "metadata": {"window": "We've introduced two new Senior Vice President positions responsible for leading the \ncore operating businesses of retail, which includes digital and loyalty programs and our distribution solutions and \nspecialty health business i n Canada.  This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients.  I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n Moving on to MRxTS, the business continues to show strong growth in both new and existing products.  In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization.  During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications.  This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n", "original_text": "Moving on to MRxTS, the business continues to show strong growth in both new and existing products. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16e4e3917ca2778ad45dc763f652c042fe1e272a22a5efb0549c5a9575b4d04c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "736a8b79-1aa7-4f96-b8d4-461c88b3a369", "node_type": "1", "metadata": {"window": "I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n Moving on to MRxTS, the business continues to show strong growth in both new and existing products.  In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization.  During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications.  This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly.  In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S. ", "original_text": "During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications. "}, "hash": "41d843b78280e07b1f75b5e9754f086bd7698ebd6a8b338bc2b6f2ac52fd5976", "class_name": "RelatedNodeInfo"}}, "text": "In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization. ", "start_char_idx": 3109, "end_char_idx": 3249, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "736a8b79-1aa7-4f96-b8d4-461c88b3a369": {"__data__": {"id_": "736a8b79-1aa7-4f96-b8d4-461c88b3a369", "embedding": null, "metadata": {"window": "I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n Moving on to MRxTS, the business continues to show strong growth in both new and existing products.  In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization.  During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications.  This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly.  In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S. ", "original_text": "During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f9f2496-560e-43f1-95b3-4bd1cd2a2a60", "node_type": "1", "metadata": {"window": "This strategic change will enable our Canadian operations to work even \nbetter together as we deepen relationships with manufacturers and retail partners and drive real value for \npatients.  I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n Moving on to MRxTS, the business continues to show strong growth in both new and existing products.  In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization.  During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications.  This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly. ", "original_text": "In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1163fe92179942889f9b7656bd7adaa4f096a584f17efb437c675832d4daaffc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0c5e3fa-0c10-4d6b-9097-aab185a556b9", "node_type": "1", "metadata": {"window": "Moving on to MRxTS, the business continues to show strong growth in both new and existing products.  In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization.  During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications.  This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly.  In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S.  to access their specialty medications 27% faster than traditional hub \nprograms, fundamentally improving the way patient support is provide d. AMP also provides high -touch services \nfor patient cases that need intervention support beyond the automated technology platform, such as proactive \nclinical support, behavioral coaching, and financial assistance, improving adherence and helping to suppor t better \noutcomes for patients. ", "original_text": "This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n"}, "hash": "b6af72386e293b0cc7c95cde74918a5eab75528d833c694988c1f1d9bbeaa802", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications. ", "start_char_idx": 3249, "end_char_idx": 3526, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0c5e3fa-0c10-4d6b-9097-aab185a556b9": {"__data__": {"id_": "a0c5e3fa-0c10-4d6b-9097-aab185a556b9", "embedding": null, "metadata": {"window": "Moving on to MRxTS, the business continues to show strong growth in both new and existing products.  In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization.  During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications.  This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly.  In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S.  to access their specialty medications 27% faster than traditional hub \nprograms, fundamentally improving the way patient support is provide d. AMP also provides high -touch services \nfor patient cases that need intervention support beyond the automated technology platform, such as proactive \nclinical support, behavioral coaching, and financial assistance, improving adherence and helping to suppor t better \noutcomes for patients. ", "original_text": "This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "736a8b79-1aa7-4f96-b8d4-461c88b3a369", "node_type": "1", "metadata": {"window": "I believe we have the right talent to move the company for ward and contribute to a better healthcare \nsystem for all Canadians.  \n \n Moving on to MRxTS, the business continues to show strong growth in both new and existing products.  In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization.  During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications.  This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly.  In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S. ", "original_text": "During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8e35a9325718eb905ad46c785ac55833d458ad20680a9abf3348b51fc7ee4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a44a30ba-1226-4b26-ba36-4c4916f13326", "node_type": "1", "metadata": {"window": "In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization.  During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications.  This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly.  In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S.  to access their specialty medications 27% faster than traditional hub \nprograms, fundamentally improving the way patient support is provide d. AMP also provides high -touch services \nfor patient cases that need intervention support beyond the automated technology platform, such as proactive \nclinical support, behavioral coaching, and financial assistance, improving adherence and helping to suppor t better \noutcomes for patients.  We're very excited about this cross -collaboration, as it again exemplifies our mission to ", "original_text": "The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly. "}, "hash": "59a6a31ee740b0f6b6c229667be41e8bff67120b5d52f9069757a8968d12bf2c", "class_name": "RelatedNodeInfo"}}, "text": "This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n", "start_char_idx": 3526, "end_char_idx": 3832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a44a30ba-1226-4b26-ba36-4c4916f13326": {"__data__": {"id_": "a44a30ba-1226-4b26-ba36-4c4916f13326", "embedding": null, "metadata": {"window": "In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization.  During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications.  This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly.  In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S.  to access their specialty medications 27% faster than traditional hub \nprograms, fundamentally improving the way patient support is provide d. AMP also provides high -touch services \nfor patient cases that need intervention support beyond the automated technology platform, such as proactive \nclinical support, behavioral coaching, and financial assistance, improving adherence and helping to suppor t better \noutcomes for patients.  We're very excited about this cross -collaboration, as it again exemplifies our mission to ", "original_text": "The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0c5e3fa-0c10-4d6b-9097-aab185a556b9", "node_type": "1", "metadata": {"window": "Moving on to MRxTS, the business continues to show strong growth in both new and existing products.  In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization.  During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications.  This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly.  In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S.  to access their specialty medications 27% faster than traditional hub \nprograms, fundamentally improving the way patient support is provide d. AMP also provides high -touch services \nfor patient cases that need intervention support beyond the automated technology platform, such as proactive \nclinical support, behavioral coaching, and financial assistance, improving adherence and helping to suppor t better \noutcomes for patients. ", "original_text": "This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a0fc146b02338b0bf9ea7a243193f1eff1a123f30d29d46519752469e2d50cab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40ca992b-0989-4e36-9d1e-5a2aea990e6f", "node_type": "1", "metadata": {"window": "During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications.  This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly.  In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S.  to access their specialty medications 27% faster than traditional hub \nprograms, fundamentally improving the way patient support is provide d. AMP also provides high -touch services \nfor patient cases that need intervention support beyond the automated technology platform, such as proactive \nclinical support, behavioral coaching, and financial assistance, improving adherence and helping to suppor t better \noutcomes for patients.  We're very excited about this cross -collaboration, as it again exemplifies our mission to ", "original_text": "In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S. "}, "hash": "b1ba1974d0f26e3e22c7bdcd114b7cae0db6ce2c7caf6f390e8de009008e5414", "class_name": "RelatedNodeInfo"}}, "text": "The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly. ", "start_char_idx": 3832, "end_char_idx": 4005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40ca992b-0989-4e36-9d1e-5a2aea990e6f": {"__data__": {"id_": "40ca992b-0989-4e36-9d1e-5a2aea990e6f", "embedding": null, "metadata": {"window": "During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications.  This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly.  In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S.  to access their specialty medications 27% faster than traditional hub \nprograms, fundamentally improving the way patient support is provide d. AMP also provides high -touch services \nfor patient cases that need intervention support beyond the automated technology platform, such as proactive \nclinical support, behavioral coaching, and financial assistance, improving adherence and helping to suppor t better \noutcomes for patients.  We're very excited about this cross -collaboration, as it again exemplifies our mission to ", "original_text": "In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a44a30ba-1226-4b26-ba36-4c4916f13326", "node_type": "1", "metadata": {"window": "In \naddition, our CoverMyMeds business, which is focused on electronic prior authorization, continues to innovate \nacross the organization.  During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications.  This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly.  In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S.  to access their specialty medications 27% faster than traditional hub \nprograms, fundamentally improving the way patient support is provide d. AMP also provides high -touch services \nfor patient cases that need intervention support beyond the automated technology platform, such as proactive \nclinical support, behavioral coaching, and financial assistance, improving adherence and helping to suppor t better \noutcomes for patients.  We're very excited about this cross -collaboration, as it again exemplifies our mission to ", "original_text": "The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05f6a0fa23c473dc0c33c4ed381ea31fab57312c3e4ad013656af3217e01a3aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24e5f9a1-2c35-4875-ad47-2a1eb2951334", "node_type": "1", "metadata": {"window": "This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly.  In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S.  to access their specialty medications 27% faster than traditional hub \nprograms, fundamentally improving the way patient support is provide d. AMP also provides high -touch services \nfor patient cases that need intervention support beyond the automated technology platform, such as proactive \nclinical support, behavioral coaching, and financial assistance, improving adherence and helping to suppor t better \noutcomes for patients.  We're very excited about this cross -collaboration, as it again exemplifies our mission to ", "original_text": "to access their specialty medications 27% faster than traditional hub \nprograms, fundamentally improving the way patient support is provide d. AMP also provides high -touch services \nfor patient cases that need intervention support beyond the automated technology platform, such as proactive \nclinical support, behavioral coaching, and financial assistance, improving adherence and helping to suppor t better \noutcomes for patients. "}, "hash": "30c660d000793848ba430a6e238bdb47df5b51006bf0f2d144b69eada522aff4", "class_name": "RelatedNodeInfo"}}, "text": "In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S. ", "start_char_idx": 4005, "end_char_idx": 4088, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24e5f9a1-2c35-4875-ad47-2a1eb2951334": {"__data__": {"id_": "24e5f9a1-2c35-4875-ad47-2a1eb2951334", "embedding": null, "metadata": {"window": "This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly.  In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S.  to access their specialty medications 27% faster than traditional hub \nprograms, fundamentally improving the way patient support is provide d. AMP also provides high -touch services \nfor patient cases that need intervention support beyond the automated technology platform, such as proactive \nclinical support, behavioral coaching, and financial assistance, improving adherence and helping to suppor t better \noutcomes for patients.  We're very excited about this cross -collaboration, as it again exemplifies our mission to ", "original_text": "to access their specialty medications 27% faster than traditional hub \nprograms, fundamentally improving the way patient support is provide d. AMP also provides high -touch services \nfor patient cases that need intervention support beyond the automated technology platform, such as proactive \nclinical support, behavioral coaching, and financial assistance, improving adherence and helping to suppor t better \noutcomes for patients. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40ca992b-0989-4e36-9d1e-5a2aea990e6f", "node_type": "1", "metadata": {"window": "During the quarter, CoverMyMeds and RxCrossroads by McKesson announced the \nlaunch of AMP, which stands for Access for More Patients, a first -in-class, technology -driven patient -support \nsolution that transforms how patients access, afford, and adhere to their medications.  This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly.  In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S.  to access their specialty medications 27% faster than traditional hub \nprograms, fundamentally improving the way patient support is provide d. AMP also provides high -touch services \nfor patient cases that need intervention support beyond the automated technology platform, such as proactive \nclinical support, behavioral coaching, and financial assistance, improving adherence and helping to suppor t better \noutcomes for patients.  We're very excited about this cross -collaboration, as it again exemplifies our mission to ", "original_text": "In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a511e9cb3a76beaa4d7ecdd89130e37ec47664fa4f6e8c304ae18433fc22523e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc96eb87-e502-4766-be24-43ee305d1451", "node_type": "1", "metadata": {"window": "The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly.  In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S.  to access their specialty medications 27% faster than traditional hub \nprograms, fundamentally improving the way patient support is provide d. AMP also provides high -touch services \nfor patient cases that need intervention support beyond the automated technology platform, such as proactive \nclinical support, behavioral coaching, and financial assistance, improving adherence and helping to suppor t better \noutcomes for patients.  We're very excited about this cross -collaboration, as it again exemplifies our mission to ", "original_text": "We're very excited about this cross -collaboration, as it again exemplifies our mission to "}, "hash": "7cac87a6a3361ce99f512cf6959af59903c098913e2e936c25252fc2c0cf8010", "class_name": "RelatedNodeInfo"}}, "text": "to access their specialty medications 27% faster than traditional hub \nprograms, fundamentally improving the way patient support is provide d. AMP also provides high -touch services \nfor patient cases that need intervention support beyond the automated technology platform, such as proactive \nclinical support, behavioral coaching, and financial assistance, improving adherence and helping to suppor t better \noutcomes for patients. ", "start_char_idx": 4088, "end_char_idx": 4521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc96eb87-e502-4766-be24-43ee305d1451": {"__data__": {"id_": "bc96eb87-e502-4766-be24-43ee305d1451", "embedding": null, "metadata": {"window": "The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly.  In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S.  to access their specialty medications 27% faster than traditional hub \nprograms, fundamentally improving the way patient support is provide d. AMP also provides high -touch services \nfor patient cases that need intervention support beyond the automated technology platform, such as proactive \nclinical support, behavioral coaching, and financial assistance, improving adherence and helping to suppor t better \noutcomes for patients.  We're very excited about this cross -collaboration, as it again exemplifies our mission to ", "original_text": "We're very excited about this cross -collaboration, as it again exemplifies our mission to ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19ba0d02-650b-49fe-901a-dabf020f901c", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b2df600fbf05303348bb90e815bfdf558a0e14c7e8d263853e1ae32a5b056cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24e5f9a1-2c35-4875-ad47-2a1eb2951334", "node_type": "1", "metadata": {"window": "This collaboration brings \ntogether the robust technology platform and established provider network of CoverMyMeds with the deep \nspecialty experience and commercialization experti se of RxCrossroads by McKesson and is designed to \nautomate access to specialty medications for physicians and patients.  \n \n The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly.  In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S.  to access their specialty medications 27% faster than traditional hub \nprograms, fundamentally improving the way patient support is provide d. AMP also provides high -touch services \nfor patient cases that need intervention support beyond the automated technology platform, such as proactive \nclinical support, behavioral coaching, and financial assistance, improving adherence and helping to suppor t better \noutcomes for patients.  We're very excited about this cross -collaboration, as it again exemplifies our mission to ", "original_text": "to access their specialty medications 27% faster than traditional hub \nprograms, fundamentally improving the way patient support is provide d. AMP also provides high -touch services \nfor patient cases that need intervention support beyond the automated technology platform, such as proactive \nclinical support, behavioral coaching, and financial assistance, improving adherence and helping to suppor t better \noutcomes for patients. ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "775815161a453afcfd40db3faf363fd38b7f7014310d65570cec34ae1d742bc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1c405d5-01f3-4f94-a474-c2bdc6c57b65", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nimprove patient care by providing innovative service offerings and demonstrates the value of our McKesson team \nand our broad set of ca pabilities.  This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n Let's move on to Change Healthcare. ", "original_text": "McKesson Corp.  "}, "hash": "496273552e869864eee594a63a95638a8752c289d41e76ec95ba359d18757350", "class_name": "RelatedNodeInfo"}}, "text": "We're very excited about this cross -collaboration, as it again exemplifies our mission to ", "start_char_idx": 4521, "end_char_idx": 4612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1c405d5-01f3-4f94-a474-c2bdc6c57b65": {"__data__": {"id_": "f1c405d5-01f3-4f94-a474-c2bdc6c57b65", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nimprove patient care by providing innovative service offerings and demonstrates the value of our McKesson team \nand our broad set of ca pabilities.  This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n Let's move on to Change Healthcare. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc96eb87-e502-4766-be24-43ee305d1451", "node_type": "1", "metadata": {"window": "The traditional hub model has had complex requirements and many times relied on time -consuming manual \nprocesses, which typically delay treatment, sometimes significantly.  In our pilot case study, McKesson's AMP \nsolution enabled patients across the U.S.  to access their specialty medications 27% faster than traditional hub \nprograms, fundamentally improving the way patient support is provide d. AMP also provides high -touch services \nfor patient cases that need intervention support beyond the automated technology platform, such as proactive \nclinical support, behavioral coaching, and financial assistance, improving adherence and helping to suppor t better \noutcomes for patients.  We're very excited about this cross -collaboration, as it again exemplifies our mission to ", "original_text": "We're very excited about this cross -collaboration, as it again exemplifies our mission to ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2f0bf4671b5d307835d7f8839081883b5f03b45b458f35e1534647b248129e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77e77a9c-e9de-4004-adc3-43ad61205216", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nimprove patient care by providing innovative service offerings and demonstrates the value of our McKesson team \nand our broad set of ca pabilities.  This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n Let's move on to Change Healthcare.  Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nimprove patient care by providing innovative service offerings and demonstrates the value of our McKesson team \nand our broad set of ca pabilities. "}, "hash": "17cc5a6313712569915d697319f60451ce2305466224ac5a6cb9d2518d591ea5", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77e77a9c-e9de-4004-adc3-43ad61205216": {"__data__": {"id_": "77e77a9c-e9de-4004-adc3-43ad61205216", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nimprove patient care by providing innovative service offerings and demonstrates the value of our McKesson team \nand our broad set of ca pabilities.  This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n Let's move on to Change Healthcare.  Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nimprove patient care by providing innovative service offerings and demonstrates the value of our McKesson team \nand our broad set of ca pabilities. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1c405d5-01f3-4f94-a474-c2bdc6c57b65", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nimprove patient care by providing innovative service offerings and demonstrates the value of our McKesson team \nand our broad set of ca pabilities.  This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n Let's move on to Change Healthcare. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48684446f5821a7675f8f8c245ba3f93bbbbe98b26f65775a7b86b1edeb2b482", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95d1e874-fccc-4b33-984c-9b5300818c57", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nimprove patient care by providing innovative service offerings and demonstrates the value of our McKesson team \nand our broad set of ca pabilities.  This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n Let's move on to Change Healthcare.  Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company.  It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses. ", "original_text": "This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n"}, "hash": "076d27a5aad205a5b3f9d62ebe0d65d9480216359718011f1b36e8035f02b8f7", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nimprove patient care by providing innovative service offerings and demonstrates the value of our McKesson team \nand our broad set of ca pabilities. ", "start_char_idx": 16, "end_char_idx": 328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95d1e874-fccc-4b33-984c-9b5300818c57": {"__data__": {"id_": "95d1e874-fccc-4b33-984c-9b5300818c57", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nimprove patient care by providing innovative service offerings and demonstrates the value of our McKesson team \nand our broad set of ca pabilities.  This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n Let's move on to Change Healthcare.  Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company.  It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses. ", "original_text": "This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77e77a9c-e9de-4004-adc3-43ad61205216", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nimprove patient care by providing innovative service offerings and demonstrates the value of our McKesson team \nand our broad set of ca pabilities.  This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n Let's move on to Change Healthcare.  Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nimprove patient care by providing innovative service offerings and demonstrates the value of our McKesson team \nand our broad set of ca pabilities. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bae824d5febf195893e5488f2341377a72298b121dd72db8753d942df0bb128", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6dfc654a-971b-4639-b39a-b1276ef75c70", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nimprove patient care by providing innovative service offerings and demonstrates the value of our McKesson team \nand our broad set of ca pabilities.  This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n Let's move on to Change Healthcare.  Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company.  It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses.  We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner. ", "original_text": "Let's move on to Change Healthcare. "}, "hash": "cbd1ff9b60c5d70c53e16f59e68eb128726d9cab44399c85cfe02a398e70bdec", "class_name": "RelatedNodeInfo"}}, "text": "This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n", "start_char_idx": 328, "end_char_idx": 422, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6dfc654a-971b-4639-b39a-b1276ef75c70": {"__data__": {"id_": "6dfc654a-971b-4639-b39a-b1276ef75c70", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nimprove patient care by providing innovative service offerings and demonstrates the value of our McKesson team \nand our broad set of ca pabilities.  This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n Let's move on to Change Healthcare.  Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company.  It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses.  We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner. ", "original_text": "Let's move on to Change Healthcare. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95d1e874-fccc-4b33-984c-9b5300818c57", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nimprove patient care by providing innovative service offerings and demonstrates the value of our McKesson team \nand our broad set of ca pabilities.  This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n Let's move on to Change Healthcare.  Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company.  It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses. ", "original_text": "This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a58fd31d6b9b71c8655186833aac79b1584b3a009da37e65de00a28da7393e65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5838afb-62a0-4861-9244-0a8f74ea0720", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nimprove patient care by providing innovative service offerings and demonstrates the value of our McKesson team \nand our broad set of ca pabilities.  This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n Let's move on to Change Healthcare.  Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company.  It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses.  We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner.  This drove certain charges that impacted our results for the second quarter. ", "original_text": "Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company. "}, "hash": "ad8a876c3412dbd776cb086329b0d693306cd4c92de03688b4be1b707cdd4112", "class_name": "RelatedNodeInfo"}}, "text": "Let's move on to Change Healthcare. ", "start_char_idx": 422, "end_char_idx": 458, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5838afb-62a0-4861-9244-0a8f74ea0720": {"__data__": {"id_": "d5838afb-62a0-4861-9244-0a8f74ea0720", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nimprove patient care by providing innovative service offerings and demonstrates the value of our McKesson team \nand our broad set of ca pabilities.  This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n Let's move on to Change Healthcare.  Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company.  It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses.  We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner.  This drove certain charges that impacted our results for the second quarter. ", "original_text": "Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6dfc654a-971b-4639-b39a-b1276ef75c70", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nimprove patient care by providing innovative service offerings and demonstrates the value of our McKesson team \nand our broad set of ca pabilities.  This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n Let's move on to Change Healthcare.  Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company.  It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses.  We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner. ", "original_text": "Let's move on to Change Healthcare. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91d5345dfa1e6b6be0ed921db197e6c90016953a1f9dc689dff898c0c8b64e79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eaff5322-c47c-4736-9eaa-a6cd4a46b7d9", "node_type": "1", "metadata": {"window": "This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n Let's move on to Change Healthcare.  Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company.  It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses.  We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner.  This drove certain charges that impacted our results for the second quarter.  Britt will walk you \nthrough these accounting details later in the call.  \n \n", "original_text": "It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses. "}, "hash": "39f35bf9c49d338eb0e99fbec58fd2fc10e1f4a76038a250545fa3df4a5bb413", "class_name": "RelatedNodeInfo"}}, "text": "Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company. ", "start_char_idx": 458, "end_char_idx": 623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eaff5322-c47c-4736-9eaa-a6cd4a46b7d9": {"__data__": {"id_": "eaff5322-c47c-4736-9eaa-a6cd4a46b7d9", "embedding": null, "metadata": {"window": "This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n Let's move on to Change Healthcare.  Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company.  It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses.  We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner.  This drove certain charges that impacted our results for the second quarter.  Britt will walk you \nthrough these accounting details later in the call.  \n \n", "original_text": "It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5838afb-62a0-4861-9244-0a8f74ea0720", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nimprove patient care by providing innovative service offerings and demonstrates the value of our McKesson team \nand our broad set of ca pabilities.  This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n Let's move on to Change Healthcare.  Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company.  It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses.  We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner.  This drove certain charges that impacted our results for the second quarter. ", "original_text": "Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cf1800c9a26c04610670bd99d8f07bbc541adf3c9c708e2b9b278166b84a4c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6dcf2b61-add2-4e65-a364-25ae9992674d", "node_type": "1", "metadata": {"window": "Let's move on to Change Healthcare.  Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company.  It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses.  We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner.  This drove certain charges that impacted our results for the second quarter.  Britt will walk you \nthrough these accounting details later in the call.  \n \n In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy. ", "original_text": "We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner. "}, "hash": "eb218181c9019ed4d6d1122e07783f33771b4901afcf493c67b9dca9c0293cdb", "class_name": "RelatedNodeInfo"}}, "text": "It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses. ", "start_char_idx": 623, "end_char_idx": 777, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6dcf2b61-add2-4e65-a364-25ae9992674d": {"__data__": {"id_": "6dcf2b61-add2-4e65-a364-25ae9992674d", "embedding": null, "metadata": {"window": "Let's move on to Change Healthcare.  Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company.  It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses.  We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner.  This drove certain charges that impacted our results for the second quarter.  Britt will walk you \nthrough these accounting details later in the call.  \n \n In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy. ", "original_text": "We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eaff5322-c47c-4736-9eaa-a6cd4a46b7d9", "node_type": "1", "metadata": {"window": "This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n Let's move on to Change Healthcare.  Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company.  It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses.  We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner.  This drove certain charges that impacted our results for the second quarter.  Britt will walk you \nthrough these accounting details later in the call.  \n \n", "original_text": "It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "271a7c53ac0723b291dec41f654e4287c66e3b688d8d80f7ceec6a16812b0d2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93741a31-05b0-4d89-a307-41c7815069a2", "node_type": "1", "metadata": {"window": "Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company.  It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses.  We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner.  This drove certain charges that impacted our results for the second quarter.  Britt will walk you \nthrough these accounting details later in the call.  \n \n In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy.  It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future. ", "original_text": "This drove certain charges that impacted our results for the second quarter. "}, "hash": "66223f1a98da56ca3715707eaee2a94185d2147b884d316d19dd889d5b51e2c3", "class_name": "RelatedNodeInfo"}}, "text": "We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner. ", "start_char_idx": 777, "end_char_idx": 884, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93741a31-05b0-4d89-a307-41c7815069a2": {"__data__": {"id_": "93741a31-05b0-4d89-a307-41c7815069a2", "embedding": null, "metadata": {"window": "Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company.  It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses.  We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner.  This drove certain charges that impacted our results for the second quarter.  Britt will walk you \nthrough these accounting details later in the call.  \n \n In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy.  It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future. ", "original_text": "This drove certain charges that impacted our results for the second quarter. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6dcf2b61-add2-4e65-a364-25ae9992674d", "node_type": "1", "metadata": {"window": "Let's move on to Change Healthcare.  Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company.  It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses.  We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner.  This drove certain charges that impacted our results for the second quarter.  Britt will walk you \nthrough these accounting details later in the call.  \n \n In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy. ", "original_text": "We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2065b88aeb74d5d374515591501b54d7a48dd76c33b473c667d6c2132f9741bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02a4c5fc-781e-436f-bceb-cdd5eca5f370", "node_type": "1", "metadata": {"window": "It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses.  We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner.  This drove certain charges that impacted our results for the second quarter.  Britt will walk you \nthrough these accounting details later in the call.  \n \n In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy.  It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future.  I'm very pleased by the exec ution across our \nbusinesses in the second quarter. ", "original_text": "Britt will walk you \nthrough these accounting details later in the call.  \n \n"}, "hash": "dcc8012fec0329662f4809c8e9bf7257e8f0e342ec0f29c5c9a0c0a92995f918", "class_name": "RelatedNodeInfo"}}, "text": "This drove certain charges that impacted our results for the second quarter. ", "start_char_idx": 884, "end_char_idx": 961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02a4c5fc-781e-436f-bceb-cdd5eca5f370": {"__data__": {"id_": "02a4c5fc-781e-436f-bceb-cdd5eca5f370", "embedding": null, "metadata": {"window": "It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses.  We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner.  This drove certain charges that impacted our results for the second quarter.  Britt will walk you \nthrough these accounting details later in the call.  \n \n In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy.  It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future.  I'm very pleased by the exec ution across our \nbusinesses in the second quarter. ", "original_text": "Britt will walk you \nthrough these accounting details later in the call.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93741a31-05b0-4d89-a307-41c7815069a2", "node_type": "1", "metadata": {"window": "Our value -creating transaction with Change Healthcare provided McKesson \nwith a cash payment up -front that allowed us t o retain 70% ownership of the new company.  It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses.  We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner.  This drove certain charges that impacted our results for the second quarter.  Britt will walk you \nthrough these accounting details later in the call.  \n \n In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy.  It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future. ", "original_text": "This drove certain charges that impacted our results for the second quarter. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09477dd63a3c81b19735e89f6723e4d0f75a54e50da08030ceae502c3b47bd5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fbab286-9438-422c-b91f-54defb5486fa", "node_type": "1", "metadata": {"window": "We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner.  This drove certain charges that impacted our results for the second quarter.  Britt will walk you \nthrough these accounting details later in the call.  \n \n In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy.  It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future.  I'm very pleased by the exec ution across our \nbusinesses in the second quarter.  That execution included the impact of our cost savings initiatives across the \nenterprise. ", "original_text": "In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy. "}, "hash": "642e597073363535734650af78b23b8e66d90299c120f7efdf775b576bfb922d", "class_name": "RelatedNodeInfo"}}, "text": "Britt will walk you \nthrough these accounting details later in the call.  \n \n", "start_char_idx": 961, "end_char_idx": 1038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fbab286-9438-422c-b91f-54defb5486fa": {"__data__": {"id_": "6fbab286-9438-422c-b91f-54defb5486fa", "embedding": null, "metadata": {"window": "We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner.  This drove certain charges that impacted our results for the second quarter.  Britt will walk you \nthrough these accounting details later in the call.  \n \n In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy.  It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future.  I'm very pleased by the exec ution across our \nbusinesses in the second quarter.  That execution included the impact of our cost savings initiatives across the \nenterprise. ", "original_text": "In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02a4c5fc-781e-436f-bceb-cdd5eca5f370", "node_type": "1", "metadata": {"window": "It created a scaled \nhealthcare software and analytics and technology -enabled services company that will unlock the value of our \nlegacy MTS businesses.  We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner.  This drove certain charges that impacted our results for the second quarter.  Britt will walk you \nthrough these accounting details later in the call.  \n \n In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy.  It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future.  I'm very pleased by the exec ution across our \nbusinesses in the second quarter. ", "original_text": "Britt will walk you \nthrough these accounting details later in the call.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25fb0dd9991529c358a5541690bd9d140204f819382b718e6f7d91e17d240980", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f4682b5-3b52-4b13-8225-a965c3959a1b", "node_type": "1", "metadata": {"window": "This drove certain charges that impacted our results for the second quarter.  Britt will walk you \nthrough these accounting details later in the call.  \n \n In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy.  It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future.  I'm very pleased by the exec ution across our \nbusinesses in the second quarter.  That execution included the impact of our cost savings initiatives across the \nenterprise.  Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n", "original_text": "It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future. "}, "hash": "959ad672e820d75660a3c3845906acbb85215452739445bd6e0a5041a3a6355e", "class_name": "RelatedNodeInfo"}}, "text": "In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy. ", "start_char_idx": 1038, "end_char_idx": 1178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f4682b5-3b52-4b13-8225-a965c3959a1b": {"__data__": {"id_": "6f4682b5-3b52-4b13-8225-a965c3959a1b", "embedding": null, "metadata": {"window": "This drove certain charges that impacted our results for the second quarter.  Britt will walk you \nthrough these accounting details later in the call.  \n \n In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy.  It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future.  I'm very pleased by the exec ution across our \nbusinesses in the second quarter.  That execution included the impact of our cost savings initiatives across the \nenterprise.  Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n", "original_text": "It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fbab286-9438-422c-b91f-54defb5486fa", "node_type": "1", "metadata": {"window": "We have begun activities to exit the investment in the next si x to 12 months in a tax -\nefficient manner.  This drove certain charges that impacted our results for the second quarter.  Britt will walk you \nthrough these accounting details later in the call.  \n \n In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy.  It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future.  I'm very pleased by the exec ution across our \nbusinesses in the second quarter.  That execution included the impact of our cost savings initiatives across the \nenterprise. ", "original_text": "In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45d1fa15bf3a264310256ab5b03af70150af43d5d4e4b813b94c57952aa61035", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70005fa1-a660-4e09-86c0-b19a97266740", "node_type": "1", "metadata": {"window": "Britt will walk you \nthrough these accounting details later in the call.  \n \n In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy.  It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future.  I'm very pleased by the exec ution across our \nbusinesses in the second quarter.  That execution included the impact of our cost savings initiatives across the \nenterprise.  Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency. ", "original_text": "I'm very pleased by the exec ution across our \nbusinesses in the second quarter. "}, "hash": "cd94567b7159cd2cfa368f2cd37829583505e6c7e2315d312823e814155b3f98", "class_name": "RelatedNodeInfo"}}, "text": "It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future. ", "start_char_idx": 1178, "end_char_idx": 1333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70005fa1-a660-4e09-86c0-b19a97266740": {"__data__": {"id_": "70005fa1-a660-4e09-86c0-b19a97266740", "embedding": null, "metadata": {"window": "Britt will walk you \nthrough these accounting details later in the call.  \n \n In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy.  It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future.  I'm very pleased by the exec ution across our \nbusinesses in the second quarter.  That execution included the impact of our cost savings initiatives across the \nenterprise.  Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency. ", "original_text": "I'm very pleased by the exec ution across our \nbusinesses in the second quarter. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f4682b5-3b52-4b13-8225-a965c3959a1b", "node_type": "1", "metadata": {"window": "This drove certain charges that impacted our results for the second quarter.  Britt will walk you \nthrough these accounting details later in the call.  \n \n In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy.  It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future.  I'm very pleased by the exec ution across our \nbusinesses in the second quarter.  That execution included the impact of our cost savings initiatives across the \nenterprise.  Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n", "original_text": "It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ef2f9ff16aed8f91e113220649aa923b6d8484f8324d45489ef9afc53ca1e5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fbc8040-1e4c-42b5-a2d2-30e45a255f3a", "node_type": "1", "metadata": {"window": "In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy.  It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future.  I'm very pleased by the exec ution across our \nbusinesses in the second quarter.  That execution included the impact of our cost savings initiatives across the \nenterprise.  Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency.  In \nMed-Surg, I talked about t he partnership with the U.S. ", "original_text": "That execution included the impact of our cost savings initiatives across the \nenterprise. "}, "hash": "c415fa12dd6fbb2cc238653cd9c00c00c79940f03acd9b4a480dd743d4458455", "class_name": "RelatedNodeInfo"}}, "text": "I'm very pleased by the exec ution across our \nbusinesses in the second quarter. ", "start_char_idx": 1333, "end_char_idx": 1414, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fbc8040-1e4c-42b5-a2d2-30e45a255f3a": {"__data__": {"id_": "8fbc8040-1e4c-42b5-a2d2-30e45a255f3a", "embedding": null, "metadata": {"window": "In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy.  It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future.  I'm very pleased by the exec ution across our \nbusinesses in the second quarter.  That execution included the impact of our cost savings initiatives across the \nenterprise.  Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency.  In \nMed-Surg, I talked about t he partnership with the U.S. ", "original_text": "That execution included the impact of our cost savings initiatives across the \nenterprise. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70005fa1-a660-4e09-86c0-b19a97266740", "node_type": "1", "metadata": {"window": "Britt will walk you \nthrough these accounting details later in the call.  \n \n In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy.  It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future.  I'm very pleased by the exec ution across our \nbusinesses in the second quarter.  That execution included the impact of our cost savings initiatives across the \nenterprise.  Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency. ", "original_text": "I'm very pleased by the exec ution across our \nbusinesses in the second quarter. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ddcbb56597f4594e573ebfcaa1a0e028e68f774a85ff7667454f0b8be163b1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79280fa7-9103-49c0-947b-e109bdcf0d65", "node_type": "1", "metadata": {"window": "It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future.  I'm very pleased by the exec ution across our \nbusinesses in the second quarter.  That execution included the impact of our cost savings initiatives across the \nenterprise.  Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency.  In \nMed-Surg, I talked about t he partnership with the U.S.  Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way. ", "original_text": "Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n"}, "hash": "bfe11da347d53ba59d4d0ef5739cf15b14143e8cc2cec73e90e67d98470bb330", "class_name": "RelatedNodeInfo"}}, "text": "That execution included the impact of our cost savings initiatives across the \nenterprise. ", "start_char_idx": 1414, "end_char_idx": 1505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79280fa7-9103-49c0-947b-e109bdcf0d65": {"__data__": {"id_": "79280fa7-9103-49c0-947b-e109bdcf0d65", "embedding": null, "metadata": {"window": "It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future.  I'm very pleased by the exec ution across our \nbusinesses in the second quarter.  That execution included the impact of our cost savings initiatives across the \nenterprise.  Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency.  In \nMed-Surg, I talked about t he partnership with the U.S.  Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way. ", "original_text": "Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fbc8040-1e4c-42b5-a2d2-30e45a255f3a", "node_type": "1", "metadata": {"window": "In the Change Healthcare transaction, we found a way to create v alue while exiting businesses that weren't core \nto our McKesson strategy.  It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future.  I'm very pleased by the exec ution across our \nbusinesses in the second quarter.  That execution included the impact of our cost savings initiatives across the \nenterprise.  Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency.  In \nMed-Surg, I talked about t he partnership with the U.S. ", "original_text": "That execution included the impact of our cost savings initiatives across the \nenterprise. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e091da81c34d2106a0a3070894781041f192beea50f1bf56c949d3fc4f137e72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45d8ccf3-e336-42bb-846d-7a9eafa36094", "node_type": "1", "metadata": {"window": "I'm very pleased by the exec ution across our \nbusinesses in the second quarter.  That execution included the impact of our cost savings initiatives across the \nenterprise.  Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency.  In \nMed-Surg, I talked about t he partnership with the U.S.  Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way.  And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP. ", "original_text": "For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency. "}, "hash": "94ef608204f34d23ceaee1e7757aeafa848aca0fe94bf86499840254ca758585", "class_name": "RelatedNodeInfo"}}, "text": "Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n", "start_char_idx": 1505, "end_char_idx": 1740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45d8ccf3-e336-42bb-846d-7a9eafa36094": {"__data__": {"id_": "45d8ccf3-e336-42bb-846d-7a9eafa36094", "embedding": null, "metadata": {"window": "I'm very pleased by the exec ution across our \nbusinesses in the second quarter.  That execution included the impact of our cost savings initiatives across the \nenterprise.  Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency.  In \nMed-Surg, I talked about t he partnership with the U.S.  Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way.  And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP. ", "original_text": "For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79280fa7-9103-49c0-947b-e109bdcf0d65", "node_type": "1", "metadata": {"window": "It's a great example of how McKesson regularly evaluates our portfolio to ensure we \nhave the right set of assets for the present but also for the future.  I'm very pleased by the exec ution across our \nbusinesses in the second quarter.  That execution included the impact of our cost savings initiatives across the \nenterprise.  Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency.  In \nMed-Surg, I talked about t he partnership with the U.S.  Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way. ", "original_text": "Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d6947dd46491b95a696865dd6a83c6690065e6be10bb026516d03eb9c403781", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f5884fe-4f89-4016-a276-d5974961c0dc", "node_type": "1", "metadata": {"window": "That execution included the impact of our cost savings initiatives across the \nenterprise.  Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency.  In \nMed-Surg, I talked about t he partnership with the U.S.  Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way.  And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP.  Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape. ", "original_text": "In \nMed-Surg, I talked about t he partnership with the U.S. "}, "hash": "5a51d7ae41e39badf700a3cdfef5f966dbcc51b6fd674ffefbb1bb9c1890836a", "class_name": "RelatedNodeInfo"}}, "text": "For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency. ", "start_char_idx": 1740, "end_char_idx": 1853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f5884fe-4f89-4016-a276-d5974961c0dc": {"__data__": {"id_": "2f5884fe-4f89-4016-a276-d5974961c0dc", "embedding": null, "metadata": {"window": "That execution included the impact of our cost savings initiatives across the \nenterprise.  Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency.  In \nMed-Surg, I talked about t he partnership with the U.S.  Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way.  And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP.  Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape. ", "original_text": "In \nMed-Surg, I talked about t he partnership with the U.S. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45d8ccf3-e336-42bb-846d-7a9eafa36094", "node_type": "1", "metadata": {"window": "I'm very pleased by the exec ution across our \nbusinesses in the second quarter.  That execution included the impact of our cost savings initiatives across the \nenterprise.  Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency.  In \nMed-Surg, I talked about t he partnership with the U.S.  Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way.  And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP. ", "original_text": "For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e687db001a99f36f5baaf5bd2ce0ca7e15e55991a8d0d6fc520df4ce92fb169", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89032ea7-9e3c-4c3d-b6f9-c229ca796142", "node_type": "1", "metadata": {"window": "Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency.  In \nMed-Surg, I talked about t he partnership with the U.S.  Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way.  And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP.  Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape.  We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set. ", "original_text": "Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way. "}, "hash": "d3580d8fdbcb7058f8b728a0bc8bffdd737805724def723d7326508c4ec08706", "class_name": "RelatedNodeInfo"}}, "text": "In \nMed-Surg, I talked about t he partnership with the U.S. ", "start_char_idx": 1853, "end_char_idx": 1913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89032ea7-9e3c-4c3d-b6f9-c229ca796142": {"__data__": {"id_": "89032ea7-9e3c-4c3d-b6f9-c229ca796142", "embedding": null, "metadata": {"window": "Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency.  In \nMed-Surg, I talked about t he partnership with the U.S.  Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way.  And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP.  Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape.  We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set. ", "original_text": "Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f5884fe-4f89-4016-a276-d5974961c0dc", "node_type": "1", "metadata": {"window": "That execution included the impact of our cost savings initiatives across the \nenterprise.  Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency.  In \nMed-Surg, I talked about t he partnership with the U.S.  Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way.  And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP.  Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape. ", "original_text": "In \nMed-Surg, I talked about t he partnership with the U.S. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3da88011de825361e3703f1598ef9ea1800d5bedda6491f4ec2da56d1a7f59b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "399765c4-59dc-44bb-9e44-6c8ba6ea9595", "node_type": "1", "metadata": {"window": "For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency.  In \nMed-Surg, I talked about t he partnership with the U.S.  Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way.  And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP.  Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape.  We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set.  I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n", "original_text": "And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP. "}, "hash": "56b9333c151f265b27d8633ed9eedf3d278fb2966547c92a6333fb2338c8a8bb", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way. ", "start_char_idx": 1913, "end_char_idx": 2058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "399765c4-59dc-44bb-9e44-6c8ba6ea9595": {"__data__": {"id_": "399765c4-59dc-44bb-9e44-6c8ba6ea9595", "embedding": null, "metadata": {"window": "For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency.  In \nMed-Surg, I talked about t he partnership with the U.S.  Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way.  And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP.  Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape.  We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set.  I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n", "original_text": "And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89032ea7-9e3c-4c3d-b6f9-c229ca796142", "node_type": "1", "metadata": {"window": "Britt will get into more of the details, but I think from my remarks, you can see evidence of not only the \nsavings efforts, but the partnership across the businesses and overall cultural change happening across the \norganization.  \n \n For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency.  In \nMed-Surg, I talked about t he partnership with the U.S.  Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way.  And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP.  Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape.  We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set. ", "original_text": "Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce274c64361d8bfa7b2b5fac52dce67a1a2e8503c6fed0d1a8b78e9409ca40d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e8792a4-6bd8-40ce-8450-09ae1d2be940", "node_type": "1", "metadata": {"window": "In \nMed-Surg, I talked about t he partnership with the U.S.  Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way.  And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP.  Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape.  We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set.  I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to. ", "original_text": "Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape. "}, "hash": "a449b403b055371d7f1acecf92739cda267582954ed87607b9dc88588419e546", "class_name": "RelatedNodeInfo"}}, "text": "And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP. ", "start_char_idx": 2058, "end_char_idx": 2147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e8792a4-6bd8-40ce-8450-09ae1d2be940": {"__data__": {"id_": "0e8792a4-6bd8-40ce-8450-09ae1d2be940", "embedding": null, "metadata": {"window": "In \nMed-Surg, I talked about t he partnership with the U.S.  Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way.  And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP.  Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape.  We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set.  I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to. ", "original_text": "Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "399765c4-59dc-44bb-9e44-6c8ba6ea9595", "node_type": "1", "metadata": {"window": "For example, we've centralized our IT organization, implementing a center -led hub model to increase efficiency.  In \nMed-Surg, I talked about t he partnership with the U.S.  Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way.  And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP.  Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape.  We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set.  I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n", "original_text": "And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82c3fec045b7fb096d1c7f99abf52afdce7c53d5fdc48af7996efab9d7c67436", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "069bee2e-5dbd-4941-8b5e-f3b9e2557dfe", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way.  And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP.  Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape.  We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set.  I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to.  Britt?  \n ", "original_text": "We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set. "}, "hash": "e57f517e9d1b7719f0bbaff15492c0501aba762723e415c5c76b1d614e4d2004", "class_name": "RelatedNodeInfo"}}, "text": "Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape. ", "start_char_idx": 2147, "end_char_idx": 2314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "069bee2e-5dbd-4941-8b5e-f3b9e2557dfe": {"__data__": {"id_": "069bee2e-5dbd-4941-8b5e-f3b9e2557dfe", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way.  And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP.  Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape.  We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set.  I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to.  Britt?  \n ", "original_text": "We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e8792a4-6bd8-40ce-8450-09ae1d2be940", "node_type": "1", "metadata": {"window": "In \nMed-Surg, I talked about t he partnership with the U.S.  Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way.  And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP.  Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape.  We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set.  I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to. ", "original_text": "Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9f6a95a05c8cbeedb4f8c42070ae14f9a2620f2b5ce7b231b73c491bfbd9371", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc06dd7e-536b-429f-a184-6d26621ea712", "node_type": "1", "metadata": {"window": "And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP.  Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape.  We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set.  I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to.  Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "original_text": "I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n"}, "hash": "2a9ec09b9b8f8d8545b2f2bc9a959d8abb95cd7a65e194f9659f4f41900f00b0", "class_name": "RelatedNodeInfo"}}, "text": "We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set. ", "start_char_idx": 2314, "end_char_idx": 2462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc06dd7e-536b-429f-a184-6d26621ea712": {"__data__": {"id_": "cc06dd7e-536b-429f-a184-6d26621ea712", "embedding": null, "metadata": {"window": "And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP.  Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape.  We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set.  I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to.  Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "original_text": "I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "069bee2e-5dbd-4941-8b5e-f3b9e2557dfe", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions segment to ensure \nphysicians receive the pharmaceuticals they need to run their practice in an easy way.  And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP.  Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape.  We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set.  I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to.  Britt?  \n ", "original_text": "We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e50e7ca96e304016f460ab8e5806808ccf816d07259ae7415a2e1dc9cba22fee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c43b9f8-82b4-4421-962c-ed087c9c6a2f", "node_type": "1", "metadata": {"window": "Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape.  We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set.  I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to.  Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good morning. ", "original_text": "And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to. "}, "hash": "8b15812119b4d8155ef886da4e83b7990d3d61952b208ea80ad2477f3bc99b3d", "class_name": "RelatedNodeInfo"}}, "text": "I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n", "start_char_idx": 2462, "end_char_idx": 2614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c43b9f8-82b4-4421-962c-ed087c9c6a2f": {"__data__": {"id_": "5c43b9f8-82b4-4421-962c-ed087c9c6a2f", "embedding": null, "metadata": {"window": "Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape.  We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set.  I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to.  Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good morning. ", "original_text": "And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc06dd7e-536b-429f-a184-6d26621ea712", "node_type": "1", "metadata": {"window": "And in MRxTS, I talked \nabout the partnership with RxCrossroads business to launch A MP.  Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape.  We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set.  I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to.  Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "original_text": "I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a2dd94a511920f256748b1a2b223df5e885466afd581d50e5a0ab2b79f9bf10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20a89366-b8da-40c1-8c97-d83aa7da96bf", "node_type": "1", "metadata": {"window": "We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set.  I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to.  Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good morning.  I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n", "original_text": "Britt?  \n "}, "hash": "ab69cb5facf0c566c2fcb79b92c99838001842a3536c8460a13cf77e02d36745", "class_name": "RelatedNodeInfo"}}, "text": "And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to. ", "start_char_idx": 2614, "end_char_idx": 2729, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20a89366-b8da-40c1-8c97-d83aa7da96bf": {"__data__": {"id_": "20a89366-b8da-40c1-8c97-d83aa7da96bf", "embedding": null, "metadata": {"window": "We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set.  I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to.  Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good morning.  I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n", "original_text": "Britt?  \n ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c43b9f8-82b4-4421-962c-ed087c9c6a2f", "node_type": "1", "metadata": {"window": "Overall, we're evolving behaviors as it relates \nto company collaboration and spending and are focused on moving with speed in an ever changing healthcare \nlandscape.  We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set.  I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to.  Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good morning. ", "original_text": "And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1241a644a1e5be955df93e7e403a1ad466ef947e0aeb40626287411ca4a3b80e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a3eca3c-57b1-4cf4-9f80-1c5bdbed3c71", "node_type": "1", "metadata": {"window": "I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to.  Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good morning.  I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n"}, "hash": "352afb3ab1bab919e3e5595c1c03fb56545c3ab835589992ff1d59a1b06d564b", "class_name": "RelatedNodeInfo"}}, "text": "Britt?  \n ", "start_char_idx": 2729, "end_char_idx": 2739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a3eca3c-57b1-4cf4-9f80-1c5bdbed3c71": {"__data__": {"id_": "4a3eca3c-57b1-4cf4-9f80-1c5bdbed3c71", "embedding": null, "metadata": {"window": "I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to.  Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good morning.  I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20a89366-b8da-40c1-8c97-d83aa7da96bf", "node_type": "1", "metadata": {"window": "We're building upon our strong culture, leveraging our diverse perspectives to make dec isions with an \nenterprise -first, Team McKesson mind -set.  I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to.  Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good morning.  I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n", "original_text": "Britt?  \n ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e93667f52b6e0914abb55d27ffc2ca2ff47d4d45b9bfed18f009503f180427b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7971047-3143-49e9-baeb-822b6ccf64ea", "node_type": "1", "metadata": {"window": "And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to.  Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good morning.  I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019.  Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness. ", "original_text": "Thanks, Brian, and good morning. "}, "hash": "7cffe5b91b9fb3eea8b70c21b95d53c65ccad81f35723c89774e7df595eca968", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "start_char_idx": 2739, "end_char_idx": 3085, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7971047-3143-49e9-baeb-822b6ccf64ea": {"__data__": {"id_": "f7971047-3143-49e9-baeb-822b6ccf64ea", "embedding": null, "metadata": {"window": "And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to.  Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good morning.  I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019.  Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness. ", "original_text": "Thanks, Brian, and good morning. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a3eca3c-57b1-4cf4-9f80-1c5bdbed3c71", "node_type": "1", "metadata": {"window": "I feel confident in the execution I've seen across our businesses in the \nfirst half of fiscal 2020, and I feel great about the future of McKesson.  \n \n And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to.  Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good morning.  I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1372156949c68febc8011c22750f564bcc6b29d71caab36fde1da5b3f8af71db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3d789a0-3e2d-494e-9081-9a33b783d1a5", "node_type": "1", "metadata": {"window": "Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good morning.  I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019.  Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness.  And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n", "original_text": "I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n"}, "hash": "245a8b0e022f662a1586537965353288fd75ba7fb82171a845a35be5907cd764", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Brian, and good morning. ", "start_char_idx": 3085, "end_char_idx": 3118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3d789a0-3e2d-494e-9081-9a33b783d1a5": {"__data__": {"id_": "f3d789a0-3e2d-494e-9081-9a33b783d1a5", "embedding": null, "metadata": {"window": "Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good morning.  I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019.  Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness.  And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n", "original_text": "I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7971047-3143-49e9-baeb-822b6ccf64ea", "node_type": "1", "metadata": {"window": "And with that, let me turn the call over to Britt t o go over the financials and some of the details I alluded to.  Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good morning.  I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019.  Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness. ", "original_text": "Thanks, Brian, and good morning. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2deed10d497d44fa91b760cc7151c202d9654000172bdcef4685081188e301a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3732f2f-912f-40b8-9010-73217bb7cca9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good morning.  I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019.  Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness.  And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n", "original_text": "We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019. "}, "hash": "19226e5cb6f6677d74b6652b30ccb30520f24761a2662b3eb6d554264d2973c6", "class_name": "RelatedNodeInfo"}}, "text": "I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n", "start_char_idx": 3118, "end_char_idx": 3263, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3732f2f-912f-40b8-9010-73217bb7cca9": {"__data__": {"id_": "c3732f2f-912f-40b8-9010-73217bb7cca9", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good morning.  I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019.  Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness.  And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n", "original_text": "We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3d789a0-3e2d-494e-9081-9a33b783d1a5", "node_type": "1", "metadata": {"window": "Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good morning.  I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019.  Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness.  And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n", "original_text": "I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73c5617ce78640d0054c3d04ce9173264993866a15d034b4276c270abcda6578", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77380607-4a39-4883-846e-c9d1f981a052", "node_type": "1", "metadata": {"window": "Thanks, Brian, and good morning.  I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019.  Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness.  And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n", "original_text": "Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness. "}, "hash": "f270034a2c1e727f59a616c238b1c71bd826683b81b19a4dcbf6d52b36322c2e", "class_name": "RelatedNodeInfo"}}, "text": "We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019. ", "start_char_idx": 3263, "end_char_idx": 3481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77380607-4a39-4883-846e-c9d1f981a052": {"__data__": {"id_": "77380607-4a39-4883-846e-c9d1f981a052", "embedding": null, "metadata": {"window": "Thanks, Brian, and good morning.  I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019.  Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness.  And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n", "original_text": "Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3732f2f-912f-40b8-9010-73217bb7cca9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good morning.  I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019.  Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness.  And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n", "original_text": "We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf3f6d2120d9714025152ed28f22d3e44cc1153c8615c038b766587030f21837", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbf48eff-5500-4156-b569-83461a993aa8", "node_type": "1", "metadata": {"window": "I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019.  Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness.  And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths. ", "original_text": "And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n"}, "hash": "e408e092f7ed718105afdf8e3d947742c660250f8d11dc1a8c36c4db0a27f37b", "class_name": "RelatedNodeInfo"}}, "text": "Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness. ", "start_char_idx": 3481, "end_char_idx": 3605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbf48eff-5500-4156-b569-83461a993aa8": {"__data__": {"id_": "cbf48eff-5500-4156-b569-83461a993aa8", "embedding": null, "metadata": {"window": "I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019.  Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness.  And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths. ", "original_text": "And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77380607-4a39-4883-846e-c9d1f981a052", "node_type": "1", "metadata": {"window": "Thanks, Brian, and good morning.  I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019.  Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness.  And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n", "original_text": "Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "310596bfb3dcbc135eaecdb4047da114ce9befa6dabae0e747a03edf42320142", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7e701dd-17c9-43df-beed-8658a84b62dd", "node_type": "1", "metadata": {"window": "We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019.  Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness.  And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths.  As we've previously communicated, we  will execute this transaction in a tax -efficient manner, and we \nexpect that this transaction will continue to deliver value to McKesson's shareholders. ", "original_text": "Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n"}, "hash": "216445a63471baba1215cd8f84608484d4176e20bd277917a5586760eda727c7", "class_name": "RelatedNodeInfo"}}, "text": "And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n", "start_char_idx": 3605, "end_char_idx": 3706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7e701dd-17c9-43df-beed-8658a84b62dd": {"__data__": {"id_": "d7e701dd-17c9-43df-beed-8658a84b62dd", "embedding": null, "metadata": {"window": "We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019.  Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness.  And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths.  As we've previously communicated, we  will execute this transaction in a tax -efficient manner, and we \nexpect that this transaction will continue to deliver value to McKesson's shareholders. ", "original_text": "Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbf48eff-5500-4156-b569-83461a993aa8", "node_type": "1", "metadata": {"window": "I'll begin with a few comments on second quarter results, includi ng changes to \nour guidance for you to consider as you update your models.  \n \n We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019.  Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness.  And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths. ", "original_text": "And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "71d26c63e377ad27e038de4fb4e3577716eeb040d22b0b2436348656475fe0f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6171a771-7bf5-4a55-aae5-9e07f66641d1", "node_type": "1", "metadata": {"window": "Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness.  And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths.  As we've previously communicated, we  will execute this transaction in a tax -efficient manner, and we \nexpect that this transaction will continue to deliver value to McKesson's shareholders.  We believe that this \ntransaction better positions McKesson to focus on its core set of businesses.  ", "original_text": "Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n"}, "hash": "cda2dc5ff895a60a802a13f4a5f2643345934642edb5a51ce44cf7eafe021fd8", "class_name": "RelatedNodeInfo"}}, "text": "Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n", "start_char_idx": 3706, "end_char_idx": 3838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6171a771-7bf5-4a55-aae5-9e07f66641d1": {"__data__": {"id_": "6171a771-7bf5-4a55-aae5-9e07f66641d1", "embedding": null, "metadata": {"window": "Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness.  And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths.  As we've previously communicated, we  will execute this transaction in a tax -efficient manner, and we \nexpect that this transaction will continue to deliver value to McKesson's shareholders.  We believe that this \ntransaction better positions McKesson to focus on its core set of businesses.  ", "original_text": "Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7e701dd-17c9-43df-beed-8658a84b62dd", "node_type": "1", "metadata": {"window": "We are pleased with our adjusted earnings per diluted share results in the second quarter, which were in line with \nconsensus and grew 10% over the prior year, when excluding a one-time $90 million benefit in FY 2019.  Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness.  And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths.  As we've previously communicated, we  will execute this transaction in a tax -efficient manner, and we \nexpect that this transaction will continue to deliver value to McKesson's shareholders. ", "original_text": "Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de015b52cff4ae9d159f7cda02e4161693b33f3b5d3291715d8ecba09801274c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6aa5403c-7978-4eb9-972a-69d8deb2a2d4", "node_type": "1", "metadata": {"window": "And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths.  As we've previously communicated, we  will execute this transaction in a tax -efficient manner, and we \nexpect that this transaction will continue to deliver value to McKesson's shareholders.  We believe that this \ntransaction better positions McKesson to focus on its core set of businesses.  ", "original_text": "First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths. "}, "hash": "b3f51e5d168ae9bfb86d808da51136afb80fc9a8cc26ac11330c5565ccdd20d7", "class_name": "RelatedNodeInfo"}}, "text": "Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n", "start_char_idx": 3838, "end_char_idx": 3951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6aa5403c-7978-4eb9-972a-69d8deb2a2d4": {"__data__": {"id_": "6aa5403c-7978-4eb9-972a-69d8deb2a2d4", "embedding": null, "metadata": {"window": "And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths.  As we've previously communicated, we  will execute this transaction in a tax -efficient manner, and we \nexpect that this transaction will continue to deliver value to McKesson's shareholders.  We believe that this \ntransaction better positions McKesson to focus on its core set of businesses.  ", "original_text": "First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6171a771-7bf5-4a55-aae5-9e07f66641d1", "node_type": "1", "metadata": {"window": "Our \nperformance through the first half of fiscal 2020 was solid, and we're pleased with the momentum across the \nbusiness.  And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths.  As we've previously communicated, we  will execute this transaction in a tax -efficient manner, and we \nexpect that this transaction will continue to deliver value to McKesson's shareholders.  We believe that this \ntransaction better positions McKesson to focus on its core set of businesses.  ", "original_text": "Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "103fd9db9c29c10c12859509fff59f23b8ed123791a30d581954152154922d0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5482b71-8d19-4e45-bf81-10cc45b53f81", "node_type": "1", "metadata": {"window": "Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths.  As we've previously communicated, we  will execute this transaction in a tax -efficient manner, and we \nexpect that this transaction will continue to deliver value to McKesson's shareholders.  We believe that this \ntransaction better positions McKesson to focus on its core set of businesses.  ", "original_text": "As we've previously communicated, we  will execute this transaction in a tax -efficient manner, and we \nexpect that this transaction will continue to deliver value to McKesson's shareholders. "}, "hash": "7149a8156ae4fa747d2c40bf4a8fd3bb9ed15c2e94ca9cfbd2ee4fe5b492b4e0", "class_name": "RelatedNodeInfo"}}, "text": "First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths. ", "start_char_idx": 3951, "end_char_idx": 4183, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5482b71-8d19-4e45-bf81-10cc45b53f81": {"__data__": {"id_": "f5482b71-8d19-4e45-bf81-10cc45b53f81", "embedding": null, "metadata": {"window": "Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths.  As we've previously communicated, we  will execute this transaction in a tax -efficient manner, and we \nexpect that this transaction will continue to deliver value to McKesson's shareholders.  We believe that this \ntransaction better positions McKesson to focus on its core set of businesses.  ", "original_text": "As we've previously communicated, we  will execute this transaction in a tax -efficient manner, and we \nexpect that this transaction will continue to deliver value to McKesson's shareholders. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6aa5403c-7978-4eb9-972a-69d8deb2a2d4", "node_type": "1", "metadata": {"window": "And we're reiterating our fiscal 2020 adjusted earnings outlook of $14 to $14.60 per diluted share. \n Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths.  As we've previously communicated, we  will execute this transaction in a tax -efficient manner, and we \nexpect that this transaction will continue to deliver value to McKesson's shareholders.  We believe that this \ntransaction better positions McKesson to focus on its core set of businesses.  ", "original_text": "First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c496055ab5d13d12844e1860f9b853281b6534d01a08b5efe428ceceb797c53b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ffcaa6a-d7a5-4749-934d-1ed913a89c0c", "node_type": "1", "metadata": {"window": "Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths.  As we've previously communicated, we  will execute this transaction in a tax -efficient manner, and we \nexpect that this transaction will continue to deliver value to McKesson's shareholders.  We believe that this \ntransaction better positions McKesson to focus on its core set of businesses.  ", "original_text": "We believe that this \ntransaction better positions McKesson to focus on its core set of businesses.  "}, "hash": "4c89a0f468c7a90304e10381dfff49c38fafc7cf271a2d3853955070cf44b88a", "class_name": "RelatedNodeInfo"}}, "text": "As we've previously communicated, we  will execute this transaction in a tax -efficient manner, and we \nexpect that this transaction will continue to deliver value to McKesson's shareholders. ", "start_char_idx": 4183, "end_char_idx": 4375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ffcaa6a-d7a5-4749-934d-1ed913a89c0c": {"__data__": {"id_": "9ffcaa6a-d7a5-4749-934d-1ed913a89c0c", "embedding": null, "metadata": {"window": "Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths.  As we've previously communicated, we  will execute this transaction in a tax -efficient manner, and we \nexpect that this transaction will continue to deliver value to McKesson's shareholders.  We believe that this \ntransaction better positions McKesson to focus on its core set of businesses.  ", "original_text": "We believe that this \ntransaction better positions McKesson to focus on its core set of businesses.  ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b04e4d0d4ecbe1e66c9712c5b82f07d9af32f79f01ddf54cc4d32cdbaf501b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5482b71-8d19-4e45-bf81-10cc45b53f81", "node_type": "1", "metadata": {"window": "Updated guidance assumptions can be found in our second quarter earnings slide posted to the Investors section \nof our website.  \n \n Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths.  As we've previously communicated, we  will execute this transaction in a tax -efficient manner, and we \nexpect that this transaction will continue to deliver value to McKesson's shareholders.  We believe that this \ntransaction better positions McKesson to focus on its core set of businesses.  ", "original_text": "As we've previously communicated, we  will execute this transaction in a tax -efficient manner, and we \nexpect that this transaction will continue to deliver value to McKesson's shareholders. ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "83cf62e61ae13c4455a2e9d5678926aee11f165d86cee4b94d9bdb0e67b543ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddedbadc-035c-486d-933a-11a5ed0c73b9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs part of this work, we completed a market value assessment and recorded a non -cash, pre -tax impairment \ncharge of $1.2 billion in our fiscal 2020 second quarter.  It's important to note this charge in no way reflects the \nfuture value of Change Healthcare.  Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process. ", "original_text": "McKesson Corp.  "}, "hash": "b39be999623edff3ed9251208d18dafdf5f8e04aca573af7cffea0cdef19019c", "class_name": "RelatedNodeInfo"}}, "text": "We believe that this \ntransaction better positions McKesson to focus on its core set of businesses.  ", "start_char_idx": 4375, "end_char_idx": 4476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddedbadc-035c-486d-933a-11a5ed0c73b9": {"__data__": {"id_": "ddedbadc-035c-486d-933a-11a5ed0c73b9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs part of this work, we completed a market value assessment and recorded a non -cash, pre -tax impairment \ncharge of $1.2 billion in our fiscal 2020 second quarter.  It's important to note this charge in no way reflects the \nfuture value of Change Healthcare.  Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ffcaa6a-d7a5-4749-934d-1ed913a89c0c", "node_type": "1", "metadata": {"window": "Before we get into the details of the results, I want to address two items that impacted our GAAP only results. \n First, we 've concluded it's the appropriate time to exit our remaining stake in Change Healthcare, and we've \nbegun activities expected to lead to an exit of the investment, which we anticipate will occur within six to 12 \nmonths.  As we've previously communicated, we  will execute this transaction in a tax -efficient manner, and we \nexpect that this transaction will continue to deliver value to McKesson's shareholders.  We believe that this \ntransaction better positions McKesson to focus on its core set of businesses.  ", "original_text": "We believe that this \ntransaction better positions McKesson to focus on its core set of businesses.  ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6c1880b5cbbd03cc192abdc9601c52d70c179f0f0011e5bacf4570e28f66c04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94300abf-ea59-4a48-861c-0f0d18f90807", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs part of this work, we completed a market value assessment and recorded a non -cash, pre -tax impairment \ncharge of $1.2 billion in our fiscal 2020 second quarter.  It's important to note this charge in no way reflects the \nfuture value of Change Healthcare.  Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process.  Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs part of this work, we completed a market value assessment and recorded a non -cash, pre -tax impairment \ncharge of $1.2 billion in our fiscal 2020 second quarter. "}, "hash": "4222eaec88951170fc44444a46695906359973b86d1211b7874d9dd632405a9d", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94300abf-ea59-4a48-861c-0f0d18f90807": {"__data__": {"id_": "94300abf-ea59-4a48-861c-0f0d18f90807", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs part of this work, we completed a market value assessment and recorded a non -cash, pre -tax impairment \ncharge of $1.2 billion in our fiscal 2020 second quarter.  It's important to note this charge in no way reflects the \nfuture value of Change Healthcare.  Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process.  Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs part of this work, we completed a market value assessment and recorded a non -cash, pre -tax impairment \ncharge of $1.2 billion in our fiscal 2020 second quarter. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddedbadc-035c-486d-933a-11a5ed0c73b9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs part of this work, we completed a market value assessment and recorded a non -cash, pre -tax impairment \ncharge of $1.2 billion in our fiscal 2020 second quarter.  It's important to note this charge in no way reflects the \nfuture value of Change Healthcare.  Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb022a85ef5401729113c0acafa79d2340e75114c3b91e0ba607fa326fd462ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6c0fd15-6c8c-4d84-bd3f-ffca4e349011", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs part of this work, we completed a market value assessment and recorded a non -cash, pre -tax impairment \ncharge of $1.2 billion in our fiscal 2020 second quarter.  It's important to note this charge in no way reflects the \nfuture value of Change Healthcare.  Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process.  Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n", "original_text": "It's important to note this charge in no way reflects the \nfuture value of Change Healthcare. "}, "hash": "9b37a2cd9c3c0b26d94b9b34f1a7e1f07cfbe9fd9d7b3b8191e98a2e3259af33", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs part of this work, we completed a market value assessment and recorded a non -cash, pre -tax impairment \ncharge of $1.2 billion in our fiscal 2020 second quarter. ", "start_char_idx": 16, "end_char_idx": 348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6c0fd15-6c8c-4d84-bd3f-ffca4e349011": {"__data__": {"id_": "e6c0fd15-6c8c-4d84-bd3f-ffca4e349011", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs part of this work, we completed a market value assessment and recorded a non -cash, pre -tax impairment \ncharge of $1.2 billion in our fiscal 2020 second quarter.  It's important to note this charge in no way reflects the \nfuture value of Change Healthcare.  Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process.  Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n", "original_text": "It's important to note this charge in no way reflects the \nfuture value of Change Healthcare. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94300abf-ea59-4a48-861c-0f0d18f90807", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs part of this work, we completed a market value assessment and recorded a non -cash, pre -tax impairment \ncharge of $1.2 billion in our fiscal 2020 second quarter.  It's important to note this charge in no way reflects the \nfuture value of Change Healthcare.  Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process.  Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs part of this work, we completed a market value assessment and recorded a non -cash, pre -tax impairment \ncharge of $1.2 billion in our fiscal 2020 second quarter. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f215e02275e6978f5156fee712f6179d0cc24c209b86e3635f50d02465732158", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ff00a40-ed80-440a-bf78-b92d2bcb941b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs part of this work, we completed a market value assessment and recorded a non -cash, pre -tax impairment \ncharge of $1.2 billion in our fiscal 2020 second quarter.  It's important to note this charge in no way reflects the \nfuture value of Change Healthcare.  Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process.  Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n Moving to the adjusted earnings results for the quarter. ", "original_text": "Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process. "}, "hash": "9a0e6917903160b7e779d5dbb06d1169f7c2e0184f7229b5bfb070ea84547d2b", "class_name": "RelatedNodeInfo"}}, "text": "It's important to note this charge in no way reflects the \nfuture value of Change Healthcare. ", "start_char_idx": 348, "end_char_idx": 442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ff00a40-ed80-440a-bf78-b92d2bcb941b": {"__data__": {"id_": "0ff00a40-ed80-440a-bf78-b92d2bcb941b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs part of this work, we completed a market value assessment and recorded a non -cash, pre -tax impairment \ncharge of $1.2 billion in our fiscal 2020 second quarter.  It's important to note this charge in no way reflects the \nfuture value of Change Healthcare.  Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process.  Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n Moving to the adjusted earnings results for the quarter. ", "original_text": "Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6c0fd15-6c8c-4d84-bd3f-ffca4e349011", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs part of this work, we completed a market value assessment and recorded a non -cash, pre -tax impairment \ncharge of $1.2 billion in our fiscal 2020 second quarter.  It's important to note this charge in no way reflects the \nfuture value of Change Healthcare.  Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process.  Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n", "original_text": "It's important to note this charge in no way reflects the \nfuture value of Change Healthcare. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "681db3500b9417c94f702e832ea13547f88e32b785b01d7e303156dd17861534", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d13d889-949a-48b7-8730-7929e5422660", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs part of this work, we completed a market value assessment and recorded a non -cash, pre -tax impairment \ncharge of $1.2 billion in our fiscal 2020 second quarter.  It's important to note this charge in no way reflects the \nfuture value of Change Healthcare.  Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process.  Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n Moving to the adjusted earnings results for the quarter.  On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year. ", "original_text": "Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n"}, "hash": "5fcf075d22bcaffc8bca3cdec5d21716cdba45be67137bc3006093eb7dd54f1e", "class_name": "RelatedNodeInfo"}}, "text": "Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process. ", "start_char_idx": 442, "end_char_idx": 597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d13d889-949a-48b7-8730-7929e5422660": {"__data__": {"id_": "9d13d889-949a-48b7-8730-7929e5422660", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs part of this work, we completed a market value assessment and recorded a non -cash, pre -tax impairment \ncharge of $1.2 billion in our fiscal 2020 second quarter.  It's important to note this charge in no way reflects the \nfuture value of Change Healthcare.  Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process.  Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n Moving to the adjusted earnings results for the quarter.  On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year. ", "original_text": "Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ff00a40-ed80-440a-bf78-b92d2bcb941b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs part of this work, we completed a market value assessment and recorded a non -cash, pre -tax impairment \ncharge of $1.2 billion in our fiscal 2020 second quarter.  It's important to note this charge in no way reflects the \nfuture value of Change Healthcare.  Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process.  Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n Moving to the adjusted earnings results for the quarter. ", "original_text": "Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53374ad81b575b3c5de10c0009e69626c9a582c5fe90b08fe37a21db26eac75b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1050306f-0f1c-43ed-a7aa-f0b50816af22", "node_type": "1", "metadata": {"window": "It's important to note this charge in no way reflects the \nfuture value of Change Healthcare.  Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process.  Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n Moving to the adjusted earnings results for the quarter.  On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year.  As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare. ", "original_text": "Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n"}, "hash": "17de04577de08ce2c792a7f3ded832d8bdda5f6f8b388c1fad40be111cf75164", "class_name": "RelatedNodeInfo"}}, "text": "Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n", "start_char_idx": 597, "end_char_idx": 720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1050306f-0f1c-43ed-a7aa-f0b50816af22": {"__data__": {"id_": "1050306f-0f1c-43ed-a7aa-f0b50816af22", "embedding": null, "metadata": {"window": "It's important to note this charge in no way reflects the \nfuture value of Change Healthcare.  Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process.  Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n Moving to the adjusted earnings results for the quarter.  On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year.  As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare. ", "original_text": "Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d13d889-949a-48b7-8730-7929e5422660", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs part of this work, we completed a market value assessment and recorded a non -cash, pre -tax impairment \ncharge of $1.2 billion in our fiscal 2020 second quarter.  It's important to note this charge in no way reflects the \nfuture value of Change Healthcare.  Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process.  Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n Moving to the adjusted earnings results for the quarter.  On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year. ", "original_text": "Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d34f58b00388909bd1f1bfe76c6f38d996a1ae322b2b68387ec63539903b7d9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea8a4c6b-f757-4962-98e8-64b8566e1a2e", "node_type": "1", "metadata": {"window": "Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process.  Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n Moving to the adjusted earnings results for the quarter.  On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year.  As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare.  Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses. ", "original_text": "Moving to the adjusted earnings results for the quarter. "}, "hash": "897d9c9c4538a3051d745f3e3a0944f41c8e070892d348f17670deaca05e6f84", "class_name": "RelatedNodeInfo"}}, "text": "Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n", "start_char_idx": 720, "end_char_idx": 968, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea8a4c6b-f757-4962-98e8-64b8566e1a2e": {"__data__": {"id_": "ea8a4c6b-f757-4962-98e8-64b8566e1a2e", "embedding": null, "metadata": {"window": "Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process.  Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n Moving to the adjusted earnings results for the quarter.  On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year.  As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare.  Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses. ", "original_text": "Moving to the adjusted earnings results for the quarter. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1050306f-0f1c-43ed-a7aa-f0b50816af22", "node_type": "1", "metadata": {"window": "It's important to note this charge in no way reflects the \nfuture value of Change Healthcare.  Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process.  Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n Moving to the adjusted earnings results for the quarter.  On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year.  As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare. ", "original_text": "Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63b141f6e2ab122c966c362c39dad29a2cf7fe3b72a9beb9cdce6ccea7f0f84c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4561008-dc76-4cfe-8f07-a5b2e0da7f41", "node_type": "1", "metadata": {"window": "Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n Moving to the adjusted earnings results for the quarter.  On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year.  As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare.  Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses.  Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year. ", "original_text": "On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year. "}, "hash": "482ca24245c01862c33da0256be2a4d723fad1d9b74fa9f1179df9da9508168b", "class_name": "RelatedNodeInfo"}}, "text": "Moving to the adjusted earnings results for the quarter. ", "start_char_idx": 968, "end_char_idx": 1025, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4561008-dc76-4cfe-8f07-a5b2e0da7f41": {"__data__": {"id_": "d4561008-dc76-4cfe-8f07-a5b2e0da7f41", "embedding": null, "metadata": {"window": "Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n Moving to the adjusted earnings results for the quarter.  On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year.  As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare.  Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses.  Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year. ", "original_text": "On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea8a4c6b-f757-4962-98e8-64b8566e1a2e", "node_type": "1", "metadata": {"window": "Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process.  Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n Moving to the adjusted earnings results for the quarter.  On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year.  As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare.  Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses. ", "original_text": "Moving to the adjusted earnings results for the quarter. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8500e763d593f459dd01c2a7505af40a7197ee7c87fb0c2d6d140d8e0f81160", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1baa2b9f-2017-42de-ac5b-f525d199a5be", "node_type": "1", "metadata": {"window": "Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n Moving to the adjusted earnings results for the quarter.  On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year.  As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare.  Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses.  Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year.  Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n", "original_text": "As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare. "}, "hash": "f032a51a05f00001d7db60ac217df87a5ac5c0ae3f9aa747f5ee4aea8f1d062a", "class_name": "RelatedNodeInfo"}}, "text": "On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year. ", "start_char_idx": 1025, "end_char_idx": 1147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1baa2b9f-2017-42de-ac5b-f525d199a5be": {"__data__": {"id_": "1baa2b9f-2017-42de-ac5b-f525d199a5be", "embedding": null, "metadata": {"window": "Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n Moving to the adjusted earnings results for the quarter.  On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year.  As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare.  Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses.  Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year.  Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n", "original_text": "As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4561008-dc76-4cfe-8f07-a5b2e0da7f41", "node_type": "1", "metadata": {"window": "Overall, the Change Healthcare \ntransaction has been and continues to be value -creating for McKesson's shar eholders.  \n \n Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n Moving to the adjusted earnings results for the quarter.  On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year.  As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare.  Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses.  Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year. ", "original_text": "On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7482c3d844915efe08402a429f6965626f1b78687ad1130573a55ec61251a66b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f7c5d15-6b53-4f77-8d7d-6028c8472892", "node_type": "1", "metadata": {"window": "Moving to the adjusted earnings results for the quarter.  On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year.  As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare.  Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses.  Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year.  Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n Moving to the details of our consolidated results on slide 4. ", "original_text": "Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses. "}, "hash": "b70c359a7e39b8db699b4a545d8cd9049a64046c4a643e960580511a0c2bd99a", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare. ", "start_char_idx": 1147, "end_char_idx": 1383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f7c5d15-6b53-4f77-8d7d-6028c8472892": {"__data__": {"id_": "6f7c5d15-6b53-4f77-8d7d-6028c8472892", "embedding": null, "metadata": {"window": "Moving to the adjusted earnings results for the quarter.  On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year.  As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare.  Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses.  Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year.  Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n Moving to the details of our consolidated results on slide 4. ", "original_text": "Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1baa2b9f-2017-42de-ac5b-f525d199a5be", "node_type": "1", "metadata": {"window": "Second, as Brian mentioned earlier, we recorded a pre -tax charge of $82 million after settling all claims against \nMcKesson in the suits filed by Cuyahoga and Summit counties of Ohio in the first track of the multidistrict opioid \nlitigation.  \n \n Moving to the adjusted earnings results for the quarter.  On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year.  As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare.  Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses.  Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year.  Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n", "original_text": "As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afd1dda5fa1635b208b7166ae6436d86fb04274aa74fc3a59186c2a32e663d38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2190ee8-b01f-4599-ac33-face6b020bfe", "node_type": "1", "metadata": {"window": "On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year.  As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare.  Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses.  Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year.  Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n Moving to the details of our consolidated results on slide 4.  Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S. ", "original_text": "Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year. "}, "hash": "08b9c38396eec87020664c66920b2e55dadec69c80e7e54c9252a7b38b89b0c6", "class_name": "RelatedNodeInfo"}}, "text": "Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses. ", "start_char_idx": 1383, "end_char_idx": 1598, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2190ee8-b01f-4599-ac33-face6b020bfe": {"__data__": {"id_": "b2190ee8-b01f-4599-ac33-face6b020bfe", "embedding": null, "metadata": {"window": "On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year.  As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare.  Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses.  Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year.  Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n Moving to the details of our consolidated results on slide 4.  Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S. ", "original_text": "Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f7c5d15-6b53-4f77-8d7d-6028c8472892", "node_type": "1", "metadata": {"window": "Moving to the adjusted earnings results for the quarter.  On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year.  As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare.  Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses.  Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year.  Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n Moving to the details of our consolidated results on slide 4. ", "original_text": "Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd40d02b4113688d3627edd4b035cc860c5b7bf28f6e0bdf881ca839e98d04b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d712f18-ac5f-4f14-88a3-ae9a94c9103b", "node_type": "1", "metadata": {"window": "As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare.  Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses.  Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year.  Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n Moving to the details of our consolidated results on slide 4.  Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S.  Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n", "original_text": "Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n"}, "hash": "88becd9c53878ac4f371b38ac365b5811d45051868ea0bf48c06f1b48e499371", "class_name": "RelatedNodeInfo"}}, "text": "Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year. ", "start_char_idx": 1598, "end_char_idx": 1694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d712f18-ac5f-4f14-88a3-ae9a94c9103b": {"__data__": {"id_": "5d712f18-ac5f-4f14-88a3-ae9a94c9103b", "embedding": null, "metadata": {"window": "As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare.  Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses.  Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year.  Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n Moving to the details of our consolidated results on slide 4.  Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S.  Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n", "original_text": "Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2190ee8-b01f-4599-ac33-face6b020bfe", "node_type": "1", "metadata": {"window": "On slide 3 of the presentation, our second quarter \nadjusted earnings of $3.60 per diluted share was flat year over year.  As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare.  Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses.  Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year.  Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n Moving to the details of our consolidated results on slide 4.  Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S. ", "original_text": "Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1661634e0ee2373af5149a5a9d7f6b304fcd9e8ea1af2ec203c369df6336467e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adc45e8b-e6a5-48a9-96fb-38877a4ab447", "node_type": "1", "metadata": {"window": "Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses.  Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year.  Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n Moving to the details of our consolidated results on slide 4.  Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S.  Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n", "original_text": "Moving to the details of our consolidated results on slide 4. "}, "hash": "8485458bac7abf086c61da30436a22d067387cab7b0acd59f6d4db45478c7b08", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n", "start_char_idx": 1694, "end_char_idx": 1840, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adc45e8b-e6a5-48a9-96fb-38877a4ab447": {"__data__": {"id_": "adc45e8b-e6a5-48a9-96fb-38877a4ab447", "embedding": null, "metadata": {"window": "Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses.  Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year.  Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n Moving to the details of our consolidated results on slide 4.  Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S.  Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n", "original_text": "Moving to the details of our consolidated results on slide 4. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d712f18-ac5f-4f14-88a3-ae9a94c9103b", "node_type": "1", "metadata": {"window": "As a reminder, in the second quarter of fiscal \n2019, McKesson recorded a $90 mill ion or $0.33 per diluted share pre -tax benefit related to the reversal of a \ncontractual liability associated with our investment in Change Healthcare.  Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses.  Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year.  Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n Moving to the details of our consolidated results on slide 4.  Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S.  Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n", "original_text": "Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50bd95cb2a65d5861a385fc4dfa1ae62c77c0c910060bbd07035a546fa779cea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3d76097-3905-44fc-8b99-96709b2aae91", "node_type": "1", "metadata": {"window": "Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year.  Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n Moving to the details of our consolidated results on slide 4.  Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S.  Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S. ", "original_text": "Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S. "}, "hash": "3ef92bb84fe612bb521c08a2a700cc69a69d4b27ade912aae6fcefb8e17e4f43", "class_name": "RelatedNodeInfo"}}, "text": "Moving to the details of our consolidated results on slide 4. ", "start_char_idx": 1840, "end_char_idx": 1902, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3d76097-3905-44fc-8b99-96709b2aae91": {"__data__": {"id_": "f3d76097-3905-44fc-8b99-96709b2aae91", "embedding": null, "metadata": {"window": "Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year.  Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n Moving to the details of our consolidated results on slide 4.  Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S.  Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S. ", "original_text": "Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adc45e8b-e6a5-48a9-96fb-38877a4ab447", "node_type": "1", "metadata": {"window": "Excluding this one -time item, second \nquarter adjusted earnings per diluted share increased 10%, driven by  a lower share count and growth in the \nMedical -Surgical and prescription technology or MRxTS businesses.  Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year.  Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n Moving to the details of our consolidated results on slide 4.  Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S.  Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n", "original_text": "Moving to the details of our consolidated results on slide 4. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d66149d892a593cd7570d36e9b72a72c40f093ae6873b351303d78d79705432f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31d203f4-9ee9-4dbf-961f-b600b7565dd9", "node_type": "1", "metadata": {"window": "Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n Moving to the details of our consolidated results on slide 4.  Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S.  Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S.  Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n", "original_text": "Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n"}, "hash": "6f32340d679c36df60ee65285feb7341f6553e1fac208ba48346fdc86b3a596e", "class_name": "RelatedNodeInfo"}}, "text": "Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S. ", "start_char_idx": 1902, "end_char_idx": 2022, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31d203f4-9ee9-4dbf-961f-b600b7565dd9": {"__data__": {"id_": "31d203f4-9ee9-4dbf-961f-b600b7565dd9", "embedding": null, "metadata": {"window": "Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n Moving to the details of our consolidated results on slide 4.  Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S.  Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S.  Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n", "original_text": "Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3d76097-3905-44fc-8b99-96709b2aae91", "node_type": "1", "metadata": {"window": "Year to date, adjusted earnings per diluted \nshare was $6.91, an increase of 6% year over year.  Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n Moving to the details of our consolidated results on slide 4.  Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S.  Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S. ", "original_text": "Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7e932680ceaee3a195d146d770b9e53f05924dc57b30df43840d58a670c2361", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eaf8ea55-4bad-48de-a906-399d210f28d5", "node_type": "1", "metadata": {"window": "Moving to the details of our consolidated results on slide 4.  Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S.  Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S.  Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n Second quarter adjuste d operating expenses increased 5% year over year. ", "original_text": "Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n"}, "hash": "bf0b4682a73140b89b0fc328a1c37ca40b94024cc292daaa3d19a765868a4fb2", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n", "start_char_idx": 2022, "end_char_idx": 2168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eaf8ea55-4bad-48de-a906-399d210f28d5": {"__data__": {"id_": "eaf8ea55-4bad-48de-a906-399d210f28d5", "embedding": null, "metadata": {"window": "Moving to the details of our consolidated results on slide 4.  Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S.  Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S.  Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n Second quarter adjuste d operating expenses increased 5% year over year. ", "original_text": "Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31d203f4-9ee9-4dbf-961f-b600b7565dd9", "node_type": "1", "metadata": {"window": "Excluding the previously mentioned one -time benefit in F Y \n2019, year -to-date adjusted earnings per diluted share grew 12% year over year.  \n \n Moving to the details of our consolidated results on slide 4.  Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S.  Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S.  Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n", "original_text": "Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8e621d5b4895582cd6e35243599526ed94e2faa5a9244a11e7fb800a15dca08c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04574c41-dabf-4e11-8bc2-3c5873a84a63", "node_type": "1", "metadata": {"window": "Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S.  Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S.  Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n Second quarter adjuste d operating expenses increased 5% year over year.  Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n", "original_text": "Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S. "}, "hash": "6b93d5bddeba88554ed2830007ad3e6b723cc6c529399ee53a4893ea1435b7c3", "class_name": "RelatedNodeInfo"}}, "text": "Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n", "start_char_idx": 2168, "end_char_idx": 2349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04574c41-dabf-4e11-8bc2-3c5873a84a63": {"__data__": {"id_": "04574c41-dabf-4e11-8bc2-3c5873a84a63", "embedding": null, "metadata": {"window": "Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S.  Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S.  Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n Second quarter adjuste d operating expenses increased 5% year over year.  Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n", "original_text": "Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eaf8ea55-4bad-48de-a906-399d210f28d5", "node_type": "1", "metadata": {"window": "Moving to the details of our consolidated results on slide 4.  Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S.  Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S.  Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n Second quarter adjuste d operating expenses increased 5% year over year. ", "original_text": "Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "798aea2e82a6db3e31fbdb7001e8663da29f1bd5dd1bd409e6ae328d1ce93c12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60e5d99f-af33-47dc-ab8f-222765515197", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S.  Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n Second quarter adjuste d operating expenses increased 5% year over year.  Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year. ", "original_text": "Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n"}, "hash": "c6e1c56a12b6932b1cb587a7b4b7a6d6bf6fac7b75b0f91f75ba266a3aad44f0", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S. ", "start_char_idx": 2349, "end_char_idx": 2612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60e5d99f-af33-47dc-ab8f-222765515197": {"__data__": {"id_": "60e5d99f-af33-47dc-ab8f-222765515197", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S.  Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n Second quarter adjuste d operating expenses increased 5% year over year.  Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year. ", "original_text": "Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04574c41-dabf-4e11-8bc2-3c5873a84a63", "node_type": "1", "metadata": {"window": "Consolidated revenues for the quarter increased 9% \nyear over year, due to higher -than-anticipated growth in the  U.S.  Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S.  Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n Second quarter adjuste d operating expenses increased 5% year over year.  Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n", "original_text": "Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9134f4335d33fe48ef768422aafe0265ec06d7eca453288206a75bf9c5a5f582", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d4287e0-e90c-442c-9fe0-d6bf911e5cec", "node_type": "1", "metadata": {"window": "Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S.  Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n Second quarter adjuste d operating expenses increased 5% year over year.  Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year.  However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n", "original_text": "Second quarter adjuste d operating expenses increased 5% year over year. "}, "hash": "08161a9b7e60dc01ae00b6e71d809a4194984ccb677d6c073b3d2f267efb924e", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n", "start_char_idx": 2612, "end_char_idx": 2777, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d4287e0-e90c-442c-9fe0-d6bf911e5cec": {"__data__": {"id_": "6d4287e0-e90c-442c-9fe0-d6bf911e5cec", "embedding": null, "metadata": {"window": "Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S.  Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n Second quarter adjuste d operating expenses increased 5% year over year.  Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year.  However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n", "original_text": "Second quarter adjuste d operating expenses increased 5% year over year. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60e5d99f-af33-47dc-ab8f-222765515197", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions \nsegment, in part related to increased Caremark volumes associated with the onboarding of a new customer. \n Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S.  Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n Second quarter adjuste d operating expenses increased 5% year over year.  Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year. ", "original_text": "Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1c836a584516c7d7783c4d3518a9eddae13f64718995d1509251373196cf494", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69ec0362-5197-4b5c-b43e-302d2e836164", "node_type": "1", "metadata": {"window": "Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S.  Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n Second quarter adjuste d operating expenses increased 5% year over year.  Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year.  However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year. ", "original_text": "Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n"}, "hash": "f4e9dcb47595389fe6191b33bf02e8dfb25a85a41069d684aa6b85bf8495ed58", "class_name": "RelatedNodeInfo"}}, "text": "Second quarter adjuste d operating expenses increased 5% year over year. ", "start_char_idx": 2777, "end_char_idx": 2850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69ec0362-5197-4b5c-b43e-302d2e836164": {"__data__": {"id_": "69ec0362-5197-4b5c-b43e-302d2e836164", "embedding": null, "metadata": {"window": "Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S.  Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n Second quarter adjuste d operating expenses increased 5% year over year.  Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year.  However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year. ", "original_text": "Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d4287e0-e90c-442c-9fe0-d6bf911e5cec", "node_type": "1", "metadata": {"window": "Taking this into account, we are updating our consolidated revenues guidance from low to mid -single digit growth \nto mid to high single digit percentage growth year over year.  \n \n Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S.  Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n Second quarter adjuste d operating expenses increased 5% year over year.  Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year.  However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n", "original_text": "Second quarter adjuste d operating expenses increased 5% year over year. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9678f723afc594405a46912f70a9fb14d1544c7a8a3c8b384cd8eee8e245d998", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4da2f897-21fd-4385-b9fb-96054473abcb", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n Second quarter adjuste d operating expenses increased 5% year over year.  Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year.  However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year.  Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million. ", "original_text": "Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year. "}, "hash": "db2b9a7b7611f91c9a7e43348c01b94f847656054c12fa79b45b29df62387f0e", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n", "start_char_idx": 2850, "end_char_idx": 2997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4da2f897-21fd-4385-b9fb-96054473abcb": {"__data__": {"id_": "4da2f897-21fd-4385-b9fb-96054473abcb", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n Second quarter adjuste d operating expenses increased 5% year over year.  Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year.  However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year.  Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million. ", "original_text": "Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69ec0362-5197-4b5c-b43e-302d2e836164", "node_type": "1", "metadata": {"window": "Adjusted gross profit increased 2% year over year, or 3% on an FX adjusted basis, mainly driven by a strong \nprimary care pharmaceutical volumes within our Medical -Surgical segment, conti nued growth in our specialty \nprovider solutions business within our U.S.  Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n Second quarter adjuste d operating expenses increased 5% year over year.  Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year.  However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year. ", "original_text": "Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef1dd098d997ccb8f7f45fcb91b3dd72f4e45d7ab16215d2eada0597eb682316", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57c03939-57d9-445c-9574-5c1211d9fd59", "node_type": "1", "metadata": {"window": "Second quarter adjuste d operating expenses increased 5% year over year.  Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year.  However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year.  Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million.  And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n", "original_text": "However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n"}, "hash": "cf31decb0d36d0799ad2f33992a17b919cc82f5319bfaa3f0e13f1e6dde2c5d7", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year. ", "start_char_idx": 2997, "end_char_idx": 3100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57c03939-57d9-445c-9574-5c1211d9fd59": {"__data__": {"id_": "57c03939-57d9-445c-9574-5c1211d9fd59", "embedding": null, "metadata": {"window": "Second quarter adjuste d operating expenses increased 5% year over year.  Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year.  However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year.  Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million.  And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n", "original_text": "However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4da2f897-21fd-4385-b9fb-96054473abcb", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions segment, and growth across \nour existing MRxTS offerings, principally within our electronic prior authorization products.  \n \n Second quarter adjuste d operating expenses increased 5% year over year.  Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year.  However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year.  Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million. ", "original_text": "Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a17a86c26f6c97ba2f3cf5eeb78f682f1d01f299a9f913e87299b050d329edb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b2c56ff-e455-4cd9-9c4d-118dd71d3e6a", "node_type": "1", "metadata": {"window": "Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year.  However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year.  Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million.  And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year. ", "original_text": "Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year. "}, "hash": "cdc2b1ef86e77623159b718cfffd8837ca26a2016b6f66d185f437956571fe9b", "class_name": "RelatedNodeInfo"}}, "text": "However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n", "start_char_idx": 3100, "end_char_idx": 3228, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b2c56ff-e455-4cd9-9c4d-118dd71d3e6a": {"__data__": {"id_": "4b2c56ff-e455-4cd9-9c4d-118dd71d3e6a", "embedding": null, "metadata": {"window": "Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year.  However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year.  Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million.  And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year. ", "original_text": "Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57c03939-57d9-445c-9574-5c1211d9fd59", "node_type": "1", "metadata": {"window": "Second quarter adjuste d operating expenses increased 5% year over year.  Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year.  However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year.  Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million.  And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n", "original_text": "However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dff8ef2c885a2f3649f585d718d468cfe0c31ddf4f8044c792d01a5188cc4977", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee8e2c05-e187-41de-9fa6-6d4dc12f4998", "node_type": "1", "metadata": {"window": "Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year.  However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year.  Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million.  And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year.  As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n", "original_text": "Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million. "}, "hash": "17f0e448975d6e226bc8eb1b7bbd3ae92b4f28f3f8d07762d69a576d5364af11", "class_name": "RelatedNodeInfo"}}, "text": "Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year. ", "start_char_idx": 3228, "end_char_idx": 3323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee8e2c05-e187-41de-9fa6-6d4dc12f4998": {"__data__": {"id_": "ee8e2c05-e187-41de-9fa6-6d4dc12f4998", "embedding": null, "metadata": {"window": "Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year.  However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year.  Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million.  And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year.  As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n", "original_text": "Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b2c56ff-e455-4cd9-9c4d-118dd71d3e6a", "node_type": "1", "metadata": {"window": "Excluding the prior -year $90 million \ncontractual liability reversal, operating expenses increased 2.5% year over year on an FX -adjusted basis. \n Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year.  However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year.  Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million.  And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year. ", "original_text": "Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65a797d01e36c5c85c21eeb7ca58e59374d39d613aed11bbb01f81663bc4e797", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ae3234e-a25a-41af-b1cf-47334e7ac130", "node_type": "1", "metadata": {"window": "However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year.  Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million.  And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year.  As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n Moving now to our segment results, which can be found on slides 6 through 9.  ", "original_text": "And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n"}, "hash": "15b66f2c5fbbe6968d06688350c4f38383c2e1ee252f60c0c7cf2b9d9ceda76f", "class_name": "RelatedNodeInfo"}}, "text": "Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million. ", "start_char_idx": 3323, "end_char_idx": 3438, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ae3234e-a25a-41af-b1cf-47334e7ac130": {"__data__": {"id_": "0ae3234e-a25a-41af-b1cf-47334e7ac130", "embedding": null, "metadata": {"window": "However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year.  Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million.  And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year.  As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n Moving now to our segment results, which can be found on slides 6 through 9.  ", "original_text": "And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee8e2c05-e187-41de-9fa6-6d4dc12f4998", "node_type": "1", "metadata": {"window": "Adjusted income from operations before tax was $859 million for  the quarter, 6% below the prior year.  However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year.  Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million.  And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year.  As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n", "original_text": "Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c8692ab8a11276355f743f023625961e711c160c76c524a82bc01ddeab96d8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64022cdd-b261-4bf1-bdaa-3bce602993f7", "node_type": "1", "metadata": {"window": "Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year.  Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million.  And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year.  As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n Moving now to our segment results, which can be found on slides 6 through 9.   And I'll start with U.S. \n", "original_text": "During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year. "}, "hash": "80d63c22bcf879d29b6c6d7f2650132fb6da821388a012be5685164276fda688", "class_name": "RelatedNodeInfo"}}, "text": "And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n", "start_char_idx": 3438, "end_char_idx": 3677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64022cdd-b261-4bf1-bdaa-3bce602993f7": {"__data__": {"id_": "64022cdd-b261-4bf1-bdaa-3bce602993f7", "embedding": null, "metadata": {"window": "Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year.  Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million.  And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year.  As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n Moving now to our segment results, which can be found on slides 6 through 9.   And I'll start with U.S. \n", "original_text": "During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ae3234e-a25a-41af-b1cf-47334e7ac130", "node_type": "1", "metadata": {"window": "However, \nexcluding the one -time prior -year $90 million benefit, adjusted income from operations before tax increased 4%.  \n \n Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year.  Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million.  And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year.  As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n Moving now to our segment results, which can be found on slides 6 through 9.  ", "original_text": "And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ede26f5fc7f8c4399ec92b9e4855bb5ae325b520e257401d25aa12c4993f9b3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77465d0c-eef4-47cc-a81d-a93ecd1ed860", "node_type": "1", "metadata": {"window": "Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million.  And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year.  As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n Moving now to our segment results, which can be found on slides 6 through 9.   And I'll start with U.S. \n Pharmaceutical and Specialty Solutions. ", "original_text": "As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n"}, "hash": "9c388f39164b81910e24c9a206f738a0b3dcfe9585fe49bb1e2d5fd5dd5b89a0", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year. ", "start_char_idx": 3677, "end_char_idx": 3866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77465d0c-eef4-47cc-a81d-a93ecd1ed860": {"__data__": {"id_": "77465d0c-eef4-47cc-a81d-a93ecd1ed860", "embedding": null, "metadata": {"window": "Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million.  And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year.  As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n Moving now to our segment results, which can be found on slides 6 through 9.   And I'll start with U.S. \n Pharmaceutical and Specialty Solutions. ", "original_text": "As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64022cdd-b261-4bf1-bdaa-3bce602993f7", "node_type": "1", "metadata": {"window": "Interest expense was $64 million for the quarter, a decrease of 3% compared to the prior year.  Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million.  And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year.  As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n Moving now to our segment results, which can be found on slides 6 through 9.   And I'll start with U.S. \n", "original_text": "During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2300d0e8eee658f8c800da6d742da33cdc161c2e65665bed76a896422f502052", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba5b3b66-1987-4ada-883a-a5975cb581fa", "node_type": "1", "metadata": {"window": "And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year.  As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n Moving now to our segment results, which can be found on slides 6 through 9.   And I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Second quarter revenues were $46 billion, up 10% year over year, ", "original_text": "Moving now to our segment results, which can be found on slides 6 through 9.  "}, "hash": "2e3be8cc58f455a1db2c428286ddbcd586337c90541053085dba3fe15b2a62f7", "class_name": "RelatedNodeInfo"}}, "text": "As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n", "start_char_idx": 3866, "end_char_idx": 4030, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba5b3b66-1987-4ada-883a-a5975cb581fa": {"__data__": {"id_": "ba5b3b66-1987-4ada-883a-a5975cb581fa", "embedding": null, "metadata": {"window": "And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year.  As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n Moving now to our segment results, which can be found on slides 6 through 9.   And I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Second quarter revenues were $46 billion, up 10% year over year, ", "original_text": "Moving now to our segment results, which can be found on slides 6 through 9.  ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77465d0c-eef4-47cc-a81d-a93ecd1ed860", "node_type": "1", "metadata": {"window": "Our adjusted tax \nrate was 17% for the quarter, which included discrete tax benefits of approximately $31 million.  And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year.  As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n Moving now to our segment results, which can be found on slides 6 through 9.   And I'll start with U.S. \n Pharmaceutical and Specialty Solutions. ", "original_text": "As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "712d6a0572c546b95b1a13647cca01ed39cbb187e04a8250ec9b2b47d95ef9d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a25dad6d-4541-4058-982f-3dff45a267fd", "node_type": "1", "metadata": {"window": "During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year.  As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n Moving now to our segment results, which can be found on slides 6 through 9.   And I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Second quarter revenues were $46 billion, up 10% year over year, ", "original_text": "And I'll start with U.S. \n"}, "hash": "a1235e2ce214fe30cbd8212b17ed72c2716fdd14a0adc27ae36bcbfb568d62c0", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to our segment results, which can be found on slides 6 through 9.  ", "start_char_idx": 4030, "end_char_idx": 4108, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a25dad6d-4541-4058-982f-3dff45a267fd": {"__data__": {"id_": "a25dad6d-4541-4058-982f-3dff45a267fd", "embedding": null, "metadata": {"window": "During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year.  As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n Moving now to our segment results, which can be found on slides 6 through 9.   And I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Second quarter revenues were $46 billion, up 10% year over year, ", "original_text": "And I'll start with U.S. \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba5b3b66-1987-4ada-883a-a5975cb581fa", "node_type": "1", "metadata": {"window": "And we continue \nto assume a full -year adjusted tax rate of approximately 18% to 19%, which may vary from quarter to quarter and \nincludes antic ipated discrete tax items that we expect to realize in the back half of the fiscal year.  \n \n During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year.  As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n Moving now to our segment results, which can be found on slides 6 through 9.   And I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Second quarter revenues were $46 billion, up 10% year over year, ", "original_text": "Moving now to our segment results, which can be found on slides 6 through 9.  ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da1283091c7aaedd47e67cc4ed9e4113aca8b4a1f38c3035daefbce35c747d25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aafd0e9e-bae2-461f-8ddb-cd483fc989e4", "node_type": "1", "metadata": {"window": "As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n Moving now to our segment results, which can be found on slides 6 through 9.   And I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Second quarter revenues were $46 billion, up 10% year over year, ", "original_text": "Pharmaceutical and Specialty Solutions. "}, "hash": "2e70a57fa3267136e16db94bf444d1d26a2daede732c93db329f3d495a9a1213", "class_name": "RelatedNodeInfo"}}, "text": "And I'll start with U.S. \n", "start_char_idx": 4108, "end_char_idx": 4134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aafd0e9e-bae2-461f-8ddb-cd483fc989e4": {"__data__": {"id_": "aafd0e9e-bae2-461f-8ddb-cd483fc989e4", "embedding": null, "metadata": {"window": "As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n Moving now to our segment results, which can be found on slides 6 through 9.   And I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Second quarter revenues were $46 billion, up 10% year over year, ", "original_text": "Pharmaceutical and Specialty Solutions. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a25dad6d-4541-4058-982f-3dff45a267fd", "node_type": "1", "metadata": {"window": "During the quarter, we completed $750 million of share repurchases, and our diluted weighted average shares \noutstanding were 184 million for the quarter, a decrease o f 8% year over year.  As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n Moving now to our segment results, which can be found on slides 6 through 9.   And I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Second quarter revenues were $46 billion, up 10% year over year, ", "original_text": "And I'll start with U.S. \n", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6698a7bc1d589b7d0ba007fc89e934d064bb23ed0d401df7b9f29a9fa252a29e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7ccdf7f-4f3d-43af-a100-f202496e3522", "node_type": "1", "metadata": {"window": "Moving now to our segment results, which can be found on slides 6 through 9.   And I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Second quarter revenues were $46 billion, up 10% year over year, ", "original_text": "Second quarter revenues were $46 billion, up 10% year over year, "}, "hash": "9af47ee65832043afeb14c9004f20c2710b631f7b0b88abad3158296208e38d8", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty Solutions. ", "start_char_idx": 4134, "end_char_idx": 4174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7ccdf7f-4f3d-43af-a100-f202496e3522": {"__data__": {"id_": "e7ccdf7f-4f3d-43af-a100-f202496e3522", "embedding": null, "metadata": {"window": "Moving now to our segment results, which can be found on slides 6 through 9.   And I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Second quarter revenues were $46 billion, up 10% year over year, ", "original_text": "Second quarter revenues were $46 billion, up 10% year over year, ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9d134837127b0537d48dfe96630e6a5cb2b044d0e6034879c4d43ca3d686eb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aafd0e9e-bae2-461f-8ddb-cd483fc989e4", "node_type": "1", "metadata": {"window": "As a result of share repurchase \nactivity this year, we're updating our guidance to diluted weighted average shares of approximately 184 million for \nthe year.  \n \n Moving now to our segment results, which can be found on slides 6 through 9.   And I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Second quarter revenues were $46 billion, up 10% year over year, ", "original_text": "Pharmaceutical and Specialty Solutions. ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cdadde1bb53eb2ea809088af9ab25386b4020641408c9183218635efbd687d25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e37754d-e707-46e3-a748-3a79d7ab9587", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ndriven by branded pharmaceutical price increases and the previously mentioned increase in Caremark volumes, \nwhich were largel y specialty products and were partially offset by branded to generic conversions.  Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark. ", "original_text": "McKesson Corp.  "}, "hash": "3d9e9d6e9460975a469e8797ba2ead107acc85711167ac6ed9d766a99cd7c8f4", "class_name": "RelatedNodeInfo"}}, "text": "Second quarter revenues were $46 billion, up 10% year over year, ", "start_char_idx": 4174, "end_char_idx": 4239, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e37754d-e707-46e3-a748-3a79d7ab9587": {"__data__": {"id_": "8e37754d-e707-46e3-a748-3a79d7ab9587", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ndriven by branded pharmaceutical price increases and the previously mentioned increase in Caremark volumes, \nwhich were largel y specialty products and were partially offset by branded to generic conversions.  Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7ccdf7f-4f3d-43af-a100-f202496e3522", "node_type": "1", "metadata": {"window": "Moving now to our segment results, which can be found on slides 6 through 9.   And I'll start with U.S. \n Pharmaceutical and Specialty Solutions.  Second quarter revenues were $46 billion, up 10% year over year, ", "original_text": "Second quarter revenues were $46 billion, up 10% year over year, ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5a067016976fe1a4c276addeaf970a9b56f43ce0e022c1c91c1c1b7c7fee8cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63340611-5892-4cf9-b3a9-43bb1804cde9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ndriven by branded pharmaceutical price increases and the previously mentioned increase in Caremark volumes, \nwhich were largel y specialty products and were partially offset by branded to generic conversions.  Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark.  Year to date, segment \nadjusted operating profit growth is 6%.  \n \n", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ndriven by branded pharmaceutical price increases and the previously mentioned increase in Caremark volumes, \nwhich were largel y specialty products and were partially offset by branded to generic conversions. "}, "hash": "4cc10b8cc937fdb237da2da4ee5e8840311e90e2e12554ccfe439139630e83bd", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63340611-5892-4cf9-b3a9-43bb1804cde9": {"__data__": {"id_": "63340611-5892-4cf9-b3a9-43bb1804cde9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ndriven by branded pharmaceutical price increases and the previously mentioned increase in Caremark volumes, \nwhich were largel y specialty products and were partially offset by branded to generic conversions.  Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark.  Year to date, segment \nadjusted operating profit growth is 6%.  \n \n", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ndriven by branded pharmaceutical price increases and the previously mentioned increase in Caremark volumes, \nwhich were largel y specialty products and were partially offset by branded to generic conversions. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e37754d-e707-46e3-a748-3a79d7ab9587", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ndriven by branded pharmaceutical price increases and the previously mentioned increase in Caremark volumes, \nwhich were largel y specialty products and were partially offset by branded to generic conversions.  Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f0590253a38500e5f31bf2d9cfa9a33b9d35725275463a7d953a59e37990d22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50ccf63b-fd7d-40cb-9fef-df8c1c5439f3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ndriven by branded pharmaceutical price increases and the previously mentioned increase in Caremark volumes, \nwhich were largel y specialty products and were partially offset by branded to generic conversions.  Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark.  Year to date, segment \nadjusted operating profit growth is 6%.  \n \n As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices. ", "original_text": "Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n"}, "hash": "30d74de780cb16650a175080a814657575e885eb69c22d6191bdd9cea2e4919e", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ndriven by branded pharmaceutical price increases and the previously mentioned increase in Caremark volumes, \nwhich were largel y specialty products and were partially offset by branded to generic conversions. ", "start_char_idx": 16, "end_char_idx": 389, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50ccf63b-fd7d-40cb-9fef-df8c1c5439f3": {"__data__": {"id_": "50ccf63b-fd7d-40cb-9fef-df8c1c5439f3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ndriven by branded pharmaceutical price increases and the previously mentioned increase in Caremark volumes, \nwhich were largel y specialty products and were partially offset by branded to generic conversions.  Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark.  Year to date, segment \nadjusted operating profit growth is 6%.  \n \n As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices. ", "original_text": "Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63340611-5892-4cf9-b3a9-43bb1804cde9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ndriven by branded pharmaceutical price increases and the previously mentioned increase in Caremark volumes, \nwhich were largel y specialty products and were partially offset by branded to generic conversions.  Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark.  Year to date, segment \nadjusted operating profit growth is 6%.  \n \n", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ndriven by branded pharmaceutical price increases and the previously mentioned increase in Caremark volumes, \nwhich were largel y specialty products and were partially offset by branded to generic conversions. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe7e379f041b5d0a887333e108b49e410c8064113373cdbce111399021e6d5ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3135ada3-2390-4e8f-a27d-561f86463e9b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ndriven by branded pharmaceutical price increases and the previously mentioned increase in Caremark volumes, \nwhich were largel y specialty products and were partially offset by branded to generic conversions.  Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark.  Year to date, segment \nadjusted operating profit growth is 6%.  \n \n As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices.  As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions. ", "original_text": "Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark. "}, "hash": "ca32224d499e9632d2efba07250ac2af2d4358ef9edffff12145cfd862aae72c", "class_name": "RelatedNodeInfo"}}, "text": "Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n", "start_char_idx": 389, "end_char_idx": 536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3135ada3-2390-4e8f-a27d-561f86463e9b": {"__data__": {"id_": "3135ada3-2390-4e8f-a27d-561f86463e9b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ndriven by branded pharmaceutical price increases and the previously mentioned increase in Caremark volumes, \nwhich were largel y specialty products and were partially offset by branded to generic conversions.  Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark.  Year to date, segment \nadjusted operating profit growth is 6%.  \n \n As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices.  As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions. ", "original_text": "Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50ccf63b-fd7d-40cb-9fef-df8c1c5439f3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ndriven by branded pharmaceutical price increases and the previously mentioned increase in Caremark volumes, \nwhich were largel y specialty products and were partially offset by branded to generic conversions.  Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark.  Year to date, segment \nadjusted operating profit growth is 6%.  \n \n As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices. ", "original_text": "Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8e61ccae55c534d811bc839d860033f954d9b0402cb298e6b299d14b2140d67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa437b25-3271-4dfe-849a-5ba7e6b3809f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ndriven by branded pharmaceutical price increases and the previously mentioned increase in Caremark volumes, \nwhich were largel y specialty products and were partially offset by branded to generic conversions.  Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark.  Year to date, segment \nadjusted operating profit growth is 6%.  \n \n As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices.  As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions.  Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n", "original_text": "Year to date, segment \nadjusted operating profit growth is 6%.  \n \n"}, "hash": "9faca862ee2b44e66cddb23835c1bb486fcf61bbf59b9e387272fe9ab6979dfa", "class_name": "RelatedNodeInfo"}}, "text": "Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark. ", "start_char_idx": 536, "end_char_idx": 849, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa437b25-3271-4dfe-849a-5ba7e6b3809f": {"__data__": {"id_": "fa437b25-3271-4dfe-849a-5ba7e6b3809f", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ndriven by branded pharmaceutical price increases and the previously mentioned increase in Caremark volumes, \nwhich were largel y specialty products and were partially offset by branded to generic conversions.  Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark.  Year to date, segment \nadjusted operating profit growth is 6%.  \n \n As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices.  As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions.  Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n", "original_text": "Year to date, segment \nadjusted operating profit growth is 6%.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3135ada3-2390-4e8f-a27d-561f86463e9b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ndriven by branded pharmaceutical price increases and the previously mentioned increase in Caremark volumes, \nwhich were largel y specialty products and were partially offset by branded to generic conversions.  Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark.  Year to date, segment \nadjusted operating profit growth is 6%.  \n \n As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices.  As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions. ", "original_text": "Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27b909297e57bf1037a6c856551095825aeba7a4b88230ad5cc186e52531674a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd0ddcb9-652d-4ae7-af08-000374986d5e", "node_type": "1", "metadata": {"window": "Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark.  Year to date, segment \nadjusted operating profit growth is 6%.  \n \n As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices.  As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions.  Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n Next, European Pharmaceutical Solutions. ", "original_text": "As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices. "}, "hash": "bdb7c2f5f8f9a96456a7f9a819cfa6ae640f2feab018a73e00df4d2085cd51dd", "class_name": "RelatedNodeInfo"}}, "text": "Year to date, segment \nadjusted operating profit growth is 6%.  \n \n", "start_char_idx": 849, "end_char_idx": 916, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd0ddcb9-652d-4ae7-af08-000374986d5e": {"__data__": {"id_": "cd0ddcb9-652d-4ae7-af08-000374986d5e", "embedding": null, "metadata": {"window": "Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark.  Year to date, segment \nadjusted operating profit growth is 6%.  \n \n As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices.  As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions.  Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n Next, European Pharmaceutical Solutions. ", "original_text": "As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa437b25-3271-4dfe-849a-5ba7e6b3809f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ndriven by branded pharmaceutical price increases and the previously mentioned increase in Caremark volumes, \nwhich were largel y specialty products and were partially offset by branded to generic conversions.  Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark.  Year to date, segment \nadjusted operating profit growth is 6%.  \n \n As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices.  As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions.  Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n", "original_text": "Year to date, segment \nadjusted operating profit growth is 6%.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "931ece9a38f7c862869200b5c69595e7aa24cd93fe80fe7a63cdae7d018d62f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "613b00e9-11b8-48e4-889c-e40d06f3ea0e", "node_type": "1", "metadata": {"window": "Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark.  Year to date, segment \nadjusted operating profit growth is 6%.  \n \n As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices.  As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions.  Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n Next, European Pharmaceutical Solutions.  Second quarter revenues were down 1% year over year to $6.6 billion. \n", "original_text": "As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions. "}, "hash": "0829dae57021377ad30da0f54b50c38499236f51c38fca47cbbccb867cf444ab", "class_name": "RelatedNodeInfo"}}, "text": "As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices. ", "start_char_idx": 916, "end_char_idx": 1036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "613b00e9-11b8-48e4-889c-e40d06f3ea0e": {"__data__": {"id_": "613b00e9-11b8-48e4-889c-e40d06f3ea0e", "embedding": null, "metadata": {"window": "Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark.  Year to date, segment \nadjusted operating profit growth is 6%.  \n \n As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices.  As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions.  Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n Next, European Pharmaceutical Solutions.  Second quarter revenues were down 1% year over year to $6.6 billion. \n", "original_text": "As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd0ddcb9-652d-4ae7-af08-000374986d5e", "node_type": "1", "metadata": {"window": "Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark.  Year to date, segment \nadjusted operating profit growth is 6%.  \n \n As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices.  As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions.  Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n Next, European Pharmaceutical Solutions. ", "original_text": "As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "71b30df75e0ba86dae7080d6ae9aa63821fa094f5abff485968e821104278836", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cf28759-e3e9-46c4-bb85-43cf0425668c", "node_type": "1", "metadata": {"window": "Year to date, segment \nadjusted operating profit growth is 6%.  \n \n As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices.  As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions.  Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n Next, European Pharmaceutical Solutions.  Second quarter revenues were down 1% year over year to $6.6 billion. \n On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business. ", "original_text": "Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n"}, "hash": "5ba464a5bdb87af07e00cb8dcb8cad2d1c79b341e68165b905c0560e822280f9", "class_name": "RelatedNodeInfo"}}, "text": "As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions. ", "start_char_idx": 1036, "end_char_idx": 1161, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cf28759-e3e9-46c4-bb85-43cf0425668c": {"__data__": {"id_": "0cf28759-e3e9-46c4-bb85-43cf0425668c", "embedding": null, "metadata": {"window": "Year to date, segment \nadjusted operating profit growth is 6%.  \n \n As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices.  As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions.  Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n Next, European Pharmaceutical Solutions.  Second quarter revenues were down 1% year over year to $6.6 billion. \n On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business. ", "original_text": "Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "613b00e9-11b8-48e4-889c-e40d06f3ea0e", "node_type": "1", "metadata": {"window": "Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark.  Year to date, segment \nadjusted operating profit growth is 6%.  \n \n As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices.  As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions.  Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n Next, European Pharmaceutical Solutions.  Second quarter revenues were down 1% year over year to $6.6 billion. \n", "original_text": "As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e4d5b2ab0c2fe27f6eef5205f8cd1e25292c53f76ed2a160fb11220d16e7c15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1963bc1-327a-48a3-9fab-4a2916c38feb", "node_type": "1", "metadata": {"window": "As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices.  As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions.  Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n Next, European Pharmaceutical Solutions.  Second quarter revenues were down 1% year over year to $6.6 billion. \n On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business.  Segment a djusted operating profit was down 23% to $41 million. ", "original_text": "Next, European Pharmaceutical Solutions. "}, "hash": "0343e4687f7d733060149431cc6238ed8ee69d00c64a26e2b6b17789ec95ab00", "class_name": "RelatedNodeInfo"}}, "text": "Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n", "start_char_idx": 1161, "end_char_idx": 1329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1963bc1-327a-48a3-9fab-4a2916c38feb": {"__data__": {"id_": "f1963bc1-327a-48a3-9fab-4a2916c38feb", "embedding": null, "metadata": {"window": "As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices.  As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions.  Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n Next, European Pharmaceutical Solutions.  Second quarter revenues were down 1% year over year to $6.6 billion. \n On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business.  Segment a djusted operating profit was down 23% to $41 million. ", "original_text": "Next, European Pharmaceutical Solutions. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cf28759-e3e9-46c4-bb85-43cf0425668c", "node_type": "1", "metadata": {"window": "Year to date, segment \nadjusted operating profit growth is 6%.  \n \n As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices.  As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions.  Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n Next, European Pharmaceutical Solutions.  Second quarter revenues were down 1% year over year to $6.6 billion. \n On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business. ", "original_text": "Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf3b52f9a7cae950ef77770f0444224d2d28de9268471aa852d5e506a91eaf76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc52f88c-1f2e-41ba-8565-61053a3747a6", "node_type": "1", "metadata": {"window": "As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions.  Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n Next, European Pharmaceutical Solutions.  Second quarter revenues were down 1% year over year to $6.6 billion. \n On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business.  Segment a djusted operating profit was down 23% to $41 million.  On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K. ", "original_text": "Second quarter revenues were down 1% year over year to $6.6 billion. \n"}, "hash": "ee054f73cda52a756e5c195bf6e2eaa3bae6ee8f52f6a79745c501677b73323f", "class_name": "RelatedNodeInfo"}}, "text": "Next, European Pharmaceutical Solutions. ", "start_char_idx": 1329, "end_char_idx": 1370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc52f88c-1f2e-41ba-8565-61053a3747a6": {"__data__": {"id_": "bc52f88c-1f2e-41ba-8565-61053a3747a6", "embedding": null, "metadata": {"window": "As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions.  Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n Next, European Pharmaceutical Solutions.  Second quarter revenues were down 1% year over year to $6.6 billion. \n On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business.  Segment a djusted operating profit was down 23% to $41 million.  On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K. ", "original_text": "Second quarter revenues were down 1% year over year to $6.6 billion. \n", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1963bc1-327a-48a3-9fab-4a2916c38feb", "node_type": "1", "metadata": {"window": "As Brian discussed, we have differentiated assets and capabilities in the areas of oncology and manufacturer \nservices.  As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions.  Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n Next, European Pharmaceutical Solutions.  Second quarter revenues were down 1% year over year to $6.6 billion. \n On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business.  Segment a djusted operating profit was down 23% to $41 million. ", "original_text": "Next, European Pharmaceutical Solutions. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4354c34cd3cd2acf4677df478226a08d5b51aee00d75d2bfdea9b67d58c2635", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b63ef83-aac8-4099-8ad0-63f9244fe953", "node_type": "1", "metadata": {"window": "Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n Next, European Pharmaceutical Solutions.  Second quarter revenues were down 1% year over year to $6.6 billion. \n On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business.  Segment a djusted operating profit was down 23% to $41 million.  On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K.  retail \npharmacy environment. ", "original_text": "On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business. "}, "hash": "57714c773eb48121bc7952010563c50e2b119148e10009d8f5b996409286241e", "class_name": "RelatedNodeInfo"}}, "text": "Second quarter revenues were down 1% year over year to $6.6 billion. \n", "start_char_idx": 1370, "end_char_idx": 1440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b63ef83-aac8-4099-8ad0-63f9244fe953": {"__data__": {"id_": "4b63ef83-aac8-4099-8ad0-63f9244fe953", "embedding": null, "metadata": {"window": "Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n Next, European Pharmaceutical Solutions.  Second quarter revenues were down 1% year over year to $6.6 billion. \n On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business.  Segment a djusted operating profit was down 23% to $41 million.  On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K.  retail \npharmacy environment. ", "original_text": "On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc52f88c-1f2e-41ba-8565-61053a3747a6", "node_type": "1", "metadata": {"window": "As such, we will be investing an incremental $25 mill ion in the second half of the year to extend these \nleading positions.  Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n Next, European Pharmaceutical Solutions.  Second quarter revenues were down 1% year over year to $6.6 billion. \n On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business.  Segment a djusted operating profit was down 23% to $41 million.  On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K. ", "original_text": "Second quarter revenues were down 1% year over year to $6.6 billion. \n", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8295237690259da78007ddb270050719457be57aa33c3bf23dec555f12d82be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c14c9361-f444-449e-b8f5-0a6bf5aee928", "node_type": "1", "metadata": {"window": "Next, European Pharmaceutical Solutions.  Second quarter revenues were down 1% year over year to $6.6 billion. \n On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business.  Segment a djusted operating profit was down 23% to $41 million.  On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K.  retail \npharmacy environment.  As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS. ", "original_text": "Segment a djusted operating profit was down 23% to $41 million. "}, "hash": "c0d31a509a4331b3af5e7f41e1b688237aa6eac566c7c7d2d5bab8176d68dc13", "class_name": "RelatedNodeInfo"}}, "text": "On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business. ", "start_char_idx": 1440, "end_char_idx": 1594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c14c9361-f444-449e-b8f5-0a6bf5aee928": {"__data__": {"id_": "c14c9361-f444-449e-b8f5-0a6bf5aee928", "embedding": null, "metadata": {"window": "Next, European Pharmaceutical Solutions.  Second quarter revenues were down 1% year over year to $6.6 billion. \n On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business.  Segment a djusted operating profit was down 23% to $41 million.  On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K.  retail \npharmacy environment.  As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS. ", "original_text": "Segment a djusted operating profit was down 23% to $41 million. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b63ef83-aac8-4099-8ad0-63f9244fe953", "node_type": "1", "metadata": {"window": "Inclusive of these additional investments, we are reiterating our adjusted operating profit \nguidance of low to mid -single digit percent growth for the full year.  \n \n Next, European Pharmaceutical Solutions.  Second quarter revenues were down 1% year over year to $6.6 billion. \n On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business.  Segment a djusted operating profit was down 23% to $41 million.  On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K.  retail \npharmacy environment. ", "original_text": "On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0ca71809173733a824ad712f33b0d3284e209b672013ef7994b56a1660f7830", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b527132e-caa0-46c5-8bb4-86085bcb2e5a", "node_type": "1", "metadata": {"window": "Second quarter revenues were down 1% year over year to $6.6 billion. \n On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business.  Segment a djusted operating profit was down 23% to $41 million.  On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K.  retail \npharmacy environment.  As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS.  And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe. ", "original_text": "On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K. "}, "hash": "e91b2fdc029a77cb9d94c76d42ead77ef7300a2dd022285f331068549d6ff728", "class_name": "RelatedNodeInfo"}}, "text": "Segment a djusted operating profit was down 23% to $41 million. ", "start_char_idx": 1594, "end_char_idx": 1658, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b527132e-caa0-46c5-8bb4-86085bcb2e5a": {"__data__": {"id_": "b527132e-caa0-46c5-8bb4-86085bcb2e5a", "embedding": null, "metadata": {"window": "Second quarter revenues were down 1% year over year to $6.6 billion. \n On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business.  Segment a djusted operating profit was down 23% to $41 million.  On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K.  retail \npharmacy environment.  As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS.  And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe. ", "original_text": "On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c14c9361-f444-449e-b8f5-0a6bf5aee928", "node_type": "1", "metadata": {"window": "Next, European Pharmaceutical Solutions.  Second quarter revenues were down 1% year over year to $6.6 billion. \n On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business.  Segment a djusted operating profit was down 23% to $41 million.  On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K.  retail \npharmacy environment.  As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS. ", "original_text": "Segment a djusted operating profit was down 23% to $41 million. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b8b89cd1459b01a6f11059365737860c7d2811e146da9ca94652029f8cfd3bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bc7f41c-8435-4dd4-b70f-328bebb8d480", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business.  Segment a djusted operating profit was down 23% to $41 million.  On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K.  retail \npharmacy environment.  As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS.  And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe.  Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n", "original_text": "retail \npharmacy environment. "}, "hash": "0be2d79deb0ac62bd966e5ce857e3a139a2325d42bfa57048ac040bf1a69242e", "class_name": "RelatedNodeInfo"}}, "text": "On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K. ", "start_char_idx": 1658, "end_char_idx": 1776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bc7f41c-8435-4dd4-b70f-328bebb8d480": {"__data__": {"id_": "3bc7f41c-8435-4dd4-b70f-328bebb8d480", "embedding": null, "metadata": {"window": "On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business.  Segment a djusted operating profit was down 23% to $41 million.  On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K.  retail \npharmacy environment.  As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS.  And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe.  Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n", "original_text": "retail \npharmacy environment. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b527132e-caa0-46c5-8bb4-86085bcb2e5a", "node_type": "1", "metadata": {"window": "Second quarter revenues were down 1% year over year to $6.6 billion. \n On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business.  Segment a djusted operating profit was down 23% to $41 million.  On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K.  retail \npharmacy environment.  As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS.  And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe. ", "original_text": "On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdbe2999218db4337f449b7257779a0145e5a7f5e9e19006410156a20f66a3b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1ab77e4-5b2b-4380-b12f-c32fe13db818", "node_type": "1", "metadata": {"window": "Segment a djusted operating profit was down 23% to $41 million.  On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K.  retail \npharmacy environment.  As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS.  And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe.  Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n Moving now to Medical -Surgical Solutions. ", "original_text": "As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS. "}, "hash": "511d1d3b3870271b1d5fe6348f8ecf31b7f14a2874696f69c2bb9254793362e6", "class_name": "RelatedNodeInfo"}}, "text": "retail \npharmacy environment. ", "start_char_idx": 1776, "end_char_idx": 1806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1ab77e4-5b2b-4380-b12f-c32fe13db818": {"__data__": {"id_": "c1ab77e4-5b2b-4380-b12f-c32fe13db818", "embedding": null, "metadata": {"window": "Segment a djusted operating profit was down 23% to $41 million.  On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K.  retail \npharmacy environment.  As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS.  And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe.  Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n Moving now to Medical -Surgical Solutions. ", "original_text": "As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bc7f41c-8435-4dd4-b70f-328bebb8d480", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, revenues grew 4%, in line with our original expectations, driven by market growth in the \npharmaceutical distribution business.  Segment a djusted operating profit was down 23% to $41 million.  On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K.  retail \npharmacy environment.  As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS.  And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe.  Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n", "original_text": "retail \npharmacy environment. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72d80680a8bf363bc5a34857b72fce9cda69d80c62c9b2fa3d1c19e1d49c2c82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ced2213-dc70-4aa3-9171-ebc8f18b7bc4", "node_type": "1", "metadata": {"window": "On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K.  retail \npharmacy environment.  As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS.  And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe.  Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n Moving now to Medical -Surgical Solutions.  Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business. ", "original_text": "And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe. "}, "hash": "df825b0f6a257746d19bc98c2fe0b09b5cec8d4d7d251fd96eaeb41b12708a14", "class_name": "RelatedNodeInfo"}}, "text": "As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS. ", "start_char_idx": 1806, "end_char_idx": 1921, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ced2213-dc70-4aa3-9171-ebc8f18b7bc4": {"__data__": {"id_": "1ced2213-dc70-4aa3-9171-ebc8f18b7bc4", "embedding": null, "metadata": {"window": "On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K.  retail \npharmacy environment.  As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS.  And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe.  Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n Moving now to Medical -Surgical Solutions.  Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business. ", "original_text": "And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1ab77e4-5b2b-4380-b12f-c32fe13db818", "node_type": "1", "metadata": {"window": "Segment a djusted operating profit was down 23% to $41 million.  On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K.  retail \npharmacy environment.  As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS.  And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe.  Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n Moving now to Medical -Surgical Solutions. ", "original_text": "As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76acf2e27358b1479ecad5a99d5c06e8f17c3de88dcf65c870467060728d15c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a70ad8b5-4b5a-4965-b142-77e5e7b38052", "node_type": "1", "metadata": {"window": "retail \npharmacy environment.  As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS.  And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe.  Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n Moving now to Medical -Surgical Solutions.  Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business.  Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year. ", "original_text": "Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n"}, "hash": "ffcd367dca44c1d4222820f626e5df331b2c1d9e0362ddf391e281c19f3d90a4", "class_name": "RelatedNodeInfo"}}, "text": "And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe. ", "start_char_idx": 1921, "end_char_idx": 2067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a70ad8b5-4b5a-4965-b142-77e5e7b38052": {"__data__": {"id_": "a70ad8b5-4b5a-4965-b142-77e5e7b38052", "embedding": null, "metadata": {"window": "retail \npharmacy environment.  As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS.  And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe.  Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n Moving now to Medical -Surgical Solutions.  Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business.  Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year. ", "original_text": "Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ced2213-dc70-4aa3-9171-ebc8f18b7bc4", "node_type": "1", "metadata": {"window": "On an FX -\nadjusted basis, adjusted operating profit was $43 million, down 19%, due to continued weakness in the U.K.  retail \npharmacy environment.  As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS.  And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe.  Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n Moving now to Medical -Surgical Solutions.  Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business. ", "original_text": "And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "382575ffbfcd0d6cea5dc3a3c2d107ec9054b46db5c851847a7b9c944629029b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91223e94-6807-4ea8-805f-b1f5b0b1dd59", "node_type": "1", "metadata": {"window": "As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS.  And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe.  Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n Moving now to Medical -Surgical Solutions.  Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business.  Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year.  The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n", "original_text": "Moving now to Medical -Surgical Solutions. "}, "hash": "59988380151809c941f43e75f06ffccb25b95e4cde4dbdff19d9ead937a637b7", "class_name": "RelatedNodeInfo"}}, "text": "Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n", "start_char_idx": 2067, "end_char_idx": 2212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91223e94-6807-4ea8-805f-b1f5b0b1dd59": {"__data__": {"id_": "91223e94-6807-4ea8-805f-b1f5b0b1dd59", "embedding": null, "metadata": {"window": "As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS.  And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe.  Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n Moving now to Medical -Surgical Solutions.  Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business.  Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year.  The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n", "original_text": "Moving now to Medical -Surgical Solutions. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a70ad8b5-4b5a-4965-b142-77e5e7b38052", "node_type": "1", "metadata": {"window": "retail \npharmacy environment.  As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS.  And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe.  Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n Moving now to Medical -Surgical Solutions.  Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business.  Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year. ", "original_text": "Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "75150cdfe987912e5f4f1f21026c400a1befd6616af367234d420a77b18c9481", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b1d199c-4381-4db7-b7c9-290a736d031b", "node_type": "1", "metadata": {"window": "And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe.  Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n Moving now to Medical -Surgical Solutions.  Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business.  Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year.  The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n And finishing our business review with Other. ", "original_text": "Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business. "}, "hash": "2059ba56b5571fc59dd761f06c48daab41bad38029cd5967b9190e2e04c5a53e", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to Medical -Surgical Solutions. ", "start_char_idx": 2212, "end_char_idx": 2255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b1d199c-4381-4db7-b7c9-290a736d031b": {"__data__": {"id_": "7b1d199c-4381-4db7-b7c9-290a736d031b", "embedding": null, "metadata": {"window": "And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe.  Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n Moving now to Medical -Surgical Solutions.  Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business.  Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year.  The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n And finishing our business review with Other. ", "original_text": "Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91223e94-6807-4ea8-805f-b1f5b0b1dd59", "node_type": "1", "metadata": {"window": "As Brian mentioned, we are expecting partial recovery of the underfunding we \nexperienced year to date by the NHS.  And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe.  Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n Moving now to Medical -Surgical Solutions.  Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business.  Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year.  The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n", "original_text": "Moving now to Medical -Surgical Solutions. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ec872447dc648204de1177607e70a43d0658aa3cd1fafb822ebd80ad7a3f18d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8edc0581-4e5e-42e7-981a-b2288f777d06", "node_type": "1", "metadata": {"window": "Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n Moving now to Medical -Surgical Solutions.  Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business.  Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year.  The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n And finishing our business review with Other.  Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business. ", "original_text": "Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year. "}, "hash": "529735204e1a9f11c12784e716fe6979b3bb7cb66289a15245cdb3187c250b7c", "class_name": "RelatedNodeInfo"}}, "text": "Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business. ", "start_char_idx": 2255, "end_char_idx": 2399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8edc0581-4e5e-42e7-981a-b2288f777d06": {"__data__": {"id_": "8edc0581-4e5e-42e7-981a-b2288f777d06", "embedding": null, "metadata": {"window": "Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n Moving now to Medical -Surgical Solutions.  Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business.  Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year.  The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n And finishing our business review with Other.  Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business. ", "original_text": "Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b1d199c-4381-4db7-b7c9-290a736d031b", "node_type": "1", "metadata": {"window": "And while we continue to anticipate improvement in the second half of \nfiscal 2020, we are, however, updating our full -year guidance for Europe.  Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n Moving now to Medical -Surgical Solutions.  Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business.  Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year.  The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n And finishing our business review with Other. ", "original_text": "Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b8a2b7df4ea8c7a2f239399608363340ee57a6d514b8a84efa62436cc08c83da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a17a3dc4-365d-4746-89a7-464c9ff2e689", "node_type": "1", "metadata": {"window": "Moving now to Medical -Surgical Solutions.  Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business.  Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year.  The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n And finishing our business review with Other.  Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business.  Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year. ", "original_text": "The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n"}, "hash": "6deed301310b874fbcbf13f05ed90815b717f0abf8f309c9746ea78503c3feee", "class_name": "RelatedNodeInfo"}}, "text": "Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year. ", "start_char_idx": 2399, "end_char_idx": 2612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a17a3dc4-365d-4746-89a7-464c9ff2e689": {"__data__": {"id_": "a17a3dc4-365d-4746-89a7-464c9ff2e689", "embedding": null, "metadata": {"window": "Moving now to Medical -Surgical Solutions.  Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business.  Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year.  The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n And finishing our business review with Other.  Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business.  Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year. ", "original_text": "The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8edc0581-4e5e-42e7-981a-b2288f777d06", "node_type": "1", "metadata": {"window": "Our updated revenue guidance is flat to \nlow single digi t percentage decline and adjusted operating profit growth in the low single digits.  \n \n Moving now to Medical -Surgical Solutions.  Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business.  Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year.  The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n And finishing our business review with Other.  Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business. ", "original_text": "Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b82197d1d2559f93ff24a3ca59826428cc0a19c51f8c641e4b7b4868e14cc8a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8ad1932-1f98-4d6e-939b-77758925b39c", "node_type": "1", "metadata": {"window": "Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business.  Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year.  The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n And finishing our business review with Other.  Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business.  Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year.  This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n", "original_text": "And finishing our business review with Other. "}, "hash": "800c9f3767b8efe8e447c9ed04f80ccf107f2978ba34d79ef85ed844509173c6", "class_name": "RelatedNodeInfo"}}, "text": "The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n", "start_char_idx": 2612, "end_char_idx": 2786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8ad1932-1f98-4d6e-939b-77758925b39c": {"__data__": {"id_": "e8ad1932-1f98-4d6e-939b-77758925b39c", "embedding": null, "metadata": {"window": "Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business.  Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year.  The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n And finishing our business review with Other.  Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business.  Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year.  This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n", "original_text": "And finishing our business review with Other. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a17a3dc4-365d-4746-89a7-464c9ff2e689", "node_type": "1", "metadata": {"window": "Moving now to Medical -Surgical Solutions.  Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business.  Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year.  The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n And finishing our business review with Other.  Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business.  Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year. ", "original_text": "The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c62bf7263b6b8b098b1b9090e62d99210d28d3a299cde1186733b5802d569fbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "443a9c2f-1b02-478b-8fbd-beb1782fad5e", "node_type": "1", "metadata": {"window": "Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year.  The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n And finishing our business review with Other.  Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business.  Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year.  This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business. ", "original_text": "Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business. "}, "hash": "0a3b225b0ad69209286da46090cf611e2cbf2b84338668ad86438ebca86f504a", "class_name": "RelatedNodeInfo"}}, "text": "And finishing our business review with Other. ", "start_char_idx": 2786, "end_char_idx": 2832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "443a9c2f-1b02-478b-8fbd-beb1782fad5e": {"__data__": {"id_": "443a9c2f-1b02-478b-8fbd-beb1782fad5e", "embedding": null, "metadata": {"window": "Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year.  The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n And finishing our business review with Other.  Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business.  Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year.  This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business. ", "original_text": "Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8ad1932-1f98-4d6e-939b-77758925b39c", "node_type": "1", "metadata": {"window": "Second quarter revenues were $2.1 billion, up 6% year over year, \ndriven by growth in pharmaceutical volumes within our Primary Ca re business.  Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year.  The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n And finishing our business review with Other.  Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business.  Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year.  This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n", "original_text": "And finishing our business review with Other. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "92a9233d2772773c3a41b736b5bea6a5110825159875592d0370d6de80003eb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b044249-ff7b-40a0-9380-89a4d3381306", "node_type": "1", "metadata": {"window": "The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n And finishing our business review with Other.  Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business.  Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year.  This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business.  Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year. ", "original_text": "Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year. "}, "hash": "e95a88966ae32e3b2aa587f9f3ed78a02ea45ffb787d1beeae3e7731a46adb67", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business. ", "start_char_idx": 2832, "end_char_idx": 3063, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b044249-ff7b-40a0-9380-89a4d3381306": {"__data__": {"id_": "6b044249-ff7b-40a0-9380-89a4d3381306", "embedding": null, "metadata": {"window": "The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n And finishing our business review with Other.  Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business.  Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year.  This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business.  Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year. ", "original_text": "Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "443a9c2f-1b02-478b-8fbd-beb1782fad5e", "node_type": "1", "metadata": {"window": "Segment adjusted operating profit \nfor the quarter increased 20% to $166 million, primarily reflecting the previously mentioned organic growth and \nthe lapping of $8 million of bad debt expense in the prior year.  The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n And finishing our business review with Other.  Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business.  Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year.  This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business. ", "original_text": "Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e806162de080b90cbe19e6f26ea7d76984582063469d1a8bafe9dc77bebd75bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08c28aa3-fe0d-4606-9be3-557526290f23", "node_type": "1", "metadata": {"window": "And finishing our business review with Other.  Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business.  Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year.  This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business.  Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year.  And we continue to expect adjusted operating profit \nto be down low  to mid -single digits. ", "original_text": "This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n"}, "hash": "8b109308858a127920bc0ab6e9a5ce5d06d87730b50663c37fcd27cca072836b", "class_name": "RelatedNodeInfo"}}, "text": "Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year. ", "start_char_idx": 3063, "end_char_idx": 3222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08c28aa3-fe0d-4606-9be3-557526290f23": {"__data__": {"id_": "08c28aa3-fe0d-4606-9be3-557526290f23", "embedding": null, "metadata": {"window": "And finishing our business review with Other.  Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business.  Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year.  This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business.  Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year.  And we continue to expect adjusted operating profit \nto be down low  to mid -single digits. ", "original_text": "This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b044249-ff7b-40a0-9380-89a4d3381306", "node_type": "1", "metadata": {"window": "The segment adjusted operating m argin rate was \n807 basis points, an increase of 99 basis points, driven by organic growth and lapping of prior -year bad debt \nexpense.  \n \n And finishing our business review with Other.  Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business.  Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year.  This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business.  Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year. ", "original_text": "Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54eb2db43a1da46832575f9cfc7644bb8d9048ef112b17b13eae29cf1cb237f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "041f86d2-c900-436c-b0ab-b0dbe5eabb24", "node_type": "1", "metadata": {"window": "Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business.  Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year.  This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business.  Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year.  And we continue to expect adjusted operating profit \nto be down low  to mid -single digits.  Year to date, our adjusted equity income from Change Healthcare was $147 \nmillion, and we continue to anticipate the adjusted equity earnings from our investment in Change Healthcare in \nfiscal 2020 to be in the range of $250 million t o $270 million.  \n ", "original_text": "Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business. "}, "hash": "28395ac0a9d7f6b2410a533771ef38fd5c556062be2937fa0c352bf290f213de", "class_name": "RelatedNodeInfo"}}, "text": "This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n", "start_char_idx": 3222, "end_char_idx": 3363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "041f86d2-c900-436c-b0ab-b0dbe5eabb24": {"__data__": {"id_": "041f86d2-c900-436c-b0ab-b0dbe5eabb24", "embedding": null, "metadata": {"window": "Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business.  Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year.  This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business.  Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year.  And we continue to expect adjusted operating profit \nto be down low  to mid -single digits.  Year to date, our adjusted equity income from Change Healthcare was $147 \nmillion, and we continue to anticipate the adjusted equity earnings from our investment in Change Healthcare in \nfiscal 2020 to be in the range of $250 million t o $270 million.  \n ", "original_text": "Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08c28aa3-fe0d-4606-9be3-557526290f23", "node_type": "1", "metadata": {"window": "And finishing our business review with Other.  Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business.  Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year.  This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business.  Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year.  And we continue to expect adjusted operating profit \nto be down low  to mid -single digits. ", "original_text": "This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2466ce80c74be2f98eb3ae35383234278cce904bddeb48474f957fea4bcfc2f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "430bb652-b16c-44e4-8a0f-d02e8e1cfa2b", "node_type": "1", "metadata": {"window": "Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year.  This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business.  Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year.  And we continue to expect adjusted operating profit \nto be down low  to mid -single digits.  Year to date, our adjusted equity income from Change Healthcare was $147 \nmillion, and we continue to anticipate the adjusted equity earnings from our investment in Change Healthcare in \nfiscal 2020 to be in the range of $250 million t o $270 million.  \n ", "original_text": "Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year. "}, "hash": "68a7e72718cf0955871589c42d721fd84edb7ae598496f83ec9976566a3a063b", "class_name": "RelatedNodeInfo"}}, "text": "Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business. ", "start_char_idx": 3363, "end_char_idx": 3743, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "430bb652-b16c-44e4-8a0f-d02e8e1cfa2b": {"__data__": {"id_": "430bb652-b16c-44e4-8a0f-d02e8e1cfa2b", "embedding": null, "metadata": {"window": "Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year.  This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business.  Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year.  And we continue to expect adjusted operating profit \nto be down low  to mid -single digits.  Year to date, our adjusted equity income from Change Healthcare was $147 \nmillion, and we continue to anticipate the adjusted equity earnings from our investment in Change Healthcare in \nfiscal 2020 to be in the range of $250 million t o $270 million.  \n ", "original_text": "Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "041f86d2-c900-436c-b0ab-b0dbe5eabb24", "node_type": "1", "metadata": {"window": "Revenues were $3 billion for the quarter, up 4% year over year due \nto organic growth in the Canadian wholesale business and higher volumes of our prior authorization products \nwithin the prescription technology or MRxTS business.  Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year.  This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business.  Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year.  And we continue to expect adjusted operating profit \nto be down low  to mid -single digits.  Year to date, our adjusted equity income from Change Healthcare was $147 \nmillion, and we continue to anticipate the adjusted equity earnings from our investment in Change Healthcare in \nfiscal 2020 to be in the range of $250 million t o $270 million.  \n ", "original_text": "Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db9dbf5fa2c2d76be6de8f173613bb7eb3dec90cf2790f0be21c8532165d7ad3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cef18880-49f7-4eec-94a1-5788e8665174", "node_type": "1", "metadata": {"window": "This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business.  Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year.  And we continue to expect adjusted operating profit \nto be down low  to mid -single digits.  Year to date, our adjusted equity income from Change Healthcare was $147 \nmillion, and we continue to anticipate the adjusted equity earnings from our investment in Change Healthcare in \nfiscal 2020 to be in the range of $250 million t o $270 million.  \n ", "original_text": "And we continue to expect adjusted operating profit \nto be down low  to mid -single digits. "}, "hash": "ef200e6516907a720bce2acee01f679e33f70f7fb62616f3f6d020d835dd5f13", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year. ", "start_char_idx": 3743, "end_char_idx": 3877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cef18880-49f7-4eec-94a1-5788e8665174": {"__data__": {"id_": "cef18880-49f7-4eec-94a1-5788e8665174", "embedding": null, "metadata": {"window": "This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business.  Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year.  And we continue to expect adjusted operating profit \nto be down low  to mid -single digits.  Year to date, our adjusted equity income from Change Healthcare was $147 \nmillion, and we continue to anticipate the adjusted equity earnings from our investment in Change Healthcare in \nfiscal 2020 to be in the range of $250 million t o $270 million.  \n ", "original_text": "And we continue to expect adjusted operating profit \nto be down low  to mid -single digits. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "430bb652-b16c-44e4-8a0f-d02e8e1cfa2b", "node_type": "1", "metadata": {"window": "Our original revenue guidance for Other reflected the \nanticipated exit of an unprofitable custome r in our Canadian business at the onset of the fiscal year.  This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business.  Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year.  And we continue to expect adjusted operating profit \nto be down low  to mid -single digits.  Year to date, our adjusted equity income from Change Healthcare was $147 \nmillion, and we continue to anticipate the adjusted equity earnings from our investment in Change Healthcare in \nfiscal 2020 to be in the range of $250 million t o $270 million.  \n ", "original_text": "Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e77ab01887089fac34e0c649643c93e91b2a9a8ba747864d9884c3876721178", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96172edf-a056-4ce6-b970-d8fd8764a4f8", "node_type": "1", "metadata": {"window": "Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business.  Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year.  And we continue to expect adjusted operating profit \nto be down low  to mid -single digits.  Year to date, our adjusted equity income from Change Healthcare was $147 \nmillion, and we continue to anticipate the adjusted equity earnings from our investment in Change Healthcare in \nfiscal 2020 to be in the range of $250 million t o $270 million.  \n ", "original_text": "Year to date, our adjusted equity income from Change Healthcare was $147 \nmillion, and we continue to anticipate the adjusted equity earnings from our investment in Change Healthcare in \nfiscal 2020 to be in the range of $250 million t o $270 million.  \n "}, "hash": "5ca24cf24ae20ff3e6b6dc3763a28cb867bdb2f44a695bd21329595ed1aeda32", "class_name": "RelatedNodeInfo"}}, "text": "And we continue to expect adjusted operating profit \nto be down low  to mid -single digits. ", "start_char_idx": 3877, "end_char_idx": 3969, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96172edf-a056-4ce6-b970-d8fd8764a4f8": {"__data__": {"id_": "96172edf-a056-4ce6-b970-d8fd8764a4f8", "embedding": null, "metadata": {"window": "Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business.  Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year.  And we continue to expect adjusted operating profit \nto be down low  to mid -single digits.  Year to date, our adjusted equity income from Change Healthcare was $147 \nmillion, and we continue to anticipate the adjusted equity earnings from our investment in Change Healthcare in \nfiscal 2020 to be in the range of $250 million t o $270 million.  \n ", "original_text": "Year to date, our adjusted equity income from Change Healthcare was $147 \nmillion, and we continue to anticipate the adjusted equity earnings from our investment in Change Healthcare in \nfiscal 2020 to be in the range of $250 million t o $270 million.  \n ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b70bd738-8725-4b16-bdab-efc24137999d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f701a58faebfde78f92f312e0eef5e051f8bf8eec9d799ebf6bd52ded07e1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cef18880-49f7-4eec-94a1-5788e8665174", "node_type": "1", "metadata": {"window": "This \ntransition has been delayed, and as a result we are updating revenue guidance for Other to grow low single digits \nin fiscal 2020.  \n \n Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business.  Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year.  And we continue to expect adjusted operating profit \nto be down low  to mid -single digits.  Year to date, our adjusted equity income from Change Healthcare was $147 \nmillion, and we continue to anticipate the adjusted equity earnings from our investment in Change Healthcare in \nfiscal 2020 to be in the range of $250 million t o $270 million.  \n ", "original_text": "And we continue to expect adjusted operating profit \nto be down low  to mid -single digits. ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "39faafaa69970e405e17ebb1afbba10d7fe3b601777e85fdbea8f2167a31b291", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd16dc02-7353-4383-a845-c6d066139767", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMoving now to corporate expenses.  McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate. ", "original_text": "McKesson Corp.  "}, "hash": "b2c2fb737763e5ab4a39393eb4afb74626b2bc51ffaeb451098bb45d74639f1e", "class_name": "RelatedNodeInfo"}}, "text": "Year to date, our adjusted equity income from Change Healthcare was $147 \nmillion, and we continue to anticipate the adjusted equity earnings from our investment in Change Healthcare in \nfiscal 2020 to be in the range of $250 million t o $270 million.  \n ", "start_char_idx": 3969, "end_char_idx": 4224, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd16dc02-7353-4383-a845-c6d066139767": {"__data__": {"id_": "cd16dc02-7353-4383-a845-c6d066139767", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMoving now to corporate expenses.  McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96172edf-a056-4ce6-b970-d8fd8764a4f8", "node_type": "1", "metadata": {"window": "Other adjusted operating profit decreased 26% to $221 millio n, driven by the prior -year $90 million contractual \nliability reversal and lower contribution from our investment in Change Healthcare, partially offset by higher \ntransaction volumes in our MRxTS business, principally from our electronic prior authorizatio n products and \ngrowth in our Canadian wholesale business.  Excluding the prior -year $90 million contractual liability reversal, \nOther adjusted operating profit grew 5% versus the prior year.  And we continue to expect adjusted operating profit \nto be down low  to mid -single digits.  Year to date, our adjusted equity income from Change Healthcare was $147 \nmillion, and we continue to anticipate the adjusted equity earnings from our investment in Change Healthcare in \nfiscal 2020 to be in the range of $250 million t o $270 million.  \n ", "original_text": "Year to date, our adjusted equity income from Change Healthcare was $147 \nmillion, and we continue to anticipate the adjusted equity earnings from our investment in Change Healthcare in \nfiscal 2020 to be in the range of $250 million t o $270 million.  \n ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7a0cc61c77f91b7f387a18298e8655c8d8a4d7d86b6a7b46c50c428d884fe65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc62b00f-66bd-4761-acff-7d7e2cce6cf5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMoving now to corporate expenses.  McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate.  We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMoving now to corporate expenses. "}, "hash": "438f28fd4ecf4ed633d9fb71745f984e448b43b1fe1116c0f4955b89fda4e1d1", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc62b00f-66bd-4761-acff-7d7e2cce6cf5": {"__data__": {"id_": "fc62b00f-66bd-4761-acff-7d7e2cce6cf5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMoving now to corporate expenses.  McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate.  We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMoving now to corporate expenses. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd16dc02-7353-4383-a845-c6d066139767", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMoving now to corporate expenses.  McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa33e7f3b317d94d508763ecf4c2e4a6b798cd5e4aa248eeb05489d236b31332", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4efdc087-cb9d-4584-a0e2-093c19e0d541", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMoving now to corporate expenses.  McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate.  We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020.  Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n", "original_text": "McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n"}, "hash": "5acc1626b534bf78747993184800deae8ee82093d20e38a2a086c5ca477c891a", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMoving now to corporate expenses. ", "start_char_idx": 16, "end_char_idx": 214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4efdc087-cb9d-4584-a0e2-093c19e0d541": {"__data__": {"id_": "4efdc087-cb9d-4584-a0e2-093c19e0d541", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMoving now to corporate expenses.  McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate.  We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020.  Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n", "original_text": "McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc62b00f-66bd-4761-acff-7d7e2cce6cf5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMoving now to corporate expenses.  McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate.  We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMoving now to corporate expenses. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b97e625933e2113ac083686b78b2155564e0f87bc565b9eaf50748f59f45122a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edf4aa71-c7ef-40a6-997c-085d4b5f5c4c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMoving now to corporate expenses.  McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate.  We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020.  Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n Turning now to cash, which can be found on slide 10. ", "original_text": "McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate. "}, "hash": "54d6187f34f200ed19c0d17f122a5ee420c74bc9fcd1ad1f9d950b2d87a718ac", "class_name": "RelatedNodeInfo"}}, "text": "McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n", "start_char_idx": 214, "end_char_idx": 397, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edf4aa71-c7ef-40a6-997c-085d4b5f5c4c": {"__data__": {"id_": "edf4aa71-c7ef-40a6-997c-085d4b5f5c4c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMoving now to corporate expenses.  McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate.  We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020.  Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n Turning now to cash, which can be found on slide 10. ", "original_text": "McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4efdc087-cb9d-4584-a0e2-093c19e0d541", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMoving now to corporate expenses.  McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate.  We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020.  Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n", "original_text": "McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec88ce59360ca638e153198d97b6fbaf814a9564decfac1aa091e75946661c56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35b60864-fbd6-4280-905c-cac803760c50", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMoving now to corporate expenses.  McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate.  We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020.  Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n Turning now to cash, which can be found on slide 10.  We ended the quarter with a cash ba lance of $1.4 billion. \n", "original_text": "We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020. "}, "hash": "77aa9c8a58666ad3c34978392d62303ef58a29378f588784cad27289bd739fd9", "class_name": "RelatedNodeInfo"}}, "text": "McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate. ", "start_char_idx": 397, "end_char_idx": 520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35b60864-fbd6-4280-905c-cac803760c50": {"__data__": {"id_": "35b60864-fbd6-4280-905c-cac803760c50", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMoving now to corporate expenses.  McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate.  We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020.  Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n Turning now to cash, which can be found on slide 10.  We ended the quarter with a cash ba lance of $1.4 billion. \n", "original_text": "We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edf4aa71-c7ef-40a6-997c-085d4b5f5c4c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMoving now to corporate expenses.  McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate.  We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020.  Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n Turning now to cash, which can be found on slide 10. ", "original_text": "McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7752acab8b9dcf4a9a35b1cd8687621ef422a878cf27ca3d2567e96e963e443d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf17456e-494b-46fc-a2e3-9d1a5e0c644b", "node_type": "1", "metadata": {"window": "McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate.  We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020.  Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n Turning now to cash, which can be found on slide 10.  We ended the quarter with a cash ba lance of $1.4 billion. \n For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations. ", "original_text": "Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n"}, "hash": "db38c59506fb939dbd119612c2d377af896aad118bc364f3457f2c1174702490", "class_name": "RelatedNodeInfo"}}, "text": "We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020. ", "start_char_idx": 520, "end_char_idx": 624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf17456e-494b-46fc-a2e3-9d1a5e0c644b": {"__data__": {"id_": "cf17456e-494b-46fc-a2e3-9d1a5e0c644b", "embedding": null, "metadata": {"window": "McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate.  We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020.  Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n Turning now to cash, which can be found on slide 10.  We ended the quarter with a cash ba lance of $1.4 billion. \n For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations. ", "original_text": "Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35b60864-fbd6-4280-905c-cac803760c50", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMoving now to corporate expenses.  McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate.  We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020.  Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n Turning now to cash, which can be found on slide 10.  We ended the quarter with a cash ba lance of $1.4 billion. \n", "original_text": "We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77fa5a0ed8b63fe4b012d095e9b3a431379b193947ba7ec3573119983bf1cd99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "528ab49d-3406-4e74-84f9-e2e555a88d8c", "node_type": "1", "metadata": {"window": "McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate.  We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020.  Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n Turning now to cash, which can be found on slide 10.  We ended the quarter with a cash ba lance of $1.4 billion. \n For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations.  We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million. ", "original_text": "Turning now to cash, which can be found on slide 10. "}, "hash": "bdfcbb8a8006fa9a3827146ba9ba119c9bb3c9485a6c2d32cb1309be6a242185", "class_name": "RelatedNodeInfo"}}, "text": "Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n", "start_char_idx": 624, "end_char_idx": 855, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "528ab49d-3406-4e74-84f9-e2e555a88d8c": {"__data__": {"id_": "528ab49d-3406-4e74-84f9-e2e555a88d8c", "embedding": null, "metadata": {"window": "McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate.  We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020.  Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n Turning now to cash, which can be found on slide 10.  We ended the quarter with a cash ba lance of $1.4 billion. \n For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations.  We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million. ", "original_text": "Turning now to cash, which can be found on slide 10. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf17456e-494b-46fc-a2e3-9d1a5e0c644b", "node_type": "1", "metadata": {"window": "McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate.  We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020.  Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n Turning now to cash, which can be found on slide 10.  We ended the quarter with a cash ba lance of $1.4 billion. \n For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations. ", "original_text": "Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1cadd9ff1dd43fb7a7279c8205d41a25219f90caabd311ba0d814367779e914", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f21937a7-a417-4c15-9dbb-747c8a87d520", "node_type": "1", "metadata": {"window": "We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020.  Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n Turning now to cash, which can be found on slide 10.  We ended the quarter with a cash ba lance of $1.4 billion. \n For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations.  We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million.  For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n", "original_text": "We ended the quarter with a cash ba lance of $1.4 billion. \n"}, "hash": "351ac2397a47ae55ad8ecaa6d89df3d2508aa2e22bc8bcf073a860130df133eb", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to cash, which can be found on slide 10. ", "start_char_idx": 855, "end_char_idx": 908, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f21937a7-a417-4c15-9dbb-747c8a87d520": {"__data__": {"id_": "f21937a7-a417-4c15-9dbb-747c8a87d520", "embedding": null, "metadata": {"window": "We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020.  Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n Turning now to cash, which can be found on slide 10.  We ended the quarter with a cash ba lance of $1.4 billion. \n For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations.  We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million.  For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n", "original_text": "We ended the quarter with a cash ba lance of $1.4 billion. \n", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "528ab49d-3406-4e74-84f9-e2e555a88d8c", "node_type": "1", "metadata": {"window": "McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate.  We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020.  Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n Turning now to cash, which can be found on slide 10.  We ended the quarter with a cash ba lance of $1.4 billion. \n For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations.  We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million. ", "original_text": "Turning now to cash, which can be found on slide 10. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd5e860a8387eca93f4968cf56cf0a13bad97f61c245448a62cb6651fcce9489", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee672efa-3f2f-411c-9c7c-f28a6f019dfb", "node_type": "1", "metadata": {"window": "Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n Turning now to cash, which can be found on slide 10.  We ended the quarter with a cash ba lance of $1.4 billion. \n For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations.  We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million.  For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter. ", "original_text": "For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations. "}, "hash": "483aa0e57d1fc24f0304f0a1102f4cd31a75281e1ceba0f9c3f8bc6a6e012bc0", "class_name": "RelatedNodeInfo"}}, "text": "We ended the quarter with a cash ba lance of $1.4 billion. \n", "start_char_idx": 908, "end_char_idx": 968, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee672efa-3f2f-411c-9c7c-f28a6f019dfb": {"__data__": {"id_": "ee672efa-3f2f-411c-9c7c-f28a6f019dfb", "embedding": null, "metadata": {"window": "Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n Turning now to cash, which can be found on slide 10.  We ended the quarter with a cash ba lance of $1.4 billion. \n For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations.  We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million.  For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter. ", "original_text": "For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f21937a7-a417-4c15-9dbb-747c8a87d520", "node_type": "1", "metadata": {"window": "We continue to assume opioid -related litigation costs to be approximately $150 million in fiscal 2020.  Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n Turning now to cash, which can be found on slide 10.  We ended the quarter with a cash ba lance of $1.4 billion. \n For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations.  We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million.  For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n", "original_text": "We ended the quarter with a cash ba lance of $1.4 billion. \n", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cba43611df7a7f9a4daeb521ecac3f4f5a080d213d6d243f079a166aa8802f08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d82bd0d-7c74-45c4-9b7f-1525562dc882", "node_type": "1", "metadata": {"window": "Turning now to cash, which can be found on slide 10.  We ended the quarter with a cash ba lance of $1.4 billion. \n For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations.  We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million.  For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter.  I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years. ", "original_text": "We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million. "}, "hash": "33dbb4ab65536bb29d1c5f00278a6f02591631990bf79d77286f772b94d91c0b", "class_name": "RelatedNodeInfo"}}, "text": "For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations. ", "start_char_idx": 968, "end_char_idx": 1060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d82bd0d-7c74-45c4-9b7f-1525562dc882": {"__data__": {"id_": "7d82bd0d-7c74-45c4-9b7f-1525562dc882", "embedding": null, "metadata": {"window": "Turning now to cash, which can be found on slide 10.  We ended the quarter with a cash ba lance of $1.4 billion. \n For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations.  We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million.  For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter.  I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years. ", "original_text": "We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee672efa-3f2f-411c-9c7c-f28a6f019dfb", "node_type": "1", "metadata": {"window": "Based \non the progress against our cost initiative program  and the anticipated timing of planned technology investments, \nwe are updating our corporate expense guidance to a range of $695 million to $745 million for the year.  \n \n Turning now to cash, which can be found on slide 10.  We ended the quarter with a cash ba lance of $1.4 billion. \n For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations.  We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million.  For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter. ", "original_text": "For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "187f4572224081b83c165ee42aa715e078a838a1dc669accdd533b66cbefb3b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4418bf77-0f2c-44d5-a170-cc63eb8c5756", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash ba lance of $1.4 billion. \n For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations.  We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million.  For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter.  I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years.  In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion. ", "original_text": "For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n"}, "hash": "e6680d94abf4a32bc785d262cc73ba9bd9fe36d6e6e78fb83e0c6aaae9db738d", "class_name": "RelatedNodeInfo"}}, "text": "We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million. ", "start_char_idx": 1060, "end_char_idx": 1169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4418bf77-0f2c-44d5-a170-cc63eb8c5756": {"__data__": {"id_": "4418bf77-0f2c-44d5-a170-cc63eb8c5756", "embedding": null, "metadata": {"window": "We ended the quarter with a cash ba lance of $1.4 billion. \n For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations.  We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million.  For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter.  I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years.  In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion. ", "original_text": "For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d82bd0d-7c74-45c4-9b7f-1525562dc882", "node_type": "1", "metadata": {"window": "Turning now to cash, which can be found on slide 10.  We ended the quarter with a cash ba lance of $1.4 billion. \n For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations.  We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million.  For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter.  I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years. ", "original_text": "We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be9fe9e2effd5cfef611bdd9661c4ae7838da9353d45c7712246cc386000ee31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "201f74c7-8b9e-4cdb-83ef-0dd066170f52", "node_type": "1", "metadata": {"window": "For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations.  We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million.  For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter.  I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years.  In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion.  Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n", "original_text": "Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter. "}, "hash": "bff461554dac19bd28594c7df4e36e049c484230cb5a7c40f6674725c4eaf9e5", "class_name": "RelatedNodeInfo"}}, "text": "For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n", "start_char_idx": 1169, "end_char_idx": 1411, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "201f74c7-8b9e-4cdb-83ef-0dd066170f52": {"__data__": {"id_": "201f74c7-8b9e-4cdb-83ef-0dd066170f52", "embedding": null, "metadata": {"window": "For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations.  We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million.  For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter.  I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years.  In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion.  Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n", "original_text": "Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4418bf77-0f2c-44d5-a170-cc63eb8c5756", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash ba lance of $1.4 billion. \n For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations.  We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million.  For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter.  I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years.  In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion. ", "original_text": "For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9db87efa057cf99264e3bd65007746f0e6528189a728ca8da15037a5e4c781c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdb703be-16b0-46ac-99dc-34aa08780672", "node_type": "1", "metadata": {"window": "We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million.  For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter.  I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years.  In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion.  Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year. ", "original_text": "I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years. "}, "hash": "85aad0178492fa295dc7e675be4eede253435bc720c3891ad0896594e294713a", "class_name": "RelatedNodeInfo"}}, "text": "Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter. ", "start_char_idx": 1411, "end_char_idx": 1596, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdb703be-16b0-46ac-99dc-34aa08780672": {"__data__": {"id_": "fdb703be-16b0-46ac-99dc-34aa08780672", "embedding": null, "metadata": {"window": "We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million.  For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter.  I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years.  In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion.  Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year. ", "original_text": "I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "201f74c7-8b9e-4cdb-83ef-0dd066170f52", "node_type": "1", "metadata": {"window": "For the first half of fiscal 2020, McKesson used $159 million in cash flow from operations.  We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million.  For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter.  I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years.  In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion.  Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n", "original_text": "Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf620637bff7f13e56294fe5b5ecdfb01b37d23b00cd4320c32cafa516a5444e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba50cefe-f894-4b54-8868-50428571b111", "node_type": "1", "metadata": {"window": "For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter.  I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years.  In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion.  Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year.  And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n", "original_text": "In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion. "}, "hash": "79f811fe0b42210cf7e65e44f20245b80bd34c5b438becfec4267a8f9e7eda1d", "class_name": "RelatedNodeInfo"}}, "text": "I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years. ", "start_char_idx": 1596, "end_char_idx": 1798, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba50cefe-f894-4b54-8868-50428571b111": {"__data__": {"id_": "ba50cefe-f894-4b54-8868-50428571b111", "embedding": null, "metadata": {"window": "For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter.  I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years.  In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion.  Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year.  And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n", "original_text": "In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdb703be-16b0-46ac-99dc-34aa08780672", "node_type": "1", "metadata": {"window": "We used $184 million \nfor internal capital investment, resulting in negative free cash flow of $343 million.  For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter.  I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years.  In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion.  Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year. ", "original_text": "I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30fc47c7edc318dce2fd8be886931451964361c5e624225360a1abfda4e2cb03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd72cf13-5c0e-4e89-9d73-d07f0c5b3166", "node_type": "1", "metadata": {"window": "Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter.  I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years.  In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion.  Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year.  And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n Let me take a minute to update you on the optimization of our operating model and cost structure. ", "original_text": "Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n"}, "hash": "89d96f989ec2f5eb4a71a7fcba6824c04e8a79f54f071c76b63cf7571b50d843", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion. ", "start_char_idx": 1798, "end_char_idx": 1957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd72cf13-5c0e-4e89-9d73-d07f0c5b3166": {"__data__": {"id_": "dd72cf13-5c0e-4e89-9d73-d07f0c5b3166", "embedding": null, "metadata": {"window": "Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter.  I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years.  In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion.  Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year.  And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n Let me take a minute to update you on the optimization of our operating model and cost structure. ", "original_text": "Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba50cefe-f894-4b54-8868-50428571b111", "node_type": "1", "metadata": {"window": "For the first half of the fiscal \nyear, McKesson also paid $95 million for acquisitions, and we returned a $1.6 billion to our shareholders through \nthe repurchase of $1.4 billion in common stock and payment of $148 million in dividends.  \n \n Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter.  I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years.  In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion.  Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year.  And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n", "original_text": "In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df12836faa223cd357a0248d08d80a4b5e32e1d4a74d1a0392507831e1f56834", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb844866-94b2-46ea-80bc-ed17de4145f3", "node_type": "1", "metadata": {"window": "I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years.  In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion.  Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year.  And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n Let me take a minute to update you on the optimization of our operating model and cost structure.  Our cost \nprogram is called Spend Sma rt. ", "original_text": "Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year. "}, "hash": "0778583625cd0d51f3d1794c4285f0e52498690dbf7b2e7e04d1b1c322b2e9a0", "class_name": "RelatedNodeInfo"}}, "text": "Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n", "start_char_idx": 1957, "end_char_idx": 2166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb844866-94b2-46ea-80bc-ed17de4145f3": {"__data__": {"id_": "cb844866-94b2-46ea-80bc-ed17de4145f3", "embedding": null, "metadata": {"window": "I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years.  In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion.  Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year.  And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n Let me take a minute to update you on the optimization of our operating model and cost structure.  Our cost \nprogram is called Spend Sma rt. ", "original_text": "Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd72cf13-5c0e-4e89-9d73-d07f0c5b3166", "node_type": "1", "metadata": {"window": "Finally, I would remind you that our working capital  metrics and resulting cash flow may be impacted by timing, \nincluding the day of the week that marks the close of a given quarter.  I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years.  In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion.  Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year.  And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n Let me take a minute to update you on the optimization of our operating model and cost structure. ", "original_text": "Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ddc68c0ff5d30574f5d64579e5bbee31c8c5a79dd4221dac47988896a817607c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a59551df-0a82-429a-ace6-bd3b23f850f6", "node_type": "1", "metadata": {"window": "In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion.  Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year.  And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n Let me take a minute to update you on the optimization of our operating model and cost structure.  Our cost \nprogram is called Spend Sma rt.  This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise. ", "original_text": "And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n"}, "hash": "ffb2cb3632803b5f59007da9ccca17c0c0b96af55da7d79ba5e6759ade97461b", "class_name": "RelatedNodeInfo"}}, "text": "Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year. ", "start_char_idx": 2166, "end_char_idx": 2354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a59551df-0a82-429a-ace6-bd3b23f850f6": {"__data__": {"id_": "a59551df-0a82-429a-ace6-bd3b23f850f6", "embedding": null, "metadata": {"window": "In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion.  Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year.  And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n Let me take a minute to update you on the optimization of our operating model and cost structure.  Our cost \nprogram is called Spend Sma rt.  This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise. ", "original_text": "And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb844866-94b2-46ea-80bc-ed17de4145f3", "node_type": "1", "metadata": {"window": "I would also remind you we typically \ngenerate the majority of our annual operating cash flow in the second half of the fiscal  year, with more than $3 \nbillion generated in each of the past two years.  In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion.  Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year.  And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n Let me take a minute to update you on the optimization of our operating model and cost structure.  Our cost \nprogram is called Spend Sma rt. ", "original_text": "Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edf1a24e553b5ba991fbf7bc8eb11062ad46cc415f4094066d401fa88d7bdb04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "239b6c3e-0843-47df-acff-17d046074562", "node_type": "1", "metadata": {"window": "Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year.  And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n Let me take a minute to update you on the optimization of our operating model and cost structure.  Our cost \nprogram is called Spend Sma rt.  This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise.  We're seeing good progress in reducing costs to be a competitive \nand lean operator. ", "original_text": "Let me take a minute to update you on the optimization of our operating model and cost structure. "}, "hash": "689e16679ea2dcd7a9c210b87067101b78f6ace69d318d11fe76d52c7239d932", "class_name": "RelatedNodeInfo"}}, "text": "And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n", "start_char_idx": 2354, "end_char_idx": 2630, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "239b6c3e-0843-47df-acff-17d046074562": {"__data__": {"id_": "239b6c3e-0843-47df-acff-17d046074562", "embedding": null, "metadata": {"window": "Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year.  And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n Let me take a minute to update you on the optimization of our operating model and cost structure.  Our cost \nprogram is called Spend Sma rt.  This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise.  We're seeing good progress in reducing costs to be a competitive \nand lean operator. ", "original_text": "Let me take a minute to update you on the optimization of our operating model and cost structure. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a59551df-0a82-429a-ace6-bd3b23f850f6", "node_type": "1", "metadata": {"window": "In fiscal 2020, we continue to expect internal capital investments \nof between $500 million and $700 million and free cash flow of $2.8 billion to $3 billion.  Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year.  And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n Let me take a minute to update you on the optimization of our operating model and cost structure.  Our cost \nprogram is called Spend Sma rt.  This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise. ", "original_text": "And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4fc18844b1590a0040a2bfc1a130e067426d9e9910f416163a58c67faa51da47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b31ecd45-d0f4-4932-adc7-d1200a5f7386", "node_type": "1", "metadata": {"window": "Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year.  And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n Let me take a minute to update you on the optimization of our operating model and cost structure.  Our cost \nprogram is called Spend Sma rt.  This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise.  We're seeing good progress in reducing costs to be a competitive \nand lean operator.  As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n", "original_text": "Our cost \nprogram is called Spend Sma rt. "}, "hash": "0c6f9be533e5db56bf5962253cd4d988e6d17aca1462b49c6386d225d31e36dc", "class_name": "RelatedNodeInfo"}}, "text": "Let me take a minute to update you on the optimization of our operating model and cost structure. ", "start_char_idx": 2630, "end_char_idx": 2728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b31ecd45-d0f4-4932-adc7-d1200a5f7386": {"__data__": {"id_": "b31ecd45-d0f4-4932-adc7-d1200a5f7386", "embedding": null, "metadata": {"window": "Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year.  And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n Let me take a minute to update you on the optimization of our operating model and cost structure.  Our cost \nprogram is called Spend Sma rt.  This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise.  We're seeing good progress in reducing costs to be a competitive \nand lean operator.  As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n", "original_text": "Our cost \nprogram is called Spend Sma rt. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "239b6c3e-0843-47df-acff-17d046074562", "node_type": "1", "metadata": {"window": "Our disciplined approach  \nto capital deployment is committed to maintaining our investment -grade rating, which underpins our financial \nflexibility, and delivering value and returns to our shareholders.  \n \n Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year.  And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n Let me take a minute to update you on the optimization of our operating model and cost structure.  Our cost \nprogram is called Spend Sma rt.  This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise.  We're seeing good progress in reducing costs to be a competitive \nand lean operator. ", "original_text": "Let me take a minute to update you on the optimization of our operating model and cost structure. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f54e93daaf6f0eb15868fc749fa5e89995b0160a5c962ddf678bb03628239f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8a8ce5e-397d-4105-8f4d-302d52fe23df", "node_type": "1", "metadata": {"window": "And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n Let me take a minute to update you on the optimization of our operating model and cost structure.  Our cost \nprogram is called Spend Sma rt.  This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise.  We're seeing good progress in reducing costs to be a competitive \nand lean operator.  As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers. ", "original_text": "This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise. "}, "hash": "cd907ea0caba335c6597c3c08f5a4cc613819f50d764c7587a3c5397a04b0f7e", "class_name": "RelatedNodeInfo"}}, "text": "Our cost \nprogram is called Spend Sma rt. ", "start_char_idx": 2728, "end_char_idx": 2770, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8a8ce5e-397d-4105-8f4d-302d52fe23df": {"__data__": {"id_": "d8a8ce5e-397d-4105-8f4d-302d52fe23df", "embedding": null, "metadata": {"window": "And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n Let me take a minute to update you on the optimization of our operating model and cost structure.  Our cost \nprogram is called Spend Sma rt.  This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise.  We're seeing good progress in reducing costs to be a competitive \nand lean operator.  As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers. ", "original_text": "This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b31ecd45-d0f4-4932-adc7-d1200a5f7386", "node_type": "1", "metadata": {"window": "Before I wrap up, we are updating our guidance around the impact of foreign cu rrency exchange rate movements \nto a net unfavorable impact of up to $0.05 per diluted share year over year.  And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n Let me take a minute to update you on the optimization of our operating model and cost structure.  Our cost \nprogram is called Spend Sma rt.  This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise.  We're seeing good progress in reducing costs to be a competitive \nand lean operator.  As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n", "original_text": "Our cost \nprogram is called Spend Sma rt. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27cab7895d976c5cac77dc90e0f97ac57ce069840de28be25541f8ecf8895c64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1817dad5-4354-447c-a6e3-57eca6c00972", "node_type": "1", "metadata": {"window": "Let me take a minute to update you on the optimization of our operating model and cost structure.  Our cost \nprogram is called Spend Sma rt.  This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise.  We're seeing good progress in reducing costs to be a competitive \nand lean operator.  As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers.  We've already made great progress in transforming finance and IT. ", "original_text": "We're seeing good progress in reducing costs to be a competitive \nand lean operator. "}, "hash": "10a9324c9bccc3613154d5cdd600e7fdbe9f5c444f7dc36f66593ca373f38e92", "class_name": "RelatedNodeInfo"}}, "text": "This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise. ", "start_char_idx": 2770, "end_char_idx": 2897, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1817dad5-4354-447c-a6e3-57eca6c00972": {"__data__": {"id_": "1817dad5-4354-447c-a6e3-57eca6c00972", "embedding": null, "metadata": {"window": "Let me take a minute to update you on the optimization of our operating model and cost structure.  Our cost \nprogram is called Spend Sma rt.  This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise.  We're seeing good progress in reducing costs to be a competitive \nand lean operator.  As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers.  We've already made great progress in transforming finance and IT. ", "original_text": "We're seeing good progress in reducing costs to be a competitive \nand lean operator. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8a8ce5e-397d-4105-8f4d-302d52fe23df", "node_type": "1", "metadata": {"window": "And in terms of fiscal 2020 earnings \nprogression, we continue to expect that the fourth quarter will be our largest in terms of EPS contribution, si milar \nto prior years, and the first half earnings progression as compared to the second half will be similar to FY 2019.  \n \n Let me take a minute to update you on the optimization of our operating model and cost structure.  Our cost \nprogram is called Spend Sma rt.  This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise.  We're seeing good progress in reducing costs to be a competitive \nand lean operator.  As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers. ", "original_text": "This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d01780fead36e47965c166531ec791440ab96ac2d2ab921182915c1db0b16948", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ff7c952-7d7e-4c2f-bc7d-437d8cf78a3a", "node_type": "1", "metadata": {"window": "Our cost \nprogram is called Spend Sma rt.  This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise.  We're seeing good progress in reducing costs to be a competitive \nand lean operator.  As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers.  We've already made great progress in transforming finance and IT.  And we've seen tangible \nresults from our investments in technology, more specifically data and analytics. ", "original_text": "As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n"}, "hash": "e6ba2e3d858fe90bded25e009425eed19a0d1befa7619c5bcfd9e3e69ab787ed", "class_name": "RelatedNodeInfo"}}, "text": "We're seeing good progress in reducing costs to be a competitive \nand lean operator. ", "start_char_idx": 2897, "end_char_idx": 2982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ff7c952-7d7e-4c2f-bc7d-437d8cf78a3a": {"__data__": {"id_": "8ff7c952-7d7e-4c2f-bc7d-437d8cf78a3a", "embedding": null, "metadata": {"window": "Our cost \nprogram is called Spend Sma rt.  This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise.  We're seeing good progress in reducing costs to be a competitive \nand lean operator.  As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers.  We've already made great progress in transforming finance and IT.  And we've seen tangible \nresults from our investments in technology, more specifically data and analytics. ", "original_text": "As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1817dad5-4354-447c-a6e3-57eca6c00972", "node_type": "1", "metadata": {"window": "Let me take a minute to update you on the optimization of our operating model and cost structure.  Our cost \nprogram is called Spend Sma rt.  This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise.  We're seeing good progress in reducing costs to be a competitive \nand lean operator.  As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers.  We've already made great progress in transforming finance and IT. ", "original_text": "We're seeing good progress in reducing costs to be a competitive \nand lean operator. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50de14350de094a3a196df252b8c519ae2fda750a8402d4cf1c8e9a8fa0d2de9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff7186e3-6bda-428c-b172-059a35bb1f79", "node_type": "1", "metadata": {"window": "This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise.  We're seeing good progress in reducing costs to be a competitive \nand lean operator.  As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers.  We've already made great progress in transforming finance and IT.  And we've seen tangible \nresults from our investments in technology, more specifically data and analytics.  And we're confident that our \nfocus in this area will unlock additional be nefits. ", "original_text": "Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers. "}, "hash": "337aee12d9a8c170cfcb8237622e111291472889765b3b5dbb3058f2e974f012", "class_name": "RelatedNodeInfo"}}, "text": "As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n", "start_char_idx": 2982, "end_char_idx": 3304, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff7186e3-6bda-428c-b172-059a35bb1f79": {"__data__": {"id_": "ff7186e3-6bda-428c-b172-059a35bb1f79", "embedding": null, "metadata": {"window": "This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise.  We're seeing good progress in reducing costs to be a competitive \nand lean operator.  As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers.  We've already made great progress in transforming finance and IT.  And we've seen tangible \nresults from our investments in technology, more specifically data and analytics.  And we're confident that our \nfocus in this area will unlock additional be nefits. ", "original_text": "Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ff7c952-7d7e-4c2f-bc7d-437d8cf78a3a", "node_type": "1", "metadata": {"window": "Our cost \nprogram is called Spend Sma rt.  This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise.  We're seeing good progress in reducing costs to be a competitive \nand lean operator.  As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers.  We've already made great progress in transforming finance and IT.  And we've seen tangible \nresults from our investments in technology, more specifically data and analytics. ", "original_text": "As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b387b31f52e95ab4cab6206fd7ef8a7ac786140abee9abf07be542119ec34699", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cef1816-79ae-458d-ba11-ceb632239593", "node_type": "1", "metadata": {"window": "We're seeing good progress in reducing costs to be a competitive \nand lean operator.  As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers.  We've already made great progress in transforming finance and IT.  And we've seen tangible \nresults from our investments in technology, more specifically data and analytics.  And we're confident that our \nfocus in this area will unlock additional be nefits.  The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n", "original_text": "We've already made great progress in transforming finance and IT. "}, "hash": "a9039d916d07b858e16d77cd7d79b3dde0a7135fc2ed302224d1b64126cefac0", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers. ", "start_char_idx": 3304, "end_char_idx": 3557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cef1816-79ae-458d-ba11-ceb632239593": {"__data__": {"id_": "7cef1816-79ae-458d-ba11-ceb632239593", "embedding": null, "metadata": {"window": "We're seeing good progress in reducing costs to be a competitive \nand lean operator.  As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers.  We've already made great progress in transforming finance and IT.  And we've seen tangible \nresults from our investments in technology, more specifically data and analytics.  And we're confident that our \nfocus in this area will unlock additional be nefits.  The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n", "original_text": "We've already made great progress in transforming finance and IT. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff7186e3-6bda-428c-b172-059a35bb1f79", "node_type": "1", "metadata": {"window": "This emphasizes that everyone in the organization must think like an owner and \nthat we will leverage to scale the enterprise.  We're seeing good progress in reducing costs to be a competitive \nand lean operator.  As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers.  We've already made great progress in transforming finance and IT.  And we've seen tangible \nresults from our investments in technology, more specifically data and analytics.  And we're confident that our \nfocus in this area will unlock additional be nefits. ", "original_text": "Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5886210c298e46dc8f48db221d5a7663514aae37d195df19336dd2e95f69616b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ef37c75-bab1-41c7-ad7a-8ddc42588c22", "node_type": "1", "metadata": {"window": "As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers.  We've already made great progress in transforming finance and IT.  And we've seen tangible \nresults from our investments in technology, more specifically data and analytics.  And we're confident that our \nfocus in this area will unlock additional be nefits.  The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise. ", "original_text": "And we've seen tangible \nresults from our investments in technology, more specifically data and analytics. "}, "hash": "06a61218dc4c0063bc8b29529777ae2470565ad918cddeabdabaf61885e8990a", "class_name": "RelatedNodeInfo"}}, "text": "We've already made great progress in transforming finance and IT. ", "start_char_idx": 3557, "end_char_idx": 3623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ef37c75-bab1-41c7-ad7a-8ddc42588c22": {"__data__": {"id_": "0ef37c75-bab1-41c7-ad7a-8ddc42588c22", "embedding": null, "metadata": {"window": "As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers.  We've already made great progress in transforming finance and IT.  And we've seen tangible \nresults from our investments in technology, more specifically data and analytics.  And we're confident that our \nfocus in this area will unlock additional be nefits.  The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise. ", "original_text": "And we've seen tangible \nresults from our investments in technology, more specifically data and analytics. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cef1816-79ae-458d-ba11-ceb632239593", "node_type": "1", "metadata": {"window": "We're seeing good progress in reducing costs to be a competitive \nand lean operator.  As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers.  We've already made great progress in transforming finance and IT.  And we've seen tangible \nresults from our investments in technology, more specifically data and analytics.  And we're confident that our \nfocus in this area will unlock additional be nefits.  The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n", "original_text": "We've already made great progress in transforming finance and IT. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d51e9ee6b5a64de08d7f1ea1fc08a7c90777c7df9ea51ec3fcc68b6bde94de1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc12fd39-9c4e-4db4-ad1d-8b907cc0026c", "node_type": "1", "metadata": {"window": "Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers.  We've already made great progress in transforming finance and IT.  And we've seen tangible \nresults from our investments in technology, more specifically data and analytics.  And we're confident that our \nfocus in this area will unlock additional be nefits.  The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise.  As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n", "original_text": "And we're confident that our \nfocus in this area will unlock additional be nefits. "}, "hash": "76182385b3038036dbc21f856d31335372af159ca54c95133a482d335901a513", "class_name": "RelatedNodeInfo"}}, "text": "And we've seen tangible \nresults from our investments in technology, more specifically data and analytics. ", "start_char_idx": 3623, "end_char_idx": 3730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc12fd39-9c4e-4db4-ad1d-8b907cc0026c": {"__data__": {"id_": "dc12fd39-9c4e-4db4-ad1d-8b907cc0026c", "embedding": null, "metadata": {"window": "Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers.  We've already made great progress in transforming finance and IT.  And we've seen tangible \nresults from our investments in technology, more specifically data and analytics.  And we're confident that our \nfocus in this area will unlock additional be nefits.  The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise.  As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n", "original_text": "And we're confident that our \nfocus in this area will unlock additional be nefits. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ef37c75-bab1-41c7-ad7a-8ddc42588c22", "node_type": "1", "metadata": {"window": "As we have stated previously, we expect th at a portion of these savings will flow through profit, \nas evidenced by our lower corporate expense guide and overall operating expense results, and a portion will be \nreinvested in growth, such as the investments I discussed earlier in oncology and manufac turer services.  \n \n Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers.  We've already made great progress in transforming finance and IT.  And we've seen tangible \nresults from our investments in technology, more specifically data and analytics.  And we're confident that our \nfocus in this area will unlock additional be nefits.  The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise. ", "original_text": "And we've seen tangible \nresults from our investments in technology, more specifically data and analytics. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0fb7bb47884bc804ff490e66f4857a5d235f2d4399b798f795ef11533d6763d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7cf11a0-b7f4-4c19-9788-096aa1dea0bf", "node_type": "1", "metadata": {"window": "We've already made great progress in transforming finance and IT.  And we've seen tangible \nresults from our investments in technology, more specifically data and analytics.  And we're confident that our \nfocus in this area will unlock additional be nefits.  The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise.  As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n With that, I'll turn the call over to the operator for your questions. ", "original_text": "The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n"}, "hash": "98cffd1672df5c78b576f67e6a61bc880f47cecb6135f12961032a3a3d18eaaa", "class_name": "RelatedNodeInfo"}}, "text": "And we're confident that our \nfocus in this area will unlock additional be nefits. ", "start_char_idx": 3730, "end_char_idx": 3813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7cf11a0-b7f4-4c19-9788-096aa1dea0bf": {"__data__": {"id_": "f7cf11a0-b7f4-4c19-9788-096aa1dea0bf", "embedding": null, "metadata": {"window": "We've already made great progress in transforming finance and IT.  And we've seen tangible \nresults from our investments in technology, more specifically data and analytics.  And we're confident that our \nfocus in this area will unlock additional be nefits.  The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise.  As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n With that, I'll turn the call over to the operator for your questions. ", "original_text": "The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc12fd39-9c4e-4db4-ad1d-8b907cc0026c", "node_type": "1", "metadata": {"window": "Additionally, we are on track to successfully transition several business unit functional and back -office services to \na more centralized hub model, allowing us to further increase standardization, gain efficiencies, and drive focus to \nour customers.  We've already made great progress in transforming finance and IT.  And we've seen tangible \nresults from our investments in technology, more specifically data and analytics.  And we're confident that our \nfocus in this area will unlock additional be nefits.  The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise.  As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n", "original_text": "And we're confident that our \nfocus in this area will unlock additional be nefits. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "daf66be1aaadbd776d67fea6e18712d1ef38756171aa9f812961a9e9bfd8a109", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49163009-bf74-48a8-97dc-57debddd822b", "node_type": "1", "metadata": {"window": "And we've seen tangible \nresults from our investments in technology, more specifically data and analytics.  And we're confident that our \nfocus in this area will unlock additional be nefits.  The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise.  As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate. ", "original_text": "In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise. "}, "hash": "0d205f700ccf87929a91ebb28b7221beb262d8c4bc2747f073a4b0b75af3cbd8", "class_name": "RelatedNodeInfo"}}, "text": "The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n", "start_char_idx": 3813, "end_char_idx": 3949, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49163009-bf74-48a8-97dc-57debddd822b": {"__data__": {"id_": "49163009-bf74-48a8-97dc-57debddd822b", "embedding": null, "metadata": {"window": "And we've seen tangible \nresults from our investments in technology, more specifically data and analytics.  And we're confident that our \nfocus in this area will unlock additional be nefits.  The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise.  As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate. ", "original_text": "In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7cf11a0-b7f4-4c19-9788-096aa1dea0bf", "node_type": "1", "metadata": {"window": "We've already made great progress in transforming finance and IT.  And we've seen tangible \nresults from our investments in technology, more specifically data and analytics.  And we're confident that our \nfocus in this area will unlock additional be nefits.  The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise.  As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n With that, I'll turn the call over to the operator for your questions. ", "original_text": "The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8e8f763b1b302486c36618104425dc77e72e61c6d5f44bc06703d7314ab1a99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af464f57-84fe-4664-8e50-7f948944d067", "node_type": "1", "metadata": {"window": "And we're confident that our \nfocus in this area will unlock additional be nefits.  The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise.  As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n"}, "hash": "89da35d4ea12953bd862179ac5a86641c98734141135cf4bdad9e6dcdc61ee0f", "class_name": "RelatedNodeInfo"}}, "text": "In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise. ", "start_char_idx": 3949, "end_char_idx": 4148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af464f57-84fe-4664-8e50-7f948944d067": {"__data__": {"id_": "af464f57-84fe-4664-8e50-7f948944d067", "embedding": null, "metadata": {"window": "And we're confident that our \nfocus in this area will unlock additional be nefits.  The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise.  As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49163009-bf74-48a8-97dc-57debddd822b", "node_type": "1", "metadata": {"window": "And we've seen tangible \nresults from our investments in technology, more specifically data and analytics.  And we're confident that our \nfocus in this area will unlock additional be nefits.  The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise.  As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate. ", "original_text": "In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42b54254ffbb898ee7afc98e9e20d2f0cd83e83a150c3923323fd7bc56ad33a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7163724-725f-4390-8767-91ef930e634f", "node_type": "1", "metadata": {"window": "The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise.  As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "With that, I'll turn the call over to the operator for your questions. "}, "hash": "40edc017f23ba5a5de9a77a1a8bc8a828ec7ad61c7cd7d7adecfc0e054f522ac", "class_name": "RelatedNodeInfo"}}, "text": "As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n", "start_char_idx": 4148, "end_char_idx": 4266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7163724-725f-4390-8767-91ef930e634f": {"__data__": {"id_": "c7163724-725f-4390-8767-91ef930e634f", "embedding": null, "metadata": {"window": "The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise.  As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "With that, I'll turn the call over to the operator for your questions. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af464f57-84fe-4664-8e50-7f948944d067", "node_type": "1", "metadata": {"window": "And we're confident that our \nfocus in this area will unlock additional be nefits.  The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise.  As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82139956b34fc97abd4f2c0e40d2d2d0f8e5f9558883ed414d0f990b3c6e1989", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da9ddd8c-9bd8-49bd-9a97-10eb7ec3d76d", "node_type": "1", "metadata": {"window": "In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise.  As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate. "}, "hash": "a8fa00aec856b926620d0fc678c1c9299e4d99d07d1dd73b497b5566fb9768bb", "class_name": "RelatedNodeInfo"}}, "text": "With that, I'll turn the call over to the operator for your questions. ", "start_char_idx": 4266, "end_char_idx": 4337, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da9ddd8c-9bd8-49bd-9a97-10eb7ec3d76d": {"__data__": {"id_": "da9ddd8c-9bd8-49bd-9a97-10eb7ec3d76d", "embedding": null, "metadata": {"window": "In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise.  As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7163724-725f-4390-8767-91ef930e634f", "node_type": "1", "metadata": {"window": "The collective efforts and focus of our associates across the \nenterprise have resulted in meaningful savings for the organization.  \n \n In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise.  As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "With that, I'll turn the call over to the operator for your questions. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb20a8f99b8487b7da8bbd3624bb59d8a48db51a0651207db76fb81951867360", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbebbc0c-89ab-4b8d-a3f8-75a06c416c2e", "node_type": "1", "metadata": {"window": "As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "Operator?  \n  "}, "hash": "66c2ad71b59bd649ab95ef546084dc4366b8fef30b4b50e339528c8ed6500ae8", "class_name": "RelatedNodeInfo"}}, "text": "In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate. ", "start_char_idx": 4337, "end_char_idx": 4482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbebbc0c-89ab-4b8d-a3f8-75a06c416c2e": {"__data__": {"id_": "dbebbc0c-89ab-4b8d-a3f8-75a06c416c2e", "embedding": null, "metadata": {"window": "As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "Operator?  \n  ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0931f8ae-0095-4499-aa82-d2680f84c6de", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b89f12006ddaa4a70d9a34c2e0e744b6786befc28b9435eca6daa8346ee7bed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da9ddd8c-9bd8-49bd-9a97-10eb7ec3d76d", "node_type": "1", "metadata": {"window": "In closing, we are encouraged by the continued positive momentum across our businesses through the first half of \nfiscal 2020, led by the focus and execution of our associates across the enterprise.  As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate. ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76d134d217525d2b228340940db3b0a2eee3bc368be29359158d413d206340d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0dc51c7e-44c7-47bd-9a04-bc5809e8ff06", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch.  Your line is open.  \n ", "original_text": "McKesson Corp.  "}, "hash": "11b6bd34f859f49260193430d20488622c3692b63b3a83a50dd99b96ce129b6d", "class_name": "RelatedNodeInfo"}}, "text": "Operator?  \n  ", "start_char_idx": 4482, "end_char_idx": 4496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0dc51c7e-44c7-47bd-9a04-bc5809e8ff06": {"__data__": {"id_": "0dc51c7e-44c7-47bd-9a04-bc5809e8ff06", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch.  Your line is open.  \n ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbebbc0c-89ab-4b8d-a3f8-75a06c416c2e", "node_type": "1", "metadata": {"window": "As a result, we are reiterating \nour fiscal 2020 outlook of adjusted earnings per diluted share of $14 to $14.60.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ", "original_text": "Operator?  \n  ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "483dbb576756eb97da2f36f35ce32d7f3ad9af346dd3f1261d1b158f8adb6eb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e9443f0-d73d-49ca-bc00-a6f98629a23b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. "}, "hash": "399b3aeed025dff6b1ae83324724fc589214b489cbd982e80eee9d0fe2cb170c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e9443f0-d73d-49ca-bc00-a6f98629a23b": {"__data__": {"id_": "6e9443f0-d73d-49ca-bc00-a6f98629a23b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0dc51c7e-44c7-47bd-9a04-bc5809e8ff06", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch.  Your line is open.  \n ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b8ab1e3ab88c1eef72288c5ae04e4007c74242168d4d9b63fab26bb429f297f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7aa55f4a-7d0a-495d-916f-78dd2f1aa2fd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU. ", "original_text": "[Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch. "}, "hash": "1c9d85de65b0de0e4f19271aec5c3dad80611e3d90efb472d2e294f592c47d46", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "start_char_idx": 16, "end_char_idx": 238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7aa55f4a-7d0a-495d-916f-78dd2f1aa2fd": {"__data__": {"id_": "7aa55f4a-7d0a-495d-916f-78dd2f1aa2fd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU. ", "original_text": "[Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e9443f0-d73d-49ca-bc00-a6f98629a23b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ebec6fbc5fbf8e00b0f411fdc9aa8cc4a611800f2457a6ba9a6978170d0aff9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22eb43aa-0e89-468d-aff9-ef69b2995fc0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU.  Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n ", "original_text": "Your line is open.  \n "}, "hash": "9c5f617b8f1f19e4cca576501e1429dc76c352746cdab48bcb5510aae20a90f5", "class_name": "RelatedNodeInfo"}}, "text": "[Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch. ", "start_char_idx": 238, "end_char_idx": 340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22eb43aa-0e89-468d-aff9-ef69b2995fc0": {"__data__": {"id_": "22eb43aa-0e89-468d-aff9-ef69b2995fc0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU.  Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n ", "original_text": "Your line is open.  \n ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7aa55f4a-7d0a-495d-916f-78dd2f1aa2fd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU. ", "original_text": "[Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c48048386680702fd77deb16320542a61ae8650473fbf251b9797bd03b0cd9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "005c1aa9-ae2f-4225-895c-3f8b8a8a2fe5", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU.  Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. "}, "hash": "07da62a3fe1b10e30f5f49b0064185d3a61e5f876c9155036c012fa3bf138c01", "class_name": "RelatedNodeInfo"}}, "text": "Your line is open.  \n ", "start_char_idx": 340, "end_char_idx": 362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "005c1aa9-ae2f-4225-895c-3f8b8a8a2fe5": {"__data__": {"id_": "005c1aa9-ae2f-4225-895c-3f8b8a8a2fe5", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU.  Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22eb43aa-0e89-468d-aff9-ef69b2995fc0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU.  Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n ", "original_text": "Your line is open.  \n ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a275b424afad7f3b2df8618c5fb6b40516e409acbb5f84f0dd6962328dfb66be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4f03459-e1ff-44e7-a24f-814a4cf85ab3", "node_type": "1", "metadata": {"window": "[Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU.  Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, hey, Eric. ", "original_text": "Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU. "}, "hash": "dea35f3eb22ef699e49e01ef59286b689953b0aeb3964e8ebe3fdb7e98bf4895", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "start_char_idx": 362, "end_char_idx": 679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4f03459-e1ff-44e7-a24f-814a4cf85ab3": {"__data__": {"id_": "f4f03459-e1ff-44e7-a24f-814a4cf85ab3", "embedding": null, "metadata": {"window": "[Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU.  Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, hey, Eric. ", "original_text": "Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "005c1aa9-ae2f-4225-895c-3f8b8a8a2fe5", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU.  Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8e011af94c4669231be71d0a4690d945c479763029327a573c5c1161ec7d129", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c05a166-0ca0-4a9e-8ca3-b7e8ffe25a50", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU.  Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, hey, Eric.  Thanks for that question. ", "original_text": "Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n "}, "hash": "a0edaa4d295a6b44816680d923f9520500cac143eb28cab3296c901f2af8f3fd", "class_name": "RelatedNodeInfo"}}, "text": "Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU. ", "start_char_idx": 679, "end_char_idx": 818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c05a166-0ca0-4a9e-8ca3-b7e8ffe25a50": {"__data__": {"id_": "3c05a166-0ca0-4a9e-8ca3-b7e8ffe25a50", "embedding": null, "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU.  Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, hey, Eric.  Thanks for that question. ", "original_text": "Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4f03459-e1ff-44e7-a24f-814a4cf85ab3", "node_type": "1", "metadata": {"window": "[Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU.  Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, hey, Eric. ", "original_text": "Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a45f49a2ae374a20b7deae30845cb4e46de353fb13ef59f65ebdb1034cfec1c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d26b5eb-dc78-40bd-b021-1c9d3462ada9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU.  Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, hey, Eric.  Thanks for that question.  As we ta lked about, we had significant growth in revenues in the \nquarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "97d224a867bb929b580ee75d466304145c46591837bd48dff36d1474ad68e5e9", "class_name": "RelatedNodeInfo"}}, "text": "Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n ", "start_char_idx": 818, "end_char_idx": 936, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d26b5eb-dc78-40bd-b021-1c9d3462ada9": {"__data__": {"id_": "8d26b5eb-dc78-40bd-b021-1c9d3462ada9", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU.  Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, hey, Eric.  Thanks for that question.  As we ta lked about, we had significant growth in revenues in the \nquarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c05a166-0ca0-4a9e-8ca3-b7e8ffe25a50", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU.  Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, hey, Eric.  Thanks for that question. ", "original_text": "Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "84774a8a79a7262af25335c04474c1c5e1be84519a853209c52bc388422026b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54a1492d-5739-4f72-a982-d01694deda0b", "node_type": "1", "metadata": {"window": "Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU.  Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, hey, Eric.  Thanks for that question.  As we ta lked about, we had significant growth in revenues in the \nquarter.  And as I mentioned, specifically in our U.S. ", "original_text": "A \nYeah, hey, Eric. "}, "hash": "835648afae5e06b8ba0968185cee43fa6791d525e8d3880d3fa565d5fec4246d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 936, "end_char_idx": 1262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54a1492d-5739-4f72-a982-d01694deda0b": {"__data__": {"id_": "54a1492d-5739-4f72-a982-d01694deda0b", "embedding": null, "metadata": {"window": "Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU.  Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, hey, Eric.  Thanks for that question.  As we ta lked about, we had significant growth in revenues in the \nquarter.  And as I mentioned, specifically in our U.S. ", "original_text": "A \nYeah, hey, Eric. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d26b5eb-dc78-40bd-b021-1c9d3462ada9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU.  Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, hey, Eric.  Thanks for that question.  As we ta lked about, we had significant growth in revenues in the \nquarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4db757b68cef8fd8f4fed426c81412bedcb87d9294bb0c182bab20cdd49509df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd2ca06c-bb18-4247-99de-d13973e20a12", "node_type": "1", "metadata": {"window": "Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, hey, Eric.  Thanks for that question.  As we ta lked about, we had significant growth in revenues in the \nquarter.  And as I mentioned, specifically in our U.S.  Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year. ", "original_text": "Thanks for that question. "}, "hash": "4160d30129524685e9679d5efbb304ea19b7ca52e4beff3e4a064b542f969928", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, hey, Eric. ", "start_char_idx": 1262, "end_char_idx": 1282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd2ca06c-bb18-4247-99de-d13973e20a12": {"__data__": {"id_": "fd2ca06c-bb18-4247-99de-d13973e20a12", "embedding": null, "metadata": {"window": "Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, hey, Eric.  Thanks for that question.  As we ta lked about, we had significant growth in revenues in the \nquarter.  And as I mentioned, specifically in our U.S.  Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year. ", "original_text": "Thanks for that question. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54a1492d-5739-4f72-a982-d01694deda0b", "node_type": "1", "metadata": {"window": "Maybe to begin, it's hard to disaggregate the underlying gross margin trend for pharma in particular, \ngiven what has  going on in the EU.  Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, hey, Eric.  Thanks for that question.  As we ta lked about, we had significant growth in revenues in the \nquarter.  And as I mentioned, specifically in our U.S. ", "original_text": "A \nYeah, hey, Eric. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdc530656826ebc958aa66648d37f2b3ff354aeca31338896c977914dafd3e55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4be3590-8335-4170-b0cd-e49467aa7f5c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, hey, Eric.  Thanks for that question.  As we ta lked about, we had significant growth in revenues in the \nquarter.  And as I mentioned, specifically in our U.S.  Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year.  And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere. ", "original_text": "As we ta lked about, we had significant growth in revenues in the \nquarter. "}, "hash": "b2e3187f37fcbfd190977f6ad422bdf4854e7635007919a36254d0cf84cfda01", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for that question. ", "start_char_idx": 1282, "end_char_idx": 1308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4be3590-8335-4170-b0cd-e49467aa7f5c": {"__data__": {"id_": "f4be3590-8335-4170-b0cd-e49467aa7f5c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, hey, Eric.  Thanks for that question.  As we ta lked about, we had significant growth in revenues in the \nquarter.  And as I mentioned, specifically in our U.S.  Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year.  And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere. ", "original_text": "As we ta lked about, we had significant growth in revenues in the \nquarter. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd2ca06c-bb18-4247-99de-d13973e20a12", "node_type": "1", "metadata": {"window": "Can you give us some perspective on what gross margin is doing and -maybe \ngross margin and absolute gross profit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, hey, Eric.  Thanks for that question.  As we ta lked about, we had significant growth in revenues in the \nquarter.  And as I mentioned, specifically in our U.S.  Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year. ", "original_text": "Thanks for that question. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16822a3db1d2c4596b1381b496cfa1585d45c807c3333315ee32313b5ba35189", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27ea4e44-fef6-4c9d-8747-9a71e23af10b", "node_type": "1", "metadata": {"window": "A \nYeah, hey, Eric.  Thanks for that question.  As we ta lked about, we had significant growth in revenues in the \nquarter.  And as I mentioned, specifically in our U.S.  Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year.  And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere.  And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n", "original_text": "And as I mentioned, specifically in our U.S. "}, "hash": "9fb68cfeb76ba9be2f21cd4ccec0fc72bbfdbe2e1d9988a1d8ec551fddf2ae8f", "class_name": "RelatedNodeInfo"}}, "text": "As we ta lked about, we had significant growth in revenues in the \nquarter. ", "start_char_idx": 1308, "end_char_idx": 1384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27ea4e44-fef6-4c9d-8747-9a71e23af10b": {"__data__": {"id_": "27ea4e44-fef6-4c9d-8747-9a71e23af10b", "embedding": null, "metadata": {"window": "A \nYeah, hey, Eric.  Thanks for that question.  As we ta lked about, we had significant growth in revenues in the \nquarter.  And as I mentioned, specifically in our U.S.  Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year.  And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere.  And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n", "original_text": "And as I mentioned, specifically in our U.S. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4be3590-8335-4170-b0cd-e49467aa7f5c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, hey, Eric.  Thanks for that question.  As we ta lked about, we had significant growth in revenues in the \nquarter.  And as I mentioned, specifically in our U.S.  Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year.  And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere. ", "original_text": "As we ta lked about, we had significant growth in revenues in the \nquarter. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef21dd18ac74141e209d8f7c92934fe204b59cb871fb4ee577b07dd38267ecbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4db7756f-8ec9-467a-a3f4-e4db4f70a04d", "node_type": "1", "metadata": {"window": "Thanks for that question.  As we ta lked about, we had significant growth in revenues in the \nquarter.  And as I mentioned, specifically in our U.S.  Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year.  And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere.  And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n We di d have a 1% impact from foreign exchange. ", "original_text": "Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year. "}, "hash": "2ea793c932154b12de6b46cbbb81ce620bb0a7ab6a8a7d26d96735fc38f00b9e", "class_name": "RelatedNodeInfo"}}, "text": "And as I mentioned, specifically in our U.S. ", "start_char_idx": 1384, "end_char_idx": 1429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4db7756f-8ec9-467a-a3f4-e4db4f70a04d": {"__data__": {"id_": "4db7756f-8ec9-467a-a3f4-e4db4f70a04d", "embedding": null, "metadata": {"window": "Thanks for that question.  As we ta lked about, we had significant growth in revenues in the \nquarter.  And as I mentioned, specifically in our U.S.  Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year.  And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere.  And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n We di d have a 1% impact from foreign exchange. ", "original_text": "Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27ea4e44-fef6-4c9d-8747-9a71e23af10b", "node_type": "1", "metadata": {"window": "A \nYeah, hey, Eric.  Thanks for that question.  As we ta lked about, we had significant growth in revenues in the \nquarter.  And as I mentioned, specifically in our U.S.  Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year.  And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere.  And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n", "original_text": "And as I mentioned, specifically in our U.S. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "026d55b47867c28bca18aa36ee676257fe5e874d386b867d875020013f552927", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9765429c-4733-4757-84d6-c7c33c1241ba", "node_type": "1", "metadata": {"window": "As we ta lked about, we had significant growth in revenues in the \nquarter.  And as I mentioned, specifically in our U.S.  Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year.  And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere.  And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n We di d have a 1% impact from foreign exchange.  So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange. ", "original_text": "And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere. "}, "hash": "6ea3846efd4b9b39073614d8fe9882b2a175be3d582b50bb00d26f0b78af50dc", "class_name": "RelatedNodeInfo"}}, "text": "Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year. ", "start_char_idx": 1429, "end_char_idx": 1541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9765429c-4733-4757-84d6-c7c33c1241ba": {"__data__": {"id_": "9765429c-4733-4757-84d6-c7c33c1241ba", "embedding": null, "metadata": {"window": "As we ta lked about, we had significant growth in revenues in the \nquarter.  And as I mentioned, specifically in our U.S.  Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year.  And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere.  And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n We di d have a 1% impact from foreign exchange.  So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange. ", "original_text": "And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4db7756f-8ec9-467a-a3f4-e4db4f70a04d", "node_type": "1", "metadata": {"window": "Thanks for that question.  As we ta lked about, we had significant growth in revenues in the \nquarter.  And as I mentioned, specifically in our U.S.  Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year.  And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere.  And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n We di d have a 1% impact from foreign exchange. ", "original_text": "Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e707d7effd1460d514e14c7c473ce25178267954553c0d7efe096f84f872cbd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b79ba90-84d0-4a8c-b6d4-c28b367d5d15", "node_type": "1", "metadata": {"window": "And as I mentioned, specifically in our U.S.  Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year.  And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere.  And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n We di d have a 1% impact from foreign exchange.  So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange.  But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.  ", "original_text": "And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n"}, "hash": "bceb3dd716f7d1189c105c5f3cb2f7734048788dc9e00e5a1f6d8f0e2289f161", "class_name": "RelatedNodeInfo"}}, "text": "And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere. ", "start_char_idx": 1541, "end_char_idx": 1718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b79ba90-84d0-4a8c-b6d4-c28b367d5d15": {"__data__": {"id_": "5b79ba90-84d0-4a8c-b6d4-c28b367d5d15", "embedding": null, "metadata": {"window": "And as I mentioned, specifically in our U.S.  Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year.  And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere.  And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n We di d have a 1% impact from foreign exchange.  So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange.  But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.  ", "original_text": "And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9765429c-4733-4757-84d6-c7c33c1241ba", "node_type": "1", "metadata": {"window": "As we ta lked about, we had significant growth in revenues in the \nquarter.  And as I mentioned, specifically in our U.S.  Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year.  And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere.  And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n We di d have a 1% impact from foreign exchange.  So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange. ", "original_text": "And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5312360cfb508ccf0167cd76d962765ab47a8b4997bea65cf9eb4cdbf14d1760", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53e4d9a7-e3a2-42b9-94ef-1e35ea738183", "node_type": "1", "metadata": {"window": "Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year.  And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere.  And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n We di d have a 1% impact from foreign exchange.  So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange.  But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.   It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products. ", "original_text": "We di d have a 1% impact from foreign exchange. "}, "hash": "7cb42c3740c499e3bf5ecf062131518ba3408af33024a0e5747f0a8f3c706259", "class_name": "RelatedNodeInfo"}}, "text": "And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n", "start_char_idx": 1718, "end_char_idx": 1833, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53e4d9a7-e3a2-42b9-94ef-1e35ea738183": {"__data__": {"id_": "53e4d9a7-e3a2-42b9-94ef-1e35ea738183", "embedding": null, "metadata": {"window": "Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year.  And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere.  And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n We di d have a 1% impact from foreign exchange.  So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange.  But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.   It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products. ", "original_text": "We di d have a 1% impact from foreign exchange. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b79ba90-84d0-4a8c-b6d4-c28b367d5d15", "node_type": "1", "metadata": {"window": "And as I mentioned, specifically in our U.S.  Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year.  And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere.  And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n We di d have a 1% impact from foreign exchange.  So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange.  But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.  ", "original_text": "And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a247b8ec619c4e41d85d7ba9e4cf91695dbf40c8e95a794491c1824c0f41f6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e051b6e-ceb3-44d8-8309-544fbe414914", "node_type": "1", "metadata": {"window": "And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere.  And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n We di d have a 1% impact from foreign exchange.  So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange.  But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.   It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products.  And that's largely what's driving that delta between re venue growth and gross profit growth.  \n ", "original_text": "So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange. "}, "hash": "48e200a4c744a48808f6776d84268c35b98c2a499dd63793f9220f38d27b0219", "class_name": "RelatedNodeInfo"}}, "text": "We di d have a 1% impact from foreign exchange. ", "start_char_idx": 1833, "end_char_idx": 1881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e051b6e-ceb3-44d8-8309-544fbe414914": {"__data__": {"id_": "0e051b6e-ceb3-44d8-8309-544fbe414914", "embedding": null, "metadata": {"window": "And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere.  And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n We di d have a 1% impact from foreign exchange.  So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange.  But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.   It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products.  And that's largely what's driving that delta between re venue growth and gross profit growth.  \n ", "original_text": "So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53e4d9a7-e3a2-42b9-94ef-1e35ea738183", "node_type": "1", "metadata": {"window": "Pharma and Specialty Solutions business, we had growth \nthat caused us to raise our guidance for the full year.  And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere.  And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n We di d have a 1% impact from foreign exchange.  So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange.  But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.   It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products. ", "original_text": "We di d have a 1% impact from foreign exchange. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b8dbb55a2745cae8131aa4736e0c32b6ab702a180596ee35bea1b8696f702f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de818cbc-d1fe-4e44-a47a-2d4e9d9d087e", "node_type": "1", "metadata": {"window": "And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n We di d have a 1% impact from foreign exchange.  So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange.  But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.   It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products.  And that's largely what's driving that delta between re venue growth and gross profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty. ", "original_text": "But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.  "}, "hash": "c684ff0e5875b35b99269b32a90c064aa60624d4b1b09b1e9bca2813283d7ac0", "class_name": "RelatedNodeInfo"}}, "text": "So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange. ", "start_char_idx": 1881, "end_char_idx": 1975, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de818cbc-d1fe-4e44-a47a-2d4e9d9d087e": {"__data__": {"id_": "de818cbc-d1fe-4e44-a47a-2d4e9d9d087e", "embedding": null, "metadata": {"window": "And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n We di d have a 1% impact from foreign exchange.  So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange.  But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.   It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products.  And that's largely what's driving that delta between re venue growth and gross profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty. ", "original_text": "But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.  ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e051b6e-ceb3-44d8-8309-544fbe414914", "node_type": "1", "metadata": {"window": "And I also pointed to the fact tha t a great portion of that \ncame from specialty products and in particular from the growth of Caremark through growth in new customers \nthere.  And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n We di d have a 1% impact from foreign exchange.  So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange.  But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.   It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products.  And that's largely what's driving that delta between re venue growth and gross profit growth.  \n ", "original_text": "So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "34ed76c3ab7550d4d5986c6fc4e68b72e54d07ee6613a943b864cb9717e731d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2671470-6b64-4b7e-87ab-4be18646da3b", "node_type": "1", "metadata": {"window": "We di d have a 1% impact from foreign exchange.  So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange.  But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.   It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products.  And that's largely what's driving that delta between re venue growth and gross profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty.  And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n ", "original_text": "It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products. "}, "hash": "1f2ae0fe0a99240a58de9a89e01c321c4b966b7a55d89e05bd90c936cd07e51e", "class_name": "RelatedNodeInfo"}}, "text": "But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.  ", "start_char_idx": 1975, "end_char_idx": 2099, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2671470-6b64-4b7e-87ab-4be18646da3b": {"__data__": {"id_": "e2671470-6b64-4b7e-87ab-4be18646da3b", "embedding": null, "metadata": {"window": "We di d have a 1% impact from foreign exchange.  So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange.  But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.   It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products.  And that's largely what's driving that delta between re venue growth and gross profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty.  And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n ", "original_text": "It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de818cbc-d1fe-4e44-a47a-2d4e9d9d087e", "node_type": "1", "metadata": {"window": "And that had an impact on our gross profit rate in terms of in terms of comparing that to our revenue \ngrowth.  \n \n We di d have a 1% impact from foreign exchange.  So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange.  But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.   It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products.  And that's largely what's driving that delta between re venue growth and gross profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty. ", "original_text": "But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.  ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48d393c42c96ab0e76e78f8b88ed7e48a7639f923701e9a5aca4fdbb67c99d95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08101f4b-093f-45f1-aaa0-0e005e0e6e93", "node_type": "1", "metadata": {"window": "So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange.  But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.   It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products.  And that's largely what's driving that delta between re venue growth and gross profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty.  And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And that's largely what's driving that delta between re venue growth and gross profit growth.  \n "}, "hash": "d9a6b96fd29ed8efd13bd822457c7c11c3d3733ed1ebc345f7d97d874959f6bb", "class_name": "RelatedNodeInfo"}}, "text": "It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products. ", "start_char_idx": 2099, "end_char_idx": 2301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08101f4b-093f-45f1-aaa0-0e005e0e6e93": {"__data__": {"id_": "08101f4b-093f-45f1-aaa0-0e005e0e6e93", "embedding": null, "metadata": {"window": "So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange.  But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.   It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products.  And that's largely what's driving that delta between re venue growth and gross profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty.  And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And that's largely what's driving that delta between re venue growth and gross profit growth.  \n ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2671470-6b64-4b7e-87ab-4be18646da3b", "node_type": "1", "metadata": {"window": "We di d have a 1% impact from foreign exchange.  So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange.  But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.   It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products.  And that's largely what's driving that delta between re venue growth and gross profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty.  And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n ", "original_text": "It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b50f667354d03668faa6f7cb9308a068bb2029f1775bc3e67447f4322d2aa63a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d461682-4aaf-4db8-a01b-13a636623bfa", "node_type": "1", "metadata": {"window": "But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.   It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products.  And that's largely what's driving that delta between re venue growth and gross profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty.  And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, Eric, we are seeing that. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty. "}, "hash": "55ee3e212bdfc2e77e2d20a40d85386c62f445070ea28cec8f80609802d14e08", "class_name": "RelatedNodeInfo"}}, "text": "And that's largely what's driving that delta between re venue growth and gross profit growth.  \n ", "start_char_idx": 2301, "end_char_idx": 2398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d461682-4aaf-4db8-a01b-13a636623bfa": {"__data__": {"id_": "4d461682-4aaf-4db8-a01b-13a636623bfa", "embedding": null, "metadata": {"window": "But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.   It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products.  And that's largely what's driving that delta between re venue growth and gross profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty.  And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, Eric, we are seeing that. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08101f4b-093f-45f1-aaa0-0e005e0e6e93", "node_type": "1", "metadata": {"window": "So, when you looked at our gross profit, 3% when you exclude \nthe impact of foreign exchange.  But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.   It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products.  And that's largely what's driving that delta between re venue growth and gross profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty.  And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And that's largely what's driving that delta between re venue growth and gross profit growth.  \n ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5dc391475f9a3062ef28c42d5939e0161969c66db96023c846c969a25a8e72f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eba80418-dba1-449f-bc08-8b7235914fa3", "node_type": "1", "metadata": {"window": "It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products.  And that's largely what's driving that delta between re venue growth and gross profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty.  And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, Eric, we are seeing that.  As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization. ", "original_text": "And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n "}, "hash": "447ce0aa105e16508ee0bd2aaf17670479bf87180976adfaa20c28b4e3efec04", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty. ", "start_char_idx": 2398, "end_char_idx": 2767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eba80418-dba1-449f-bc08-8b7235914fa3": {"__data__": {"id_": "eba80418-dba1-449f-bc08-8b7235914fa3", "embedding": null, "metadata": {"window": "It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products.  And that's largely what's driving that delta between re venue growth and gross profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty.  And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, Eric, we are seeing that.  As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization. ", "original_text": "And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d461682-4aaf-4db8-a01b-13a636623bfa", "node_type": "1", "metadata": {"window": "But I would point you back to the fact that our revenue grew faster than we had \nanticipated at the beginning of the year.   It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products.  And that's largely what's driving that delta between re venue growth and gross profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty.  And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, Eric, we are seeing that. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c148b5f6e6e7400d70fed9a5cf4ea69a1e5f46bf1c744a7bd0dec958a475be8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3652068-897c-4623-b3da-a400ba020f19", "node_type": "1", "metadata": {"window": "And that's largely what's driving that delta between re venue growth and gross profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty.  And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, Eric, we are seeing that.  As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization.  We were able to generate good savings there this year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "cc5c09010f0218bebf5779394de3e37cb69946a590f4275deb0ea1ed925a8630", "class_name": "RelatedNodeInfo"}}, "text": "And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n ", "start_char_idx": 2767, "end_char_idx": 2961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3652068-897c-4623-b3da-a400ba020f19": {"__data__": {"id_": "f3652068-897c-4623-b3da-a400ba020f19", "embedding": null, "metadata": {"window": "And that's largely what's driving that delta between re venue growth and gross profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty.  And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, Eric, we are seeing that.  As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization.  We were able to generate good savings there this year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eba80418-dba1-449f-bc08-8b7235914fa3", "node_type": "1", "metadata": {"window": "It's largely coming from the onboarding of some customer wins through \nCaremark, and there's a customer and product mix aspect to that where the products are largely coming through \nspecialty products.  And that's largely what's driving that delta between re venue growth and gross profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty.  And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, Eric, we are seeing that.  As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization. ", "original_text": "And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49539fef3e3f7bf65a0b79fecd331e9893dcbc6eac4df876cb5f7fc7fdd1f268", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d070a76a-abf1-47df-a2df-eceb81c9491c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty.  And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, Eric, we are seeing that.  As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization.  We were able to generate good savings there this year.  We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective. ", "original_text": "A \nYeah, Eric, we are seeing that. "}, "hash": "53dc1a4df7155728ada3f5e61993a83e90f33a342416c6f3c5abded2e7f3bb01", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 2961, "end_char_idx": 3306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d070a76a-abf1-47df-a2df-eceb81c9491c": {"__data__": {"id_": "d070a76a-abf1-47df-a2df-eceb81c9491c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty.  And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, Eric, we are seeing that.  As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization.  We were able to generate good savings there this year.  We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective. ", "original_text": "A \nYeah, Eric, we are seeing that. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3652068-897c-4623-b3da-a400ba020f19", "node_type": "1", "metadata": {"window": "And that's largely what's driving that delta between re venue growth and gross profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty.  And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, Eric, we are seeing that.  As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization.  We were able to generate good savings there this year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c10bfd670d514ae907eee9048ed4e525061ca442bc5a8ac6ba7ef49a5a2e1d09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63b10b55-4bc4-4cc7-a436-cf7aa665054b", "node_type": "1", "metadata": {"window": "And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, Eric, we are seeing that.  As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization.  We were able to generate good savings there this year.  We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective.  In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S. ", "original_text": "As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization. "}, "hash": "fda3fc57b8721f5ccb9c3e05ea6fb00b6ed702c08ba0ad750671da3efc8b692e", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, Eric, we are seeing that. ", "start_char_idx": 3306, "end_char_idx": 3341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63b10b55-4bc4-4cc7-a436-cf7aa665054b": {"__data__": {"id_": "63b10b55-4bc4-4cc7-a436-cf7aa665054b", "embedding": null, "metadata": {"window": "And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, Eric, we are seeing that.  As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization.  We were able to generate good savings there this year.  We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective.  In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S. ", "original_text": "As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d070a76a-abf1-47df-a2df-eceb81c9491c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nAnd on an absolute basis, you're seeing growth from specialty.  And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, Eric, we are seeing that.  As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization.  We were able to generate good savings there this year.  We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective. ", "original_text": "A \nYeah, Eric, we are seeing that. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a62ad828a025b1ec812b2e15b1010f8e7bacbb6d5e7a6172597e22af4ee6bdd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbb8ffd9-21b5-4111-93f7-0096f59c784f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, Eric, we are seeing that.  As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization.  We were able to generate good savings there this year.  We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective.  In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S.  oncology as an asset. ", "original_text": "We were able to generate good savings there this year. "}, "hash": "11c30cab38bb6021f6687a5beb9ad5b71b1a67afd4bcec7335cf3e82fc474818", "class_name": "RelatedNodeInfo"}}, "text": "As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization. ", "start_char_idx": 3341, "end_char_idx": 3449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbb8ffd9-21b5-4111-93f7-0096f59c784f": {"__data__": {"id_": "bbb8ffd9-21b5-4111-93f7-0096f59c784f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, Eric, we are seeing that.  As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization.  We were able to generate good savings there this year.  We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective.  In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S.  oncology as an asset. ", "original_text": "We were able to generate good savings there this year. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63b10b55-4bc4-4cc7-a436-cf7aa665054b", "node_type": "1", "metadata": {"window": "And is it also reasonable to expect, that given the \nstability you speak to in the generic marketplace and given sourcing, that we're seeing generic profitability grow \non an absolute basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, Eric, we are seeing that.  As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization.  We were able to generate good savings there this year.  We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective.  In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S. ", "original_text": "As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9017195e2c5342f1b0ed4b56d74539ac4e441a38eb46f256f4250dbb2fa74b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec8e9e79-a366-4ded-8c0a-6f8257ba6e9e", "node_type": "1", "metadata": {"window": "A \nYeah, Eric, we are seeing that.  As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization.  We were able to generate good savings there this year.  We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective.  In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S.  oncology as an asset.  But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution. ", "original_text": "We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective. "}, "hash": "6a8e3f2be071bfe51013ff9e31c8556b578148bc1c50300587f2640dfc03df72", "class_name": "RelatedNodeInfo"}}, "text": "We were able to generate good savings there this year. ", "start_char_idx": 3449, "end_char_idx": 3504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec8e9e79-a366-4ded-8c0a-6f8257ba6e9e": {"__data__": {"id_": "ec8e9e79-a366-4ded-8c0a-6f8257ba6e9e", "embedding": null, "metadata": {"window": "A \nYeah, Eric, we are seeing that.  As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization.  We were able to generate good savings there this year.  We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective.  In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S.  oncology as an asset.  But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution. ", "original_text": "We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbb8ffd9-21b5-4111-93f7-0096f59c784f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, Eric, we are seeing that.  As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization.  We were able to generate good savings there this year.  We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective.  In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S.  oncology as an asset. ", "original_text": "We were able to generate good savings there this year. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "789c0f9a480d81c70d4b03ba84f143a9c02d5e9d9862249eadaf066b38279f55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd981027-851d-43d2-a072-d50f2a108de0", "node_type": "1", "metadata": {"window": "As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization.  We were able to generate good savings there this year.  We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective.  In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S.  oncology as an asset.  But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution.  And as I mentioned, that's particularly coming from the growth \nof large customers like Caremark.  \n ", "original_text": "In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S. "}, "hash": "75ca9c945a3c222297ca1cec9d3089cb21c91fa4a02c09579621411a4c263d89", "class_name": "RelatedNodeInfo"}}, "text": "We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective. ", "start_char_idx": 3504, "end_char_idx": 3629, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd981027-851d-43d2-a072-d50f2a108de0": {"__data__": {"id_": "cd981027-851d-43d2-a072-d50f2a108de0", "embedding": null, "metadata": {"window": "As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization.  We were able to generate good savings there this year.  We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective.  In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S.  oncology as an asset.  But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution.  And as I mentioned, that's particularly coming from the growth \nof large customers like Caremark.  \n ", "original_text": "In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec8e9e79-a366-4ded-8c0a-6f8257ba6e9e", "node_type": "1", "metadata": {"window": "A \nYeah, Eric, we are seeing that.  As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization.  We were able to generate good savings there this year.  We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective.  In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S.  oncology as an asset.  But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution. ", "original_text": "We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b38e88e55e33d6ba1cd463dd5af967623e6ca23744d9e643f721e24214c3d067", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4a7524f-ae65-42a2-98f6-f9b9f03ff3a5", "node_type": "1", "metadata": {"window": "We were able to generate good savings there this year.  We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective.  In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S.  oncology as an asset.  But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution.  And as I mentioned, that's particularly coming from the growth \nof large customers like Caremark.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  ", "original_text": "oncology as an asset. "}, "hash": "06bee8ae9407810ca63c9abc62a4eaa33cb7d3c215391ce37ebc4d45dc58ed4f", "class_name": "RelatedNodeInfo"}}, "text": "In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S. ", "start_char_idx": 3629, "end_char_idx": 3808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4a7524f-ae65-42a2-98f6-f9b9f03ff3a5": {"__data__": {"id_": "d4a7524f-ae65-42a2-98f6-f9b9f03ff3a5", "embedding": null, "metadata": {"window": "We were able to generate good savings there this year.  We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective.  In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S.  oncology as an asset.  But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution.  And as I mentioned, that's particularly coming from the growth \nof large customers like Caremark.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  ", "original_text": "oncology as an asset. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd981027-851d-43d2-a072-d50f2a108de0", "node_type": "1", "metadata": {"window": "As Brian talked about, we continue to see great ben efits coming from our \nClarusONE Sourcing organization.  We were able to generate good savings there this year.  We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective.  In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S.  oncology as an asset.  But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution.  And as I mentioned, that's particularly coming from the growth \nof large customers like Caremark.  \n ", "original_text": "In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "69caca910d09cee24dd78699bfb14e08cb743488abf5ddde5f93b8e7c7146063", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef99390e-8340-4272-af97-4c73085700d2", "node_type": "1", "metadata": {"window": "We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective.  In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S.  oncology as an asset.  But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution.  And as I mentioned, that's particularly coming from the growth \nof large customers like Caremark.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  ", "original_text": "But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution. "}, "hash": "d3676ad7b973ca632667129430fe7976bcb69ad2e2c204b2bd2cca8d003686b2", "class_name": "RelatedNodeInfo"}}, "text": "oncology as an asset. ", "start_char_idx": 3808, "end_char_idx": 3830, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef99390e-8340-4272-af97-4c73085700d2": {"__data__": {"id_": "ef99390e-8340-4272-af97-4c73085700d2", "embedding": null, "metadata": {"window": "We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective.  In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S.  oncology as an asset.  But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution.  And as I mentioned, that's particularly coming from the growth \nof large customers like Caremark.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  ", "original_text": "But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4a7524f-ae65-42a2-98f6-f9b9f03ff3a5", "node_type": "1", "metadata": {"window": "We were able to generate good savings there this year.  We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective.  In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S.  oncology as an asset.  But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution.  And as I mentioned, that's particularly coming from the growth \nof large customers like Caremark.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  ", "original_text": "oncology as an asset. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c1703183a3fa6c8e88cc6a372c2c062fbd3651a7285bfd5c0ac773e99fa2066", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61a825a9-0801-4465-9489-5c9e8ff39285", "node_type": "1", "metadata": {"window": "In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S.  oncology as an asset.  But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution.  And as I mentioned, that's particularly coming from the growth \nof large customers like Caremark.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  ", "original_text": "And as I mentioned, that's particularly coming from the growth \nof large customers like Caremark.  \n "}, "hash": "d572ca7bac8bfbbbef27187ff33a84befda3dcdac75304a7b2eb8d73cb505663", "class_name": "RelatedNodeInfo"}}, "text": "But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution. ", "start_char_idx": 3830, "end_char_idx": 3926, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61a825a9-0801-4465-9489-5c9e8ff39285": {"__data__": {"id_": "61a825a9-0801-4465-9489-5c9e8ff39285", "embedding": null, "metadata": {"window": "In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S.  oncology as an asset.  But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution.  And as I mentioned, that's particularly coming from the growth \nof large customers like Caremark.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  ", "original_text": "And as I mentioned, that's particularly coming from the growth \nof large customers like Caremark.  \n ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef99390e-8340-4272-af97-4c73085700d2", "node_type": "1", "metadata": {"window": "We're seeing stability \non the sell side, and that's allowing us to continue to create a spread from a generics perspective.  In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S.  oncology as an asset.  But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution.  And as I mentioned, that's particularly coming from the growth \nof large customers like Caremark.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  ", "original_text": "But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution. ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1282ed7457231d014c17ee314370db38c6305e5c190b2b75594e2b8498138807", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "001cd8c7-5783-4f5a-9b86-9430923d7499", "node_type": "1", "metadata": {"window": "oncology as an asset.  But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution.  And as I mentioned, that's particularly coming from the growth \nof large customers like Caremark.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  "}, "hash": "f47785b850ad58ea7db00f5017f1c3ffc5a8378b62dd865329d7021f11f3e5db", "class_name": "RelatedNodeInfo"}}, "text": "And as I mentioned, that's particularly coming from the growth \nof large customers like Caremark.  \n ", "start_char_idx": 3926, "end_char_idx": 4027, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "001cd8c7-5783-4f5a-9b86-9430923d7499": {"__data__": {"id_": "001cd8c7-5783-4f5a-9b86-9430923d7499", "embedding": null, "metadata": {"window": "oncology as an asset.  But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution.  And as I mentioned, that's particularly coming from the growth \nof large customers like Caremark.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdcb0664-a94c-4c33-a4de-df390c909441", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7819f3fef61e7d5a00db6e26c528a1c91bf9759cf00f013bd77a7eb46ccd58f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61a825a9-0801-4465-9489-5c9e8ff39285", "node_type": "1", "metadata": {"window": "In our specialty \nbusin esses, Brian I think talked a lot about our provider business, our advances that we have in manufacturer \nservices, and the lead that we have in from U.S.  oncology as an asset.  But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution.  And as I mentioned, that's particularly coming from the growth \nof large customers like Caremark.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  ", "original_text": "And as I mentioned, that's particularly coming from the growth \nof large customers like Caremark.  \n ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8cd89a83d251d11c1a15863ce2db54de29ceeb0e210161e1120aaf24a95e5416", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55d5b02b-bc25-4279-a844-88426f0c4014", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nOperator : And our next question comes from the line of Lisa Gill of JPMorgan.  Your li ne is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. ", "original_text": "McKesson Corp.  "}, "hash": "48b8960ae033b7eb5175bb1dccd86832a2217b2017248635eb9c87b79af2522c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  ", "start_char_idx": 4027, "end_char_idx": 4345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55d5b02b-bc25-4279-a844-88426f0c4014": {"__data__": {"id_": "55d5b02b-bc25-4279-a844-88426f0c4014", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nOperator : And our next question comes from the line of Lisa Gill of JPMorgan.  Your li ne is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "001cd8c7-5783-4f5a-9b86-9430923d7499", "node_type": "1", "metadata": {"window": "oncology as an asset.  But we're seeing a lot of growth that is \ncoming through our full -line wholesale distribution.  And as I mentioned, that's particularly coming from the growth \nof large customers like Caremark.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e00649a46a926c8a086e61518693e75e425d69c220e19f923682657c486e997a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a73a692-6b30-426f-80a8-3ce0d05b808e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nOperator : And our next question comes from the line of Lisa Gill of JPMorgan.  Your li ne is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thank you. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nOperator : And our next question comes from the line of Lisa Gill of JPMorgan. "}, "hash": "4291d19fe17b849b35fc2549768e7f5948a977ec32574da6c992ca8be13d4ff0", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a73a692-6b30-426f-80a8-3ce0d05b808e": {"__data__": {"id_": "1a73a692-6b30-426f-80a8-3ce0d05b808e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nOperator : And our next question comes from the line of Lisa Gill of JPMorgan.  Your li ne is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thank you. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nOperator : And our next question comes from the line of Lisa Gill of JPMorgan. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55d5b02b-bc25-4279-a844-88426f0c4014", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nOperator : And our next question comes from the line of Lisa Gill of JPMorgan.  Your li ne is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b56e4e674e631b4e2678c9a2edddffc53af2fff8956a30398e4bb64620dbecb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0467886e-512e-4fa0-8a14-394e0aae0b99", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nOperator : And our next question comes from the line of Lisa Gill of JPMorgan.  Your li ne is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thank you.  Good morning. ", "original_text": "Your li ne is open.  \n "}, "hash": "3a1c81315969942d4670a8268dbff4fbb4847dde3ab39d82a4f3ca4e8306baab", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nOperator : And our next question comes from the line of Lisa Gill of JPMorgan. ", "start_char_idx": 16, "end_char_idx": 262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0467886e-512e-4fa0-8a14-394e0aae0b99": {"__data__": {"id_": "0467886e-512e-4fa0-8a14-394e0aae0b99", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nOperator : And our next question comes from the line of Lisa Gill of JPMorgan.  Your li ne is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thank you.  Good morning. ", "original_text": "Your li ne is open.  \n ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a73a692-6b30-426f-80a8-3ce0d05b808e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nOperator : And our next question comes from the line of Lisa Gill of JPMorgan.  Your li ne is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thank you. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nOperator : And our next question comes from the line of Lisa Gill of JPMorgan. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7fa412b7ca6aca92a229ac0b9bc61d19939b8092b067bfce6702be79468a123f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8129a874-cf93-4c4c-be2a-c159c73621ac", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nOperator : And our next question comes from the line of Lisa Gill of JPMorgan.  Your li ne is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thank you.  Good morning.  Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. "}, "hash": "e9f9aacbacba41671c7774582584205a1ce9183a510586f1836eb1364f923d19", "class_name": "RelatedNodeInfo"}}, "text": "Your li ne is open.  \n ", "start_char_idx": 262, "end_char_idx": 285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8129a874-cf93-4c4c-be2a-c159c73621ac": {"__data__": {"id_": "8129a874-cf93-4c4c-be2a-c159c73621ac", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nOperator : And our next question comes from the line of Lisa Gill of JPMorgan.  Your li ne is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thank you.  Good morning.  Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0467886e-512e-4fa0-8a14-394e0aae0b99", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nOperator : And our next question comes from the line of Lisa Gill of JPMorgan.  Your li ne is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thank you.  Good morning. ", "original_text": "Your li ne is open.  \n ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74ab74d250fcb8e4051d53acde1e948b31875b0cf551d066d2a33d1da8fdef31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cd3a5a6-3aab-4af3-9fb4-4651b37b2567", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nOperator : And our next question comes from the line of Lisa Gill of JPMorgan.  Your li ne is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thank you.  Good morning.  Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement.  If I do the math, 38% of the settlement was McKesson. ", "original_text": "Thank you. "}, "hash": "6dd900bd8cd20836ea95ba7b5386a79719bb531e666eaf799df4b8d6c43a2b15", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. ", "start_char_idx": 285, "end_char_idx": 601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cd3a5a6-3aab-4af3-9fb4-4651b37b2567": {"__data__": {"id_": "6cd3a5a6-3aab-4af3-9fb4-4651b37b2567", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nOperator : And our next question comes from the line of Lisa Gill of JPMorgan.  Your li ne is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thank you.  Good morning.  Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement.  If I do the math, 38% of the settlement was McKesson. ", "original_text": "Thank you. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8129a874-cf93-4c4c-be2a-c159c73621ac", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nOperator : And our next question comes from the line of Lisa Gill of JPMorgan.  Your li ne is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thank you.  Good morning.  Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dedf7b3f1f87c3b688fa25f5ef70a655645b2a1ac1b09930aa3444d88e86bdca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76abd67b-4a37-46e1-8727-937a61bcc4c9", "node_type": "1", "metadata": {"window": "Your li ne is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thank you.  Good morning.  Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement.  If I do the math, 38% of the settlement was McKesson.  Should I think about that \u2013 that was the \nmarket share in those two counties? ", "original_text": "Good morning. "}, "hash": "465fa677dc57572c78d029b72ae297581a984b04cc2ef4f5ca5e7f5f96e515ce", "class_name": "RelatedNodeInfo"}}, "text": "Thank you. ", "start_char_idx": 601, "end_char_idx": 612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76abd67b-4a37-46e1-8727-937a61bcc4c9": {"__data__": {"id_": "76abd67b-4a37-46e1-8727-937a61bcc4c9", "embedding": null, "metadata": {"window": "Your li ne is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thank you.  Good morning.  Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement.  If I do the math, 38% of the settlement was McKesson.  Should I think about that \u2013 that was the \nmarket share in those two counties? ", "original_text": "Good morning. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cd3a5a6-3aab-4af3-9fb4-4651b37b2567", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nOperator : And our next question comes from the line of Lisa Gill of JPMorgan.  Your li ne is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thank you.  Good morning.  Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement.  If I do the math, 38% of the settlement was McKesson. ", "original_text": "Thank you. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd1c52c869d9ac50e5436398149c9153b42b5753e9c87c8ec865056239cac74a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88ad401b-dea7-4da2-8f0e-8257c9d78e09", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thank you.  Good morning.  Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement.  If I do the math, 38% of the settlement was McKesson.  Should I think about that \u2013 that was the \nmarket share in those two counties?  Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n ", "original_text": "Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement. "}, "hash": "bdbb26e9dd161f6a0ff776ca1f37ac415eb239ef5c6ed93404131eddb58f32c3", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 612, "end_char_idx": 626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88ad401b-dea7-4da2-8f0e-8257c9d78e09": {"__data__": {"id_": "88ad401b-dea7-4da2-8f0e-8257c9d78e09", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thank you.  Good morning.  Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement.  If I do the math, 38% of the settlement was McKesson.  Should I think about that \u2013 that was the \nmarket share in those two counties?  Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n ", "original_text": "Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76abd67b-4a37-46e1-8727-937a61bcc4c9", "node_type": "1", "metadata": {"window": "Your li ne is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thank you.  Good morning.  Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement.  If I do the math, 38% of the settlement was McKesson.  Should I think about that \u2013 that was the \nmarket share in those two counties? ", "original_text": "Good morning. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28c77dc0162149432f98d1022ec77a081393d8f81038f249624ffd207747931e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae30c295-4b8f-46dc-8374-a945e00d10b1", "node_type": "1", "metadata": {"window": "Thank you.  Good morning.  Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement.  If I do the math, 38% of the settlement was McKesson.  Should I think about that \u2013 that was the \nmarket share in those two counties?  Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "If I do the math, 38% of the settlement was McKesson. "}, "hash": "7d0cc4d9d763b1bc97038fcecc74ea9322b018b4098d2ee0b6a62dbf240e7153", "class_name": "RelatedNodeInfo"}}, "text": "Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement. ", "start_char_idx": 626, "end_char_idx": 721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae30c295-4b8f-46dc-8374-a945e00d10b1": {"__data__": {"id_": "ae30c295-4b8f-46dc-8374-a945e00d10b1", "embedding": null, "metadata": {"window": "Thank you.  Good morning.  Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement.  If I do the math, 38% of the settlement was McKesson.  Should I think about that \u2013 that was the \nmarket share in those two counties?  Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "If I do the math, 38% of the settlement was McKesson. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88ad401b-dea7-4da2-8f0e-8257c9d78e09", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thank you.  Good morning.  Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement.  If I do the math, 38% of the settlement was McKesson.  Should I think about that \u2013 that was the \nmarket share in those two counties?  Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n ", "original_text": "Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d809429961a702bbc2d8502b5725a027904019bc2dbd2ca7967f8f43de660b06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "768c278b-3d0f-4eba-b011-277735c3ddd8", "node_type": "1", "metadata": {"window": "Good morning.  Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement.  If I do the math, 38% of the settlement was McKesson.  Should I think about that \u2013 that was the \nmarket share in those two counties?  Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nOh, good morning, Lisa. ", "original_text": "Should I think about that \u2013 that was the \nmarket share in those two counties? "}, "hash": "ddc54046d193bb2eeb8bbb15e450ae7fa36df1074b42083bdc7c7f3d67f1b0e5", "class_name": "RelatedNodeInfo"}}, "text": "If I do the math, 38% of the settlement was McKesson. ", "start_char_idx": 721, "end_char_idx": 775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "768c278b-3d0f-4eba-b011-277735c3ddd8": {"__data__": {"id_": "768c278b-3d0f-4eba-b011-277735c3ddd8", "embedding": null, "metadata": {"window": "Good morning.  Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement.  If I do the math, 38% of the settlement was McKesson.  Should I think about that \u2013 that was the \nmarket share in those two counties?  Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nOh, good morning, Lisa. ", "original_text": "Should I think about that \u2013 that was the \nmarket share in those two counties? ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae30c295-4b8f-46dc-8374-a945e00d10b1", "node_type": "1", "metadata": {"window": "Thank you.  Good morning.  Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement.  If I do the math, 38% of the settlement was McKesson.  Should I think about that \u2013 that was the \nmarket share in those two counties?  Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "If I do the math, 38% of the settlement was McKesson. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6402e6055f02f73dec8ecacc36c4eb53ed05a4d883cbf2fb8c284fac0b34d125", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49c4ac34-b0f0-417e-8d7c-a7c8f130fb33", "node_type": "1", "metadata": {"window": "Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement.  If I do the math, 38% of the settlement was McKesson.  Should I think about that \u2013 that was the \nmarket share in those two counties?  Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nOh, good morning, Lisa.  Thank you for the question. ", "original_text": "Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n "}, "hash": "eed52ba1e4ee184c508ee94befd614a9f38cd2609770d8c6fd3ed2b35bb0dacd", "class_name": "RelatedNodeInfo"}}, "text": "Should I think about that \u2013 that was the \nmarket share in those two counties? ", "start_char_idx": 775, "end_char_idx": 853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49c4ac34-b0f0-417e-8d7c-a7c8f130fb33": {"__data__": {"id_": "49c4ac34-b0f0-417e-8d7c-a7c8f130fb33", "embedding": null, "metadata": {"window": "Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement.  If I do the math, 38% of the settlement was McKesson.  Should I think about that \u2013 that was the \nmarket share in those two counties?  Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nOh, good morning, Lisa.  Thank you for the question. ", "original_text": "Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "768c278b-3d0f-4eba-b011-277735c3ddd8", "node_type": "1", "metadata": {"window": "Good morning.  Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement.  If I do the math, 38% of the settlement was McKesson.  Should I think about that \u2013 that was the \nmarket share in those two counties?  Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nOh, good morning, Lisa. ", "original_text": "Should I think about that \u2013 that was the \nmarket share in those two counties? ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56dc75208d05ad95ab18c07f186f25d4c38194f57ff92d4404407ba74c650854", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a16dc9af-f9f7-4bea-881f-987ab6a5051a", "node_type": "1", "metadata": {"window": "If I do the math, 38% of the settlement was McKesson.  Should I think about that \u2013 that was the \nmarket share in those two counties?  Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nOh, good morning, Lisa.  Thank you for the question.  You did your math correct. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "49068de0b8c9e04c605a2f65bd127685542f221eef565413660bdcda3dd0200e", "class_name": "RelatedNodeInfo"}}, "text": "Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n ", "start_char_idx": 853, "end_char_idx": 1059, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a16dc9af-f9f7-4bea-881f-987ab6a5051a": {"__data__": {"id_": "a16dc9af-f9f7-4bea-881f-987ab6a5051a", "embedding": null, "metadata": {"window": "If I do the math, 38% of the settlement was McKesson.  Should I think about that \u2013 that was the \nmarket share in those two counties?  Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nOh, good morning, Lisa.  Thank you for the question.  You did your math correct. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49c4ac34-b0f0-417e-8d7c-a7c8f130fb33", "node_type": "1", "metadata": {"window": "Brian, I just wanted to go back to your comments around the opioid litigation \nand settlement.  If I do the math, 38% of the settlement was McKesson.  Should I think about that \u2013 that was the \nmarket share in those two counties?  Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nOh, good morning, Lisa.  Thank you for the question. ", "original_text": "Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "13b56665f0cde0286950a937181c734e4f3669d33862934fba081a2f55b4b477", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6f382a2-17a2-47da-b85a-caa2f868f6ad", "node_type": "1", "metadata": {"window": "Should I think about that \u2013 that was the \nmarket share in those two counties?  Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nOh, good morning, Lisa.  Thank you for the question.  You did your math correct.  We were 38% of that settlement. \n", "original_text": "A \nOh, good morning, Lisa. "}, "hash": "b45b92307193020095f06032329fd3ef2a7c1096d0429e68e19f29b801041144", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1059, "end_char_idx": 1385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6f382a2-17a2-47da-b85a-caa2f868f6ad": {"__data__": {"id_": "d6f382a2-17a2-47da-b85a-caa2f868f6ad", "embedding": null, "metadata": {"window": "Should I think about that \u2013 that was the \nmarket share in those two counties?  Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nOh, good morning, Lisa.  Thank you for the question.  You did your math correct.  We were 38% of that settlement. \n", "original_text": "A \nOh, good morning, Lisa. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a16dc9af-f9f7-4bea-881f-987ab6a5051a", "node_type": "1", "metadata": {"window": "If I do the math, 38% of the settlement was McKesson.  Should I think about that \u2013 that was the \nmarket share in those two counties?  Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nOh, good morning, Lisa.  Thank you for the question.  You did your math correct. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbf215c1b4e4f8cb5a4433bd28b6144c45b445c67e65e3767dfb5f5fee10f54d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b56d7d5-eb74-4e33-974e-4e6299724325", "node_type": "1", "metadata": {"window": "Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nOh, good morning, Lisa.  Thank you for the question.  You did your math correct.  We were 38% of that settlement. \n Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with. ", "original_text": "Thank you for the question. "}, "hash": "4d3ab8000465f670bc0696d0276ceb589e846e17640f79a711395ffa7a14efb6", "class_name": "RelatedNodeInfo"}}, "text": "A \nOh, good morning, Lisa. ", "start_char_idx": 1385, "end_char_idx": 1412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b56d7d5-eb74-4e33-974e-4e6299724325": {"__data__": {"id_": "8b56d7d5-eb74-4e33-974e-4e6299724325", "embedding": null, "metadata": {"window": "Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nOh, good morning, Lisa.  Thank you for the question.  You did your math correct.  We were 38% of that settlement. \n Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with. ", "original_text": "Thank you for the question. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6f382a2-17a2-47da-b85a-caa2f868f6ad", "node_type": "1", "metadata": {"window": "Should I think about that \u2013 that was the \nmarket share in those two counties?  Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nOh, good morning, Lisa.  Thank you for the question.  You did your math correct.  We were 38% of that settlement. \n", "original_text": "A \nOh, good morning, Lisa. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1b1f273c8453bb49df68aa1d83928da7dd5f3011a73ed8528ac38bf8b9bf7fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d3b6eed-a481-4071-89d0-df18b74388d6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nOh, good morning, Lisa.  Thank you for the question.  You did your math correct.  We were 38% of that settlement. \n Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with.  That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera. ", "original_text": "You did your math correct. "}, "hash": "092328cbea055a69a0b96ea612e5dcdabe1016ecc6cf230cd9f711464ed03565", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for the question. ", "start_char_idx": 1412, "end_char_idx": 1440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d3b6eed-a481-4071-89d0-df18b74388d6": {"__data__": {"id_": "9d3b6eed-a481-4071-89d0-df18b74388d6", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nOh, good morning, Lisa.  Thank you for the question.  You did your math correct.  We were 38% of that settlement. \n Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with.  That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera. ", "original_text": "You did your math correct. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b56d7d5-eb74-4e33-974e-4e6299724325", "node_type": "1", "metadata": {"window": "Or do you anticipate, just given your overall market share with the \nindependents in the U.S., that if we think about any settlement, it would be somewhere in that type of range on a \npercen tage basis?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nOh, good morning, Lisa.  Thank you for the question.  You did your math correct.  We were 38% of that settlement. \n Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with. ", "original_text": "Thank you for the question. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f25cf90e7a2badae4ce8b613fc671a8fe10387cec1ba81c17f8391ddb4762324", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "359efbf7-1c79-417c-b2e7-745f88e39f6d", "node_type": "1", "metadata": {"window": "A \nOh, good morning, Lisa.  Thank you for the question.  You did your math correct.  We were 38% of that settlement. \n Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with.  That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera.  And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology. ", "original_text": "We were 38% of that settlement. \n"}, "hash": "5ab13ec231e2186304ce812eb69c29bf30e227d51ee0c0644a5c7a01d4c14fe9", "class_name": "RelatedNodeInfo"}}, "text": "You did your math correct. ", "start_char_idx": 1440, "end_char_idx": 1467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "359efbf7-1c79-417c-b2e7-745f88e39f6d": {"__data__": {"id_": "359efbf7-1c79-417c-b2e7-745f88e39f6d", "embedding": null, "metadata": {"window": "A \nOh, good morning, Lisa.  Thank you for the question.  You did your math correct.  We were 38% of that settlement. \n Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with.  That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera.  And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology. ", "original_text": "We were 38% of that settlement. \n", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d3b6eed-a481-4071-89d0-df18b74388d6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nOh, good morning, Lisa.  Thank you for the question.  You did your math correct.  We were 38% of that settlement. \n Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with.  That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera. ", "original_text": "You did your math correct. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a219d8cb239db6e9bd58813dcf515bb6e35fa909f10f7134218619dc9a64b72b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30c44125-2944-4a76-a0a3-b62bf16fc9c8", "node_type": "1", "metadata": {"window": "Thank you for the question.  You did your math correct.  We were 38% of that settlement. \n Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with.  That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera.  And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology.  And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n ", "original_text": "Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with. "}, "hash": "f91ee210576ca8ba3d2e4142a8ea98261261bb73c551ba55b44fedf7eba9f159", "class_name": "RelatedNodeInfo"}}, "text": "We were 38% of that settlement. \n", "start_char_idx": 1467, "end_char_idx": 1500, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30c44125-2944-4a76-a0a3-b62bf16fc9c8": {"__data__": {"id_": "30c44125-2944-4a76-a0a3-b62bf16fc9c8", "embedding": null, "metadata": {"window": "Thank you for the question.  You did your math correct.  We were 38% of that settlement. \n Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with.  That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera.  And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology.  And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n ", "original_text": "Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "359efbf7-1c79-417c-b2e7-745f88e39f6d", "node_type": "1", "metadata": {"window": "A \nOh, good morning, Lisa.  Thank you for the question.  You did your math correct.  We were 38% of that settlement. \n Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with.  That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera.  And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology. ", "original_text": "We were 38% of that settlement. \n", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b182b9a3013fc5808af7f2ba762677f9002156538166e48af3b51dc560f66426", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70289ae7-4698-4553-b8a0-4fb4bbf1ef47", "node_type": "1", "metadata": {"window": "You did your math correct.  We were 38% of that settlement. \n Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with.  That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera.  And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology.  And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay. ", "original_text": "That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera. "}, "hash": "2f5ad85ddc106c6588462e5840628d5aeab0dabf66711d6861383129cb66b745", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with. ", "start_char_idx": 1500, "end_char_idx": 1626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70289ae7-4698-4553-b8a0-4fb4bbf1ef47": {"__data__": {"id_": "70289ae7-4698-4553-b8a0-4fb4bbf1ef47", "embedding": null, "metadata": {"window": "You did your math correct.  We were 38% of that settlement. \n Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with.  That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera.  And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology.  And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay. ", "original_text": "That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30c44125-2944-4a76-a0a3-b62bf16fc9c8", "node_type": "1", "metadata": {"window": "Thank you for the question.  You did your math correct.  We were 38% of that settlement. \n Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with.  That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera.  And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology.  And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n ", "original_text": "Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4461f956da50b057b61cc6ca1354d06f1a578b61a489605e3f7548c7b8b9c4f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "072d0628-b94b-41d6-a6ad-927f5314c7d0", "node_type": "1", "metadata": {"window": "We were 38% of that settlement. \n Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with.  That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera.  And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology.  And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay.  T hat's helpful. ", "original_text": "And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology. "}, "hash": "49ebd03572826030ebe0473f1b579c63a9d710f7913f3eb02503bf3fd1da6a38", "class_name": "RelatedNodeInfo"}}, "text": "That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera. ", "start_char_idx": 1626, "end_char_idx": 1801, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "072d0628-b94b-41d6-a6ad-927f5314c7d0": {"__data__": {"id_": "072d0628-b94b-41d6-a6ad-927f5314c7d0", "embedding": null, "metadata": {"window": "We were 38% of that settlement. \n Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with.  That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera.  And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology.  And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay.  T hat's helpful. ", "original_text": "And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70289ae7-4698-4553-b8a0-4fb4bbf1ef47", "node_type": "1", "metadata": {"window": "You did your math correct.  We were 38% of that settlement. \n Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with.  That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera.  And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology.  And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay. ", "original_text": "That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e36cecea9ba5cd70b0433ac75af77e52ed9c59c1e2b8d638ddf629b5bc4413f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbb94884-77f6-4e02-8492-55045d1a6cd5", "node_type": "1", "metadata": {"window": "Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with.  That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera.  And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology.  And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay.  T hat's helpful.  And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed. ", "original_text": "And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n "}, "hash": "c2829ea9e48d4b6be5cfe197f2b0937bb48b6a549eadd1cf73aa502996a07299", "class_name": "RelatedNodeInfo"}}, "text": "And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology. ", "start_char_idx": 1801, "end_char_idx": 1923, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbb94884-77f6-4e02-8492-55045d1a6cd5": {"__data__": {"id_": "dbb94884-77f6-4e02-8492-55045d1a6cd5", "embedding": null, "metadata": {"window": "Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with.  That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera.  And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology.  And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay.  T hat's helpful.  And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed. ", "original_text": "And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "072d0628-b94b-41d6-a6ad-927f5314c7d0", "node_type": "1", "metadata": {"window": "We were 38% of that settlement. \n Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with.  That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera.  And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology.  And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay.  T hat's helpful. ", "original_text": "And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8645091d613f15e10c2dd6390a7e26e0c152c920accd12912558b028382b0a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2cb53bd-a61d-4f74-985f-fddfa118c33b", "node_type": "1", "metadata": {"window": "That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera.  And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology.  And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay.  T hat's helpful.  And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed.  My understanding is that the next court case isn't until sometime next summer. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay. "}, "hash": "10ba42082be26b2f367481762fd2433f7a30f8407520d96efe3ef4843219d0f9", "class_name": "RelatedNodeInfo"}}, "text": "And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n ", "start_char_idx": 1923, "end_char_idx": 2027, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2cb53bd-a61d-4f74-985f-fddfa118c33b": {"__data__": {"id_": "d2cb53bd-a61d-4f74-985f-fddfa118c33b", "embedding": null, "metadata": {"window": "That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera.  And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology.  And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay.  T hat's helpful.  And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed.  My understanding is that the next court case isn't until sometime next summer. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbb94884-77f6-4e02-8492-55045d1a6cd5", "node_type": "1", "metadata": {"window": "Obviously, there is data in the marketplace, the ARCOS data in  particular, that many of you are aware of and \nfamiliar with.  That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera.  And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology.  And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay.  T hat's helpful.  And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed. ", "original_text": "And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c3d0c2d94682a897c48c9460d22a1bb8b19111622a9bf6b9d0cf2153eea4f8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2650dfe-bdaa-4f13-bddb-86458fd858da", "node_type": "1", "metadata": {"window": "And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology.  And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay.  T hat's helpful.  And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed.  My understanding is that the next court case isn't until sometime next summer.  So \ndoes that mean that that kind of g ives you this time between now and then for a settlement? ", "original_text": "T hat's helpful. "}, "hash": "b49dbb493d904ff34af71e3e3946828a9308514c880bf3a798e8254e5fbecd91", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay. ", "start_char_idx": 2027, "end_char_idx": 2342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2650dfe-bdaa-4f13-bddb-86458fd858da": {"__data__": {"id_": "d2650dfe-bdaa-4f13-bddb-86458fd858da", "embedding": null, "metadata": {"window": "And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology.  And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay.  T hat's helpful.  And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed.  My understanding is that the next court case isn't until sometime next summer.  So \ndoes that mean that that kind of g ives you this time between now and then for a settlement? ", "original_text": "T hat's helpful. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2cb53bd-a61d-4f74-985f-fddfa118c33b", "node_type": "1", "metadata": {"window": "That data can be cut lots of ways, depending on how you look at time periods, and how you look at \nthe customer segments and whether you consider doses, et cetera, et cetera.  And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology.  And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay.  T hat's helpful.  And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed.  My understanding is that the next court case isn't until sometime next summer. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ceea5c540f5fbc1376b1c9aad66ce0f367033e5dfb00fbb1075b11f0f697ad44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80380ad3-442a-4af2-918b-65a172850487", "node_type": "1", "metadata": {"window": "And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay.  T hat's helpful.  And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed.  My understanding is that the next court case isn't until sometime next summer.  So \ndoes that mean that that kind of g ives you this time between now and then for a settlement?  And any update that \nyou can give us on where you are on a potential global settlement. ", "original_text": "And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed. "}, "hash": "fa13eb1ff86251a55e6350f1645874458f6064e445eb5c6e55350adb8d014dd6", "class_name": "RelatedNodeInfo"}}, "text": "T hat's helpful. ", "start_char_idx": 2342, "end_char_idx": 2359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80380ad3-442a-4af2-918b-65a172850487": {"__data__": {"id_": "80380ad3-442a-4af2-918b-65a172850487", "embedding": null, "metadata": {"window": "And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay.  T hat's helpful.  And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed.  My understanding is that the next court case isn't until sometime next summer.  So \ndoes that mean that that kind of g ives you this time between now and then for a settlement?  And any update that \nyou can give us on where you are on a potential global settlement. ", "original_text": "And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2650dfe-bdaa-4f13-bddb-86458fd858da", "node_type": "1", "metadata": {"window": "And so part of the d iscussions that \nwe had to go through was a methodology, and we landed on a data -based methodology.  And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay.  T hat's helpful.  And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed.  My understanding is that the next court case isn't until sometime next summer.  So \ndoes that mean that that kind of g ives you this time between now and then for a settlement? ", "original_text": "T hat's helpful. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51e59184bfc94b89ed22b77860de5a855e539eaed0210c5304eb1d43a396892c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "704c2b21-b7da-4994-8709-94efaa399ba1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay.  T hat's helpful.  And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed.  My understanding is that the next court case isn't until sometime next summer.  So \ndoes that mean that that kind of g ives you this time between now and then for a settlement?  And any update that \nyou can give us on where you are on a potential global settlement.  Because if I remember correctly, I think that's \nwhat you've talked about in the past, right? ", "original_text": "My understanding is that the next court case isn't until sometime next summer. "}, "hash": "4512549253ec7839c0ebc624858d44c1ba31e98c2ba9b317ef99ac40ecf2e5e2", "class_name": "RelatedNodeInfo"}}, "text": "And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed. ", "start_char_idx": 2359, "end_char_idx": 2485, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "704c2b21-b7da-4994-8709-94efaa399ba1": {"__data__": {"id_": "704c2b21-b7da-4994-8709-94efaa399ba1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay.  T hat's helpful.  And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed.  My understanding is that the next court case isn't until sometime next summer.  So \ndoes that mean that that kind of g ives you this time between now and then for a settlement?  And any update that \nyou can give us on where you are on a potential global settlement.  Because if I remember correctly, I think that's \nwhat you've talked about in the past, right? ", "original_text": "My understanding is that the next court case isn't until sometime next summer. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80380ad3-442a-4af2-918b-65a172850487", "node_type": "1", "metadata": {"window": "And so you can roughly \nthink of 38% as the McKesson representation of, quote -unquote, \"our share.\"  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay.  T hat's helpful.  And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed.  My understanding is that the next court case isn't until sometime next summer.  So \ndoes that mean that that kind of g ives you this time between now and then for a settlement?  And any update that \nyou can give us on where you are on a potential global settlement. ", "original_text": "And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b22a8fcd00185556209aab3beb21ae1ada0d5920aeb56aefe7bff49e36751ebc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ad173e2-19ab-49d7-854e-9accfc1e25df", "node_type": "1", "metadata": {"window": "T hat's helpful.  And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed.  My understanding is that the next court case isn't until sometime next summer.  So \ndoes that mean that that kind of g ives you this time between now and then for a settlement?  And any update that \nyou can give us on where you are on a potential global settlement.  Because if I remember correctly, I think that's \nwhat you've talked about in the past, right?  Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n ", "original_text": "So \ndoes that mean that that kind of g ives you this time between now and then for a settlement? "}, "hash": "b3ceb410881c921f53abd329506af3056fdf1a2cd9299e170beef56e9f1f60c6", "class_name": "RelatedNodeInfo"}}, "text": "My understanding is that the next court case isn't until sometime next summer. ", "start_char_idx": 2485, "end_char_idx": 2564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ad173e2-19ab-49d7-854e-9accfc1e25df": {"__data__": {"id_": "8ad173e2-19ab-49d7-854e-9accfc1e25df", "embedding": null, "metadata": {"window": "T hat's helpful.  And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed.  My understanding is that the next court case isn't until sometime next summer.  So \ndoes that mean that that kind of g ives you this time between now and then for a settlement?  And any update that \nyou can give us on where you are on a potential global settlement.  Because if I remember correctly, I think that's \nwhat you've talked about in the past, right?  Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n ", "original_text": "So \ndoes that mean that that kind of g ives you this time between now and then for a settlement? ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "704c2b21-b7da-4994-8709-94efaa399ba1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nOkay.  T hat's helpful.  And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed.  My understanding is that the next court case isn't until sometime next summer.  So \ndoes that mean that that kind of g ives you this time between now and then for a settlement?  And any update that \nyou can give us on where you are on a potential global settlement.  Because if I remember correctly, I think that's \nwhat you've talked about in the past, right? ", "original_text": "My understanding is that the next court case isn't until sometime next summer. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "053ea443e9337ca10f9b574f1798fe560598d5160dbcbb2f329edf302e7d19a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7148ba0-baf6-4b25-aa4d-8275a71d120a", "node_type": "1", "metadata": {"window": "And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed.  My understanding is that the next court case isn't until sometime next summer.  So \ndoes that mean that that kind of g ives you this time between now and then for a settlement?  And any update that \nyou can give us on where you are on a potential global settlement.  Because if I remember correctly, I think that's \nwhat you've talked about in the past, right?  Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And any update that \nyou can give us on where you are on a potential global settlement. "}, "hash": "51a45cce834447f16aeea95ade4f516f9520e2576fb5600e925b51aef981f7aa", "class_name": "RelatedNodeInfo"}}, "text": "So \ndoes that mean that that kind of g ives you this time between now and then for a settlement? ", "start_char_idx": 2564, "end_char_idx": 2661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7148ba0-baf6-4b25-aa4d-8275a71d120a": {"__data__": {"id_": "e7148ba0-baf6-4b25-aa4d-8275a71d120a", "embedding": null, "metadata": {"window": "And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed.  My understanding is that the next court case isn't until sometime next summer.  So \ndoes that mean that that kind of g ives you this time between now and then for a settlement?  And any update that \nyou can give us on where you are on a potential global settlement.  Because if I remember correctly, I think that's \nwhat you've talked about in the past, right?  Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And any update that \nyou can give us on where you are on a potential global settlement. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ad173e2-19ab-49d7-854e-9accfc1e25df", "node_type": "1", "metadata": {"window": "T hat's helpful.  And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed.  My understanding is that the next court case isn't until sometime next summer.  So \ndoes that mean that that kind of g ives you this time between now and then for a settlement?  And any update that \nyou can give us on where you are on a potential global settlement.  Because if I remember correctly, I think that's \nwhat you've talked about in the past, right?  Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n ", "original_text": "So \ndoes that mean that that kind of g ives you this time between now and then for a settlement? ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b480f636a69f16420d90a24a2059a1cc57947a6b65274e9fcdc960e0a5cb5822", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27c86039-cdaf-41c7-9c5c-0ff5ed449a18", "node_type": "1", "metadata": {"window": "My understanding is that the next court case isn't until sometime next summer.  So \ndoes that mean that that kind of g ives you this time between now and then for a settlement?  And any update that \nyou can give us on where you are on a potential global settlement.  Because if I remember correctly, I think that's \nwhat you've talked about in the past, right?  Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "Because if I remember correctly, I think that's \nwhat you've talked about in the past, right? "}, "hash": "e3a2078ee93de83c4a123fbd3e9817960da8001dee512e17d246f6dd629b4670", "class_name": "RelatedNodeInfo"}}, "text": "And any update that \nyou can give us on where you are on a potential global settlement. ", "start_char_idx": 2661, "end_char_idx": 2749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27c86039-cdaf-41c7-9c5c-0ff5ed449a18": {"__data__": {"id_": "27c86039-cdaf-41c7-9c5c-0ff5ed449a18", "embedding": null, "metadata": {"window": "My understanding is that the next court case isn't until sometime next summer.  So \ndoes that mean that that kind of g ives you this time between now and then for a settlement?  And any update that \nyou can give us on where you are on a potential global settlement.  Because if I remember correctly, I think that's \nwhat you've talked about in the past, right?  Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "Because if I remember correctly, I think that's \nwhat you've talked about in the past, right? ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7148ba0-baf6-4b25-aa4d-8275a71d120a", "node_type": "1", "metadata": {"window": "And then just as we think about the timeline of this, I know you said that you're prepared to \ndefend and litigate if needed.  My understanding is that the next court case isn't until sometime next summer.  So \ndoes that mean that that kind of g ives you this time between now and then for a settlement?  And any update that \nyou can give us on where you are on a potential global settlement.  Because if I remember correctly, I think that's \nwhat you've talked about in the past, right?  Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And any update that \nyou can give us on where you are on a potential global settlement. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "31c2afe5f888896c438a4e22c391dd750333bfb922aa442aa872b5b0868e2bf1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f966f1b9-e464-408b-a50b-88bc0afdeaf6", "node_type": "1", "metadata": {"window": "So \ndoes that mean that that kind of g ives you this time between now and then for a settlement?  And any update that \nyou can give us on where you are on a potential global settlement.  Because if I remember correctly, I think that's \nwhat you've talked about in the past, right?  Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Yeah. ", "original_text": "Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n "}, "hash": "3aebf5fcd40abbe292fd632faa32b601c81b7767563f90a2c69a0620f82dab23", "class_name": "RelatedNodeInfo"}}, "text": "Because if I remember correctly, I think that's \nwhat you've talked about in the past, right? ", "start_char_idx": 2749, "end_char_idx": 2843, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f966f1b9-e464-408b-a50b-88bc0afdeaf6": {"__data__": {"id_": "f966f1b9-e464-408b-a50b-88bc0afdeaf6", "embedding": null, "metadata": {"window": "So \ndoes that mean that that kind of g ives you this time between now and then for a settlement?  And any update that \nyou can give us on where you are on a potential global settlement.  Because if I remember correctly, I think that's \nwhat you've talked about in the past, right?  Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Yeah. ", "original_text": "Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27c86039-cdaf-41c7-9c5c-0ff5ed449a18", "node_type": "1", "metadata": {"window": "My understanding is that the next court case isn't until sometime next summer.  So \ndoes that mean that that kind of g ives you this time between now and then for a settlement?  And any update that \nyou can give us on where you are on a potential global settlement.  Because if I remember correctly, I think that's \nwhat you've talked about in the past, right?  Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "Because if I remember correctly, I think that's \nwhat you've talked about in the past, right? ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a30c67547920b3de698d52d74cc68b0667a14239f69dc4acecb2b4fd3b9ce53d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ab3b3b1-00cd-4e0a-8654-69b3013cd073", "node_type": "1", "metadata": {"window": "And any update that \nyou can give us on where you are on a potential global settlement.  Because if I remember correctly, I think that's \nwhat you've talked about in the past, right?  Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Yeah.  Yes. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "c69c0d5721d34190699abb99a6ab6ed0a43516adf731b02c4181cdefa565d317", "class_name": "RelatedNodeInfo"}}, "text": "Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n ", "start_char_idx": 2843, "end_char_idx": 2946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ab3b3b1-00cd-4e0a-8654-69b3013cd073": {"__data__": {"id_": "8ab3b3b1-00cd-4e0a-8654-69b3013cd073", "embedding": null, "metadata": {"window": "And any update that \nyou can give us on where you are on a potential global settlement.  Because if I remember correctly, I think that's \nwhat you've talked about in the past, right?  Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Yeah.  Yes. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f966f1b9-e464-408b-a50b-88bc0afdeaf6", "node_type": "1", "metadata": {"window": "So \ndoes that mean that that kind of g ives you this time between now and then for a settlement?  And any update that \nyou can give us on where you are on a potential global settlement.  Because if I remember correctly, I think that's \nwhat you've talked about in the past, right?  Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Yeah. ", "original_text": "Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc569bee235ec62c1c9f5a653f9ade2488c0ec3038ef9f18722940869c504e34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa27878d-d451-4e93-9fc7-6900cf80f272", "node_type": "1", "metadata": {"window": "Because if I remember correctly, I think that's \nwhat you've talked about in the past, right?  Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Yeah.  Yes.  That's right. ", "original_text": "A \nYeah. "}, "hash": "5475ea38b234db31aee0c3b77db320aa2d2ba34f56e2bd3a6f8ce6519515d05d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1059, "end_char_idx": 1385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa27878d-d451-4e93-9fc7-6900cf80f272": {"__data__": {"id_": "fa27878d-d451-4e93-9fc7-6900cf80f272", "embedding": null, "metadata": {"window": "Because if I remember correctly, I think that's \nwhat you've talked about in the past, right?  Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Yeah.  Yes.  That's right. ", "original_text": "A \nYeah. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ab3b3b1-00cd-4e0a-8654-69b3013cd073", "node_type": "1", "metadata": {"window": "And any update that \nyou can give us on where you are on a potential global settlement.  Because if I remember correctly, I think that's \nwhat you've talked about in the past, right?  Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Yeah.  Yes. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "054b495bfae0916868b8f726d8faa02c5bba4a38af09309546dfc7713fb9e830", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5ff4ba4-b51f-4c18-a793-dc9626d5b5aa", "node_type": "1", "metadata": {"window": "Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Yeah.  Yes.  That's right.  Thank you, Lisa. ", "original_text": "Yeah. "}, "hash": "13c2606763d2d4d508aaa9dbba761694c107ea760bee3de99c097ffa68b7f95b", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 3272, "end_char_idx": 3281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5ff4ba4-b51f-4c18-a793-dc9626d5b5aa": {"__data__": {"id_": "a5ff4ba4-b51f-4c18-a793-dc9626d5b5aa", "embedding": null, "metadata": {"window": "Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Yeah.  Yes.  That's right.  Thank you, Lisa. ", "original_text": "Yeah. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa27878d-d451-4e93-9fc7-6900cf80f272", "node_type": "1", "metadata": {"window": "Because if I remember correctly, I think that's \nwhat you've talked about in the past, right?  Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Yeah.  Yes.  That's right. ", "original_text": "A \nYeah. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ceeabb0fce27f00fd659387d4ad164e67af3c3aababe8ac036e984ff32a8fde1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b6b3d5a-08a6-438b-9e92-7fde487df823", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Yeah.  Yes.  That's right.  Thank you, Lisa.  I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing. ", "original_text": "Yes. "}, "hash": "ab75fa03b23523e9f8201be9847ca1e9180edfd219eeb1434801656cd0c3a652", "class_name": "RelatedNodeInfo"}}, "text": "Yeah. ", "start_char_idx": 3275, "end_char_idx": 3281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b6b3d5a-08a6-438b-9e92-7fde487df823": {"__data__": {"id_": "2b6b3d5a-08a6-438b-9e92-7fde487df823", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Yeah.  Yes.  That's right.  Thank you, Lisa.  I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing. ", "original_text": "Yes. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5ff4ba4-b51f-4c18-a793-dc9626d5b5aa", "node_type": "1", "metadata": {"window": "Ring -fencing those  and having a global settlement, not doing these \none-off \u2013 as each case comes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Yeah.  Yes.  That's right.  Thank you, Lisa. ", "original_text": "Yeah. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb481e256b5674e2f698af79ef3945490406cfa648e9bd7fd34e9852a304b29a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47fa42b0-e7e3-4850-ac72-ef4d5c7d09f0", "node_type": "1", "metadata": {"window": "A \nYeah.  Yeah.  Yes.  That's right.  Thank you, Lisa.  I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing.  And that remains our priority. ", "original_text": "That's right. "}, "hash": "a398f077bcec65a82ac512d4dfccbd3e0e66b645fcbb2ff0ba4a3081c846d835", "class_name": "RelatedNodeInfo"}}, "text": "Yes. ", "start_char_idx": 3287, "end_char_idx": 3292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47fa42b0-e7e3-4850-ac72-ef4d5c7d09f0": {"__data__": {"id_": "47fa42b0-e7e3-4850-ac72-ef4d5c7d09f0", "embedding": null, "metadata": {"window": "A \nYeah.  Yeah.  Yes.  That's right.  Thank you, Lisa.  I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing.  And that remains our priority. ", "original_text": "That's right. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b6b3d5a-08a6-438b-9e92-7fde487df823", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Yeah.  Yes.  That's right.  Thank you, Lisa.  I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing. ", "original_text": "Yes. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e154e1d1f8b8a76aed72288e811e6e7126172395ab5db57ba56cafc047d97a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbd12ba3-fa10-40d9-b8c0-23460c6e76c0", "node_type": "1", "metadata": {"window": "Yeah.  Yes.  That's right.  Thank you, Lisa.  I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing.  And that remains our priority.  Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress. ", "original_text": "Thank you, Lisa. "}, "hash": "b9c144d9834fef0022fc76728f9d2987a17468242c0c30fc2b494ac6c2ce7e60", "class_name": "RelatedNodeInfo"}}, "text": "That's right. ", "start_char_idx": 3292, "end_char_idx": 3306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbd12ba3-fa10-40d9-b8c0-23460c6e76c0": {"__data__": {"id_": "dbd12ba3-fa10-40d9-b8c0-23460c6e76c0", "embedding": null, "metadata": {"window": "Yeah.  Yes.  That's right.  Thank you, Lisa.  I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing.  And that remains our priority.  Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress. ", "original_text": "Thank you, Lisa. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47fa42b0-e7e3-4850-ac72-ef4d5c7d09f0", "node_type": "1", "metadata": {"window": "A \nYeah.  Yeah.  Yes.  That's right.  Thank you, Lisa.  I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing.  And that remains our priority. ", "original_text": "That's right. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2439973db7acb40dca140bb56dc67969c1752b2ba1ee5c95b73919dd1b52b4d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4a8f209-cfd7-409f-a31c-5f1a93936aca", "node_type": "1", "metadata": {"window": "Yes.  That's right.  Thank you, Lisa.  I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing.  And that remains our priority.  Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress.  And so we're encouraged by the status of the \ndiscussions. ", "original_text": "I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing. "}, "hash": "87f822ce68eaa1da74cdff176939100711eabf353b4446af2f09988f04e03bb5", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Lisa. ", "start_char_idx": 3306, "end_char_idx": 3323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4a8f209-cfd7-409f-a31c-5f1a93936aca": {"__data__": {"id_": "a4a8f209-cfd7-409f-a31c-5f1a93936aca", "embedding": null, "metadata": {"window": "Yes.  That's right.  Thank you, Lisa.  I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing.  And that remains our priority.  Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress.  And so we're encouraged by the status of the \ndiscussions. ", "original_text": "I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbd12ba3-fa10-40d9-b8c0-23460c6e76c0", "node_type": "1", "metadata": {"window": "Yeah.  Yes.  That's right.  Thank you, Lisa.  I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing.  And that remains our priority.  Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress. ", "original_text": "Thank you, Lisa. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d2234cc57f407a6081aa9bb564ba77ad5948d7a5a72bb519aeea0c4f7665414", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "896abb23-94b2-4f98-9fa7-980ce136d477", "node_type": "1", "metadata": {"window": "That's right.  Thank you, Lisa.  I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing.  And that remains our priority.  Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress.  And so we're encouraged by the status of the \ndiscussions.  There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those. ", "original_text": "And that remains our priority. "}, "hash": "8d5145f1c7b9c1ac2ca5c984a48897d5b45382b9a9f7690009818754c2e344f4", "class_name": "RelatedNodeInfo"}}, "text": "I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing. ", "start_char_idx": 3323, "end_char_idx": 3437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "896abb23-94b2-4f98-9fa7-980ce136d477": {"__data__": {"id_": "896abb23-94b2-4f98-9fa7-980ce136d477", "embedding": null, "metadata": {"window": "That's right.  Thank you, Lisa.  I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing.  And that remains our priority.  Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress.  And so we're encouraged by the status of the \ndiscussions.  There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those. ", "original_text": "And that remains our priority. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4a8f209-cfd7-409f-a31c-5f1a93936aca", "node_type": "1", "metadata": {"window": "Yes.  That's right.  Thank you, Lisa.  I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing.  And that remains our priority.  Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress.  And so we're encouraged by the status of the \ndiscussions. ", "original_text": "I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc49cae2fccbf482369ba0aafa5b4fdf13bb42358cb146e50a091b341eb5fa15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a31b71f-00c9-4b10-8a21-56384a6d0be7", "node_type": "1", "metadata": {"window": "Thank you, Lisa.  I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing.  And that remains our priority.  Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress.  And so we're encouraged by the status of the \ndiscussions.  There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those.  We're working through those with some urgency.  ", "original_text": "Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress. "}, "hash": "2d0a9103c7310e17745a685e02c48a783b0dba69d87125c2cb6ee7281aaadd7a", "class_name": "RelatedNodeInfo"}}, "text": "And that remains our priority. ", "start_char_idx": 3437, "end_char_idx": 3468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a31b71f-00c9-4b10-8a21-56384a6d0be7": {"__data__": {"id_": "5a31b71f-00c9-4b10-8a21-56384a6d0be7", "embedding": null, "metadata": {"window": "Thank you, Lisa.  I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing.  And that remains our priority.  Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress.  And so we're encouraged by the status of the \ndiscussions.  There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those.  We're working through those with some urgency.  ", "original_text": "Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "896abb23-94b2-4f98-9fa7-980ce136d477", "node_type": "1", "metadata": {"window": "That's right.  Thank you, Lisa.  I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing.  And that remains our priority.  Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress.  And so we're encouraged by the status of the \ndiscussions.  There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those. ", "original_text": "And that remains our priority. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0200d7551c606c4bd0e00e8ec4c307e27567f2060c82c31c0f5bf9dd91373e4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25af618c-4a06-48fe-b1a3-ef2bec6c5b5e", "node_type": "1", "metadata": {"window": "I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing.  And that remains our priority.  Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress.  And so we're encouraged by the status of the \ndiscussions.  There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those.  We're working through those with some urgency.   But it will take a bit of time to get through \nthose.  \n \n", "original_text": "And so we're encouraged by the status of the \ndiscussions. "}, "hash": "8b2d2e460e2864f392d66c2a86fd12673bc0e42ccd15a403b93b4da3a3bc620b", "class_name": "RelatedNodeInfo"}}, "text": "Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress. ", "start_char_idx": 3468, "end_char_idx": 3672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25af618c-4a06-48fe-b1a3-ef2bec6c5b5e": {"__data__": {"id_": "25af618c-4a06-48fe-b1a3-ef2bec6c5b5e", "embedding": null, "metadata": {"window": "I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing.  And that remains our priority.  Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress.  And so we're encouraged by the status of the \ndiscussions.  There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those.  We're working through those with some urgency.   But it will take a bit of time to get through \nthose.  \n \n", "original_text": "And so we're encouraged by the status of the \ndiscussions. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a31b71f-00c9-4b10-8a21-56384a6d0be7", "node_type": "1", "metadata": {"window": "Thank you, Lisa.  I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing.  And that remains our priority.  Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress.  And so we're encouraged by the status of the \ndiscussions.  There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those.  We're working through those with some urgency.  ", "original_text": "Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25e31fc5a31bf0b5a3069e92ed096b255756a0b23cc359978a34055310a71527", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a317770-53bc-4989-a87b-d54e17354910", "node_type": "1", "metadata": {"window": "And that remains our priority.  Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress.  And so we're encouraged by the status of the \ndiscussions.  There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those.  We're working through those with some urgency.   But it will take a bit of time to get through \nthose.  \n \n We're talking about 50 states, and we're talking about subdivisions within states. ", "original_text": "There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those. "}, "hash": "323ddb9d1874763d43cbd8a20b462622b622f6a92c9ea0933e809f2e50b4b549", "class_name": "RelatedNodeInfo"}}, "text": "And so we're encouraged by the status of the \ndiscussions. ", "start_char_idx": 3672, "end_char_idx": 3731, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a317770-53bc-4989-a87b-d54e17354910": {"__data__": {"id_": "6a317770-53bc-4989-a87b-d54e17354910", "embedding": null, "metadata": {"window": "And that remains our priority.  Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress.  And so we're encouraged by the status of the \ndiscussions.  There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those.  We're working through those with some urgency.   But it will take a bit of time to get through \nthose.  \n \n We're talking about 50 states, and we're talking about subdivisions within states. ", "original_text": "There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25af618c-4a06-48fe-b1a3-ef2bec6c5b5e", "node_type": "1", "metadata": {"window": "I mean, our objective and priority continues to be \u2013 we'll call it \nsometimes global resolution or ring -fencing.  And that remains our priority.  Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress.  And so we're encouraged by the status of the \ndiscussions.  There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those.  We're working through those with some urgency.   But it will take a bit of time to get through \nthose.  \n \n", "original_text": "And so we're encouraged by the status of the \ndiscussions. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c8e93e6b910857d79ce0b6a5c77ab27caedc50997aa471546cfe1171bab0536", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b438509-2823-48c8-a60f-85fcb54aadc5", "node_type": "1", "metadata": {"window": "Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress.  And so we're encouraged by the status of the \ndiscussions.  There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those.  We're working through those with some urgency.   But it will take a bit of time to get through \nthose.  \n \n We're talking about 50 states, and we're talking about subdivisions within states.  So we've got a framework that \nwe're very optimistic about. ", "original_text": "We're working through those with some urgency.  "}, "hash": "1e9389fb35def07dd0f5fdf1a6578e71f7f7832d2cbf0c0162cea5bcadf28bc5", "class_name": "RelatedNodeInfo"}}, "text": "There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those. ", "start_char_idx": 3731, "end_char_idx": 3855, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b438509-2823-48c8-a60f-85fcb54aadc5": {"__data__": {"id_": "8b438509-2823-48c8-a60f-85fcb54aadc5", "embedding": null, "metadata": {"window": "Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress.  And so we're encouraged by the status of the \ndiscussions.  There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those.  We're working through those with some urgency.   But it will take a bit of time to get through \nthose.  \n \n We're talking about 50 states, and we're talking about subdivisions within states.  So we've got a framework that \nwe're very optimistic about. ", "original_text": "We're working through those with some urgency.  ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a317770-53bc-4989-a87b-d54e17354910", "node_type": "1", "metadata": {"window": "And that remains our priority.  Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress.  And so we're encouraged by the status of the \ndiscussions.  There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those.  We're working through those with some urgency.   But it will take a bit of time to get through \nthose.  \n \n We're talking about 50 states, and we're talking about subdivisions within states. ", "original_text": "There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a283b1c52b8ebe6d40ba05519e811a1d8ba6713bc92815b3593746dbde427ecd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2151fdf1-be64-4a63-a4f7-0e922054fd94", "node_type": "1", "metadata": {"window": "And so we're encouraged by the status of the \ndiscussions.  There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those.  We're working through those with some urgency.   But it will take a bit of time to get through \nthose.  \n \n We're talking about 50 states, and we're talking about subdivisions within states.  So we've got a framework that \nwe're very optimistic about.  The teams are working diligently to address the issues. ", "original_text": "But it will take a bit of time to get through \nthose.  \n \n"}, "hash": "9717531e0253dc09be6af50d6204b974cc2baa536b1d4c5f659665fdfe55a815", "class_name": "RelatedNodeInfo"}}, "text": "We're working through those with some urgency.  ", "start_char_idx": 3855, "end_char_idx": 3903, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2151fdf1-be64-4a63-a4f7-0e922054fd94": {"__data__": {"id_": "2151fdf1-be64-4a63-a4f7-0e922054fd94", "embedding": null, "metadata": {"window": "And so we're encouraged by the status of the \ndiscussions.  There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those.  We're working through those with some urgency.   But it will take a bit of time to get through \nthose.  \n \n We're talking about 50 states, and we're talking about subdivisions within states.  So we've got a framework that \nwe're very optimistic about.  The teams are working diligently to address the issues. ", "original_text": "But it will take a bit of time to get through \nthose.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b438509-2823-48c8-a60f-85fcb54aadc5", "node_type": "1", "metadata": {"window": "Our view on these two counties and \ncoming to the settlement agreement we did with them was that was an important stepping -stone or building block \nfor momentum for more glo bal discussions to progress.  And so we're encouraged by the status of the \ndiscussions.  There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those.  We're working through those with some urgency.   But it will take a bit of time to get through \nthose.  \n \n We're talking about 50 states, and we're talking about subdivisions within states.  So we've got a framework that \nwe're very optimistic about. ", "original_text": "We're working through those with some urgency.  ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "71b1ba2e09fd5651ecda305cb33ea23405eb8b4f1ea4be9a6b8f50daa20ccda8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd19bc64-b8a4-4eb8-a0d2-4da3da3865a6", "node_type": "1", "metadata": {"window": "There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those.  We're working through those with some urgency.   But it will take a bit of time to get through \nthose.  \n \n We're talking about 50 states, and we're talking about subdivisions within states.  So we've got a framework that \nwe're very optimistic about.  The teams are working diligently to address the issues.  We' ll progress it as quickly as \nwe can. ", "original_text": "We're talking about 50 states, and we're talking about subdivisions within states. "}, "hash": "d694ccaec462319cba33470cfb7e29239617fc1d85797e88f8184485120e8a61", "class_name": "RelatedNodeInfo"}}, "text": "But it will take a bit of time to get through \nthose.  \n \n", "start_char_idx": 3903, "end_char_idx": 3961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd19bc64-b8a4-4eb8-a0d2-4da3da3865a6": {"__data__": {"id_": "fd19bc64-b8a4-4eb8-a0d2-4da3da3865a6", "embedding": null, "metadata": {"window": "There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those.  We're working through those with some urgency.   But it will take a bit of time to get through \nthose.  \n \n We're talking about 50 states, and we're talking about subdivisions within states.  So we've got a framework that \nwe're very optimistic about.  The teams are working diligently to address the issues.  We' ll progress it as quickly as \nwe can. ", "original_text": "We're talking about 50 states, and we're talking about subdivisions within states. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2151fdf1-be64-4a63-a4f7-0e922054fd94", "node_type": "1", "metadata": {"window": "And so we're encouraged by the status of the \ndiscussions.  There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those.  We're working through those with some urgency.   But it will take a bit of time to get through \nthose.  \n \n We're talking about 50 states, and we're talking about subdivisions within states.  So we've got a framework that \nwe're very optimistic about.  The teams are working diligently to address the issues. ", "original_text": "But it will take a bit of time to get through \nthose.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2dbbd40ccbf608d8de4c2479517fe0b86d8feb680b9cf75d7ade25eb7377d621", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23309721-d072-4e00-bcfb-fedd89ae681f", "node_type": "1", "metadata": {"window": "We're working through those with some urgency.   But it will take a bit of time to get through \nthose.  \n \n We're talking about 50 states, and we're talking about subdivisions within states.  So we've got a framework that \nwe're very optimistic about.  The teams are working diligently to address the issues.  We' ll progress it as quickly as \nwe can.  But obviously as we contemplate the two paths we've always talked about \u2013 there's a path to litigate, \nwhich we can project an amount of time and amount of dollars to go down that path, and then there's a path that \nwe th ink ring -fences the risk and can give us other resolution \u2013 that we'll take the path that we think is most \nbeneficial for our shareholders. ", "original_text": "So we've got a framework that \nwe're very optimistic about. "}, "hash": "259bbab19d82fc6da3e52c603f9858a8dbdcf5c6a901a1fd96e514a7c0679fe6", "class_name": "RelatedNodeInfo"}}, "text": "We're talking about 50 states, and we're talking about subdivisions within states. ", "start_char_idx": 3961, "end_char_idx": 4044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23309721-d072-4e00-bcfb-fedd89ae681f": {"__data__": {"id_": "23309721-d072-4e00-bcfb-fedd89ae681f", "embedding": null, "metadata": {"window": "We're working through those with some urgency.   But it will take a bit of time to get through \nthose.  \n \n We're talking about 50 states, and we're talking about subdivisions within states.  So we've got a framework that \nwe're very optimistic about.  The teams are working diligently to address the issues.  We' ll progress it as quickly as \nwe can.  But obviously as we contemplate the two paths we've always talked about \u2013 there's a path to litigate, \nwhich we can project an amount of time and amount of dollars to go down that path, and then there's a path that \nwe th ink ring -fences the risk and can give us other resolution \u2013 that we'll take the path that we think is most \nbeneficial for our shareholders. ", "original_text": "So we've got a framework that \nwe're very optimistic about. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd19bc64-b8a4-4eb8-a0d2-4da3da3865a6", "node_type": "1", "metadata": {"window": "There is a lot of activity and things that we need to continue to work through, and we are actively \nworking through those.  We're working through those with some urgency.   But it will take a bit of time to get through \nthose.  \n \n We're talking about 50 states, and we're talking about subdivisions within states.  So we've got a framework that \nwe're very optimistic about.  The teams are working diligently to address the issues.  We' ll progress it as quickly as \nwe can. ", "original_text": "We're talking about 50 states, and we're talking about subdivisions within states. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1b93742bddd13c5a3d4b5dc4dc729a4cd035b5d32ba97c8dc4ac70e78f8497cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62de4da5-32cf-4c6a-984d-ccb4000b481e", "node_type": "1", "metadata": {"window": "But it will take a bit of time to get through \nthose.  \n \n We're talking about 50 states, and we're talking about subdivisions within states.  So we've got a framework that \nwe're very optimistic about.  The teams are working diligently to address the issues.  We' ll progress it as quickly as \nwe can.  But obviously as we contemplate the two paths we've always talked about \u2013 there's a path to litigate, \nwhich we can project an amount of time and amount of dollars to go down that path, and then there's a path that \nwe th ink ring -fences the risk and can give us other resolution \u2013 that we'll take the path that we think is most \nbeneficial for our shareholders.  We certainly are anxious to find a resolution that gets care to patients and the ", "original_text": "The teams are working diligently to address the issues. "}, "hash": "1397419e12e057ae8a6d52f447c344f91b5f200a94c8c7596e9b8dc66a2351eb", "class_name": "RelatedNodeInfo"}}, "text": "So we've got a framework that \nwe're very optimistic about. ", "start_char_idx": 4044, "end_char_idx": 4104, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62de4da5-32cf-4c6a-984d-ccb4000b481e": {"__data__": {"id_": "62de4da5-32cf-4c6a-984d-ccb4000b481e", "embedding": null, "metadata": {"window": "But it will take a bit of time to get through \nthose.  \n \n We're talking about 50 states, and we're talking about subdivisions within states.  So we've got a framework that \nwe're very optimistic about.  The teams are working diligently to address the issues.  We' ll progress it as quickly as \nwe can.  But obviously as we contemplate the two paths we've always talked about \u2013 there's a path to litigate, \nwhich we can project an amount of time and amount of dollars to go down that path, and then there's a path that \nwe th ink ring -fences the risk and can give us other resolution \u2013 that we'll take the path that we think is most \nbeneficial for our shareholders.  We certainly are anxious to find a resolution that gets care to patients and the ", "original_text": "The teams are working diligently to address the issues. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23309721-d072-4e00-bcfb-fedd89ae681f", "node_type": "1", "metadata": {"window": "We're working through those with some urgency.   But it will take a bit of time to get through \nthose.  \n \n We're talking about 50 states, and we're talking about subdivisions within states.  So we've got a framework that \nwe're very optimistic about.  The teams are working diligently to address the issues.  We' ll progress it as quickly as \nwe can.  But obviously as we contemplate the two paths we've always talked about \u2013 there's a path to litigate, \nwhich we can project an amount of time and amount of dollars to go down that path, and then there's a path that \nwe th ink ring -fences the risk and can give us other resolution \u2013 that we'll take the path that we think is most \nbeneficial for our shareholders. ", "original_text": "So we've got a framework that \nwe're very optimistic about. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c555bd59b6f6f4fcd2bf5edf2020065ca02b227fb44dbdbebb0763f763de223", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96878600-efae-41fb-be97-47244d16c873", "node_type": "1", "metadata": {"window": "We're talking about 50 states, and we're talking about subdivisions within states.  So we've got a framework that \nwe're very optimistic about.  The teams are working diligently to address the issues.  We' ll progress it as quickly as \nwe can.  But obviously as we contemplate the two paths we've always talked about \u2013 there's a path to litigate, \nwhich we can project an amount of time and amount of dollars to go down that path, and then there's a path that \nwe th ink ring -fences the risk and can give us other resolution \u2013 that we'll take the path that we think is most \nbeneficial for our shareholders.  We certainly are anxious to find a resolution that gets care to patients and the ", "original_text": "We' ll progress it as quickly as \nwe can. "}, "hash": "b728e351e093fbdde48cff67dc11c1089ed61fd4fb0c6e9a6bf1bf6b3effd7d2", "class_name": "RelatedNodeInfo"}}, "text": "The teams are working diligently to address the issues. ", "start_char_idx": 4104, "end_char_idx": 4160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96878600-efae-41fb-be97-47244d16c873": {"__data__": {"id_": "96878600-efae-41fb-be97-47244d16c873", "embedding": null, "metadata": {"window": "We're talking about 50 states, and we're talking about subdivisions within states.  So we've got a framework that \nwe're very optimistic about.  The teams are working diligently to address the issues.  We' ll progress it as quickly as \nwe can.  But obviously as we contemplate the two paths we've always talked about \u2013 there's a path to litigate, \nwhich we can project an amount of time and amount of dollars to go down that path, and then there's a path that \nwe th ink ring -fences the risk and can give us other resolution \u2013 that we'll take the path that we think is most \nbeneficial for our shareholders.  We certainly are anxious to find a resolution that gets care to patients and the ", "original_text": "We' ll progress it as quickly as \nwe can. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62de4da5-32cf-4c6a-984d-ccb4000b481e", "node_type": "1", "metadata": {"window": "But it will take a bit of time to get through \nthose.  \n \n We're talking about 50 states, and we're talking about subdivisions within states.  So we've got a framework that \nwe're very optimistic about.  The teams are working diligently to address the issues.  We' ll progress it as quickly as \nwe can.  But obviously as we contemplate the two paths we've always talked about \u2013 there's a path to litigate, \nwhich we can project an amount of time and amount of dollars to go down that path, and then there's a path that \nwe th ink ring -fences the risk and can give us other resolution \u2013 that we'll take the path that we think is most \nbeneficial for our shareholders.  We certainly are anxious to find a resolution that gets care to patients and the ", "original_text": "The teams are working diligently to address the issues. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "39fe6a73cb383c954f9008c807a00dfae9377826255b66bf0108a3fa051972de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9653c590-8d50-4575-a9cd-522b576028e7", "node_type": "1", "metadata": {"window": "So we've got a framework that \nwe're very optimistic about.  The teams are working diligently to address the issues.  We' ll progress it as quickly as \nwe can.  But obviously as we contemplate the two paths we've always talked about \u2013 there's a path to litigate, \nwhich we can project an amount of time and amount of dollars to go down that path, and then there's a path that \nwe th ink ring -fences the risk and can give us other resolution \u2013 that we'll take the path that we think is most \nbeneficial for our shareholders.  We certainly are anxious to find a resolution that gets care to patients and the ", "original_text": "But obviously as we contemplate the two paths we've always talked about \u2013 there's a path to litigate, \nwhich we can project an amount of time and amount of dollars to go down that path, and then there's a path that \nwe th ink ring -fences the risk and can give us other resolution \u2013 that we'll take the path that we think is most \nbeneficial for our shareholders. "}, "hash": "e2f8618b7cd48c95c8f5a3bf01ddf97f517ed0670230c59eb70531d74e60637d", "class_name": "RelatedNodeInfo"}}, "text": "We' ll progress it as quickly as \nwe can. ", "start_char_idx": 4160, "end_char_idx": 4202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9653c590-8d50-4575-a9cd-522b576028e7": {"__data__": {"id_": "9653c590-8d50-4575-a9cd-522b576028e7", "embedding": null, "metadata": {"window": "So we've got a framework that \nwe're very optimistic about.  The teams are working diligently to address the issues.  We' ll progress it as quickly as \nwe can.  But obviously as we contemplate the two paths we've always talked about \u2013 there's a path to litigate, \nwhich we can project an amount of time and amount of dollars to go down that path, and then there's a path that \nwe th ink ring -fences the risk and can give us other resolution \u2013 that we'll take the path that we think is most \nbeneficial for our shareholders.  We certainly are anxious to find a resolution that gets care to patients and the ", "original_text": "But obviously as we contemplate the two paths we've always talked about \u2013 there's a path to litigate, \nwhich we can project an amount of time and amount of dollars to go down that path, and then there's a path that \nwe th ink ring -fences the risk and can give us other resolution \u2013 that we'll take the path that we think is most \nbeneficial for our shareholders. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96878600-efae-41fb-be97-47244d16c873", "node_type": "1", "metadata": {"window": "We're talking about 50 states, and we're talking about subdivisions within states.  So we've got a framework that \nwe're very optimistic about.  The teams are working diligently to address the issues.  We' ll progress it as quickly as \nwe can.  But obviously as we contemplate the two paths we've always talked about \u2013 there's a path to litigate, \nwhich we can project an amount of time and amount of dollars to go down that path, and then there's a path that \nwe th ink ring -fences the risk and can give us other resolution \u2013 that we'll take the path that we think is most \nbeneficial for our shareholders.  We certainly are anxious to find a resolution that gets care to patients and the ", "original_text": "We' ll progress it as quickly as \nwe can. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9347648efbd06764296ee36b23536cf8fbdf44bef73ad7cd54e2d3e25789b4a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a34652a-a18c-4a35-8fc4-790c6c4b8483", "node_type": "1", "metadata": {"window": "The teams are working diligently to address the issues.  We' ll progress it as quickly as \nwe can.  But obviously as we contemplate the two paths we've always talked about \u2013 there's a path to litigate, \nwhich we can project an amount of time and amount of dollars to go down that path, and then there's a path that \nwe th ink ring -fences the risk and can give us other resolution \u2013 that we'll take the path that we think is most \nbeneficial for our shareholders.  We certainly are anxious to find a resolution that gets care to patients and the ", "original_text": "We certainly are anxious to find a resolution that gets care to patients and the "}, "hash": "2b067747b7ada3131cdd81202f4c43c9904be3a73008949bad289464a542a9b9", "class_name": "RelatedNodeInfo"}}, "text": "But obviously as we contemplate the two paths we've always talked about \u2013 there's a path to litigate, \nwhich we can project an amount of time and amount of dollars to go down that path, and then there's a path that \nwe th ink ring -fences the risk and can give us other resolution \u2013 that we'll take the path that we think is most \nbeneficial for our shareholders. ", "start_char_idx": 4202, "end_char_idx": 4566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a34652a-a18c-4a35-8fc4-790c6c4b8483": {"__data__": {"id_": "6a34652a-a18c-4a35-8fc4-790c6c4b8483", "embedding": null, "metadata": {"window": "The teams are working diligently to address the issues.  We' ll progress it as quickly as \nwe can.  But obviously as we contemplate the two paths we've always talked about \u2013 there's a path to litigate, \nwhich we can project an amount of time and amount of dollars to go down that path, and then there's a path that \nwe th ink ring -fences the risk and can give us other resolution \u2013 that we'll take the path that we think is most \nbeneficial for our shareholders.  We certainly are anxious to find a resolution that gets care to patients and the ", "original_text": "We certainly are anxious to find a resolution that gets care to patients and the ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7380b2d9-8cb2-4667-a432-051970e943d2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db19246243f7f32ef96ab57a1b494f5a23c05901f2a11e2a2e098e7789e9f25f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9653c590-8d50-4575-a9cd-522b576028e7", "node_type": "1", "metadata": {"window": "So we've got a framework that \nwe're very optimistic about.  The teams are working diligently to address the issues.  We' ll progress it as quickly as \nwe can.  But obviously as we contemplate the two paths we've always talked about \u2013 there's a path to litigate, \nwhich we can project an amount of time and amount of dollars to go down that path, and then there's a path that \nwe th ink ring -fences the risk and can give us other resolution \u2013 that we'll take the path that we think is most \nbeneficial for our shareholders.  We certainly are anxious to find a resolution that gets care to patients and the ", "original_text": "But obviously as we contemplate the two paths we've always talked about \u2013 there's a path to litigate, \nwhich we can project an amount of time and amount of dollars to go down that path, and then there's a path that \nwe th ink ring -fences the risk and can give us other resolution \u2013 that we'll take the path that we think is most \nbeneficial for our shareholders. ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15a77f625926f7a2441aba993258a218b7b0f5dd6bf60f0c76df2186eb08fef5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "480a10fd-d38f-4c31-958a-6a05a19e51bc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ncommunities they serve as quickly a s they can.  But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies. ", "original_text": "McKesson Corp.  "}, "hash": "920554f018b53bab8ca0d968a1dcc1a6a97aedd326ffb3355f43b9bb43f98999", "class_name": "RelatedNodeInfo"}}, "text": "We certainly are anxious to find a resolution that gets care to patients and the ", "start_char_idx": 4566, "end_char_idx": 4647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "480a10fd-d38f-4c31-958a-6a05a19e51bc": {"__data__": {"id_": "480a10fd-d38f-4c31-958a-6a05a19e51bc", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ncommunities they serve as quickly a s they can.  But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a34652a-a18c-4a35-8fc4-790c6c4b8483", "node_type": "1", "metadata": {"window": "The teams are working diligently to address the issues.  We' ll progress it as quickly as \nwe can.  But obviously as we contemplate the two paths we've always talked about \u2013 there's a path to litigate, \nwhich we can project an amount of time and amount of dollars to go down that path, and then there's a path that \nwe th ink ring -fences the risk and can give us other resolution \u2013 that we'll take the path that we think is most \nbeneficial for our shareholders.  We certainly are anxious to find a resolution that gets care to patients and the ", "original_text": "We certainly are anxious to find a resolution that gets care to patients and the ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ce77e78876cd7af90b1ad1de269cb541bd86744a50b5227c1c5dc93868c70a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6f17db7-6d7f-4966-81bb-7387e5d8ddfe", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ncommunities they serve as quickly a s they can.  But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies.  Your line is open.  \n ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ncommunities they serve as quickly a s they can. "}, "hash": "226084ba8e9e7ac3ead7315b0644b024ad844acb97e6eacc005711083d7d9106", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6f17db7-6d7f-4966-81bb-7387e5d8ddfe": {"__data__": {"id_": "b6f17db7-6d7f-4966-81bb-7387e5d8ddfe", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ncommunities they serve as quickly a s they can.  But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies.  Your line is open.  \n ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ncommunities they serve as quickly a s they can. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "480a10fd-d38f-4c31-958a-6a05a19e51bc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ncommunities they serve as quickly a s they can.  But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77cd22302abf5dfcfa7ab9d87dd89a471de5f0864e6ecfc76bf8e70e0492b867", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebe138e7-ee4e-41fa-89ea-8fcf96c87ee5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ncommunities they serve as quickly a s they can.  But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing? ", "original_text": "But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n "}, "hash": "8e7123988cb7597f6e41f89c66bc3d7a326fa8173e45c8c69033cf4bc88f476d", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ncommunities they serve as quickly a s they can. ", "start_char_idx": 16, "end_char_idx": 229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebe138e7-ee4e-41fa-89ea-8fcf96c87ee5": {"__data__": {"id_": "ebe138e7-ee4e-41fa-89ea-8fcf96c87ee5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ncommunities they serve as quickly a s they can.  But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing? ", "original_text": "But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6f17db7-6d7f-4966-81bb-7387e5d8ddfe", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ncommunities they serve as quickly a s they can.  But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies.  Your line is open.  \n ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ncommunities they serve as quickly a s they can. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe3ed586cdf2cd380801daf2f4e449bf02fb10225e58099c8f713f6fbbf65d31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58e4417e-6083-4281-bd5c-792c4967f75c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ncommunities they serve as quickly a s they can.  But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing?  Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies. "}, "hash": "b861d63cfdc41b4f4a56265c003420fd4cc6b60f59efd5823b7ac1275871832a", "class_name": "RelatedNodeInfo"}}, "text": "But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n ", "start_char_idx": 229, "end_char_idx": 351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58e4417e-6083-4281-bd5c-792c4967f75c": {"__data__": {"id_": "58e4417e-6083-4281-bd5c-792c4967f75c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ncommunities they serve as quickly a s they can.  But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing?  Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebe138e7-ee4e-41fa-89ea-8fcf96c87ee5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ncommunities they serve as quickly a s they can.  But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing? ", "original_text": "But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1156aeaf27b014ce09988a5c5465f199eae48762fe4bce629f1a98104a1a84e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83dfb6cc-15c3-436c-b616-5aa4844810e0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ncommunities they serve as quickly a s they can.  But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing?  Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Your line is open.  \n "}, "hash": "b3a9e7dbd1f2a3fd1bdd1adbb1a130114bbe568c92ab560083c6ee3462b8b84f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies. ", "start_char_idx": 351, "end_char_idx": 696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83dfb6cc-15c3-436c-b616-5aa4844810e0": {"__data__": {"id_": "83dfb6cc-15c3-436c-b616-5aa4844810e0", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ncommunities they serve as quickly a s they can.  But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing?  Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Your line is open.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58e4417e-6083-4281-bd5c-792c4967f75c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ncommunities they serve as quickly a s they can.  But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing?  Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c2779d10f1e6cc388be05e79f82e4d87652868207df8b53b1a161eb295c4f8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a176bd4a-dccc-49b2-90d7-77af1307d46c", "node_type": "1", "metadata": {"window": "But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing?  Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing? "}, "hash": "f78bb06729b0b4cabfcb732b1bc22c310c4d9f4babd9a3833238b1c2ee87a62a", "class_name": "RelatedNodeInfo"}}, "text": "Your line is open.  \n ", "start_char_idx": 696, "end_char_idx": 718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a176bd4a-dccc-49b2-90d7-77af1307d46c": {"__data__": {"id_": "a176bd4a-dccc-49b2-90d7-77af1307d46c", "embedding": null, "metadata": {"window": "But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing?  Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing? ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83dfb6cc-15c3-436c-b616-5aa4844810e0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ncommunities they serve as quickly a s they can.  But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing?  Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Your line is open.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e74005ffa503a4e06fce38d9ac94e45b609f912f716b8409c59f156ed80e153", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a51316ee-afd4-4c97-9127-fd185e62ea2f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing?  Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great. ", "original_text": "Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n "}, "hash": "412deb7b894f053933729aabe63f9288bf9cc8d3aa27b8d7fe6abf708b91cb03", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing? ", "start_char_idx": 718, "end_char_idx": 1195, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a51316ee-afd4-4c97-9127-fd185e62ea2f": {"__data__": {"id_": "a51316ee-afd4-4c97-9127-fd185e62ea2f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing?  Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great. ", "original_text": "Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a176bd4a-dccc-49b2-90d7-77af1307d46c", "node_type": "1", "metadata": {"window": "But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing?  Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing? ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3367a167ddf659933873fc32a2874c3f55c0b4150f68fd02c8c7d2293e89b03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3791155-b03a-464b-a923-3576cb065840", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing?  Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great.  Thank you for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "682c9e66dd9c046f460c659b64af45466fbacddd5dc6e7ea384653be8192135d", "class_name": "RelatedNodeInfo"}}, "text": "Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n ", "start_char_idx": 1195, "end_char_idx": 1394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3791155-b03a-464b-a923-3576cb065840": {"__data__": {"id_": "f3791155-b03a-464b-a923-3576cb065840", "embedding": null, "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing?  Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great.  Thank you for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a51316ee-afd4-4c97-9127-fd185e62ea2f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing?  Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great. ", "original_text": "Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "39a6903a70c3b0e522ee46a1237b0d0b0587f9bb1d839550e4dc98475638a5e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfc79314-0022-426a-a751-a8cd5ec99b6f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing?  Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great.  Thank you for the question.  Maybe to  frame my answer a little bit, I'd go back in time. ", "original_text": "A \nYeah. "}, "hash": "86354f88258bf3cfaf4e74968c45cc2fcc070bdbdd0ad4027787437e57c8fd14", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1394, "end_char_idx": 1720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfc79314-0022-426a-a751-a8cd5ec99b6f": {"__data__": {"id_": "bfc79314-0022-426a-a751-a8cd5ec99b6f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing?  Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great.  Thank you for the question.  Maybe to  frame my answer a little bit, I'd go back in time. ", "original_text": "A \nYeah. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3791155-b03a-464b-a923-3576cb065840", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing?  Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great.  Thank you for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e873a92ce09bed03640e21b19db9fa3ef5138a6afb6d328fc9fad0dc35640d5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ee59b8d-0e48-408a-a68d-f7236dd14465", "node_type": "1", "metadata": {"window": "Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great.  Thank you for the question.  Maybe to  frame my answer a little bit, I'd go back in time.  I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings. ", "original_text": "Great. "}, "hash": "faf6915fd849ffaa720d46bfa9d4a49bd5de6a38badfb1fbadf663e53648ba6b", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 1720, "end_char_idx": 1729, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ee59b8d-0e48-408a-a68d-f7236dd14465": {"__data__": {"id_": "8ee59b8d-0e48-408a-a68d-f7236dd14465", "embedding": null, "metadata": {"window": "Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great.  Thank you for the question.  Maybe to  frame my answer a little bit, I'd go back in time.  I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings. ", "original_text": "Great. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfc79314-0022-426a-a751-a8cd5ec99b6f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilu t \nAnalyst, Jefferies LLC  Q \nBrian, just as I think about your comments about the strength that you saw with the medical side on the primary \ncare physician offices resupply, how are you strategizing?  Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great.  Thank you for the question.  Maybe to  frame my answer a little bit, I'd go back in time. ", "original_text": "A \nYeah. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3a7a895a2e8fa8878fc10bc62b02c61d368fde77389c1726f161568d74c2e97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "739ef4bd-e0a2-40f5-a51b-e8866914f194", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great.  Thank you for the question.  Maybe to  frame my answer a little bit, I'd go back in time.  I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings.  At one point in time, that was urgent care clinics. ", "original_text": "Thank you for the question. "}, "hash": "e9382db1a479f8dbbdaba1b58181d14fecbdd42694606a45d490284c8d93bf9b", "class_name": "RelatedNodeInfo"}}, "text": "Great. ", "start_char_idx": 1729, "end_char_idx": 1736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "739ef4bd-e0a2-40f5-a51b-e8866914f194": {"__data__": {"id_": "739ef4bd-e0a2-40f5-a51b-e8866914f194", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great.  Thank you for the question.  Maybe to  frame my answer a little bit, I'd go back in time.  I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings.  At one point in time, that was urgent care clinics. ", "original_text": "Thank you for the question. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ee59b8d-0e48-408a-a68d-f7236dd14465", "node_type": "1", "metadata": {"window": "Or how are you thinking about the emergence of retail -\nbased care delivery on the primary care side, whether that's Walmart, who's your client obviously, or the \ncompetitors in the retail space?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great.  Thank you for the question.  Maybe to  frame my answer a little bit, I'd go back in time.  I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings. ", "original_text": "Great. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "90ce1b49eb7caf619faa8ccbc2876583cb373b56a2891daa6f762053fe51b83d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24f0eba6-2651-4d71-a41b-b20f101fafc3", "node_type": "1", "metadata": {"window": "A \nYeah.  Great.  Thank you for the question.  Maybe to  frame my answer a little bit, I'd go back in time.  I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings.  At one point in time, that was urgent care clinics.  We have a large footpri nt in the retail -based clinics that \nare out there today. ", "original_text": "Maybe to  frame my answer a little bit, I'd go back in time. "}, "hash": "ba720860d1a3a2fc555dced96e395c16d951520716874adc844815e6cca6451c", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for the question. ", "start_char_idx": 1736, "end_char_idx": 1764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24f0eba6-2651-4d71-a41b-b20f101fafc3": {"__data__": {"id_": "24f0eba6-2651-4d71-a41b-b20f101fafc3", "embedding": null, "metadata": {"window": "A \nYeah.  Great.  Thank you for the question.  Maybe to  frame my answer a little bit, I'd go back in time.  I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings.  At one point in time, that was urgent care clinics.  We have a large footpri nt in the retail -based clinics that \nare out there today. ", "original_text": "Maybe to  frame my answer a little bit, I'd go back in time. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "739ef4bd-e0a2-40f5-a51b-e8866914f194", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great.  Thank you for the question.  Maybe to  frame my answer a little bit, I'd go back in time.  I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings.  At one point in time, that was urgent care clinics. ", "original_text": "Thank you for the question. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6fc4cda4313ef199136f3a7c10b86a2b16f77ef71b7c7d976c7bc21679eeeb09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70ca4295-a3e3-450c-a409-d369bfcd2700", "node_type": "1", "metadata": {"window": "Great.  Thank you for the question.  Maybe to  frame my answer a little bit, I'd go back in time.  I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings.  At one point in time, that was urgent care clinics.  We have a large footpri nt in the retail -based clinics that \nare out there today.  And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have. ", "original_text": "I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings. "}, "hash": "850185036cc0fa55f98185d794c35a2d8dcb81e63954f041ed4711e509e81209", "class_name": "RelatedNodeInfo"}}, "text": "Maybe to  frame my answer a little bit, I'd go back in time. ", "start_char_idx": 1764, "end_char_idx": 1825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70ca4295-a3e3-450c-a409-d369bfcd2700": {"__data__": {"id_": "70ca4295-a3e3-450c-a409-d369bfcd2700", "embedding": null, "metadata": {"window": "Great.  Thank you for the question.  Maybe to  frame my answer a little bit, I'd go back in time.  I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings.  At one point in time, that was urgent care clinics.  We have a large footpri nt in the retail -based clinics that \nare out there today.  And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have. ", "original_text": "I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24f0eba6-2651-4d71-a41b-b20f101fafc3", "node_type": "1", "metadata": {"window": "A \nYeah.  Great.  Thank you for the question.  Maybe to  frame my answer a little bit, I'd go back in time.  I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings.  At one point in time, that was urgent care clinics.  We have a large footpri nt in the retail -based clinics that \nare out there today. ", "original_text": "Maybe to  frame my answer a little bit, I'd go back in time. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1cb6ea7636392f2b10aee9f1f42845682a7bf9561283748e6f0ea5b8d9fce96f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "036d79ac-421b-4e50-aad8-d291a97ec81e", "node_type": "1", "metadata": {"window": "Thank you for the question.  Maybe to  frame my answer a little bit, I'd go back in time.  I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings.  At one point in time, that was urgent care clinics.  We have a large footpri nt in the retail -based clinics that \nare out there today.  And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have.  So \nmy view is it's just the continued evolution in a new segment. ", "original_text": "At one point in time, that was urgent care clinics. "}, "hash": "382a2e63d16a762e7ea8eddc5cb65f1c7ea60854d1b9f242e853f9ff1d1f35c8", "class_name": "RelatedNodeInfo"}}, "text": "I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings. ", "start_char_idx": 1825, "end_char_idx": 1956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "036d79ac-421b-4e50-aad8-d291a97ec81e": {"__data__": {"id_": "036d79ac-421b-4e50-aad8-d291a97ec81e", "embedding": null, "metadata": {"window": "Thank you for the question.  Maybe to  frame my answer a little bit, I'd go back in time.  I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings.  At one point in time, that was urgent care clinics.  We have a large footpri nt in the retail -based clinics that \nare out there today.  And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have.  So \nmy view is it's just the continued evolution in a new segment. ", "original_text": "At one point in time, that was urgent care clinics. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70ca4295-a3e3-450c-a409-d369bfcd2700", "node_type": "1", "metadata": {"window": "Great.  Thank you for the question.  Maybe to  frame my answer a little bit, I'd go back in time.  I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings.  At one point in time, that was urgent care clinics.  We have a large footpri nt in the retail -based clinics that \nare out there today.  And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have. ", "original_text": "I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a0717f084b74b02a6ac6424214fe2fd0f551016a5e333fdb33f753d917910b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa74016a-c1cc-43e8-a990-9a5175ea5c10", "node_type": "1", "metadata": {"window": "Maybe to  frame my answer a little bit, I'd go back in time.  I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings.  At one point in time, that was urgent care clinics.  We have a large footpri nt in the retail -based clinics that \nare out there today.  And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have.  So \nmy view is it's just the continued evolution in a new segment.  And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n ", "original_text": "We have a large footpri nt in the retail -based clinics that \nare out there today. "}, "hash": "10143ddbb9e4b34921d7d58a01ae5477505a20046439b12bb6aa193b8123b13f", "class_name": "RelatedNodeInfo"}}, "text": "At one point in time, that was urgent care clinics. ", "start_char_idx": 1956, "end_char_idx": 2008, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa74016a-c1cc-43e8-a990-9a5175ea5c10": {"__data__": {"id_": "aa74016a-c1cc-43e8-a990-9a5175ea5c10", "embedding": null, "metadata": {"window": "Maybe to  frame my answer a little bit, I'd go back in time.  I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings.  At one point in time, that was urgent care clinics.  We have a large footpri nt in the retail -based clinics that \nare out there today.  And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have.  So \nmy view is it's just the continued evolution in a new segment.  And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n ", "original_text": "We have a large footpri nt in the retail -based clinics that \nare out there today. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "036d79ac-421b-4e50-aad8-d291a97ec81e", "node_type": "1", "metadata": {"window": "Thank you for the question.  Maybe to  frame my answer a little bit, I'd go back in time.  I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings.  At one point in time, that was urgent care clinics.  We have a large footpri nt in the retail -based clinics that \nare out there today.  And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have.  So \nmy view is it's just the continued evolution in a new segment. ", "original_text": "At one point in time, that was urgent care clinics. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c16db60a666b4315b612892321d4e79116206346de72c222178eae8dfee9f398", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e877184e-774e-41dc-9b74-37c130fe384d", "node_type": "1", "metadata": {"window": "I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings.  At one point in time, that was urgent care clinics.  We have a large footpri nt in the retail -based clinics that \nare out there today.  And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have.  So \nmy view is it's just the continued evolution in a new segment.  And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt. ", "original_text": "And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have. "}, "hash": "2635da8c73f1dce2c66aa402c10eb75222e9592fc6908d1f8f6ae62d81de953e", "class_name": "RelatedNodeInfo"}}, "text": "We have a large footpri nt in the retail -based clinics that \nare out there today. ", "start_char_idx": 2008, "end_char_idx": 2091, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e877184e-774e-41dc-9b74-37c130fe384d": {"__data__": {"id_": "e877184e-774e-41dc-9b74-37c130fe384d", "embedding": null, "metadata": {"window": "I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings.  At one point in time, that was urgent care clinics.  We have a large footpri nt in the retail -based clinics that \nare out there today.  And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have.  So \nmy view is it's just the continued evolution in a new segment.  And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt. ", "original_text": "And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa74016a-c1cc-43e8-a990-9a5175ea5c10", "node_type": "1", "metadata": {"window": "Maybe to  frame my answer a little bit, I'd go back in time.  I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings.  At one point in time, that was urgent care clinics.  We have a large footpri nt in the retail -based clinics that \nare out there today.  And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have.  So \nmy view is it's just the continued evolution in a new segment.  And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n ", "original_text": "We have a large footpri nt in the retail -based clinics that \nare out there today. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be5361fae919895bf640dad8ce58f52d58064f4a2de4b8c29974db6ce3166520", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54007c23-c45f-4466-8bc7-f953a6834970", "node_type": "1", "metadata": {"window": "At one point in time, that was urgent care clinics.  We have a large footpri nt in the retail -based clinics that \nare out there today.  And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have.  So \nmy view is it's just the continued evolution in a new segment.  And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt.  As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n ", "original_text": "So \nmy view is it's just the continued evolution in a new segment. "}, "hash": "73886b4bd74d12a455842100e25ccc1e190a6d8d6b03f237920b1033fe064a79", "class_name": "RelatedNodeInfo"}}, "text": "And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have. ", "start_char_idx": 2091, "end_char_idx": 2292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54007c23-c45f-4466-8bc7-f953a6834970": {"__data__": {"id_": "54007c23-c45f-4466-8bc7-f953a6834970", "embedding": null, "metadata": {"window": "At one point in time, that was urgent care clinics.  We have a large footpri nt in the retail -based clinics that \nare out there today.  And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have.  So \nmy view is it's just the continued evolution in a new segment.  And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt.  As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n ", "original_text": "So \nmy view is it's just the continued evolution in a new segment. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e877184e-774e-41dc-9b74-37c130fe384d", "node_type": "1", "metadata": {"window": "I think the \nmedical business has been very successful at following the emergence of new channels in the alternate site \nsettings.  At one point in time, that was urgent care clinics.  We have a large footpri nt in the retail -based clinics that \nare out there today.  And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have.  So \nmy view is it's just the continued evolution in a new segment.  And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt. ", "original_text": "And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95a4ab7925290eecf3fc2a9522523de4cdb6152f3342c3c5ad214a0f195a7e7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e7e3cc4-ecc8-4c75-93ab-c685247cde45", "node_type": "1", "metadata": {"window": "We have a large footpri nt in the retail -based clinics that \nare out there today.  And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have.  So \nmy view is it's just the continued evolution in a new segment.  And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt.  As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.  ", "original_text": "And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n "}, "hash": "1e5b757e002e5910df50b9eb0848d5dadc605056b8528a30ad269c3d902fd331", "class_name": "RelatedNodeInfo"}}, "text": "So \nmy view is it's just the continued evolution in a new segment. ", "start_char_idx": 2292, "end_char_idx": 2359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e7e3cc4-ecc8-4c75-93ab-c685247cde45": {"__data__": {"id_": "8e7e3cc4-ecc8-4c75-93ab-c685247cde45", "embedding": null, "metadata": {"window": "We have a large footpri nt in the retail -based clinics that \nare out there today.  And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have.  So \nmy view is it's just the continued evolution in a new segment.  And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt.  As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.  ", "original_text": "And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54007c23-c45f-4466-8bc7-f953a6834970", "node_type": "1", "metadata": {"window": "At one point in time, that was urgent care clinics.  We have a large footpri nt in the retail -based clinics that \nare out there today.  And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have.  So \nmy view is it's just the continued evolution in a new segment.  And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt.  As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n ", "original_text": "So \nmy view is it's just the continued evolution in a new segment. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d6bf0c81aad442acb616a97a4304676cdbd723427b1a8a0b4ff7589629272e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d59af89a-3ac0-4640-b800-151730ae6293", "node_type": "1", "metadata": {"window": "And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have.  So \nmy view is it's just the continued evolution in a new segment.  And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt.  As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.   A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt. "}, "hash": "6caf0c8089c1f9d201735cd898cd4a2fe7a274fe74370376e5306d391257142a", "class_name": "RelatedNodeInfo"}}, "text": "And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n ", "start_char_idx": 2359, "end_char_idx": 2564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d59af89a-3ac0-4640-b800-151730ae6293": {"__data__": {"id_": "d59af89a-3ac0-4640-b800-151730ae6293", "embedding": null, "metadata": {"window": "And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have.  So \nmy view is it's just the continued evolution in a new segment.  And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt.  As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.   A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e7e3cc4-ecc8-4c75-93ab-c685247cde45", "node_type": "1", "metadata": {"window": "We have a large footpri nt in the retail -based clinics that \nare out there today.  And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have.  So \nmy view is it's just the continued evolution in a new segment.  And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt.  As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.  ", "original_text": "And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ecd471b1e864de74b8cacd7ba94f2be14f5eef5b92c061918de955376fa3f53b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1773b0b2-dc45-4d71-a349-0b08f8bb037f", "node_type": "1", "metadata": {"window": "So \nmy view is it's just the continued evolution in a new segment.  And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt.  As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.   A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit.  We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation. ", "original_text": "As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n "}, "hash": "f0b251872a48e7829458c5afafab709c0d6e480b9fc707cc89e14aceda737e61", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt. ", "start_char_idx": 2564, "end_char_idx": 2916, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1773b0b2-dc45-4d71-a349-0b08f8bb037f": {"__data__": {"id_": "1773b0b2-dc45-4d71-a349-0b08f8bb037f", "embedding": null, "metadata": {"window": "So \nmy view is it's just the continued evolution in a new segment.  And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt.  As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.   A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit.  We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation. ", "original_text": "As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d59af89a-3ac0-4640-b800-151730ae6293", "node_type": "1", "metadata": {"window": "And so we think as these new models for community -based care emerge, the solutions that \nwe have in the medical business are right on point for the needs that those businesses and services will have.  So \nmy view is it's just the continued evolution in a new segment.  And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt.  As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.   A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "575d34920b9abb4714e5e603e6d0b77eccbb54b988536a51a99d4f6b43ec9393", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ae16911-bd34-447f-a98a-380678742381", "node_type": "1", "metadata": {"window": "And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt.  As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.   A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit.  We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation.  So we're \ncontinuing to view brand price in the mid -single digits. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.  "}, "hash": "a55c6dd1b685201517d8aaf4f953c8fd7a1fc5d3938a73f9546a22da61dd4e45", "class_name": "RelatedNodeInfo"}}, "text": "As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n ", "start_char_idx": 2916, "end_char_idx": 3025, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ae16911-bd34-447f-a98a-380678742381": {"__data__": {"id_": "5ae16911-bd34-447f-a98a-380678742381", "embedding": null, "metadata": {"window": "And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt.  As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.   A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit.  We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation.  So we're \ncontinuing to view brand price in the mid -single digits. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1773b0b2-dc45-4d71-a349-0b08f8bb037f", "node_type": "1", "metadata": {"window": "So \nmy view is it's just the continued evolution in a new segment.  And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt.  As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.   A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit.  We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation. ", "original_text": "As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d975ad0c57683f5a74430114a7b6dc2ca4c5ad8312921280819345cf59d49e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "997779ef-d58f-455d-97e5-fdbcc031581b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt.  As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.   A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit.  We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation.  So we're \ncontinuing to view brand price in the mid -single digits.  Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n ", "original_text": "A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit. "}, "hash": "a6f93548f3d23701aab90b4b2ae993c9ceb62b07d47483263f11eb38d4f17c0b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.  ", "start_char_idx": 3025, "end_char_idx": 3371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "997779ef-d58f-455d-97e5-fdbcc031581b": {"__data__": {"id_": "997779ef-d58f-455d-97e5-fdbcc031581b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt.  As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.   A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit.  We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation.  So we're \ncontinuing to view brand price in the mid -single digits.  Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n ", "original_text": "A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ae16911-bd34-447f-a98a-380678742381", "node_type": "1", "metadata": {"window": "And our team has proven quite adept and quite \neffective at evolving our capabilities and really leading the way as these segments emerge, and I would expect \nthat's what the team is focused o n today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt.  As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.   A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit.  We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation.  So we're \ncontinuing to view brand price in the mid -single digits. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "62cb8021e87d14c865971ed5e8e630641de48bf6af0af47240f60f709b69c813", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd31c989-69b2-414d-828b-05ce3e9eafb5", "node_type": "1", "metadata": {"window": "As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.   A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit.  We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation.  So we're \ncontinuing to view brand price in the mid -single digits.  Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research. ", "original_text": "We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation. "}, "hash": "b44c4de070db1d305855299615541ff0fd2d8962287095f3c05ef6bc068a35fb", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit. ", "start_char_idx": 3371, "end_char_idx": 3480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd31c989-69b2-414d-828b-05ce3e9eafb5": {"__data__": {"id_": "dd31c989-69b2-414d-828b-05ce3e9eafb5", "embedding": null, "metadata": {"window": "As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.   A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit.  We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation.  So we're \ncontinuing to view brand price in the mid -single digits.  Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research. ", "original_text": "We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "997779ef-d58f-455d-97e5-fdbcc031581b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nAnd then I guess just my follow -up for Britt.  As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.   A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit.  We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation.  So we're \ncontinuing to view brand price in the mid -single digits.  Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n ", "original_text": "A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb076444ea4163287b049a9b16b2df09fcb20326aa641a8be11ec5771421f129", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6700482-5e7f-4562-8a7e-e2b16fb8fa48", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.   A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit.  We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation.  So we're \ncontinuing to view brand price in the mid -single digits.  Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research.  Your line is open.  \n ", "original_text": "So we're \ncontinuing to view brand price in the mid -single digits. "}, "hash": "9f0422abb8a84d188d4703c776e0b0eeece4b67f3e2e07f7629aac990cfcd47d", "class_name": "RelatedNodeInfo"}}, "text": "We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation. ", "start_char_idx": 3480, "end_char_idx": 3603, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6700482-5e7f-4562-8a7e-e2b16fb8fa48": {"__data__": {"id_": "e6700482-5e7f-4562-8a7e-e2b16fb8fa48", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.   A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit.  We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation.  So we're \ncontinuing to view brand price in the mid -single digits.  Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research.  Your line is open.  \n ", "original_text": "So we're \ncontinuing to view brand price in the mid -single digits. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd31c989-69b2-414d-828b-05ce3e9eafb5", "node_type": "1", "metadata": {"window": "As I think about calendar 2020, what are your expectations in terms of \nbrand pricing just for January 1?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.   A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit.  We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation.  So we're \ncontinuing to view brand price in the mid -single digits.  Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research. ", "original_text": "We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c7e073e70b1015c0644bc747812e5b52ff039cd411a262d1bcdc9b01efe55f2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08c0eabc-2e67-4b02-884c-6a70ef4ee5d5", "node_type": "1", "metadata": {"window": "A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit.  We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation.  So we're \ncontinuing to view brand price in the mid -single digits.  Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question. ", "original_text": "Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n "}, "hash": "d141870ff6702291a448334052ee3ae17f4d19103305775b9770aac96eb62c5c", "class_name": "RelatedNodeInfo"}}, "text": "So we're \ncontinuing to view brand price in the mid -single digits. ", "start_char_idx": 3603, "end_char_idx": 3671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08c0eabc-2e67-4b02-884c-6a70ef4ee5d5": {"__data__": {"id_": "08c0eabc-2e67-4b02-884c-6a70ef4ee5d5", "embedding": null, "metadata": {"window": "A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit.  We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation.  So we're \ncontinuing to view brand price in the mid -single digits.  Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question. ", "original_text": "Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6700482-5e7f-4562-8a7e-e2b16fb8fa48", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Ch ief Financial Officer, McKesson Corp.   A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit.  We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation.  So we're \ncontinuing to view brand price in the mid -single digits.  Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research.  Your line is open.  \n ", "original_text": "So we're \ncontinuing to view brand price in the mid -single digits. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91d541f64e76d5ef21b6cf9b7dff7103bf19793c6d6fd44c805ff5575b3ca825", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9471e6b6-6209-4ee6-90ec-a95e7a3bd296", "node_type": "1", "metadata": {"window": "We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation.  So we're \ncontinuing to view brand price in the mid -single digits.  Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question.  So I'm trying to understand the magnitude of the revenue revision in the U.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research. "}, "hash": "3f3024f3a31fb6462f390155556d174f860a4f2dc47c94635382fde0e795be22", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n ", "start_char_idx": 3671, "end_char_idx": 3814, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9471e6b6-6209-4ee6-90ec-a95e7a3bd296": {"__data__": {"id_": "9471e6b6-6209-4ee6-90ec-a95e7a3bd296", "embedding": null, "metadata": {"window": "We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation.  So we're \ncontinuing to view brand price in the mid -single digits.  Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question.  So I'm trying to understand the magnitude of the revenue revision in the U.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08c0eabc-2e67-4b02-884c-6a70ef4ee5d5", "node_type": "1", "metadata": {"window": "A \nYeah, what I would say is that we're reiterating our view that brand price inflation's mid -single digit.  We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation.  So we're \ncontinuing to view brand price in the mid -single digits.  Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question. ", "original_text": "Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ccf2ee698779d6c43cc1dc777bb188bd4af99bc64f32610cb21d7a5bb4a77e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "190df7a7-1eb4-49ab-a00d-d8ead5fba6e4", "node_type": "1", "metadata": {"window": "So we're \ncontinuing to view brand price in the mid -single digits.  Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question.  So I'm trying to understand the magnitude of the revenue revision in the U.S.  pharma \nbusiness. ", "original_text": "Your line is open.  \n "}, "hash": "c35620205828ad939256ef1edc02e6e5504a2dffd41844bea826ad60b4cd0d5a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research. ", "start_char_idx": 3814, "end_char_idx": 4164, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "190df7a7-1eb4-49ab-a00d-d8ead5fba6e4": {"__data__": {"id_": "190df7a7-1eb4-49ab-a00d-d8ead5fba6e4", "embedding": null, "metadata": {"window": "So we're \ncontinuing to view brand price in the mid -single digits.  Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question.  So I'm trying to understand the magnitude of the revenue revision in the U.S.  pharma \nbusiness. ", "original_text": "Your line is open.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9471e6b6-6209-4ee6-90ec-a95e7a3bd296", "node_type": "1", "metadata": {"window": "We don't see \nanything that has occurred in the first half of the year or this quarter that would change that expectation.  So we're \ncontinuing to view brand price in the mid -single digits.  Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question.  So I'm trying to understand the magnitude of the revenue revision in the U.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97c872791add7c5c219ef848de0778bee50e049b3cc081b765f97d4fed22881e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4656f2cb-76ae-49f7-b586-ff186ec6bc92", "node_type": "1", "metadata": {"window": "Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question.  So I'm trying to understand the magnitude of the revenue revision in the U.S.  pharma \nbusiness.  Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question. "}, "hash": "fb96db310ae45b14afc40c21e576b80831fde6e456e1b494c007d0d204ca66da", "class_name": "RelatedNodeInfo"}}, "text": "Your line is open.  \n ", "start_char_idx": 696, "end_char_idx": 718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4656f2cb-76ae-49f7-b586-ff186ec6bc92": {"__data__": {"id_": "4656f2cb-76ae-49f7-b586-ff186ec6bc92", "embedding": null, "metadata": {"window": "Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question.  So I'm trying to understand the magnitude of the revenue revision in the U.S.  pharma \nbusiness.  Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "190df7a7-1eb4-49ab-a00d-d8ead5fba6e4", "node_type": "1", "metadata": {"window": "So we're \ncontinuing to view brand price in the mid -single digits.  Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question.  So I'm trying to understand the magnitude of the revenue revision in the U.S.  pharma \nbusiness. ", "original_text": "Your line is open.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5922c42c9da3998275c561fba2210c867b7fe870c83cd97a5133e3ef49d2a1f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25357b59-6c6a-41e9-8512-4dda854d9736", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question.  So I'm trying to understand the magnitude of the revenue revision in the U.S.  pharma \nbusiness.  Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels.  So I guess, first, can you help us understand what why that is? ", "original_text": "So I'm trying to understand the magnitude of the revenue revision in the U.S. "}, "hash": "fc56fccded8ba90db3c4a9ce3c8943797e811f6f89e05e47ecc306a2dfac96c6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question. ", "start_char_idx": 4186, "end_char_idx": 4521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25357b59-6c6a-41e9-8512-4dda854d9736": {"__data__": {"id_": "25357b59-6c6a-41e9-8512-4dda854d9736", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question.  So I'm trying to understand the magnitude of the revenue revision in the U.S.  pharma \nbusiness.  Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels.  So I guess, first, can you help us understand what why that is? ", "original_text": "So I'm trying to understand the magnitude of the revenue revision in the U.S. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4656f2cb-76ae-49f7-b586-ff186ec6bc92", "node_type": "1", "metadata": {"window": "Obviously, January is usually an important month, \nhistorically, but at this point, we're not changing our view on branded price inflation.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question.  So I'm trying to understand the magnitude of the revenue revision in the U.S.  pharma \nbusiness.  Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c49008c69953f85dce79724a3263d230a416ba9a576f2ec1da79046815780912", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4344030d-cff4-474a-874f-e272f8724c6d", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question.  So I'm trying to understand the magnitude of the revenue revision in the U.S.  pharma \nbusiness.  Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels.  So I guess, first, can you help us understand what why that is?  And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook. ", "original_text": "pharma \nbusiness. "}, "hash": "3d3cd2bfa38311bc83679ea5c4aabb1938675c211611bb820d61fba4dfde3f7e", "class_name": "RelatedNodeInfo"}}, "text": "So I'm trying to understand the magnitude of the revenue revision in the U.S. ", "start_char_idx": 4521, "end_char_idx": 4599, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4344030d-cff4-474a-874f-e272f8724c6d": {"__data__": {"id_": "4344030d-cff4-474a-874f-e272f8724c6d", "embedding": null, "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question.  So I'm trying to understand the magnitude of the revenue revision in the U.S.  pharma \nbusiness.  Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels.  So I guess, first, can you help us understand what why that is?  And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook. ", "original_text": "pharma \nbusiness. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25357b59-6c6a-41e9-8512-4dda854d9736", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question com es from the line of Stephen Baxter of Wolfe Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question.  So I'm trying to understand the magnitude of the revenue revision in the U.S.  pharma \nbusiness.  Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels.  So I guess, first, can you help us understand what why that is? ", "original_text": "So I'm trying to understand the magnitude of the revenue revision in the U.S. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f337d4086c92d624702e60e48e3957bb8c863ad6548cd9ab11c3d09485dd20e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d8a9fee-9851-43bf-9b2c-1c93a40a3de0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question.  So I'm trying to understand the magnitude of the revenue revision in the U.S.  pharma \nbusiness.  Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels.  So I guess, first, can you help us understand what why that is?  And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook.  I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings. ", "original_text": "Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels. "}, "hash": "7f504a19ce127439f18deec1c83801fecd2c75f9d9acc78f168f5c6a9d886eda", "class_name": "RelatedNodeInfo"}}, "text": "pharma \nbusiness. ", "start_char_idx": 4599, "end_char_idx": 4617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d8a9fee-9851-43bf-9b2c-1c93a40a3de0": {"__data__": {"id_": "5d8a9fee-9851-43bf-9b2c-1c93a40a3de0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question.  So I'm trying to understand the magnitude of the revenue revision in the U.S.  pharma \nbusiness.  Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels.  So I guess, first, can you help us understand what why that is?  And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook.  I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings. ", "original_text": "Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4344030d-cff4-474a-874f-e272f8724c6d", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question.  So I'm trying to understand the magnitude of the revenue revision in the U.S.  pharma \nbusiness.  Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels.  So I guess, first, can you help us understand what why that is?  And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook. ", "original_text": "pharma \nbusiness. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e98c171e3cdbd815b83fa0a571eac2f12df22f1ea75250d32c41ee4233954d04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39b737cc-eaaf-4d3c-8a00-e9e448586ac4", "node_type": "1", "metadata": {"window": "So I'm trying to understand the magnitude of the revenue revision in the U.S.  pharma \nbusiness.  Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels.  So I guess, first, can you help us understand what why that is?  And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook.  I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings.  So I guess how should we be  thinking about that? ", "original_text": "So I guess, first, can you help us understand what why that is? "}, "hash": "a145e62a5ca310e6af4e7a980b17ac265d5e9fbb3f4b7757c7416e2a25b924de", "class_name": "RelatedNodeInfo"}}, "text": "Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels. ", "start_char_idx": 4617, "end_char_idx": 4749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39b737cc-eaaf-4d3c-8a00-e9e448586ac4": {"__data__": {"id_": "39b737cc-eaaf-4d3c-8a00-e9e448586ac4", "embedding": null, "metadata": {"window": "So I'm trying to understand the magnitude of the revenue revision in the U.S.  pharma \nbusiness.  Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels.  So I guess, first, can you help us understand what why that is?  And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook.  I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings.  So I guess how should we be  thinking about that? ", "original_text": "So I guess, first, can you help us understand what why that is? ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d8a9fee-9851-43bf-9b2c-1c93a40a3de0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks for the question.  So I'm trying to understand the magnitude of the revenue revision in the U.S.  pharma \nbusiness.  Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels.  So I guess, first, can you help us understand what why that is?  And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook.  I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings. ", "original_text": "Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67a7f32f9d4907e69a9d1e0c5e742ffd18b6b43f44ef11c35fa7eee6b79314bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24ec2e1a-a02c-4b60-822a-98e277793e59", "node_type": "1", "metadata": {"window": "pharma \nbusiness.  Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels.  So I guess, first, can you help us understand what why that is?  And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook.  I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings.  So I guess how should we be  thinking about that?  And is there \nsomething about the rest of the business we should be keeping in mind? ", "original_text": "And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook. "}, "hash": "e46e1d433d831100bba723ebab27c280b7e5b79e838c081a00459b86a2ee2df2", "class_name": "RelatedNodeInfo"}}, "text": "So I guess, first, can you help us understand what why that is? ", "start_char_idx": 4749, "end_char_idx": 4813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24ec2e1a-a02c-4b60-822a-98e277793e59": {"__data__": {"id_": "24ec2e1a-a02c-4b60-822a-98e277793e59", "embedding": null, "metadata": {"window": "pharma \nbusiness.  Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels.  So I guess, first, can you help us understand what why that is?  And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook.  I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings.  So I guess how should we be  thinking about that?  And is there \nsomething about the rest of the business we should be keeping in mind? ", "original_text": "And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39b737cc-eaaf-4d3c-8a00-e9e448586ac4", "node_type": "1", "metadata": {"window": "So I'm trying to understand the magnitude of the revenue revision in the U.S.  pharma \nbusiness.  Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels.  So I guess, first, can you help us understand what why that is?  And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook.  I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings.  So I guess how should we be  thinking about that? ", "original_text": "So I guess, first, can you help us understand what why that is? ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5621d16083d8c4b8a1dbd672b65e2abdef0b9dc6bc27cd12756fad0fe16dbdb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3966f54e-52de-4176-9a44-0f2ea4a7067a", "node_type": "1", "metadata": {"window": "Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels.  So I guess, first, can you help us understand what why that is?  And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook.  I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings.  So I guess how should we be  thinking about that?  And is there \nsomething about the rest of the business we should be keeping in mind?  Thanks.  ", "original_text": "I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings. "}, "hash": "88fae260e5b626f67c85e7cf0b85d118c8d86fae62fd9c64eba4587f1e16214a", "class_name": "RelatedNodeInfo"}}, "text": "And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook. ", "start_char_idx": 4813, "end_char_idx": 4973, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3966f54e-52de-4176-9a44-0f2ea4a7067a": {"__data__": {"id_": "3966f54e-52de-4176-9a44-0f2ea4a7067a", "embedding": null, "metadata": {"window": "Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels.  So I guess, first, can you help us understand what why that is?  And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook.  I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings.  So I guess how should we be  thinking about that?  And is there \nsomething about the rest of the business we should be keeping in mind?  Thanks.  ", "original_text": "I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24ec2e1a-a02c-4b60-822a-98e277793e59", "node_type": "1", "metadata": {"window": "pharma \nbusiness.  Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels.  So I guess, first, can you help us understand what why that is?  And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook.  I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings.  So I guess how should we be  thinking about that?  And is there \nsomething about the rest of the business we should be keeping in mind? ", "original_text": "And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74c36a7258c7523fc49b2285875efaf8f241f3e773f5a146438d018938395896", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4565dff-8995-4f1a-8d43-45f846a41bef", "node_type": "1", "metadata": {"window": "So I guess, first, can you help us understand what why that is?  And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook.  I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings.  So I guess how should we be  thinking about that?  And is there \nsomething about the rest of the business we should be keeping in mind?  Thanks.  ", "original_text": "So I guess how should we be  thinking about that? "}, "hash": "84ffaa5a56c9be1d27a6f5faed5d208c01dd2ba2cd5dfb5fdbf580d2ed8d9a79", "class_name": "RelatedNodeInfo"}}, "text": "I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings. ", "start_char_idx": 4973, "end_char_idx": 5116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4565dff-8995-4f1a-8d43-45f846a41bef": {"__data__": {"id_": "e4565dff-8995-4f1a-8d43-45f846a41bef", "embedding": null, "metadata": {"window": "So I guess, first, can you help us understand what why that is?  And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook.  I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings.  So I guess how should we be  thinking about that?  And is there \nsomething about the rest of the business we should be keeping in mind?  Thanks.  ", "original_text": "So I guess how should we be  thinking about that? ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3966f54e-52de-4176-9a44-0f2ea4a7067a", "node_type": "1", "metadata": {"window": "Now, I appreciate the color on Caremark, but it sounds like you're suggesting this is coming in a lot \nbetter than expected levels.  So I guess, first, can you help us understand what why that is?  And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook.  I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings.  So I guess how should we be  thinking about that?  And is there \nsomething about the rest of the business we should be keeping in mind?  Thanks.  ", "original_text": "I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings. ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd699e40764436cd1d56f4f9655356a565209965550ac5e87bef41dc99cc8fbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5f13821-4092-4861-ad79-4aa9da46aecf", "node_type": "1", "metadata": {"window": "And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook.  I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings.  So I guess how should we be  thinking about that?  And is there \nsomething about the rest of the business we should be keeping in mind?  Thanks.  ", "original_text": "And is there \nsomething about the rest of the business we should be keeping in mind? "}, "hash": "a14204ae49860c2b37a7779074cbc4eb787a7b744f7a3cf2ee67bcc3895801c9", "class_name": "RelatedNodeInfo"}}, "text": "So I guess how should we be  thinking about that? ", "start_char_idx": 5116, "end_char_idx": 5166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5f13821-4092-4861-ad79-4aa9da46aecf": {"__data__": {"id_": "c5f13821-4092-4861-ad79-4aa9da46aecf", "embedding": null, "metadata": {"window": "And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook.  I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings.  So I guess how should we be  thinking about that?  And is there \nsomething about the rest of the business we should be keeping in mind?  Thanks.  ", "original_text": "And is there \nsomething about the rest of the business we should be keeping in mind? ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4565dff-8995-4f1a-8d43-45f846a41bef", "node_type": "1", "metadata": {"window": "So I guess, first, can you help us understand what why that is?  And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook.  I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings.  So I guess how should we be  thinking about that?  And is there \nsomething about the rest of the business we should be keeping in mind?  Thanks.  ", "original_text": "So I guess how should we be  thinking about that? ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bbad3f81bb4c4ea5ad5f38852e841e542fde64444fc5ae45cb8c3751e6f78d80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "852a04c8-2740-4d90-b425-d1e38ebcf3f8", "node_type": "1", "metadata": {"window": "I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings.  So I guess how should we be  thinking about that?  And is there \nsomething about the rest of the business we should be keeping in mind?  Thanks.  ", "original_text": "Thanks.  "}, "hash": "c483a9f4f07d77b9d78295c75a87866eb4d98144e55b3c2c32a390ecee19df08", "class_name": "RelatedNodeInfo"}}, "text": "And is there \nsomething about the rest of the business we should be keeping in mind? ", "start_char_idx": 5166, "end_char_idx": 5251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "852a04c8-2740-4d90-b425-d1e38ebcf3f8": {"__data__": {"id_": "852a04c8-2740-4d90-b425-d1e38ebcf3f8", "embedding": null, "metadata": {"window": "I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings.  So I guess how should we be  thinking about that?  And is there \nsomething about the rest of the business we should be keeping in mind?  Thanks.  ", "original_text": "Thanks.  ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74fc7dc29650e67555bb8d4eea328443b50eb3ac921654ba9b41299bb4aa8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5f13821-4092-4861-ad79-4aa9da46aecf", "node_type": "1", "metadata": {"window": "And then I guess the \nfollow -up would be you're raising revenue guida nce here by what looks like roughly 3% to 5% but not changing \nyour EBIT growth outlook.  I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings.  So I guess how should we be  thinking about that?  And is there \nsomething about the rest of the business we should be keeping in mind?  Thanks.  ", "original_text": "And is there \nsomething about the rest of the business we should be keeping in mind? ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "84312e545e277c554bf4c3d6b28a2c88d3766b6ff437dfc5d531386cf49dbc62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0e3d11e-1cbe-4bb3-8825-185288c0b990", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for that question.  So let me just step back to the revenue g uidance. ", "original_text": "McKesson Corp.  "}, "hash": "e9f1b30f3e8865e8dc3570c800958d733ea1bbc1a7684d85c326936fd696401c", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  ", "start_char_idx": 5251, "end_char_idx": 5260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0e3d11e-1cbe-4bb3-8825-185288c0b990": {"__data__": {"id_": "a0e3d11e-1cbe-4bb3-8825-185288c0b990", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for that question.  So let me just step back to the revenue g uidance. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "852a04c8-2740-4d90-b425-d1e38ebcf3f8", "node_type": "1", "metadata": {"window": "I get that we're talking about specialty and Caremark, but it's surprising there isn't there \nreally any noticeable drop -through to earnings.  So I guess how should we be  thinking about that?  And is there \nsomething about the rest of the business we should be keeping in mind?  Thanks.  ", "original_text": "Thanks.  ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42d8ce47c32ebbb5a57a5a6683c3b84f025dee4047bc6d3be594ac627a27a82c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a89d1093-94b3-4ece-b5b5-5a57983d77c5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for that question.  So let me just step back to the revenue g uidance.  Our prior revenue guidance was \nlow single digit to mid -single digit. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "cf1511d57eee4a6bcffe6f877088e49be378e0a6163145cdf96f6ea5b9aeaaf0", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a89d1093-94b3-4ece-b5b5-5a57983d77c5": {"__data__": {"id_": "a89d1093-94b3-4ece-b5b5-5a57983d77c5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for that question.  So let me just step back to the revenue g uidance.  Our prior revenue guidance was \nlow single digit to mid -single digit. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0e3d11e-1cbe-4bb3-8825-185288c0b990", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for that question.  So let me just step back to the revenue g uidance. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "75940b86a4e91ab95c72ae462ad9baee1973a09d6983096df3f650ed61ec7da7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3df840a5-0618-456a-ab1f-dc71807663c9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for that question.  So let me just step back to the revenue g uidance.  Our prior revenue guidance was \nlow single digit to mid -single digit.  And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer. ", "original_text": "A \nYeah, thanks for that question. "}, "hash": "273d4895ac9d46e0653d9b125f935b627326ea56376fd560c2f5d9ae47b47f0b", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3df840a5-0618-456a-ab1f-dc71807663c9": {"__data__": {"id_": "3df840a5-0618-456a-ab1f-dc71807663c9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for that question.  So let me just step back to the revenue g uidance.  Our prior revenue guidance was \nlow single digit to mid -single digit.  And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer. ", "original_text": "A \nYeah, thanks for that question. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a89d1093-94b3-4ece-b5b5-5a57983d77c5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for that question.  So let me just step back to the revenue g uidance.  Our prior revenue guidance was \nlow single digit to mid -single digit. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ccb9946c17ea48a44338dad81bb6e71da17f722517447b4da82958b4f806bce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fba2a9e-e649-4286-a695-d09eae1bd2e0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for that question.  So let me just step back to the revenue g uidance.  Our prior revenue guidance was \nlow single digit to mid -single digit.  And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer.  That's really what's driving this.  \n \n", "original_text": "So let me just step back to the revenue g uidance. "}, "hash": "2ad1eb750ce45694922e1fa8823807c2d782e674c977525e406d98a600cdc816", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, thanks for that question. ", "start_char_idx": 250, "end_char_idx": 285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fba2a9e-e649-4286-a695-d09eae1bd2e0": {"__data__": {"id_": "6fba2a9e-e649-4286-a695-d09eae1bd2e0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for that question.  So let me just step back to the revenue g uidance.  Our prior revenue guidance was \nlow single digit to mid -single digit.  And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer.  That's really what's driving this.  \n \n", "original_text": "So let me just step back to the revenue g uidance. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3df840a5-0618-456a-ab1f-dc71807663c9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for that question.  So let me just step back to the revenue g uidance.  Our prior revenue guidance was \nlow single digit to mid -single digit.  And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer. ", "original_text": "A \nYeah, thanks for that question. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4bad441a8e99c992cea136e074940424a3ed82f37682543d694d33a070cbf48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f06db92b-aecd-425f-a9a9-d213a9a2062d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for that question.  So let me just step back to the revenue g uidance.  Our prior revenue guidance was \nlow single digit to mid -single digit.  And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer.  That's really what's driving this.  \n \n In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness. ", "original_text": "Our prior revenue guidance was \nlow single digit to mid -single digit. "}, "hash": "f53ac19fce26b76279f0a8926a5989f529ede5c85f9e64f429a0565eb23595c5", "class_name": "RelatedNodeInfo"}}, "text": "So let me just step back to the revenue g uidance. ", "start_char_idx": 285, "end_char_idx": 336, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f06db92b-aecd-425f-a9a9-d213a9a2062d": {"__data__": {"id_": "f06db92b-aecd-425f-a9a9-d213a9a2062d", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for that question.  So let me just step back to the revenue g uidance.  Our prior revenue guidance was \nlow single digit to mid -single digit.  And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer.  That's really what's driving this.  \n \n In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness. ", "original_text": "Our prior revenue guidance was \nlow single digit to mid -single digit. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fba2a9e-e649-4286-a695-d09eae1bd2e0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for that question.  So let me just step back to the revenue g uidance.  Our prior revenue guidance was \nlow single digit to mid -single digit.  And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer.  That's really what's driving this.  \n \n", "original_text": "So let me just step back to the revenue g uidance. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25b8128bbd8d0a2830628f420ab52692cb66b09464a7eda0f5025107491c4471", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cb40e20-6651-42e0-9ba3-2ab0e3db08fc", "node_type": "1", "metadata": {"window": "A \nYeah, thanks for that question.  So let me just step back to the revenue g uidance.  Our prior revenue guidance was \nlow single digit to mid -single digit.  And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer.  That's really what's driving this.  \n \n In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness.  I talked about $25 million of investments in our oncology and m anufacturer services capabilities. ", "original_text": "And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer. "}, "hash": "820d7ad4527c05ba211352299b9f81e95b7221c2dcc9c0c603b1059091efa562", "class_name": "RelatedNodeInfo"}}, "text": "Our prior revenue guidance was \nlow single digit to mid -single digit. ", "start_char_idx": 336, "end_char_idx": 407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cb40e20-6651-42e0-9ba3-2ab0e3db08fc": {"__data__": {"id_": "9cb40e20-6651-42e0-9ba3-2ab0e3db08fc", "embedding": null, "metadata": {"window": "A \nYeah, thanks for that question.  So let me just step back to the revenue g uidance.  Our prior revenue guidance was \nlow single digit to mid -single digit.  And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer.  That's really what's driving this.  \n \n In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness.  I talked about $25 million of investments in our oncology and m anufacturer services capabilities. ", "original_text": "And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f06db92b-aecd-425f-a9a9-d213a9a2062d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for that question.  So let me just step back to the revenue g uidance.  Our prior revenue guidance was \nlow single digit to mid -single digit.  And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer.  That's really what's driving this.  \n \n In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness. ", "original_text": "Our prior revenue guidance was \nlow single digit to mid -single digit. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c42e9a3e6ed82ac881d7d52438372057203186a71a42a7b6fd6c28bd48f7fdf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "023a7b56-eb00-4dbd-b9ef-2f8445bc86f6", "node_type": "1", "metadata": {"window": "So let me just step back to the revenue g uidance.  Our prior revenue guidance was \nlow single digit to mid -single digit.  And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer.  That's really what's driving this.  \n \n In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness.  I talked about $25 million of investments in our oncology and m anufacturer services capabilities.  And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n", "original_text": "That's really what's driving this.  \n \n"}, "hash": "82bb3b966bbe84028d7687f6b5d1920f4e1fa1467a1c23ddfccff988b767ad7d", "class_name": "RelatedNodeInfo"}}, "text": "And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer. ", "start_char_idx": 407, "end_char_idx": 622, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "023a7b56-eb00-4dbd-b9ef-2f8445bc86f6": {"__data__": {"id_": "023a7b56-eb00-4dbd-b9ef-2f8445bc86f6", "embedding": null, "metadata": {"window": "So let me just step back to the revenue g uidance.  Our prior revenue guidance was \nlow single digit to mid -single digit.  And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer.  That's really what's driving this.  \n \n In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness.  I talked about $25 million of investments in our oncology and m anufacturer services capabilities.  And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n", "original_text": "That's really what's driving this.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cb40e20-6651-42e0-9ba3-2ab0e3db08fc", "node_type": "1", "metadata": {"window": "A \nYeah, thanks for that question.  So let me just step back to the revenue g uidance.  Our prior revenue guidance was \nlow single digit to mid -single digit.  And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer.  That's really what's driving this.  \n \n In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness.  I talked about $25 million of investments in our oncology and m anufacturer services capabilities. ", "original_text": "And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96e49ffe4cf919da9d17d4862bc6722bda3c66b8e63ac05c8ead96a396cef5c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "564cba84-ef45-4e65-a2ba-d42e814c9b67", "node_type": "1", "metadata": {"window": "Our prior revenue guidance was \nlow single digit to mid -single digit.  And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer.  That's really what's driving this.  \n \n In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness.  I talked about $25 million of investments in our oncology and m anufacturer services capabilities.  And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n So I would call this as growth from one of our customers that is primarily coming through specialty. ", "original_text": "In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness. "}, "hash": "f5f6beee7ae899d4b33300c2abee3bc110bdc085d8d90affb5f3ee3d44dd3cbd", "class_name": "RelatedNodeInfo"}}, "text": "That's really what's driving this.  \n \n", "start_char_idx": 622, "end_char_idx": 661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "564cba84-ef45-4e65-a2ba-d42e814c9b67": {"__data__": {"id_": "564cba84-ef45-4e65-a2ba-d42e814c9b67", "embedding": null, "metadata": {"window": "Our prior revenue guidance was \nlow single digit to mid -single digit.  And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer.  That's really what's driving this.  \n \n In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness.  I talked about $25 million of investments in our oncology and m anufacturer services capabilities.  And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n So I would call this as growth from one of our customers that is primarily coming through specialty. ", "original_text": "In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "023a7b56-eb00-4dbd-b9ef-2f8445bc86f6", "node_type": "1", "metadata": {"window": "So let me just step back to the revenue g uidance.  Our prior revenue guidance was \nlow single digit to mid -single digit.  And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer.  That's really what's driving this.  \n \n In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness.  I talked about $25 million of investments in our oncology and m anufacturer services capabilities.  And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n", "original_text": "That's really what's driving this.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b46f2e7cab85a0dd3f9d35f9612d4ae000982572eacc144cf664b310a56ac9b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b05d7ae8-2a31-4f15-a867-89e16ae45f3e", "node_type": "1", "metadata": {"window": "And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer.  That's really what's driving this.  \n \n In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness.  I talked about $25 million of investments in our oncology and m anufacturer services capabilities.  And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n So I would call this as growth from one of our customers that is primarily coming through specialty.  We're making \ninvestments where we have leading positions and great capabilities. ", "original_text": "I talked about $25 million of investments in our oncology and m anufacturer services capabilities. "}, "hash": "e54fc444ea75497df40d674bc5014a7f130b32ef40b45520135397b24c6f420f", "class_name": "RelatedNodeInfo"}}, "text": "In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness. ", "start_char_idx": 661, "end_char_idx": 786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b05d7ae8-2a31-4f15-a867-89e16ae45f3e": {"__data__": {"id_": "b05d7ae8-2a31-4f15-a867-89e16ae45f3e", "embedding": null, "metadata": {"window": "And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer.  That's really what's driving this.  \n \n In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness.  I talked about $25 million of investments in our oncology and m anufacturer services capabilities.  And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n So I would call this as growth from one of our customers that is primarily coming through specialty.  We're making \ninvestments where we have leading positions and great capabilities. ", "original_text": "I talked about $25 million of investments in our oncology and m anufacturer services capabilities. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "564cba84-ef45-4e65-a2ba-d42e814c9b67", "node_type": "1", "metadata": {"window": "Our prior revenue guidance was \nlow single digit to mid -single digit.  And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer.  That's really what's driving this.  \n \n In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness.  I talked about $25 million of investments in our oncology and m anufacturer services capabilities.  And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n So I would call this as growth from one of our customers that is primarily coming through specialty. ", "original_text": "In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "522475bd3903907b023d90d5c84dcb30a2d5e3b1d31b0e2b5b825ef5f78574ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8ee2a13-c9e3-4753-8ff5-1f7f5035ffcb", "node_type": "1", "metadata": {"window": "That's really what's driving this.  \n \n In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness.  I talked about $25 million of investments in our oncology and m anufacturer services capabilities.  And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n So I would call this as growth from one of our customers that is primarily coming through specialty.  We're making \ninvestments where we have leading positions and great capabilities.  And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n ", "original_text": "And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n"}, "hash": "7a2f3aecae47e61bcef16e80a0bed366daca5254cfafde16dee0e3e2e536766e", "class_name": "RelatedNodeInfo"}}, "text": "I talked about $25 million of investments in our oncology and m anufacturer services capabilities. ", "start_char_idx": 786, "end_char_idx": 885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8ee2a13-c9e3-4753-8ff5-1f7f5035ffcb": {"__data__": {"id_": "e8ee2a13-c9e3-4753-8ff5-1f7f5035ffcb", "embedding": null, "metadata": {"window": "That's really what's driving this.  \n \n In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness.  I talked about $25 million of investments in our oncology and m anufacturer services capabilities.  And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n So I would call this as growth from one of our customers that is primarily coming through specialty.  We're making \ninvestments where we have leading positions and great capabilities.  And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n ", "original_text": "And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b05d7ae8-2a31-4f15-a867-89e16ae45f3e", "node_type": "1", "metadata": {"window": "And so we've updated that to high single digit, and that's largely reflective of the \ngrowth that we're seeing that's coming from Caremark and particularly specialty products that  are going through \nthat customer.  That's really what's driving this.  \n \n In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness.  I talked about $25 million of investments in our oncology and m anufacturer services capabilities.  And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n So I would call this as growth from one of our customers that is primarily coming through specialty.  We're making \ninvestments where we have leading positions and great capabilities. ", "original_text": "I talked about $25 million of investments in our oncology and m anufacturer services capabilities. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c919c37437e88027cf4ea0f977cdfc87b50eca1afc32036c34e2bebad99ad1cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "660b3754-f698-4007-81b7-ca29d6a3fec3", "node_type": "1", "metadata": {"window": "In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness.  I talked about $25 million of investments in our oncology and m anufacturer services capabilities.  And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n So I would call this as growth from one of our customers that is primarily coming through specialty.  We're making \ninvestments where we have leading positions and great capabilities.  And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it. ", "original_text": "So I would call this as growth from one of our customers that is primarily coming through specialty. "}, "hash": "93685b65078cb276010fb0ddb8b492b32b27c2c684fab01d4a9264b62b91a560", "class_name": "RelatedNodeInfo"}}, "text": "And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n", "start_char_idx": 885, "end_char_idx": 1049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "660b3754-f698-4007-81b7-ca29d6a3fec3": {"__data__": {"id_": "660b3754-f698-4007-81b7-ca29d6a3fec3", "embedding": null, "metadata": {"window": "In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness.  I talked about $25 million of investments in our oncology and m anufacturer services capabilities.  And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n So I would call this as growth from one of our customers that is primarily coming through specialty.  We're making \ninvestments where we have leading positions and great capabilities.  And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it. ", "original_text": "So I would call this as growth from one of our customers that is primarily coming through specialty. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8ee2a13-c9e3-4753-8ff5-1f7f5035ffcb", "node_type": "1", "metadata": {"window": "That's really what's driving this.  \n \n In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness.  I talked about $25 million of investments in our oncology and m anufacturer services capabilities.  And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n So I would call this as growth from one of our customers that is primarily coming through specialty.  We're making \ninvestments where we have leading positions and great capabilities.  And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n ", "original_text": "And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5b9aa0b60244ecce57cb63b62ba071c93412381fc44a719db973c9f6e311418", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cc7f8dc-11f7-49c3-ab2f-9382c9222e54", "node_type": "1", "metadata": {"window": "I talked about $25 million of investments in our oncology and m anufacturer services capabilities.  And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n So I would call this as growth from one of our customers that is primarily coming through specialty.  We're making \ninvestments where we have leading positions and great capabilities.  And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it.  And I guess just coming back to what is better than was expected going into the year. ", "original_text": "We're making \ninvestments where we have leading positions and great capabilities. "}, "hash": "7d23cfefd4956499d5f8361ee3fba6bdaceba5f7e5cd65670d7f89914b4fcc7f", "class_name": "RelatedNodeInfo"}}, "text": "So I would call this as growth from one of our customers that is primarily coming through specialty. ", "start_char_idx": 1049, "end_char_idx": 1150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cc7f8dc-11f7-49c3-ab2f-9382c9222e54": {"__data__": {"id_": "0cc7f8dc-11f7-49c3-ab2f-9382c9222e54", "embedding": null, "metadata": {"window": "I talked about $25 million of investments in our oncology and m anufacturer services capabilities.  And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n So I would call this as growth from one of our customers that is primarily coming through specialty.  We're making \ninvestments where we have leading positions and great capabilities.  And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it.  And I guess just coming back to what is better than was expected going into the year. ", "original_text": "We're making \ninvestments where we have leading positions and great capabilities. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "660b3754-f698-4007-81b7-ca29d6a3fec3", "node_type": "1", "metadata": {"window": "In terms of the drop -through to the bottom line, we're really pleased that we're able to make investments in the \nbusiness.  I talked about $25 million of investments in our oncology and m anufacturer services capabilities.  And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n So I would call this as growth from one of our customers that is primarily coming through specialty.  We're making \ninvestments where we have leading positions and great capabilities.  And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it. ", "original_text": "So I would call this as growth from one of our customers that is primarily coming through specialty. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67872d2de3a5f3e58b7fc7405962c4babeef2f8fe5e1c47af88e02018b72a465", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2331f3b9-e84c-4d80-bde4-7fec773ea4d4", "node_type": "1", "metadata": {"window": "And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n So I would call this as growth from one of our customers that is primarily coming through specialty.  We're making \ninvestments where we have leading positions and great capabilities.  And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it.  And I guess just coming back to what is better than was expected going into the year.  Is there any clarity \nyou can provide on that? ", "original_text": "And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n "}, "hash": "502ead9c59a9d84f4ed0afaae6a9df96de372aaade5fa7c18a26a50ca4d7c4df", "class_name": "RelatedNodeInfo"}}, "text": "We're making \ninvestments where we have leading positions and great capabilities. ", "start_char_idx": 1150, "end_char_idx": 1232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2331f3b9-e84c-4d80-bde4-7fec773ea4d4": {"__data__": {"id_": "2331f3b9-e84c-4d80-bde4-7fec773ea4d4", "embedding": null, "metadata": {"window": "And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n So I would call this as growth from one of our customers that is primarily coming through specialty.  We're making \ninvestments where we have leading positions and great capabilities.  And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it.  And I guess just coming back to what is better than was expected going into the year.  Is there any clarity \nyou can provide on that? ", "original_text": "And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cc7f8dc-11f7-49c3-ab2f-9382c9222e54", "node_type": "1", "metadata": {"window": "I talked about $25 million of investments in our oncology and m anufacturer services capabilities.  And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n So I would call this as growth from one of our customers that is primarily coming through specialty.  We're making \ninvestments where we have leading positions and great capabilities.  And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it.  And I guess just coming back to what is better than was expected going into the year. ", "original_text": "We're making \ninvestments where we have leading positions and great capabilities. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1a71f3a9c501296efa06add5bc4d19d34e7c1d6820d3a269a3f8c053a213378", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0d58a80-22e6-4a77-a3f6-5aab2144aa6e", "node_type": "1", "metadata": {"window": "So I would call this as growth from one of our customers that is primarily coming through specialty.  We're making \ninvestments where we have leading positions and great capabilities.  And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it.  And I guess just coming back to what is better than was expected going into the year.  Is there any clarity \nyou can provide on that?  I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it. "}, "hash": "e559b98b1abc5ea5a9a1e3b4a609324deda065cdcf6a9c6d843c184cea9584c0", "class_name": "RelatedNodeInfo"}}, "text": "And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n ", "start_char_idx": 1232, "end_char_idx": 1365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0d58a80-22e6-4a77-a3f6-5aab2144aa6e": {"__data__": {"id_": "c0d58a80-22e6-4a77-a3f6-5aab2144aa6e", "embedding": null, "metadata": {"window": "So I would call this as growth from one of our customers that is primarily coming through specialty.  We're making \ninvestments where we have leading positions and great capabilities.  And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it.  And I guess just coming back to what is better than was expected going into the year.  Is there any clarity \nyou can provide on that?  I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2331f3b9-e84c-4d80-bde4-7fec773ea4d4", "node_type": "1", "metadata": {"window": "And \ndespite those investments we're pleased to be able to hold and affirm our guidance for the segment on AOP at \nthat low single to mid -single digit number.  \n \n So I would call this as growth from one of our customers that is primarily coming through specialty.  We're making \ninvestments where we have leading positions and great capabilities.  And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it.  And I guess just coming back to what is better than was expected going into the year.  Is there any clarity \nyou can provide on that? ", "original_text": "And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8929a753db4bd9feb327ca94c8c485091bcbb1af51ece213a98e381a862e83d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfc95602-dee1-49e6-afac-7d6029c3bc0b", "node_type": "1", "metadata": {"window": "We're making \ninvestments where we have leading positions and great capabilities.  And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it.  And I guess just coming back to what is better than was expected going into the year.  Is there any clarity \nyou can provide on that?  I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great.  Thanks.  \n ", "original_text": "And I guess just coming back to what is better than was expected going into the year. "}, "hash": "5447d253d8b6c8b2fd891e912fd2257d402f658b2ba615f38780c8bd29980c60", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it. ", "start_char_idx": 1365, "end_char_idx": 1680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfc95602-dee1-49e6-afac-7d6029c3bc0b": {"__data__": {"id_": "bfc95602-dee1-49e6-afac-7d6029c3bc0b", "embedding": null, "metadata": {"window": "We're making \ninvestments where we have leading positions and great capabilities.  And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it.  And I guess just coming back to what is better than was expected going into the year.  Is there any clarity \nyou can provide on that?  I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great.  Thanks.  \n ", "original_text": "And I guess just coming back to what is better than was expected going into the year. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0d58a80-22e6-4a77-a3f6-5aab2144aa6e", "node_type": "1", "metadata": {"window": "So I would call this as growth from one of our customers that is primarily coming through specialty.  We're making \ninvestments where we have leading positions and great capabilities.  And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it.  And I guess just coming back to what is better than was expected going into the year.  Is there any clarity \nyou can provide on that?  I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "199e70f76a4e60141a7384d33dd53e0e3d3da2e89f666ff6a37bc6fa103e2974", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99d71e39-1a6f-42c3-9535-050260f0a1ba", "node_type": "1", "metadata": {"window": "And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it.  And I guess just coming back to what is better than was expected going into the year.  Is there any clarity \nyou can provide on that?  I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Is there any clarity \nyou can provide on that? "}, "hash": "4b33ddcaf4d834bf5cb5f50691d1054affbe853e1f9a7ba5810ae4cc730b2db8", "class_name": "RelatedNodeInfo"}}, "text": "And I guess just coming back to what is better than was expected going into the year. ", "start_char_idx": 1680, "end_char_idx": 1766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99d71e39-1a6f-42c3-9535-050260f0a1ba": {"__data__": {"id_": "99d71e39-1a6f-42c3-9535-050260f0a1ba", "embedding": null, "metadata": {"window": "And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it.  And I guess just coming back to what is better than was expected going into the year.  Is there any clarity \nyou can provide on that?  I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Is there any clarity \nyou can provide on that? ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfc95602-dee1-49e6-afac-7d6029c3bc0b", "node_type": "1", "metadata": {"window": "We're making \ninvestments where we have leading positions and great capabilities.  And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it.  And I guess just coming back to what is better than was expected going into the year.  Is there any clarity \nyou can provide on that?  I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great.  Thanks.  \n ", "original_text": "And I guess just coming back to what is better than was expected going into the year. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "21e15140a6989a9962e0f65164073809063cf99c88b3600df804ff1115f38f90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2af3907-52e7-41f5-983f-5b8fcaa8d2f8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it.  And I guess just coming back to what is better than was expected going into the year.  Is there any clarity \nyou can provide on that?  I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure. ", "original_text": "I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great. "}, "hash": "d445cec5b6cc38bbacabf4bfc3cac9315a6d078ba340a5fef7035ff17e01532a", "class_name": "RelatedNodeInfo"}}, "text": "Is there any clarity \nyou can provide on that? ", "start_char_idx": 1766, "end_char_idx": 1813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2af3907-52e7-41f5-983f-5b8fcaa8d2f8": {"__data__": {"id_": "d2af3907-52e7-41f5-983f-5b8fcaa8d2f8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it.  And I guess just coming back to what is better than was expected going into the year.  Is there any clarity \nyou can provide on that?  I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure. ", "original_text": "I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99d71e39-1a6f-42c3-9535-050260f0a1ba", "node_type": "1", "metadata": {"window": "And I talked about that as being an additional \n$25 million, but we're still holding and affirming the AOP guide for the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it.  And I guess just coming back to what is better than was expected going into the year.  Is there any clarity \nyou can provide on that?  I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Is there any clarity \nyou can provide on that? ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49034bacfe72111deb8d8c9cb4ee86c745a4fea48898f8d759388fb27fcce9d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc0ea8f2-8efa-4473-bef4-66a1f16f94a7", "node_type": "1", "metadata": {"window": "And I guess just coming back to what is better than was expected going into the year.  Is there any clarity \nyou can provide on that?  I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, I'd just reiterate a couple things. ", "original_text": "Thanks.  \n "}, "hash": "d3ccd742985bde96e1ec783f3a37873082baea574dd36e1137f7deb6a9e26333", "class_name": "RelatedNodeInfo"}}, "text": "I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great. ", "start_char_idx": 1813, "end_char_idx": 1930, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc0ea8f2-8efa-4473-bef4-66a1f16f94a7": {"__data__": {"id_": "cc0ea8f2-8efa-4473-bef4-66a1f16f94a7", "embedding": null, "metadata": {"window": "And I guess just coming back to what is better than was expected going into the year.  Is there any clarity \nyou can provide on that?  I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, I'd just reiterate a couple things. ", "original_text": "Thanks.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2af3907-52e7-41f5-983f-5b8fcaa8d2f8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteph en Baxter  \nAnalyst, Wolfe Research LLC  Q \nGot it.  And I guess just coming back to what is better than was expected going into the year.  Is there any clarity \nyou can provide on that?  I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure. ", "original_text": "I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c814afaa5b9423efac7b33a8a8ccd28fc1c46d0db02d7fd3a2554f95f8414356", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88ecdf42-27af-4e96-995f-413644de20ff", "node_type": "1", "metadata": {"window": "Is there any clarity \nyou can provide on that?  I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, I'd just reiterate a couple things.  Branded pricing inflation is performing as we had anticipated. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "2d016b0fc5832627782d84f335054891d14e88c24f1f14f7d94d08dc1d603011", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 1930, "end_char_idx": 1941, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88ecdf42-27af-4e96-995f-413644de20ff": {"__data__": {"id_": "88ecdf42-27af-4e96-995f-413644de20ff", "embedding": null, "metadata": {"window": "Is there any clarity \nyou can provide on that?  I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, I'd just reiterate a couple things.  Branded pricing inflation is performing as we had anticipated. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc0ea8f2-8efa-4473-bef4-66a1f16f94a7", "node_type": "1", "metadata": {"window": "And I guess just coming back to what is better than was expected going into the year.  Is there any clarity \nyou can provide on that?  I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, I'd just reiterate a couple things. ", "original_text": "Thanks.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09c064fa52a642215ba6fcbc9ce94a2f75c7bdb996b36133986d50788358ccf7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b805c01-232f-4f87-a051-c3a2e934594c", "node_type": "1", "metadata": {"window": "I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, I'd just reiterate a couple things.  Branded pricing inflation is performing as we had anticipated.  We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace. ", "original_text": "A \nSure. "}, "hash": "3aa0b319667ec8b2146f40736b4b8a82339c377d809fc446660d7213f35c6ed8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 1941, "end_char_idx": 2286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b805c01-232f-4f87-a051-c3a2e934594c": {"__data__": {"id_": "4b805c01-232f-4f87-a051-c3a2e934594c", "embedding": null, "metadata": {"window": "I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, I'd just reiterate a couple things.  Branded pricing inflation is performing as we had anticipated.  We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace. ", "original_text": "A \nSure. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88ecdf42-27af-4e96-995f-413644de20ff", "node_type": "1", "metadata": {"window": "Is there any clarity \nyou can provide on that?  I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, I'd just reiterate a couple things.  Branded pricing inflation is performing as we had anticipated. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "38301f9eb07640a5ba764a1f6d320fb39b2fd7f326ad291ff6b8ae1e53b0eef8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbc39247-f91c-4f64-9e19-4fdce88d60d7", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, I'd just reiterate a couple things.  Branded pricing inflation is performing as we had anticipated.  We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace.  I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well. ", "original_text": "Well, I'd just reiterate a couple things. "}, "hash": "62fde10e6af5c7c66f25719b6adbedbd7a415bad1b87b51c627d401b510733cc", "class_name": "RelatedNodeInfo"}}, "text": "A \nSure. ", "start_char_idx": 2286, "end_char_idx": 2295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbc39247-f91c-4f64-9e19-4fdce88d60d7": {"__data__": {"id_": "dbc39247-f91c-4f64-9e19-4fdce88d60d7", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, I'd just reiterate a couple things.  Branded pricing inflation is performing as we had anticipated.  We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace.  I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well. ", "original_text": "Well, I'd just reiterate a couple things. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b805c01-232f-4f87-a051-c3a2e934594c", "node_type": "1", "metadata": {"window": "I appreciate what the driver is in absolute terms, but understanding versus  your prior \nexpectation would be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, I'd just reiterate a couple things.  Branded pricing inflation is performing as we had anticipated.  We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace. ", "original_text": "A \nSure. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aec1d33cd80f9f5b780740fe7f7c1a230a6be1e55c1e8c17e94e6656dedf8176", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7a0dc7f-96e9-436f-9e5a-ca90a04c4f26", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, I'd just reiterate a couple things.  Branded pricing inflation is performing as we had anticipated.  We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace.  I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well.  And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n", "original_text": "Branded pricing inflation is performing as we had anticipated. "}, "hash": "c84e1ecacd4d0ba5f37a6b82598e4fe108cf8f12e29ff705cfb14eb0bfda6822", "class_name": "RelatedNodeInfo"}}, "text": "Well, I'd just reiterate a couple things. ", "start_char_idx": 2295, "end_char_idx": 2337, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7a0dc7f-96e9-436f-9e5a-ca90a04c4f26": {"__data__": {"id_": "f7a0dc7f-96e9-436f-9e5a-ca90a04c4f26", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, I'd just reiterate a couple things.  Branded pricing inflation is performing as we had anticipated.  We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace.  I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well.  And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n", "original_text": "Branded pricing inflation is performing as we had anticipated. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbc39247-f91c-4f64-9e19-4fdce88d60d7", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, I'd just reiterate a couple things.  Branded pricing inflation is performing as we had anticipated.  We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace.  I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well. ", "original_text": "Well, I'd just reiterate a couple things. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd2d445d9daefba32e8379443ef4c69d43d234796f70ff1452d4f21b2a3c511b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fc6e1d5-4f82-4f64-93a0-19743da607bf", "node_type": "1", "metadata": {"window": "A \nSure.  Well, I'd just reiterate a couple things.  Branded pricing inflation is performing as we had anticipated.  We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace.  I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well.  And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n So I think as you think about our specialty business, we're getting a lot of growth through customer wins. ", "original_text": "We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace. "}, "hash": "f9c156c870f77cbda2fd10da6596f0667598dc18d659dbd49ae127debbcfa698", "class_name": "RelatedNodeInfo"}}, "text": "Branded pricing inflation is performing as we had anticipated. ", "start_char_idx": 2337, "end_char_idx": 2400, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fc6e1d5-4f82-4f64-93a0-19743da607bf": {"__data__": {"id_": "8fc6e1d5-4f82-4f64-93a0-19743da607bf", "embedding": null, "metadata": {"window": "A \nSure.  Well, I'd just reiterate a couple things.  Branded pricing inflation is performing as we had anticipated.  We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace.  I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well.  And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n So I think as you think about our specialty business, we're getting a lot of growth through customer wins. ", "original_text": "We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7a0dc7f-96e9-436f-9e5a-ca90a04c4f26", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, I'd just reiterate a couple things.  Branded pricing inflation is performing as we had anticipated.  We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace.  I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well.  And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n", "original_text": "Branded pricing inflation is performing as we had anticipated. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "048a560e62f297b19d09eabbad8b81681306dca0260d32592832b897e49a36fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b8f25cd-4ed5-443b-91ce-f5409e97e877", "node_type": "1", "metadata": {"window": "Well, I'd just reiterate a couple things.  Branded pricing inflation is performing as we had anticipated.  We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace.  I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well.  And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n So I think as you think about our specialty business, we're getting a lot of growth through customer wins.  In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n ", "original_text": "I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well. "}, "hash": "133d46aa60f02bbd6f8cba4dba55d3a9a9b21c94b5aecf4cb72d0b6abe8a7ff1", "class_name": "RelatedNodeInfo"}}, "text": "We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace. ", "start_char_idx": 2400, "end_char_idx": 2582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b8f25cd-4ed5-443b-91ce-f5409e97e877": {"__data__": {"id_": "9b8f25cd-4ed5-443b-91ce-f5409e97e877", "embedding": null, "metadata": {"window": "Well, I'd just reiterate a couple things.  Branded pricing inflation is performing as we had anticipated.  We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace.  I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well.  And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n So I think as you think about our specialty business, we're getting a lot of growth through customer wins.  In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n ", "original_text": "I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fc6e1d5-4f82-4f64-93a0-19743da607bf", "node_type": "1", "metadata": {"window": "A \nSure.  Well, I'd just reiterate a couple things.  Branded pricing inflation is performing as we had anticipated.  We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace.  I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well.  And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n So I think as you think about our specialty business, we're getting a lot of growth through customer wins. ", "original_text": "We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "030e1d3508dfcdc617f4d56e52137b832f8552c64acc07e4ab775cc7dcb61eec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2f7f4dc-bab3-4d9c-801a-2fd16359b0be", "node_type": "1", "metadata": {"window": "Branded pricing inflation is performing as we had anticipated.  We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace.  I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well.  And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n So I think as you think about our specialty business, we're getting a lot of growth through customer wins.  In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch. ", "original_text": "And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n"}, "hash": "397135dd79d30e69718e6565ae23e5b46c1dd6c1708ddf7ecda5a0b713897bb7", "class_name": "RelatedNodeInfo"}}, "text": "I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well. ", "start_char_idx": 2582, "end_char_idx": 2723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2f7f4dc-bab3-4d9c-801a-2fd16359b0be": {"__data__": {"id_": "d2f7f4dc-bab3-4d9c-801a-2fd16359b0be", "embedding": null, "metadata": {"window": "Branded pricing inflation is performing as we had anticipated.  We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace.  I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well.  And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n So I think as you think about our specialty business, we're getting a lot of growth through customer wins.  In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch. ", "original_text": "And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b8f25cd-4ed5-443b-91ce-f5409e97e877", "node_type": "1", "metadata": {"window": "Well, I'd just reiterate a couple things.  Branded pricing inflation is performing as we had anticipated.  We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace.  I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well.  And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n So I think as you think about our specialty business, we're getting a lot of growth through customer wins.  In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n ", "original_text": "I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a15d7f68e55812cc579aeec3d69a9018a96c599b645f970e81094e8ceb880f23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d02cc29b-f017-453d-b039-c559c759d460", "node_type": "1", "metadata": {"window": "We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace.  I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well.  And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n So I think as you think about our specialty business, we're getting a lot of growth through customer wins.  In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch.  Your \nline is open.  \n ", "original_text": "So I think as you think about our specialty business, we're getting a lot of growth through customer wins. "}, "hash": "8588af8e75e76c991e7ff2e2b9314bd5ccfe9bd10f517240bf1e368e6b0adc2e", "class_name": "RelatedNodeInfo"}}, "text": "And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n", "start_char_idx": 2723, "end_char_idx": 2894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d02cc29b-f017-453d-b039-c559c759d460": {"__data__": {"id_": "d02cc29b-f017-453d-b039-c559c759d460", "embedding": null, "metadata": {"window": "We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace.  I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well.  And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n So I think as you think about our specialty business, we're getting a lot of growth through customer wins.  In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch.  Your \nline is open.  \n ", "original_text": "So I think as you think about our specialty business, we're getting a lot of growth through customer wins. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2f7f4dc-bab3-4d9c-801a-2fd16359b0be", "node_type": "1", "metadata": {"window": "Branded pricing inflation is performing as we had anticipated.  We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace.  I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well.  And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n So I think as you think about our specialty business, we're getting a lot of growth through customer wins.  In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch. ", "original_text": "And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72503bf02908c1290f599fdc5ec1057a946917e2c36392a70071be00d10cf838", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d0aea8f-24c4-4ab6-a931-1b4a70a9886b", "node_type": "1", "metadata": {"window": "I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well.  And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n So I think as you think about our specialty business, we're getting a lot of growth through customer wins.  In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch.  Your \nline is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question. ", "original_text": "In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n "}, "hash": "ea51a09169f84d0b83c03cefa5c9486d1a1be5134d6074893c135eedf589399e", "class_name": "RelatedNodeInfo"}}, "text": "So I think as you think about our specialty business, we're getting a lot of growth through customer wins. ", "start_char_idx": 2894, "end_char_idx": 3001, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d0aea8f-24c4-4ab6-a931-1b4a70a9886b": {"__data__": {"id_": "6d0aea8f-24c4-4ab6-a931-1b4a70a9886b", "embedding": null, "metadata": {"window": "I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well.  And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n So I think as you think about our specialty business, we're getting a lot of growth through customer wins.  In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch.  Your \nline is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question. ", "original_text": "In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d02cc29b-f017-453d-b039-c559c759d460", "node_type": "1", "metadata": {"window": "We're \nseeing really good progress out of ClarusONE, and so our \u2013 from a generics perspective, I think it's performing as \nwe had anticipated, still stable, competitive marketplace.  I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well.  And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n So I think as you think about our specialty business, we're getting a lot of growth through customer wins.  In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch.  Your \nline is open.  \n ", "original_text": "So I think as you think about our specialty business, we're getting a lot of growth through customer wins. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1cd7ccbd04862bfb7dd4efbc2091473f4c2baeff6ff4e3e3b238435c0a15097", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8768916f-34a6-4302-9b70-6ebec20925f1", "node_type": "1", "metadata": {"window": "And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n So I think as you think about our specialty business, we're getting a lot of growth through customer wins.  In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch.  Your \nline is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question.  So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch. "}, "hash": "9d8df1a7af23c864304f6ad9ebd86b315033261bec9aebf16c40bd396444075a", "class_name": "RelatedNodeInfo"}}, "text": "In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n ", "start_char_idx": 3001, "end_char_idx": 3143, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8768916f-34a6-4302-9b70-6ebec20925f1": {"__data__": {"id_": "8768916f-34a6-4302-9b70-6ebec20925f1", "embedding": null, "metadata": {"window": "And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n So I think as you think about our specialty business, we're getting a lot of growth through customer wins.  In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch.  Your \nline is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question.  So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d0aea8f-24c4-4ab6-a931-1b4a70a9886b", "node_type": "1", "metadata": {"window": "I think a couple things that I would point out that Brian \nreally talked about is ou r specialty provider business is performing quite well.  And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n So I think as you think about our specialty business, we're getting a lot of growth through customer wins.  In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch.  Your \nline is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question. ", "original_text": "In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58890d017d02a80188510560bc1ff1a22bbf7b45919c66216ed31131465f8a7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30cab0f2-623b-411c-9cdb-f8104d7a2520", "node_type": "1", "metadata": {"window": "So I think as you think about our specialty business, we're getting a lot of growth through customer wins.  In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch.  Your \nline is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question.  So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics.  Now it's been about three years since we had a shift in the \nindependent market. ", "original_text": "Your \nline is open.  \n "}, "hash": "b2cab76fc30f6ee0a0c845b81527f87b1d2d54ef8bb0fc67dc12bc717748643f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch. ", "start_char_idx": 3143, "end_char_idx": 3507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30cab0f2-623b-411c-9cdb-f8104d7a2520": {"__data__": {"id_": "30cab0f2-623b-411c-9cdb-f8104d7a2520", "embedding": null, "metadata": {"window": "So I think as you think about our specialty business, we're getting a lot of growth through customer wins.  In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch.  Your \nline is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question.  So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics.  Now it's been about three years since we had a shift in the \nindependent market. ", "original_text": "Your \nline is open.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8768916f-34a6-4302-9b70-6ebec20925f1", "node_type": "1", "metadata": {"window": "And certainly the investments that \nwe've been making in our manufacturer service capabilities and that we are continuing to make there, that's also \nperforming well.  \n \n So I think as you think about our specialty business, we're getting a lot of growth through customer wins.  In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch.  Your \nline is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question.  So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "625151ecb5b971cf87b1a76a686755aad38186d2cbfee88f49a1132799bb46ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a6b2756-ad05-4fd9-80f5-bdebe3917fed", "node_type": "1", "metadata": {"window": "In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch.  Your \nline is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question.  So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics.  Now it's been about three years since we had a shift in the \nindependent market.  You also highlighted some of the value that you provide in terms of the independent \ncustomers. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question. "}, "hash": "992c04a0429f044fb842423bbc4835c36509cd400974abff9861071bc18a5ae9", "class_name": "RelatedNodeInfo"}}, "text": "Your \nline is open.  \n ", "start_char_idx": 3507, "end_char_idx": 3530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a6b2756-ad05-4fd9-80f5-bdebe3917fed": {"__data__": {"id_": "6a6b2756-ad05-4fd9-80f5-bdebe3917fed", "embedding": null, "metadata": {"window": "In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch.  Your \nline is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question.  So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics.  Now it's been about three years since we had a shift in the \nindependent market.  You also highlighted some of the value that you provide in terms of the independent \ncustomers. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30cab0f2-623b-411c-9cdb-f8104d7a2520", "node_type": "1", "metadata": {"window": "So I think as you think about our specialty business, we're getting a lot of growth through customer wins.  In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch.  Your \nline is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question.  So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics.  Now it's been about three years since we had a shift in the \nindependent market. ", "original_text": "Your \nline is open.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8e1b3c76473503545674c47b88e4f5f208362068d72fd719e6ac318c21eba657", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6da2b37b-45d7-47e8-93e2-5e856c717871", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch.  Your \nline is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question.  So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics.  Now it's been about three years since we had a shift in the \nindependent market.  You also highlighted some of the value that you provide in terms of the independent \ncustomers.  And so I guess as we go forw ard, how do you think about the activity and kind of the puts and takes \nthat go on with the independent market and how they think about negotiating, especially as they all tend to get \ninto their own specific buying groups?  ", "original_text": "So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics. "}, "hash": "b4de51b2965ef14eea8e5a583238379a962bbd9d9321804fc74d46d30a584bba", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question. ", "start_char_idx": 3530, "end_char_idx": 3887, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6da2b37b-45d7-47e8-93e2-5e856c717871": {"__data__": {"id_": "6da2b37b-45d7-47e8-93e2-5e856c717871", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch.  Your \nline is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question.  So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics.  Now it's been about three years since we had a shift in the \nindependent market.  You also highlighted some of the value that you provide in terms of the independent \ncustomers.  And so I guess as we go forw ard, how do you think about the activity and kind of the puts and takes \nthat go on with the independent market and how they think about negotiating, especially as they all tend to get \ninto their own specific buying groups?  ", "original_text": "So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a6b2756-ad05-4fd9-80f5-bdebe3917fed", "node_type": "1", "metadata": {"window": "In our \nwholesale distribution business, we're making great advances in our provider business and our manufacturer \nservices capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch.  Your \nline is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question.  So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics.  Now it's been about three years since we had a shift in the \nindependent market.  You also highlighted some of the value that you provide in terms of the independent \ncustomers. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "43a63a97940373a0fdc51ff7879dee315b89754e0f9cd41de32885b226db1a9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0404367-398d-4a00-bdf2-c333c2b534af", "node_type": "1", "metadata": {"window": "Your \nline is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question.  So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics.  Now it's been about three years since we had a shift in the \nindependent market.  You also highlighted some of the value that you provide in terms of the independent \ncustomers.  And so I guess as we go forw ard, how do you think about the activity and kind of the puts and takes \nthat go on with the independent market and how they think about negotiating, especially as they all tend to get \ninto their own specific buying groups?  ", "original_text": "Now it's been about three years since we had a shift in the \nindependent market. "}, "hash": "bcec6aafa228229f3000156c1b8f7e82985e1ff1ae54eed5007dd738b5b662ba", "class_name": "RelatedNodeInfo"}}, "text": "So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics. ", "start_char_idx": 3887, "end_char_idx": 4018, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0404367-398d-4a00-bdf2-c333c2b534af": {"__data__": {"id_": "a0404367-398d-4a00-bdf2-c333c2b534af", "embedding": null, "metadata": {"window": "Your \nline is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question.  So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics.  Now it's been about three years since we had a shift in the \nindependent market.  You also highlighted some of the value that you provide in terms of the independent \ncustomers.  And so I guess as we go forw ard, how do you think about the activity and kind of the puts and takes \nthat go on with the independent market and how they think about negotiating, especially as they all tend to get \ninto their own specific buying groups?  ", "original_text": "Now it's been about three years since we had a shift in the \nindependent market. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6da2b37b-45d7-47e8-93e2-5e856c717871", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Michael Cherny of Bank of America Merrill Lynch.  Your \nline is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question.  So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics.  Now it's been about three years since we had a shift in the \nindependent market.  You also highlighted some of the value that you provide in terms of the independent \ncustomers.  And so I guess as we go forw ard, how do you think about the activity and kind of the puts and takes \nthat go on with the independent market and how they think about negotiating, especially as they all tend to get \ninto their own specific buying groups?  ", "original_text": "So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ecae5feb3d5144ed9755a724523b839eb1d94f0edf9f8f01f767f94397dd145", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d228fc14-38df-4eb6-9de7-3d84d9519855", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question.  So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics.  Now it's been about three years since we had a shift in the \nindependent market.  You also highlighted some of the value that you provide in terms of the independent \ncustomers.  And so I guess as we go forw ard, how do you think about the activity and kind of the puts and takes \nthat go on with the independent market and how they think about negotiating, especially as they all tend to get \ninto their own specific buying groups?  ", "original_text": "You also highlighted some of the value that you provide in terms of the independent \ncustomers. "}, "hash": "de0b802b99a52d0161f524946779a55129dca2b6f249f9a3a7f88e05349b0c3b", "class_name": "RelatedNodeInfo"}}, "text": "Now it's been about three years since we had a shift in the \nindependent market. ", "start_char_idx": 4018, "end_char_idx": 4099, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d228fc14-38df-4eb6-9de7-3d84d9519855": {"__data__": {"id_": "d228fc14-38df-4eb6-9de7-3d84d9519855", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question.  So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics.  Now it's been about three years since we had a shift in the \nindependent market.  You also highlighted some of the value that you provide in terms of the independent \ncustomers.  And so I guess as we go forw ard, how do you think about the activity and kind of the puts and takes \nthat go on with the independent market and how they think about negotiating, especially as they all tend to get \ninto their own specific buying groups?  ", "original_text": "You also highlighted some of the value that you provide in terms of the independent \ncustomers. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0404367-398d-4a00-bdf2-c333c2b534af", "node_type": "1", "metadata": {"window": "Your \nline is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question.  So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics.  Now it's been about three years since we had a shift in the \nindependent market.  You also highlighted some of the value that you provide in terms of the independent \ncustomers.  And so I guess as we go forw ard, how do you think about the activity and kind of the puts and takes \nthat go on with the independent market and how they think about negotiating, especially as they all tend to get \ninto their own specific buying groups?  ", "original_text": "Now it's been about three years since we had a shift in the \nindependent market. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "127bfd72048551e5bfb867cdeef5e3085ef5929ef688fd6778fa63ecd550e85e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa0dd67f-176e-4853-aef8-0dfba68c79e0", "node_type": "1", "metadata": {"window": "So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics.  Now it's been about three years since we had a shift in the \nindependent market.  You also highlighted some of the value that you provide in terms of the independent \ncustomers.  And so I guess as we go forw ard, how do you think about the activity and kind of the puts and takes \nthat go on with the independent market and how they think about negotiating, especially as they all tend to get \ninto their own specific buying groups?  ", "original_text": "And so I guess as we go forw ard, how do you think about the activity and kind of the puts and takes \nthat go on with the independent market and how they think about negotiating, especially as they all tend to get \ninto their own specific buying groups?  "}, "hash": "aeecc17cc687d008f06466850a2c6b89d5da2d371d5374b7aa1788c21e335979", "class_name": "RelatedNodeInfo"}}, "text": "You also highlighted some of the value that you provide in terms of the independent \ncustomers. ", "start_char_idx": 4099, "end_char_idx": 4195, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa0dd67f-176e-4853-aef8-0dfba68c79e0": {"__data__": {"id_": "fa0dd67f-176e-4853-aef8-0dfba68c79e0", "embedding": null, "metadata": {"window": "So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics.  Now it's been about three years since we had a shift in the \nindependent market.  You also highlighted some of the value that you provide in terms of the independent \ncustomers.  And so I guess as we go forw ard, how do you think about the activity and kind of the puts and takes \nthat go on with the independent market and how they think about negotiating, especially as they all tend to get \ninto their own specific buying groups?  ", "original_text": "And so I guess as we go forw ard, how do you think about the activity and kind of the puts and takes \nthat go on with the independent market and how they think about negotiating, especially as they all tend to get \ninto their own specific buying groups?  ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f63045fadfcad74cd0466d51962a60620ad27367087afaa2fea7968259f8fc92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d228fc14-38df-4eb6-9de7-3d84d9519855", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks so much for taking the question.  So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics.  Now it's been about three years since we had a shift in the \nindependent market.  You also highlighted some of the value that you provide in terms of the independent \ncustomers.  And so I guess as we go forw ard, how do you think about the activity and kind of the puts and takes \nthat go on with the independent market and how they think about negotiating, especially as they all tend to get \ninto their own specific buying groups?  ", "original_text": "You also highlighted some of the value that you provide in terms of the independent \ncustomers. ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "323841449a1c0f0a5fa978954d2b4e343ba408d63def4bcdbf39372a07e46968", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f89c5a60-e684-4a72-b208-2d49ecab2ecb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYeah, sure.  Thank you for the question. ", "original_text": "McKesson Corp.  "}, "hash": "6293d035b6063f9d6891d1a82f25d727392167c121560c6d1895492cd23a3bbd", "class_name": "RelatedNodeInfo"}}, "text": "And so I guess as we go forw ard, how do you think about the activity and kind of the puts and takes \nthat go on with the independent market and how they think about negotiating, especially as they all tend to get \ninto their own specific buying groups?  ", "start_char_idx": 4195, "end_char_idx": 4450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f89c5a60-e684-4a72-b208-2d49ecab2ecb": {"__data__": {"id_": "f89c5a60-e684-4a72-b208-2d49ecab2ecb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYeah, sure.  Thank you for the question. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa0dd67f-176e-4853-aef8-0dfba68c79e0", "node_type": "1", "metadata": {"window": "So I want to go back to the comment you made, Brian, about stability of \nwhat you're seeing on the sell side relative to generics.  Now it's been about three years since we had a shift in the \nindependent market.  You also highlighted some of the value that you provide in terms of the independent \ncustomers.  And so I guess as we go forw ard, how do you think about the activity and kind of the puts and takes \nthat go on with the independent market and how they think about negotiating, especially as they all tend to get \ninto their own specific buying groups?  ", "original_text": "And so I guess as we go forw ard, how do you think about the activity and kind of the puts and takes \nthat go on with the independent market and how they think about negotiating, especially as they all tend to get \ninto their own specific buying groups?  ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "478aa87f1618eb9eb041e87d24058b3ea01f2f2b310b0b80a7d34742e229501d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "516d4a88-f647-4031-b462-2edd64e1d829", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYeah, sure.  Thank you for the question.  I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Of ficer & Director, McKesson Corp.  "}, "hash": "613bf3a99a66dfda7a3207427f11ffd3ee2d781cbebfe6bb23731be979578912", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "516d4a88-f647-4031-b462-2edd64e1d829": {"__data__": {"id_": "516d4a88-f647-4031-b462-2edd64e1d829", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYeah, sure.  Thank you for the question.  I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Of ficer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f89c5a60-e684-4a72-b208-2d49ecab2ecb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYeah, sure.  Thank you for the question. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ca57030ddc7dfdd8aff5cfea839d37438e407a5a6df5d81191029af2406719d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd7dfb22-a079-4194-be28-c1040338d97b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYeah, sure.  Thank you for the question.  I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business.  And \nthat's not a unusual number. ", "original_text": "A \nYeah, sure. "}, "hash": "5e6f5902af4128a45081b344fdb8b9d041f25ab444eca569137c8f9c4badaadf", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Of ficer & Director, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd7dfb22-a079-4194-be28-c1040338d97b": {"__data__": {"id_": "bd7dfb22-a079-4194-be28-c1040338d97b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYeah, sure.  Thank you for the question.  I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business.  And \nthat's not a unusual number. ", "original_text": "A \nYeah, sure. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "516d4a88-f647-4031-b462-2edd64e1d829", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYeah, sure.  Thank you for the question.  I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Of ficer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec7952d5cd232d6065195a15893ea6922c1a286aacb10f2f8b694adee1e474a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bba9f927-ba48-44a8-9806-8b5b2536f396", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYeah, sure.  Thank you for the question.  I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business.  And \nthat's not a unusual number.  I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment. ", "original_text": "Thank you for the question. "}, "hash": "92e6e8c73477720187c9ec897451f6bd5c68ec76dd796ac28596e7470f9f97e2", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, sure. ", "start_char_idx": 251, "end_char_idx": 266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bba9f927-ba48-44a8-9806-8b5b2536f396": {"__data__": {"id_": "bba9f927-ba48-44a8-9806-8b5b2536f396", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYeah, sure.  Thank you for the question.  I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business.  And \nthat's not a unusual number.  I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment. ", "original_text": "Thank you for the question. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd7dfb22-a079-4194-be28-c1040338d97b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYeah, sure.  Thank you for the question.  I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business.  And \nthat's not a unusual number. ", "original_text": "A \nYeah, sure. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67f0e2a890f792b0c4a39c39a3324b9a9f6e973b459094114edc75572e1ed1c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ca1df4f-cded-42f5-bf35-378070226038", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYeah, sure.  Thank you for the question.  I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business.  And \nthat's not a unusual number.  I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment.  Some of those are family -planning and transition exits. ", "original_text": "I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business. "}, "hash": "80761da4c3c1f807a031d42e458801ebb64011ec5ec10a6306c5912e0a0ae8f1", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for the question. ", "start_char_idx": 266, "end_char_idx": 294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ca1df4f-cded-42f5-bf35-378070226038": {"__data__": {"id_": "5ca1df4f-cded-42f5-bf35-378070226038", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYeah, sure.  Thank you for the question.  I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business.  And \nthat's not a unusual number.  I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment.  Some of those are family -planning and transition exits. ", "original_text": "I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bba9f927-ba48-44a8-9806-8b5b2536f396", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYeah, sure.  Thank you for the question.  I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business.  And \nthat's not a unusual number.  I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment. ", "original_text": "Thank you for the question. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50c44e53abbd9038ee067cbf7b918e3ff81ff190874f2f0e326c1ad08c977719", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22b98fbd-292f-4571-8bd3-937eecf1f6d3", "node_type": "1", "metadata": {"window": "A \nYeah, sure.  Thank you for the question.  I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business.  And \nthat's not a unusual number.  I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment.  Some of those are family -planning and transition exits.  Some are script file \nsales. ", "original_text": "And \nthat's not a unusual number. "}, "hash": "164ff4bc4f66dea0eb7a69e708d1d62c32fce12cb254dddc86e221c251adea73", "class_name": "RelatedNodeInfo"}}, "text": "I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business. ", "start_char_idx": 294, "end_char_idx": 470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22b98fbd-292f-4571-8bd3-937eecf1f6d3": {"__data__": {"id_": "22b98fbd-292f-4571-8bd3-937eecf1f6d3", "embedding": null, "metadata": {"window": "A \nYeah, sure.  Thank you for the question.  I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business.  And \nthat's not a unusual number.  I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment.  Some of those are family -planning and transition exits.  Some are script file \nsales. ", "original_text": "And \nthat's not a unusual number. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ca1df4f-cded-42f5-bf35-378070226038", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYeah, sure.  Thank you for the question.  I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business.  And \nthat's not a unusual number.  I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment.  Some of those are family -planning and transition exits. ", "original_text": "I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d48dc2408b68c4cc7e5455f74d40355aa529dfae20c8b79453fbd77d939784d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3122c6f1-7dba-4bba-a5db-930e86471dee", "node_type": "1", "metadata": {"window": "Thank you for the question.  I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business.  And \nthat's not a unusual number.  I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment.  Some of those are family -planning and transition exits.  Some are script file \nsales.  But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years. ", "original_text": "I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment. "}, "hash": "80dac9908893141414909c2f1978571780656ac08b19b0a83a8de210968ea462", "class_name": "RelatedNodeInfo"}}, "text": "And \nthat's not a unusual number. ", "start_char_idx": 470, "end_char_idx": 504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3122c6f1-7dba-4bba-a5db-930e86471dee": {"__data__": {"id_": "3122c6f1-7dba-4bba-a5db-930e86471dee", "embedding": null, "metadata": {"window": "Thank you for the question.  I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business.  And \nthat's not a unusual number.  I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment.  Some of those are family -planning and transition exits.  Some are script file \nsales.  But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years. ", "original_text": "I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22b98fbd-292f-4571-8bd3-937eecf1f6d3", "node_type": "1", "metadata": {"window": "A \nYeah, sure.  Thank you for the question.  I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business.  And \nthat's not a unusual number.  I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment.  Some of those are family -planning and transition exits.  Some are script file \nsales. ", "original_text": "And \nthat's not a unusual number. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e29fa334746c115150d44e919660915a649dff9b9bce5d6a1ce0b3a9d6353fb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a31c7d5-6899-409f-a42d-76e7c46e525a", "node_type": "1", "metadata": {"window": "I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business.  And \nthat's not a unusual number.  I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment.  Some of those are family -planning and transition exits.  Some are script file \nsales.  But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years.  And that trend we continue to see today. ", "original_text": "Some of those are family -planning and transition exits. "}, "hash": "1c31b363e071d95ba64ff3f4581c20a454b34dffc09a77e5336093075485ca97", "class_name": "RelatedNodeInfo"}}, "text": "I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment. ", "start_char_idx": 504, "end_char_idx": 610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a31c7d5-6899-409f-a42d-76e7c46e525a": {"__data__": {"id_": "4a31c7d5-6899-409f-a42d-76e7c46e525a", "embedding": null, "metadata": {"window": "I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business.  And \nthat's not a unusual number.  I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment.  Some of those are family -planning and transition exits.  Some are script file \nsales.  But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years.  And that trend we continue to see today. ", "original_text": "Some of those are family -planning and transition exits. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3122c6f1-7dba-4bba-a5db-930e86471dee", "node_type": "1", "metadata": {"window": "Thank you for the question.  I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business.  And \nthat's not a unusual number.  I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment.  Some of those are family -planning and transition exits.  Some are script file \nsales.  But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years. ", "original_text": "I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "87cd306b0a50ff47648321a82f0e38ef257fdaee04506e519a40ce3cfad769e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1dad8d5a-8cd9-4b98-a16e-cdf8e783577a", "node_type": "1", "metadata": {"window": "And \nthat's not a unusual number.  I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment.  Some of those are family -planning and transition exits.  Some are script file \nsales.  But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years.  And that trend we continue to see today.  Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve. ", "original_text": "Some are script file \nsales. "}, "hash": "d12f4eb256ee9f4ceeb62c69d59b9184d64b590c5cc0e7ddc52d65da14076e86", "class_name": "RelatedNodeInfo"}}, "text": "Some of those are family -planning and transition exits. ", "start_char_idx": 610, "end_char_idx": 667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1dad8d5a-8cd9-4b98-a16e-cdf8e783577a": {"__data__": {"id_": "1dad8d5a-8cd9-4b98-a16e-cdf8e783577a", "embedding": null, "metadata": {"window": "And \nthat's not a unusual number.  I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment.  Some of those are family -planning and transition exits.  Some are script file \nsales.  But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years.  And that trend we continue to see today.  Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve. ", "original_text": "Some are script file \nsales. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a31c7d5-6899-409f-a42d-76e7c46e525a", "node_type": "1", "metadata": {"window": "I mean, I referenced in my comments RxOwnership program and the fact \nthat 700 -ish new pharmacy owners we helped in opening or establishing or transferring into the business.  And \nthat's not a unusual number.  I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment.  Some of those are family -planning and transition exits.  Some are script file \nsales.  But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years.  And that trend we continue to see today. ", "original_text": "Some of those are family -planning and transition exits. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d20d1285ce03084a49338570c4f28fea86e0e9237580b5770b38523e25d9d7ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e89e9e5-aa97-4e93-97fb-73e85a39cd3a", "node_type": "1", "metadata": {"window": "I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment.  Some of those are family -planning and transition exits.  Some are script file \nsales.  But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years.  And that trend we continue to see today.  Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve.  But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n ", "original_text": "But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years. "}, "hash": "df9be7de9b09d3495bb365522b8c8925d1558ed0cecffac12cd45a0606942eb4", "class_name": "RelatedNodeInfo"}}, "text": "Some are script file \nsales. ", "start_char_idx": 667, "end_char_idx": 696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e89e9e5-aa97-4e93-97fb-73e85a39cd3a": {"__data__": {"id_": "8e89e9e5-aa97-4e93-97fb-73e85a39cd3a", "embedding": null, "metadata": {"window": "I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment.  Some of those are family -planning and transition exits.  Some are script file \nsales.  But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years.  And that trend we continue to see today.  Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve.  But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n ", "original_text": "But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1dad8d5a-8cd9-4b98-a16e-cdf8e783577a", "node_type": "1", "metadata": {"window": "And \nthat's not a unusual number.  I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment.  Some of those are family -planning and transition exits.  Some are script file \nsales.  But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years.  And that trend we continue to see today.  Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve. ", "original_text": "Some are script file \nsales. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5bb7e921a5582b5ebb124a19f40eae2786ab633b47cacf5f2608dc422b62a2a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "decc5f2a-74fa-41f9-9217-aa7916ea660d", "node_type": "1", "metadata": {"window": "Some of those are family -planning and transition exits.  Some are script file \nsales.  But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years.  And that trend we continue to see today.  Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve.  But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks. ", "original_text": "And that trend we continue to see today. "}, "hash": "d88dfe2bd6f2be3ad79ffc83ff4ccac08c5e4e81fe485884ed078f7968ca1bbe", "class_name": "RelatedNodeInfo"}}, "text": "But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years. ", "start_char_idx": 696, "end_char_idx": 825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "decc5f2a-74fa-41f9-9217-aa7916ea660d": {"__data__": {"id_": "decc5f2a-74fa-41f9-9217-aa7916ea660d", "embedding": null, "metadata": {"window": "Some of those are family -planning and transition exits.  Some are script file \nsales.  But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years.  And that trend we continue to see today.  Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve.  But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks. ", "original_text": "And that trend we continue to see today. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e89e9e5-aa97-4e93-97fb-73e85a39cd3a", "node_type": "1", "metadata": {"window": "I mean, if you go back many, many years, we often see lots of exits in the \nindependent pharmacy segment.  Some of those are family -planning and transition exits.  Some are script file \nsales.  But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years.  And that trend we continue to see today.  Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve.  But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n ", "original_text": "But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc60acede6c56dbdd9b2eb72fcacde3f4cab91f296bf2d571e00b622debaea26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db8eb874-f61d-4920-aad8-b53e37ed0ef9", "node_type": "1", "metadata": {"window": "Some are script file \nsales.  But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years.  And that trend we continue to see today.  Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve.  But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks.  And then just one quick question on capital deployment. ", "original_text": "Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve. "}, "hash": "dc36c08b8e387f37bff867f4f064fe09334e7bec78a131b57158c5e23ff311c9", "class_name": "RelatedNodeInfo"}}, "text": "And that trend we continue to see today. ", "start_char_idx": 825, "end_char_idx": 866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db8eb874-f61d-4920-aad8-b53e37ed0ef9": {"__data__": {"id_": "db8eb874-f61d-4920-aad8-b53e37ed0ef9", "embedding": null, "metadata": {"window": "Some are script file \nsales.  But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years.  And that trend we continue to see today.  Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve.  But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks.  And then just one quick question on capital deployment. ", "original_text": "Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "decc5f2a-74fa-41f9-9217-aa7916ea660d", "node_type": "1", "metadata": {"window": "Some of those are family -planning and transition exits.  Some are script file \nsales.  But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years.  And that trend we continue to see today.  Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve.  But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks. ", "original_text": "And that trend we continue to see today. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091927334cc86af3be331c2c4a290773a670282dabbaa9eebb83fc6bd6aef5d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1cc4963-a2ef-4b16-a8b9-6ded8b0ad0d2", "node_type": "1", "metadata": {"window": "But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years.  And that trend we continue to see today.  Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve.  But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks.  And then just one quick question on capital deployment.  As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities? ", "original_text": "But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n "}, "hash": "3087164db04cc28e7e4a6ae62022f22768212aca45c70ab4647817958b9f582c", "class_name": "RelatedNodeInfo"}}, "text": "Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve. ", "start_char_idx": 866, "end_char_idx": 1118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1cc4963-a2ef-4b16-a8b9-6ded8b0ad0d2": {"__data__": {"id_": "b1cc4963-a2ef-4b16-a8b9-6ded8b0ad0d2", "embedding": null, "metadata": {"window": "But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years.  And that trend we continue to see today.  Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve.  But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks.  And then just one quick question on capital deployment.  As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities? ", "original_text": "But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db8eb874-f61d-4920-aad8-b53e37ed0ef9", "node_type": "1", "metadata": {"window": "Some are script file \nsales.  But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years.  And that trend we continue to see today.  Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve.  But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks.  And then just one quick question on capital deployment. ", "original_text": "Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "452aba9ef41f797fc1213a7a84a202ffb26dec05d5e3da894157ba7b7d7a7b8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d865bd5c-b74e-41b9-ab05-0bd61035edd9", "node_type": "1", "metadata": {"window": "And that trend we continue to see today.  Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve.  But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks.  And then just one quick question on capital deployment.  As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities?  And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks. "}, "hash": "5e36595db219d235cce6378646eea359c3a13349c771c1275d1f33b62bbaaa24", "class_name": "RelatedNodeInfo"}}, "text": "But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n ", "start_char_idx": 1118, "end_char_idx": 1292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d865bd5c-b74e-41b9-ab05-0bd61035edd9": {"__data__": {"id_": "d865bd5c-b74e-41b9-ab05-0bd61035edd9", "embedding": null, "metadata": {"window": "And that trend we continue to see today.  Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve.  But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks.  And then just one quick question on capital deployment.  As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities?  And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1cc4963-a2ef-4b16-a8b9-6ded8b0ad0d2", "node_type": "1", "metadata": {"window": "But we also see as many new openings or many new storefronts come into play, and so it's been \nremarkably stable over the years.  And that trend we continue to see today.  Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve.  But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks.  And then just one quick question on capital deployment.  As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities? ", "original_text": "But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "39c11a03cc0967a2644dfe85687aea555c712c10b3a84f95caeea7068468720b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bde1ff7-83e9-429d-af93-689d880fb461", "node_type": "1", "metadata": {"window": "Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve.  But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks.  And then just one quick question on capital deployment.  As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities?  And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And then just one quick question on capital deployment. "}, "hash": "aa97d64017850eb66ac74e806fe4cfc6b9b6207f761c9dd1a8032432258b474d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks. ", "start_char_idx": 1292, "end_char_idx": 1617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9bde1ff7-83e9-429d-af93-689d880fb461": {"__data__": {"id_": "9bde1ff7-83e9-429d-af93-689d880fb461", "embedding": null, "metadata": {"window": "Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve.  But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks.  And then just one quick question on capital deployment.  As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities?  And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And then just one quick question on capital deployment. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d865bd5c-b74e-41b9-ab05-0bd61035edd9", "node_type": "1", "metadata": {"window": "And that trend we continue to see today.  Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve.  But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks.  And then just one quick question on capital deployment.  As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities?  And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8cdc9745aa33dfff4069b9a1f31dc19f09041ca57e2ed5fba38545d09d0f4141", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b22c8212-3ba5-4a7d-8047-4b6d9d63b637", "node_type": "1", "metadata": {"window": "But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks.  And then just one quick question on capital deployment.  As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities?  And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would say this. ", "original_text": "As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities? "}, "hash": "4539c8bab9450c872326b9334706c6999cc351b730f34871d6b39c6c8fcc00d7", "class_name": "RelatedNodeInfo"}}, "text": "And then just one quick question on capital deployment. ", "start_char_idx": 1617, "end_char_idx": 1673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b22c8212-3ba5-4a7d-8047-4b6d9d63b637": {"__data__": {"id_": "b22c8212-3ba5-4a7d-8047-4b6d9d63b637", "embedding": null, "metadata": {"window": "But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks.  And then just one quick question on capital deployment.  As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities?  And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would say this. ", "original_text": "As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities? ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bde1ff7-83e9-429d-af93-689d880fb461", "node_type": "1", "metadata": {"window": "Now, we do \u2013 over the years we have \nand we continue to invest in these tools and these services that we think help independent pharmacists stay \nindependent, stay healthy businesses, and stay vibrant in the communities and the patients that we serve.  But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks.  And then just one quick question on capital deployment.  As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities?  And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And then just one quick question on capital deployment. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23af9e065aab096494394c9edbe24f01781475c1e9d8f927bacc047b49719587", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fe6d126-bd36-47e7-85f8-7d1eef2ac75f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks.  And then just one quick question on capital deployment.  As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities?  And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would say this.  I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that. ", "original_text": "And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n "}, "hash": "f2a4bc41aa8927473a81624b3d4993cc97f0634f51d2d0a38866d3343ea97e40", "class_name": "RelatedNodeInfo"}}, "text": "As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities? ", "start_char_idx": 1673, "end_char_idx": 1863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fe6d126-bd36-47e7-85f8-7d1eef2ac75f": {"__data__": {"id_": "2fe6d126-bd36-47e7-85f8-7d1eef2ac75f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks.  And then just one quick question on capital deployment.  As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities?  And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would say this.  I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that. ", "original_text": "And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b22c8212-3ba5-4a7d-8047-4b6d9d63b637", "node_type": "1", "metadata": {"window": "But we \nreally haven't seen anything that I would say was a massive trend break in terms of the \u2013 there's always ins and \nthere's alway s outs in the independent segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks.  And then just one quick question on capital deployment.  As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities?  And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would say this. ", "original_text": "As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities? ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5320ad500a8ee8a0a4fc5448b3d2d480af9406842e67ccef93572e15f2fe642", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9478a0b3-3407-471c-8bdc-6940cc3d0805", "node_type": "1", "metadata": {"window": "And then just one quick question on capital deployment.  As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities?  And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would say this.  I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that.  And what I would say is we have not made a change to that portfolio approach. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "5610453cab82fe0eab806cc2fadfbaa9d3b45d46afc4f47708b421182e177b9e", "class_name": "RelatedNodeInfo"}}, "text": "And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n ", "start_char_idx": 1863, "end_char_idx": 2026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9478a0b3-3407-471c-8bdc-6940cc3d0805": {"__data__": {"id_": "9478a0b3-3407-471c-8bdc-6940cc3d0805", "embedding": null, "metadata": {"window": "And then just one quick question on capital deployment.  As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities?  And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would say this.  I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that.  And what I would say is we have not made a change to that portfolio approach. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fe6d126-bd36-47e7-85f8-7d1eef2ac75f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nThanks.  And then just one quick question on capital deployment.  As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities?  And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would say this.  I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that. ", "original_text": "And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "865440a1516f1cf3fe99e55aa24038ef57d366647f8cb6285fbbc4dc0bbbe496", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b211f33-a6fb-45b6-b611-6fd8b0ee5c77", "node_type": "1", "metadata": {"window": "As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities?  And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would say this.  I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that.  And what I would say is we have not made a change to that portfolio approach. \n We continue to make investments internally that we think will drive future growth. ", "original_text": "A \nI would say this. "}, "hash": "af4d04ff1a3aadf9de4b7e880980e6667ae54ede1418c61195c41c6619350980", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2026, "end_char_idx": 2352, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b211f33-a6fb-45b6-b611-6fd8b0ee5c77": {"__data__": {"id_": "7b211f33-a6fb-45b6-b611-6fd8b0ee5c77", "embedding": null, "metadata": {"window": "As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities?  And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would say this.  I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that.  And what I would say is we have not made a change to that portfolio approach. \n We continue to make investments internally that we think will drive future growth. ", "original_text": "A \nI would say this. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9478a0b3-3407-471c-8bdc-6940cc3d0805", "node_type": "1", "metadata": {"window": "And then just one quick question on capital deployment.  As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities?  And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would say this.  I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that.  And what I would say is we have not made a change to that portfolio approach. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3372eabd074a37a68e6d19cecd8f5b8a22874649c217283f6b949413158559d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdb88d73-2103-43e6-9035-eb11f9f18fc5", "node_type": "1", "metadata": {"window": "And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would say this.  I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that.  And what I would say is we have not made a change to that portfolio approach. \n We continue to make investments internally that we think will drive future growth.  We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are. ", "original_text": "I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that. "}, "hash": "f0f0a6caa074083fe4ec046807431d3fa8a7e30a50e85716a124f2b064782bef", "class_name": "RelatedNodeInfo"}}, "text": "A \nI would say this. ", "start_char_idx": 2352, "end_char_idx": 2373, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdb88d73-2103-43e6-9035-eb11f9f18fc5": {"__data__": {"id_": "bdb88d73-2103-43e6-9035-eb11f9f18fc5", "embedding": null, "metadata": {"window": "And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would say this.  I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that.  And what I would say is we have not made a change to that portfolio approach. \n We continue to make investments internally that we think will drive future growth.  We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are. ", "original_text": "I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b211f33-a6fb-45b6-b611-6fd8b0ee5c77", "node_type": "1", "metadata": {"window": "As you think about the discussions and debates \ngoing on relative to the push for a global settlement, does that have any impact on your cash availability or capital \ndeployment priorities?  And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would say this.  I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that.  And what I would say is we have not made a change to that portfolio approach. \n We continue to make investments internally that we think will drive future growth. ", "original_text": "A \nI would say this. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1d19d9ed5f195c617827adae192c492e9855ab3f3c44586a3b1070eae90e521", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8078d93e-8a80-49e7-a6c2-0395e4c9abec", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would say this.  I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that.  And what I would say is we have not made a change to that portfolio approach. \n We continue to make investments internally that we think will drive future growth.  We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are.  But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n ", "original_text": "And what I would say is we have not made a change to that portfolio approach. \n"}, "hash": "d013d7a26c85b8ee87894efeb985e899a1ff2670880eb026ebb0072983fa10c6", "class_name": "RelatedNodeInfo"}}, "text": "I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that. ", "start_char_idx": 2373, "end_char_idx": 2504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8078d93e-8a80-49e7-a6c2-0395e4c9abec": {"__data__": {"id_": "8078d93e-8a80-49e7-a6c2-0395e4c9abec", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would say this.  I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that.  And what I would say is we have not made a change to that portfolio approach. \n We continue to make investments internally that we think will drive future growth.  We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are.  But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n ", "original_text": "And what I would say is we have not made a change to that portfolio approach. \n", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdb88d73-2103-43e6-9035-eb11f9f18fc5", "node_type": "1", "metadata": {"window": "And I know not from a reserving perspective per se, but do you think about keeping some \nlevel of cash to present itself for any type of potential settlements?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would say this.  I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that.  And what I would say is we have not made a change to that portfolio approach. \n We continue to make investments internally that we think will drive future growth.  We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are. ", "original_text": "I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3a490a50eef82e92b061c4056000f27e8873cbdf99bdc20c5d56dd053541c5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18f44346-0449-43cc-a810-bc7286cd3f37", "node_type": "1", "metadata": {"window": "A \nI would say this.  I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that.  And what I would say is we have not made a change to that portfolio approach. \n We continue to make investments internally that we think will drive future growth.  We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are.  But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.  ", "original_text": "We continue to make investments internally that we think will drive future growth. "}, "hash": "b8b21a1aca55c631e3fa4754f1028488e3b8a3af19e1907cc04cfd3dd1af4b3c", "class_name": "RelatedNodeInfo"}}, "text": "And what I would say is we have not made a change to that portfolio approach. \n", "start_char_idx": 2504, "end_char_idx": 2583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18f44346-0449-43cc-a810-bc7286cd3f37": {"__data__": {"id_": "18f44346-0449-43cc-a810-bc7286cd3f37", "embedding": null, "metadata": {"window": "A \nI would say this.  I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that.  And what I would say is we have not made a change to that portfolio approach. \n We continue to make investments internally that we think will drive future growth.  We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are.  But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.  ", "original_text": "We continue to make investments internally that we think will drive future growth. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8078d93e-8a80-49e7-a6c2-0395e4c9abec", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI would say this.  I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that.  And what I would say is we have not made a change to that portfolio approach. \n We continue to make investments internally that we think will drive future growth.  We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are.  But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n ", "original_text": "And what I would say is we have not made a change to that portfolio approach. \n", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8419c6813ff309d775f10c4b57187b154afa11824915f3eb577125313933b20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a7c4ff7-38da-49f8-b997-ca4b2b0705cc", "node_type": "1", "metadata": {"window": "I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that.  And what I would say is we have not made a change to that portfolio approach. \n We continue to make investments internally that we think will drive future growth.  We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are.  But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed. ", "original_text": "We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are. "}, "hash": "ef3321db7c1762059fcabd0c2655a3451c54e7f0b4022267e1e2842fcbbe2e28", "class_name": "RelatedNodeInfo"}}, "text": "We continue to make investments internally that we think will drive future growth. ", "start_char_idx": 2583, "end_char_idx": 2666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a7c4ff7-38da-49f8-b997-ca4b2b0705cc": {"__data__": {"id_": "7a7c4ff7-38da-49f8-b997-ca4b2b0705cc", "embedding": null, "metadata": {"window": "I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that.  And what I would say is we have not made a change to that portfolio approach. \n We continue to make investments internally that we think will drive future growth.  We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are.  But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed. ", "original_text": "We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18f44346-0449-43cc-a810-bc7286cd3f37", "node_type": "1", "metadata": {"window": "A \nI would say this.  I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that.  And what I would say is we have not made a change to that portfolio approach. \n We continue to make investments internally that we think will drive future growth.  We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are.  But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.  ", "original_text": "We continue to make investments internally that we think will drive future growth. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "29474f97e456998b884a7fc741995fce01ed322c0a7da5cdc6ce6877f7c0207a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f97fe97b-34bd-489d-a9f9-9a5ef9aa31fa", "node_type": "1", "metadata": {"window": "And what I would say is we have not made a change to that portfolio approach. \n We continue to make investments internally that we think will drive future growth.  We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are.  But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed.  We've returned a lot of capital to our shareholders, particularly in the second quarter. \n", "original_text": "But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n "}, "hash": "7c8bec8303ffabd582ee23fe1e4b375b98e168b1c20ffcdbee8af01fbb7a2851", "class_name": "RelatedNodeInfo"}}, "text": "We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are. ", "start_char_idx": 2666, "end_char_idx": 2858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f97fe97b-34bd-489d-a9f9-9a5ef9aa31fa": {"__data__": {"id_": "f97fe97b-34bd-489d-a9f9-9a5ef9aa31fa", "embedding": null, "metadata": {"window": "And what I would say is we have not made a change to that portfolio approach. \n We continue to make investments internally that we think will drive future growth.  We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are.  But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed.  We've returned a lot of capital to our shareholders, particularly in the second quarter. \n", "original_text": "But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a7c4ff7-38da-49f8-b997-ca4b2b0705cc", "node_type": "1", "metadata": {"window": "I think we've been pretty clear on what our capital deployment philosophy has been in the past, a \nvery balanced approach to that.  And what I would say is we have not made a change to that portfolio approach. \n We continue to make investments internally that we think will drive future growth.  We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are.  But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed. ", "original_text": "We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ac530c7e19a3f721a60d50643e6c6241378c55d6f2de1ec249070e5c08f24a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d83d35ad-65c0-4d84-866c-b07985bd7208", "node_type": "1", "metadata": {"window": "We continue to make investments internally that we think will drive future growth.  We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are.  But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed.  We've returned a lot of capital to our shareholders, particularly in the second quarter. \n And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.  "}, "hash": "c0a29611ce6e24bdd068f7422d87cb393864895e98800b117944c9584b3251db", "class_name": "RelatedNodeInfo"}}, "text": "But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n ", "start_char_idx": 2858, "end_char_idx": 2987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d83d35ad-65c0-4d84-866c-b07985bd7208": {"__data__": {"id_": "d83d35ad-65c0-4d84-866c-b07985bd7208", "embedding": null, "metadata": {"window": "We continue to make investments internally that we think will drive future growth.  We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are.  But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed.  We've returned a lot of capital to our shareholders, particularly in the second quarter. \n And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f97fe97b-34bd-489d-a9f9-9a5ef9aa31fa", "node_type": "1", "metadata": {"window": "And what I would say is we have not made a change to that portfolio approach. \n We continue to make investments internally that we think will drive future growth.  We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are.  But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed.  We've returned a lot of capital to our shareholders, particularly in the second quarter. \n", "original_text": "But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a98fa795b3cd1d9d89c9c6ea4fbdefb8014d7485a3dd563cf6ac2f530621f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01f0a8bd-4390-4105-9302-7c7ca7114bbc", "node_type": "1", "metadata": {"window": "We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are.  But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed.  We've returned a lot of capital to our shareholders, particularly in the second quarter. \n And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen. ", "original_text": "A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed. "}, "hash": "12425e8fec1de7ea7cda42cba9622e514fc4ad442d71df7d4cd44d75c2f82ce8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.  ", "start_char_idx": 2987, "end_char_idx": 3333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01f0a8bd-4390-4105-9302-7c7ca7114bbc": {"__data__": {"id_": "01f0a8bd-4390-4105-9302-7c7ca7114bbc", "embedding": null, "metadata": {"window": "We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are.  But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed.  We've returned a lot of capital to our shareholders, particularly in the second quarter. \n And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen. ", "original_text": "A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d83d35ad-65c0-4d84-866c-b07985bd7208", "node_type": "1", "metadata": {"window": "We continue to make investments internally that we think will drive future growth.  We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are.  But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed.  We've returned a lot of capital to our shareholders, particularly in the second quarter. \n And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60c35557727adee040b986e4104d38e0e8740cf111295a68417f91af0b477643", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18d63caf-9e8a-4577-a21b-b42c9af1530f", "node_type": "1", "metadata": {"window": "But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed.  We've returned a lot of capital to our shareholders, particularly in the second quarter. \n And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen.  Your line is open.  \n ", "original_text": "We've returned a lot of capital to our shareholders, particularly in the second quarter. \n"}, "hash": "beba6103a9f319c1de7c2c32fe939f4d164dce1e924d06209324e78207b8fcbd", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed. ", "start_char_idx": 3333, "end_char_idx": 3484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18d63caf-9e8a-4577-a21b-b42c9af1530f": {"__data__": {"id_": "18d63caf-9e8a-4577-a21b-b42c9af1530f", "embedding": null, "metadata": {"window": "But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed.  We've returned a lot of capital to our shareholders, particularly in the second quarter. \n And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen.  Your line is open.  \n ", "original_text": "We've returned a lot of capital to our shareholders, particularly in the second quarter. \n", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01f0a8bd-4390-4105-9302-7c7ca7114bbc", "node_type": "1", "metadata": {"window": "We continue to be open to M&A, \nwhere we can find the M&A that makes sense, balancing obviously valuation expectations, where our sh are price \nis, what alternate returns of that capital are.  But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed.  We've returned a lot of capital to our shareholders, particularly in the second quarter. \n And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen. ", "original_text": "A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6eb9bae681877d6160afff0dc99124f614b52576f99507379b7162b0acd421f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c04692eb-00df-4594-bf8a-62d26b49fb56", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed.  We've returned a lot of capital to our shareholders, particularly in the second quarter. \n And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n "}, "hash": "925913af5ed934265091d7c5a288cfbe77128d119a6440311b7e133b6022e0ae", "class_name": "RelatedNodeInfo"}}, "text": "We've returned a lot of capital to our shareholders, particularly in the second quarter. \n", "start_char_idx": 3484, "end_char_idx": 3574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c04692eb-00df-4594-bf8a-62d26b49fb56": {"__data__": {"id_": "c04692eb-00df-4594-bf8a-62d26b49fb56", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed.  We've returned a lot of capital to our shareholders, particularly in the second quarter. \n And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18d63caf-9e8a-4577-a21b-b42c9af1530f", "node_type": "1", "metadata": {"window": "But that was a long answer to give you the short answer, that it really \nhas not impacted our approach to capital deployment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed.  We've returned a lot of capital to our shareholders, particularly in the second quarter. \n And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen.  Your line is open.  \n ", "original_text": "We've returned a lot of capital to our shareholders, particularly in the second quarter. \n", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8f8a53036276ed85163463a861adff9fcadd7b01698af06079eae180563f2f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fcb0119-23a8-4276-b7fa-b9e4819fe79e", "node_type": "1", "metadata": {"window": "A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed.  We've returned a lot of capital to our shareholders, particularly in the second quarter. \n And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, hey. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen. "}, "hash": "a3d574c6867734d3cb434431f5632e50f2b8c4583368d4bad9899ce8a60e33c6", "class_name": "RelatedNodeInfo"}}, "text": "And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n ", "start_char_idx": 3574, "end_char_idx": 3755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fcb0119-23a8-4276-b7fa-b9e4819fe79e": {"__data__": {"id_": "5fcb0119-23a8-4276-b7fa-b9e4819fe79e", "embedding": null, "metadata": {"window": "A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed.  We've returned a lot of capital to our shareholders, particularly in the second quarter. \n And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, hey. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c04692eb-00df-4594-bf8a-62d26b49fb56", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed.  We've returned a lot of capital to our shareholders, particularly in the second quarter. \n And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1e2902f9297ddf68b7c71b6984a8e021d61b12e1095d7a9e1bbc8ff81e7d632", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "019e5835-8e2d-461e-abc2-eb1398b410f0", "node_type": "1", "metadata": {"window": "We've returned a lot of capital to our shareholders, particularly in the second quarter. \n And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, hey.  Thanks for taking the question. ", "original_text": "Your line is open.  \n "}, "hash": "57e335bbc5efc070c112b28c122466afb0dffe448852187f815317adda8a1237", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen. ", "start_char_idx": 3755, "end_char_idx": 4094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "019e5835-8e2d-461e-abc2-eb1398b410f0": {"__data__": {"id_": "019e5835-8e2d-461e-abc2-eb1398b410f0", "embedding": null, "metadata": {"window": "We've returned a lot of capital to our shareholders, particularly in the second quarter. \n And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, hey.  Thanks for taking the question. ", "original_text": "Your line is open.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fcb0119-23a8-4276-b7fa-b9e4819fe79e", "node_type": "1", "metadata": {"window": "A \nAnd I think if you look at how we've deployed capital in the first half of the year, it's pretty historical \u2013 amount of \ncapital has been deployed.  We've returned a lot of capital to our shareholders, particularly in the second quarter. \n And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, hey. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7934952f82e3128f990631261c476751733265689307e1b4a9bef917b6c7f1cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7de45917-80bb-4e1b-be9d-a1d2bea76a97", "node_type": "1", "metadata": {"window": "And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, hey.  Thanks for taking the question.  Just wanted to go back, Brian, about the framework here. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "7f371e9da7448019863448090119a716cc2d83ecca4e84da420bf66bfd087dbe", "class_name": "RelatedNodeInfo"}}, "text": "Your line is open.  \n ", "start_char_idx": 4094, "end_char_idx": 4116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7de45917-80bb-4e1b-be9d-a1d2bea76a97": {"__data__": {"id_": "7de45917-80bb-4e1b-be9d-a1d2bea76a97", "embedding": null, "metadata": {"window": "And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, hey.  Thanks for taking the question.  Just wanted to go back, Brian, about the framework here. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "019e5835-8e2d-461e-abc2-eb1398b410f0", "node_type": "1", "metadata": {"window": "We've returned a lot of capital to our shareholders, particularly in the second quarter. \n And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, hey.  Thanks for taking the question. ", "original_text": "Your line is open.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8fc551f1e0376f37a18b01ab8de480cffc29c7c1ecbf713ff235de779fb88809", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20b9bac2-9b12-4a1f-9b35-49cd9e579169", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, hey.  Thanks for taking the question.  Just wanted to go back, Brian, about the framework here.  You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here. ", "original_text": "LLC  Q \nYeah, hey. "}, "hash": "977630539bf52362691e1a250a8a36d1542ff6a1888027895e160275b8fa22de", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 4116, "end_char_idx": 4410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20b9bac2-9b12-4a1f-9b35-49cd9e579169": {"__data__": {"id_": "20b9bac2-9b12-4a1f-9b35-49cd9e579169", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, hey.  Thanks for taking the question.  Just wanted to go back, Brian, about the framework here.  You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here. ", "original_text": "LLC  Q \nYeah, hey. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7de45917-80bb-4e1b-be9d-a1d2bea76a97", "node_type": "1", "metadata": {"window": "And as Brian mentioned, we'll continue to evaluate really on a balanced perspective, but we haven't made any \nchanges to the amount or how we're deploying capital at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, hey.  Thanks for taking the question.  Just wanted to go back, Brian, about the framework here. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "474a2a9344061fb00c6f6d5f4eaf1ad48d7246b861138b21bbd40b1c6150d09e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3c11edc-88eb-4ec9-8252-c9b97c4a667e", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, hey.  Thanks for taking the question.  Just wanted to go back, Brian, about the framework here.  You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here.  Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs? ", "original_text": "Thanks for taking the question. "}, "hash": "7ebe355602f89ac1508b8d0e84596a39c904faf8765ec87e705fe6f52bc26da9", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYeah, hey. ", "start_char_idx": 4410, "end_char_idx": 4429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3c11edc-88eb-4ec9-8252-c9b97c4a667e": {"__data__": {"id_": "f3c11edc-88eb-4ec9-8252-c9b97c4a667e", "embedding": null, "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, hey.  Thanks for taking the question.  Just wanted to go back, Brian, about the framework here.  You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here.  Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs? ", "original_text": "Thanks for taking the question. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20b9bac2-9b12-4a1f-9b35-49cd9e579169", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Charles Rhyee of Cowen.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, hey.  Thanks for taking the question.  Just wanted to go back, Brian, about the framework here.  You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here. ", "original_text": "LLC  Q \nYeah, hey. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5bbbb807c452e4b6f817322f1d8726e22109da638da93dc068ac01d5d35644e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d27008b7-9325-49cc-824a-1dc9987c756a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, hey.  Thanks for taking the question.  Just wanted to go back, Brian, about the framework here.  You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here.  Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs?  (47:40) You might have mentioned \nthat. ", "original_text": "Just wanted to go back, Brian, about the framework here. "}, "hash": "e68afa6c54f4a4e7ffb54772e6b80653835fe0c9571e90181470d98b76efca14", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 4429, "end_char_idx": 4461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d27008b7-9325-49cc-824a-1dc9987c756a": {"__data__": {"id_": "d27008b7-9325-49cc-824a-1dc9987c756a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, hey.  Thanks for taking the question.  Just wanted to go back, Brian, about the framework here.  You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here.  Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs?  (47:40) You might have mentioned \nthat. ", "original_text": "Just wanted to go back, Brian, about the framework here. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3c11edc-88eb-4ec9-8252-c9b97c4a667e", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, hey.  Thanks for taking the question.  Just wanted to go back, Brian, about the framework here.  You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here.  Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs? ", "original_text": "Thanks for taking the question. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f628f935e7467d76bc7d356e06b8480241eaf969697b6a351ed3906a4785198", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "670439c4-3715-49ea-a581-80c3b84e2336", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah, hey.  Thanks for taking the question.  Just wanted to go back, Brian, about the framework here.  You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here.  Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs?  (47:40) You might have mentioned \nthat.  I just couldn't catch that clearly.  \n ", "original_text": "You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here. "}, "hash": "45285cded03d0764ec3c33029501aebb94d8d6987b52e5f123d681e059fe99f5", "class_name": "RelatedNodeInfo"}}, "text": "Just wanted to go back, Brian, about the framework here. ", "start_char_idx": 4461, "end_char_idx": 4518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "670439c4-3715-49ea-a581-80c3b84e2336": {"__data__": {"id_": "670439c4-3715-49ea-a581-80c3b84e2336", "embedding": null, "metadata": {"window": "LLC  Q \nYeah, hey.  Thanks for taking the question.  Just wanted to go back, Brian, about the framework here.  You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here.  Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs?  (47:40) You might have mentioned \nthat.  I just couldn't catch that clearly.  \n ", "original_text": "You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d27008b7-9325-49cc-824a-1dc9987c756a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah, hey.  Thanks for taking the question.  Just wanted to go back, Brian, about the framework here.  You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here.  Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs?  (47:40) You might have mentioned \nthat. ", "original_text": "Just wanted to go back, Brian, about the framework here. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed29588d0e662d15c5c22140597a2ba4e7cc42820562750d01fa15d1404489f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "100f4621-b3a9-494a-b2d9-8b7a35a1d780", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Just wanted to go back, Brian, about the framework here.  You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here.  Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs?  (47:40) You might have mentioned \nthat.  I just couldn't catch that clearly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs? "}, "hash": "83ab2cc396c8297674dd52c08b6371e025ed89a498f143c714df11fa01e23700", "class_name": "RelatedNodeInfo"}}, "text": "You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here. ", "start_char_idx": 4518, "end_char_idx": 4620, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "100f4621-b3a9-494a-b2d9-8b7a35a1d780": {"__data__": {"id_": "100f4621-b3a9-494a-b2d9-8b7a35a1d780", "embedding": null, "metadata": {"window": "Thanks for taking the question.  Just wanted to go back, Brian, about the framework here.  You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here.  Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs?  (47:40) You might have mentioned \nthat.  I just couldn't catch that clearly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs? ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "670439c4-3715-49ea-a581-80c3b84e2336", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah, hey.  Thanks for taking the question.  Just wanted to go back, Brian, about the framework here.  You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here.  Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs?  (47:40) You might have mentioned \nthat.  I just couldn't catch that clearly.  \n ", "original_text": "You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e93f1321cd0864ed6be11adb64e16b851f3b0a30d522f7fffd6ff15dab0ca454", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04963552-cfdd-4b81-8a5b-1b5648c26531", "node_type": "1", "metadata": {"window": "Just wanted to go back, Brian, about the framework here.  You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here.  Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs?  (47:40) You might have mentioned \nthat.  I just couldn't catch that clearly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "(47:40) You might have mentioned \nthat. "}, "hash": "c4c34648806d5d236e82436ab4c6d75d195edb29f14bcf8e7e8905a2b317c3b5", "class_name": "RelatedNodeInfo"}}, "text": "Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs? ", "start_char_idx": 4620, "end_char_idx": 4731, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04963552-cfdd-4b81-8a5b-1b5648c26531": {"__data__": {"id_": "04963552-cfdd-4b81-8a5b-1b5648c26531", "embedding": null, "metadata": {"window": "Just wanted to go back, Brian, about the framework here.  You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here.  Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs?  (47:40) You might have mentioned \nthat.  I just couldn't catch that clearly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "(47:40) You might have mentioned \nthat. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "100f4621-b3a9-494a-b2d9-8b7a35a1d780", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Just wanted to go back, Brian, about the framework here.  You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here.  Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs?  (47:40) You might have mentioned \nthat.  I just couldn't catch that clearly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs? ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "78ba8436b53c13b0f17c56841467e26f36ea9920103d5319148d02c93e5a9bce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ef8834c-c5b4-4fa4-b00f-cdcd100c3655", "node_type": "1", "metadata": {"window": "You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here.  Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs?  (47:40) You might have mentioned \nthat.  I just couldn't catch that clearly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "I just couldn't catch that clearly.  \n "}, "hash": "b0eeee522cb905f5b06197463b6c5f93060e5be79513260d0916d665ee895f76", "class_name": "RelatedNodeInfo"}}, "text": "(47:40) You might have mentioned \nthat. ", "start_char_idx": 4731, "end_char_idx": 4771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ef8834c-c5b4-4fa4-b00f-cdcd100c3655": {"__data__": {"id_": "1ef8834c-c5b4-4fa4-b00f-cdcd100c3655", "embedding": null, "metadata": {"window": "You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here.  Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs?  (47:40) You might have mentioned \nthat.  I just couldn't catch that clearly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "I just couldn't catch that clearly.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04963552-cfdd-4b81-8a5b-1b5648c26531", "node_type": "1", "metadata": {"window": "Just wanted to go back, Brian, about the framework here.  You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here.  Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs?  (47:40) You might have mentioned \nthat.  I just couldn't catch that clearly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "(47:40) You might have mentioned \nthat. ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1332700b80092476e916322aa3188b7902348699e99e55528e97423d28dd02f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a309d6b6-7155-401c-9025-a55f953bc26e", "node_type": "1", "metadata": {"window": "Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs?  (47:40) You might have mentioned \nthat.  I just couldn't catch that clearly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   "}, "hash": "3522b32bd92330484f338345ee9922feb0408c546b68640bbf2f5e0dc6c36a52", "class_name": "RelatedNodeInfo"}}, "text": "I just couldn't catch that clearly.  \n ", "start_char_idx": 4771, "end_char_idx": 4810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a309d6b6-7155-401c-9025-a55f953bc26e": {"__data__": {"id_": "a309d6b6-7155-401c-9025-a55f953bc26e", "embedding": null, "metadata": {"window": "Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs?  (47:40) You might have mentioned \nthat.  I just couldn't catch that clearly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2622b821f582a3bd523d50e0396aa8f5ed2baefdf5b7eefb8419d294d3882362", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ef8834c-c5b4-4fa4-b00f-cdcd100c3655", "node_type": "1", "metadata": {"window": "You're \noptimistic about in terms of getting toward sort of more of a global kind of settlement here.  Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs?  (47:40) You might have mentioned \nthat.  I just couldn't catch that clearly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "I just couldn't catch that clearly.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9159b5b19e26597189858c10e73add28b9a1699a017c6cccf17336f7173360f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bba34f7-48b1-4bcb-9616-677856aa42f7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nYou were breaking up a little bit.  Let me \u2013 I think the question was coming back to the framework. ", "original_text": "McKesson Corp.  "}, "hash": "4c36960aafb3354f02cc5790eb91bdf8c5cc82d9244f4b4d553879e9ca9c2fd7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "start_char_idx": 1292, "end_char_idx": 1548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bba34f7-48b1-4bcb-9616-677856aa42f7": {"__data__": {"id_": "5bba34f7-48b1-4bcb-9616-677856aa42f7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nYou were breaking up a little bit.  Let me \u2013 I think the question was coming back to the framework. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a309d6b6-7155-401c-9025-a55f953bc26e", "node_type": "1", "metadata": {"window": "Just to clarify, in these \nkinds of discussions, is it clear to you that [ph] you'll encompass all plaintiffs?  (47:40) You might have mentioned \nthat.  I just couldn't catch that clearly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4287a85cbaf2bcb0ca2d44445e4fbaeeca900d51fc46f8711562579183c3496f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2055d9a-31d3-47df-ae3b-53b79bb4facf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nYou were breaking up a little bit.  Let me \u2013 I think the question was coming back to the framework.  Is it going to be \nall encompassing of all the litigation? ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.  "}, "hash": "d7ffd3c499bd9f7a26b31c6b13af8221e5be0ecc9728c5d51338dddf046b1faa", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2055d9a-31d3-47df-ae3b-53b79bb4facf": {"__data__": {"id_": "c2055d9a-31d3-47df-ae3b-53b79bb4facf", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nYou were breaking up a little bit.  Let me \u2013 I think the question was coming back to the framework.  Is it going to be \nall encompassing of all the litigation? ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bba34f7-48b1-4bcb-9616-677856aa42f7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nYou were breaking up a little bit.  Let me \u2013 I think the question was coming back to the framework. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f01f9e185312cc415edf878a2dcf53656fe8a7a7625968fc436829bddf4a989c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99915be1-8e04-4596-9eb3-99f94dfbab31", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nYou were breaking up a little bit.  Let me \u2013 I think the question was coming back to the framework.  Is it going to be \nall encompassing of all the litigation?  And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n ", "original_text": "A \nYou were breaking up a little bit. "}, "hash": "1353975b637d834672699d9aace217d185891db6d838ca984e65644ea9d519c8", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99915be1-8e04-4596-9eb3-99f94dfbab31": {"__data__": {"id_": "99915be1-8e04-4596-9eb3-99f94dfbab31", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nYou were breaking up a little bit.  Let me \u2013 I think the question was coming back to the framework.  Is it going to be \nall encompassing of all the litigation?  And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n ", "original_text": "A \nYou were breaking up a little bit. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2055d9a-31d3-47df-ae3b-53b79bb4facf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nYou were breaking up a little bit.  Let me \u2013 I think the question was coming back to the framework.  Is it going to be \nall encompassing of all the litigation? ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "998bd1d59841c6febc98d907d064a6a757434c6b2bcac45ae1f094b0ca05961c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13ad8f41-196e-44c7-aaf2-80ccd51f31ae", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nYou were breaking up a little bit.  Let me \u2013 I think the question was coming back to the framework.  Is it going to be \nall encompassing of all the litigation?  And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Let me \u2013 I think the question was coming back to the framework. "}, "hash": "c61243bf7f3d2d15bada6a383e7369504d7e6cdf0f0ce3b040a569a5fbb53604", "class_name": "RelatedNodeInfo"}}, "text": "A \nYou were breaking up a little bit. ", "start_char_idx": 251, "end_char_idx": 289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13ad8f41-196e-44c7-aaf2-80ccd51f31ae": {"__data__": {"id_": "13ad8f41-196e-44c7-aaf2-80ccd51f31ae", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nYou were breaking up a little bit.  Let me \u2013 I think the question was coming back to the framework.  Is it going to be \nall encompassing of all the litigation?  And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Let me \u2013 I think the question was coming back to the framework. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99915be1-8e04-4596-9eb3-99f94dfbab31", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nYou were breaking up a little bit.  Let me \u2013 I think the question was coming back to the framework.  Is it going to be \nall encompassing of all the litigation?  And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n ", "original_text": "A \nYou were breaking up a little bit. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a2ec0285d1035b6464758b5c94a76246d27422c4d8c91bdf3179f2cb93dd93d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54347623-4a44-4ddb-a4ab-4768d1b4d0d8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nYou were breaking up a little bit.  Let me \u2013 I think the question was coming back to the framework.  Is it going to be \nall encompassing of all the litigation?  And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this? ", "original_text": "Is it going to be \nall encompassing of all the litigation? "}, "hash": "c63a1835a3dffefa20dc24fecaa0c181a24bff8ca92eab4e09ca498d4e3a2a83", "class_name": "RelatedNodeInfo"}}, "text": "Let me \u2013 I think the question was coming back to the framework. ", "start_char_idx": 289, "end_char_idx": 353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54347623-4a44-4ddb-a4ab-4768d1b4d0d8": {"__data__": {"id_": "54347623-4a44-4ddb-a4ab-4768d1b4d0d8", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nYou were breaking up a little bit.  Let me \u2013 I think the question was coming back to the framework.  Is it going to be \nall encompassing of all the litigation?  And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this? ", "original_text": "Is it going to be \nall encompassing of all the litigation? ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13ad8f41-196e-44c7-aaf2-80ccd51f31ae", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nYou were breaking up a little bit.  Let me \u2013 I think the question was coming back to the framework.  Is it going to be \nall encompassing of all the litigation?  And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Let me \u2013 I think the question was coming back to the framework. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a9275a5fbab0b09f76588f9cf0914c858bb954814cfb10c45f3528c6ff8413c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34104dfa-1182-4efd-8c3c-ec990dc7c0c9", "node_type": "1", "metadata": {"window": "A \nYou were breaking up a little bit.  Let me \u2013 I think the question was coming back to the framework.  Is it going to be \nall encompassing of all the litigation?  And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this?  And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n ", "original_text": "And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n "}, "hash": "c189a0a561dc84cbc1807adb11f52a8bbffe5a5a6beecafbb8ebda585d015b17", "class_name": "RelatedNodeInfo"}}, "text": "Is it going to be \nall encompassing of all the litigation? ", "start_char_idx": 353, "end_char_idx": 412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34104dfa-1182-4efd-8c3c-ec990dc7c0c9": {"__data__": {"id_": "34104dfa-1182-4efd-8c3c-ec990dc7c0c9", "embedding": null, "metadata": {"window": "A \nYou were breaking up a little bit.  Let me \u2013 I think the question was coming back to the framework.  Is it going to be \nall encompassing of all the litigation?  And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this?  And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n ", "original_text": "And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54347623-4a44-4ddb-a4ab-4768d1b4d0d8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nYou were breaking up a little bit.  Let me \u2013 I think the question was coming back to the framework.  Is it going to be \nall encompassing of all the litigation?  And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this? ", "original_text": "Is it going to be \nall encompassing of all the litigation? ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "402e52593048b07866a867c4b8a402b22dffb10fe7a1eec5b7583a10a3ae9d67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfdd9054-40fb-48e7-9e90-cd469ccc359f", "node_type": "1", "metadata": {"window": "Let me \u2013 I think the question was coming back to the framework.  Is it going to be \nall encompassing of all the litigation?  And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this?  And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "38b278efe1d33703e05ed62e2f1c462ec29c408ff8e60a9129d799741223608e", "class_name": "RelatedNodeInfo"}}, "text": "And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n ", "start_char_idx": 412, "end_char_idx": 691, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfdd9054-40fb-48e7-9e90-cd469ccc359f": {"__data__": {"id_": "cfdd9054-40fb-48e7-9e90-cd469ccc359f", "embedding": null, "metadata": {"window": "Let me \u2013 I think the question was coming back to the framework.  Is it going to be \nall encompassing of all the litigation?  And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this?  And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34104dfa-1182-4efd-8c3c-ec990dc7c0c9", "node_type": "1", "metadata": {"window": "A \nYou were breaking up a little bit.  Let me \u2013 I think the question was coming back to the framework.  Is it going to be \nall encompassing of all the litigation?  And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this?  And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n ", "original_text": "And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c232cec4195f932ac1b41db3619cfd95f0cb44ab0898c987c0cbc49a0499d544", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80718301-12c9-43f6-ac46-1fbb070d0ded", "node_type": "1", "metadata": {"window": "Is it going to be \nall encompassing of all the litigation?  And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this?  And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this? "}, "hash": "048ce16f111f867be9e9dfce25eb6a90a80de780006ae3986f95724ad5da27bf", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 691, "end_char_idx": 985, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80718301-12c9-43f6-ac46-1fbb070d0ded": {"__data__": {"id_": "80718301-12c9-43f6-ac46-1fbb070d0ded", "embedding": null, "metadata": {"window": "Is it going to be \nall encompassing of all the litigation?  And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this?  And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this? ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfdd9054-40fb-48e7-9e90-cd469ccc359f", "node_type": "1", "metadata": {"window": "Let me \u2013 I think the question was coming back to the framework.  Is it going to be \nall encompassing of all the litigation?  And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this?  And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6797cdf6593fcbc7c0caf3c72e0e6dbb0f0785d87123f51f4cac0606faf232eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b58e9d5c-f743-42c8-a87d-19715f4f413d", "node_type": "1", "metadata": {"window": "And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this?  And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So I guess the easiest way to answer that is to say that this is a complex legal situation. ", "original_text": "And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n "}, "hash": "8897943f2a1aa70c0ae37f30c2fb2c32fd6fad34e160383b6efe38654fd97d88", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this? ", "start_char_idx": 985, "end_char_idx": 1154, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b58e9d5c-f743-42c8-a87d-19715f4f413d": {"__data__": {"id_": "b58e9d5c-f743-42c8-a87d-19715f4f413d", "embedding": null, "metadata": {"window": "And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this?  And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So I guess the easiest way to answer that is to say that this is a complex legal situation. ", "original_text": "And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80718301-12c9-43f6-ac46-1fbb070d0ded", "node_type": "1", "metadata": {"window": "Is it going to be \nall encompassing of all the litigation?  And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this?  And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this? ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9523a0d92aae14943548c4b01723f78a60f851178d7e706bbe2bc17ffe8c3940", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09624e07-e5e9-49ae-8009-2e8ba09bfdbe", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this?  And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So I guess the easiest way to answer that is to say that this is a complex legal situation.  We have \nestablished a framework and had good discussion around that framework. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "242b3f77f1177e58fe84608518ec679c216ec2410deaaee8cf1eaacd9e3b617e", "class_name": "RelatedNodeInfo"}}, "text": "And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n ", "start_char_idx": 1154, "end_char_idx": 1582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09624e07-e5e9-49ae-8009-2e8ba09bfdbe": {"__data__": {"id_": "09624e07-e5e9-49ae-8009-2e8ba09bfdbe", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this?  And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So I guess the easiest way to answer that is to say that this is a complex legal situation.  We have \nestablished a framework and had good discussion around that framework. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b58e9d5c-f743-42c8-a87d-19715f4f413d", "node_type": "1", "metadata": {"window": "And what I would say is that relative to the states and relative to the \nsubdivisio ns in those states, our goal is to get as comprehensive of a settlement within that framework as we can, \nand that is a majority of the outstanding litigation, but it is not all of the cases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this?  And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So I guess the easiest way to answer that is to say that this is a complex legal situation. ", "original_text": "And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "92e98f61ebb514bd5dda12f75be897e5bce2e11c199ced86063b49f5e03e489b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03a2d54c-e670-42c4-bfa6-342b72f341c2", "node_type": "1", "metadata": {"window": "LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this?  And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So I guess the easiest way to answer that is to say that this is a complex legal situation.  We have \nestablished a framework and had good discussion around that framework.  It is very much a process, though, and \nwe are very much working through the details of how that process will unfold. ", "original_text": "A \nYeah. "}, "hash": "8ab0637925d08daa76d4c7ad0b2475abaecce92f73e1a7ace091824dd607e0f2", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1582, "end_char_idx": 1908, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03a2d54c-e670-42c4-bfa6-342b72f341c2": {"__data__": {"id_": "03a2d54c-e670-42c4-bfa6-342b72f341c2", "embedding": null, "metadata": {"window": "LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this?  And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So I guess the easiest way to answer that is to say that this is a complex legal situation.  We have \nestablished a framework and had good discussion around that framework.  It is very much a process, though, and \nwe are very much working through the details of how that process will unfold. ", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09624e07-e5e9-49ae-8009-2e8ba09bfdbe", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this?  And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So I guess the easiest way to answer that is to say that this is a complex legal situation.  We have \nestablished a framework and had good discussion around that framework. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a3a9833728d93a105d2526d7d1a2143608e3eabef25a18b33fedb004257728f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46daac5b-d13d-4f83-82d6-e53abfc08ad0", "node_type": "1", "metadata": {"window": "And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So I guess the easiest way to answer that is to say that this is a complex legal situation.  We have \nestablished a framework and had good discussion around that framework.  It is very much a process, though, and \nwe are very much working through the details of how that process will unfold.  And there's really not a lot more I \ncan add to it at this time.  \n ", "original_text": "So I guess the easiest way to answer that is to say that this is a complex legal situation. "}, "hash": "aa7d01f36c130b7c3da225cce0caee530563f814fd0bc614edda58f2dca1cf75", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 1908, "end_char_idx": 1917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46daac5b-d13d-4f83-82d6-e53abfc08ad0": {"__data__": {"id_": "46daac5b-d13d-4f83-82d6-e53abfc08ad0", "embedding": null, "metadata": {"window": "And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So I guess the easiest way to answer that is to say that this is a complex legal situation.  We have \nestablished a framework and had good discussion around that framework.  It is very much a process, though, and \nwe are very much working through the details of how that process will unfold.  And there's really not a lot more I \ncan add to it at this time.  \n ", "original_text": "So I guess the easiest way to answer that is to say that this is a complex legal situation. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03a2d54c-e670-42c4-bfa6-342b72f341c2", "node_type": "1", "metadata": {"window": "LLC  Q \nAnd is that something  mechanically that you would kind of reach a framework and then wait for all the parties to \nthen look at it and say we're okay with this?  And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So I guess the easiest way to answer that is to say that this is a complex legal situation.  We have \nestablished a framework and had good discussion around that framework.  It is very much a process, though, and \nwe are very much working through the details of how that process will unfold. ", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26339d05ea0c4801d785fd0aa1679923f883a66e5f77e24ef1e159e1ae43b9ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5954d1a5-5fbe-42e7-8893-9cd9b4f13f51", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So I guess the easiest way to answer that is to say that this is a complex legal situation.  We have \nestablished a framework and had good discussion around that framework.  It is very much a process, though, and \nwe are very much working through the details of how that process will unfold.  And there's really not a lot more I \ncan add to it at this time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  ", "original_text": "We have \nestablished a framework and had good discussion around that framework. "}, "hash": "6783a2eae8a5d9fb4891427352e4ad25dba0d0543fe87107a59e4e215a0cd37b", "class_name": "RelatedNodeInfo"}}, "text": "So I guess the easiest way to answer that is to say that this is a complex legal situation. ", "start_char_idx": 1917, "end_char_idx": 2009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5954d1a5-5fbe-42e7-8893-9cd9b4f13f51": {"__data__": {"id_": "5954d1a5-5fbe-42e7-8893-9cd9b4f13f51", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So I guess the easiest way to answer that is to say that this is a complex legal situation.  We have \nestablished a framework and had good discussion around that framework.  It is very much a process, though, and \nwe are very much working through the details of how that process will unfold.  And there's really not a lot more I \ncan add to it at this time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  ", "original_text": "We have \nestablished a framework and had good discussion around that framework. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46daac5b-d13d-4f83-82d6-e53abfc08ad0", "node_type": "1", "metadata": {"window": "And is there some type of \u2013 from your standpoint as you kind of look \nat it and then think, all right, this is enough t hat we will move forward, or this is not enough and we will not agree \nto this because it's maybe \u2013 you might have thought some large percentage were okay with it, but in the end, lot \nof the subdivisions said we're not satisfied with this, and in this case you'd go [ph] up to a different track (48:59)?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So I guess the easiest way to answer that is to say that this is a complex legal situation.  We have \nestablished a framework and had good discussion around that framework.  It is very much a process, though, and \nwe are very much working through the details of how that process will unfold.  And there's really not a lot more I \ncan add to it at this time.  \n ", "original_text": "So I guess the easiest way to answer that is to say that this is a complex legal situation. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04e152d3f7181f19625e6c10a17ce50039aa0c3e7826fc5f94b5f8a243858bfe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3e97f48-1bf4-42e7-8f28-efe234e82160", "node_type": "1", "metadata": {"window": "A \nYeah.  So I guess the easiest way to answer that is to say that this is a complex legal situation.  We have \nestablished a framework and had good discussion around that framework.  It is very much a process, though, and \nwe are very much working through the details of how that process will unfold.  And there's really not a lot more I \ncan add to it at this time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.   LLC Q \nOkay. ", "original_text": "It is very much a process, though, and \nwe are very much working through the details of how that process will unfold. "}, "hash": "496244b5b43bc94e1e2ac19f3feed78f6a317125faf2df4631a3e59dc0d2336d", "class_name": "RelatedNodeInfo"}}, "text": "We have \nestablished a framework and had good discussion around that framework. ", "start_char_idx": 2009, "end_char_idx": 2089, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3e97f48-1bf4-42e7-8f28-efe234e82160": {"__data__": {"id_": "a3e97f48-1bf4-42e7-8f28-efe234e82160", "embedding": null, "metadata": {"window": "A \nYeah.  So I guess the easiest way to answer that is to say that this is a complex legal situation.  We have \nestablished a framework and had good discussion around that framework.  It is very much a process, though, and \nwe are very much working through the details of how that process will unfold.  And there's really not a lot more I \ncan add to it at this time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.   LLC Q \nOkay. ", "original_text": "It is very much a process, though, and \nwe are very much working through the details of how that process will unfold. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5954d1a5-5fbe-42e7-8893-9cd9b4f13f51", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So I guess the easiest way to answer that is to say that this is a complex legal situation.  We have \nestablished a framework and had good discussion around that framework.  It is very much a process, though, and \nwe are very much working through the details of how that process will unfold.  And there's really not a lot more I \ncan add to it at this time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  ", "original_text": "We have \nestablished a framework and had good discussion around that framework. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b620b13eaa1d308e00bef5e7d5916993e596c03b1c26a2c9ccc9ca4dbfb22c5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "527decb7-89d2-4d63-8fb3-fee312d66e78", "node_type": "1", "metadata": {"window": "So I guess the easiest way to answer that is to say that this is a complex legal situation.  We have \nestablished a framework and had good discussion around that framework.  It is very much a process, though, and \nwe are very much working through the details of how that process will unfold.  And there's really not a lot more I \ncan add to it at this time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.   LLC Q \nOkay.  Thank you. ", "original_text": "And there's really not a lot more I \ncan add to it at this time.  \n "}, "hash": "2bf6d7da3c09512f202a9aedfe5af974a9225b5a9e2c3f2f3d4f065b96730085", "class_name": "RelatedNodeInfo"}}, "text": "It is very much a process, though, and \nwe are very much working through the details of how that process will unfold. ", "start_char_idx": 2089, "end_char_idx": 2207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "527decb7-89d2-4d63-8fb3-fee312d66e78": {"__data__": {"id_": "527decb7-89d2-4d63-8fb3-fee312d66e78", "embedding": null, "metadata": {"window": "So I guess the easiest way to answer that is to say that this is a complex legal situation.  We have \nestablished a framework and had good discussion around that framework.  It is very much a process, though, and \nwe are very much working through the details of how that process will unfold.  And there's really not a lot more I \ncan add to it at this time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.   LLC Q \nOkay.  Thank you. ", "original_text": "And there's really not a lot more I \ncan add to it at this time.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3e97f48-1bf4-42e7-8f28-efe234e82160", "node_type": "1", "metadata": {"window": "A \nYeah.  So I guess the easiest way to answer that is to say that this is a complex legal situation.  We have \nestablished a framework and had good discussion around that framework.  It is very much a process, though, and \nwe are very much working through the details of how that process will unfold.  And there's really not a lot more I \ncan add to it at this time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.   LLC Q \nOkay. ", "original_text": "It is very much a process, though, and \nwe are very much working through the details of how that process will unfold. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1a7c0fa7ca473675a319899b6779c5428065d56053471c7ac1330d12ea0d893", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e89ab7b7-cc68-4187-8712-19ad586d650e", "node_type": "1", "metadata": {"window": "We have \nestablished a framework and had good discussion around that framework.  It is very much a process, though, and \nwe are very much working through the details of how that process will unfold.  And there's really not a lot more I \ncan add to it at this time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.   LLC Q \nOkay.  Thank you.  And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  "}, "hash": "c0eebc716cc7c5626769d558b8bcb06df91edacb7c37ce057542742f58cc2c5e", "class_name": "RelatedNodeInfo"}}, "text": "And there's really not a lot more I \ncan add to it at this time.  \n ", "start_char_idx": 2207, "end_char_idx": 2275, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e89ab7b7-cc68-4187-8712-19ad586d650e": {"__data__": {"id_": "e89ab7b7-cc68-4187-8712-19ad586d650e", "embedding": null, "metadata": {"window": "We have \nestablished a framework and had good discussion around that framework.  It is very much a process, though, and \nwe are very much working through the details of how that process will unfold.  And there's really not a lot more I \ncan add to it at this time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.   LLC Q \nOkay.  Thank you.  And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "527decb7-89d2-4d63-8fb3-fee312d66e78", "node_type": "1", "metadata": {"window": "So I guess the easiest way to answer that is to say that this is a complex legal situation.  We have \nestablished a framework and had good discussion around that framework.  It is very much a process, though, and \nwe are very much working through the details of how that process will unfold.  And there's really not a lot more I \ncan add to it at this time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.   LLC Q \nOkay.  Thank you. ", "original_text": "And there's really not a lot more I \ncan add to it at this time.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f16d73c5563cc2fa5176b1fc865fa4cfa663dbf34b16eacd97c1db011b5228d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a265481c-9d2b-4133-9ce4-5ff023e6f882", "node_type": "1", "metadata": {"window": "It is very much a process, though, and \nwe are very much working through the details of how that process will unfold.  And there's really not a lot more I \ncan add to it at this time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.   LLC Q \nOkay.  Thank you.  And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45). ", "original_text": "LLC Q \nOkay. "}, "hash": "cc3dae53bc8a8bb4f31ae0d78147b0c82280d313ee13557eba939b7e59a37bec", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  ", "start_char_idx": 2275, "end_char_idx": 2570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a265481c-9d2b-4133-9ce4-5ff023e6f882": {"__data__": {"id_": "a265481c-9d2b-4133-9ce4-5ff023e6f882", "embedding": null, "metadata": {"window": "It is very much a process, though, and \nwe are very much working through the details of how that process will unfold.  And there's really not a lot more I \ncan add to it at this time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.   LLC Q \nOkay.  Thank you.  And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45). ", "original_text": "LLC Q \nOkay. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e89ab7b7-cc68-4187-8712-19ad586d650e", "node_type": "1", "metadata": {"window": "We have \nestablished a framework and had good discussion around that framework.  It is very much a process, though, and \nwe are very much working through the details of how that process will unfold.  And there's really not a lot more I \ncan add to it at this time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.   LLC Q \nOkay.  Thank you.  And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbfb3e3191fd617f7420a3c00a190ecba4199698ea580d8126da9e0aeb02a7f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8851f959-85e9-4013-95a3-41f43f79296f", "node_type": "1", "metadata": {"window": "And there's really not a lot more I \ncan add to it at this time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.   LLC Q \nOkay.  Thank you.  And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45).  Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half? ", "original_text": "Thank you. "}, "hash": "544433b597a6153056e5d1622f1dbd8a361a39c5bc064a2906ec93129ff3658a", "class_name": "RelatedNodeInfo"}}, "text": "LLC Q \nOkay. ", "start_char_idx": 2570, "end_char_idx": 2583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8851f959-85e9-4013-95a3-41f43f79296f": {"__data__": {"id_": "8851f959-85e9-4013-95a3-41f43f79296f", "embedding": null, "metadata": {"window": "And there's really not a lot more I \ncan add to it at this time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.   LLC Q \nOkay.  Thank you.  And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45).  Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half? ", "original_text": "Thank you. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a265481c-9d2b-4133-9ce4-5ff023e6f882", "node_type": "1", "metadata": {"window": "It is very much a process, though, and \nwe are very much working through the details of how that process will unfold.  And there's really not a lot more I \ncan add to it at this time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.   LLC Q \nOkay.  Thank you.  And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45). ", "original_text": "LLC Q \nOkay. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02128603a755639e6c055240e14afb4d662d7aafe9267d6b765217451fed6c08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc63b861-54ae-4994-aa8d-0705046842e9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.   LLC Q \nOkay.  Thank you.  And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45).  Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half?  Thanks.  \n ", "original_text": "And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n"}, "hash": "554c40c81b2f3f7ccf1bcc1073fcc81aa96288db9d2c1175ffa44536f6eda8b5", "class_name": "RelatedNodeInfo"}}, "text": "Thank you. ", "start_char_idx": 2583, "end_char_idx": 2594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc63b861-54ae-4994-aa8d-0705046842e9": {"__data__": {"id_": "fc63b861-54ae-4994-aa8d-0705046842e9", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.   LLC Q \nOkay.  Thank you.  And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45).  Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half?  Thanks.  \n ", "original_text": "And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8851f959-85e9-4013-95a3-41f43f79296f", "node_type": "1", "metadata": {"window": "And there's really not a lot more I \ncan add to it at this time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.   LLC Q \nOkay.  Thank you.  And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45).  Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half? ", "original_text": "Thank you. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c223b98aa3b2173d5f3a704865864cbe35c6ee6d4dbdf84c5641e19f9496e97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "148c942a-ab40-4b88-8209-9322cf0ad1d6", "node_type": "1", "metadata": {"window": "LLC Q \nOkay.  Thank you.  And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45).  Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45). "}, "hash": "8ba74e0acffb047c9e03601a15ba64f7989d648661a1abe4482dac8730c288b1", "class_name": "RelatedNodeInfo"}}, "text": "And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n", "start_char_idx": 2594, "end_char_idx": 2691, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "148c942a-ab40-4b88-8209-9322cf0ad1d6": {"__data__": {"id_": "148c942a-ab40-4b88-8209-9322cf0ad1d6", "embedding": null, "metadata": {"window": "LLC Q \nOkay.  Thank you.  And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45).  Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45). ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc63b861-54ae-4994-aa8d-0705046842e9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.   LLC Q \nOkay.  Thank you.  And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45).  Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half?  Thanks.  \n ", "original_text": "And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a9398a6ef11b351019880959c56baaed28643bcd95cecb52d7885162e7bf761", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "253d45c5-448f-492e-873c-135283d863a8", "node_type": "1", "metadata": {"window": "Thank you.  And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45).  Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half? "}, "hash": "e89b5b26707f46dafb32cd53a2ea81539f5015d10d4cdad73d5f7c5516179c9c", "class_name": "RelatedNodeInfo"}}, "text": "It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45). ", "start_char_idx": 2691, "end_char_idx": 2807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "253d45c5-448f-492e-873c-135283d863a8": {"__data__": {"id_": "253d45c5-448f-492e-873c-135283d863a8", "embedding": null, "metadata": {"window": "Thank you.  And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45).  Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half? ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "148c942a-ab40-4b88-8209-9322cf0ad1d6", "node_type": "1", "metadata": {"window": "LLC Q \nOkay.  Thank you.  And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45).  Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45). ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe5300a27eb1889d8c29dbe9896e12eb561e74d285e37daffd9d098d2e5577b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00988ef4-2fe1-48d0-b551-cc37c13a9c4d", "node_type": "1", "metadata": {"window": "And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45).  Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question. ", "original_text": "Thanks.  \n "}, "hash": "0d58a9a12dd716df7071e15f44df5d84568cca3a16f504ae216c8c9a2b520210", "class_name": "RelatedNodeInfo"}}, "text": "Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half? ", "start_char_idx": 2807, "end_char_idx": 2898, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00988ef4-2fe1-48d0-b551-cc37c13a9c4d": {"__data__": {"id_": "00988ef4-2fe1-48d0-b551-cc37c13a9c4d", "embedding": null, "metadata": {"window": "And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45).  Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question. ", "original_text": "Thanks.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "253d45c5-448f-492e-873c-135283d863a8", "node_type": "1", "metadata": {"window": "Thank you.  And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45).  Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half? ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2692d575d1c66979214eaec819d85a5caddb8ef1a94bb70efd7b20c11372cba7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab3193a8-84f1-445a-b760-2f32146dc391", "node_type": "1", "metadata": {"window": "It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45).  Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "ea13d9063f1c104f578c9345fef5ea44f7a6c3d634f13721c46f9d54d5327d5a", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 2898, "end_char_idx": 2909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab3193a8-84f1-445a-b760-2f32146dc391": {"__data__": {"id_": "ab3193a8-84f1-445a-b760-2f32146dc391", "embedding": null, "metadata": {"window": "It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45).  Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00988ef4-2fe1-48d0-b551-cc37c13a9c4d", "node_type": "1", "metadata": {"window": "And, Britt, just to follow up one real quick question on the European segment, on the guidance. \n It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45).  Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question. ", "original_text": "Thanks.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dcc684f5a8c673210182cc6962e918b9fa6e3587b78d83da38fb126162bb5c28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94f15379-34e9-49d8-bf77-f4a48f7012c4", "node_type": "1", "metadata": {"window": "Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half.  And then Brian also talked about some nominal increases in the tariffs in the U.K. \n", "original_text": "A \nYeah. "}, "hash": "2c0f5b9704ea1bfcb4230224e410e7838958fe6cb613161dd164f23735d2823b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 2909, "end_char_idx": 3254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94f15379-34e9-49d8-bf77-f4a48f7012c4": {"__data__": {"id_": "94f15379-34e9-49d8-bf77-f4a48f7012c4", "embedding": null, "metadata": {"window": "Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half.  And then Brian also talked about some nominal increases in the tariffs in the U.K. \n", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab3193a8-84f1-445a-b760-2f32146dc391", "node_type": "1", "metadata": {"window": "It looks like you're still looking for operating profit guidance in the low single digits, [indiscernible] (49:45).  Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94a92a680673fe3cd24c1bb3d712dee252a416cfe0f49cb6936548554b4db4d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f0b6c60-72bb-47af-9842-a566d6dab5fd", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half.  And then Brian also talked about some nominal increases in the tariffs in the U.K. \n And we would expect that there could be additional increases in the back half for the year. ", "original_text": "Thanks for the question. "}, "hash": "bbcc3f760535df9a5b5782f6a44e0767eb45a41657510112d6bededf6473a63e", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 1908, "end_char_idx": 1917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f0b6c60-72bb-47af-9842-a566d6dab5fd": {"__data__": {"id_": "2f0b6c60-72bb-47af-9842-a566d6dab5fd", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half.  And then Brian also talked about some nominal increases in the tariffs in the U.K. \n And we would expect that there could be additional increases in the back half for the year. ", "original_text": "Thanks for the question. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94f15379-34e9-49d8-bf77-f4a48f7012c4", "node_type": "1", "metadata": {"window": "Can you \ngive us a l ittle bit more thoughts on what helps you get there in the back half?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half.  And then Brian also talked about some nominal increases in the tariffs in the U.K. \n", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08c4b53cd215c63fdc1068ffec61aa678c410df6ba1f760b0765ab73877fe43f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b41e8f56-d098-45de-a489-c37e7294a208", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half.  And then Brian also talked about some nominal increases in the tariffs in the U.K. \n And we would expect that there could be additional increases in the back half for the year.  So that's really what is \ndriving that second -half performance.  \n ", "original_text": "I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half. "}, "hash": "8fc227796013e8f3aecc03ce4ddead3ed5f953da685d26397b807b805d0b00cf", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 3263, "end_char_idx": 3288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b41e8f56-d098-45de-a489-c37e7294a208": {"__data__": {"id_": "b41e8f56-d098-45de-a489-c37e7294a208", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half.  And then Brian also talked about some nominal increases in the tariffs in the U.K. \n And we would expect that there could be additional increases in the back half for the year.  So that's really what is \ndriving that second -half performance.  \n ", "original_text": "I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f0b6c60-72bb-47af-9842-a566d6dab5fd", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half.  And then Brian also talked about some nominal increases in the tariffs in the U.K. \n And we would expect that there could be additional increases in the back half for the year. ", "original_text": "Thanks for the question. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6be6e9e2df960442b52f2573dcc452afe951c54ae5bee58aa9c926cb67490c1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a87c623e-b8fe-449f-8627-79006ecb3420", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for the question.  I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half.  And then Brian also talked about some nominal increases in the tariffs in the U.K. \n And we would expect that there could be additional increases in the back half for the year.  So that's really what is \ndriving that second -half performance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays. ", "original_text": "And then Brian also talked about some nominal increases in the tariffs in the U.K. \n"}, "hash": "7f28135a3901ea6929e62f0553476a1a3567e3e5dbae936948bf0194a718ea4e", "class_name": "RelatedNodeInfo"}}, "text": "I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half. ", "start_char_idx": 3288, "end_char_idx": 3405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a87c623e-b8fe-449f-8627-79006ecb3420": {"__data__": {"id_": "a87c623e-b8fe-449f-8627-79006ecb3420", "embedding": null, "metadata": {"window": "A \nYeah.  Thanks for the question.  I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half.  And then Brian also talked about some nominal increases in the tariffs in the U.K. \n And we would expect that there could be additional increases in the back half for the year.  So that's really what is \ndriving that second -half performance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays. ", "original_text": "And then Brian also talked about some nominal increases in the tariffs in the U.K. \n", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b41e8f56-d098-45de-a489-c37e7294a208", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half.  And then Brian also talked about some nominal increases in the tariffs in the U.K. \n And we would expect that there could be additional increases in the back half for the year.  So that's really what is \ndriving that second -half performance.  \n ", "original_text": "I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ffe514f595aab51740eae5e4492441161b966abef57785c9fca70e965b0997d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ba95780-2175-41c7-8fd4-799c086f6f17", "node_type": "1", "metadata": {"window": "Thanks for the question.  I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half.  And then Brian also talked about some nominal increases in the tariffs in the U.K. \n And we would expect that there could be additional increases in the back half for the year.  So that's really what is \ndriving that second -half performance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays.  Your line is open.  \n ", "original_text": "And we would expect that there could be additional increases in the back half for the year. "}, "hash": "7494e8d58477a69194f126a7a2e0a23d965eb11da9bf3f3845f26a7702aac0a7", "class_name": "RelatedNodeInfo"}}, "text": "And then Brian also talked about some nominal increases in the tariffs in the U.K. \n", "start_char_idx": 3405, "end_char_idx": 3489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ba95780-2175-41c7-8fd4-799c086f6f17": {"__data__": {"id_": "3ba95780-2175-41c7-8fd4-799c086f6f17", "embedding": null, "metadata": {"window": "Thanks for the question.  I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half.  And then Brian also talked about some nominal increases in the tariffs in the U.K. \n And we would expect that there could be additional increases in the back half for the year.  So that's really what is \ndriving that second -half performance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays.  Your line is open.  \n ", "original_text": "And we would expect that there could be additional increases in the back half for the year. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a87c623e-b8fe-449f-8627-79006ecb3420", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for the question.  I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half.  And then Brian also talked about some nominal increases in the tariffs in the U.K. \n And we would expect that there could be additional increases in the back half for the year.  So that's really what is \ndriving that second -half performance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays. ", "original_text": "And then Brian also talked about some nominal increases in the tariffs in the U.K. \n", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c0bd2eba4c31cbef37ca0f781fcdd73e2c3c9f973b1e94e3604f9f7cd94902a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e90d7c71-6e3a-41a9-9810-bc2c45d683b1", "node_type": "1", "metadata": {"window": "I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half.  And then Brian also talked about some nominal increases in the tariffs in the U.K. \n And we would expect that there could be additional increases in the back half for the year.  So that's really what is \ndriving that second -half performance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "So that's really what is \ndriving that second -half performance.  \n "}, "hash": "8d1b210c4e78b9e25bdc384de0a589f5fa13e8ddc4c1d719898c826fc2495c41", "class_name": "RelatedNodeInfo"}}, "text": "And we would expect that there could be additional increases in the back half for the year. ", "start_char_idx": 3489, "end_char_idx": 3581, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e90d7c71-6e3a-41a9-9810-bc2c45d683b1": {"__data__": {"id_": "e90d7c71-6e3a-41a9-9810-bc2c45d683b1", "embedding": null, "metadata": {"window": "I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half.  And then Brian also talked about some nominal increases in the tariffs in the U.K. \n And we would expect that there could be additional increases in the back half for the year.  So that's really what is \ndriving that second -half performance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "So that's really what is \ndriving that second -half performance.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ba95780-2175-41c7-8fd4-799c086f6f17", "node_type": "1", "metadata": {"window": "Thanks for the question.  I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half.  And then Brian also talked about some nominal increases in the tariffs in the U.K. \n And we would expect that there could be additional increases in the back half for the year.  So that's really what is \ndriving that second -half performance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays.  Your line is open.  \n ", "original_text": "And we would expect that there could be additional increases in the back half for the year. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a8882c05dc01ca1d4ad39338a00855a10182c32da37458bb27a8f53dff74c78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25d65221-bcf4-48f0-a4f9-6b5a4831bf50", "node_type": "1", "metadata": {"window": "And then Brian also talked about some nominal increases in the tariffs in the U.K. \n And we would expect that there could be additional increases in the back half for the year.  So that's really what is \ndriving that second -half performance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat, thanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays. "}, "hash": "f31a001e42d03d70d4a41ddd105352b454aa3eb6a2351791dcd7dd8efe6a644b", "class_name": "RelatedNodeInfo"}}, "text": "So that's really what is \ndriving that second -half performance.  \n ", "start_char_idx": 3581, "end_char_idx": 3649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25d65221-bcf4-48f0-a4f9-6b5a4831bf50": {"__data__": {"id_": "25d65221-bcf4-48f0-a4f9-6b5a4831bf50", "embedding": null, "metadata": {"window": "And then Brian also talked about some nominal increases in the tariffs in the U.K. \n And we would expect that there could be additional increases in the back half for the year.  So that's really what is \ndriving that second -half performance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat, thanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e90d7c71-6e3a-41a9-9810-bc2c45d683b1", "node_type": "1", "metadata": {"window": "I think, as we've talked about, we expected the business will continue to improve \nits performance in the back half.  And then Brian also talked about some nominal increases in the tariffs in the U.K. \n And we would expect that there could be additional increases in the back half for the year.  So that's really what is \ndriving that second -half performance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "So that's really what is \ndriving that second -half performance.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f083e5b167aa05b76340866a0266c1836187c9061b68ff0dcd765fc4323bf7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98cecef0-35dd-4584-93fe-954fc4c10914", "node_type": "1", "metadata": {"window": "And we would expect that there could be additional increases in the back half for the year.  So that's really what is \ndriving that second -half performance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat, thanks.  Good morning. ", "original_text": "Your line is open.  \n "}, "hash": "f3e59d2ddc20620f335e1f61c2a4dd4242965c20be7f59f2a8d77ba01b530b3b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays. ", "start_char_idx": 3649, "end_char_idx": 3995, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98cecef0-35dd-4584-93fe-954fc4c10914": {"__data__": {"id_": "98cecef0-35dd-4584-93fe-954fc4c10914", "embedding": null, "metadata": {"window": "And we would expect that there could be additional increases in the back half for the year.  So that's really what is \ndriving that second -half performance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat, thanks.  Good morning. ", "original_text": "Your line is open.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25d65221-bcf4-48f0-a4f9-6b5a4831bf50", "node_type": "1", "metadata": {"window": "And then Brian also talked about some nominal increases in the tariffs in the U.K. \n And we would expect that there could be additional increases in the back half for the year.  So that's really what is \ndriving that second -half performance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat, thanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23827fc3b69d86fa2c2823e5badd614328bff272bd846696303daa60096a2ec0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8c729df-e092-4dc5-a7cb-cc29463071dc", "node_type": "1", "metadata": {"window": "So that's really what is \ndriving that second -half performance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat, thanks.  Good morning.  Thanks for taking th e question here. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  "}, "hash": "84afcb2878eb164df9d1139e7698613c0a6c1bd6295e1131d306481d21975ffe", "class_name": "RelatedNodeInfo"}}, "text": "Your line is open.  \n ", "start_char_idx": 3995, "end_char_idx": 4017, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8c729df-e092-4dc5-a7cb-cc29463071dc": {"__data__": {"id_": "c8c729df-e092-4dc5-a7cb-cc29463071dc", "embedding": null, "metadata": {"window": "So that's really what is \ndriving that second -half performance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat, thanks.  Good morning.  Thanks for taking th e question here. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98cecef0-35dd-4584-93fe-954fc4c10914", "node_type": "1", "metadata": {"window": "And we would expect that there could be additional increases in the back half for the year.  So that's really what is \ndriving that second -half performance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat, thanks.  Good morning. ", "original_text": "Your line is open.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01097d006c190953b4c12605630ba8bdcc06bfa5b20b895c5f28266534ee6e10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3053796-dbc4-4247-a600-5380865e2433", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat, thanks.  Good morning.  Thanks for taking th e question here.  So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress. ", "original_text": "Q \nGreat, thanks. "}, "hash": "df288696c7a305a1550a4494a3f05c15548975607f0683dfa2bb842bceefbcc6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "start_char_idx": 4017, "end_char_idx": 4330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3053796-dbc4-4247-a600-5380865e2433": {"__data__": {"id_": "f3053796-dbc4-4247-a600-5380865e2433", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat, thanks.  Good morning.  Thanks for taking th e question here.  So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress. ", "original_text": "Q \nGreat, thanks. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8c729df-e092-4dc5-a7cb-cc29463071dc", "node_type": "1", "metadata": {"window": "So that's really what is \ndriving that second -half performance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat, thanks.  Good morning.  Thanks for taking th e question here. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5576f6cb0a0b19c11fc8307f8d19eaa33c4cd9adf79970d4a0674d776e58aaea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa8db448-5c4f-490d-ba8f-fae3238eded5", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat, thanks.  Good morning.  Thanks for taking th e question here.  So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress.  And tied into that, based on a little bit of the \nmargin compression in the U.S. ", "original_text": "Good morning. "}, "hash": "2ed33f517c424de4fb0da9a9b785d67a7a23bde76415bc44bc2a03278fc5cb7a", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGreat, thanks. ", "start_char_idx": 4330, "end_char_idx": 4348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa8db448-5c4f-490d-ba8f-fae3238eded5": {"__data__": {"id_": "aa8db448-5c4f-490d-ba8f-fae3238eded5", "embedding": null, "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat, thanks.  Good morning.  Thanks for taking th e question here.  So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress.  And tied into that, based on a little bit of the \nmargin compression in the U.S. ", "original_text": "Good morning. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3053796-dbc4-4247-a600-5380865e2433", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Steven Valiquette of Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat, thanks.  Good morning.  Thanks for taking th e question here.  So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress. ", "original_text": "Q \nGreat, thanks. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94265be1fae48b3338cd5b8f26df27145e7ac0ae70406b2995ecd732a17efa4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc1bf378-cab2-4d24-9e45-ae7315fa73b7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat, thanks.  Good morning.  Thanks for taking th e question here.  So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress.  And tied into that, based on a little bit of the \nmargin compression in the U.S.  Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter? ", "original_text": "Thanks for taking th e question here. "}, "hash": "5bd5e170d3a0e9c14526f9158e98fe7cc699a9d80b5e13389eda605082409b63", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 4348, "end_char_idx": 4362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc1bf378-cab2-4d24-9e45-ae7315fa73b7": {"__data__": {"id_": "cc1bf378-cab2-4d24-9e45-ae7315fa73b7", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat, thanks.  Good morning.  Thanks for taking th e question here.  So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress.  And tied into that, based on a little bit of the \nmargin compression in the U.S.  Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter? ", "original_text": "Thanks for taking th e question here. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa8db448-5c4f-490d-ba8f-fae3238eded5", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat, thanks.  Good morning.  Thanks for taking th e question here.  So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress.  And tied into that, based on a little bit of the \nmargin compression in the U.S. ", "original_text": "Good morning. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ddad93a471984088659663fbf1f921ba229caac311e2da9c9cdde5d240680cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "393a5c37-e3b0-4fe0-a3f1-2c02d91b1810", "node_type": "1", "metadata": {"window": "Q \nGreat, thanks.  Good morning.  Thanks for taking th e question here.  So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress.  And tied into that, based on a little bit of the \nmargin compression in the U.S.  Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter?  Or in your mind was that relationship still relatively consistent during the quarter? ", "original_text": "So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress. "}, "hash": "e6bd1729877203158692fab6ac0738e745eb5f770dfa169ed6cda08d3f66bce2", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking th e question here. ", "start_char_idx": 4362, "end_char_idx": 4400, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "393a5c37-e3b0-4fe0-a3f1-2c02d91b1810": {"__data__": {"id_": "393a5c37-e3b0-4fe0-a3f1-2c02d91b1810", "embedding": null, "metadata": {"window": "Q \nGreat, thanks.  Good morning.  Thanks for taking th e question here.  So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress.  And tied into that, based on a little bit of the \nmargin compression in the U.S.  Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter?  Or in your mind was that relationship still relatively consistent during the quarter? ", "original_text": "So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc1bf378-cab2-4d24-9e45-ae7315fa73b7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat, thanks.  Good morning.  Thanks for taking th e question here.  So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress.  And tied into that, based on a little bit of the \nmargin compression in the U.S.  Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter? ", "original_text": "Thanks for taking th e question here. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "856906f9ea2c2b90582919df0e8dab82dfcfeea5745546f53a46d08e0987f317", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53f6ce17-d066-44f6-bb90-c686d4020dcc", "node_type": "1", "metadata": {"window": "Good morning.  Thanks for taking th e question here.  So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress.  And tied into that, based on a little bit of the \nmargin compression in the U.S.  Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter?  Or in your mind was that relationship still relatively consistent during the quarter?  Thanks.  \n ", "original_text": "And tied into that, based on a little bit of the \nmargin compression in the U.S. "}, "hash": "e7a8b38bf3e6514086abffc803140707902d649cc5445d590e74d789199cd7db", "class_name": "RelatedNodeInfo"}}, "text": "So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress. ", "start_char_idx": 4400, "end_char_idx": 4517, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53f6ce17-d066-44f6-bb90-c686d4020dcc": {"__data__": {"id_": "53f6ce17-d066-44f6-bb90-c686d4020dcc", "embedding": null, "metadata": {"window": "Good morning.  Thanks for taking th e question here.  So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress.  And tied into that, based on a little bit of the \nmargin compression in the U.S.  Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter?  Or in your mind was that relationship still relatively consistent during the quarter?  Thanks.  \n ", "original_text": "And tied into that, based on a little bit of the \nmargin compression in the U.S. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "393a5c37-e3b0-4fe0-a3f1-2c02d91b1810", "node_type": "1", "metadata": {"window": "Q \nGreat, thanks.  Good morning.  Thanks for taking th e question here.  So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress.  And tied into that, based on a little bit of the \nmargin compression in the U.S.  Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter?  Or in your mind was that relationship still relatively consistent during the quarter? ", "original_text": "So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f3a3c0c2c444b576d0e2a7a808184d76598989703d67298d0ada473b9b52370", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7beded7b-b6be-479a-b097-7ed17dbf72c8", "node_type": "1", "metadata": {"window": "Thanks for taking th e question here.  So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress.  And tied into that, based on a little bit of the \nmargin compression in the U.S.  Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter?  Or in your mind was that relationship still relatively consistent during the quarter?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter? "}, "hash": "c427500b0bbb0b1e3ab4992441078fb427a9a26c49238a78a6123157a45dc125", "class_name": "RelatedNodeInfo"}}, "text": "And tied into that, based on a little bit of the \nmargin compression in the U.S. ", "start_char_idx": 4517, "end_char_idx": 4598, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7beded7b-b6be-479a-b097-7ed17dbf72c8": {"__data__": {"id_": "7beded7b-b6be-479a-b097-7ed17dbf72c8", "embedding": null, "metadata": {"window": "Thanks for taking th e question here.  So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress.  And tied into that, based on a little bit of the \nmargin compression in the U.S.  Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter?  Or in your mind was that relationship still relatively consistent during the quarter?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter? ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53f6ce17-d066-44f6-bb90-c686d4020dcc", "node_type": "1", "metadata": {"window": "Good morning.  Thanks for taking th e question here.  So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress.  And tied into that, based on a little bit of the \nmargin compression in the U.S.  Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter?  Or in your mind was that relationship still relatively consistent during the quarter?  Thanks.  \n ", "original_text": "And tied into that, based on a little bit of the \nmargin compression in the U.S. ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "78da159591beb7bde47ef67f0bc2ea9c3a57ee8d4c63fc3fd8dddd10c914d428", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc7906bb-7338-4862-a5d2-8aa5d73db2b6", "node_type": "1", "metadata": {"window": "So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress.  And tied into that, based on a little bit of the \nmargin compression in the U.S.  Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter?  Or in your mind was that relationship still relatively consistent during the quarter?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Or in your mind was that relationship still relatively consistent during the quarter? "}, "hash": "837c415f493f93bc3195b475dc3b9978ed9a6348e651e4d53b755f3cff4315c7", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter? ", "start_char_idx": 4598, "end_char_idx": 4805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc7906bb-7338-4862-a5d2-8aa5d73db2b6": {"__data__": {"id_": "fc7906bb-7338-4862-a5d2-8aa5d73db2b6", "embedding": null, "metadata": {"window": "So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress.  And tied into that, based on a little bit of the \nmargin compression in the U.S.  Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter?  Or in your mind was that relationship still relatively consistent during the quarter?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Or in your mind was that relationship still relatively consistent during the quarter? ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7beded7b-b6be-479a-b097-7ed17dbf72c8", "node_type": "1", "metadata": {"window": "Thanks for taking th e question here.  So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress.  And tied into that, based on a little bit of the \nmargin compression in the U.S.  Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter?  Or in your mind was that relationship still relatively consistent during the quarter?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter? ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef8a45bd311ec8f0f21b2165b257b4e45929b7039359e743d43f0cd14fecc0bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "942408f1-4240-4c83-a0bf-8424bbd11af9", "node_type": "1", "metadata": {"window": "And tied into that, based on a little bit of the \nmargin compression in the U.S.  Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter?  Or in your mind was that relationship still relatively consistent during the quarter?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Thanks.  \n "}, "hash": "762ab0fed9dae8e332097cdea7078b24507b9ddc0dad7e4e9de6f1b172e60913", "class_name": "RelatedNodeInfo"}}, "text": "Or in your mind was that relationship still relatively consistent during the quarter? ", "start_char_idx": 4805, "end_char_idx": 4891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "942408f1-4240-4c83-a0bf-8424bbd11af9": {"__data__": {"id_": "942408f1-4240-4c83-a0bf-8424bbd11af9", "embedding": null, "metadata": {"window": "And tied into that, based on a little bit of the \nmargin compression in the U.S.  Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter?  Or in your mind was that relationship still relatively consistent during the quarter?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Thanks.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc7906bb-7338-4862-a5d2-8aa5d73db2b6", "node_type": "1", "metadata": {"window": "So I guess this has been touched on a little bit, \nbut I guess I'm looking for any update on the ClarusONE progress.  And tied into that, based on a little bit of the \nmargin compression in the U.S.  Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter?  Or in your mind was that relationship still relatively consistent during the quarter?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Or in your mind was that relationship still relatively consistent during the quarter? ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bbe8c441ae1ad4d93f8b9a77da7de1fbbb9249ab15e83a23b6fdc416bfacfa5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7aaf9043-188f-492b-aec7-a2ff6af49c93", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter?  Or in your mind was that relationship still relatively consistent during the quarter?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   "}, "hash": "43a5d71ece5f075099f1d9b993bffdbbab809991262b3494ea699839682fa410", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 2898, "end_char_idx": 2909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7aaf9043-188f-492b-aec7-a2ff6af49c93": {"__data__": {"id_": "7aaf9043-188f-492b-aec7-a2ff6af49c93", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter?  Or in your mind was that relationship still relatively consistent during the quarter?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde1aec04b59e3e23bd34a05c3acf78aeb3fa883e49aef70922edf1f742fef28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "942408f1-4240-4c83-a0bf-8424bbd11af9", "node_type": "1", "metadata": {"window": "And tied into that, based on a little bit of the \nmargin compression in the U.S.  Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter?  Or in your mind was that relationship still relatively consistent during the quarter?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Thanks.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c528295a1dffce293e6cb0cc78e1bf1566a52d7b184fc2c966e46793f4986cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55faefa0-d053-46c0-b39b-b742148ddecd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question. ", "original_text": "McKesson Corp.  "}, "hash": "d56b8621648d9e48f29275aeadf8e89689862d7fd8d437ad0ffb0e90593b5394", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "start_char_idx": 691, "end_char_idx": 947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55faefa0-d053-46c0-b39b-b742148ddecd": {"__data__": {"id_": "55faefa0-d053-46c0-b39b-b742148ddecd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question. ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7aaf9043-188f-492b-aec7-a2ff6af49c93", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty business, shou ld we assume that the relationship \nbetween the procurement price on generics versus your sell -side pricing may have fallen off a little bit during the \nquarter?  Or in your mind was that relationship still relatively consistent during the quarter?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "360e35b76cd2b4f263511cfa293f6a6125fe1aacc9eb4e61ac16869c84f5a68a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dedba8dc-fc96-464e-b05f-7fc0086d3cf9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "14dd47f60b415fd30afc1ffd632e23db106571aa6a18a6001db4c15b66cae914", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dedba8dc-fc96-464e-b05f-7fc0086d3cf9": {"__data__": {"id_": "dedba8dc-fc96-464e-b05f-7fc0086d3cf9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55faefa0-d053-46c0-b39b-b742148ddecd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question. ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc03f453666884e223ebe0256e9bb2dfd580dde4b6893857a5659588cbe9998a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf5b1ce5-f64c-414c-9cdf-9b911b3a4e8a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year.  We're continuing to see that organization drive \ngreat value, which is very helpful. ", "original_text": "A \nYeah. "}, "hash": "5ab1cd1012a5590dbc2a90e0f5bee27efcb747a57c5598ae20f3b84823c8b375", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf5b1ce5-f64c-414c-9cdf-9b911b3a4e8a": {"__data__": {"id_": "bf5b1ce5-f64c-414c-9cdf-9b911b3a4e8a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year.  We're continuing to see that organization drive \ngreat value, which is very helpful. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dedba8dc-fc96-464e-b05f-7fc0086d3cf9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef43c0422d2320fde669fe6c3efa3249180d0da674f7c9b5dfeb61c7fdb1a3a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0d78ab0-8c47-4ca8-9a0f-f9995e54d7ef", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year.  We're continuing to see that organization drive \ngreat value, which is very helpful.  As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment. ", "original_text": "Thanks for that question. "}, "hash": "5104008cba868dd72ef30bfa214c06073a8bfa9aac9e313d53a1492717741038", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 269, "end_char_idx": 278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0d78ab0-8c47-4ca8-9a0f-f9995e54d7ef": {"__data__": {"id_": "d0d78ab0-8c47-4ca8-9a0f-f9995e54d7ef", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year.  We're continuing to see that organization drive \ngreat value, which is very helpful.  As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment. ", "original_text": "Thanks for that question. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf5b1ce5-f64c-414c-9cdf-9b911b3a4e8a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year.  We're continuing to see that organization drive \ngreat value, which is very helpful. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6607e1d8266e86af5ca288a14b38582f4b0e0e0b53d113ecba1944e3e775e6df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfc7f5d6-623e-4d0d-8ada-fa2262d3788a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year.  We're continuing to see that organization drive \ngreat value, which is very helpful.  As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment.  We're pleased with Clarus ONE. ", "original_text": "We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year. "}, "hash": "729e90144c9b74fd312ff99e72cf07fe2f733961c5c14ccb751d3ff8d01c0a4f", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for that question. ", "start_char_idx": 278, "end_char_idx": 304, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfc7f5d6-623e-4d0d-8ada-fa2262d3788a": {"__data__": {"id_": "dfc7f5d6-623e-4d0d-8ada-fa2262d3788a", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year.  We're continuing to see that organization drive \ngreat value, which is very helpful.  As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment.  We're pleased with Clarus ONE. ", "original_text": "We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0d78ab0-8c47-4ca8-9a0f-f9995e54d7ef", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year.  We're continuing to see that organization drive \ngreat value, which is very helpful.  As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment. ", "original_text": "Thanks for that question. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0aff8d1e0cac1b64cc1a27123ec18d21aadcb95ef67998a8ebe80774510adb4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f47966e-b2d3-4efa-8d34-cfae25675b25", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for that question.  We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year.  We're continuing to see that organization drive \ngreat value, which is very helpful.  As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment.  We're pleased with Clarus ONE.  It's performing as we had \nanticipated. ", "original_text": "We're continuing to see that organization drive \ngreat value, which is very helpful. "}, "hash": "f864d0016fc89f4bc20040f69b00fee7813e0ead721f9038e3770de6d48ea522", "class_name": "RelatedNodeInfo"}}, "text": "We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year. ", "start_char_idx": 304, "end_char_idx": 451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f47966e-b2d3-4efa-8d34-cfae25675b25": {"__data__": {"id_": "6f47966e-b2d3-4efa-8d34-cfae25675b25", "embedding": null, "metadata": {"window": "A \nYeah.  Thanks for that question.  We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year.  We're continuing to see that organization drive \ngreat value, which is very helpful.  As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment.  We're pleased with Clarus ONE.  It's performing as we had \nanticipated. ", "original_text": "We're continuing to see that organization drive \ngreat value, which is very helpful. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfc7f5d6-623e-4d0d-8ada-fa2262d3788a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year.  We're continuing to see that organization drive \ngreat value, which is very helpful.  As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment.  We're pleased with Clarus ONE. ", "original_text": "We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e6fae98b090a12f3bdacd69526cbf78bab7957c2d6e6379105121c94b660e75c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b25200ba-3318-4977-bf7d-89482eea3275", "node_type": "1", "metadata": {"window": "Thanks for that question.  We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year.  We're continuing to see that organization drive \ngreat value, which is very helpful.  As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment.  We're pleased with Clarus ONE.  It's performing as we had \nanticipated.  We think that there's still great value to be gained out of that organization. ", "original_text": "As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment. "}, "hash": "5e9fe2e15747eb42bee8112ea4258a9ed33bc121c91d61a39f41034506710cd6", "class_name": "RelatedNodeInfo"}}, "text": "We're continuing to see that organization drive \ngreat value, which is very helpful. ", "start_char_idx": 451, "end_char_idx": 536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b25200ba-3318-4977-bf7d-89482eea3275": {"__data__": {"id_": "b25200ba-3318-4977-bf7d-89482eea3275", "embedding": null, "metadata": {"window": "Thanks for that question.  We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year.  We're continuing to see that organization drive \ngreat value, which is very helpful.  As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment.  We're pleased with Clarus ONE.  It's performing as we had \nanticipated.  We think that there's still great value to be gained out of that organization. ", "original_text": "As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f47966e-b2d3-4efa-8d34-cfae25675b25", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for that question.  We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year.  We're continuing to see that organization drive \ngreat value, which is very helpful.  As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment.  We're pleased with Clarus ONE.  It's performing as we had \nanticipated. ", "original_text": "We're continuing to see that organization drive \ngreat value, which is very helpful. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ae3755a88faa26cb3bf14999f9684aeb28943eed8ba87343b3f11660de08a9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0171073-cd9c-4ed8-b1a0-6ecb25b8c979", "node_type": "1", "metadata": {"window": "We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year.  We're continuing to see that organization drive \ngreat value, which is very helpful.  As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment.  We're pleased with Clarus ONE.  It's performing as we had \nanticipated.  We think that there's still great value to be gained out of that organization.  And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n ", "original_text": "We're pleased with Clarus ONE. "}, "hash": "903f5a5e2e59cd2f8434a937765fb7895a08ce5285f9b70251bb0b2a2487d33b", "class_name": "RelatedNodeInfo"}}, "text": "As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment. ", "start_char_idx": 536, "end_char_idx": 675, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0171073-cd9c-4ed8-b1a0-6ecb25b8c979": {"__data__": {"id_": "f0171073-cd9c-4ed8-b1a0-6ecb25b8c979", "embedding": null, "metadata": {"window": "We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year.  We're continuing to see that organization drive \ngreat value, which is very helpful.  As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment.  We're pleased with Clarus ONE.  It's performing as we had \nanticipated.  We think that there's still great value to be gained out of that organization.  And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n ", "original_text": "We're pleased with Clarus ONE. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b25200ba-3318-4977-bf7d-89482eea3275", "node_type": "1", "metadata": {"window": "Thanks for that question.  We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year.  We're continuing to see that organization drive \ngreat value, which is very helpful.  As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment.  We're pleased with Clarus ONE.  It's performing as we had \nanticipated.  We think that there's still great value to be gained out of that organization. ", "original_text": "As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7564ea573dd377bbd8cc716bdf07b22c60f8931969b578cb092c7e483d27c16e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8e1658a-12a8-4bb6-a120-3120b55b07ed", "node_type": "1", "metadata": {"window": "We're continuing to see that organization drive \ngreat value, which is very helpful.  As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment.  We're pleased with Clarus ONE.  It's performing as we had \nanticipated.  We think that there's still great value to be gained out of that organization.  And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "It's performing as we had \nanticipated. "}, "hash": "fe690091cf39e435173efaac419e4f383917a678956ded42ede21263ad7c03c2", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased with Clarus ONE. ", "start_char_idx": 675, "end_char_idx": 706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8e1658a-12a8-4bb6-a120-3120b55b07ed": {"__data__": {"id_": "e8e1658a-12a8-4bb6-a120-3120b55b07ed", "embedding": null, "metadata": {"window": "We're continuing to see that organization drive \ngreat value, which is very helpful.  As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment.  We're pleased with Clarus ONE.  It's performing as we had \nanticipated.  We think that there's still great value to be gained out of that organization.  And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "It's performing as we had \nanticipated. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0171073-cd9c-4ed8-b1a0-6ecb25b8c979", "node_type": "1", "metadata": {"window": "We're really pleased with the performance of ClarusONE, and it's performing in \nline with what our expectations were at the beginning of the year.  We're continuing to see that organization drive \ngreat value, which is very helpful.  As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment.  We're pleased with Clarus ONE.  It's performing as we had \nanticipated.  We think that there's still great value to be gained out of that organization.  And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n ", "original_text": "We're pleased with Clarus ONE. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dbef8f993028ef83afb5c44369025399c9baa03d991ffbb34ab51ce555f79e6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1d7e319-9257-4744-9286-7c0213ba0667", "node_type": "1", "metadata": {"window": "As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment.  We're pleased with Clarus ONE.  It's performing as we had \nanticipated.  We think that there's still great value to be gained out of that organization.  And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nOkay. ", "original_text": "We think that there's still great value to be gained out of that organization. "}, "hash": "c7f31d86f9a56715f4599fa69b78a2ed783b6e7540c898b7d49986867c1994a4", "class_name": "RelatedNodeInfo"}}, "text": "It's performing as we had \nanticipated. ", "start_char_idx": 706, "end_char_idx": 746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1d7e319-9257-4744-9286-7c0213ba0667": {"__data__": {"id_": "a1d7e319-9257-4744-9286-7c0213ba0667", "embedding": null, "metadata": {"window": "As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment.  We're pleased with Clarus ONE.  It's performing as we had \nanticipated.  We think that there's still great value to be gained out of that organization.  And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nOkay. ", "original_text": "We think that there's still great value to be gained out of that organization. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8e1658a-12a8-4bb6-a120-3120b55b07ed", "node_type": "1", "metadata": {"window": "We're continuing to see that organization drive \ngreat value, which is very helpful.  As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment.  We're pleased with Clarus ONE.  It's performing as we had \nanticipated.  We think that there's still great value to be gained out of that organization.  And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "It's performing as we had \nanticipated. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e23bf6f764fb48e8388a3e44d507e3a2e184d945df21c9446cbe7b9a229a9a87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97d37524-9901-4aa8-afb8-30648651d0e5", "node_type": "1", "metadata": {"window": "We're pleased with Clarus ONE.  It's performing as we had \nanticipated.  We think that there's still great value to be gained out of that organization.  And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nOkay.  What about the relationship, then, between the buy side versus sell -side pricing? ", "original_text": "And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n "}, "hash": "3fcae90a72f530135294c32e22ad45fef9b4410ce76d4509f1b75e3221ec1e39", "class_name": "RelatedNodeInfo"}}, "text": "We think that there's still great value to be gained out of that organization. ", "start_char_idx": 746, "end_char_idx": 825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97d37524-9901-4aa8-afb8-30648651d0e5": {"__data__": {"id_": "97d37524-9901-4aa8-afb8-30648651d0e5", "embedding": null, "metadata": {"window": "We're pleased with Clarus ONE.  It's performing as we had \nanticipated.  We think that there's still great value to be gained out of that organization.  And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nOkay.  What about the relationship, then, between the buy side versus sell -side pricing? ", "original_text": "And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1d7e319-9257-4744-9286-7c0213ba0667", "node_type": "1", "metadata": {"window": "As we think about the sell -side, which is, as we've talked about now for several \nquarters, still a competitive but a stable environment.  We're pleased with Clarus ONE.  It's performing as we had \nanticipated.  We think that there's still great value to be gained out of that organization.  And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nOkay. ", "original_text": "We think that there's still great value to be gained out of that organization. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57093389f87628b02b5f904490c12705a0fdef164358bff7c027a897a2243db2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1739dd3c-db8f-44b9-9a17-4bfe52aa6fc7", "node_type": "1", "metadata": {"window": "It's performing as we had \nanticipated.  We think that there's still great value to be gained out of that organization.  And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nOkay.  What about the relationship, then, between the buy side versus sell -side pricing?  Was that consistent \nduring the quarter, or was there some slight erosion? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.  "}, "hash": "62dc89d3d22e7603fdce5902da512ffe32241613ecfe167d88b48b277a19ec5d", "class_name": "RelatedNodeInfo"}}, "text": "And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n ", "start_char_idx": 825, "end_char_idx": 951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1739dd3c-db8f-44b9-9a17-4bfe52aa6fc7": {"__data__": {"id_": "1739dd3c-db8f-44b9-9a17-4bfe52aa6fc7", "embedding": null, "metadata": {"window": "It's performing as we had \nanticipated.  We think that there's still great value to be gained out of that organization.  And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nOkay.  What about the relationship, then, between the buy side versus sell -side pricing?  Was that consistent \nduring the quarter, or was there some slight erosion? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97d37524-9901-4aa8-afb8-30648651d0e5", "node_type": "1", "metadata": {"window": "We're pleased with Clarus ONE.  It's performing as we had \nanticipated.  We think that there's still great value to be gained out of that organization.  And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nOkay.  What about the relationship, then, between the buy side versus sell -side pricing? ", "original_text": "And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8afa7c182da292cd03125a4bd7dc2d5ac353a90e5e72c6516aa06b5721cb3a54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18d089af-5cb2-4378-ac68-069541200a9f", "node_type": "1", "metadata": {"window": "We think that there's still great value to be gained out of that organization.  And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nOkay.  What about the relationship, then, between the buy side versus sell -side pricing?  Was that consistent \nduring the quarter, or was there some slight erosion?  Just curious, just a high -level comment on that . \n ", "original_text": "Q \nOkay. "}, "hash": "a3a6cad8d107cde677e272d1dce4128f50431d0a8cd47b3e26394116296dcdcb", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "start_char_idx": 951, "end_char_idx": 1265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18d089af-5cb2-4378-ac68-069541200a9f": {"__data__": {"id_": "18d089af-5cb2-4378-ac68-069541200a9f", "embedding": null, "metadata": {"window": "We think that there's still great value to be gained out of that organization.  And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nOkay.  What about the relationship, then, between the buy side versus sell -side pricing?  Was that consistent \nduring the quarter, or was there some slight erosion?  Just curious, just a high -level comment on that . \n ", "original_text": "Q \nOkay. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1739dd3c-db8f-44b9-9a17-4bfe52aa6fc7", "node_type": "1", "metadata": {"window": "It's performing as we had \nanticipated.  We think that there's still great value to be gained out of that organization.  And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nOkay.  What about the relationship, then, between the buy side versus sell -side pricing?  Was that consistent \nduring the quarter, or was there some slight erosion? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "642c69bfeb308d1cbd9a790ae8f4b7f16c03edc1332ca1f04c0e047c9aa1555a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccbc2dee-b693-44f8-b4ff-9c676df49640", "node_type": "1", "metadata": {"window": "And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nOkay.  What about the relationship, then, between the buy side versus sell -side pricing?  Was that consistent \nduring the quarter, or was there some slight erosion?  Just curious, just a high -level comment on that . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "What about the relationship, then, between the buy side versus sell -side pricing? "}, "hash": "1f16900eeb7ce5cb9340f80f60e69909faa9a58f860d0fd14474373d24600f4b", "class_name": "RelatedNodeInfo"}}, "text": "Q \nOkay. ", "start_char_idx": 1265, "end_char_idx": 1274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccbc2dee-b693-44f8-b4ff-9c676df49640": {"__data__": {"id_": "ccbc2dee-b693-44f8-b4ff-9c676df49640", "embedding": null, "metadata": {"window": "And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nOkay.  What about the relationship, then, between the buy side versus sell -side pricing?  Was that consistent \nduring the quarter, or was there some slight erosion?  Just curious, just a high -level comment on that . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "What about the relationship, then, between the buy side versus sell -side pricing? ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18d089af-5cb2-4378-ac68-069541200a9f", "node_type": "1", "metadata": {"window": "We think that there's still great value to be gained out of that organization.  And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nOkay.  What about the relationship, then, between the buy side versus sell -side pricing?  Was that consistent \nduring the quarter, or was there some slight erosion?  Just curious, just a high -level comment on that . \n ", "original_text": "Q \nOkay. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a36bdbd4b3bd6008386f544857329a24ef74d23491268120a6d33457aca1c699", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "146293cb-f77d-4d4f-9cf9-c37fe3aa87d7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nOkay.  What about the relationship, then, between the buy side versus sell -side pricing?  Was that consistent \nduring the quarter, or was there some slight erosion?  Just curious, just a high -level comment on that . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure. ", "original_text": "Was that consistent \nduring the quarter, or was there some slight erosion? "}, "hash": "3dc57cc53eb63fadd1db3b642feea5fc6b9d9038d57833303e59b08b58b6c6c0", "class_name": "RelatedNodeInfo"}}, "text": "What about the relationship, then, between the buy side versus sell -side pricing? ", "start_char_idx": 1274, "end_char_idx": 1357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "146293cb-f77d-4d4f-9cf9-c37fe3aa87d7": {"__data__": {"id_": "146293cb-f77d-4d4f-9cf9-c37fe3aa87d7", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nOkay.  What about the relationship, then, between the buy side versus sell -side pricing?  Was that consistent \nduring the quarter, or was there some slight erosion?  Just curious, just a high -level comment on that . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure. ", "original_text": "Was that consistent \nduring the quarter, or was there some slight erosion? ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccbc2dee-b693-44f8-b4ff-9c676df49640", "node_type": "1", "metadata": {"window": "And we're pleased with the \npartnership that we have with our partner Walmart as we continue in that relationship as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nOkay.  What about the relationship, then, between the buy side versus sell -side pricing?  Was that consistent \nduring the quarter, or was there some slight erosion?  Just curious, just a high -level comment on that . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "What about the relationship, then, between the buy side versus sell -side pricing? ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a2504b4acce227ab53ec0072bc2b837836ef7b4de98c3e7ba20d5b7324572d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87648df8-4091-477f-83d1-dee7f4fa08ba", "node_type": "1", "metadata": {"window": "Q \nOkay.  What about the relationship, then, between the buy side versus sell -side pricing?  Was that consistent \nduring the quarter, or was there some slight erosion?  Just curious, just a high -level comment on that . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure.  No, it's consistent. ", "original_text": "Just curious, just a high -level comment on that . \n "}, "hash": "9029897a04b16c9738d12cb598142168de2cda304811cb3a9f0aa9aeda41d0a9", "class_name": "RelatedNodeInfo"}}, "text": "Was that consistent \nduring the quarter, or was there some slight erosion? ", "start_char_idx": 1357, "end_char_idx": 1432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87648df8-4091-477f-83d1-dee7f4fa08ba": {"__data__": {"id_": "87648df8-4091-477f-83d1-dee7f4fa08ba", "embedding": null, "metadata": {"window": "Q \nOkay.  What about the relationship, then, between the buy side versus sell -side pricing?  Was that consistent \nduring the quarter, or was there some slight erosion?  Just curious, just a high -level comment on that . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure.  No, it's consistent. ", "original_text": "Just curious, just a high -level comment on that . \n ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "146293cb-f77d-4d4f-9cf9-c37fe3aa87d7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven J.  Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nOkay.  What about the relationship, then, between the buy side versus sell -side pricing?  Was that consistent \nduring the quarter, or was there some slight erosion?  Just curious, just a high -level comment on that . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure. ", "original_text": "Was that consistent \nduring the quarter, or was there some slight erosion? ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ea4128941ecc7df00f9f905201bfdc14c2287c79681661a3de069eba5e7a5ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66f9f817-9493-4b39-8d0c-031065192948", "node_type": "1", "metadata": {"window": "What about the relationship, then, between the buy side versus sell -side pricing?  Was that consistent \nduring the quarter, or was there some slight erosion?  Just curious, just a high -level comment on that . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure.  No, it's consistent.  We're seeing consistency over the last several quarters now. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "3a8be010224de81546f34fba9cee87a8c5660fe084b047bb47ada8c238c85b40", "class_name": "RelatedNodeInfo"}}, "text": "Just curious, just a high -level comment on that . \n ", "start_char_idx": 1432, "end_char_idx": 1485, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66f9f817-9493-4b39-8d0c-031065192948": {"__data__": {"id_": "66f9f817-9493-4b39-8d0c-031065192948", "embedding": null, "metadata": {"window": "What about the relationship, then, between the buy side versus sell -side pricing?  Was that consistent \nduring the quarter, or was there some slight erosion?  Just curious, just a high -level comment on that . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure.  No, it's consistent.  We're seeing consistency over the last several quarters now. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87648df8-4091-477f-83d1-dee7f4fa08ba", "node_type": "1", "metadata": {"window": "Q \nOkay.  What about the relationship, then, between the buy side versus sell -side pricing?  Was that consistent \nduring the quarter, or was there some slight erosion?  Just curious, just a high -level comment on that . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure.  No, it's consistent. ", "original_text": "Just curious, just a high -level comment on that . \n ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8c00c7788d80b6153a7c3aace6f24fd7be4706ddec2430f645794e53699e89e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5be56ab-676d-494b-9263-b1e5dc772920", "node_type": "1", "metadata": {"window": "Was that consistent \nduring the quarter, or was there some slight erosion?  Just curious, just a high -level comment on that . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure.  No, it's consistent.  We're seeing consistency over the last several quarters now.  And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n ", "original_text": "A \nYeah, sure. "}, "hash": "4cff1a35d3f3390615101321b5e56b57dd43398d42ed3856dd2c25d8a634b74e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 1485, "end_char_idx": 1830, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5be56ab-676d-494b-9263-b1e5dc772920": {"__data__": {"id_": "a5be56ab-676d-494b-9263-b1e5dc772920", "embedding": null, "metadata": {"window": "Was that consistent \nduring the quarter, or was there some slight erosion?  Just curious, just a high -level comment on that . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure.  No, it's consistent.  We're seeing consistency over the last several quarters now.  And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n ", "original_text": "A \nYeah, sure. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66f9f817-9493-4b39-8d0c-031065192948", "node_type": "1", "metadata": {"window": "What about the relationship, then, between the buy side versus sell -side pricing?  Was that consistent \nduring the quarter, or was there some slight erosion?  Just curious, just a high -level comment on that . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure.  No, it's consistent.  We're seeing consistency over the last several quarters now. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15324564c772ad2083d84eab38fb39200e847ea069dbebc12bab5e5aa8f16cbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d67b0819-6262-4438-a997-feeddb812aae", "node_type": "1", "metadata": {"window": "Just curious, just a high -level comment on that . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure.  No, it's consistent.  We're seeing consistency over the last several quarters now.  And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs. ", "original_text": "No, it's consistent. "}, "hash": "bfc2ed85cc96b6bfee39233d0dea0a581f3adedb6643f0fd1e35a3ffe684d689", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, sure. ", "start_char_idx": 1830, "end_char_idx": 1845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d67b0819-6262-4438-a997-feeddb812aae": {"__data__": {"id_": "d67b0819-6262-4438-a997-feeddb812aae", "embedding": null, "metadata": {"window": "Just curious, just a high -level comment on that . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure.  No, it's consistent.  We're seeing consistency over the last several quarters now.  And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs. ", "original_text": "No, it's consistent. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5be56ab-676d-494b-9263-b1e5dc772920", "node_type": "1", "metadata": {"window": "Was that consistent \nduring the quarter, or was there some slight erosion?  Just curious, just a high -level comment on that . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure.  No, it's consistent.  We're seeing consistency over the last several quarters now.  And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n ", "original_text": "A \nYeah, sure. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7e990a60bb1c633fd387b5a5de4947795d71bbd9d0eb4486f12795bac9d3fb69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8bdd93b-f25c-4eb8-bc08-1f1033e712cd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure.  No, it's consistent.  We're seeing consistency over the last several quarters now.  And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs.  Your line is open.  \n ", "original_text": "We're seeing consistency over the last several quarters now. "}, "hash": "22383aa768ade2b64d31335fecc33c34c1e07e64d232d1b60c705058da25b952", "class_name": "RelatedNodeInfo"}}, "text": "No, it's consistent. ", "start_char_idx": 1845, "end_char_idx": 1866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8bdd93b-f25c-4eb8-bc08-1f1033e712cd": {"__data__": {"id_": "e8bdd93b-f25c-4eb8-bc08-1f1033e712cd", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure.  No, it's consistent.  We're seeing consistency over the last several quarters now.  And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs.  Your line is open.  \n ", "original_text": "We're seeing consistency over the last several quarters now. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d67b0819-6262-4438-a997-feeddb812aae", "node_type": "1", "metadata": {"window": "Just curious, just a high -level comment on that . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure.  No, it's consistent.  We're seeing consistency over the last several quarters now.  And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs. ", "original_text": "No, it's consistent. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8229398e4ef4d1c31091d0861e2b692472f854eb151e44d4b701997da92cf198", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7fa67ef-6e05-4334-853d-7509ddbb04a4", "node_type": "1", "metadata": {"window": "A \nYeah, sure.  No, it's consistent.  We're seeing consistency over the last several quarters now.  And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n "}, "hash": "011d6a7af126f68be626b4deee16fe802e1555939c467dcc18d3c3d921433a5e", "class_name": "RelatedNodeInfo"}}, "text": "We're seeing consistency over the last several quarters now. ", "start_char_idx": 1866, "end_char_idx": 1927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7fa67ef-6e05-4334-853d-7509ddbb04a4": {"__data__": {"id_": "c7fa67ef-6e05-4334-853d-7509ddbb04a4", "embedding": null, "metadata": {"window": "A \nYeah, sure.  No, it's consistent.  We're seeing consistency over the last several quarters now.  And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8bdd93b-f25c-4eb8-bc08-1f1033e712cd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure.  No, it's consistent.  We're seeing consistency over the last several quarters now.  And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs.  Your line is open.  \n ", "original_text": "We're seeing consistency over the last several quarters now. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a9f1d254e6fa518da777204fb3586b326b21b888d9dc1fc46526e132fe7c2cb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4704b8a0-17ff-460f-ae1b-9dee6c542e19", "node_type": "1", "metadata": {"window": "No, it's consistent.  We're seeing consistency over the last several quarters now.  And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs. "}, "hash": "03ccb417f11e4bfa1d3b1d13efa9858d1aa3a4c43b34d299101b275d7d76125c", "class_name": "RelatedNodeInfo"}}, "text": "And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n ", "start_char_idx": 1927, "end_char_idx": 2119, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4704b8a0-17ff-460f-ae1b-9dee6c542e19": {"__data__": {"id_": "4704b8a0-17ff-460f-ae1b-9dee6c542e19", "embedding": null, "metadata": {"window": "No, it's consistent.  We're seeing consistency over the last several quarters now.  And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7fa67ef-6e05-4334-853d-7509ddbb04a4", "node_type": "1", "metadata": {"window": "A \nYeah, sure.  No, it's consistent.  We're seeing consistency over the last several quarters now.  And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "472978d503df77c5582897fcd4a15abd35f1c2facd7df60fc46551e7401955e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "205c5571-e7c6-4c6c-a069-75bb37bb78be", "node_type": "1", "metadata": {"window": "We're seeing consistency over the last several quarters now.  And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions. ", "original_text": "Your line is open.  \n "}, "hash": "8d02565b04aa95b6e8c04756dd4b96197ca95f015ddfce5ce0b0723b29c37ef3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs. ", "start_char_idx": 2119, "end_char_idx": 2462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "205c5571-e7c6-4c6c-a069-75bb37bb78be": {"__data__": {"id_": "205c5571-e7c6-4c6c-a069-75bb37bb78be", "embedding": null, "metadata": {"window": "We're seeing consistency over the last several quarters now.  And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions. ", "original_text": "Your line is open.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4704b8a0-17ff-460f-ae1b-9dee6c542e19", "node_type": "1", "metadata": {"window": "No, it's consistent.  We're seeing consistency over the last several quarters now.  And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b881ae53e19720170b34d5bb6b52df6fcc8d98d8fe74d76a351bd203d96a240", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b20c5bd-6556-4f16-9e5e-63da996989d4", "node_type": "1", "metadata": {"window": "And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just a couple to go back to specialty, Brian, if I could. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. "}, "hash": "ccb5aab8283785008426abfa9e4cda53b9f5860a47f185803a53eaf96ccee075", "class_name": "RelatedNodeInfo"}}, "text": "Your line is open.  \n ", "start_char_idx": 2462, "end_char_idx": 2484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b20c5bd-6556-4f16-9e5e-63da996989d4": {"__data__": {"id_": "1b20c5bd-6556-4f16-9e5e-63da996989d4", "embedding": null, "metadata": {"window": "And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just a couple to go back to specialty, Brian, if I could. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "205c5571-e7c6-4c6c-a069-75bb37bb78be", "node_type": "1", "metadata": {"window": "We're seeing consistency over the last several quarters now.  And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions. ", "original_text": "Your line is open.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8878e5474f3a3fbd825fcf6e6778a05bc62d96ec031adbe315a677f74503843e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3453872-29db-4824-86a4-f3c4c1631b7c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just a couple to go back to specialty, Brian, if I could.  You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there . ", "original_text": "LLC  Q \nGreat. "}, "hash": "3aa3eeba25d8ea0645f45838afee73db6296ba71ce6b7c02d413db19d48f1d5a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "start_char_idx": 2484, "end_char_idx": 2788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3453872-29db-4824-86a4-f3c4c1631b7c": {"__data__": {"id_": "c3453872-29db-4824-86a4-f3c4c1631b7c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just a couple to go back to specialty, Brian, if I could.  You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there . ", "original_text": "LLC  Q \nGreat. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b20c5bd-6556-4f16-9e5e-63da996989d4", "node_type": "1", "metadata": {"window": "And, again, a good \nperformance on ClarusONE and a stable competitive e nvironment on the sell side, and that's in line with our \nexpectations and what we've seen now for several quarters.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just a couple to go back to specialty, Brian, if I could. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15681e3f55ef4d7f2745faddd381341ddf07d09f72e398a67ea1a8dbf77ca671", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27dc5df4-3d11-4a67-98af-632629374ac5", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just a couple to go back to specialty, Brian, if I could.  You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there .  And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically. ", "original_text": "Thanks for the questions. "}, "hash": "bc325caa0312ab519bc7670e2778d59539eac5f5d5ccf516b9b532324234f45d", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nGreat. ", "start_char_idx": 2788, "end_char_idx": 2803, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27dc5df4-3d11-4a67-98af-632629374ac5": {"__data__": {"id_": "27dc5df4-3d11-4a67-98af-632629374ac5", "embedding": null, "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just a couple to go back to specialty, Brian, if I could.  You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there .  And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically. ", "original_text": "Thanks for the questions. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3453872-29db-4824-86a4-f3c4c1631b7c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Bob Jones of Goldman Sachs.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just a couple to go back to specialty, Brian, if I could.  You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there . ", "original_text": "LLC  Q \nGreat. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "435bd9b0497388db85fd0c789a90acf1dd9d1c74174aad12acaf60c97a4b5807", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6449bfe2-fe34-42aa-b314-e2df073dc406", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just a couple to go back to specialty, Brian, if I could.  You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there .  And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically.  But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter. ", "original_text": "I guess just a couple to go back to specialty, Brian, if I could. "}, "hash": "09fe59543ac808d7db415bc02bcdf1a668d1d9a17e0f425dee7f593b99b9f2c8", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the questions. ", "start_char_idx": 2803, "end_char_idx": 2829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6449bfe2-fe34-42aa-b314-e2df073dc406": {"__data__": {"id_": "6449bfe2-fe34-42aa-b314-e2df073dc406", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just a couple to go back to specialty, Brian, if I could.  You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there .  And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically.  But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter. ", "original_text": "I guess just a couple to go back to specialty, Brian, if I could. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27dc5df4-3d11-4a67-98af-632629374ac5", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just a couple to go back to specialty, Brian, if I could.  You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there .  And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically. ", "original_text": "Thanks for the questions. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "699110db323cbdb8cc934c8361b1144bff4d657e2944fe126ba7b3945ebf4ee8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e717e525-0c11-40db-a715-34661bd5bb35", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat.  Thanks for the questions.  I guess just a couple to go back to specialty, Brian, if I could.  You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there .  And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically.  But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter.  I t just sounds like there's a lot of secular tailwinds there. ", "original_text": "You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there . "}, "hash": "20e0e2b4521599aa3593e3c42354cf5cb5f651c27b63ee7f5e676097d11569e5", "class_name": "RelatedNodeInfo"}}, "text": "I guess just a couple to go back to specialty, Brian, if I could. ", "start_char_idx": 2829, "end_char_idx": 2895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e717e525-0c11-40db-a715-34661bd5bb35": {"__data__": {"id_": "e717e525-0c11-40db-a715-34661bd5bb35", "embedding": null, "metadata": {"window": "LLC  Q \nGreat.  Thanks for the questions.  I guess just a couple to go back to specialty, Brian, if I could.  You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there .  And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically.  But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter.  I t just sounds like there's a lot of secular tailwinds there. ", "original_text": "You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there . ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6449bfe2-fe34-42aa-b314-e2df073dc406", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just a couple to go back to specialty, Brian, if I could.  You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there .  And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically.  But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter. ", "original_text": "I guess just a couple to go back to specialty, Brian, if I could. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a9a9db37d57eb6e0946a78d45a1e5ede9ba3d01d80cec0d404f66a64bf418ce5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e032aa65-4c98-464a-aecb-e0d1bfd8cc5b", "node_type": "1", "metadata": {"window": "Thanks for the questions.  I guess just a couple to go back to specialty, Brian, if I could.  You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there .  And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically.  But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter.  I t just sounds like there's a lot of secular tailwinds there.  So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n ", "original_text": "And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically. "}, "hash": "7ef9b5642cab08ba3a156fa567d5d7f637dc6703521c32e26331a5a5240b18c0", "class_name": "RelatedNodeInfo"}}, "text": "You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there . ", "start_char_idx": 2895, "end_char_idx": 3038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e032aa65-4c98-464a-aecb-e0d1bfd8cc5b": {"__data__": {"id_": "e032aa65-4c98-464a-aecb-e0d1bfd8cc5b", "embedding": null, "metadata": {"window": "Thanks for the questions.  I guess just a couple to go back to specialty, Brian, if I could.  You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there .  And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically.  But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter.  I t just sounds like there's a lot of secular tailwinds there.  So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n ", "original_text": "And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e717e525-0c11-40db-a715-34661bd5bb35", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat.  Thanks for the questions.  I guess just a couple to go back to specialty, Brian, if I could.  You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there .  And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically.  But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter.  I t just sounds like there's a lot of secular tailwinds there. ", "original_text": "You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there . ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "62300dc6926cc61569f704c9c326f518b87d0e60cf079e681654b39b8b26e98a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65c4973a-8360-4bc0-b87e-b0988e0d1712", "node_type": "1", "metadata": {"window": "I guess just a couple to go back to specialty, Brian, if I could.  You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there .  And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically.  But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter.  I t just sounds like there's a lot of secular tailwinds there.  So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter. "}, "hash": "a6352a31db4c29e3454441a7da47925064410d1e25ae533feb1cc48230a2d827", "class_name": "RelatedNodeInfo"}}, "text": "And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically. ", "start_char_idx": 3038, "end_char_idx": 3164, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65c4973a-8360-4bc0-b87e-b0988e0d1712": {"__data__": {"id_": "65c4973a-8360-4bc0-b87e-b0988e0d1712", "embedding": null, "metadata": {"window": "I guess just a couple to go back to specialty, Brian, if I could.  You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there .  And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically.  But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter.  I t just sounds like there's a lot of secular tailwinds there.  So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e032aa65-4c98-464a-aecb-e0d1bfd8cc5b", "node_type": "1", "metadata": {"window": "Thanks for the questions.  I guess just a couple to go back to specialty, Brian, if I could.  You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there .  And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically.  But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter.  I t just sounds like there's a lot of secular tailwinds there.  So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n ", "original_text": "And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2eee0174ddf5507880dab15c0283463203bc2d6df9d32798fa3bc7200c6b8d3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8e1f858-2679-4189-a58c-3f9d6639ab04", "node_type": "1", "metadata": {"window": "You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there .  And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically.  But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter.  I t just sounds like there's a lot of secular tailwinds there.  So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great. ", "original_text": "I t just sounds like there's a lot of secular tailwinds there. "}, "hash": "c820d623b14fbfaca116c82a7ff6fb9c2b63f4a8501ea88e00269baadd02e90b", "class_name": "RelatedNodeInfo"}}, "text": "But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter. ", "start_char_idx": 3164, "end_char_idx": 3293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8e1f858-2679-4189-a58c-3f9d6639ab04": {"__data__": {"id_": "e8e1f858-2679-4189-a58c-3f9d6639ab04", "embedding": null, "metadata": {"window": "You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there .  And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically.  But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter.  I t just sounds like there's a lot of secular tailwinds there.  So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great. ", "original_text": "I t just sounds like there's a lot of secular tailwinds there. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65c4973a-8360-4bc0-b87e-b0988e0d1712", "node_type": "1", "metadata": {"window": "I guess just a couple to go back to specialty, Brian, if I could.  You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there .  And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically.  But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter.  I t just sounds like there's a lot of secular tailwinds there.  So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f32aa5448b8b9f524ec5da6aaafe9f50d768fceb043ec4998aab0cbf1a6089f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26071d12-2810-4918-9ab6-385f91a42e10", "node_type": "1", "metadata": {"window": "And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically.  But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter.  I t just sounds like there's a lot of secular tailwinds there.  So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great.  Thank you. ", "original_text": "So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n "}, "hash": "0e714cdb2060c0b2fcbd28b616d14fab1435d89b5d4001b43008c8269f9ee8c4", "class_name": "RelatedNodeInfo"}}, "text": "I t just sounds like there's a lot of secular tailwinds there. ", "start_char_idx": 3293, "end_char_idx": 3356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26071d12-2810-4918-9ab6-385f91a42e10": {"__data__": {"id_": "26071d12-2810-4918-9ab6-385f91a42e10", "embedding": null, "metadata": {"window": "And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically.  But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter.  I t just sounds like there's a lot of secular tailwinds there.  So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great.  Thank you. ", "original_text": "So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8e1f858-2679-4189-a58c-3f9d6639ab04", "node_type": "1", "metadata": {"window": "You discussed the \nthree main areas within specialty, and it sounds like generally very pleased with the performance across the \nboard there .  And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically.  But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter.  I t just sounds like there's a lot of secular tailwinds there.  So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great. ", "original_text": "I t just sounds like there's a lot of secular tailwinds there. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b1f48efd0a1025f3f5dc19d815c6cfef977f175d5908a2b9b74beffbb1b3b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56eacc46-1598-4394-93c9-9d399818de69", "node_type": "1", "metadata": {"window": "But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter.  I t just sounds like there's a lot of secular tailwinds there.  So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great.  Thank you.  And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "af7f42de6240096b836b4d85606e094649d6b3116f88d14a2158a2c5388b5d45", "class_name": "RelatedNodeInfo"}}, "text": "So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n ", "start_char_idx": 3356, "end_char_idx": 3566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56eacc46-1598-4394-93c9-9d399818de69": {"__data__": {"id_": "56eacc46-1598-4394-93c9-9d399818de69", "embedding": null, "metadata": {"window": "But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter.  I t just sounds like there's a lot of secular tailwinds there.  So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great.  Thank you.  And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26071d12-2810-4918-9ab6-385f91a42e10", "node_type": "1", "metadata": {"window": "And I think most of us get the mix dynamic that you guys have discussed within specialty pharmacy \nand Caremark specifically.  But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter.  I t just sounds like there's a lot of secular tailwinds there.  So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great.  Thank you. ", "original_text": "So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3324ca8e0bc49f9326cef1349ea33a413f69ab4cb64f5525ea66cf25735a39fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef3d089d-2139-42bb-a147-90a18542b9f4", "node_type": "1", "metadata": {"window": "I t just sounds like there's a lot of secular tailwinds there.  So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great.  Thank you.  And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment.  And if you think about the three segments we highlighted, they are all performing very well. \n", "original_text": "A \nYeah, great. "}, "hash": "cae716581170bb6def28762ba050bae6e21927e5d3622c7960c7c626a8185958", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 3566, "end_char_idx": 3892, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef3d089d-2139-42bb-a147-90a18542b9f4": {"__data__": {"id_": "ef3d089d-2139-42bb-a147-90a18542b9f4", "embedding": null, "metadata": {"window": "I t just sounds like there's a lot of secular tailwinds there.  So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great.  Thank you.  And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment.  And if you think about the three segments we highlighted, they are all performing very well. \n", "original_text": "A \nYeah, great. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56eacc46-1598-4394-93c9-9d399818de69", "node_type": "1", "metadata": {"window": "But I guess if we take a step back, the operating profit for the overall pharma and \nspecialty segment was up 1% in the quarter.  I t just sounds like there's a lot of secular tailwinds there.  So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great.  Thank you.  And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bea9e7c2d1a32b41efd507e48aa1c90ca5028e671661e8fb574a513730c8647", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88034bc9-4f52-4057-8a4a-28c9b495e433", "node_type": "1", "metadata": {"window": "So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great.  Thank you.  And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment.  And if you think about the three segments we highlighted, they are all performing very well. \n And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n", "original_text": "Thank you. "}, "hash": "d9a263dc92fbc4757c7b1985512e15584f13b690b1754e370ae77014b4eee322", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, great. ", "start_char_idx": 3892, "end_char_idx": 3908, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88034bc9-4f52-4057-8a4a-28c9b495e433": {"__data__": {"id_": "88034bc9-4f52-4057-8a4a-28c9b495e433", "embedding": null, "metadata": {"window": "So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great.  Thank you.  And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment.  And if you think about the three segments we highlighted, they are all performing very well. \n And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n", "original_text": "Thank you. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef3d089d-2139-42bb-a147-90a18542b9f4", "node_type": "1", "metadata": {"window": "I t just sounds like there's a lot of secular tailwinds there.  So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great.  Thank you.  And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment.  And if you think about the three segments we highlighted, they are all performing very well. \n", "original_text": "A \nYeah, great. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eecd7d8feabb82905ff4d744d6ccded90b655be0d89d18266d1516dcfd0281ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3722800f-64a8-4205-96b7-7b69638f9e49", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great.  Thank you.  And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment.  And if you think about the three segments we highlighted, they are all performing very well. \n And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n And so those businesses are continuing to perform well. ", "original_text": "And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment. "}, "hash": "d0cb7f077e24d6f719bfe172788d99a694dc202f278bd94d098212b10da9ffd2", "class_name": "RelatedNodeInfo"}}, "text": "Thank you. ", "start_char_idx": 3908, "end_char_idx": 3919, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3722800f-64a8-4205-96b7-7b69638f9e49": {"__data__": {"id_": "3722800f-64a8-4205-96b7-7b69638f9e49", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great.  Thank you.  And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment.  And if you think about the three segments we highlighted, they are all performing very well. \n And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n And so those businesses are continuing to perform well. ", "original_text": "And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88034bc9-4f52-4057-8a4a-28c9b495e433", "node_type": "1", "metadata": {"window": "So I guess \njust wondering if you could shed a little bit more light on how you think about overall EBIT growth as it relates \nspecifically to what seems like some pretty strong tailwinds within sp ecialty.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great.  Thank you.  And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment.  And if you think about the three segments we highlighted, they are all performing very well. \n And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n", "original_text": "Thank you. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b2505155164f30d11ce3d5aaa0d258d98c443d335a2b3f9e8ba08ac64d2f2d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8907b920-8711-4188-8fd3-b9ba5fa8d954", "node_type": "1", "metadata": {"window": "A \nYeah, great.  Thank you.  And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment.  And if you think about the three segments we highlighted, they are all performing very well. \n And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n And so those businesses are continuing to perform well.  They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty. ", "original_text": "And if you think about the three segments we highlighted, they are all performing very well. \n"}, "hash": "7a5ed86ee978fc38e7e9d024796da043515c635c47d8fab986d88a403519280a", "class_name": "RelatedNodeInfo"}}, "text": "And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment. ", "start_char_idx": 3919, "end_char_idx": 4137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8907b920-8711-4188-8fd3-b9ba5fa8d954": {"__data__": {"id_": "8907b920-8711-4188-8fd3-b9ba5fa8d954", "embedding": null, "metadata": {"window": "A \nYeah, great.  Thank you.  And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment.  And if you think about the three segments we highlighted, they are all performing very well. \n And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n And so those businesses are continuing to perform well.  They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty. ", "original_text": "And if you think about the three segments we highlighted, they are all performing very well. \n", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3722800f-64a8-4205-96b7-7b69638f9e49", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, great.  Thank you.  And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment.  And if you think about the three segments we highlighted, they are all performing very well. \n And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n And so those businesses are continuing to perform well. ", "original_text": "And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d1be6644af1e32395b3538c6568c99bdcf3331340a9043ea653f1492555d093", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed8b58fb-46e3-4f70-bf6e-c7743f32c0ca", "node_type": "1", "metadata": {"window": "Thank you.  And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment.  And if you think about the three segments we highlighted, they are all performing very well. \n And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n And so those businesses are continuing to perform well.  They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty.  It is \nthe more retail, mail -order oriented specialty products, and Britt talked a lot about the impact we've seen of the \ngrowth in the Caremark book of business that has been \u2013 the mix has been slanted t owards those specialty \nproducts, which tends to be the lower margin profile for us. ", "original_text": "And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n"}, "hash": "0ac6d6d0bbacc61843ffa0a324c66798b8bf4eb46c619f89f6debe57db3f3ea6", "class_name": "RelatedNodeInfo"}}, "text": "And if you think about the three segments we highlighted, they are all performing very well. \n", "start_char_idx": 4137, "end_char_idx": 4231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed8b58fb-46e3-4f70-bf6e-c7743f32c0ca": {"__data__": {"id_": "ed8b58fb-46e3-4f70-bf6e-c7743f32c0ca", "embedding": null, "metadata": {"window": "Thank you.  And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment.  And if you think about the three segments we highlighted, they are all performing very well. \n And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n And so those businesses are continuing to perform well.  They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty.  It is \nthe more retail, mail -order oriented specialty products, and Britt talked a lot about the impact we've seen of the \ngrowth in the Caremark book of business that has been \u2013 the mix has been slanted t owards those specialty \nproducts, which tends to be the lower margin profile for us. ", "original_text": "And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8907b920-8711-4188-8fd3-b9ba5fa8d954", "node_type": "1", "metadata": {"window": "A \nYeah, great.  Thank you.  And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment.  And if you think about the three segments we highlighted, they are all performing very well. \n And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n And so those businesses are continuing to perform well.  They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty. ", "original_text": "And if you think about the three segments we highlighted, they are all performing very well. \n", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d410158c8d3c6e560f468bb230fdc9ccd86371bdc49b97bf940a94c4d994bdf5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa9dbfef-cdd5-436f-a382-fdc3fe000ec6", "node_type": "1", "metadata": {"window": "And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment.  And if you think about the three segments we highlighted, they are all performing very well. \n And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n And so those businesses are continuing to perform well.  They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty.  It is \nthe more retail, mail -order oriented specialty products, and Britt talked a lot about the impact we've seen of the \ngrowth in the Caremark book of business that has been \u2013 the mix has been slanted t owards those specialty \nproducts, which tends to be the lower margin profile for us.  So when you net all that all out, that's how you get to \nthe results that you're seeing today.  ", "original_text": "And so those businesses are continuing to perform well. "}, "hash": "23e8d1a8886ea6132decd942bf986b0d55b7b648e33136939220a9b3f76c6d13", "class_name": "RelatedNodeInfo"}}, "text": "And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n", "start_char_idx": 4231, "end_char_idx": 4421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa9dbfef-cdd5-436f-a382-fdc3fe000ec6": {"__data__": {"id_": "fa9dbfef-cdd5-436f-a382-fdc3fe000ec6", "embedding": null, "metadata": {"window": "And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment.  And if you think about the three segments we highlighted, they are all performing very well. \n And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n And so those businesses are continuing to perform well.  They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty.  It is \nthe more retail, mail -order oriented specialty products, and Britt talked a lot about the impact we've seen of the \ngrowth in the Caremark book of business that has been \u2013 the mix has been slanted t owards those specialty \nproducts, which tends to be the lower margin profile for us.  So when you net all that all out, that's how you get to \nthe results that you're seeing today.  ", "original_text": "And so those businesses are continuing to perform well. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed8b58fb-46e3-4f70-bf6e-c7743f32c0ca", "node_type": "1", "metadata": {"window": "Thank you.  And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment.  And if you think about the three segments we highlighted, they are all performing very well. \n And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n And so those businesses are continuing to perform well.  They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty.  It is \nthe more retail, mail -order oriented specialty products, and Britt talked a lot about the impact we've seen of the \ngrowth in the Caremark book of business that has been \u2013 the mix has been slanted t owards those specialty \nproducts, which tends to be the lower margin profile for us. ", "original_text": "And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "072210278cad000b384e7e7b36f97c3226f3e9eba0f7ad7cd6bbae896bbf3610", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30cf5c4f-791c-4382-8129-c6ccee4c7d3e", "node_type": "1", "metadata": {"window": "And if you think about the three segments we highlighted, they are all performing very well. \n And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n And so those businesses are continuing to perform well.  They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty.  It is \nthe more retail, mail -order oriented specialty products, and Britt talked a lot about the impact we've seen of the \ngrowth in the Caremark book of business that has been \u2013 the mix has been slanted t owards those specialty \nproducts, which tends to be the lower margin profile for us.  So when you net all that all out, that's how you get to \nthe results that you're seeing today.  ", "original_text": "They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty. "}, "hash": "9e0383e6c55bf0cd97603d5ea196f3717c8a20855319fd273c4c7c2917d6173b", "class_name": "RelatedNodeInfo"}}, "text": "And so those businesses are continuing to perform well. ", "start_char_idx": 4421, "end_char_idx": 4477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30cf5c4f-791c-4382-8129-c6ccee4c7d3e": {"__data__": {"id_": "30cf5c4f-791c-4382-8129-c6ccee4c7d3e", "embedding": null, "metadata": {"window": "And if you think about the three segments we highlighted, they are all performing very well. \n And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n And so those businesses are continuing to perform well.  They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty.  It is \nthe more retail, mail -order oriented specialty products, and Britt talked a lot about the impact we've seen of the \ngrowth in the Caremark book of business that has been \u2013 the mix has been slanted t owards those specialty \nproducts, which tends to be the lower margin profile for us.  So when you net all that all out, that's how you get to \nthe results that you're seeing today.  ", "original_text": "They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa9dbfef-cdd5-436f-a382-fdc3fe000ec6", "node_type": "1", "metadata": {"window": "And we reflected on the questions we've had over the last few quarters, and that's why \nwe included a little more description or color on the specialty businesses that we have in the Pharmaceutical \nSolutions segment.  And if you think about the three segments we highlighted, they are all performing very well. \n And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n And so those businesses are continuing to perform well.  They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty.  It is \nthe more retail, mail -order oriented specialty products, and Britt talked a lot about the impact we've seen of the \ngrowth in the Caremark book of business that has been \u2013 the mix has been slanted t owards those specialty \nproducts, which tends to be the lower margin profile for us.  So when you net all that all out, that's how you get to \nthe results that you're seeing today.  ", "original_text": "And so those businesses are continuing to perform well. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e976e934630a90bb7b1430aca2abd504e87179992b89f4b5fd8234e870356c33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d87de445-690e-4506-8acc-2dd1d2a0b55e", "node_type": "1", "metadata": {"window": "And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n And so those businesses are continuing to perform well.  They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty.  It is \nthe more retail, mail -order oriented specialty products, and Britt talked a lot about the impact we've seen of the \ngrowth in the Caremark book of business that has been \u2013 the mix has been slanted t owards those specialty \nproducts, which tends to be the lower margin profile for us.  So when you net all that all out, that's how you get to \nthe results that you're seeing today.  ", "original_text": "It is \nthe more retail, mail -order oriented specialty products, and Britt talked a lot about the impact we've seen of the \ngrowth in the Caremark book of business that has been \u2013 the mix has been slanted t owards those specialty \nproducts, which tends to be the lower margin profile for us. "}, "hash": "5b243984c102a739408f388c35c33a43acbc46e2707dd07e9f36e2c071a546f4", "class_name": "RelatedNodeInfo"}}, "text": "They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty. ", "start_char_idx": 4477, "end_char_idx": 4645, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d87de445-690e-4506-8acc-2dd1d2a0b55e": {"__data__": {"id_": "d87de445-690e-4506-8acc-2dd1d2a0b55e", "embedding": null, "metadata": {"window": "And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n And so those businesses are continuing to perform well.  They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty.  It is \nthe more retail, mail -order oriented specialty products, and Britt talked a lot about the impact we've seen of the \ngrowth in the Caremark book of business that has been \u2013 the mix has been slanted t owards those specialty \nproducts, which tends to be the lower margin profile for us.  So when you net all that all out, that's how you get to \nthe results that you're seeing today.  ", "original_text": "It is \nthe more retail, mail -order oriented specialty products, and Britt talked a lot about the impact we've seen of the \ngrowth in the Caremark book of business that has been \u2013 the mix has been slanted t owards those specialty \nproducts, which tends to be the lower margin profile for us. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30cf5c4f-791c-4382-8129-c6ccee4c7d3e", "node_type": "1", "metadata": {"window": "And if you think about the three segments we highlighted, they are all performing very well. \n And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n And so those businesses are continuing to perform well.  They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty.  It is \nthe more retail, mail -order oriented specialty products, and Britt talked a lot about the impact we've seen of the \ngrowth in the Caremark book of business that has been \u2013 the mix has been slanted t owards those specialty \nproducts, which tends to be the lower margin profile for us.  So when you net all that all out, that's how you get to \nthe results that you're seeing today.  ", "original_text": "They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0fb1d4cc012e9272dee10b258815acb04e14ab031b04c26762037e1eb4df0869", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38651076-8702-4bb1-ba4a-a63d0fa84fda", "node_type": "1", "metadata": {"window": "And so those businesses are continuing to perform well.  They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty.  It is \nthe more retail, mail -order oriented specialty products, and Britt talked a lot about the impact we've seen of the \ngrowth in the Caremark book of business that has been \u2013 the mix has been slanted t owards those specialty \nproducts, which tends to be the lower margin profile for us.  So when you net all that all out, that's how you get to \nthe results that you're seeing today.  ", "original_text": "So when you net all that all out, that's how you get to \nthe results that you're seeing today.  "}, "hash": "905750153db88a53a932cce98617b0fc1f2dd3a21e2530a2a2eb87977c7646f0", "class_name": "RelatedNodeInfo"}}, "text": "It is \nthe more retail, mail -order oriented specialty products, and Britt talked a lot about the impact we've seen of the \ngrowth in the Caremark book of business that has been \u2013 the mix has been slanted t owards those specialty \nproducts, which tends to be the lower margin profile for us. ", "start_char_idx": 4645, "end_char_idx": 4937, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38651076-8702-4bb1-ba4a-a63d0fa84fda": {"__data__": {"id_": "38651076-8702-4bb1-ba4a-a63d0fa84fda", "embedding": null, "metadata": {"window": "And so those businesses are continuing to perform well.  They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty.  It is \nthe more retail, mail -order oriented specialty products, and Britt talked a lot about the impact we've seen of the \ngrowth in the Caremark book of business that has been \u2013 the mix has been slanted t owards those specialty \nproducts, which tends to be the lower margin profile for us.  So when you net all that all out, that's how you get to \nthe results that you're seeing today.  ", "original_text": "So when you net all that all out, that's how you get to \nthe results that you're seeing today.  ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e815b9242e0305dc8aba9c1ee545577766f73ba1f9f5b905bbb22cced94dfbfc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d87de445-690e-4506-8acc-2dd1d2a0b55e", "node_type": "1", "metadata": {"window": "And we think in all cases, we have assets that are not only competitive with the market, but proba bly one of the \nmost robust set of solutions and services when taken in the aggregate.  \n \n And so those businesses are continuing to perform well.  They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty.  It is \nthe more retail, mail -order oriented specialty products, and Britt talked a lot about the impact we've seen of the \ngrowth in the Caremark book of business that has been \u2013 the mix has been slanted t owards those specialty \nproducts, which tends to be the lower margin profile for us.  So when you net all that all out, that's how you get to \nthe results that you're seeing today.  ", "original_text": "It is \nthe more retail, mail -order oriented specialty products, and Britt talked a lot about the impact we've seen of the \ngrowth in the Caremark book of business that has been \u2013 the mix has been slanted t owards those specialty \nproducts, which tends to be the lower margin profile for us. ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a10521c294a7be841c72ceecb2e5ca1222d005d21b2b5ad9c47b90368a1f466", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "202187bb-3bb1-4f4c-9529-52fb5100b9ba", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt.  I mean, just to maybe understand that a little bit better. ", "original_text": "McKesson Corp.  "}, "hash": "9603f68c0d1063f57f2a5acfdd4f1899dac80f97c1d8cd10b06bbdb3d930f339", "class_name": "RelatedNodeInfo"}}, "text": "So when you net all that all out, that's how you get to \nthe results that you're seeing today.  ", "start_char_idx": 4937, "end_char_idx": 5033, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "202187bb-3bb1-4f4c-9529-52fb5100b9ba": {"__data__": {"id_": "202187bb-3bb1-4f4c-9529-52fb5100b9ba", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt.  I mean, just to maybe understand that a little bit better. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38651076-8702-4bb1-ba4a-a63d0fa84fda", "node_type": "1", "metadata": {"window": "And so those businesses are continuing to perform well.  They're delivering good growth, and they're performing \nright in line with where we thought they would for the yea r. Obviously, there is another segment in specialty.  It is \nthe more retail, mail -order oriented specialty products, and Britt talked a lot about the impact we've seen of the \ngrowth in the Caremark book of business that has been \u2013 the mix has been slanted t owards those specialty \nproducts, which tends to be the lower margin profile for us.  So when you net all that all out, that's how you get to \nthe results that you're seeing today.  ", "original_text": "So when you net all that all out, that's how you get to \nthe results that you're seeing today.  ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "abd6c7ba0294da2613bf27b0b184aeec6e38a17ab2371f9e1197ae9b40292546", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52f14eca-6e8d-4cd8-b906-0a8417eb0088", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt.  I mean, just to maybe understand that a little bit better.  I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. "}, "hash": "b6f849021db143b298d3209b8ad4382def4a749bd2afad977403957b33f292e8", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52f14eca-6e8d-4cd8-b906-0a8417eb0088": {"__data__": {"id_": "52f14eca-6e8d-4cd8-b906-0a8417eb0088", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt.  I mean, just to maybe understand that a little bit better.  I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "202187bb-3bb1-4f4c-9529-52fb5100b9ba", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt.  I mean, just to maybe understand that a little bit better. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ac378560e8ed931b2aa631ea5196a0960724e3c1319192242c61e95c88606efd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6081764d-4cc0-4565-844f-21bc33228e2c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt.  I mean, just to maybe understand that a little bit better.  I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say.  And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n", "original_text": "LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt. "}, "hash": "8ad6acc346ca6c1f210647e3b2f786b57a3036435acca31ce0bb495187a676a4", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "start_char_idx": 16, "end_char_idx": 228, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6081764d-4cc0-4565-844f-21bc33228e2c": {"__data__": {"id_": "6081764d-4cc0-4565-844f-21bc33228e2c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt.  I mean, just to maybe understand that a little bit better.  I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say.  And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n", "original_text": "LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52f14eca-6e8d-4cd8-b906-0a8417eb0088", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt.  I mean, just to maybe understand that a little bit better.  I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ff5bac9f6a144b990eeccfbdffcbaf722c6b007ac4bf06760002bdf3857ac1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27b1eee7-e7aa-4b2c-9ac5-96a2e7b027e3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt.  I mean, just to maybe understand that a little bit better.  I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say.  And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n Thanks.  \n ", "original_text": "I mean, just to maybe understand that a little bit better. "}, "hash": "b2be4f39edb764e4aa0d350767178cf179ad08c4bf9f9c2e87eb14dab24ef703", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt. ", "start_char_idx": 228, "end_char_idx": 294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27b1eee7-e7aa-4b2c-9ac5-96a2e7b027e3": {"__data__": {"id_": "27b1eee7-e7aa-4b2c-9ac5-96a2e7b027e3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt.  I mean, just to maybe understand that a little bit better.  I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say.  And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n Thanks.  \n ", "original_text": "I mean, just to maybe understand that a little bit better. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6081764d-4cc0-4565-844f-21bc33228e2c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt.  I mean, just to maybe understand that a little bit better.  I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say.  And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n", "original_text": "LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7da52c64d1f044c2c0b8473ac04aa055a8037997c90a3ca821ec9b00e50eb895", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ef16751-2ac7-4635-ae39-745866787c3b", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt.  I mean, just to maybe understand that a little bit better.  I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say.  And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say. "}, "hash": "9ba3e7b9e243b4beb36e10fa7165afe6785b527b1a1b65ad5b369382086fe959", "class_name": "RelatedNodeInfo"}}, "text": "I mean, just to maybe understand that a little bit better. ", "start_char_idx": 294, "end_char_idx": 353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ef16751-2ac7-4635-ae39-745866787c3b": {"__data__": {"id_": "4ef16751-2ac7-4635-ae39-745866787c3b", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt.  I mean, just to maybe understand that a little bit better.  I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say.  And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27b1eee7-e7aa-4b2c-9ac5-96a2e7b027e3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt.  I mean, just to maybe understand that a little bit better.  I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say.  And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n Thanks.  \n ", "original_text": "I mean, just to maybe understand that a little bit better. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "61d39b73057634241d0738d3dbebf5b86fe19b90e223d022f74b22897df03de2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02ff784d-455e-4165-a4cd-6a8b7ae61d4d", "node_type": "1", "metadata": {"window": "LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt.  I mean, just to maybe understand that a little bit better.  I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say.  And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n"}, "hash": "af14c31f0141b43960b707697092614827657f0bbd4b60ff7fe1f945ed00ca71", "class_name": "RelatedNodeInfo"}}, "text": "I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say. ", "start_char_idx": 353, "end_char_idx": 485, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02ff784d-455e-4165-a4cd-6a8b7ae61d4d": {"__data__": {"id_": "02ff784d-455e-4165-a4cd-6a8b7ae61d4d", "embedding": null, "metadata": {"window": "LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt.  I mean, just to maybe understand that a little bit better.  I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say.  And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ef16751-2ac7-4635-ae39-745866787c3b", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt.  I mean, just to maybe understand that a little bit better.  I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say.  And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4281694ed3f940e5c5cd5b027040593bba37a4fdbccd1c54a886e61e9a731f93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8775781e-ab0e-49a7-9e00-9c4df1a07797", "node_type": "1", "metadata": {"window": "I mean, just to maybe understand that a little bit better.  I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say.  And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate. ", "original_text": "Thanks.  \n "}, "hash": "974089ca80e3b7f845fd19f5e278afda2fe6ea39d032a1e5b9ab95c4e96bce64", "class_name": "RelatedNodeInfo"}}, "text": "And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n", "start_char_idx": 485, "end_char_idx": 696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8775781e-ab0e-49a7-9e00-9c4df1a07797": {"__data__": {"id_": "8775781e-ab0e-49a7-9e00-9c4df1a07797", "embedding": null, "metadata": {"window": "I mean, just to maybe understand that a little bit better.  I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say.  And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate. ", "original_text": "Thanks.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02ff784d-455e-4165-a4cd-6a8b7ae61d4d", "node_type": "1", "metadata": {"window": "LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt.  I mean, just to maybe understand that a little bit better.  I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say.  And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01cc54786295fff210265082532f5dd65396081980769b1f5c9781fabcae2b7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f6149c4-7f97-41b9-8ef6-049423305406", "node_type": "1", "metadata": {"window": "I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say.  And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate.  We still participate in the profit dollars. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "3545e4658e2df6222d7c389395e0d41b7aa950d21e6d0c0e9a77cfa9e8a12a32", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 696, "end_char_idx": 707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f6149c4-7f97-41b9-8ef6-049423305406": {"__data__": {"id_": "4f6149c4-7f97-41b9-8ef6-049423305406", "embedding": null, "metadata": {"window": "I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say.  And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate.  We still participate in the profit dollars. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8775781e-ab0e-49a7-9e00-9c4df1a07797", "node_type": "1", "metadata": {"window": "I mean, just to maybe understand that a little bit better.  I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say.  And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate. ", "original_text": "Thanks.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "181a12920209a60f44a060862ddb95061cc6b1cd263385d3f01818243876d822", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "662c69bf-31ec-403f-a01e-b5ef7f321490", "node_type": "1", "metadata": {"window": "And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate.  We still participate in the profit dollars.  It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth. ", "original_text": "A \nYeah. "}, "hash": "2369592a720f28ab97648980e2441be8be07a3aa3114a04e73609ed7f346bff1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 707, "end_char_idx": 1052, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "662c69bf-31ec-403f-a01e-b5ef7f321490": {"__data__": {"id_": "662c69bf-31ec-403f-a01e-b5ef7f321490", "embedding": null, "metadata": {"window": "And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate.  We still participate in the profit dollars.  It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth. ", "original_text": "A \nYeah. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f6149c4-7f97-41b9-8ef6-049423305406", "node_type": "1", "metadata": {"window": "I \nmean, these kind of outsized growth within Caremark products, I mean these aren't margin or EBIT dilutive, I \nguess I would say.  And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate.  We still participate in the profit dollars. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "314cd4c2ca183abb38a55699cf889c2f9b62b86b61efee3630ed0e42ee935e69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c15150c9-cb32-411b-bc48-691b2fc2483c", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate.  We still participate in the profit dollars.  It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth.  As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services. ", "original_text": "As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate. "}, "hash": "bfcbba7081cfc6040ad93bb7973cc5de5a4fa2df905c464e9a76019b308597fa", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 1052, "end_char_idx": 1061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c15150c9-cb32-411b-bc48-691b2fc2483c": {"__data__": {"id_": "c15150c9-cb32-411b-bc48-691b2fc2483c", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate.  We still participate in the profit dollars.  It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth.  As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services. ", "original_text": "As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "662c69bf-31ec-403f-a01e-b5ef7f321490", "node_type": "1", "metadata": {"window": "And then just on the $25 million inv estment that you mentioned in the back half, maybe just a \nlittle bit more specificity around what area within specialty those would be pointed, that would be helpful, too. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate.  We still participate in the profit dollars.  It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth. ", "original_text": "A \nYeah. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "109b3f22162bd6f94a9b57c566faefbcc4d1d180b73e99ae0b61c0aab0c2fece", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1287af3-1dd4-44d4-a3d4-664784b45840", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate.  We still participate in the profit dollars.  It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth.  As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services.  And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets. ", "original_text": "We still participate in the profit dollars. "}, "hash": "e6dee6f375b1c33aa2c9b7e8cdc31d3ad7e1481fd90d985b4860ccf478fd6523", "class_name": "RelatedNodeInfo"}}, "text": "As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate. ", "start_char_idx": 1061, "end_char_idx": 1216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1287af3-1dd4-44d4-a3d4-664784b45840": {"__data__": {"id_": "f1287af3-1dd4-44d4-a3d4-664784b45840", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate.  We still participate in the profit dollars.  It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth.  As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services.  And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets. ", "original_text": "We still participate in the profit dollars. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c15150c9-cb32-411b-bc48-691b2fc2483c", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate.  We still participate in the profit dollars.  It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth.  As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services. ", "original_text": "As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f65259425af9d6f80e529f38e3d361bcff6c753cd50aa05795cd7b29af4f40c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ac8c6e1-b193-4c5e-ad07-502c008c43c8", "node_type": "1", "metadata": {"window": "A \nYeah.  As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate.  We still participate in the profit dollars.  It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth.  As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services.  And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets.  But, again, we're continuing to invest in our manufacturing services \ncapabilities as well. ", "original_text": "It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth. "}, "hash": "6a77e5cc98da702e2e84ac2803f2b194685a5bc5a6d828a62fb5e6907acbc9e0", "class_name": "RelatedNodeInfo"}}, "text": "We still participate in the profit dollars. ", "start_char_idx": 1216, "end_char_idx": 1260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ac8c6e1-b193-4c5e-ad07-502c008c43c8": {"__data__": {"id_": "5ac8c6e1-b193-4c5e-ad07-502c008c43c8", "embedding": null, "metadata": {"window": "A \nYeah.  As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate.  We still participate in the profit dollars.  It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth.  As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services.  And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets.  But, again, we're continuing to invest in our manufacturing services \ncapabilities as well. ", "original_text": "It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1287af3-1dd4-44d4-a3d4-664784b45840", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate.  We still participate in the profit dollars.  It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth.  As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services.  And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets. ", "original_text": "We still participate in the profit dollars. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "109ba7f8695a9e0db5a82e41369e1a1992ae829bf15f3ca72fb42bcdd160c5f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdf69789-398f-4645-87fc-d16a2c98046b", "node_type": "1", "metadata": {"window": "As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate.  We still participate in the profit dollars.  It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth.  As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services.  And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets.  But, again, we're continuing to invest in our manufacturing services \ncapabilities as well.  But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n ", "original_text": "As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services. "}, "hash": "cf3fbfbbf212f8c6874a4c88825bd7f5432adfe92b1c326caf3230c16728f1cb", "class_name": "RelatedNodeInfo"}}, "text": "It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth. ", "start_char_idx": 1260, "end_char_idx": 1381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdf69789-398f-4645-87fc-d16a2c98046b": {"__data__": {"id_": "cdf69789-398f-4645-87fc-d16a2c98046b", "embedding": null, "metadata": {"window": "As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate.  We still participate in the profit dollars.  It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth.  As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services.  And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets.  But, again, we're continuing to invest in our manufacturing services \ncapabilities as well.  But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n ", "original_text": "As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ac8c6e1-b193-4c5e-ad07-502c008c43c8", "node_type": "1", "metadata": {"window": "A \nYeah.  As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate.  We still participate in the profit dollars.  It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth.  As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services.  And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets.  But, again, we're continuing to invest in our manufacturing services \ncapabilities as well. ", "original_text": "It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aeb739b883879fede1c60169902043ff673eea2d3f4f6391baa7fc5692af29e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9abe786-4c53-436a-884b-f0619c6b0d41", "node_type": "1", "metadata": {"window": "We still participate in the profit dollars.  It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth.  As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services.  And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets.  But, again, we're continuing to invest in our manufacturing services \ncapabilities as well.  But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets. "}, "hash": "ddd6bea6a1d3c7e73f8fdf848195c09e3d13d27f5d904644c3564eae412ae2e6", "class_name": "RelatedNodeInfo"}}, "text": "As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services. ", "start_char_idx": 1381, "end_char_idx": 1574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9abe786-4c53-436a-884b-f0619c6b0d41": {"__data__": {"id_": "b9abe786-4c53-436a-884b-f0619c6b0d41", "embedding": null, "metadata": {"window": "We still participate in the profit dollars.  It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth.  As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services.  And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets.  But, again, we're continuing to invest in our manufacturing services \ncapabilities as well.  But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdf69789-398f-4645-87fc-d16a2c98046b", "node_type": "1", "metadata": {"window": "As we've talked about before, and as we think about specialty distribution in our line of wholesale business, \nthey do have a dilutive impact on the rate.  We still participate in the profit dollars.  It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth.  As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services.  And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets.  But, again, we're continuing to invest in our manufacturing services \ncapabilities as well.  But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n ", "original_text": "As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4edf5ef823a3adc9eb8b6a0a36402bef19026114b8848f2af5d03b366d295898", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "181cf335-fe3c-40ba-bfc3-830e91f0ca0f", "node_type": "1", "metadata": {"window": "It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth.  As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services.  And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets.  But, again, we're continuing to invest in our manufacturing services \ncapabilities as well.  But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust to build on that. ", "original_text": "But, again, we're continuing to invest in our manufacturing services \ncapabilities as well. "}, "hash": "27414d651954b74e61ee88b75b95d9e8cadc1e61c7a1772a9091bb3b4d3ab5ac", "class_name": "RelatedNodeInfo"}}, "text": "And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets. ", "start_char_idx": 1574, "end_char_idx": 1680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "181cf335-fe3c-40ba-bfc3-830e91f0ca0f": {"__data__": {"id_": "181cf335-fe3c-40ba-bfc3-830e91f0ca0f", "embedding": null, "metadata": {"window": "It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth.  As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services.  And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets.  But, again, we're continuing to invest in our manufacturing services \ncapabilities as well.  But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust to build on that. ", "original_text": "But, again, we're continuing to invest in our manufacturing services \ncapabilities as well. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9abe786-4c53-436a-884b-f0619c6b0d41", "node_type": "1", "metadata": {"window": "We still participate in the profit dollars.  It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth.  As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services.  And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets.  But, again, we're continuing to invest in our manufacturing services \ncapabilities as well.  But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a9969783dec830c6031766118af257d498bf9978f96daae28a825b5ffbb46b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85b8ad1e-d651-4f98-b5d1-fcf5bf33d490", "node_type": "1", "metadata": {"window": "As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services.  And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets.  But, again, we're continuing to invest in our manufacturing services \ncapabilities as well.  But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust to build on that.  I mean, these investments are tied to our strategy. ", "original_text": "But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n "}, "hash": "96cbb6cd3b7dcec52669aa17365b0968b89dae74e96a46684b93115ba25e66bf", "class_name": "RelatedNodeInfo"}}, "text": "But, again, we're continuing to invest in our manufacturing services \ncapabilities as well. ", "start_char_idx": 1680, "end_char_idx": 1772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85b8ad1e-d651-4f98-b5d1-fcf5bf33d490": {"__data__": {"id_": "85b8ad1e-d651-4f98-b5d1-fcf5bf33d490", "embedding": null, "metadata": {"window": "As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services.  And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets.  But, again, we're continuing to invest in our manufacturing services \ncapabilities as well.  But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust to build on that.  I mean, these investments are tied to our strategy. ", "original_text": "But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "181cf335-fe3c-40ba-bfc3-830e91f0ca0f", "node_type": "1", "metadata": {"window": "It's just grown a lot faster than \nwe had anticipated, and that's had a much more dilutive impact on the rate of growth.  As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services.  And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets.  But, again, we're continuing to invest in our manufacturing services \ncapabilities as well.  But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust to build on that. ", "original_text": "But, again, we're continuing to invest in our manufacturing services \ncapabilities as well. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f01874d9359508e91dcb5743fcf4137b9f9e9b5b253882f23396bff02a2c7ad1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fa1634f-5a78-4847-a3e1-efb8c34d6500", "node_type": "1", "metadata": {"window": "And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets.  But, again, we're continuing to invest in our manufacturing services \ncapabilities as well.  But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust to build on that.  I mean, these investments are tied to our strategy.  Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "424ff0b406439278f0eba2669f9c377094ed90b69ac49446c64295458508e831", "class_name": "RelatedNodeInfo"}}, "text": "But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n ", "start_char_idx": 1772, "end_char_idx": 1912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fa1634f-5a78-4847-a3e1-efb8c34d6500": {"__data__": {"id_": "3fa1634f-5a78-4847-a3e1-efb8c34d6500", "embedding": null, "metadata": {"window": "And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets.  But, again, we're continuing to invest in our manufacturing services \ncapabilities as well.  But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust to build on that.  I mean, these investments are tied to our strategy.  Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85b8ad1e-d651-4f98-b5d1-fcf5bf33d490", "node_type": "1", "metadata": {"window": "As we think about the \ninvestments that we're making, as Brian talked about, we are very pleased with our positions in oncology, our \npositions that we're developing in man ufacturer services.  And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets.  But, again, we're continuing to invest in our manufacturing services \ncapabilities as well.  But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust to build on that.  I mean, these investments are tied to our strategy. ", "original_text": "But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35e615dbf62ff41b30e3c5ef239d631e50ba86c00a0e2f6e88061228b1d697a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "027f45b4-5f33-422b-b23a-4d38bd322a4c", "node_type": "1", "metadata": {"window": "But, again, we're continuing to invest in our manufacturing services \ncapabilities as well.  But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust to build on that.  I mean, these investments are tied to our strategy.  Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth.  And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n ", "original_text": "A \nJust to build on that. "}, "hash": "3e2aadf4a86bcedae8ab127fe0c960444cd3670d0d6ada31f18963dce70a6c5b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1912, "end_char_idx": 2238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "027f45b4-5f33-422b-b23a-4d38bd322a4c": {"__data__": {"id_": "027f45b4-5f33-422b-b23a-4d38bd322a4c", "embedding": null, "metadata": {"window": "But, again, we're continuing to invest in our manufacturing services \ncapabilities as well.  But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust to build on that.  I mean, these investments are tied to our strategy.  Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth.  And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n ", "original_text": "A \nJust to build on that. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fa1634f-5a78-4847-a3e1-efb8c34d6500", "node_type": "1", "metadata": {"window": "And as we think about this $25 million, it will be largely \ninvested in oncology capabilities and assets.  But, again, we're continuing to invest in our manufacturing services \ncapabilities as well.  But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust to build on that.  I mean, these investments are tied to our strategy.  Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "986efd050915136b31d5e6add20dc6e0430c06934cab858ca8faa8d4dfffb183", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7c5bfe2-9abf-44d1-a1bd-00aa0756c71e", "node_type": "1", "metadata": {"window": "But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust to build on that.  I mean, these investments are tied to our strategy.  Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth.  And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "I mean, these investments are tied to our strategy. "}, "hash": "60781aef589f979af7453df8b2515d8bb8e9bbadc48f08e2a74be466b9a3802e", "class_name": "RelatedNodeInfo"}}, "text": "A \nJust to build on that. ", "start_char_idx": 2238, "end_char_idx": 2264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7c5bfe2-9abf-44d1-a1bd-00aa0756c71e": {"__data__": {"id_": "f7c5bfe2-9abf-44d1-a1bd-00aa0756c71e", "embedding": null, "metadata": {"window": "But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust to build on that.  I mean, these investments are tied to our strategy.  Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth.  And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "I mean, these investments are tied to our strategy. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "027f45b4-5f33-422b-b23a-4d38bd322a4c", "node_type": "1", "metadata": {"window": "But, again, we're continuing to invest in our manufacturing services \ncapabilities as well.  But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust to build on that.  I mean, these investments are tied to our strategy.  Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth.  And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n ", "original_text": "A \nJust to build on that. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3496e3737672f058c6a7b9b4bdf5c758d730d8faa69e183bb3b6e4a579b00bb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1a35b43-5bfa-4a13-b5e6-4276c2b71088", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust to build on that.  I mean, these investments are tied to our strategy.  Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth.  And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more.  \n ", "original_text": "Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth. "}, "hash": "3765fd7294c716c1f1bfdd77850dd5027995ef6e8f1726f05597e3b11887c946", "class_name": "RelatedNodeInfo"}}, "text": "I mean, these investments are tied to our strategy. ", "start_char_idx": 2264, "end_char_idx": 2316, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1a35b43-5bfa-4a13-b5e6-4276c2b71088": {"__data__": {"id_": "e1a35b43-5bfa-4a13-b5e6-4276c2b71088", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust to build on that.  I mean, these investments are tied to our strategy.  Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth.  And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more.  \n ", "original_text": "Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7c5bfe2-9abf-44d1-a1bd-00aa0756c71e", "node_type": "1", "metadata": {"window": "But you should think about this investme nt as investing where we have leading -edge \npositions, and oncology is certainly one of those.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust to build on that.  I mean, these investments are tied to our strategy.  Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth.  And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "I mean, these investments are tied to our strategy. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "932677926694d35d4d8e47ad56140f8497d9d3a379eaae21abc50da68781cc23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9da7bd18-44ec-4282-8044-ef95a24baa5d", "node_type": "1", "metadata": {"window": "A \nJust to build on that.  I mean, these investments are tied to our strategy.  Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth.  And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great. ", "original_text": "And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n "}, "hash": "88ea1a95234eb19c523c2e971560dbedd0a12ebf92cd95d7e1f5f095a82c14e5", "class_name": "RelatedNodeInfo"}}, "text": "Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth. ", "start_char_idx": 2316, "end_char_idx": 2437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9da7bd18-44ec-4282-8044-ef95a24baa5d": {"__data__": {"id_": "9da7bd18-44ec-4282-8044-ef95a24baa5d", "embedding": null, "metadata": {"window": "A \nJust to build on that.  I mean, these investments are tied to our strategy.  Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth.  And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great. ", "original_text": "And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1a35b43-5bfa-4a13-b5e6-4276c2b71088", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nJust to build on that.  I mean, these investments are tied to our strategy.  Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth.  And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more.  \n ", "original_text": "Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3bb7a476f6b2699f87bb82e7aac075f236821c5491d6c67f0499a5b17b651f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d522bc7-3a05-42a9-a807-9267fbddc7c7", "node_type": "1", "metadata": {"window": "I mean, these investments are tied to our strategy.  Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth.  And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great.  Our last question for today is Kevin Caliendo of UBS. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "bba5fed486785ea19172812e6835637650afb6b55cd6adcb03f6e50e0040aa6e", "class_name": "RelatedNodeInfo"}}, "text": "And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n ", "start_char_idx": 2437, "end_char_idx": 2576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d522bc7-3a05-42a9-a807-9267fbddc7c7": {"__data__": {"id_": "8d522bc7-3a05-42a9-a807-9267fbddc7c7", "embedding": null, "metadata": {"window": "I mean, these investments are tied to our strategy.  Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth.  And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great.  Our last question for today is Kevin Caliendo of UBS. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9da7bd18-44ec-4282-8044-ef95a24baa5d", "node_type": "1", "metadata": {"window": "A \nJust to build on that.  I mean, these investments are tied to our strategy.  Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth.  And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great. ", "original_text": "And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6254c30e5d569949812a0c445f3e59de27c59a5e868eec75c3c6b5ebca2aabb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9db6afb5-5f21-4aff-ae66-b396d12aabe9", "node_type": "1", "metadata": {"window": "Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth.  And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great.  Our last question for today is Kevin Caliendo of UBS.  Your line is open.  \n ", "original_text": "A \nOperator, we have time for one more.  \n "}, "hash": "82a62c3d192f0748abb8a00addcfaabe478f8a92ddd99d54988011fdcb7d5c80", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 2576, "end_char_idx": 2906, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9db6afb5-5f21-4aff-ae66-b396d12aabe9": {"__data__": {"id_": "9db6afb5-5f21-4aff-ae66-b396d12aabe9", "embedding": null, "metadata": {"window": "Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth.  And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great.  Our last question for today is Kevin Caliendo of UBS.  Your line is open.  \n ", "original_text": "A \nOperator, we have time for one more.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d522bc7-3a05-42a9-a807-9267fbddc7c7", "node_type": "1", "metadata": {"window": "I mean, these investments are tied to our strategy.  Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth.  And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great.  Our last question for today is Kevin Caliendo of UBS. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "faf3a176011896c39d6c78ccad8c73619d9e9ac66871e0f007dc74ef9b951eae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f70cf69-1053-483a-9ea0-127f7b650b84", "node_type": "1", "metadata": {"window": "And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great.  Our last question for today is Kevin Caliendo of UBS.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great. "}, "hash": "40e676b1c34e3a5ccf0a0a434ca6311d49d5946e7f56531178b4389955be559f", "class_name": "RelatedNodeInfo"}}, "text": "A \nOperator, we have time for one more.  \n ", "start_char_idx": 2906, "end_char_idx": 2949, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f70cf69-1053-483a-9ea0-127f7b650b84": {"__data__": {"id_": "3f70cf69-1053-483a-9ea0-127f7b650b84", "embedding": null, "metadata": {"window": "And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great.  Our last question for today is Kevin Caliendo of UBS.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9db6afb5-5f21-4aff-ae66-b396d12aabe9", "node_type": "1", "metadata": {"window": "Our strategy is anchored in where we \nbelieve we have differentiated capabilities and we have a good marketplace growth.  And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great.  Our last question for today is Kevin Caliendo of UBS.  Your line is open.  \n ", "original_text": "A \nOperator, we have time for one more.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4efc16a1a00c9ee9137fb55d7470e93c0b26aac155130009ba79d695098a8595", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ef1a387-f7e6-4be3-b501-e8c0c7ec23d6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great.  Our last question for today is Kevin Caliendo of UBS.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys.  I appreciate that. ", "original_text": "Our last question for today is Kevin Caliendo of UBS. "}, "hash": "cb1a0fa64d9dec6879ee55355e5d8ba26bafb77fa6b3ed02f6d1f044de3eae35", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great. ", "start_char_idx": 2949, "end_char_idx": 3232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ef1a387-f7e6-4be3-b501-e8c0c7ec23d6": {"__data__": {"id_": "0ef1a387-f7e6-4be3-b501-e8c0c7ec23d6", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great.  Our last question for today is Kevin Caliendo of UBS.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys.  I appreciate that. ", "original_text": "Our last question for today is Kevin Caliendo of UBS. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f70cf69-1053-483a-9ea0-127f7b650b84", "node_type": "1", "metadata": {"window": "And so we're very happy to \nbe able to say we're continuing to make these investments and still delivering on the year as we committed.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great.  Our last question for today is Kevin Caliendo of UBS.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53aab2d8470597ae6d6adf40c3a4dc05589a1359a9e32b25bd54431bb3da50dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad11e4c1-c69f-45d7-ba44-3c6acde3660f", "node_type": "1", "metadata": {"window": "A \nOperator, we have time for one more.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great.  Our last question for today is Kevin Caliendo of UBS.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys.  I appreciate that.  If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n", "original_text": "Your line is open.  \n "}, "hash": "f06bde27143feaed6f315427b2ca62e48d92a4b647ec253c03b3f641c9ce8a5d", "class_name": "RelatedNodeInfo"}}, "text": "Our last question for today is Kevin Caliendo of UBS. ", "start_char_idx": 3232, "end_char_idx": 3286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad11e4c1-c69f-45d7-ba44-3c6acde3660f": {"__data__": {"id_": "ad11e4c1-c69f-45d7-ba44-3c6acde3660f", "embedding": null, "metadata": {"window": "A \nOperator, we have time for one more.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great.  Our last question for today is Kevin Caliendo of UBS.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys.  I appreciate that.  If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n", "original_text": "Your line is open.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ef1a387-f7e6-4be3-b501-e8c0c7ec23d6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great.  Our last question for today is Kevin Caliendo of UBS.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys.  I appreciate that. ", "original_text": "Our last question for today is Kevin Caliendo of UBS. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b8a71d80f9d68e121015a0fa785f14598b48f1eebf07f6255565769026a61925", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4c490ee-7adc-4199-a9ee-82562aab8abd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great.  Our last question for today is Kevin Caliendo of UBS.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys.  I appreciate that.  If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys. "}, "hash": "cc4345c712fd25834e136e8075455373c414904c4f8bd88619f73634d77ee682", "class_name": "RelatedNodeInfo"}}, "text": "Your line is open.  \n ", "start_char_idx": 3286, "end_char_idx": 3308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4c490ee-7adc-4199-a9ee-82562aab8abd": {"__data__": {"id_": "a4c490ee-7adc-4199-a9ee-82562aab8abd", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great.  Our last question for today is Kevin Caliendo of UBS.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys.  I appreciate that.  If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad11e4c1-c69f-45d7-ba44-3c6acde3660f", "node_type": "1", "metadata": {"window": "A \nOperator, we have time for one more.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great.  Our last question for today is Kevin Caliendo of UBS.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys.  I appreciate that.  If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n", "original_text": "Your line is open.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cdea459bbefb87c94e1c046c3e54a2e67ba59a3764973004e49cbcad3b928d8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "822ee454-fa40-43cd-ac08-b2a33f61fd0b", "node_type": "1", "metadata": {"window": "Our last question for today is Kevin Caliendo of UBS.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys.  I appreciate that.  If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I appreciate that. "}, "hash": "8a5dbcfe377fba57ddc7985d9cc1048d77f1e1908dc48c6ae634497e6aa04976", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys. ", "start_char_idx": 3308, "end_char_idx": 3651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "822ee454-fa40-43cd-ac08-b2a33f61fd0b": {"__data__": {"id_": "822ee454-fa40-43cd-ac08-b2a33f61fd0b", "embedding": null, "metadata": {"window": "Our last question for today is Kevin Caliendo of UBS.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys.  I appreciate that.  If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I appreciate that. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4c490ee-7adc-4199-a9ee-82562aab8abd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Okay, great.  Our last question for today is Kevin Caliendo of UBS.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys.  I appreciate that.  If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ad7cf3ed88593d730eb401f83a0a7a7f0cf24361f4e7c6e851c33fb673fec0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "812fb29d-003f-4bda-b264-0c4619944556", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys.  I appreciate that.  If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow. ", "original_text": "If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n"}, "hash": "7908dc89214b489b90da90bea9f4943f8306fe4a483ca72009637244ac7796cf", "class_name": "RelatedNodeInfo"}}, "text": "I appreciate that. ", "start_char_idx": 3651, "end_char_idx": 3670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "812fb29d-003f-4bda-b264-0c4619944556": {"__data__": {"id_": "812fb29d-003f-4bda-b264-0c4619944556", "embedding": null, "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys.  I appreciate that.  If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow. ", "original_text": "If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "822ee454-fa40-43cd-ac08-b2a33f61fd0b", "node_type": "1", "metadata": {"window": "Our last question for today is Kevin Caliendo of UBS.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys.  I appreciate that.  If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I appreciate that. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f2c2ae112aa62ee8b40545b2f9a8b57431f028998c9e3e4b4811e1f8c5fac5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b17f361-73ea-43fd-b4fd-12022c0351a3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys.  I appreciate that.  If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow.  We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results. ", "original_text": "Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n "}, "hash": "6282696aae3d2b3ab150351f8c49b04188ec7071065bd05af09cdbbc58190920", "class_name": "RelatedNodeInfo"}}, "text": "If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n", "start_char_idx": 3670, "end_char_idx": 3853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b17f361-73ea-43fd-b4fd-12022c0351a3": {"__data__": {"id_": "6b17f361-73ea-43fd-b4fd-12022c0351a3", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys.  I appreciate that.  If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow.  We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results. ", "original_text": "Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "812fb29d-003f-4bda-b264-0c4619944556", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys.  I appreciate that.  If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow. ", "original_text": "If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67c1c9a19653131161f8592ad7f8fb3bdfb728b82cf156f20ff0e249c27f86f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5df41663-18b2-4abd-b748-30d990bf2caa", "node_type": "1", "metadata": {"window": "I appreciate that.  If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow.  We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results.  I mean, \ngreat top -line growth, but there is a margin rate impact in there. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "159d241aad7954bfe0445e511a232c1140fe64eb2164e26c0a37524fb2a45000", "class_name": "RelatedNodeInfo"}}, "text": "Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n ", "start_char_idx": 3853, "end_char_idx": 4038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5df41663-18b2-4abd-b748-30d990bf2caa": {"__data__": {"id_": "5df41663-18b2-4abd-b748-30d990bf2caa", "embedding": null, "metadata": {"window": "I appreciate that.  If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow.  We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results.  I mean, \ngreat top -line growth, but there is a margin rate impact in there. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b17f361-73ea-43fd-b4fd-12022c0351a3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for  getting me in, guys.  I appreciate that.  If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow.  We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results. ", "original_text": "Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edbeb432a979aa3a0c6f1196457ffd2836b510a7577ccfbb8b0352da7e79a735", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bda5492-df9c-4226-a984-b01ebd1c7ec3", "node_type": "1", "metadata": {"window": "If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow.  We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results.  I mean, \ngreat top -line growth, but there is a margin rate impact in there.  We're n ever disappointed when our customers \ngrow, and we think it's always additive to the business.  \n ", "original_text": "A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow. "}, "hash": "774282ac996fcc6e176625e8e4ccd3f5772602fdb6ac69c000662a9314950216", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1912, "end_char_idx": 2238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bda5492-df9c-4226-a984-b01ebd1c7ec3": {"__data__": {"id_": "5bda5492-df9c-4226-a984-b01ebd1c7ec3", "embedding": null, "metadata": {"window": "If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow.  We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results.  I mean, \ngreat top -line growth, but there is a margin rate impact in there.  We're n ever disappointed when our customers \ngrow, and we think it's always additive to the business.  \n ", "original_text": "A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5df41663-18b2-4abd-b748-30d990bf2caa", "node_type": "1", "metadata": {"window": "I appreciate that.  If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow.  We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results.  I mean, \ngreat top -line growth, but there is a margin rate impact in there. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c12d49e7f57d93769edf4fbec7e92d533b55a8e998793bda61cf8ecdc1ae608", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2a29478-410a-45eb-93cd-4d43bfdea142", "node_type": "1", "metadata": {"window": "Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow.  We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results.  I mean, \ngreat top -line growth, but there is a margin rate impact in there.  We're n ever disappointed when our customers \ngrow, and we think it's always additive to the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results. "}, "hash": "180277246c1c28a3c2cadd103e20cdeffdf7e035a5918fc449ff3112c3664f8e", "class_name": "RelatedNodeInfo"}}, "text": "A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow. ", "start_char_idx": 4364, "end_char_idx": 4473, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2a29478-410a-45eb-93cd-4d43bfdea142": {"__data__": {"id_": "a2a29478-410a-45eb-93cd-4d43bfdea142", "embedding": null, "metadata": {"window": "Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow.  We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results.  I mean, \ngreat top -line growth, but there is a margin rate impact in there.  We're n ever disappointed when our customers \ngrow, and we think it's always additive to the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bda5492-df9c-4226-a984-b01ebd1c7ec3", "node_type": "1", "metadata": {"window": "If we think about the CVS relationship and the fact that it was \njust sort of re -upped for June, is there some anticipation that over time the margin would then \u2013 could get better? \n Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow.  We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results.  I mean, \ngreat top -line growth, but there is a margin rate impact in there.  We're n ever disappointed when our customers \ngrow, and we think it's always additive to the business.  \n ", "original_text": "A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ada08a37e5d84a219de30d5fcfb3509c9467ba2ad51fad8ef866409ce0196c40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51e2288a-fd4c-4b96-9f3e-d77b371f916c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow.  We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results.  I mean, \ngreat top -line growth, but there is a margin rate impact in there.  We're n ever disappointed when our customers \ngrow, and we think it's always additive to the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "I mean, \ngreat top -line growth, but there is a margin rate impact in there. "}, "hash": "7bb1cd1d2a3b66d118de470fbcc0f49b753f7fe21a30ba55e38ecd0d87c3f594", "class_name": "RelatedNodeInfo"}}, "text": "We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results. ", "start_char_idx": 4473, "end_char_idx": 4583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51e2288a-fd4c-4b96-9f3e-d77b371f916c": {"__data__": {"id_": "51e2288a-fd4c-4b96-9f3e-d77b371f916c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow.  We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results.  I mean, \ngreat top -line growth, but there is a margin rate impact in there.  We're n ever disappointed when our customers \ngrow, and we think it's always additive to the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "I mean, \ngreat top -line growth, but there is a margin rate impact in there. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2a29478-410a-45eb-93cd-4d43bfdea142", "node_type": "1", "metadata": {"window": "Meaning are we in a situation right  now where the first sort of 12 months of this relationship, the margins from that \ncontract might be worse, and over time they could get better?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow.  We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results.  I mean, \ngreat top -line growth, but there is a margin rate impact in there.  We're n ever disappointed when our customers \ngrow, and we think it's always additive to the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df234915683815fa7e17974b5c1cbfdc716783d2b15490e982d9eefa913b019d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d97410f-6ebb-46f2-8ec7-5f4709f401db", "node_type": "1", "metadata": {"window": "A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow.  We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results.  I mean, \ngreat top -line growth, but there is a margin rate impact in there.  We're n ever disappointed when our customers \ngrow, and we think it's always additive to the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "We're n ever disappointed when our customers \ngrow, and we think it's always additive to the business.  \n "}, "hash": "59d8e81ff08e6a8a822994cb18bedf1b087ccaee594e4a00cf56e88795d8c01f", "class_name": "RelatedNodeInfo"}}, "text": "I mean, \ngreat top -line growth, but there is a margin rate impact in there. ", "start_char_idx": 4583, "end_char_idx": 4660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d97410f-6ebb-46f2-8ec7-5f4709f401db": {"__data__": {"id_": "2d97410f-6ebb-46f2-8ec7-5f4709f401db", "embedding": null, "metadata": {"window": "A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow.  We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results.  I mean, \ngreat top -line growth, but there is a margin rate impact in there.  We're n ever disappointed when our customers \ngrow, and we think it's always additive to the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "We're n ever disappointed when our customers \ngrow, and we think it's always additive to the business.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51e2288a-fd4c-4b96-9f3e-d77b371f916c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow.  We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results.  I mean, \ngreat top -line growth, but there is a margin rate impact in there.  We're n ever disappointed when our customers \ngrow, and we think it's always additive to the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "I mean, \ngreat top -line growth, but there is a margin rate impact in there. ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d25af985a4c3aa59f6bb50c305ba64fd52055de54859cbcb58dcaafcf519c0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3016a943-b8ca-49c6-9b11-b27e8693ea6e", "node_type": "1", "metadata": {"window": "We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results.  I mean, \ngreat top -line growth, but there is a margin rate impact in there.  We're n ever disappointed when our customers \ngrow, and we think it's always additive to the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   "}, "hash": "71953cbde9a9c5461a77eacef910e8ae42c94b4ea02771b0958f31eaa6e23ed6", "class_name": "RelatedNodeInfo"}}, "text": "We're n ever disappointed when our customers \ngrow, and we think it's always additive to the business.  \n ", "start_char_idx": 4660, "end_char_idx": 4766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3016a943-b8ca-49c6-9b11-b27e8693ea6e": {"__data__": {"id_": "3016a943-b8ca-49c6-9b11-b27e8693ea6e", "embedding": null, "metadata": {"window": "We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results.  I mean, \ngreat top -line growth, but there is a margin rate impact in there.  We're n ever disappointed when our customers \ngrow, and we think it's always additive to the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb175ef82809d4e95b1ef7a1a24aeb210621d982c208d52c6aeeb9fd92ad192", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d97410f-6ebb-46f2-8ec7-5f4709f401db", "node_type": "1", "metadata": {"window": "A \nWell, first let me say we're always happ y to renew our customers, and we're always happy when they grow.  We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results.  I mean, \ngreat top -line growth, but there is a margin rate impact in there.  We're n ever disappointed when our customers \ngrow, and we think it's always additive to the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "We're n ever disappointed when our customers \ngrow, and we think it's always additive to the business.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d3e57fa85a2790bc5e0695ef988d8536357ce5968ff938cd09fcaae73d8f444", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e82f7ce-8f27-49af-8c5c-e129fc4729df", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nOne quick follow -up.  Can you talk about the performance and impact Northstar would have had in the quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "McKesson Corp.  "}, "hash": "40ec7eb2ff91950c25dbaf32771b0c923d1ce9551ce2d307bf8ccdaa2f494540", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "start_char_idx": 707, "end_char_idx": 963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e82f7ce-8f27-49af-8c5c-e129fc4729df": {"__data__": {"id_": "0e82f7ce-8f27-49af-8c5c-e129fc4729df", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nOne quick follow -up.  Can you talk about the performance and impact Northstar would have had in the quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3016a943-b8ca-49c6-9b11-b27e8693ea6e", "node_type": "1", "metadata": {"window": "We \nare experiencing a shift in the mix of business that on a margin rate perspective you see in our results.  I mean, \ngreat top -line growth, but there is a margin rate impact in there.  We're n ever disappointed when our customers \ngrow, and we think it's always additive to the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99f2fd5433441e2dbc6ada988a0d5575ba031c240c4e5198b0212c55cf429b1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e579cbed-d1fb-4d70-a8e8-c4f3bcaa5f6e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nOne quick follow -up.  Can you talk about the performance and impact Northstar would have had in the quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nOne quick follow -up. "}, "hash": "00c5a8c71380665c6a42c23bb13ddc70eba09c404090874de3c4101b1d06bf90", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e579cbed-d1fb-4d70-a8e8-c4f3bcaa5f6e": {"__data__": {"id_": "e579cbed-d1fb-4d70-a8e8-c4f3bcaa5f6e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nOne quick follow -up.  Can you talk about the performance and impact Northstar would have had in the quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nOne quick follow -up. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e82f7ce-8f27-49af-8c5c-e129fc4729df", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nOne quick follow -up.  Can you talk about the performance and impact Northstar would have had in the quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40d5a3431f8c556f7a407c8105b876a609a97f97aefbdd0d80f570f48999fcfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75b242bc-7e65-47dd-b154-89dc415ad590", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nOne quick follow -up.  Can you talk about the performance and impact Northstar would have had in the quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Can you talk about the performance and impact Northstar would have had in the quarter?  \n "}, "hash": "5c7224fbb6e4b53cde65d03a6ce797558c58c6a5148e28d7ff614eee63b3152a", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nOne quick follow -up. ", "start_char_idx": 16, "end_char_idx": 252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75b242bc-7e65-47dd-b154-89dc415ad590": {"__data__": {"id_": "75b242bc-7e65-47dd-b154-89dc415ad590", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nOne quick follow -up.  Can you talk about the performance and impact Northstar would have had in the quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Can you talk about the performance and impact Northstar would have had in the quarter?  \n ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e579cbed-d1fb-4d70-a8e8-c4f3bcaa5f6e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nOne quick follow -up.  Can you talk about the performance and impact Northstar would have had in the quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nOne quick follow -up. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d363d48605383ec2e7ba8ceb68eb7a9b517b16ea8e0d2233938e68b19d8ae73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "000eab26-3f14-4ded-a2d3-ce4faa9b1ebd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nOne quick follow -up.  Can you talk about the performance and impact Northstar would have had in the quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "20cee7ad457baf9f363b2060dd26f997083cde89aafc4c759e4d070d5c011bfe", "class_name": "RelatedNodeInfo"}}, "text": "Can you talk about the performance and impact Northstar would have had in the quarter?  \n ", "start_char_idx": 252, "end_char_idx": 342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "000eab26-3f14-4ded-a2d3-ce4faa9b1ebd": {"__data__": {"id_": "000eab26-3f14-4ded-a2d3-ce4faa9b1ebd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nOne quick follow -up.  Can you talk about the performance and impact Northstar would have had in the quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75b242bc-7e65-47dd-b154-89dc415ad590", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nOne quick follow -up.  Can you talk about the performance and impact Northstar would have had in the quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Can you talk about the performance and impact Northstar would have had in the quarter?  \n ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ac0d67683752c635e6c6e1ce29d2c54bafd4f584c6ac2e08505848f4e35ac9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e964af4-881a-4400-82c1-86b06ccd82d4", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nOne quick follow -up.  Can you talk about the performance and impact Northstar would have had in the quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n "}, "hash": "0c91aca911837304aeeb08da65dc02ac710777307960c3a1feb98186ca134a29", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 342, "end_char_idx": 687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e964af4-881a-4400-82c1-86b06ccd82d4": {"__data__": {"id_": "8e964af4-881a-4400-82c1-86b06ccd82d4", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nOne quick follow -up.  Can you talk about the performance and impact Northstar would have had in the quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "000eab26-3f14-4ded-a2d3-ce4faa9b1ebd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nOne quick follow -up.  Can you talk about the performance and impact Northstar would have had in the quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da46ee245f36dd63fcb3b7be4b2f93e1b2225b4f062f7db346463a1b177a0672", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "427c8cbd-19d9-4ddb-83f3-2843c8d5ddbc", "node_type": "1", "metadata": {"window": "Can you talk about the performance and impact Northstar would have had in the quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "e457199854cc6af4fb66fd15f060a0ab42b1c6cde8a9df88e4e7a187fe96012b", "class_name": "RelatedNodeInfo"}}, "text": "A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n ", "start_char_idx": 687, "end_char_idx": 957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "427c8cbd-19d9-4ddb-83f3-2843c8d5ddbc": {"__data__": {"id_": "427c8cbd-19d9-4ddb-83f3-2843c8d5ddbc", "embedding": null, "metadata": {"window": "Can you talk about the performance and impact Northstar would have had in the quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e964af4-881a-4400-82c1-86b06ccd82d4", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nOne quick follow -up.  Can you talk about the performance and impact Northstar would have had in the quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9458daaa3050f181b834b789c360102672463530c6fe7fa1c3414ee5c73b670e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1f9a378-17ca-4d41-afcd-2324c5aabb09", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning. ", "original_text": "A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n "}, "hash": "c5a4fe6354d55280e2b9b718fcbb43f413d331a7b2b74be0318455606a210271", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 957, "end_char_idx": 1283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1f9a378-17ca-4d41-afcd-2324c5aabb09": {"__data__": {"id_": "f1f9a378-17ca-4d41-afcd-2324c5aabb09", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning. ", "original_text": "A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "427c8cbd-19d9-4ddb-83f3-2843c8d5ddbc", "node_type": "1", "metadata": {"window": "Can you talk about the performance and impact Northstar would have had in the quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc4ad65f3fc4fc4c020751e008a39a97ae15b2df9523d8cfc94bbbb3014aa491", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "815e7dc3-8653-402f-9dfd-bc17d7ccd497", "node_type": "1", "metadata": {"window": "A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning.  Thank you, Susanne, for facilitating this call.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "50d9b35571f20f5454e1a0105e9ee742cedda999fa6a9842f25890a2d48eb6d8", "class_name": "RelatedNodeInfo"}}, "text": "A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n ", "start_char_idx": 1283, "end_char_idx": 1488, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "815e7dc3-8653-402f-9dfd-bc17d7ccd497": {"__data__": {"id_": "815e7dc3-8653-402f-9dfd-bc17d7ccd497", "embedding": null, "metadata": {"window": "A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning.  Thank you, Susanne, for facilitating this call.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1f9a378-17ca-4d41-afcd-2324c5aabb09", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning. ", "original_text": "A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727af482314ac529416a9fa2fc2d25ce740793529b26af2d6442bc7ada2bc165", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f17cc2c-15ed-4601-a7db-aab101475c1a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning.  Thank you, Susanne, for facilitating this call.  \n \n Just maybe to conclude, I really think the fundamentals inside the business are strong. ", "original_text": "Okay. "}, "hash": "c301d222713ba60634d177f73156610d278d03a8cb91ccda8f2b4be614c6814b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 1488, "end_char_idx": 1815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f17cc2c-15ed-4601-a7db-aab101475c1a": {"__data__": {"id_": "0f17cc2c-15ed-4601-a7db-aab101475c1a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning.  Thank you, Susanne, for facilitating this call.  \n \n Just maybe to conclude, I really think the fundamentals inside the business are strong. ", "original_text": "Okay. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "815e7dc3-8653-402f-9dfd-bc17d7ccd497", "node_type": "1", "metadata": {"window": "A \nWe don't specifically talk about Northstar, but when we think about our generics portfolio, Northstar is obviously a \ncritical part of that, and we're really pleased wit h the performance of Northstar, and we're pleased with the \nprogress that we're making there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning.  Thank you, Susanne, for facilitating this call.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9f04661e929898a2016f7e6526aab7c20d4cc4cf79abf7ed67d989b472fb3d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ed25b09-5306-48bc-9e19-e7997a094ba1", "node_type": "1", "metadata": {"window": "A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning.  Thank you, Susanne, for facilitating this call.  \n \n Just maybe to conclude, I really think the fundamentals inside the business are strong.  The macro healthcare \nenvironment is supporting a stable market. ", "original_text": "Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning. "}, "hash": "91dffc87037a3211a19fd280e49cd2e4980d9d1e6fbc8cd87fa0af382c3e61c4", "class_name": "RelatedNodeInfo"}}, "text": "Okay. ", "start_char_idx": 1815, "end_char_idx": 1821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ed25b09-5306-48bc-9e19-e7997a094ba1": {"__data__": {"id_": "7ed25b09-5306-48bc-9e19-e7997a094ba1", "embedding": null, "metadata": {"window": "A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning.  Thank you, Susanne, for facilitating this call.  \n \n Just maybe to conclude, I really think the fundamentals inside the business are strong.  The macro healthcare \nenvironment is supporting a stable market. ", "original_text": "Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f17cc2c-15ed-4601-a7db-aab101475c1a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning.  Thank you, Susanne, for facilitating this call.  \n \n Just maybe to conclude, I really think the fundamentals inside the business are strong. ", "original_text": "Okay. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "89e38c1b9cfdc3e9b92426fd34cea6c12d8f8ada060bca72e29955e020f773b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a0412e6-f6d1-465f-8ca4-50822fa7a374", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning.  Thank you, Susanne, for facilitating this call.  \n \n Just maybe to conclude, I really think the fundamentals inside the business are strong.  The macro healthcare \nenvironment is supporting a stable market.  We executed well in the second quarter; I'm very proud of the teams \nand the execution. ", "original_text": "Thank you, Susanne, for facilitating this call.  \n \n"}, "hash": "a58a201bb0cef964ef242c0b88c32a6569b038b042194abc40d0fcaf4bb5bb64", "class_name": "RelatedNodeInfo"}}, "text": "Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning. ", "start_char_idx": 1821, "end_char_idx": 1950, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a0412e6-f6d1-465f-8ca4-50822fa7a374": {"__data__": {"id_": "9a0412e6-f6d1-465f-8ca4-50822fa7a374", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning.  Thank you, Susanne, for facilitating this call.  \n \n Just maybe to conclude, I really think the fundamentals inside the business are strong.  The macro healthcare \nenvironment is supporting a stable market.  We executed well in the second quarter; I'm very proud of the teams \nand the execution. ", "original_text": "Thank you, Susanne, for facilitating this call.  \n \n", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ed25b09-5306-48bc-9e19-e7997a094ba1", "node_type": "1", "metadata": {"window": "A \nI think the relationships with the manufacturers and Northstar have really evolved over the years and are quite \nproductive, and I think that's what's supporting the success that we're seeing there.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning.  Thank you, Susanne, for facilitating this call.  \n \n Just maybe to conclude, I really think the fundamentals inside the business are strong.  The macro healthcare \nenvironment is supporting a stable market. ", "original_text": "Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8e25f7eca64adaf8564bb08c50fbc0e6e2a9097439cde64872b532728a02d768", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a02eb7b6-80ee-456e-95e4-5dc9210bc0c4", "node_type": "1", "metadata": {"window": "Okay.  Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning.  Thank you, Susanne, for facilitating this call.  \n \n Just maybe to conclude, I really think the fundamentals inside the business are strong.  The macro healthcare \nenvironment is supporting a stable market.  We executed well in the second quarter; I'm very proud of the teams \nand the execution.  We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n", "original_text": "Just maybe to conclude, I really think the fundamentals inside the business are strong. "}, "hash": "1168ec873255d985bd4b3c98ddad6cd0dcaf76eab27049d8a754b97e2cf4d8ac", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Susanne, for facilitating this call.  \n \n", "start_char_idx": 1950, "end_char_idx": 2002, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a02eb7b6-80ee-456e-95e4-5dc9210bc0c4": {"__data__": {"id_": "a02eb7b6-80ee-456e-95e4-5dc9210bc0c4", "embedding": null, "metadata": {"window": "Okay.  Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning.  Thank you, Susanne, for facilitating this call.  \n \n Just maybe to conclude, I really think the fundamentals inside the business are strong.  The macro healthcare \nenvironment is supporting a stable market.  We executed well in the second quarter; I'm very proud of the teams \nand the execution.  We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n", "original_text": "Just maybe to conclude, I really think the fundamentals inside the business are strong. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a0412e6-f6d1-465f-8ca4-50822fa7a374", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning.  Thank you, Susanne, for facilitating this call.  \n \n Just maybe to conclude, I really think the fundamentals inside the business are strong.  The macro healthcare \nenvironment is supporting a stable market.  We executed well in the second quarter; I'm very proud of the teams \nand the execution. ", "original_text": "Thank you, Susanne, for facilitating this call.  \n \n", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5f3a095692a4df82ee150b7e4b38c464bbb6bce624584d5f96dacd434822796", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "058bc084-72dc-4890-adac-f14bb82a9fa3", "node_type": "1", "metadata": {"window": "Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning.  Thank you, Susanne, for facilitating this call.  \n \n Just maybe to conclude, I really think the fundamentals inside the business are strong.  The macro healthcare \nenvironment is supporting a stable market.  We executed well in the second quarter; I'm very proud of the teams \nand the execution.  We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity. ", "original_text": "The macro healthcare \nenvironment is supporting a stable market. "}, "hash": "4766f15cfb983a72f8cb2a67a76f7916afb6981af227d3df3c28c1143b022d80", "class_name": "RelatedNodeInfo"}}, "text": "Just maybe to conclude, I really think the fundamentals inside the business are strong. ", "start_char_idx": 2002, "end_char_idx": 2090, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "058bc084-72dc-4890-adac-f14bb82a9fa3": {"__data__": {"id_": "058bc084-72dc-4890-adac-f14bb82a9fa3", "embedding": null, "metadata": {"window": "Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning.  Thank you, Susanne, for facilitating this call.  \n \n Just maybe to conclude, I really think the fundamentals inside the business are strong.  The macro healthcare \nenvironment is supporting a stable market.  We executed well in the second quarter; I'm very proud of the teams \nand the execution.  We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity. ", "original_text": "The macro healthcare \nenvironment is supporting a stable market. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a02eb7b6-80ee-456e-95e4-5dc9210bc0c4", "node_type": "1", "metadata": {"window": "Okay.  Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning.  Thank you, Susanne, for facilitating this call.  \n \n Just maybe to conclude, I really think the fundamentals inside the business are strong.  The macro healthcare \nenvironment is supporting a stable market.  We executed well in the second quarter; I'm very proud of the teams \nand the execution.  We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n", "original_text": "Just maybe to conclude, I really think the fundamentals inside the business are strong. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b27860234c9089d86179a2653ff3b4c3d0aab0eaf8b3da12f4eb8c0e7cc5a09a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e9ac47e-e717-4c64-8dc5-57b97d1dbb1b", "node_type": "1", "metadata": {"window": "Thank you, Susanne, for facilitating this call.  \n \n Just maybe to conclude, I really think the fundamentals inside the business are strong.  The macro healthcare \nenvironment is supporting a stable market.  We executed well in the second quarter; I'm very proud of the teams \nand the execution.  We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity.  They do the right t hing, and our execution and \nsuccess are a direct result of their contributions. ", "original_text": "We executed well in the second quarter; I'm very proud of the teams \nand the execution. "}, "hash": "2d04215977b788b4ac55983a35309359d275b007da9926883b7d7f143168b522", "class_name": "RelatedNodeInfo"}}, "text": "The macro healthcare \nenvironment is supporting a stable market. ", "start_char_idx": 2090, "end_char_idx": 2155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e9ac47e-e717-4c64-8dc5-57b97d1dbb1b": {"__data__": {"id_": "6e9ac47e-e717-4c64-8dc5-57b97d1dbb1b", "embedding": null, "metadata": {"window": "Thank you, Susanne, for facilitating this call.  \n \n Just maybe to conclude, I really think the fundamentals inside the business are strong.  The macro healthcare \nenvironment is supporting a stable market.  We executed well in the second quarter; I'm very proud of the teams \nand the execution.  We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity.  They do the right t hing, and our execution and \nsuccess are a direct result of their contributions. ", "original_text": "We executed well in the second quarter; I'm very proud of the teams \nand the execution. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "058bc084-72dc-4890-adac-f14bb82a9fa3", "node_type": "1", "metadata": {"window": "Well, thank you, everyone, for your questions, and thanks again for your interest and giving us some of \nyour time this morning.  Thank you, Susanne, for facilitating this call.  \n \n Just maybe to conclude, I really think the fundamentals inside the business are strong.  The macro healthcare \nenvironment is supporting a stable market.  We executed well in the second quarter; I'm very proud of the teams \nand the execution.  We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity. ", "original_text": "The macro healthcare \nenvironment is supporting a stable market. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b6f0b5ae21cff8b626a2b47bb4817c28d99a3ef97710db7179c20705dfffb3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6a631de-f313-4622-914f-f9bac98edb35", "node_type": "1", "metadata": {"window": "Just maybe to conclude, I really think the fundamentals inside the business are strong.  The macro healthcare \nenvironment is supporting a stable market.  We executed well in the second quarter; I'm very proud of the teams \nand the execution.  We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity.  They do the right t hing, and our execution and \nsuccess are a direct result of their contributions.  So I want to say thank you to them. ", "original_text": "We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n"}, "hash": "aa7c1f88193b3358d519789004b2a25fd07051124695ec8c39efe83d780e2cff", "class_name": "RelatedNodeInfo"}}, "text": "We executed well in the second quarter; I'm very proud of the teams \nand the execution. ", "start_char_idx": 2155, "end_char_idx": 2243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6a631de-f313-4622-914f-f9bac98edb35": {"__data__": {"id_": "a6a631de-f313-4622-914f-f9bac98edb35", "embedding": null, "metadata": {"window": "Just maybe to conclude, I really think the fundamentals inside the business are strong.  The macro healthcare \nenvironment is supporting a stable market.  We executed well in the second quarter; I'm very proud of the teams \nand the execution.  We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity.  They do the right t hing, and our execution and \nsuccess are a direct result of their contributions.  So I want to say thank you to them. ", "original_text": "We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e9ac47e-e717-4c64-8dc5-57b97d1dbb1b", "node_type": "1", "metadata": {"window": "Thank you, Susanne, for facilitating this call.  \n \n Just maybe to conclude, I really think the fundamentals inside the business are strong.  The macro healthcare \nenvironment is supporting a stable market.  We executed well in the second quarter; I'm very proud of the teams \nand the execution.  We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity.  They do the right t hing, and our execution and \nsuccess are a direct result of their contributions. ", "original_text": "We executed well in the second quarter; I'm very proud of the teams \nand the execution. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ccaccad9998719716480440657341772ccbe3d208409d0e2f9a2bf803e30319c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68c0925d-7180-46ac-936a-d1dac01b0e00", "node_type": "1", "metadata": {"window": "The macro healthcare \nenvironment is supporting a stable market.  We executed well in the second quarter; I'm very proud of the teams \nand the execution.  We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity.  They do the right t hing, and our execution and \nsuccess are a direct result of their contributions.  So I want to say thank you to them.  None of this is possible \nwithout you.  \n \n", "original_text": "My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity. "}, "hash": "bad9d72380a579666ebaa40a5daef4aa54bc590fa544798e83d79582baed507a", "class_name": "RelatedNodeInfo"}}, "text": "We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n", "start_char_idx": 2243, "end_char_idx": 2485, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68c0925d-7180-46ac-936a-d1dac01b0e00": {"__data__": {"id_": "68c0925d-7180-46ac-936a-d1dac01b0e00", "embedding": null, "metadata": {"window": "The macro healthcare \nenvironment is supporting a stable market.  We executed well in the second quarter; I'm very proud of the teams \nand the execution.  We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity.  They do the right t hing, and our execution and \nsuccess are a direct result of their contributions.  So I want to say thank you to them.  None of this is possible \nwithout you.  \n \n", "original_text": "My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6a631de-f313-4622-914f-f9bac98edb35", "node_type": "1", "metadata": {"window": "Just maybe to conclude, I really think the fundamentals inside the business are strong.  The macro healthcare \nenvironment is supporting a stable market.  We executed well in the second quarter; I'm very proud of the teams \nand the execution.  We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity.  They do the right t hing, and our execution and \nsuccess are a direct result of their contributions.  So I want to say thank you to them. ", "original_text": "We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80a3aecfaecd5fe79ac5a8ef5436f666f5a5debc1b55f7b8d1d0f07c2befe351", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28771c67-effe-42f1-8c0e-a61cdb67f9de", "node_type": "1", "metadata": {"window": "We executed well in the second quarter; I'm very proud of the teams \nand the execution.  We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity.  They do the right t hing, and our execution and \nsuccess are a direct result of their contributions.  So I want to say thank you to them.  None of this is possible \nwithout you.  \n \n And now let me hand the call over to Holly for a review of our upcoming events. ", "original_text": "They do the right t hing, and our execution and \nsuccess are a direct result of their contributions. "}, "hash": "ffb5d480e2b10ed3016764baa795fc4e1e949986eab02dd7abb72a272670f12a", "class_name": "RelatedNodeInfo"}}, "text": "My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity. ", "start_char_idx": 2485, "end_char_idx": 2658, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28771c67-effe-42f1-8c0e-a61cdb67f9de": {"__data__": {"id_": "28771c67-effe-42f1-8c0e-a61cdb67f9de", "embedding": null, "metadata": {"window": "We executed well in the second quarter; I'm very proud of the teams \nand the execution.  We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity.  They do the right t hing, and our execution and \nsuccess are a direct result of their contributions.  So I want to say thank you to them.  None of this is possible \nwithout you.  \n \n And now let me hand the call over to Holly for a review of our upcoming events. ", "original_text": "They do the right t hing, and our execution and \nsuccess are a direct result of their contributions. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68c0925d-7180-46ac-936a-d1dac01b0e00", "node_type": "1", "metadata": {"window": "The macro healthcare \nenvironment is supporting a stable market.  We executed well in the second quarter; I'm very proud of the teams \nand the execution.  We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity.  They do the right t hing, and our execution and \nsuccess are a direct result of their contributions.  So I want to say thank you to them.  None of this is possible \nwithout you.  \n \n", "original_text": "My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f18d040c112438a1549df856039a61699a87b21b08fd6e55aa27904e1d47bb3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "feccfd98-5f32-4248-8a71-11b26d277927", "node_type": "1", "metadata": {"window": "We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity.  They do the right t hing, and our execution and \nsuccess are a direct result of their contributions.  So I want to say thank you to them.  None of this is possible \nwithout you.  \n \n And now let me hand the call over to Holly for a review of our upcoming events.  Holly?  \n ", "original_text": "So I want to say thank you to them. "}, "hash": "f72315ca45aeafe4130c985498fb75ff674694b6f24db33848059021eec93147", "class_name": "RelatedNodeInfo"}}, "text": "They do the right t hing, and our execution and \nsuccess are a direct result of their contributions. ", "start_char_idx": 2658, "end_char_idx": 2759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "feccfd98-5f32-4248-8a71-11b26d277927": {"__data__": {"id_": "feccfd98-5f32-4248-8a71-11b26d277927", "embedding": null, "metadata": {"window": "We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity.  They do the right t hing, and our execution and \nsuccess are a direct result of their contributions.  So I want to say thank you to them.  None of this is possible \nwithout you.  \n \n And now let me hand the call over to Holly for a review of our upcoming events.  Holly?  \n ", "original_text": "So I want to say thank you to them. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28771c67-effe-42f1-8c0e-a61cdb67f9de", "node_type": "1", "metadata": {"window": "We executed well in the second quarter; I'm very proud of the teams \nand the execution.  We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity.  They do the right t hing, and our execution and \nsuccess are a direct result of their contributions.  So I want to say thank you to them.  None of this is possible \nwithout you.  \n \n And now let me hand the call over to Holly for a review of our upcoming events. ", "original_text": "They do the right t hing, and our execution and \nsuccess are a direct result of their contributions. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53664d122d73ec6390033686c6f9307716d448a84776aac9aa528a7edcf39e02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "731773ff-4856-4848-8d2c-a861dd05faa4", "node_type": "1", "metadata": {"window": "My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity.  They do the right t hing, and our execution and \nsuccess are a direct result of their contributions.  So I want to say thank you to them.  None of this is possible \nwithout you.  \n \n And now let me hand the call over to Holly for a review of our upcoming events.  Holly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "original_text": "None of this is possible \nwithout you.  \n \n"}, "hash": "f8e751488c909d8406320adba4c82006c35f6e8af968cc781e0901267e22a31a", "class_name": "RelatedNodeInfo"}}, "text": "So I want to say thank you to them. ", "start_char_idx": 2759, "end_char_idx": 2795, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "731773ff-4856-4848-8d2c-a861dd05faa4": {"__data__": {"id_": "731773ff-4856-4848-8d2c-a861dd05faa4", "embedding": null, "metadata": {"window": "My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity.  They do the right t hing, and our execution and \nsuccess are a direct result of their contributions.  So I want to say thank you to them.  None of this is possible \nwithout you.  \n \n And now let me hand the call over to Holly for a review of our upcoming events.  Holly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "original_text": "None of this is possible \nwithout you.  \n \n", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "feccfd98-5f32-4248-8a71-11b26d277927", "node_type": "1", "metadata": {"window": "We're continuing to drive cost savings, we're continuing to speed up our decision -making, \nwe're continuing to make investments where we think we have opportunities for g rowth, and I feel good about our \nfiscal 2020 full -year outlook.  \n \n My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity.  They do the right t hing, and our execution and \nsuccess are a direct result of their contributions.  So I want to say thank you to them.  None of this is possible \nwithout you.  \n \n And now let me hand the call over to Holly for a review of our upcoming events.  Holly?  \n ", "original_text": "So I want to say thank you to them. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e15f9864092a80fe91f987495f3d13ffe1fcce6b916b678483b5063895217a25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "573ad571-1b96-4ada-b237-e06a8de4a584", "node_type": "1", "metadata": {"window": "They do the right t hing, and our execution and \nsuccess are a direct result of their contributions.  So I want to say thank you to them.  None of this is possible \nwithout you.  \n \n And now let me hand the call over to Holly for a review of our upcoming events.  Holly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Brian. ", "original_text": "And now let me hand the call over to Holly for a review of our upcoming events. "}, "hash": "65d331e4abe3acf98344ead60977a2ef87bf6a2a8e0058582bbcebcda328b745", "class_name": "RelatedNodeInfo"}}, "text": "None of this is possible \nwithout you.  \n \n", "start_char_idx": 2795, "end_char_idx": 2838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "573ad571-1b96-4ada-b237-e06a8de4a584": {"__data__": {"id_": "573ad571-1b96-4ada-b237-e06a8de4a584", "embedding": null, "metadata": {"window": "They do the right t hing, and our execution and \nsuccess are a direct result of their contributions.  So I want to say thank you to them.  None of this is possible \nwithout you.  \n \n And now let me hand the call over to Holly for a review of our upcoming events.  Holly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Brian. ", "original_text": "And now let me hand the call over to Holly for a review of our upcoming events. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "731773ff-4856-4848-8d2c-a861dd05faa4", "node_type": "1", "metadata": {"window": "My confidence is of course rooted in the 80,000 employees that come to work every day for McKesson, for our \nshareholders, really embodying our values, including integrity.  They do the right t hing, and our execution and \nsuccess are a direct result of their contributions.  So I want to say thank you to them.  None of this is possible \nwithout you.  \n \n And now let me hand the call over to Holly for a review of our upcoming events.  Holly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "original_text": "None of this is possible \nwithout you.  \n \n", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d25f2701d9f0a389426d53fac391c1171d3f920cec792a0825eb0f3928e42c62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76ac0899-877d-4fb8-bf9d-83681b20f56b", "node_type": "1", "metadata": {"window": "So I want to say thank you to them.  None of this is possible \nwithout you.  \n \n And now let me hand the call over to Holly for a review of our upcoming events.  Holly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Brian.  We will participate in the J.P. ", "original_text": "Holly?  \n "}, "hash": "e19c499f38d90ac583c56034a0ad6b93f9139a43fd1e94ddab51a696a1baa85a", "class_name": "RelatedNodeInfo"}}, "text": "And now let me hand the call over to Holly for a review of our upcoming events. ", "start_char_idx": 2838, "end_char_idx": 2918, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76ac0899-877d-4fb8-bf9d-83681b20f56b": {"__data__": {"id_": "76ac0899-877d-4fb8-bf9d-83681b20f56b", "embedding": null, "metadata": {"window": "So I want to say thank you to them.  None of this is possible \nwithout you.  \n \n And now let me hand the call over to Holly for a review of our upcoming events.  Holly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Brian.  We will participate in the J.P. ", "original_text": "Holly?  \n ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "573ad571-1b96-4ada-b237-e06a8de4a584", "node_type": "1", "metadata": {"window": "They do the right t hing, and our execution and \nsuccess are a direct result of their contributions.  So I want to say thank you to them.  None of this is possible \nwithout you.  \n \n And now let me hand the call over to Holly for a review of our upcoming events.  Holly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Brian. ", "original_text": "And now let me hand the call over to Holly for a review of our upcoming events. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bf846de61638c38fad9c812f2e84b1a9d67c8f434154ca6b7c1b4b6f2a72271", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4aac7526-7b37-401e-915d-cd3fd6b28c93", "node_type": "1", "metadata": {"window": "None of this is possible \nwithout you.  \n \n And now let me hand the call over to Holly for a review of our upcoming events.  Holly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Brian.  We will participate in the J.P.  Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n"}, "hash": "fce15d0090b97316c999d38d56e4dbea0496ce42e0e1cd627aa0ed8c1e0b6d8c", "class_name": "RelatedNodeInfo"}}, "text": "Holly?  \n ", "start_char_idx": 2918, "end_char_idx": 2928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4aac7526-7b37-401e-915d-cd3fd6b28c93": {"__data__": {"id_": "4aac7526-7b37-401e-915d-cd3fd6b28c93", "embedding": null, "metadata": {"window": "None of this is possible \nwithout you.  \n \n And now let me hand the call over to Holly for a review of our upcoming events.  Holly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Brian.  We will participate in the J.P.  Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76ac0899-877d-4fb8-bf9d-83681b20f56b", "node_type": "1", "metadata": {"window": "So I want to say thank you to them.  None of this is possible \nwithout you.  \n \n And now let me hand the call over to Holly for a review of our upcoming events.  Holly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Brian.  We will participate in the J.P. ", "original_text": "Holly?  \n ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4abcb927b44056da065bee0dc1b0cf4182f7ddd66d5db9ba409433e59c9798de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d524ae9b-5ead-4de1-811b-fff811757d53", "node_type": "1", "metadata": {"window": "And now let me hand the call over to Holly for a review of our upcoming events.  Holly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Brian.  We will participate in the J.P.  Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January.  Thank you and goo dbye.  \n ", "original_text": "Thank you, Brian. "}, "hash": "a8126e774d1c31ad0e565c0c0a33bd4f38f5e9b751e3d193ccd78f133c233f0f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "start_char_idx": 2928, "end_char_idx": 3259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d524ae9b-5ead-4de1-811b-fff811757d53": {"__data__": {"id_": "d524ae9b-5ead-4de1-811b-fff811757d53", "embedding": null, "metadata": {"window": "And now let me hand the call over to Holly for a review of our upcoming events.  Holly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Brian.  We will participate in the J.P.  Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January.  Thank you and goo dbye.  \n ", "original_text": "Thank you, Brian. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4aac7526-7b37-401e-915d-cd3fd6b28c93", "node_type": "1", "metadata": {"window": "None of this is possible \nwithout you.  \n \n And now let me hand the call over to Holly for a review of our upcoming events.  Holly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Brian.  We will participate in the J.P.  Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2998e3d150062f8dd4d601946892f4af67ae5408c364e3d5ca8292e87890487e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77140513-2181-40f6-8b45-6d699368a32e", "node_type": "1", "metadata": {"window": "Holly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Brian.  We will participate in the J.P.  Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January.  Thank you and goo dbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And thank you for joining today's conference call. ", "original_text": "We will participate in the J.P. "}, "hash": "18d48f612b7f789833ff306d7efa0009463f177f4b28b7f56dd45173fd78fb17", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Brian. ", "start_char_idx": 3259, "end_char_idx": 3277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77140513-2181-40f6-8b45-6d699368a32e": {"__data__": {"id_": "77140513-2181-40f6-8b45-6d699368a32e", "embedding": null, "metadata": {"window": "Holly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Brian.  We will participate in the J.P.  Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January.  Thank you and goo dbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And thank you for joining today's conference call. ", "original_text": "We will participate in the J.P. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d524ae9b-5ead-4de1-811b-fff811757d53", "node_type": "1", "metadata": {"window": "And now let me hand the call over to Holly for a review of our upcoming events.  Holly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Brian.  We will participate in the J.P.  Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January.  Thank you and goo dbye.  \n ", "original_text": "Thank you, Brian. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b49dae5dd01dc793f4bdff4203e6b0f20c3aa06ff279be5785878aa603ccc66e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20436f69-056d-47a6-bde7-5557f6591e83", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Brian.  We will participate in the J.P.  Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January.  Thank you and goo dbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January. "}, "hash": "3455c65124251324682085c48bc2b06b7579e8667059a42e40abd4367a382216", "class_name": "RelatedNodeInfo"}}, "text": "We will participate in the J.P. ", "start_char_idx": 3277, "end_char_idx": 3309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20436f69-056d-47a6-bde7-5557f6591e83": {"__data__": {"id_": "20436f69-056d-47a6-bde7-5557f6591e83", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Brian.  We will participate in the J.P.  Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January.  Thank you and goo dbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77140513-2181-40f6-8b45-6d699368a32e", "node_type": "1", "metadata": {"window": "Holly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Brian.  We will participate in the J.P.  Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January.  Thank you and goo dbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And thank you for joining today's conference call. ", "original_text": "We will participate in the J.P. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0dfe75f8fb32c7776aab31ac99ddcd4bf3d2ac15f1f92ff0597c1cd01123dd07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49fdec95-70e6-44d1-afcd-d788e7a92419", "node_type": "1", "metadata": {"window": "Thank you, Brian.  We will participate in the J.P.  Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January.  Thank you and goo dbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "Thank you and goo dbye.  \n "}, "hash": "c406e8c1595d31b929e8c9e6381a181c850f60614a6f15bdf334695c1349994f", "class_name": "RelatedNodeInfo"}}, "text": "Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January. ", "start_char_idx": 3309, "end_char_idx": 3441, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49fdec95-70e6-44d1-afcd-d788e7a92419": {"__data__": {"id_": "49fdec95-70e6-44d1-afcd-d788e7a92419", "embedding": null, "metadata": {"window": "Thank you, Brian.  We will participate in the J.P.  Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January.  Thank you and goo dbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "Thank you and goo dbye.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20436f69-056d-47a6-bde7-5557f6591e83", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Brian.  We will participate in the J.P.  Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January.  Thank you and goo dbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5586351093a8ead6190d93794659f658eec7d343ebc995ed43986d9537abc3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1d0a407-0e09-454a-841c-ef145343e342", "node_type": "1", "metadata": {"window": "We will participate in the J.P.  Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January.  Thank you and goo dbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And thank you for joining today's conference call. "}, "hash": "8b4d63598a809d9aebf3c866d6635ab5416d60da4f38eed4b3b4ad4dea300a3c", "class_name": "RelatedNodeInfo"}}, "text": "Thank you and goo dbye.  \n ", "start_char_idx": 3441, "end_char_idx": 3468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1d0a407-0e09-454a-841c-ef145343e342": {"__data__": {"id_": "f1d0a407-0e09-454a-841c-ef145343e342", "embedding": null, "metadata": {"window": "We will participate in the J.P.  Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January.  Thank you and goo dbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And thank you for joining today's conference call. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49fdec95-70e6-44d1-afcd-d788e7a92419", "node_type": "1", "metadata": {"window": "Thank you, Brian.  We will participate in the J.P.  Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January.  Thank you and goo dbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "Thank you and goo dbye.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6aca76ef1179cfb75fc40d45fc26f4bd8cc65dbf5065b6d2b2d138b476df279", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "365200d9-022b-4499-9df7-9d82ce784cad", "node_type": "1", "metadata": {"window": "Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January.  Thank you and goo dbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n "}, "hash": "a957bd1df6bf7a36dc35608c71339de182ac661c393d4eff858eff3abdc342c0", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And thank you for joining today's conference call. ", "start_char_idx": 3468, "end_char_idx": 3789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "365200d9-022b-4499-9df7-9d82ce784cad": {"__data__": {"id_": "365200d9-022b-4499-9df7-9d82ce784cad", "embedding": null, "metadata": {"window": "Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January.  Thank you and goo dbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda70f82f4abaa43495746154965a7e074de1bb5c940afc2286d10f794998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1d0a407-0e09-454a-841c-ef145343e342", "node_type": "1", "metadata": {"window": "We will participate in the J.P.  Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January.  Thank you and goo dbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And thank you for joining today's conference call. ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5ec4dc3aba840caa454d79b414dda0f662c351b86eac00afa586a795799c425", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a52e32e-53e0-4e68-8943-801c772ebaed", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "McKesson Corp.  "}, "hash": "1f246340c4c1b3f3b3ff32a2bf8635c542d995c459e446e813ac2b24e4075fa4", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect, and have a great day.  \n \n \n \n ", "start_char_idx": 3789, "end_char_idx": 3844, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a52e32e-53e0-4e68-8943-801c772ebaed": {"__data__": {"id_": "6a52e32e-53e0-4e68-8943-801c772ebaed", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5688580-d83a-42f1-8a16-47f74e44508d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01d765c35eab3fb0fab183e67a218d0c53f60ae6b6035735b6d8875d05f60904", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "365200d9-022b-4499-9df7-9d82ce784cad", "node_type": "1", "metadata": {"window": "Morgan Healthcare Conference in San Francisco in mid -January, \nand we will release third quarter earnings results in late January.  Thank you and goo dbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b790299447a65aa64f9c9e5b799ee606ea65a6468ba392fac626881d7896eace", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "755f3432-80df-463a-8024-6af242e5781c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n"}, "hash": "0936c43b3d6fd9a71d380db1dcd1f3e123f576cf33b8c28c679f2e0d535b29cb", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "755f3432-80df-463a-8024-6af242e5781c": {"__data__": {"id_": "755f3432-80df-463a-8024-6af242e5781c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5688580-d83a-42f1-8a16-47f74e44508d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01d765c35eab3fb0fab183e67a218d0c53f60ae6b6035735b6d8875d05f60904", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a52e32e-53e0-4e68-8943-801c772ebaed", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41c26348a81b22fe8b30c8fcb39c1d0872e73d74d58e98e16aa918af0b7a26a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff09d092-402e-4aa0-a729-b1d2e83f3bf5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. "}, "hash": "8989c837239f6df8ff801373e877f038425d57a26f0757387cb438b73e709567", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n", "start_char_idx": 16, "end_char_idx": 403, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff09d092-402e-4aa0-a729-b1d2e83f3bf5": {"__data__": {"id_": "ff09d092-402e-4aa0-a729-b1d2e83f3bf5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5688580-d83a-42f1-8a16-47f74e44508d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01d765c35eab3fb0fab183e67a218d0c53f60ae6b6035735b6d8875d05f60904", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "755f3432-80df-463a-8024-6af242e5781c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor. ", "original_text": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5706adeea4db9c09a18233fbbdc9e1c7921e09b34c6c994138c3c847077c4ded", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96d30d09-9439-4ff4-90f3-53bc018649a2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. "}, "hash": "87224b26f046b9dbe53fc1ef4a5de1dd28ebb6c1072964c959f6b6c9fd273d6a", "class_name": "RelatedNodeInfo"}}, "text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "start_char_idx": 403, "end_char_idx": 525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96d30d09-9439-4ff4-90f3-53bc018649a2": {"__data__": {"id_": "96d30d09-9439-4ff4-90f3-53bc018649a2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5688580-d83a-42f1-8a16-47f74e44508d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01d765c35eab3fb0fab183e67a218d0c53f60ae6b6035735b6d8875d05f60904", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff09d092-402e-4aa0-a729-b1d2e83f3bf5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "68d9942d7308ec52fc3f1ec32a44f23da8b5eca08dc98383d3bfb6ceffcabf04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d9e9927-fc34-457b-9a38-13c8208439e3", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC. ", "original_text": "It should not be co nstrued as advice designed to meet the particular investment needs of any investor. "}, "hash": "d9a5aefd30d3b214851240f4119b45f4e0283e24adc99be816fdb4533c38b648", "class_name": "RelatedNodeInfo"}}, "text": "You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "start_char_idx": 525, "end_char_idx": 818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d9e9927-fc34-457b-9a38-13c8208439e3": {"__data__": {"id_": "4d9e9927-fc34-457b-9a38-13c8208439e3", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC. ", "original_text": "It should not be co nstrued as advice designed to meet the particular investment needs of any investor. ", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5688580-d83a-42f1-8a16-47f74e44508d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01d765c35eab3fb0fab183e67a218d0c53f60ae6b6035735b6d8875d05f60904", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96d30d09-9439-4ff4-90f3-53bc018649a2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0be1fda86f4b25292fcf1a6b2169e7cb3163356334293bfcfd59d8a2697e0a31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec7cee9c-3f35-4ca5-9d9b-dc5afd7de27a", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. "}, "hash": "2c039f8932268cf3fe725e4692f9228ad415248a811d5a15f3dc480b5828a5e2", "class_name": "RelatedNodeInfo"}}, "text": "It should not be co nstrued as advice designed to meet the particular investment needs of any investor. ", "start_char_idx": 818, "end_char_idx": 922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec7cee9c-3f35-4ca5-9d9b-dc5afd7de27a": {"__data__": {"id_": "ec7cee9c-3f35-4ca5-9d9b-dc5afd7de27a", "embedding": null, "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5688580-d83a-42f1-8a16-47f74e44508d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01d765c35eab3fb0fab183e67a218d0c53f60ae6b6035735b6d8875d05f60904", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d9e9927-fc34-457b-9a38-13c8208439e3", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC. ", "original_text": "It should not be co nstrued as advice designed to meet the particular investment needs of any investor. ", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f6577b4c443f2b3ebf342b8e7149f834668e3a2edd5b3caed41a1483d5e8fd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfcc7329-814d-4e0f-8fcd-6c49bda189ce", "node_type": "1", "metadata": {"window": "You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. "}, "hash": "335f333adf8eaccd4ee66510a340b9b2a4632e6c9ca9be45fdb7c13158aad02a", "class_name": "RelatedNodeInfo"}}, "text": "This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "start_char_idx": 922, "end_char_idx": 1180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfcc7329-814d-4e0f-8fcd-6c49bda189ce": {"__data__": {"id_": "dfcc7329-814d-4e0f-8fcd-6c49bda189ce", "embedding": null, "metadata": {"window": "You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5688580-d83a-42f1-8a16-47f74e44508d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01d765c35eab3fb0fab183e67a218d0c53f60ae6b6035735b6d8875d05f60904", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec7cee9c-3f35-4ca5-9d9b-dc5afd7de27a", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7aa6cd53e71a810d3c5ef9edd7722acfed361d8b82de80c4e1f41fbae0c40183", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67d4617b-a8a3-476f-85e3-f20265b8be80", "node_type": "1", "metadata": {"window": "It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC. "}, "hash": "4a46346c036414228b4f20794cdab5715ec8d916f87a61cef9ddcdf325a2583c", "class_name": "RelatedNodeInfo"}}, "text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "start_char_idx": 1180, "end_char_idx": 1264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67d4617b-a8a3-476f-85e3-f20265b8be80": {"__data__": {"id_": "67d4617b-a8a3-476f-85e3-f20265b8be80", "embedding": null, "metadata": {"window": "It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC. ", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5688580-d83a-42f1-8a16-47f74e44508d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01d765c35eab3fb0fab183e67a218d0c53f60ae6b6035735b6d8875d05f60904", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfcc7329-814d-4e0f-8fcd-6c49bda189ce", "node_type": "1", "metadata": {"window": "You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7f0bd2b42c554dd1559e8224be3ce4cb11b38b9bde4de2e7882483691e07e9a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71efdae4-4a22-4c95-81e2-efcf0caebd99", "node_type": "1", "metadata": {"window": "This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n"}, "hash": "ab8d42aab2aff2fd1bec0fc1c50405e8489f804a49a181d2fed29739ffe79623", "class_name": "RelatedNodeInfo"}}, "text": "Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC. ", "start_char_idx": 1264, "end_char_idx": 1393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71efdae4-4a22-4c95-81e2-efcf0caebd99": {"__data__": {"id_": "71efdae4-4a22-4c95-81e2-efcf0caebd99", "embedding": null, "metadata": {"window": "This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5688580-d83a-42f1-8a16-47f74e44508d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01d765c35eab3fb0fab183e67a218d0c53f60ae6b6035735b6d8875d05f60904", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67d4617b-a8a3-476f-85e3-f20265b8be80", "node_type": "1", "metadata": {"window": "It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC. ", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d83b3c502fb717ac161b22fe1e4eaa402b9d461e53db6f381c8727e3c0672380", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "879371e0-82f5-44df-b57f-a2323f39418e", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. "}, "hash": "2a99ff2aba5738cabcdd42320446eaf929cb182c62573378eda93412df2b7e58", "class_name": "RelatedNodeInfo"}}, "text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "start_char_idx": 1393, "end_char_idx": 1556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "879371e0-82f5-44df-b57f-a2323f39418e": {"__data__": {"id_": "879371e0-82f5-44df-b57f-a2323f39418e", "embedding": null, "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5688580-d83a-42f1-8a16-47f74e44508d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01d765c35eab3fb0fab183e67a218d0c53f60ae6b6035735b6d8875d05f60904", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71efdae4-4a22-4c95-81e2-efcf0caebd99", "node_type": "1", "metadata": {"window": "This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5207b627967faa8c0caa13efe7b080231a952413514e020433006bdab75507c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19965a39-da82-4119-b6ef-69d0c3511a62", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n"}, "hash": "bf4db4cc08660532adef97673cb9d0560fdac71cf382b02f5db7615a00660700", "class_name": "RelatedNodeInfo"}}, "text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "start_char_idx": 1556, "end_char_idx": 1991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19965a39-da82-4119-b6ef-69d0c3511a62": {"__data__": {"id_": "19965a39-da82-4119-b6ef-69d0c3511a62", "embedding": null, "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5688580-d83a-42f1-8a16-47f74e44508d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01d765c35eab3fb0fab183e67a218d0c53f60ae6b6035735b6d8875d05f60904", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "879371e0-82f5-44df-b57f-a2323f39418e", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4edd3f194dd656af366e76aebf56233af2228a51f43e97c152114502c947f5f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ca5f54b-c75e-424e-a560-0ae253726c2d", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n"}, "hash": "058530cb331807b1543b4822aa4bfe38feb7848c2f114bd5e0640b099a4288bd", "class_name": "RelatedNodeInfo"}}, "text": "TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n", "start_char_idx": 1991, "end_char_idx": 2672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ca5f54b-c75e-424e-a560-0ae253726c2d": {"__data__": {"id_": "8ca5f54b-c75e-424e-a560-0ae253726c2d", "embedding": null, "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5688580-d83a-42f1-8a16-47f74e44508d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01d765c35eab3fb0fab183e67a218d0c53f60ae6b6035735b6d8875d05f60904", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19965a39-da82-4119-b6ef-69d0c3511a62", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad11efa665bee84dd94c1d18edace2b2c241f503ed4f80aadd9a86f995c22d10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4551d03-72da-4a9f-8a43-43d1c66eb018", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All other trademarks mentioned are trademarks of their respective companies. "}, "hash": "5d249393e7402054ded46ec2e34b8ac006d7157ecde87e98e6ebd4aba0bfb1f6", "class_name": "RelatedNodeInfo"}}, "text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n", "start_char_idx": 2672, "end_char_idx": 2862, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4551d03-72da-4a9f-8a43-43d1c66eb018": {"__data__": {"id_": "c4551d03-72da-4a9f-8a43-43d1c66eb018", "embedding": null, "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All other trademarks mentioned are trademarks of their respective companies. ", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5688580-d83a-42f1-8a16-47f74e44508d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01d765c35eab3fb0fab183e67a218d0c53f60ae6b6035735b6d8875d05f60904", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ca5f54b-c75e-424e-a560-0ae253726c2d", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "900975fe1aecdae9604d7ea21158bfa00a09c3c803a1f48e42b04f72cb96499d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1c91e00-7642-4d49-88ae-b57a113b3aaf", "node_type": "1", "metadata": {"window": "TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  "}, "hash": "a360ac3328d69d8d89a16f350bb1dc7b83e96a75c2b51dcb5dcbb2c6810b1ee7", "class_name": "RelatedNodeInfo"}}, "text": "All other trademarks mentioned are trademarks of their respective companies. ", "start_char_idx": 2862, "end_char_idx": 2939, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1c91e00-7642-4d49-88ae-b57a113b3aaf": {"__data__": {"id_": "f1c91e00-7642-4d49-88ae-b57a113b3aaf", "embedding": null, "metadata": {"window": "TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  ", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5688580-d83a-42f1-8a16-47f74e44508d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01d765c35eab3fb0fab183e67a218d0c53f60ae6b6035735b6d8875d05f60904", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4551d03-72da-4a9f-8a43-43d1c66eb018", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIE D WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, I NCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSS ES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MAT TER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All other trademarks mentioned are trademarks of their respective companies. ", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c5b48347ff521ae96c61496c5c89c758842b6b24dedafca312e64156ca5a1cc5", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved.  ", "start_char_idx": 2939, "end_char_idx": 2961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"27128e1f-79cb-4a66-87f6-31b5d6655697": {"doc_hash": "c72d818fc1b556b3f2f4e738616851b210373f23404cde4e84bb2e6dfbf4a188", "ref_doc_id": "e385906f-c0ce-4fa2-b4d2-9c45ca30478e"}, "2d7366c2-e4e8-4f21-a2c4-49d8d2be4744": {"doc_hash": "41149aa840d2fac7beb149ae57092e8a2a37982dde06aef7a4216d6aea772632", "ref_doc_id": "e385906f-c0ce-4fa2-b4d2-9c45ca30478e"}, "e73dbf6b-a88c-4195-8dc1-7b08ef125561": {"doc_hash": "572010c072395194d0633217408bc8687bdaa119668067c3c01394eea5e4d69d", "ref_doc_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02"}, "5acbfab8-3f45-4b0c-9223-d0385f6a56aa": {"doc_hash": "c5437501b1f06ebe677f0ced75d647819e853381a16f5dee06f50ad6b7ead3b7", "ref_doc_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02"}, "1703f5ac-9284-4867-94a4-0fe3a89d082c": {"doc_hash": "59c360d549a3e9a906b630687420922832e9542c131a357cbbe8d7f018601bbe", "ref_doc_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02"}, "917c26f1-58d3-4028-b7b8-bf4087e2b002": {"doc_hash": "89dee3d0a1e2e40d58d312326a0a497461af25396dabccbb64c963cfeb86c642", "ref_doc_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02"}, "73116bb2-1fce-439d-9eb3-3cea3fb4bb51": {"doc_hash": "c244859460424f71491755f06d9fc4bae1f85a03341fd9f1be6cb70480476478", "ref_doc_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02"}, "d3b91612-32f5-4f9e-80a3-961708352f4a": {"doc_hash": "97e846b8366b41b3ec253491ffe640279854b1f7dcbca9997ef7c02ac292570d", "ref_doc_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02"}, "f92643c0-0d5c-4a34-a81c-50a7c7678765": {"doc_hash": "408079dc7b12c440458799bf5169051f67d757be923bebd428ada960d549d02b", "ref_doc_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02"}, "ac9d0176-0e0f-4ab5-9406-878caca2b5cb": {"doc_hash": "d5a44b51c13a5fbb3840718638ff2fc24fc70929d4680b2adb07b7d8c5eef81d", "ref_doc_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02"}, "52e5ab9d-e0eb-460a-be7a-35947fd0bf20": {"doc_hash": "edd1090cfee270f4d14a11f8317d6bc2635a36a573bc847ecd4bd83ef63f442f", "ref_doc_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02"}, "2d1cd378-10dd-4911-9cf1-caa9062a0aef": {"doc_hash": "59c868914f80c8db9f70a52a9dc2ae8f2cb8fe8dcc5f5f163b6a2475dd59b402", "ref_doc_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02"}, "5207a613-0e01-431f-8020-b719f1a28dca": {"doc_hash": "d98c2fc1873a35f4aa62692dde916f1d30357d340a70f590141642fa8db77b25", "ref_doc_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02"}, "b17c625f-c6f2-4a53-b683-91a3a68d89f4": {"doc_hash": "2aff518886a5d870851d061fb63b7feb2bd278c5b83736876f988d4cce434365", "ref_doc_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02"}, "3a94e57b-90ac-4b26-b61e-ec58ea3e2767": {"doc_hash": "0f6908f01375f55d367455b5358ec009d26bfc63f8677ea9941ea443473dcee6", "ref_doc_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02"}, "743468f6-1d35-4ef2-8d29-e781e6e9b65e": {"doc_hash": "5adf1c9539d5d277f5b59fdb98fb8dbcbf022876fadfb507b1582ad0809f15fd", "ref_doc_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02"}, "e0b3ad52-6736-4bf6-8567-25db70a96eca": {"doc_hash": "0d078aa13fd9038eb885d1058d5a6f14f77e76c314edfc70384be0c509770aeb", "ref_doc_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02"}, "f910ec9e-673f-41a3-85b9-2264b78d5396": {"doc_hash": "f324539f38624d1957eae41aac44082437df006706f65d84b6a5007b42342556", "ref_doc_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02"}, "adf465b8-fff7-400d-b8fc-770e7a7a3cbf": {"doc_hash": "ca5966926d89f5166eb100f9615ef75f3bd696c1c499ef9d3418b24c0a4ece52", "ref_doc_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02"}, "fecab0e9-efbb-43ad-9b58-be7b0fc5b771": {"doc_hash": "a040cdeac6d3e88c798f8a7e1f74470ed9d80fcec166d1fa6f1397b43ffc4355", "ref_doc_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02"}, "383602b8-d7d5-46fb-82db-3fc3355a429b": {"doc_hash": "0cdd8e115b3c4c8b3cda83676a9bf25b9e0fc56135b4080721c83f489e428e4c", "ref_doc_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02"}, "0a9e9b89-1170-4c5d-bbca-95cb1795c117": {"doc_hash": "32022b19d59f37c38ec24c709208c0bee98f00741ee2e1f89c4b29da6fe40c53", "ref_doc_id": "3f935131-e65a-49a3-b96a-9ce83cf85c02"}, "816e888a-539e-4c9e-8855-b45b20335340": {"doc_hash": "f1b03bf672c550751b58f4db9e4f49e19f31604732c4a51cec138ae8d7bca3f3", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "094c2473-8130-45b9-a943-16911ca12ae4": {"doc_hash": "d4453bd85a250611662c1308ff13cb4683a25e53b6fb02b2a4e85f3a492a4b10", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "219d5862-3cce-4f14-85da-edb76cd4697b": {"doc_hash": "a19e5dfabb634af539ff3d28bc886b3288b04f69123caf8e08567a2c514138e4", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "9ccdc336-55bd-4b4a-9a4c-852db12eac54": {"doc_hash": "1da8cd87be806511aa591217fe4ea6bf819847ac7f2619d82cb8e9232f58692e", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "26871d99-772f-4e00-916a-39da73c26b6d": {"doc_hash": "e2c46f1fa0e117b73dd4811c978e5de40dbb39e005d7357bc5c170819dbfd752", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "107a304a-b224-4b21-a603-49ea6bb88961": {"doc_hash": "7ce314e8897afd19822a4a0e299c959c26492c38c836407f1ab31ba6f17469a9", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "1b9d1842-4db9-4c79-8af9-f0bdd38bd22a": {"doc_hash": "82930510fd32f699cecfd8d58c9f5198f79106a5385fc6e40db186de43f177e1", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "c09dc24b-31ce-465c-82b9-76b3a6fa21af": {"doc_hash": "62e23c850569243bc71a473bca2fa8077d3f189377b98a73c986a7bba2690520", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "26090125-0cf9-4fe2-8094-8cc1342d6248": {"doc_hash": "fbf88b613de6bd04b2407fd2407bdc016708a6ba915ae969d68852327643420c", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "95437e0c-6ecb-4de7-83e2-4ffacffab1f4": {"doc_hash": "f1321bfcafd700e76fae0cb23b5890deefbd32906a9650d1687a3ceba7734d52", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "c2e86462-b473-4905-bc99-afb3817f3252": {"doc_hash": "9f3237297f77a99a15727ed59483da90e3302a799e3d714b6080b2267329f89d", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "bd8f4fb2-ca4a-47b0-b864-6c919d388809": {"doc_hash": "c1889eacc778d8dfcabf7c837ca1e711d06a2f3d95f77bf5570920ef82314e69", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "eaebaba8-9700-47aa-8df5-63037cfe1ad1": {"doc_hash": "5109a1ca71befd81d5c5f6bdfaaeb111ca6072a8e80bb2d2c483521cf5afa22c", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "a244e964-f321-42ed-9858-efcef3fb46cd": {"doc_hash": "e9b36ab0a85d16f9f212fc653e75ad6c1f14405f07599ab06d56eb5fbcd42488", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "8cf3edbe-86f5-4038-8176-c3369629c8af": {"doc_hash": "7362ab06ad87d691d0c63398a3298681460370e48dd0447c6c5e1ea3105ace53", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "253fc8ec-dff1-451e-826a-c65a33a0a8ea": {"doc_hash": "4e38f3d82450f6366b4eabb072fe520fc1ac6a1d84aeb2a11a318806738adde8", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "81f3847a-f92b-4e05-a9f3-3a82dbdf6d56": {"doc_hash": "f34407e57c01004143e3eebced1181c4e36d15d5538f3a0e849402ca5bd76448", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "63d9ae78-8f8e-4abb-a5f2-8316d400e305": {"doc_hash": "e3437eba32302265cfe3386b0e05e8afa57b6cbe4e071d98d2f65b5f424a92ef", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "35a1278a-4a67-48ec-97a1-d4cc1d3155cb": {"doc_hash": "3e7fef32146655ce1864ffc975f9cc3311fcbd3c45d37f8c560d71cd166495f0", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "ffcac5a3-cc32-45eb-8fca-18048f7a7a79": {"doc_hash": "bacd61a8d861b0123de19040238ae0353000ab8786620fec2c71f470ae735517", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "346ac7ae-b936-4ddb-89de-88e37147c091": {"doc_hash": "8db9c18c8221800e5f69db1a74245b90afe084c53ab1df919192c6ed5f5e027d", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "d665882f-56e1-4274-8432-56b082d9cade": {"doc_hash": "8b979403f264ccd17215de750f94aa18165b9cf74ff9d7ebae4a0d8e71cd8d49", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "5a93b8f7-2061-426d-9967-8d918a74f637": {"doc_hash": "39f2155e8b316e0bfbf9554fa32f293925ba9e826fb918ec6c4c8a1031277b64", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "c63d36bf-6663-48d6-9fd6-93bf3d9b1101": {"doc_hash": "47b766d1e8de9ea495bc8967281a3ba6a95d12534c50b361e2df0cafeb8f8403", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "2c7d14a6-400f-4bc3-9c1e-802d57b7b73e": {"doc_hash": "56b30ea567d0a44b13889de80d3c3e87c8e11efc6d30e7c5be812fdfbf7b3f75", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "9c3bbed6-c223-4754-afc7-bda899611901": {"doc_hash": "c9150d205811440815147ffc68bc79712006e2f735ae7258f9680b148907b593", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "587c7861-d872-4dbb-8491-f6d19684775a": {"doc_hash": "ec42ad5470b05ce1c235302f1c5f0c35780774dd1629095d00b44c4cb136440f", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "caef3579-4e0e-44ef-bbe0-17c39c969fc6": {"doc_hash": "97ae0733a001a1b8b4764b829196accb2cbdbfd917bca04b015fe10070d7e28c", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "1903d3fa-ff64-4bba-84a0-499434a17460": {"doc_hash": "7877cbeea1df1baa2f617f873782f79d6d1aa9342fe5b60d2dbdc389f5e58d6d", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "d22bae23-12a8-4cce-855a-a752dc8d7ef2": {"doc_hash": "452b67b8e2bf1f56554511583aeeff87bc124fccf7293b3d537361826278d8bd", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "a89fb811-f9f8-450f-9d18-c75962736164": {"doc_hash": "b4429f42979bf322ad81b800d0340efd19b0c5f22a3bc964ee0a671e49acc3db", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "a285595f-c370-452e-b671-5247d520299b": {"doc_hash": "5630eb4f6c7f89fc5742412a93c01037aaed3a53ef0d86d14a85b788e6415810", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "42bf4aa0-4acf-44f3-8425-0c8056c2e744": {"doc_hash": "4cda0aa1dcdc2dfbdf8d164c83ccaea6f3d97f3814cc39f6eb747af35c1f9583", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "c5bd98a0-4667-492e-86f1-5fbc5a175df0": {"doc_hash": "73c2d0cad350e9ef0a298e034dc30dde60ef3007669450050c26741328209375", "ref_doc_id": "2115a28e-f168-4561-ae64-131a6ee7b2e0"}, "1ee9de18-edaf-4992-888b-8175276ea5ec": {"doc_hash": "0a02b025d0bf876120ebe0c9e48e1c4414df1b0f15e4641cb7868207a7e27757", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "74555ded-8826-4828-8435-46938e102920": {"doc_hash": "66204a34852ff6675041fedc6612e6c76e817c6ad362b63d9a5f39c3ca3eb5ca", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "b03d06e7-114f-4189-bdf0-c83ddf800263": {"doc_hash": "ae96b2aef622b0e785393442246eda8a63b78325291651d594f0911e8ad75f2d", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "a04c1f56-522f-4448-b8d4-3d1d1849abcd": {"doc_hash": "ad61c1c1a35eca7cbda5b732c13aecf7e884e7b3ffc8bcccd3bbb22ce2631622", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "a2c5a40b-b59f-4476-952e-e972b6dea690": {"doc_hash": "a3dd2c5680a3de1fd05166862a592fb0b5a904d56f558a98a1fcc2493a1ac8e1", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "555f7e0d-57dd-477c-a339-433905cddc6a": {"doc_hash": "4ceb243a8d78de0ed4185d453c1ffb6a6e0d5cbeae43c035c0a33c10f4dd929f", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "ac2cbe01-6951-4641-84c9-46b12dce1525": {"doc_hash": "bc065e8ddb37393900be959bd6fcfe8d961b86a3f36b12a1bf3266411b10452d", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "5c6150fc-8ce1-4b1a-83f0-af3cd0616080": {"doc_hash": "4a64251e316a541ed3a62030d73054ec1d905848230eec4f456bd5aabe18918e", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "74c0ecac-fc3c-4e3b-bc50-0fffe93700a0": {"doc_hash": "e95ba7ea41ca2bab6dd9099c396dc2012edb27748193b8adeb386f82b17a6656", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "b2bdf916-86ef-4e13-84f8-a80894b61da4": {"doc_hash": "cdf7552dd119b45c1dd6443c2a06b56f4b4afc2afeb3181ffbf36ab34208ea0b", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "40f8af73-563f-4cce-86a7-a147b0fb14e8": {"doc_hash": "62396faa6a22ac07bb08d1026be82900fb70ff1afd4a2136b0e110b501d6c806", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "ec510c98-9236-4eb0-b66d-87004d8b947f": {"doc_hash": "74791ebce3c186e0391a33f0d96c6e317d7bf6788d81e62c16cc5be00e7cef3a", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "696ba670-e1a6-494b-8d39-f5e6b70a043c": {"doc_hash": "e1c8fa3cd40bcbc29514419cb987b8be33214892dcbf23e8deb3572af8bd8f0c", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "b175cd96-f60e-46dd-80c5-3989c9e8e885": {"doc_hash": "3da6e2f2643ccbc2985dec84b33f2357aa7b57f24a3b3688fa2b054342b1fbe2", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "1ff80ff6-a2ec-4472-af84-be231fe815e7": {"doc_hash": "fa31070482602bce012897751ae829af22f20977749c4d7f6229b964881a04c0", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "c9e4ba94-4662-4042-91fe-ec1d864b791a": {"doc_hash": "1a69177049723f8deca62d423a88ab518160842db3d46fe6d139494d5038bbb9", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "b4dccd61-86ff-4a17-b8a3-c15a633a8dbd": {"doc_hash": "dbfc82877d04671dab3c253e03868a13c03f59a3aa1da06e356a793ff7626207", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "4e1a9184-4fe8-4b0c-b433-ec698ad71d1e": {"doc_hash": "f1380f59d421108cf42fcb20bcf37494a99550440e69786a21fe50fbc5592955", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "0d4c9cf1-014b-4c6f-9978-8193dd0f579d": {"doc_hash": "b1be51032e330a3b1b94473d78ecbaf743790efafeb5660f1caab1f193432c15", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "034b2e7a-7c6f-4b32-a25f-590eb9d0a231": {"doc_hash": "62b4e795ebd48f97b67422419d18c1c4bff670b663c4a7d78a01b17a8d934d81", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "e8a51797-594f-4032-8893-7d38c50bf06d": {"doc_hash": "4b8e2842d5f5f25c212358bb54f31d1e48d71a12cea8379678eff3dc73e00bd0", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "f5a50f5c-5c5c-4615-8208-2ad8a105a564": {"doc_hash": "a50c4915cb37d33b5d48df3c5f738f815f11c7c795fe77b6e44b74234eaabe9d", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "925f194e-ac29-437f-aae9-cf17ad9644e9": {"doc_hash": "1af6a5bdc5301aa610872aa2ec166bce4f4374b9564656ec3423553fd5a5adf3", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "b1a0e04d-ed1f-4c34-9e4c-ad596b15a1fa": {"doc_hash": "07c91184571f31780fc83142526d4e7f8304984980f1795109fb2beb072dc5b6", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "3d7716a6-9813-4729-a19a-49d702ad8cf6": {"doc_hash": "382b38a8fac9df93f4bfbfd542cec32d0238ce5c984fbcbb241feb24f269352a", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "3198a460-a31d-4426-a2de-6bb534e38568": {"doc_hash": "f2f814d3f5235f5df1e22057e9c33beecbe569b045f93416cd006ad6423836fd", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "2b36d83d-ea1c-4aad-a25b-8ce3024b426a": {"doc_hash": "a6125b3e9079faf122dbdaf07d59e0156af631faa4f6948774e196c6244549b3", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "a43141e5-8514-4598-8c07-e08e3e06dc70": {"doc_hash": "736b5f98c9d1399baa70a69737e4e2e9c098d24f10f903f3963f3dcb17bef48c", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "325a2857-c90f-4f52-9b11-1bd035e4c4d8": {"doc_hash": "dda7228b8d8c67a058e50e4161fa1e09b2e33c1d84c23abc9fa376f1f532953e", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "d33920bc-f128-4c63-87e2-0cb3eeeda48a": {"doc_hash": "37108df86f868bc88ad27521906aa1b5c990a66533c8e5de7d0c8856e7c2cbaf", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "6255426e-faf8-4bb5-b455-8aeff9917ace": {"doc_hash": "911310b40d42f9bad7c05f4a40a28f84af22c9a9d973d537b2ddaa121831592c", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "b3bf17fe-cb14-499a-8645-3a1241e9a013": {"doc_hash": "8d8ab119fbe1a09767e5a7b8a409066eceb9f6c513cb2b921d9b18ab4408cdf3", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "57a44c61-0b7a-4740-842c-54d06dbda987": {"doc_hash": "f3042428fc7b6a6ea25a38721289386774fe44b18d6cd50f495f4c186d8a70d5", "ref_doc_id": "5115b185-e381-4dac-955b-4a06264b92a1"}, "a3860da1-5f5a-42aa-a4e5-cfae38c69db9": {"doc_hash": "5511ea4d2456e053362b0970d2df3d66446436e1baba14a395e081b95978d207", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "8cf4e140-c222-4ba1-b544-9393cdbd15d7": {"doc_hash": "763074c594ae1d85f58630605c2ac16e62e7bd44f13ac4cc664b72b2775778f9", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "b0362ecd-26b6-422f-9bfa-2b0da6ffb28e": {"doc_hash": "4f4cbee23f5e36c02b7d03899064aa542b96f6291989d691efcd7d2aebaeeaee", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "7eafa46d-903a-4d32-a2d6-7b4a243ceb8f": {"doc_hash": "2cbe2c34cc539bbf4067a9ca65e1bbdf84af2063a822d5e05b8ef756a184970c", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "806ffb8a-a211-4041-9251-dde468d14eb8": {"doc_hash": "9906142d4e5a2967d399fde6263a5633dd9304750e9ef0beda83eaea0967ad08", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "4f439a4a-4605-455e-bed2-8ffcab97088d": {"doc_hash": "2f66b483a143be1ab2a253ecf65fb665dbafb94ea572d618655cd892fee24f37", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "281b25e5-e7cd-4d26-ba65-1b6824bf99cf": {"doc_hash": "d363295a47d710a9b788d5bf771db2b2a238289faa55f96802dc7a52341685d0", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "07c4e30b-063d-454c-b976-db9b86ab5f79": {"doc_hash": "194f49dda5305a25ca4ab492be48602426240f9090c10898760792e731c74782", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "cb069e4a-fb33-4580-9013-91b535786003": {"doc_hash": "4d10b3b0e96c367ed625999efdcd694d95e47de3302663b415aaa5aebcfca0e1", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "d3087752-1ee9-4a2f-b924-90ae3e083235": {"doc_hash": "1646811e3b631625ab379026f00e75cc3efa8ee2489b8cfdd9399c2d95905e70", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "eb3e0a63-31a6-400e-be1c-bb1faf57f44d": {"doc_hash": "c06a4511e5dcac61282d7ba97c84257a05511ac3c39a84604ee4346920c71e4b", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "dcdba95c-b876-47cf-97ef-067252937dbf": {"doc_hash": "dfece7ebcd31a43cd5cd27405a4a9d1f136d6c052aa429d42c6a2a60d45052de", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "f11fef06-7abd-4e91-bf06-5cf930e033da": {"doc_hash": "bb3de65bc87a746fa625f486c3336d9511310c5798ccb183f4f5a63497044d4d", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "45f5c8aa-71a9-415f-b643-ce9d621358e7": {"doc_hash": "37722c4fc6d153eb3a944d40c11f47dc9559c1e05b96a6c8f70e138f18fb5670", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "b1d9b1c9-2710-4bd6-8589-83b17fecba45": {"doc_hash": "c833e58be53f340ae163da66e053f3a00c64207c84c746ae4f1e844547453110", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "c81d37d9-2184-4e9f-9db6-4243b5978beb": {"doc_hash": "b0c203f59e24230607f8e714615efdaba866df4a3a509bd328cfb7f153881b38", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "addf21ea-785b-4e79-a148-deebc9fc2eb5": {"doc_hash": "ce138562f7cab953c1d5f9733757b2662952b530d25d89225f8db13551f89b96", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "b8e4e24a-7dff-4b2c-9298-8df345630a97": {"doc_hash": "1c813d1148931f8872dcc424e2824bc2a5f1a38fcffaeaf649f3b915ab04b2f3", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "dbfce098-4bab-4d5f-abd3-ece600e91c4f": {"doc_hash": "7c541dbda2f88464880f729562c1862e52f60680e7efba48d551d4d110135dfa", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "c64be524-0588-4166-a170-d6791e7db736": {"doc_hash": "4e0afdedb39f8ec52eeef71d4859061eae4bf7256188ca06e13b24239b85ed8f", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "b29348b3-faae-428a-a760-61d1707e2b4d": {"doc_hash": "79a64c170d09a820a3db18d471b37c1df29d9a5c0e18cfe4d00a90a27bf5b445", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "a3598aa8-6046-40e8-aa65-67b415e02a01": {"doc_hash": "74aea2781749f73603d74ab9b5ee10e30c087137bd8152a2c02cbfcb628e6dcc", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "7fee208b-bbc0-4b0d-9127-604e03300c2a": {"doc_hash": "ad7c6ad0654bcf4112dbe020034c1efa15212bdcae3f9b84489879260ee3d57e", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "67270314-9332-486d-8700-7f5ea1cc7b20": {"doc_hash": "90a6ce5f243f5b4e43171171b9cf1b194b79c45ca8281e8113363ec1899b9d32", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "1281a9c4-b649-4315-adad-d5463339ef7a": {"doc_hash": "1da3e46d3f4e79bc1f2b8617ff6420d262f4269f6addcdc22e78734da21130c0", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "9b8b528a-063a-4b9b-8ff1-25401bb5c272": {"doc_hash": "16e4e3917ca2778ad45dc763f652c042fe1e272a22a5efb0549c5a9575b4d04c", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "1f9f2496-560e-43f1-95b3-4bd1cd2a2a60": {"doc_hash": "1163fe92179942889f9b7656bd7adaa4f096a584f17efb437c675832d4daaffc", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "736a8b79-1aa7-4f96-b8d4-461c88b3a369": {"doc_hash": "bc8e35a9325718eb905ad46c785ac55833d458ad20680a9abf3348b51fc7ee4f", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "a0c5e3fa-0c10-4d6b-9097-aab185a556b9": {"doc_hash": "a0fc146b02338b0bf9ea7a243193f1eff1a123f30d29d46519752469e2d50cab", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "a44a30ba-1226-4b26-ba36-4c4916f13326": {"doc_hash": "05f6a0fa23c473dc0c33c4ed381ea31fab57312c3e4ad013656af3217e01a3aa", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "40ca992b-0989-4e36-9d1e-5a2aea990e6f": {"doc_hash": "a511e9cb3a76beaa4d7ecdd89130e37ec47664fa4f6e8c304ae18433fc22523e", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "24e5f9a1-2c35-4875-ad47-2a1eb2951334": {"doc_hash": "775815161a453afcfd40db3faf363fd38b7f7014310d65570cec34ae1d742bc3", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "bc96eb87-e502-4766-be24-43ee305d1451": {"doc_hash": "d2f0bf4671b5d307835d7f8839081883b5f03b45b458f35e1534647b248129e2", "ref_doc_id": "19ba0d02-650b-49fe-901a-dabf020f901c"}, "f1c405d5-01f3-4f94-a474-c2bdc6c57b65": {"doc_hash": "48684446f5821a7675f8f8c245ba3f93bbbbe98b26f65775a7b86b1edeb2b482", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "77e77a9c-e9de-4004-adc3-43ad61205216": {"doc_hash": "3bae824d5febf195893e5488f2341377a72298b121dd72db8753d942df0bb128", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "95d1e874-fccc-4b33-984c-9b5300818c57": {"doc_hash": "a58fd31d6b9b71c8655186833aac79b1584b3a009da37e65de00a28da7393e65", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "6dfc654a-971b-4639-b39a-b1276ef75c70": {"doc_hash": "91d5345dfa1e6b6be0ed921db197e6c90016953a1f9dc689dff898c0c8b64e79", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "d5838afb-62a0-4861-9244-0a8f74ea0720": {"doc_hash": "7cf1800c9a26c04610670bd99d8f07bbc541adf3c9c708e2b9b278166b84a4c6", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "eaff5322-c47c-4736-9eaa-a6cd4a46b7d9": {"doc_hash": "271a7c53ac0723b291dec41f654e4287c66e3b688d8d80f7ceec6a16812b0d2f", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "6dcf2b61-add2-4e65-a364-25ae9992674d": {"doc_hash": "2065b88aeb74d5d374515591501b54d7a48dd76c33b473c667d6c2132f9741bb", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "93741a31-05b0-4d89-a307-41c7815069a2": {"doc_hash": "09477dd63a3c81b19735e89f6723e4d0f75a54e50da08030ceae502c3b47bd5e", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "02a4c5fc-781e-436f-bceb-cdd5eca5f370": {"doc_hash": "25fb0dd9991529c358a5541690bd9d140204f819382b718e6f7d91e17d240980", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "6fbab286-9438-422c-b91f-54defb5486fa": {"doc_hash": "45d1fa15bf3a264310256ab5b03af70150af43d5d4e4b813b94c57952aa61035", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "6f4682b5-3b52-4b13-8225-a965c3959a1b": {"doc_hash": "2ef2f9ff16aed8f91e113220649aa923b6d8484f8324d45489ef9afc53ca1e5b", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "70005fa1-a660-4e09-86c0-b19a97266740": {"doc_hash": "4ddcbb56597f4594e573ebfcaa1a0e028e68f774a85ff7667454f0b8be163b1e", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "8fbc8040-1e4c-42b5-a2d2-30e45a255f3a": {"doc_hash": "e091da81c34d2106a0a3070894781041f192beea50f1bf56c949d3fc4f137e72", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "79280fa7-9103-49c0-947b-e109bdcf0d65": {"doc_hash": "7d6947dd46491b95a696865dd6a83c6690065e6be10bb026516d03eb9c403781", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "45d8ccf3-e336-42bb-846d-7a9eafa36094": {"doc_hash": "9e687db001a99f36f5baaf5bd2ce0ca7e15e55991a8d0d6fc520df4ce92fb169", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "2f5884fe-4f89-4016-a276-d5974961c0dc": {"doc_hash": "3da88011de825361e3703f1598ef9ea1800d5bedda6491f4ec2da56d1a7f59b3", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "89032ea7-9e3c-4c3d-b6f9-c229ca796142": {"doc_hash": "ce274c64361d8bfa7b2b5fac52dce67a1a2e8503c6fed0d1a8b78e9409ca40d3", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "399765c4-59dc-44bb-9e44-6c8ba6ea9595": {"doc_hash": "82c3fec045b7fb096d1c7f99abf52afdce7c53d5fdc48af7996efab9d7c67436", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "0e8792a4-6bd8-40ce-8450-09ae1d2be940": {"doc_hash": "e9f6a95a05c8cbeedb4f8c42070ae14f9a2620f2b5ce7b231b73c491bfbd9371", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "069bee2e-5dbd-4941-8b5e-f3b9e2557dfe": {"doc_hash": "e50e7ca96e304016f460ab8e5806808ccf816d07259ae7415a2e1dc9cba22fee", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "cc06dd7e-536b-429f-a184-6d26621ea712": {"doc_hash": "2a2dd94a511920f256748b1a2b223df5e885466afd581d50e5a0ab2b79f9bf10", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "5c43b9f8-82b4-4421-962c-ed087c9c6a2f": {"doc_hash": "1241a644a1e5be955df93e7e403a1ad466ef947e0aeb40626287411ca4a3b80e", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "20a89366-b8da-40c1-8c97-d83aa7da96bf": {"doc_hash": "e93667f52b6e0914abb55d27ffc2ca2ff47d4d45b9bfed18f009503f180427b5", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "4a3eca3c-57b1-4cf4-9f80-1c5bdbed3c71": {"doc_hash": "1372156949c68febc8011c22750f564bcc6b29d71caab36fde1da5b3f8af71db", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "f7971047-3143-49e9-baeb-822b6ccf64ea": {"doc_hash": "d2deed10d497d44fa91b760cc7151c202d9654000172bdcef4685081188e301a", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "f3d789a0-3e2d-494e-9081-9a33b783d1a5": {"doc_hash": "73c5617ce78640d0054c3d04ce9173264993866a15d034b4276c270abcda6578", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "c3732f2f-912f-40b8-9010-73217bb7cca9": {"doc_hash": "bf3f6d2120d9714025152ed28f22d3e44cc1153c8615c038b766587030f21837", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "77380607-4a39-4883-846e-c9d1f981a052": {"doc_hash": "310596bfb3dcbc135eaecdb4047da114ce9befa6dabae0e747a03edf42320142", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "cbf48eff-5500-4156-b569-83461a993aa8": {"doc_hash": "71d26c63e377ad27e038de4fb4e3577716eeb040d22b0b2436348656475fe0f6", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "d7e701dd-17c9-43df-beed-8658a84b62dd": {"doc_hash": "de015b52cff4ae9d159f7cda02e4161693b33f3b5d3291715d8ecba09801274c", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "6171a771-7bf5-4a55-aae5-9e07f66641d1": {"doc_hash": "103fd9db9c29c10c12859509fff59f23b8ed123791a30d581954152154922d0c", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "6aa5403c-7978-4eb9-972a-69d8deb2a2d4": {"doc_hash": "c496055ab5d13d12844e1860f9b853281b6534d01a08b5efe428ceceb797c53b", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "f5482b71-8d19-4e45-bf81-10cc45b53f81": {"doc_hash": "83cf62e61ae13c4455a2e9d5678926aee11f165d86cee4b94d9bdb0e67b543ea", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "9ffcaa6a-d7a5-4749-934d-1ed913a89c0c": {"doc_hash": "a6c1880b5cbbd03cc192abdc9601c52d70c179f0f0011e5bacf4570e28f66c04", "ref_doc_id": "323b6b02-da19-4cdf-80ca-a3e2f0be9c61"}, "ddedbadc-035c-486d-933a-11a5ed0c73b9": {"doc_hash": "eb022a85ef5401729113c0acafa79d2340e75114c3b91e0ba607fa326fd462ae", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "94300abf-ea59-4a48-861c-0f0d18f90807": {"doc_hash": "f215e02275e6978f5156fee712f6179d0cc24c209b86e3635f50d02465732158", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "e6c0fd15-6c8c-4d84-bd3f-ffca4e349011": {"doc_hash": "681db3500b9417c94f702e832ea13547f88e32b785b01d7e303156dd17861534", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "0ff00a40-ed80-440a-bf78-b92d2bcb941b": {"doc_hash": "53374ad81b575b3c5de10c0009e69626c9a582c5fe90b08fe37a21db26eac75b", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "9d13d889-949a-48b7-8730-7929e5422660": {"doc_hash": "d34f58b00388909bd1f1bfe76c6f38d996a1ae322b2b68387ec63539903b7d9f", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "1050306f-0f1c-43ed-a7aa-f0b50816af22": {"doc_hash": "63b141f6e2ab122c966c362c39dad29a2cf7fe3b72a9beb9cdce6ccea7f0f84c", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "ea8a4c6b-f757-4962-98e8-64b8566e1a2e": {"doc_hash": "c8500e763d593f459dd01c2a7505af40a7197ee7c87fb0c2d6d140d8e0f81160", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "d4561008-dc76-4cfe-8f07-a5b2e0da7f41": {"doc_hash": "7482c3d844915efe08402a429f6965626f1b78687ad1130573a55ec61251a66b", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "1baa2b9f-2017-42de-ac5b-f525d199a5be": {"doc_hash": "afd1dda5fa1635b208b7166ae6436d86fb04274aa74fc3a59186c2a32e663d38", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "6f7c5d15-6b53-4f77-8d7d-6028c8472892": {"doc_hash": "cd40d02b4113688d3627edd4b035cc860c5b7bf28f6e0bdf881ca839e98d04b5", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "b2190ee8-b01f-4599-ac33-face6b020bfe": {"doc_hash": "1661634e0ee2373af5149a5a9d7f6b304fcd9e8ea1af2ec203c369df6336467e", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "5d712f18-ac5f-4f14-88a3-ae9a94c9103b": {"doc_hash": "50bd95cb2a65d5861a385fc4dfa1ae62c77c0c910060bbd07035a546fa779cea", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "adc45e8b-e6a5-48a9-96fb-38877a4ab447": {"doc_hash": "d66149d892a593cd7570d36e9b72a72c40f093ae6873b351303d78d79705432f", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "f3d76097-3905-44fc-8b99-96709b2aae91": {"doc_hash": "f7e932680ceaee3a195d146d770b9e53f05924dc57b30df43840d58a670c2361", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "31d203f4-9ee9-4dbf-961f-b600b7565dd9": {"doc_hash": "8e621d5b4895582cd6e35243599526ed94e2faa5a9244a11e7fb800a15dca08c", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "eaf8ea55-4bad-48de-a906-399d210f28d5": {"doc_hash": "798aea2e82a6db3e31fbdb7001e8663da29f1bd5dd1bd409e6ae328d1ce93c12", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "04574c41-dabf-4e11-8bc2-3c5873a84a63": {"doc_hash": "9134f4335d33fe48ef768422aafe0265ec06d7eca453288206a75bf9c5a5f582", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "60e5d99f-af33-47dc-ab8f-222765515197": {"doc_hash": "e1c836a584516c7d7783c4d3518a9eddae13f64718995d1509251373196cf494", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "6d4287e0-e90c-442c-9fe0-d6bf911e5cec": {"doc_hash": "9678f723afc594405a46912f70a9fb14d1544c7a8a3c8b384cd8eee8e245d998", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "69ec0362-5197-4b5c-b43e-302d2e836164": {"doc_hash": "ef1dd098d997ccb8f7f45fcb91b3dd72f4e45d7ab16215d2eada0597eb682316", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "4da2f897-21fd-4385-b9fb-96054473abcb": {"doc_hash": "9a17a86c26f6c97ba2f3cf5eeb78f682f1d01f299a9f913e87299b050d329edb", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "57c03939-57d9-445c-9574-5c1211d9fd59": {"doc_hash": "dff8ef2c885a2f3649f585d718d468cfe0c31ddf4f8044c792d01a5188cc4977", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "4b2c56ff-e455-4cd9-9c4d-118dd71d3e6a": {"doc_hash": "65a797d01e36c5c85c21eeb7ca58e59374d39d613aed11bbb01f81663bc4e797", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "ee8e2c05-e187-41de-9fa6-6d4dc12f4998": {"doc_hash": "1c8692ab8a11276355f743f023625961e711c160c76c524a82bc01ddeab96d8f", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "0ae3234e-a25a-41af-b1cf-47334e7ac130": {"doc_hash": "ede26f5fc7f8c4399ec92b9e4855bb5ae325b520e257401d25aa12c4993f9b3c", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "64022cdd-b261-4bf1-bdaa-3bce602993f7": {"doc_hash": "2300d0e8eee658f8c800da6d742da33cdc161c2e65665bed76a896422f502052", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "77465d0c-eef4-47cc-a81d-a93ecd1ed860": {"doc_hash": "712d6a0572c546b95b1a13647cca01ed39cbb187e04a8250ec9b2b47d95ef9d2", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "ba5b3b66-1987-4ada-883a-a5975cb581fa": {"doc_hash": "da1283091c7aaedd47e67cc4ed9e4113aca8b4a1f38c3035daefbce35c747d25", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "a25dad6d-4541-4058-982f-3dff45a267fd": {"doc_hash": "6698a7bc1d589b7d0ba007fc89e934d064bb23ed0d401df7b9f29a9fa252a29e", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "aafd0e9e-bae2-461f-8ddb-cd483fc989e4": {"doc_hash": "cdadde1bb53eb2ea809088af9ab25386b4020641408c9183218635efbd687d25", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "e7ccdf7f-4f3d-43af-a100-f202496e3522": {"doc_hash": "b5a067016976fe1a4c276addeaf970a9b56f43ce0e022c1c91c1c1b7c7fee8cf", "ref_doc_id": "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948"}, "8e37754d-e707-46e3-a748-3a79d7ab9587": {"doc_hash": "1f0590253a38500e5f31bf2d9cfa9a33b9d35725275463a7d953a59e37990d22", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "63340611-5892-4cf9-b3a9-43bb1804cde9": {"doc_hash": "fe7e379f041b5d0a887333e108b49e410c8064113373cdbce111399021e6d5ec", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "50ccf63b-fd7d-40cb-9fef-df8c1c5439f3": {"doc_hash": "e8e61ccae55c534d811bc839d860033f954d9b0402cb298e6b299d14b2140d67", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "3135ada3-2390-4e8f-a27d-561f86463e9b": {"doc_hash": "27b909297e57bf1037a6c856551095825aeba7a4b88230ad5cc186e52531674a", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "fa437b25-3271-4dfe-849a-5ba7e6b3809f": {"doc_hash": "931ece9a38f7c862869200b5c69595e7aa24cd93fe80fe7a63cdae7d018d62f9", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "cd0ddcb9-652d-4ae7-af08-000374986d5e": {"doc_hash": "71b30df75e0ba86dae7080d6ae9aa63821fa094f5abff485968e821104278836", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "613b00e9-11b8-48e4-889c-e40d06f3ea0e": {"doc_hash": "3e4d5b2ab0c2fe27f6eef5205f8cd1e25292c53f76ed2a160fb11220d16e7c15", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "0cf28759-e3e9-46c4-bb85-43cf0425668c": {"doc_hash": "bf3b52f9a7cae950ef77770f0444224d2d28de9268471aa852d5e506a91eaf76", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "f1963bc1-327a-48a3-9fab-4a2916c38feb": {"doc_hash": "a4354c34cd3cd2acf4677df478226a08d5b51aee00d75d2bfdea9b67d58c2635", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "bc52f88c-1f2e-41ba-8565-61053a3747a6": {"doc_hash": "d8295237690259da78007ddb270050719457be57aa33c3bf23dec555f12d82be", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "4b63ef83-aac8-4099-8ad0-63f9244fe953": {"doc_hash": "e0ca71809173733a824ad712f33b0d3284e209b672013ef7994b56a1660f7830", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "c14c9361-f444-449e-b8f5-0a6bf5aee928": {"doc_hash": "9b8b89cd1459b01a6f11059365737860c7d2811e146da9ca94652029f8cfd3bd", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "b527132e-caa0-46c5-8bb4-86085bcb2e5a": {"doc_hash": "bdbe2999218db4337f449b7257779a0145e5a7f5e9e19006410156a20f66a3b1", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "3bc7f41c-8435-4dd4-b70f-328bebb8d480": {"doc_hash": "72d80680a8bf363bc5a34857b72fce9cda69d80c62c9b2fa3d1c19e1d49c2c82", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "c1ab77e4-5b2b-4380-b12f-c32fe13db818": {"doc_hash": "76acf2e27358b1479ecad5a99d5c06e8f17c3de88dcf65c870467060728d15c9", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "1ced2213-dc70-4aa3-9171-ebc8f18b7bc4": {"doc_hash": "382575ffbfcd0d6cea5dc3a3c2d107ec9054b46db5c851847a7b9c944629029b", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "a70ad8b5-4b5a-4965-b142-77e5e7b38052": {"doc_hash": "75150cdfe987912e5f4f1f21026c400a1befd6616af367234d420a77b18c9481", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "91223e94-6807-4ea8-805f-b1f5b0b1dd59": {"doc_hash": "6ec872447dc648204de1177607e70a43d0658aa3cd1fafb822ebd80ad7a3f18d", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "7b1d199c-4381-4db7-b7c9-290a736d031b": {"doc_hash": "b8a2b7df4ea8c7a2f239399608363340ee57a6d514b8a84efa62436cc08c83da", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "8edc0581-4e5e-42e7-981a-b2288f777d06": {"doc_hash": "b82197d1d2559f93ff24a3ca59826428cc0a19c51f8c641e4b7b4868e14cc8a0", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "a17a3dc4-365d-4746-89a7-464c9ff2e689": {"doc_hash": "c62bf7263b6b8b098b1b9090e62d99210d28d3a299cde1186733b5802d569fbc", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "e8ad1932-1f98-4d6e-939b-77758925b39c": {"doc_hash": "92a9233d2772773c3a41b736b5bea6a5110825159875592d0370d6de80003eb9", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "443a9c2f-1b02-478b-8fbd-beb1782fad5e": {"doc_hash": "e806162de080b90cbe19e6f26ea7d76984582063469d1a8bafe9dc77bebd75bc", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "6b044249-ff7b-40a0-9380-89a4d3381306": {"doc_hash": "54eb2db43a1da46832575f9cfc7644bb8d9048ef112b17b13eae29cf1cb237f3", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "08c28aa3-fe0d-4606-9be3-557526290f23": {"doc_hash": "2466ce80c74be2f98eb3ae35383234278cce904bddeb48474f957fea4bcfc2f2", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "041f86d2-c900-436c-b0ab-b0dbe5eabb24": {"doc_hash": "db9dbf5fa2c2d76be6de8f173613bb7eb3dec90cf2790f0be21c8532165d7ad3", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "430bb652-b16c-44e4-8a0f-d02e8e1cfa2b": {"doc_hash": "9e77ab01887089fac34e0c649643c93e91b2a9a8ba747864d9884c3876721178", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "cef18880-49f7-4eec-94a1-5788e8665174": {"doc_hash": "39faafaa69970e405e17ebb1afbba10d7fe3b601777e85fdbea8f2167a31b291", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "96172edf-a056-4ce6-b970-d8fd8764a4f8": {"doc_hash": "d7a0cc61c77f91b7f387a18298e8655c8d8a4d7d86b6a7b46c50c428d884fe65", "ref_doc_id": "b70bd738-8725-4b16-bdab-efc24137999d"}, "cd16dc02-7353-4383-a845-c6d066139767": {"doc_hash": "aa33e7f3b317d94d508763ecf4c2e4a6b798cd5e4aa248eeb05489d236b31332", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "fc62b00f-66bd-4761-acff-7d7e2cce6cf5": {"doc_hash": "b97e625933e2113ac083686b78b2155564e0f87bc565b9eaf50748f59f45122a", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "4efdc087-cb9d-4584-a0e2-093c19e0d541": {"doc_hash": "ec88ce59360ca638e153198d97b6fbaf814a9564decfac1aa091e75946661c56", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "edf4aa71-c7ef-40a6-997c-085d4b5f5c4c": {"doc_hash": "7752acab8b9dcf4a9a35b1cd8687621ef422a878cf27ca3d2567e96e963e443d", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "35b60864-fbd6-4280-905c-cac803760c50": {"doc_hash": "77fa5a0ed8b63fe4b012d095e9b3a431379b193947ba7ec3573119983bf1cd99", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "cf17456e-494b-46fc-a2e3-9d1a5e0c644b": {"doc_hash": "f1cadd9ff1dd43fb7a7279c8205d41a25219f90caabd311ba0d814367779e914", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "528ab49d-3406-4e74-84f9-e2e555a88d8c": {"doc_hash": "bd5e860a8387eca93f4968cf56cf0a13bad97f61c245448a62cb6651fcce9489", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "f21937a7-a417-4c15-9dbb-747c8a87d520": {"doc_hash": "cba43611df7a7f9a4daeb521ecac3f4f5a080d213d6d243f079a166aa8802f08", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "ee672efa-3f2f-411c-9c7c-f28a6f019dfb": {"doc_hash": "187f4572224081b83c165ee42aa715e078a838a1dc669accdd533b66cbefb3b2", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "7d82bd0d-7c74-45c4-9b7f-1525562dc882": {"doc_hash": "be9fe9e2effd5cfef611bdd9661c4ae7838da9353d45c7712246cc386000ee31", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "4418bf77-0f2c-44d5-a170-cc63eb8c5756": {"doc_hash": "9db87efa057cf99264e3bd65007746f0e6528189a728ca8da15037a5e4c781c8", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "201f74c7-8b9e-4cdb-83ef-0dd066170f52": {"doc_hash": "bf620637bff7f13e56294fe5b5ecdfb01b37d23b00cd4320c32cafa516a5444e", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "fdb703be-16b0-46ac-99dc-34aa08780672": {"doc_hash": "30fc47c7edc318dce2fd8be886931451964361c5e624225360a1abfda4e2cb03", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "ba50cefe-f894-4b54-8868-50428571b111": {"doc_hash": "df12836faa223cd357a0248d08d80a4b5e32e1d4a74d1a0392507831e1f56834", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "dd72cf13-5c0e-4e89-9d73-d07f0c5b3166": {"doc_hash": "ddc68c0ff5d30574f5d64579e5bbee31c8c5a79dd4221dac47988896a817607c", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "cb844866-94b2-46ea-80bc-ed17de4145f3": {"doc_hash": "edf1a24e553b5ba991fbf7bc8eb11062ad46cc415f4094066d401fa88d7bdb04", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "a59551df-0a82-429a-ace6-bd3b23f850f6": {"doc_hash": "4fc18844b1590a0040a2bfc1a130e067426d9e9910f416163a58c67faa51da47", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "239b6c3e-0843-47df-acff-17d046074562": {"doc_hash": "4f54e93daaf6f0eb15868fc749fa5e89995b0160a5c962ddf678bb03628239f0", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "b31ecd45-d0f4-4932-adc7-d1200a5f7386": {"doc_hash": "27cab7895d976c5cac77dc90e0f97ac57ce069840de28be25541f8ecf8895c64", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "d8a8ce5e-397d-4105-8f4d-302d52fe23df": {"doc_hash": "d01780fead36e47965c166531ec791440ab96ac2d2ab921182915c1db0b16948", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "1817dad5-4354-447c-a6e3-57eca6c00972": {"doc_hash": "50de14350de094a3a196df252b8c519ae2fda750a8402d4cf1c8e9a8fa0d2de9", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "8ff7c952-7d7e-4c2f-bc7d-437d8cf78a3a": {"doc_hash": "b387b31f52e95ab4cab6206fd7ef8a7ac786140abee9abf07be542119ec34699", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "ff7186e3-6bda-428c-b172-059a35bb1f79": {"doc_hash": "5886210c298e46dc8f48db221d5a7663514aae37d195df19336dd2e95f69616b", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "7cef1816-79ae-458d-ba11-ceb632239593": {"doc_hash": "7d51e9ee6b5a64de08d7f1ea1fc08a7c90777c7df9ea51ec3fcc68b6bde94de1", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "0ef37c75-bab1-41c7-ad7a-8ddc42588c22": {"doc_hash": "d0fb7bb47884bc804ff490e66f4857a5d235f2d4399b798f795ef11533d6763d", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "dc12fd39-9c4e-4db4-ad1d-8b907cc0026c": {"doc_hash": "daf66be1aaadbd776d67fea6e18712d1ef38756171aa9f812961a9e9bfd8a109", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "f7cf11a0-b7f4-4c19-9788-096aa1dea0bf": {"doc_hash": "a8e8f763b1b302486c36618104425dc77e72e61c6d5f44bc06703d7314ab1a99", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "49163009-bf74-48a8-97dc-57debddd822b": {"doc_hash": "42b54254ffbb898ee7afc98e9e20d2f0cd83e83a150c3923323fd7bc56ad33a9", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "af464f57-84fe-4664-8e50-7f948944d067": {"doc_hash": "82139956b34fc97abd4f2c0e40d2d2d0f8e5f9558883ed414d0f990b3c6e1989", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "c7163724-725f-4390-8767-91ef930e634f": {"doc_hash": "bb20a8f99b8487b7da8bbd3624bb59d8a48db51a0651207db76fb81951867360", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "da9ddd8c-9bd8-49bd-9a97-10eb7ec3d76d": {"doc_hash": "76d134d217525d2b228340940db3b0a2eee3bc368be29359158d413d206340d8", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "dbebbc0c-89ab-4b8d-a3f8-75a06c416c2e": {"doc_hash": "483dbb576756eb97da2f36f35ce32d7f3ad9af346dd3f1261d1b158f8adb6eb1", "ref_doc_id": "0931f8ae-0095-4499-aa82-d2680f84c6de"}, "0dc51c7e-44c7-47bd-9a04-bc5809e8ff06": {"doc_hash": "b8ab1e3ab88c1eef72288c5ae04e4007c74242168d4d9b63fab26bb429f297f2", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "6e9443f0-d73d-49ca-bc00-a6f98629a23b": {"doc_hash": "1ebec6fbc5fbf8e00b0f411fdc9aa8cc4a611800f2457a6ba9a6978170d0aff9", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "7aa55f4a-7d0a-495d-916f-78dd2f1aa2fd": {"doc_hash": "4c48048386680702fd77deb16320542a61ae8650473fbf251b9797bd03b0cd9e", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "22eb43aa-0e89-468d-aff9-ef69b2995fc0": {"doc_hash": "a275b424afad7f3b2df8618c5fb6b40516e409acbb5f84f0dd6962328dfb66be", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "005c1aa9-ae2f-4225-895c-3f8b8a8a2fe5": {"doc_hash": "a8e011af94c4669231be71d0a4690d945c479763029327a573c5c1161ec7d129", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "f4f03459-e1ff-44e7-a24f-814a4cf85ab3": {"doc_hash": "a45f49a2ae374a20b7deae30845cb4e46de353fb13ef59f65ebdb1034cfec1c5", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "3c05a166-0ca0-4a9e-8ca3-b7e8ffe25a50": {"doc_hash": "84774a8a79a7262af25335c04474c1c5e1be84519a853209c52bc388422026b7", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "8d26b5eb-dc78-40bd-b021-1c9d3462ada9": {"doc_hash": "4db757b68cef8fd8f4fed426c81412bedcb87d9294bb0c182bab20cdd49509df", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "54a1492d-5739-4f72-a982-d01694deda0b": {"doc_hash": "bdc530656826ebc958aa66648d37f2b3ff354aeca31338896c977914dafd3e55", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "fd2ca06c-bb18-4247-99de-d13973e20a12": {"doc_hash": "16822a3db1d2c4596b1381b496cfa1585d45c807c3333315ee32313b5ba35189", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "f4be3590-8335-4170-b0cd-e49467aa7f5c": {"doc_hash": "ef21dd18ac74141e209d8f7c92934fe204b59cb871fb4ee577b07dd38267ecbd", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "27ea4e44-fef6-4c9d-8747-9a71e23af10b": {"doc_hash": "026d55b47867c28bca18aa36ee676257fe5e874d386b867d875020013f552927", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "4db7756f-8ec9-467a-a3f4-e4db4f70a04d": {"doc_hash": "e707d7effd1460d514e14c7c473ce25178267954553c0d7efe096f84f872cbd9", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "9765429c-4733-4757-84d6-c7c33c1241ba": {"doc_hash": "5312360cfb508ccf0167cd76d962765ab47a8b4997bea65cf9eb4cdbf14d1760", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "5b79ba90-84d0-4a8c-b6d4-c28b367d5d15": {"doc_hash": "1a247b8ec619c4e41d85d7ba9e4cf91695dbf40c8e95a794491c1824c0f41f6e", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "53e4d9a7-e3a2-42b9-94ef-1e35ea738183": {"doc_hash": "3b8dbb55a2745cae8131aa4736e0c32b6ab702a180596ee35bea1b8696f702f8", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "0e051b6e-ceb3-44d8-8309-544fbe414914": {"doc_hash": "34ed76c3ab7550d4d5986c6fc4e68b72e54d07ee6613a943b864cb9717e731d5", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "de818cbc-d1fe-4e44-a47a-2d4e9d9d087e": {"doc_hash": "48d393c42c96ab0e76e78f8b88ed7e48a7639f923701e9a5aca4fdbb67c99d95", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "e2671470-6b64-4b7e-87ab-4be18646da3b": {"doc_hash": "b50f667354d03668faa6f7cb9308a068bb2029f1775bc3e67447f4322d2aa63a", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "08101f4b-093f-45f1-aaa0-0e005e0e6e93": {"doc_hash": "5dc391475f9a3062ef28c42d5939e0161969c66db96023c846c969a25a8e72f5", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "4d461682-4aaf-4db8-a01b-13a636623bfa": {"doc_hash": "4c148b5f6e6e7400d70fed9a5cf4ea69a1e5f46bf1c744a7bd0dec958a475be8", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "eba80418-dba1-449f-bc08-8b7235914fa3": {"doc_hash": "49539fef3e3f7bf65a0b79fecd331e9893dcbc6eac4df876cb5f7fc7fdd1f268", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "f3652068-897c-4623-b3da-a400ba020f19": {"doc_hash": "c10bfd670d514ae907eee9048ed4e525061ca442bc5a8ac6ba7ef49a5a2e1d09", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "d070a76a-abf1-47df-a2df-eceb81c9491c": {"doc_hash": "a62ad828a025b1ec812b2e15b1010f8e7bacbb6d5e7a6172597e22af4ee6bdd3", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "63b10b55-4bc4-4cc7-a436-cf7aa665054b": {"doc_hash": "d9017195e2c5342f1b0ed4b56d74539ac4e441a38eb46f256f4250dbb2fa74b2", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "bbb8ffd9-21b5-4111-93f7-0096f59c784f": {"doc_hash": "789c0f9a480d81c70d4b03ba84f143a9c02d5e9d9862249eadaf066b38279f55", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "ec8e9e79-a366-4ded-8c0a-6f8257ba6e9e": {"doc_hash": "b38e88e55e33d6ba1cd463dd5af967623e6ca23744d9e643f721e24214c3d067", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "cd981027-851d-43d2-a072-d50f2a108de0": {"doc_hash": "69caca910d09cee24dd78699bfb14e08cb743488abf5ddde5f93b8e7c7146063", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "d4a7524f-ae65-42a2-98f6-f9b9f03ff3a5": {"doc_hash": "2c1703183a3fa6c8e88cc6a372c2c062fbd3651a7285bfd5c0ac773e99fa2066", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "ef99390e-8340-4272-af97-4c73085700d2": {"doc_hash": "1282ed7457231d014c17ee314370db38c6305e5c190b2b75594e2b8498138807", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "61a825a9-0801-4465-9489-5c9e8ff39285": {"doc_hash": "8cd89a83d251d11c1a15863ce2db54de29ceeb0e210161e1120aaf24a95e5416", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "001cd8c7-5783-4f5a-9b86-9430923d7499": {"doc_hash": "e00649a46a926c8a086e61518693e75e425d69c220e19f923682657c486e997a", "ref_doc_id": "bdcb0664-a94c-4c33-a4de-df390c909441"}, "55d5b02b-bc25-4279-a844-88426f0c4014": {"doc_hash": "9b56e4e674e631b4e2678c9a2edddffc53af2fff8956a30398e4bb64620dbecb", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "1a73a692-6b30-426f-80a8-3ce0d05b808e": {"doc_hash": "7fa412b7ca6aca92a229ac0b9bc61d19939b8092b067bfce6702be79468a123f", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "0467886e-512e-4fa0-8a14-394e0aae0b99": {"doc_hash": "74ab74d250fcb8e4051d53acde1e948b31875b0cf551d066d2a33d1da8fdef31", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "8129a874-cf93-4c4c-be2a-c159c73621ac": {"doc_hash": "dedf7b3f1f87c3b688fa25f5ef70a655645b2a1ac1b09930aa3444d88e86bdca", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "6cd3a5a6-3aab-4af3-9fb4-4651b37b2567": {"doc_hash": "fd1c52c869d9ac50e5436398149c9153b42b5753e9c87c8ec865056239cac74a", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "76abd67b-4a37-46e1-8727-937a61bcc4c9": {"doc_hash": "28c77dc0162149432f98d1022ec77a081393d8f81038f249624ffd207747931e", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "88ad401b-dea7-4da2-8f0e-8257c9d78e09": {"doc_hash": "d809429961a702bbc2d8502b5725a027904019bc2dbd2ca7967f8f43de660b06", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "ae30c295-4b8f-46dc-8374-a945e00d10b1": {"doc_hash": "6402e6055f02f73dec8ecacc36c4eb53ed05a4d883cbf2fb8c284fac0b34d125", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "768c278b-3d0f-4eba-b011-277735c3ddd8": {"doc_hash": "56dc75208d05ad95ab18c07f186f25d4c38194f57ff92d4404407ba74c650854", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "49c4ac34-b0f0-417e-8d7c-a7c8f130fb33": {"doc_hash": "13b56665f0cde0286950a937181c734e4f3669d33862934fba081a2f55b4b477", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "a16dc9af-f9f7-4bea-881f-987ab6a5051a": {"doc_hash": "cbf215c1b4e4f8cb5a4433bd28b6144c45b445c67e65e3767dfb5f5fee10f54d", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "d6f382a2-17a2-47da-b85a-caa2f868f6ad": {"doc_hash": "c1b1f273c8453bb49df68aa1d83928da7dd5f3011a73ed8528ac38bf8b9bf7fc", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "8b56d7d5-eb74-4e33-974e-4e6299724325": {"doc_hash": "f25cf90e7a2badae4ce8b613fc671a8fe10387cec1ba81c17f8391ddb4762324", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "9d3b6eed-a481-4071-89d0-df18b74388d6": {"doc_hash": "a219d8cb239db6e9bd58813dcf515bb6e35fa909f10f7134218619dc9a64b72b", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "359efbf7-1c79-417c-b2e7-745f88e39f6d": {"doc_hash": "b182b9a3013fc5808af7f2ba762677f9002156538166e48af3b51dc560f66426", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "30c44125-2944-4a76-a0a3-b62bf16fc9c8": {"doc_hash": "4461f956da50b057b61cc6ca1354d06f1a578b61a489605e3f7548c7b8b9c4f5", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "70289ae7-4698-4553-b8a0-4fb4bbf1ef47": {"doc_hash": "e36cecea9ba5cd70b0433ac75af77e52ed9c59c1e2b8d638ddf629b5bc4413f7", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "072d0628-b94b-41d6-a6ad-927f5314c7d0": {"doc_hash": "a8645091d613f15e10c2dd6390a7e26e0c152c920accd12912558b028382b0a0", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "dbb94884-77f6-4e02-8492-55045d1a6cd5": {"doc_hash": "4c3d0c2d94682a897c48c9460d22a1bb8b19111622a9bf6b9d0cf2153eea4f8b", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "d2cb53bd-a61d-4f74-985f-fddfa118c33b": {"doc_hash": "ceea5c540f5fbc1376b1c9aad66ce0f367033e5dfb00fbb1075b11f0f697ad44", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "d2650dfe-bdaa-4f13-bddb-86458fd858da": {"doc_hash": "51e59184bfc94b89ed22b77860de5a855e539eaed0210c5304eb1d43a396892c", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "80380ad3-442a-4af2-918b-65a172850487": {"doc_hash": "b22a8fcd00185556209aab3beb21ae1ada0d5920aeb56aefe7bff49e36751ebc", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "704c2b21-b7da-4994-8709-94efaa399ba1": {"doc_hash": "053ea443e9337ca10f9b574f1798fe560598d5160dbcbb2f329edf302e7d19a5", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "8ad173e2-19ab-49d7-854e-9accfc1e25df": {"doc_hash": "b480f636a69f16420d90a24a2059a1cc57947a6b65274e9fcdc960e0a5cb5822", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "e7148ba0-baf6-4b25-aa4d-8275a71d120a": {"doc_hash": "31c2afe5f888896c438a4e22c391dd750333bfb922aa442aa872b5b0868e2bf1", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "27c86039-cdaf-41c7-9c5c-0ff5ed449a18": {"doc_hash": "a30c67547920b3de698d52d74cc68b0667a14239f69dc4acecb2b4fd3b9ce53d", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "f966f1b9-e464-408b-a50b-88bc0afdeaf6": {"doc_hash": "cc569bee235ec62c1c9f5a653f9ade2488c0ec3038ef9f18722940869c504e34", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "8ab3b3b1-00cd-4e0a-8654-69b3013cd073": {"doc_hash": "054b495bfae0916868b8f726d8faa02c5bba4a38af09309546dfc7713fb9e830", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "fa27878d-d451-4e93-9fc7-6900cf80f272": {"doc_hash": "ceeabb0fce27f00fd659387d4ad164e67af3c3aababe8ac036e984ff32a8fde1", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "a5ff4ba4-b51f-4c18-a793-dc9626d5b5aa": {"doc_hash": "eb481e256b5674e2f698af79ef3945490406cfa648e9bd7fd34e9852a304b29a", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "2b6b3d5a-08a6-438b-9e92-7fde487df823": {"doc_hash": "0e154e1d1f8b8a76aed72288e811e6e7126172395ab5db57ba56cafc047d97a4", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "47fa42b0-e7e3-4850-ac72-ef4d5c7d09f0": {"doc_hash": "2439973db7acb40dca140bb56dc67969c1752b2ba1ee5c95b73919dd1b52b4d2", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "dbd12ba3-fa10-40d9-b8c0-23460c6e76c0": {"doc_hash": "1d2234cc57f407a6081aa9bb564ba77ad5948d7a5a72bb519aeea0c4f7665414", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "a4a8f209-cfd7-409f-a31c-5f1a93936aca": {"doc_hash": "bc49cae2fccbf482369ba0aafa5b4fdf13bb42358cb146e50a091b341eb5fa15", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "896abb23-94b2-4f98-9fa7-980ce136d477": {"doc_hash": "0200d7551c606c4bd0e00e8ec4c307e27567f2060c82c31c0f5bf9dd91373e4a", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "5a31b71f-00c9-4b10-8a21-56384a6d0be7": {"doc_hash": "25e31fc5a31bf0b5a3069e92ed096b255756a0b23cc359978a34055310a71527", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "25af618c-4a06-48fe-b1a3-ef2bec6c5b5e": {"doc_hash": "8c8e93e6b910857d79ce0b6a5c77ab27caedc50997aa471546cfe1171bab0536", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "6a317770-53bc-4989-a87b-d54e17354910": {"doc_hash": "a283b1c52b8ebe6d40ba05519e811a1d8ba6713bc92815b3593746dbde427ecd", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "8b438509-2823-48c8-a60f-85fcb54aadc5": {"doc_hash": "71b1ba2e09fd5651ecda305cb33ea23405eb8b4f1ea4be9a6b8f50daa20ccda8", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "2151fdf1-be64-4a63-a4f7-0e922054fd94": {"doc_hash": "2dbbd40ccbf608d8de4c2479517fe0b86d8feb680b9cf75d7ade25eb7377d621", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "fd19bc64-b8a4-4eb8-a0d2-4da3da3865a6": {"doc_hash": "1b93742bddd13c5a3d4b5dc4dc729a4cd035b5d32ba97c8dc4ac70e78f8497cc", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "23309721-d072-4e00-bcfb-fedd89ae681f": {"doc_hash": "4c555bd59b6f6f4fcd2bf5edf2020065ca02b227fb44dbdbebb0763f763de223", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "62de4da5-32cf-4c6a-984d-ccb4000b481e": {"doc_hash": "39fe6a73cb383c954f9008c807a00dfae9377826255b66bf0108a3fa051972de", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "96878600-efae-41fb-be97-47244d16c873": {"doc_hash": "9347648efbd06764296ee36b23536cf8fbdf44bef73ad7cd54e2d3e25789b4a4", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "9653c590-8d50-4575-a9cd-522b576028e7": {"doc_hash": "15a77f625926f7a2441aba993258a218b7b0f5dd6bf60f0c76df2186eb08fef5", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "6a34652a-a18c-4a35-8fc4-790c6c4b8483": {"doc_hash": "5ce77e78876cd7af90b1ad1de269cb541bd86744a50b5227c1c5dc93868c70a2", "ref_doc_id": "7380b2d9-8cb2-4667-a432-051970e943d2"}, "480a10fd-d38f-4c31-958a-6a05a19e51bc": {"doc_hash": "77cd22302abf5dfcfa7ab9d87dd89a471de5f0864e6ecfc76bf8e70e0492b867", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "b6f17db7-6d7f-4966-81bb-7387e5d8ddfe": {"doc_hash": "fe3ed586cdf2cd380801daf2f4e449bf02fb10225e58099c8f713f6fbbf65d31", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "ebe138e7-ee4e-41fa-89ea-8fcf96c87ee5": {"doc_hash": "1156aeaf27b014ce09988a5c5465f199eae48762fe4bce629f1a98104a1a84e6", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "58e4417e-6083-4281-bd5c-792c4967f75c": {"doc_hash": "7c2779d10f1e6cc388be05e79f82e4d87652868207df8b53b1a161eb295c4f8a", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "83dfb6cc-15c3-436c-b616-5aa4844810e0": {"doc_hash": "4e74005ffa503a4e06fce38d9ac94e45b609f912f716b8409c59f156ed80e153", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "a176bd4a-dccc-49b2-90d7-77af1307d46c": {"doc_hash": "c3367a167ddf659933873fc32a2874c3f55c0b4150f68fd02c8c7d2293e89b03", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "a51316ee-afd4-4c97-9127-fd185e62ea2f": {"doc_hash": "39a6903a70c3b0e522ee46a1237b0d0b0587f9bb1d839550e4dc98475638a5e5", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "f3791155-b03a-464b-a923-3576cb065840": {"doc_hash": "e873a92ce09bed03640e21b19db9fa3ef5138a6afb6d328fc9fad0dc35640d5a", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "bfc79314-0022-426a-a751-a8cd5ec99b6f": {"doc_hash": "a3a7a895a2e8fa8878fc10bc62b02c61d368fde77389c1726f161568d74c2e97", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "8ee59b8d-0e48-408a-a68d-f7236dd14465": {"doc_hash": "90ce1b49eb7caf619faa8ccbc2876583cb373b56a2891daa6f762053fe51b83d", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "739ef4bd-e0a2-40f5-a51b-e8866914f194": {"doc_hash": "6fc4cda4313ef199136f3a7c10b86a2b16f77ef71b7c7d976c7bc21679eeeb09", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "24f0eba6-2651-4d71-a41b-b20f101fafc3": {"doc_hash": "1cb6ea7636392f2b10aee9f1f42845682a7bf9561283748e6f0ea5b8d9fce96f", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "70ca4295-a3e3-450c-a409-d369bfcd2700": {"doc_hash": "9a0717f084b74b02a6ac6424214fe2fd0f551016a5e333fdb33f753d917910b4", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "036d79ac-421b-4e50-aad8-d291a97ec81e": {"doc_hash": "c16db60a666b4315b612892321d4e79116206346de72c222178eae8dfee9f398", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "aa74016a-c1cc-43e8-a990-9a5175ea5c10": {"doc_hash": "be5361fae919895bf640dad8ce58f52d58064f4a2de4b8c29974db6ce3166520", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "e877184e-774e-41dc-9b74-37c130fe384d": {"doc_hash": "95a4ab7925290eecf3fc2a9522523de4cdb6152f3342c3c5ad214a0f195a7e7b", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "54007c23-c45f-4466-8bc7-f953a6834970": {"doc_hash": "7d6bf0c81aad442acb616a97a4304676cdbd723427b1a8a0b4ff7589629272e6", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "8e7e3cc4-ecc8-4c75-93ab-c685247cde45": {"doc_hash": "ecd471b1e864de74b8cacd7ba94f2be14f5eef5b92c061918de955376fa3f53b", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "d59af89a-3ac0-4640-b800-151730ae6293": {"doc_hash": "575d34920b9abb4714e5e603e6d0b77eccbb54b988536a51a99d4f6b43ec9393", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "1773b0b2-dc45-4d71-a349-0b08f8bb037f": {"doc_hash": "4d975ad0c57683f5a74430114a7b6dc2ca4c5ad8312921280819345cf59d49e9", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "5ae16911-bd34-447f-a98a-380678742381": {"doc_hash": "62cb8021e87d14c865971ed5e8e630641de48bf6af0af47240f60f709b69c813", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "997779ef-d58f-455d-97e5-fdbcc031581b": {"doc_hash": "fb076444ea4163287b049a9b16b2df09fcb20326aa641a8be11ec5771421f129", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "dd31c989-69b2-414d-828b-05ce3e9eafb5": {"doc_hash": "c7e073e70b1015c0644bc747812e5b52ff039cd411a262d1bcdc9b01efe55f2e", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "e6700482-5e7f-4562-8a7e-e2b16fb8fa48": {"doc_hash": "91d541f64e76d5ef21b6cf9b7dff7103bf19793c6d6fd44c805ff5575b3ca825", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "08c0eabc-2e67-4b02-884c-6a70ef4ee5d5": {"doc_hash": "8ccf2ee698779d6c43cc1dc777bb188bd4af99bc64f32610cb21d7a5bb4a77e9", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "9471e6b6-6209-4ee6-90ec-a95e7a3bd296": {"doc_hash": "97c872791add7c5c219ef848de0778bee50e049b3cc081b765f97d4fed22881e", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "190df7a7-1eb4-49ab-a00d-d8ead5fba6e4": {"doc_hash": "5922c42c9da3998275c561fba2210c867b7fe870c83cd97a5133e3ef49d2a1f2", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "4656f2cb-76ae-49f7-b586-ff186ec6bc92": {"doc_hash": "c49008c69953f85dce79724a3263d230a416ba9a576f2ec1da79046815780912", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "25357b59-6c6a-41e9-8512-4dda854d9736": {"doc_hash": "1f337d4086c92d624702e60e48e3957bb8c863ad6548cd9ab11c3d09485dd20e", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "4344030d-cff4-474a-874f-e272f8724c6d": {"doc_hash": "e98c171e3cdbd815b83fa0a571eac2f12df22f1ea75250d32c41ee4233954d04", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "5d8a9fee-9851-43bf-9b2c-1c93a40a3de0": {"doc_hash": "67a7f32f9d4907e69a9d1e0c5e742ffd18b6b43f44ef11c35fa7eee6b79314bc", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "39b737cc-eaaf-4d3c-8a00-e9e448586ac4": {"doc_hash": "5621d16083d8c4b8a1dbd672b65e2abdef0b9dc6bc27cd12756fad0fe16dbdb5", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "24ec2e1a-a02c-4b60-822a-98e277793e59": {"doc_hash": "74c36a7258c7523fc49b2285875efaf8f241f3e773f5a146438d018938395896", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "3966f54e-52de-4176-9a44-0f2ea4a7067a": {"doc_hash": "fd699e40764436cd1d56f4f9655356a565209965550ac5e87bef41dc99cc8fbd", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "e4565dff-8995-4f1a-8d43-45f846a41bef": {"doc_hash": "bbad3f81bb4c4ea5ad5f38852e841e542fde64444fc5ae45cb8c3751e6f78d80", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "c5f13821-4092-4861-ad79-4aa9da46aecf": {"doc_hash": "84312e545e277c554bf4c3d6b28a2c88d3766b6ff437dfc5d531386cf49dbc62", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "852a04c8-2740-4d90-b425-d1e38ebcf3f8": {"doc_hash": "42d8ce47c32ebbb5a57a5a6683c3b84f025dee4047bc6d3be594ac627a27a82c", "ref_doc_id": "ff57e0b1-1bf6-446a-862e-bb1331bd10f4"}, "a0e3d11e-1cbe-4bb3-8825-185288c0b990": {"doc_hash": "75940b86a4e91ab95c72ae462ad9baee1973a09d6983096df3f650ed61ec7da7", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "a89d1093-94b3-4ece-b5b5-5a57983d77c5": {"doc_hash": "3ccb9946c17ea48a44338dad81bb6e71da17f722517447b4da82958b4f806bce", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "3df840a5-0618-456a-ab1f-dc71807663c9": {"doc_hash": "e4bad441a8e99c992cea136e074940424a3ed82f37682543d694d33a070cbf48", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "6fba2a9e-e649-4286-a695-d09eae1bd2e0": {"doc_hash": "25b8128bbd8d0a2830628f420ab52692cb66b09464a7eda0f5025107491c4471", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "f06db92b-aecd-425f-a9a9-d213a9a2062d": {"doc_hash": "6c42e9a3e6ed82ac881d7d52438372057203186a71a42a7b6fd6c28bd48f7fdf", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "9cb40e20-6651-42e0-9ba3-2ab0e3db08fc": {"doc_hash": "96e49ffe4cf919da9d17d4862bc6722bda3c66b8e63ac05c8ead96a396cef5c0", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "023a7b56-eb00-4dbd-b9ef-2f8445bc86f6": {"doc_hash": "b46f2e7cab85a0dd3f9d35f9612d4ae000982572eacc144cf664b310a56ac9b8", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "564cba84-ef45-4e65-a2ba-d42e814c9b67": {"doc_hash": "522475bd3903907b023d90d5c84dcb30a2d5e3b1d31b0e2b5b825ef5f78574ed", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "b05d7ae8-2a31-4f15-a867-89e16ae45f3e": {"doc_hash": "c919c37437e88027cf4ea0f977cdfc87b50eca1afc32036c34e2bebad99ad1cf", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "e8ee2a13-c9e3-4753-8ff5-1f7f5035ffcb": {"doc_hash": "f5b9aa0b60244ecce57cb63b62ba071c93412381fc44a719db973c9f6e311418", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "660b3754-f698-4007-81b7-ca29d6a3fec3": {"doc_hash": "67872d2de3a5f3e58b7fc7405962c4babeef2f8fe5e1c47af88e02018b72a465", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "0cc7f8dc-11f7-49c3-ab2f-9382c9222e54": {"doc_hash": "f1a71f3a9c501296efa06add5bc4d19d34e7c1d6820d3a269a3f8c053a213378", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "2331f3b9-e84c-4d80-bde4-7fec773ea4d4": {"doc_hash": "8929a753db4bd9feb327ca94c8c485091bcbb1af51ece213a98e381a862e83d5", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "c0d58a80-22e6-4a77-a3f6-5aab2144aa6e": {"doc_hash": "199e70f76a4e60141a7384d33dd53e0e3d3da2e89f666ff6a37bc6fa103e2974", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "bfc95602-dee1-49e6-afac-7d6029c3bc0b": {"doc_hash": "21e15140a6989a9962e0f65164073809063cf99c88b3600df804ff1115f38f90", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "99d71e39-1a6f-42c3-9535-050260f0a1ba": {"doc_hash": "49034bacfe72111deb8d8c9cb4ee86c745a4fea48898f8d759388fb27fcce9d8", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "d2af3907-52e7-41f5-983f-5b8fcaa8d2f8": {"doc_hash": "c814afaa5b9423efac7b33a8a8ccd28fc1c46d0db02d7fd3a2554f95f8414356", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "cc0ea8f2-8efa-4473-bef4-66a1f16f94a7": {"doc_hash": "09c064fa52a642215ba6fcbc9ce94a2f75c7bdb996b36133986d50788358ccf7", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "88ecdf42-27af-4e96-995f-413644de20ff": {"doc_hash": "38301f9eb07640a5ba764a1f6d320fb39b2fd7f326ad291ff6b8ae1e53b0eef8", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "4b805c01-232f-4f87-a051-c3a2e934594c": {"doc_hash": "aec1d33cd80f9f5b780740fe7f7c1a230a6be1e55c1e8c17e94e6656dedf8176", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "dbc39247-f91c-4f64-9e19-4fdce88d60d7": {"doc_hash": "dd2d445d9daefba32e8379443ef4c69d43d234796f70ff1452d4f21b2a3c511b", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "f7a0dc7f-96e9-436f-9e5a-ca90a04c4f26": {"doc_hash": "048a560e62f297b19d09eabbad8b81681306dca0260d32592832b897e49a36fc", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "8fc6e1d5-4f82-4f64-93a0-19743da607bf": {"doc_hash": "030e1d3508dfcdc617f4d56e52137b832f8552c64acc07e4ab775cc7dcb61eec", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "9b8f25cd-4ed5-443b-91ce-f5409e97e877": {"doc_hash": "a15d7f68e55812cc579aeec3d69a9018a96c599b645f970e81094e8ceb880f23", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "d2f7f4dc-bab3-4d9c-801a-2fd16359b0be": {"doc_hash": "72503bf02908c1290f599fdc5ec1057a946917e2c36392a70071be00d10cf838", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "d02cc29b-f017-453d-b039-c559c759d460": {"doc_hash": "e1cd7ccbd04862bfb7dd4efbc2091473f4c2baeff6ff4e3e3b238435c0a15097", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "6d0aea8f-24c4-4ab6-a931-1b4a70a9886b": {"doc_hash": "58890d017d02a80188510560bc1ff1a22bbf7b45919c66216ed31131465f8a7e", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "8768916f-34a6-4302-9b70-6ebec20925f1": {"doc_hash": "625151ecb5b971cf87b1a76a686755aad38186d2cbfee88f49a1132799bb46ed", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "30cab0f2-623b-411c-9cdb-f8104d7a2520": {"doc_hash": "8e1b3c76473503545674c47b88e4f5f208362068d72fd719e6ac318c21eba657", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "6a6b2756-ad05-4fd9-80f5-bdebe3917fed": {"doc_hash": "43a63a97940373a0fdc51ff7879dee315b89754e0f9cd41de32885b226db1a9f", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "6da2b37b-45d7-47e8-93e2-5e856c717871": {"doc_hash": "3ecae5feb3d5144ed9755a724523b839eb1d94f0edf9f8f01f767f94397dd145", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "a0404367-398d-4a00-bdf2-c333c2b534af": {"doc_hash": "127bfd72048551e5bfb867cdeef5e3085ef5929ef688fd6778fa63ecd550e85e", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "d228fc14-38df-4eb6-9de7-3d84d9519855": {"doc_hash": "323841449a1c0f0a5fa978954d2b4e343ba408d63def4bcdbf39372a07e46968", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "fa0dd67f-176e-4853-aef8-0dfba68c79e0": {"doc_hash": "478aa87f1618eb9eb041e87d24058b3ea01f2f2b310b0b80a7d34742e229501d", "ref_doc_id": "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790"}, "f89c5a60-e684-4a72-b208-2d49ecab2ecb": {"doc_hash": "2ca57030ddc7dfdd8aff5cfea839d37438e407a5a6df5d81191029af2406719d", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "516d4a88-f647-4031-b462-2edd64e1d829": {"doc_hash": "ec7952d5cd232d6065195a15893ea6922c1a286aacb10f2f8b694adee1e474a8", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "bd7dfb22-a079-4194-be28-c1040338d97b": {"doc_hash": "67f0e2a890f792b0c4a39c39a3324b9a9f6e973b459094114edc75572e1ed1c4", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "bba9f927-ba48-44a8-9806-8b5b2536f396": {"doc_hash": "50c44e53abbd9038ee067cbf7b918e3ff81ff190874f2f0e326c1ad08c977719", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "5ca1df4f-cded-42f5-bf35-378070226038": {"doc_hash": "d48dc2408b68c4cc7e5455f74d40355aa529dfae20c8b79453fbd77d939784d4", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "22b98fbd-292f-4571-8bd3-937eecf1f6d3": {"doc_hash": "e29fa334746c115150d44e919660915a649dff9b9bce5d6a1ce0b3a9d6353fb6", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "3122c6f1-7dba-4bba-a5db-930e86471dee": {"doc_hash": "87cd306b0a50ff47648321a82f0e38ef257fdaee04506e519a40ce3cfad769e7", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "4a31c7d5-6899-409f-a42d-76e7c46e525a": {"doc_hash": "d20d1285ce03084a49338570c4f28fea86e0e9237580b5770b38523e25d9d7ee", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "1dad8d5a-8cd9-4b98-a16e-cdf8e783577a": {"doc_hash": "5bb7e921a5582b5ebb124a19f40eae2786ab633b47cacf5f2608dc422b62a2a3", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "8e89e9e5-aa97-4e93-97fb-73e85a39cd3a": {"doc_hash": "dc60acede6c56dbdd9b2eb72fcacde3f4cab91f296bf2d571e00b622debaea26", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "decc5f2a-74fa-41f9-9217-aa7916ea660d": {"doc_hash": "091927334cc86af3be331c2c4a290773a670282dabbaa9eebb83fc6bd6aef5d0", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "db8eb874-f61d-4920-aad8-b53e37ed0ef9": {"doc_hash": "452aba9ef41f797fc1213a7a84a202ffb26dec05d5e3da894157ba7b7d7a7b8b", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "b1cc4963-a2ef-4b16-a8b9-6ded8b0ad0d2": {"doc_hash": "39c11a03cc0967a2644dfe85687aea555c712c10b3a84f95caeea7068468720b", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "d865bd5c-b74e-41b9-ab05-0bd61035edd9": {"doc_hash": "8cdc9745aa33dfff4069b9a1f31dc19f09041ca57e2ed5fba38545d09d0f4141", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "9bde1ff7-83e9-429d-af93-689d880fb461": {"doc_hash": "23af9e065aab096494394c9edbe24f01781475c1e9d8f927bacc047b49719587", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "b22c8212-3ba5-4a7d-8047-4b6d9d63b637": {"doc_hash": "f5320ad500a8ee8a0a4fc5448b3d2d480af9406842e67ccef93572e15f2fe642", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "2fe6d126-bd36-47e7-85f8-7d1eef2ac75f": {"doc_hash": "865440a1516f1cf3fe99e55aa24038ef57d366647f8cb6285fbbc4dc0bbbe496", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "9478a0b3-3407-471c-8bdc-6940cc3d0805": {"doc_hash": "3372eabd074a37a68e6d19cecd8f5b8a22874649c217283f6b949413158559d5", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "7b211f33-a6fb-45b6-b611-6fd8b0ee5c77": {"doc_hash": "e1d19d9ed5f195c617827adae192c492e9855ab3f3c44586a3b1070eae90e521", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "bdb88d73-2103-43e6-9035-eb11f9f18fc5": {"doc_hash": "c3a490a50eef82e92b061c4056000f27e8873cbdf99bdc20c5d56dd053541c5d", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "8078d93e-8a80-49e7-a6c2-0395e4c9abec": {"doc_hash": "c8419c6813ff309d775f10c4b57187b154afa11824915f3eb577125313933b20", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "18f44346-0449-43cc-a810-bc7286cd3f37": {"doc_hash": "29474f97e456998b884a7fc741995fce01ed322c0a7da5cdc6ce6877f7c0207a", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "7a7c4ff7-38da-49f8-b997-ca4b2b0705cc": {"doc_hash": "8ac530c7e19a3f721a60d50643e6c6241378c55d6f2de1ec249070e5c08f24a5", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "f97fe97b-34bd-489d-a9f9-9a5ef9aa31fa": {"doc_hash": "98a98fa795b3cd1d9d89c9c6ea4fbdefb8014d7485a3dd563cf6ac2f530621f5", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "d83d35ad-65c0-4d84-866c-b07985bd7208": {"doc_hash": "60c35557727adee040b986e4104d38e0e8740cf111295a68417f91af0b477643", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "01f0a8bd-4390-4105-9302-7c7ca7114bbc": {"doc_hash": "d6eb9bae681877d6160afff0dc99124f614b52576f99507379b7162b0acd421f", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "18d63caf-9e8a-4577-a21b-b42c9af1530f": {"doc_hash": "f8f8a53036276ed85163463a861adff9fcadd7b01698af06079eae180563f2f3", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "c04692eb-00df-4594-bf8a-62d26b49fb56": {"doc_hash": "b1e2902f9297ddf68b7c71b6984a8e021d61b12e1095d7a9e1bbc8ff81e7d632", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "5fcb0119-23a8-4276-b7fa-b9e4819fe79e": {"doc_hash": "7934952f82e3128f990631261c476751733265689307e1b4a9bef917b6c7f1cf", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "019e5835-8e2d-461e-abc2-eb1398b410f0": {"doc_hash": "8fc551f1e0376f37a18b01ab8de480cffc29c7c1ecbf713ff235de779fb88809", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "7de45917-80bb-4e1b-be9d-a1d2bea76a97": {"doc_hash": "474a2a9344061fb00c6f6d5f4eaf1ad48d7246b861138b21bbd40b1c6150d09e", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "20b9bac2-9b12-4a1f-9b35-49cd9e579169": {"doc_hash": "5bbbb807c452e4b6f817322f1d8726e22109da638da93dc068ac01d5d35644e9", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "f3c11edc-88eb-4ec9-8252-c9b97c4a667e": {"doc_hash": "3f628f935e7467d76bc7d356e06b8480241eaf969697b6a351ed3906a4785198", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "d27008b7-9325-49cc-824a-1dc9987c756a": {"doc_hash": "ed29588d0e662d15c5c22140597a2ba4e7cc42820562750d01fa15d1404489f6", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "670439c4-3715-49ea-a581-80c3b84e2336": {"doc_hash": "e93f1321cd0864ed6be11adb64e16b851f3b0a30d522f7fffd6ff15dab0ca454", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "100f4621-b3a9-494a-b2d9-8b7a35a1d780": {"doc_hash": "78ba8436b53c13b0f17c56841467e26f36ea9920103d5319148d02c93e5a9bce", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "04963552-cfdd-4b81-8a5b-1b5648c26531": {"doc_hash": "1332700b80092476e916322aa3188b7902348699e99e55528e97423d28dd02f3", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "1ef8834c-c5b4-4fa4-b00f-cdcd100c3655": {"doc_hash": "9159b5b19e26597189858c10e73add28b9a1699a017c6cccf17336f7173360f5", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "a309d6b6-7155-401c-9025-a55f953bc26e": {"doc_hash": "4287a85cbaf2bcb0ca2d44445e4fbaeeca900d51fc46f8711562579183c3496f", "ref_doc_id": "c30d9699-f1f8-4024-94ec-d0538a8d03e7"}, "5bba34f7-48b1-4bcb-9616-677856aa42f7": {"doc_hash": "f01f9e185312cc415edf878a2dcf53656fe8a7a7625968fc436829bddf4a989c", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "c2055d9a-31d3-47df-ae3b-53b79bb4facf": {"doc_hash": "998bd1d59841c6febc98d907d064a6a757434c6b2bcac45ae1f094b0ca05961c", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "99915be1-8e04-4596-9eb3-99f94dfbab31": {"doc_hash": "0a2ec0285d1035b6464758b5c94a76246d27422c4d8c91bdf3179f2cb93dd93d", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "13ad8f41-196e-44c7-aaf2-80ccd51f31ae": {"doc_hash": "a9275a5fbab0b09f76588f9cf0914c858bb954814cfb10c45f3528c6ff8413c7", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "54347623-4a44-4ddb-a4ab-4768d1b4d0d8": {"doc_hash": "402e52593048b07866a867c4b8a402b22dffb10fe7a1eec5b7583a10a3ae9d67", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "34104dfa-1182-4efd-8c3c-ec990dc7c0c9": {"doc_hash": "c232cec4195f932ac1b41db3619cfd95f0cb44ab0898c987c0cbc49a0499d544", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "cfdd9054-40fb-48e7-9e90-cd469ccc359f": {"doc_hash": "6797cdf6593fcbc7c0caf3c72e0e6dbb0f0785d87123f51f4cac0606faf232eb", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "80718301-12c9-43f6-ac46-1fbb070d0ded": {"doc_hash": "9523a0d92aae14943548c4b01723f78a60f851178d7e706bbe2bc17ffe8c3940", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "b58e9d5c-f743-42c8-a87d-19715f4f413d": {"doc_hash": "92e98f61ebb514bd5dda12f75be897e5bce2e11c199ced86063b49f5e03e489b", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "09624e07-e5e9-49ae-8009-2e8ba09bfdbe": {"doc_hash": "7a3a9833728d93a105d2526d7d1a2143608e3eabef25a18b33fedb004257728f", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "03a2d54c-e670-42c4-bfa6-342b72f341c2": {"doc_hash": "26339d05ea0c4801d785fd0aa1679923f883a66e5f77e24ef1e159e1ae43b9ed", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "46daac5b-d13d-4f83-82d6-e53abfc08ad0": {"doc_hash": "04e152d3f7181f19625e6c10a17ce50039aa0c3e7826fc5f94b5f8a243858bfe", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "5954d1a5-5fbe-42e7-8893-9cd9b4f13f51": {"doc_hash": "b620b13eaa1d308e00bef5e7d5916993e596c03b1c26a2c9ccc9ca4dbfb22c5f", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "a3e97f48-1bf4-42e7-8f28-efe234e82160": {"doc_hash": "d1a7c0fa7ca473675a319899b6779c5428065d56053471c7ac1330d12ea0d893", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "527decb7-89d2-4d63-8fb3-fee312d66e78": {"doc_hash": "f16d73c5563cc2fa5176b1fc865fa4cfa663dbf34b16eacd97c1db011b5228d2", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "e89ab7b7-cc68-4187-8712-19ad586d650e": {"doc_hash": "fbfb3e3191fd617f7420a3c00a190ecba4199698ea580d8126da9e0aeb02a7f2", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "a265481c-9d2b-4133-9ce4-5ff023e6f882": {"doc_hash": "02128603a755639e6c055240e14afb4d662d7aafe9267d6b765217451fed6c08", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "8851f959-85e9-4013-95a3-41f43f79296f": {"doc_hash": "5c223b98aa3b2173d5f3a704865864cbe35c6ee6d4dbdf84c5641e19f9496e97", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "fc63b861-54ae-4994-aa8d-0705046842e9": {"doc_hash": "5a9398a6ef11b351019880959c56baaed28643bcd95cecb52d7885162e7bf761", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "148c942a-ab40-4b88-8209-9322cf0ad1d6": {"doc_hash": "fe5300a27eb1889d8c29dbe9896e12eb561e74d285e37daffd9d098d2e5577b8", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "253d45c5-448f-492e-873c-135283d863a8": {"doc_hash": "2692d575d1c66979214eaec819d85a5caddb8ef1a94bb70efd7b20c11372cba7", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "00988ef4-2fe1-48d0-b551-cc37c13a9c4d": {"doc_hash": "dcc684f5a8c673210182cc6962e918b9fa6e3587b78d83da38fb126162bb5c28", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "ab3193a8-84f1-445a-b760-2f32146dc391": {"doc_hash": "94a92a680673fe3cd24c1bb3d712dee252a416cfe0f49cb6936548554b4db4d9", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "94f15379-34e9-49d8-bf77-f4a48f7012c4": {"doc_hash": "08c4b53cd215c63fdc1068ffec61aa678c410df6ba1f760b0765ab73877fe43f", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "2f0b6c60-72bb-47af-9842-a566d6dab5fd": {"doc_hash": "6be6e9e2df960442b52f2573dcc452afe951c54ae5bee58aa9c926cb67490c1a", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "b41e8f56-d098-45de-a489-c37e7294a208": {"doc_hash": "3ffe514f595aab51740eae5e4492441161b966abef57785c9fca70e965b0997d", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "a87c623e-b8fe-449f-8627-79006ecb3420": {"doc_hash": "1c0bd2eba4c31cbef37ca0f781fcdd73e2c3c9f973b1e94e3604f9f7cd94902a", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "3ba95780-2175-41c7-8fd4-799c086f6f17": {"doc_hash": "0a8882c05dc01ca1d4ad39338a00855a10182c32da37458bb27a8f53dff74c78", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "e90d7c71-6e3a-41a9-9810-bc2c45d683b1": {"doc_hash": "8f083e5b167aa05b76340866a0266c1836187c9061b68ff0dcd765fc4323bf7a", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "25d65221-bcf4-48f0-a4f9-6b5a4831bf50": {"doc_hash": "23827fc3b69d86fa2c2823e5badd614328bff272bd846696303daa60096a2ec0", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "98cecef0-35dd-4584-93fe-954fc4c10914": {"doc_hash": "01097d006c190953b4c12605630ba8bdcc06bfa5b20b895c5f28266534ee6e10", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "c8c729df-e092-4dc5-a7cb-cc29463071dc": {"doc_hash": "5576f6cb0a0b19c11fc8307f8d19eaa33c4cd9adf79970d4a0674d776e58aaea", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "f3053796-dbc4-4247-a600-5380865e2433": {"doc_hash": "94265be1fae48b3338cd5b8f26df27145e7ac0ae70406b2995ecd732a17efa4b", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "aa8db448-5c4f-490d-ba8f-fae3238eded5": {"doc_hash": "8ddad93a471984088659663fbf1f921ba229caac311e2da9c9cdde5d240680cb", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "cc1bf378-cab2-4d24-9e45-ae7315fa73b7": {"doc_hash": "856906f9ea2c2b90582919df0e8dab82dfcfeea5745546f53a46d08e0987f317", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "393a5c37-e3b0-4fe0-a3f1-2c02d91b1810": {"doc_hash": "9f3a3c0c2c444b576d0e2a7a808184d76598989703d67298d0ada473b9b52370", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "53f6ce17-d066-44f6-bb90-c686d4020dcc": {"doc_hash": "78da159591beb7bde47ef67f0bc2ea9c3a57ee8d4c63fc3fd8dddd10c914d428", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "7beded7b-b6be-479a-b097-7ed17dbf72c8": {"doc_hash": "ef8a45bd311ec8f0f21b2165b257b4e45929b7039359e743d43f0cd14fecc0bd", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "fc7906bb-7338-4862-a5d2-8aa5d73db2b6": {"doc_hash": "4bbe8c441ae1ad4d93f8b9a77da7de1fbbb9249ab15e83a23b6fdc416bfacfa5", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "942408f1-4240-4c83-a0bf-8424bbd11af9": {"doc_hash": "2c528295a1dffce293e6cb0cc78e1bf1566a52d7b184fc2c966e46793f4986cb", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "7aaf9043-188f-492b-aec7-a2ff6af49c93": {"doc_hash": "360e35b76cd2b4f263511cfa293f6a6125fe1aacc9eb4e61ac16869c84f5a68a", "ref_doc_id": "03e78add-c0e1-4341-9187-cc01f92ed2b4"}, "55faefa0-d053-46c0-b39b-b742148ddecd": {"doc_hash": "dc03f453666884e223ebe0256e9bb2dfd580dde4b6893857a5659588cbe9998a", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "dedba8dc-fc96-464e-b05f-7fc0086d3cf9": {"doc_hash": "ef43c0422d2320fde669fe6c3efa3249180d0da674f7c9b5dfeb61c7fdb1a3a0", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "bf5b1ce5-f64c-414c-9cdf-9b911b3a4e8a": {"doc_hash": "6607e1d8266e86af5ca288a14b38582f4b0e0e0b53d113ecba1944e3e775e6df", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "d0d78ab0-8c47-4ca8-9a0f-f9995e54d7ef": {"doc_hash": "0aff8d1e0cac1b64cc1a27123ec18d21aadcb95ef67998a8ebe80774510adb4c", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "dfc7f5d6-623e-4d0d-8ada-fa2262d3788a": {"doc_hash": "e6fae98b090a12f3bdacd69526cbf78bab7957c2d6e6379105121c94b660e75c", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "6f47966e-b2d3-4efa-8d34-cfae25675b25": {"doc_hash": "6ae3755a88faa26cb3bf14999f9684aeb28943eed8ba87343b3f11660de08a9e", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "b25200ba-3318-4977-bf7d-89482eea3275": {"doc_hash": "7564ea573dd377bbd8cc716bdf07b22c60f8931969b578cb092c7e483d27c16e", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "f0171073-cd9c-4ed8-b1a0-6ecb25b8c979": {"doc_hash": "dbef8f993028ef83afb5c44369025399c9baa03d991ffbb34ab51ce555f79e6b", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "e8e1658a-12a8-4bb6-a120-3120b55b07ed": {"doc_hash": "e23bf6f764fb48e8388a3e44d507e3a2e184d945df21c9446cbe7b9a229a9a87", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "a1d7e319-9257-4744-9286-7c0213ba0667": {"doc_hash": "57093389f87628b02b5f904490c12705a0fdef164358bff7c027a897a2243db2", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "97d37524-9901-4aa8-afb8-30648651d0e5": {"doc_hash": "8afa7c182da292cd03125a4bd7dc2d5ac353a90e5e72c6516aa06b5721cb3a54", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "1739dd3c-db8f-44b9-9a17-4bfe52aa6fc7": {"doc_hash": "642c69bfeb308d1cbd9a790ae8f4b7f16c03edc1332ca1f04c0e047c9aa1555a", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "18d089af-5cb2-4378-ac68-069541200a9f": {"doc_hash": "a36bdbd4b3bd6008386f544857329a24ef74d23491268120a6d33457aca1c699", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "ccbc2dee-b693-44f8-b4ff-9c676df49640": {"doc_hash": "1a2504b4acce227ab53ec0072bc2b837836ef7b4de98c3e7ba20d5b7324572d6", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "146293cb-f77d-4d4f-9cf9-c37fe3aa87d7": {"doc_hash": "6ea4128941ecc7df00f9f905201bfdc14c2287c79681661a3de069eba5e7a5ce", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "87648df8-4091-477f-83d1-dee7f4fa08ba": {"doc_hash": "a8c00c7788d80b6153a7c3aace6f24fd7be4706ddec2430f645794e53699e89e", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "66f9f817-9493-4b39-8d0c-031065192948": {"doc_hash": "15324564c772ad2083d84eab38fb39200e847ea069dbebc12bab5e5aa8f16cbc", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "a5be56ab-676d-494b-9263-b1e5dc772920": {"doc_hash": "7e990a60bb1c633fd387b5a5de4947795d71bbd9d0eb4486f12795bac9d3fb69", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "d67b0819-6262-4438-a997-feeddb812aae": {"doc_hash": "8229398e4ef4d1c31091d0861e2b692472f854eb151e44d4b701997da92cf198", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "e8bdd93b-f25c-4eb8-bc08-1f1033e712cd": {"doc_hash": "a9f1d254e6fa518da777204fb3586b326b21b888d9dc1fc46526e132fe7c2cb6", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "c7fa67ef-6e05-4334-853d-7509ddbb04a4": {"doc_hash": "472978d503df77c5582897fcd4a15abd35f1c2facd7df60fc46551e7401955e5", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "4704b8a0-17ff-460f-ae1b-9dee6c542e19": {"doc_hash": "8b881ae53e19720170b34d5bb6b52df6fcc8d98d8fe74d76a351bd203d96a240", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "205c5571-e7c6-4c6c-a069-75bb37bb78be": {"doc_hash": "8878e5474f3a3fbd825fcf6e6778a05bc62d96ec031adbe315a677f74503843e", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "1b20c5bd-6556-4f16-9e5e-63da996989d4": {"doc_hash": "15681e3f55ef4d7f2745faddd381341ddf07d09f72e398a67ea1a8dbf77ca671", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "c3453872-29db-4824-86a4-f3c4c1631b7c": {"doc_hash": "435bd9b0497388db85fd0c789a90acf1dd9d1c74174aad12acaf60c97a4b5807", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "27dc5df4-3d11-4a67-98af-632629374ac5": {"doc_hash": "699110db323cbdb8cc934c8361b1144bff4d657e2944fe126ba7b3945ebf4ee8", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "6449bfe2-fe34-42aa-b314-e2df073dc406": {"doc_hash": "a9a9db37d57eb6e0946a78d45a1e5ede9ba3d01d80cec0d404f66a64bf418ce5", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "e717e525-0c11-40db-a715-34661bd5bb35": {"doc_hash": "62300dc6926cc61569f704c9c326f518b87d0e60cf079e681654b39b8b26e98a", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "e032aa65-4c98-464a-aecb-e0d1bfd8cc5b": {"doc_hash": "2eee0174ddf5507880dab15c0283463203bc2d6df9d32798fa3bc7200c6b8d3d", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "65c4973a-8360-4bc0-b87e-b0988e0d1712": {"doc_hash": "f32aa5448b8b9f524ec5da6aaafe9f50d768fceb043ec4998aab0cbf1a6089f7", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "e8e1f858-2679-4189-a58c-3f9d6639ab04": {"doc_hash": "04b1f48efd0a1025f3f5dc19d815c6cfef977f175d5908a2b9b74beffbb1b3b3", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "26071d12-2810-4918-9ab6-385f91a42e10": {"doc_hash": "3324ca8e0bc49f9326cef1349ea33a413f69ab4cb64f5525ea66cf25735a39fc", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "56eacc46-1598-4394-93c9-9d399818de69": {"doc_hash": "3bea9e7c2d1a32b41efd507e48aa1c90ca5028e671661e8fb574a513730c8647", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "ef3d089d-2139-42bb-a147-90a18542b9f4": {"doc_hash": "eecd7d8feabb82905ff4d744d6ccded90b655be0d89d18266d1516dcfd0281ba", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "88034bc9-4f52-4057-8a4a-28c9b495e433": {"doc_hash": "2b2505155164f30d11ce3d5aaa0d258d98c443d335a2b3f9e8ba08ac64d2f2d0", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "3722800f-64a8-4205-96b7-7b69638f9e49": {"doc_hash": "7d1be6644af1e32395b3538c6568c99bdcf3331340a9043ea653f1492555d093", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "8907b920-8711-4188-8fd3-b9ba5fa8d954": {"doc_hash": "d410158c8d3c6e560f468bb230fdc9ccd86371bdc49b97bf940a94c4d994bdf5", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "ed8b58fb-46e3-4f70-bf6e-c7743f32c0ca": {"doc_hash": "072210278cad000b384e7e7b36f97c3226f3e9eba0f7ad7cd6bbae896bbf3610", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "fa9dbfef-cdd5-436f-a382-fdc3fe000ec6": {"doc_hash": "e976e934630a90bb7b1430aca2abd504e87179992b89f4b5fd8234e870356c33", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "30cf5c4f-791c-4382-8129-c6ccee4c7d3e": {"doc_hash": "0fb1d4cc012e9272dee10b258815acb04e14ab031b04c26762037e1eb4df0869", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "d87de445-690e-4506-8acc-2dd1d2a0b55e": {"doc_hash": "5a10521c294a7be841c72ceecb2e5ca1222d005d21b2b5ad9c47b90368a1f466", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "38651076-8702-4bb1-ba4a-a63d0fa84fda": {"doc_hash": "abd6c7ba0294da2613bf27b0b184aeec6e38a17ab2371f9e1197ae9b40292546", "ref_doc_id": "652b9b03-6701-4e05-b5ec-91f83a9126b2"}, "202187bb-3bb1-4f4c-9529-52fb5100b9ba": {"doc_hash": "ac378560e8ed931b2aa631ea5196a0960724e3c1319192242c61e95c88606efd", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "52f14eca-6e8d-4cd8-b906-0a8417eb0088": {"doc_hash": "6ff5bac9f6a144b990eeccfbdffcbaf722c6b007ac4bf06760002bdf3857ac1e", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "6081764d-4cc0-4565-844f-21bc33228e2c": {"doc_hash": "7da52c64d1f044c2c0b8473ac04aa055a8037997c90a3ca821ec9b00e50eb895", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "27b1eee7-e7aa-4b2c-9ac5-96a2e7b027e3": {"doc_hash": "61d39b73057634241d0738d3dbebf5b86fe19b90e223d022f74b22897df03de2", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "4ef16751-2ac7-4635-ae39-745866787c3b": {"doc_hash": "4281694ed3f940e5c5cd5b027040593bba37a4fdbccd1c54a886e61e9a731f93", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "02ff784d-455e-4165-a4cd-6a8b7ae61d4d": {"doc_hash": "01cc54786295fff210265082532f5dd65396081980769b1f5c9781fabcae2b7f", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "8775781e-ab0e-49a7-9e00-9c4df1a07797": {"doc_hash": "181a12920209a60f44a060862ddb95061cc6b1cd263385d3f01818243876d822", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "4f6149c4-7f97-41b9-8ef6-049423305406": {"doc_hash": "314cd4c2ca183abb38a55699cf889c2f9b62b86b61efee3630ed0e42ee935e69", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "662c69bf-31ec-403f-a01e-b5ef7f321490": {"doc_hash": "109b3f22162bd6f94a9b57c566faefbcc4d1d180b73e99ae0b61c0aab0c2fece", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "c15150c9-cb32-411b-bc48-691b2fc2483c": {"doc_hash": "f65259425af9d6f80e529f38e3d361bcff6c753cd50aa05795cd7b29af4f40c8", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "f1287af3-1dd4-44d4-a3d4-664784b45840": {"doc_hash": "109ba7f8695a9e0db5a82e41369e1a1992ae829bf15f3ca72fb42bcdd160c5f8", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "5ac8c6e1-b193-4c5e-ad07-502c008c43c8": {"doc_hash": "aeb739b883879fede1c60169902043ff673eea2d3f4f6391baa7fc5692af29e2", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "cdf69789-398f-4645-87fc-d16a2c98046b": {"doc_hash": "4edf5ef823a3adc9eb8b6a0a36402bef19026114b8848f2af5d03b366d295898", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "b9abe786-4c53-436a-884b-f0619c6b0d41": {"doc_hash": "7a9969783dec830c6031766118af257d498bf9978f96daae28a825b5ffbb46b4", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "181cf335-fe3c-40ba-bfc3-830e91f0ca0f": {"doc_hash": "f01874d9359508e91dcb5743fcf4137b9f9e9b5b253882f23396bff02a2c7ad1", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "85b8ad1e-d651-4f98-b5d1-fcf5bf33d490": {"doc_hash": "35e615dbf62ff41b30e3c5ef239d631e50ba86c00a0e2f6e88061228b1d697a9", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "3fa1634f-5a78-4847-a3e1-efb8c34d6500": {"doc_hash": "986efd050915136b31d5e6add20dc6e0430c06934cab858ca8faa8d4dfffb183", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "027f45b4-5f33-422b-b23a-4d38bd322a4c": {"doc_hash": "3496e3737672f058c6a7b9b4bdf5c758d730d8faa69e183bb3b6e4a579b00bb6", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "f7c5bfe2-9abf-44d1-a1bd-00aa0756c71e": {"doc_hash": "932677926694d35d4d8e47ad56140f8497d9d3a379eaae21abc50da68781cc23", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "e1a35b43-5bfa-4a13-b5e6-4276c2b71088": {"doc_hash": "c3bb7a476f6b2699f87bb82e7aac075f236821c5491d6c67f0499a5b17b651f4", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "9da7bd18-44ec-4282-8044-ef95a24baa5d": {"doc_hash": "6254c30e5d569949812a0c445f3e59de27c59a5e868eec75c3c6b5ebca2aabb3", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "8d522bc7-3a05-42a9-a807-9267fbddc7c7": {"doc_hash": "faf3a176011896c39d6c78ccad8c73619d9e9ac66871e0f007dc74ef9b951eae", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "9db6afb5-5f21-4aff-ae66-b396d12aabe9": {"doc_hash": "4efc16a1a00c9ee9137fb55d7470e93c0b26aac155130009ba79d695098a8595", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "3f70cf69-1053-483a-9ea0-127f7b650b84": {"doc_hash": "53aab2d8470597ae6d6adf40c3a4dc05589a1359a9e32b25bd54431bb3da50dc", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "0ef1a387-f7e6-4be3-b501-e8c0c7ec23d6": {"doc_hash": "b8a71d80f9d68e121015a0fa785f14598b48f1eebf07f6255565769026a61925", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "ad11e4c1-c69f-45d7-ba44-3c6acde3660f": {"doc_hash": "cdea459bbefb87c94e1c046c3e54a2e67ba59a3764973004e49cbcad3b928d8e", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "a4c490ee-7adc-4199-a9ee-82562aab8abd": {"doc_hash": "3ad7cf3ed88593d730eb401f83a0a7a7f0cf24361f4e7c6e851c33fb673fec0c", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "822ee454-fa40-43cd-ac08-b2a33f61fd0b": {"doc_hash": "8f2c2ae112aa62ee8b40545b2f9a8b57431f028998c9e3e4b4811e1f8c5fac5a", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "812fb29d-003f-4bda-b264-0c4619944556": {"doc_hash": "67c1c9a19653131161f8592ad7f8fb3bdfb728b82cf156f20ff0e249c27f86f1", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "6b17f361-73ea-43fd-b4fd-12022c0351a3": {"doc_hash": "edbeb432a979aa3a0c6f1196457ffd2836b510a7577ccfbb8b0352da7e79a735", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "5df41663-18b2-4abd-b748-30d990bf2caa": {"doc_hash": "8c12d49e7f57d93769edf4fbec7e92d533b55a8e998793bda61cf8ecdc1ae608", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "5bda5492-df9c-4226-a984-b01ebd1c7ec3": {"doc_hash": "ada08a37e5d84a219de30d5fcfb3509c9467ba2ad51fad8ef866409ce0196c40", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "a2a29478-410a-45eb-93cd-4d43bfdea142": {"doc_hash": "df234915683815fa7e17974b5c1cbfdc716783d2b15490e982d9eefa913b019d", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "51e2288a-fd4c-4b96-9f3e-d77b371f916c": {"doc_hash": "6d25af985a4c3aa59f6bb50c305ba64fd52055de54859cbcb58dcaafcf519c0c", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "2d97410f-6ebb-46f2-8ec7-5f4709f401db": {"doc_hash": "5d3e57fa85a2790bc5e0695ef988d8536357ce5968ff938cd09fcaae73d8f444", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "3016a943-b8ca-49c6-9b11-b27e8693ea6e": {"doc_hash": "99f2fd5433441e2dbc6ada988a0d5575ba031c240c4e5198b0212c55cf429b1f", "ref_doc_id": "76a564a8-05aa-4e46-8113-1b328fb1f1f5"}, "0e82f7ce-8f27-49af-8c5c-e129fc4729df": {"doc_hash": "40d5a3431f8c556f7a407c8105b876a609a97f97aefbdd0d80f570f48999fcfd", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "e579cbed-d1fb-4d70-a8e8-c4f3bcaa5f6e": {"doc_hash": "1d363d48605383ec2e7ba8ceb68eb7a9b517b16ea8e0d2233938e68b19d8ae73", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "75b242bc-7e65-47dd-b154-89dc415ad590": {"doc_hash": "8ac0d67683752c635e6c6e1ce29d2c54bafd4f584c6ac2e08505848f4e35ac9b", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "000eab26-3f14-4ded-a2d3-ce4faa9b1ebd": {"doc_hash": "da46ee245f36dd63fcb3b7be4b2f93e1b2225b4f062f7db346463a1b177a0672", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "8e964af4-881a-4400-82c1-86b06ccd82d4": {"doc_hash": "9458daaa3050f181b834b789c360102672463530c6fe7fa1c3414ee5c73b670e", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "427c8cbd-19d9-4ddb-83f3-2843c8d5ddbc": {"doc_hash": "bc4ad65f3fc4fc4c020751e008a39a97ae15b2df9523d8cfc94bbbb3014aa491", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "f1f9a378-17ca-4d41-afcd-2324c5aabb09": {"doc_hash": "727af482314ac529416a9fa2fc2d25ce740793529b26af2d6442bc7ada2bc165", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "815e7dc3-8653-402f-9dfd-bc17d7ccd497": {"doc_hash": "c9f04661e929898a2016f7e6526aab7c20d4cc4cf79abf7ed67d989b472fb3d5", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "0f17cc2c-15ed-4601-a7db-aab101475c1a": {"doc_hash": "89e38c1b9cfdc3e9b92426fd34cea6c12d8f8ada060bca72e29955e020f773b6", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "7ed25b09-5306-48bc-9e19-e7997a094ba1": {"doc_hash": "8e25f7eca64adaf8564bb08c50fbc0e6e2a9097439cde64872b532728a02d768", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "9a0412e6-f6d1-465f-8ca4-50822fa7a374": {"doc_hash": "a5f3a095692a4df82ee150b7e4b38c464bbb6bce624584d5f96dacd434822796", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "a02eb7b6-80ee-456e-95e4-5dc9210bc0c4": {"doc_hash": "b27860234c9089d86179a2653ff3b4c3d0aab0eaf8b3da12f4eb8c0e7cc5a09a", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "058bc084-72dc-4890-adac-f14bb82a9fa3": {"doc_hash": "8b6f0b5ae21cff8b626a2b47bb4817c28d99a3ef97710db7179c20705dfffb3c", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "6e9ac47e-e717-4c64-8dc5-57b97d1dbb1b": {"doc_hash": "ccaccad9998719716480440657341772ccbe3d208409d0e2f9a2bf803e30319c", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "a6a631de-f313-4622-914f-f9bac98edb35": {"doc_hash": "80a3aecfaecd5fe79ac5a8ef5436f666f5a5debc1b55f7b8d1d0f07c2befe351", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "68c0925d-7180-46ac-936a-d1dac01b0e00": {"doc_hash": "f18d040c112438a1549df856039a61699a87b21b08fd6e55aa27904e1d47bb3d", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "28771c67-effe-42f1-8c0e-a61cdb67f9de": {"doc_hash": "53664d122d73ec6390033686c6f9307716d448a84776aac9aa528a7edcf39e02", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "feccfd98-5f32-4248-8a71-11b26d277927": {"doc_hash": "e15f9864092a80fe91f987495f3d13ffe1fcce6b916b678483b5063895217a25", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "731773ff-4856-4848-8d2c-a861dd05faa4": {"doc_hash": "d25f2701d9f0a389426d53fac391c1171d3f920cec792a0825eb0f3928e42c62", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "573ad571-1b96-4ada-b237-e06a8de4a584": {"doc_hash": "3bf846de61638c38fad9c812f2e84b1a9d67c8f434154ca6b7c1b4b6f2a72271", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "76ac0899-877d-4fb8-bf9d-83681b20f56b": {"doc_hash": "4abcb927b44056da065bee0dc1b0cf4182f7ddd66d5db9ba409433e59c9798de", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "4aac7526-7b37-401e-915d-cd3fd6b28c93": {"doc_hash": "2998e3d150062f8dd4d601946892f4af67ae5408c364e3d5ca8292e87890487e", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "d524ae9b-5ead-4de1-811b-fff811757d53": {"doc_hash": "b49dae5dd01dc793f4bdff4203e6b0f20c3aa06ff279be5785878aa603ccc66e", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "77140513-2181-40f6-8b45-6d699368a32e": {"doc_hash": "0dfe75f8fb32c7776aab31ac99ddcd4bf3d2ac15f1f92ff0597c1cd01123dd07", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "20436f69-056d-47a6-bde7-5557f6591e83": {"doc_hash": "b5586351093a8ead6190d93794659f658eec7d343ebc995ed43986d9537abc3e", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "49fdec95-70e6-44d1-afcd-d788e7a92419": {"doc_hash": "d6aca76ef1179cfb75fc40d45fc26f4bd8cc65dbf5065b6d2b2d138b476df279", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "f1d0a407-0e09-454a-841c-ef145343e342": {"doc_hash": "a5ec4dc3aba840caa454d79b414dda0f662c351b86eac00afa586a795799c425", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "365200d9-022b-4499-9df7-9d82ce784cad": {"doc_hash": "b790299447a65aa64f9c9e5b799ee606ea65a6468ba392fac626881d7896eace", "ref_doc_id": "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4"}, "6a52e32e-53e0-4e68-8943-801c772ebaed": {"doc_hash": "41c26348a81b22fe8b30c8fcb39c1d0872e73d74d58e98e16aa918af0b7a26a5", "ref_doc_id": "a5688580-d83a-42f1-8a16-47f74e44508d"}, "755f3432-80df-463a-8024-6af242e5781c": {"doc_hash": "5706adeea4db9c09a18233fbbdc9e1c7921e09b34c6c994138c3c847077c4ded", "ref_doc_id": "a5688580-d83a-42f1-8a16-47f74e44508d"}, "ff09d092-402e-4aa0-a729-b1d2e83f3bf5": {"doc_hash": "68d9942d7308ec52fc3f1ec32a44f23da8b5eca08dc98383d3bfb6ceffcabf04", "ref_doc_id": "a5688580-d83a-42f1-8a16-47f74e44508d"}, "96d30d09-9439-4ff4-90f3-53bc018649a2": {"doc_hash": "0be1fda86f4b25292fcf1a6b2169e7cb3163356334293bfcfd59d8a2697e0a31", "ref_doc_id": "a5688580-d83a-42f1-8a16-47f74e44508d"}, "4d9e9927-fc34-457b-9a38-13c8208439e3": {"doc_hash": "0f6577b4c443f2b3ebf342b8e7149f834668e3a2edd5b3caed41a1483d5e8fd9", "ref_doc_id": "a5688580-d83a-42f1-8a16-47f74e44508d"}, "ec7cee9c-3f35-4ca5-9d9b-dc5afd7de27a": {"doc_hash": "7aa6cd53e71a810d3c5ef9edd7722acfed361d8b82de80c4e1f41fbae0c40183", "ref_doc_id": "a5688580-d83a-42f1-8a16-47f74e44508d"}, "dfcc7329-814d-4e0f-8fcd-6c49bda189ce": {"doc_hash": "7f0bd2b42c554dd1559e8224be3ce4cb11b38b9bde4de2e7882483691e07e9a3", "ref_doc_id": "a5688580-d83a-42f1-8a16-47f74e44508d"}, "67d4617b-a8a3-476f-85e3-f20265b8be80": {"doc_hash": "d83b3c502fb717ac161b22fe1e4eaa402b9d461e53db6f381c8727e3c0672380", "ref_doc_id": "a5688580-d83a-42f1-8a16-47f74e44508d"}, "71efdae4-4a22-4c95-81e2-efcf0caebd99": {"doc_hash": "f5207b627967faa8c0caa13efe7b080231a952413514e020433006bdab75507c", "ref_doc_id": "a5688580-d83a-42f1-8a16-47f74e44508d"}, "879371e0-82f5-44df-b57f-a2323f39418e": {"doc_hash": "4edd3f194dd656af366e76aebf56233af2228a51f43e97c152114502c947f5f8", "ref_doc_id": "a5688580-d83a-42f1-8a16-47f74e44508d"}, "19965a39-da82-4119-b6ef-69d0c3511a62": {"doc_hash": "ad11efa665bee84dd94c1d18edace2b2c241f503ed4f80aadd9a86f995c22d10", "ref_doc_id": "a5688580-d83a-42f1-8a16-47f74e44508d"}, "8ca5f54b-c75e-424e-a560-0ae253726c2d": {"doc_hash": "900975fe1aecdae9604d7ea21158bfa00a09c3c803a1f48e42b04f72cb96499d", "ref_doc_id": "a5688580-d83a-42f1-8a16-47f74e44508d"}, "c4551d03-72da-4a9f-8a43-43d1c66eb018": {"doc_hash": "c5b48347ff521ae96c61496c5c89c758842b6b24dedafca312e64156ca5a1cc5", "ref_doc_id": "a5688580-d83a-42f1-8a16-47f74e44508d"}, "f1c91e00-7642-4d49-88ae-b57a113b3aaf": {"doc_hash": "e60dfa64f7bd3582633de33c33122328811f849f24dd714a44371c4cfe9d2919", "ref_doc_id": "a5688580-d83a-42f1-8a16-47f74e44508d"}}, "docstore/ref_doc_info": {"e385906f-c0ce-4fa2-b4d2-9c45ca30478e": {"node_ids": ["27128e1f-79cb-4a66-87f6-31b5d6655697", "2d7366c2-e4e8-4f21-a2c4-49d8d2be4744"], "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n30-Oct-2019  \nMcKesson Corp.   (MCK ) \nQ2 2020 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n30-Oct-2019  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "3f935131-e65a-49a3-b96a-9ce83cf85c02": {"node_ids": ["e73dbf6b-a88c-4195-8dc1-7b08ef125561", "5acbfab8-3f45-4b0c-9223-d0385f6a56aa", "1703f5ac-9284-4867-94a4-0fe3a89d082c", "917c26f1-58d3-4028-b7b8-bf4087e2b002", "73116bb2-1fce-439d-9eb3-3cea3fb4bb51", "d3b91612-32f5-4f9e-80a3-961708352f4a", "f92643c0-0d5c-4a34-a81c-50a7c7678765", "ac9d0176-0e0f-4ab5-9406-878caca2b5cb", "52e5ab9d-e0eb-460a-be7a-35947fd0bf20", "2d1cd378-10dd-4911-9cf1-caa9062a0aef", "5207a613-0e01-431f-8020-b719f1a28dca", "b17c625f-c6f2-4a53-b683-91a3a68d89f4", "3a94e57b-90ac-4b26-b61e-ec58ea3e2767", "743468f6-1d35-4ef2-8d29-e781e6e9b65e", "e0b3ad52-6736-4bf6-8567-25db70a96eca", "f910ec9e-673f-41a3-85b9-2264b78d5396", "adf465b8-fff7-400d-b8fc-770e7a7a3cbf", "fecab0e9-efbb-43ad-9b58-be7b0fc5b771", "383602b8-d7d5-46fb-82db-3fc3355a429b", "0a9e9b89-1170-4c5d-bbca-95cb1795c117"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "2115a28e-f168-4561-ae64-131a6ee7b2e0": {"node_ids": ["816e888a-539e-4c9e-8855-b45b20335340", "094c2473-8130-45b9-a943-16911ca12ae4", "219d5862-3cce-4f14-85da-edb76cd4697b", "9ccdc336-55bd-4b4a-9a4c-852db12eac54", "26871d99-772f-4e00-916a-39da73c26b6d", "107a304a-b224-4b21-a603-49ea6bb88961", "1b9d1842-4db9-4c79-8af9-f0bdd38bd22a", "c09dc24b-31ce-465c-82b9-76b3a6fa21af", "26090125-0cf9-4fe2-8094-8cc1342d6248", "95437e0c-6ecb-4de7-83e2-4ffacffab1f4", "c2e86462-b473-4905-bc99-afb3817f3252", "bd8f4fb2-ca4a-47b0-b864-6c919d388809", "eaebaba8-9700-47aa-8df5-63037cfe1ad1", "a244e964-f321-42ed-9858-efcef3fb46cd", "8cf3edbe-86f5-4038-8176-c3369629c8af", "253fc8ec-dff1-451e-826a-c65a33a0a8ea", "81f3847a-f92b-4e05-a9f3-3a82dbdf6d56", "63d9ae78-8f8e-4abb-a5f2-8316d400e305", "35a1278a-4a67-48ec-97a1-d4cc1d3155cb", "ffcac5a3-cc32-45eb-8fca-18048f7a7a79", "346ac7ae-b936-4ddb-89de-88e37147c091", "d665882f-56e1-4274-8432-56b082d9cade", "5a93b8f7-2061-426d-9967-8d918a74f637", "c63d36bf-6663-48d6-9fd6-93bf3d9b1101", "2c7d14a6-400f-4bc3-9c1e-802d57b7b73e", "9c3bbed6-c223-4754-afc7-bda899611901", "587c7861-d872-4dbb-8491-f6d19684775a", "caef3579-4e0e-44ef-bbe0-17c39c969fc6", "1903d3fa-ff64-4bba-84a0-499434a17460", "d22bae23-12a8-4cce-855a-a752dc8d7ef2", "a89fb811-f9f8-450f-9d18-c75962736164", "a285595f-c370-452e-b671-5247d520299b", "42bf4aa0-4acf-44f3-8425-0c8056c2e744", "c5bd98a0-4667-492e-86f1-5fbc5a175df0"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "5115b185-e381-4dac-955b-4a06264b92a1": {"node_ids": ["1ee9de18-edaf-4992-888b-8175276ea5ec", "74555ded-8826-4828-8435-46938e102920", "b03d06e7-114f-4189-bdf0-c83ddf800263", "a04c1f56-522f-4448-b8d4-3d1d1849abcd", "a2c5a40b-b59f-4476-952e-e972b6dea690", "555f7e0d-57dd-477c-a339-433905cddc6a", "ac2cbe01-6951-4641-84c9-46b12dce1525", "5c6150fc-8ce1-4b1a-83f0-af3cd0616080", "74c0ecac-fc3c-4e3b-bc50-0fffe93700a0", "b2bdf916-86ef-4e13-84f8-a80894b61da4", "40f8af73-563f-4cce-86a7-a147b0fb14e8", "ec510c98-9236-4eb0-b66d-87004d8b947f", "696ba670-e1a6-494b-8d39-f5e6b70a043c", "b175cd96-f60e-46dd-80c5-3989c9e8e885", "1ff80ff6-a2ec-4472-af84-be231fe815e7", "c9e4ba94-4662-4042-91fe-ec1d864b791a", "b4dccd61-86ff-4a17-b8a3-c15a633a8dbd", "4e1a9184-4fe8-4b0c-b433-ec698ad71d1e", "0d4c9cf1-014b-4c6f-9978-8193dd0f579d", "034b2e7a-7c6f-4b32-a25f-590eb9d0a231", "e8a51797-594f-4032-8893-7d38c50bf06d", "f5a50f5c-5c5c-4615-8208-2ad8a105a564", "925f194e-ac29-437f-aae9-cf17ad9644e9", "b1a0e04d-ed1f-4c34-9e4c-ad596b15a1fa", "3d7716a6-9813-4729-a19a-49d702ad8cf6", "3198a460-a31d-4426-a2de-6bb534e38568", "2b36d83d-ea1c-4aad-a25b-8ce3024b426a", "a43141e5-8514-4598-8c07-e08e3e06dc70", "325a2857-c90f-4f52-9b11-1bd035e4c4d8", "d33920bc-f128-4c63-87e2-0cb3eeeda48a", "6255426e-faf8-4bb5-b455-8aeff9917ace", "b3bf17fe-cb14-499a-8645-3a1241e9a013", "57a44c61-0b7a-4740-842c-54d06dbda987"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOur U.S.  Pharmaceutical and Specialty Solutions segment reflected solid execution in the quarter against this \nmacro backdrop.  Branded pricing is tracking in line with our fiscal 2020 assumption of mid -single digit price  \nincreases. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "19ba0d02-650b-49fe-901a-dabf020f901c": {"node_ids": ["a3860da1-5f5a-42aa-a4e5-cfae38c69db9", "8cf4e140-c222-4ba1-b544-9393cdbd15d7", "b0362ecd-26b6-422f-9bfa-2b0da6ffb28e", "7eafa46d-903a-4d32-a2d6-7b4a243ceb8f", "806ffb8a-a211-4041-9251-dde468d14eb8", "4f439a4a-4605-455e-bed2-8ffcab97088d", "281b25e5-e7cd-4d26-ba65-1b6824bf99cf", "07c4e30b-063d-454c-b976-db9b86ab5f79", "cb069e4a-fb33-4580-9013-91b535786003", "d3087752-1ee9-4a2f-b924-90ae3e083235", "eb3e0a63-31a6-400e-be1c-bb1faf57f44d", "dcdba95c-b876-47cf-97ef-067252937dbf", "f11fef06-7abd-4e91-bf06-5cf930e033da", "45f5c8aa-71a9-415f-b643-ce9d621358e7", "b1d9b1c9-2710-4bd6-8589-83b17fecba45", "c81d37d9-2184-4e9f-9db6-4243b5978beb", "addf21ea-785b-4e79-a148-deebc9fc2eb5", "b8e4e24a-7dff-4b2c-9298-8df345630a97", "dbfce098-4bab-4d5f-abd3-ece600e91c4f", "c64be524-0588-4166-a170-d6791e7db736", "b29348b3-faae-428a-a760-61d1707e2b4d", "a3598aa8-6046-40e8-aa65-67b415e02a01", "7fee208b-bbc0-4b0d-9127-604e03300c2a", "67270314-9332-486d-8700-7f5ea1cc7b20", "1281a9c4-b649-4315-adad-d5463339ef7a", "9b8b528a-063a-4b9b-8ff1-25401bb5c272", "1f9f2496-560e-43f1-95b3-4bd1cd2a2a60", "736a8b79-1aa7-4f96-b8d4-461c88b3a369", "a0c5e3fa-0c10-4d6b-9097-aab185a556b9", "a44a30ba-1226-4b26-ba36-4c4916f13326", "40ca992b-0989-4e36-9d1e-5a2aea990e6f", "24e5f9a1-2c35-4875-ad47-2a1eb2951334", "bc96eb87-e502-4766-be24-43ee305d1451"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nunderpinned by the strong portfolio of our existing offerings.  And we consistently look at ways to expand those \nofferings and create new value -adde d services for our customers.  We are investing in these businesses, \nspecifically in the areas of oncology and biopharma services. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "323b6b02-da19-4cdf-80ca-a3e2f0be9c61": {"node_ids": ["f1c405d5-01f3-4f94-a474-c2bdc6c57b65", "77e77a9c-e9de-4004-adc3-43ad61205216", "95d1e874-fccc-4b33-984c-9b5300818c57", "6dfc654a-971b-4639-b39a-b1276ef75c70", "d5838afb-62a0-4861-9244-0a8f74ea0720", "eaff5322-c47c-4736-9eaa-a6cd4a46b7d9", "6dcf2b61-add2-4e65-a364-25ae9992674d", "93741a31-05b0-4d89-a307-41c7815069a2", "02a4c5fc-781e-436f-bceb-cdd5eca5f370", "6fbab286-9438-422c-b91f-54defb5486fa", "6f4682b5-3b52-4b13-8225-a965c3959a1b", "70005fa1-a660-4e09-86c0-b19a97266740", "8fbc8040-1e4c-42b5-a2d2-30e45a255f3a", "79280fa7-9103-49c0-947b-e109bdcf0d65", "45d8ccf3-e336-42bb-846d-7a9eafa36094", "2f5884fe-4f89-4016-a276-d5974961c0dc", "89032ea7-9e3c-4c3d-b6f9-c229ca796142", "399765c4-59dc-44bb-9e44-6c8ba6ea9595", "0e8792a4-6bd8-40ce-8450-09ae1d2be940", "069bee2e-5dbd-4941-8b5e-f3b9e2557dfe", "cc06dd7e-536b-429f-a184-6d26621ea712", "5c43b9f8-82b4-4421-962c-ed087c9c6a2f", "20a89366-b8da-40c1-8c97-d83aa7da96bf", "4a3eca3c-57b1-4cf4-9f80-1c5bdbed3c71", "f7971047-3143-49e9-baeb-822b6ccf64ea", "f3d789a0-3e2d-494e-9081-9a33b783d1a5", "c3732f2f-912f-40b8-9010-73217bb7cca9", "77380607-4a39-4883-846e-c9d1f981a052", "cbf48eff-5500-4156-b569-83461a993aa8", "d7e701dd-17c9-43df-beed-8658a84b62dd", "6171a771-7bf5-4a55-aae5-9e07f66641d1", "6aa5403c-7978-4eb9-972a-69d8deb2a2d4", "f5482b71-8d19-4e45-bf81-10cc45b53f81", "9ffcaa6a-d7a5-4749-934d-1ed913a89c0c"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nimprove patient care by providing innovative service offerings and demonstrates the value of our McKesson team \nand our broad set of ca pabilities.  This represents another example of how we're investing in our differentiated \nbusinesses.  \n \n Let's move on to Change Healthcare. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "b4cc37b7-5b2b-4c9d-9e6c-843e2a003948": {"node_ids": ["ddedbadc-035c-486d-933a-11a5ed0c73b9", "94300abf-ea59-4a48-861c-0f0d18f90807", "e6c0fd15-6c8c-4d84-bd3f-ffca4e349011", "0ff00a40-ed80-440a-bf78-b92d2bcb941b", "9d13d889-949a-48b7-8730-7929e5422660", "1050306f-0f1c-43ed-a7aa-f0b50816af22", "ea8a4c6b-f757-4962-98e8-64b8566e1a2e", "d4561008-dc76-4cfe-8f07-a5b2e0da7f41", "1baa2b9f-2017-42de-ac5b-f525d199a5be", "6f7c5d15-6b53-4f77-8d7d-6028c8472892", "b2190ee8-b01f-4599-ac33-face6b020bfe", "5d712f18-ac5f-4f14-88a3-ae9a94c9103b", "adc45e8b-e6a5-48a9-96fb-38877a4ab447", "f3d76097-3905-44fc-8b99-96709b2aae91", "31d203f4-9ee9-4dbf-961f-b600b7565dd9", "eaf8ea55-4bad-48de-a906-399d210f28d5", "04574c41-dabf-4e11-8bc2-3c5873a84a63", "60e5d99f-af33-47dc-ab8f-222765515197", "6d4287e0-e90c-442c-9fe0-d6bf911e5cec", "69ec0362-5197-4b5c-b43e-302d2e836164", "4da2f897-21fd-4385-b9fb-96054473abcb", "57c03939-57d9-445c-9574-5c1211d9fd59", "4b2c56ff-e455-4cd9-9c4d-118dd71d3e6a", "ee8e2c05-e187-41de-9fa6-6d4dc12f4998", "0ae3234e-a25a-41af-b1cf-47334e7ac130", "64022cdd-b261-4bf1-bdaa-3bce602993f7", "77465d0c-eef4-47cc-a81d-a93ecd1ed860", "ba5b3b66-1987-4ada-883a-a5975cb581fa", "a25dad6d-4541-4058-982f-3dff45a267fd", "aafd0e9e-bae2-461f-8ddb-cd483fc989e4", "e7ccdf7f-4f3d-43af-a100-f202496e3522"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs part of this work, we completed a market value assessment and recorded a non -cash, pre -tax impairment \ncharge of $1.2 billion in our fiscal 2020 second quarter.  It's important to note this charge in no way reflects the \nfuture value of Change Healthcare.  Rat her, it's an adjustment of the book value to the current market value and \none of the necessary accounting activities within the planned exit process. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "b70bd738-8725-4b16-bdab-efc24137999d": {"node_ids": ["8e37754d-e707-46e3-a748-3a79d7ab9587", "63340611-5892-4cf9-b3a9-43bb1804cde9", "50ccf63b-fd7d-40cb-9fef-df8c1c5439f3", "3135ada3-2390-4e8f-a27d-561f86463e9b", "fa437b25-3271-4dfe-849a-5ba7e6b3809f", "cd0ddcb9-652d-4ae7-af08-000374986d5e", "613b00e9-11b8-48e4-889c-e40d06f3ea0e", "0cf28759-e3e9-46c4-bb85-43cf0425668c", "f1963bc1-327a-48a3-9fab-4a2916c38feb", "bc52f88c-1f2e-41ba-8565-61053a3747a6", "4b63ef83-aac8-4099-8ad0-63f9244fe953", "c14c9361-f444-449e-b8f5-0a6bf5aee928", "b527132e-caa0-46c5-8bb4-86085bcb2e5a", "3bc7f41c-8435-4dd4-b70f-328bebb8d480", "c1ab77e4-5b2b-4380-b12f-c32fe13db818", "1ced2213-dc70-4aa3-9171-ebc8f18b7bc4", "a70ad8b5-4b5a-4965-b142-77e5e7b38052", "91223e94-6807-4ea8-805f-b1f5b0b1dd59", "7b1d199c-4381-4db7-b7c9-290a736d031b", "8edc0581-4e5e-42e7-981a-b2288f777d06", "a17a3dc4-365d-4746-89a7-464c9ff2e689", "e8ad1932-1f98-4d6e-939b-77758925b39c", "443a9c2f-1b02-478b-8fbd-beb1782fad5e", "6b044249-ff7b-40a0-9380-89a4d3381306", "08c28aa3-fe0d-4606-9be3-557526290f23", "041f86d2-c900-436c-b0ab-b0dbe5eabb24", "430bb652-b16c-44e4-8a0f-d02e8e1cfa2b", "cef18880-49f7-4eec-94a1-5788e8665174", "96172edf-a056-4ce6-b970-d8fd8764a4f8"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ndriven by branded pharmaceutical price increases and the previously mentioned increase in Caremark volumes, \nwhich were largel y specialty products and were partially offset by branded to generic conversions.  Based on the \nrevenue development in the first half of the fiscal year, we are updating our guidance to revenue growth of high \nsingle digits.  \n \n Segment adjusted operating profi t for the quarter increased 1% year over year to $641 million, due to continued \ngrowth in our specialty businesses, led by the provider solutions business, partially offset by customer and \nproduct mix, which includes the new customer volumes that are flowi ng through Caremark. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "0931f8ae-0095-4499-aa82-d2680f84c6de": {"node_ids": ["cd16dc02-7353-4383-a845-c6d066139767", "fc62b00f-66bd-4761-acff-7d7e2cce6cf5", "4efdc087-cb9d-4584-a0e2-093c19e0d541", "edf4aa71-c7ef-40a6-997c-085d4b5f5c4c", "35b60864-fbd6-4280-905c-cac803760c50", "cf17456e-494b-46fc-a2e3-9d1a5e0c644b", "528ab49d-3406-4e74-84f9-e2e555a88d8c", "f21937a7-a417-4c15-9dbb-747c8a87d520", "ee672efa-3f2f-411c-9c7c-f28a6f019dfb", "7d82bd0d-7c74-45c4-9b7f-1525562dc882", "4418bf77-0f2c-44d5-a170-cc63eb8c5756", "201f74c7-8b9e-4cdb-83ef-0dd066170f52", "fdb703be-16b0-46ac-99dc-34aa08780672", "ba50cefe-f894-4b54-8868-50428571b111", "dd72cf13-5c0e-4e89-9d73-d07f0c5b3166", "cb844866-94b2-46ea-80bc-ed17de4145f3", "a59551df-0a82-429a-ace6-bd3b23f850f6", "239b6c3e-0843-47df-acff-17d046074562", "b31ecd45-d0f4-4932-adc7-d1200a5f7386", "d8a8ce5e-397d-4105-8f4d-302d52fe23df", "1817dad5-4354-447c-a6e3-57eca6c00972", "8ff7c952-7d7e-4c2f-bc7d-437d8cf78a3a", "ff7186e3-6bda-428c-b172-059a35bb1f79", "7cef1816-79ae-458d-ba11-ceb632239593", "0ef37c75-bab1-41c7-ad7a-8ddc42588c22", "dc12fd39-9c4e-4db4-ad1d-8b907cc0026c", "f7cf11a0-b7f4-4c19-9788-096aa1dea0bf", "49163009-bf74-48a8-97dc-57debddd822b", "af464f57-84fe-4664-8e50-7f948944d067", "c7163724-725f-4390-8767-91ef930e634f", "da9ddd8c-9bd8-49bd-9a97-10eb7ec3d76d", "dbebbc0c-89ab-4b8d-a3f8-75a06c416c2e"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMoving now to corporate expenses.  McKesson recorded $146 million in adjusted corporate expenses in the \nsecond quarter, an increase of 2% compared to the prior year, resulting from planned investments in technology. \n McKesson recorded $36 mi llion in opioid -related litigation expenses in the second quarter and $72 million year to \ndate. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "bdcb0664-a94c-4c33-a4de-df390c909441": {"node_ids": ["0dc51c7e-44c7-47bd-9a04-bc5809e8ff06", "6e9443f0-d73d-49ca-bc00-a6f98629a23b", "7aa55f4a-7d0a-495d-916f-78dd2f1aa2fd", "22eb43aa-0e89-468d-aff9-ef69b2995fc0", "005c1aa9-ae2f-4225-895c-3f8b8a8a2fe5", "f4f03459-e1ff-44e7-a24f-814a4cf85ab3", "3c05a166-0ca0-4a9e-8ca3-b7e8ffe25a50", "8d26b5eb-dc78-40bd-b021-1c9d3462ada9", "54a1492d-5739-4f72-a982-d01694deda0b", "fd2ca06c-bb18-4247-99de-d13973e20a12", "f4be3590-8335-4170-b0cd-e49467aa7f5c", "27ea4e44-fef6-4c9d-8747-9a71e23af10b", "4db7756f-8ec9-467a-a3f4-e4db4f70a04d", "9765429c-4733-4757-84d6-c7c33c1241ba", "5b79ba90-84d0-4a8c-b6d4-c28b367d5d15", "53e4d9a7-e3a2-42b9-94ef-1e35ea738183", "0e051b6e-ceb3-44d8-8309-544fbe414914", "de818cbc-d1fe-4e44-a47a-2d4e9d9d087e", "e2671470-6b64-4b7e-87ab-4be18646da3b", "08101f4b-093f-45f1-aaa0-0e005e0e6e93", "4d461682-4aaf-4db8-a01b-13a636623bfa", "eba80418-dba1-449f-bc08-8b7235914fa3", "f3652068-897c-4623-b3da-a400ba020f19", "d070a76a-abf1-47df-a2df-eceb81c9491c", "63b10b55-4bc4-4cc7-a436-cf7aa665054b", "bbb8ffd9-21b5-4111-93f7-0096f59c784f", "ec8e9e79-a366-4ded-8c0a-6f8257ba6e9e", "cd981027-851d-43d2-a072-d50f2a108de0", "d4a7524f-ae65-42a2-98f6-f9b9f03ff3a5", "ef99390e-8340-4272-af97-4c73085700d2", "61a825a9-0801-4465-9489-5c9e8ff39285", "001cd8c7-5783-4f5a-9b86-9430923d7499"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first ques tion comes from the line of Eric Percher of Nephron \nResearch.  Your line is open.  \n ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "7380b2d9-8cb2-4667-a432-051970e943d2": {"node_ids": ["55d5b02b-bc25-4279-a844-88426f0c4014", "1a73a692-6b30-426f-80a8-3ce0d05b808e", "0467886e-512e-4fa0-8a14-394e0aae0b99", "8129a874-cf93-4c4c-be2a-c159c73621ac", "6cd3a5a6-3aab-4af3-9fb4-4651b37b2567", "76abd67b-4a37-46e1-8727-937a61bcc4c9", "88ad401b-dea7-4da2-8f0e-8257c9d78e09", "ae30c295-4b8f-46dc-8374-a945e00d10b1", "768c278b-3d0f-4eba-b011-277735c3ddd8", "49c4ac34-b0f0-417e-8d7c-a7c8f130fb33", "a16dc9af-f9f7-4bea-881f-987ab6a5051a", "d6f382a2-17a2-47da-b85a-caa2f868f6ad", "8b56d7d5-eb74-4e33-974e-4e6299724325", "9d3b6eed-a481-4071-89d0-df18b74388d6", "359efbf7-1c79-417c-b2e7-745f88e39f6d", "30c44125-2944-4a76-a0a3-b62bf16fc9c8", "70289ae7-4698-4553-b8a0-4fb4bbf1ef47", "072d0628-b94b-41d6-a6ad-927f5314c7d0", "dbb94884-77f6-4e02-8492-55045d1a6cd5", "d2cb53bd-a61d-4f74-985f-fddfa118c33b", "d2650dfe-bdaa-4f13-bddb-86458fd858da", "80380ad3-442a-4af2-918b-65a172850487", "704c2b21-b7da-4994-8709-94efaa399ba1", "8ad173e2-19ab-49d7-854e-9accfc1e25df", "e7148ba0-baf6-4b25-aa4d-8275a71d120a", "27c86039-cdaf-41c7-9c5c-0ff5ed449a18", "f966f1b9-e464-408b-a50b-88bc0afdeaf6", "8ab3b3b1-00cd-4e0a-8654-69b3013cd073", "fa27878d-d451-4e93-9fc7-6900cf80f272", "a5ff4ba4-b51f-4c18-a793-dc9626d5b5aa", "2b6b3d5a-08a6-438b-9e92-7fde487df823", "47fa42b0-e7e3-4850-ac72-ef4d5c7d09f0", "dbd12ba3-fa10-40d9-b8c0-23460c6e76c0", "a4a8f209-cfd7-409f-a31c-5f1a93936aca", "896abb23-94b2-4f98-9fa7-980ce136d477", "5a31b71f-00c9-4b10-8a21-56384a6d0be7", "25af618c-4a06-48fe-b1a3-ef2bec6c5b5e", "6a317770-53bc-4989-a87b-d54e17354910", "8b438509-2823-48c8-a60f-85fcb54aadc5", "2151fdf1-be64-4a63-a4f7-0e922054fd94", "fd19bc64-b8a4-4eb8-a0d2-4da3da3865a6", "23309721-d072-4e00-bcfb-fedd89ae681f", "62de4da5-32cf-4c6a-984d-ccb4000b481e", "96878600-efae-41fb-be97-47244d16c873", "9653c590-8d50-4575-a9cd-522b576028e7", "6a34652a-a18c-4a35-8fc4-790c6c4b8483"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nOperator : And our next question comes from the line of Lisa Gill of JPMorgan.  Your li ne is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "ff57e0b1-1bf6-446a-862e-bb1331bd10f4": {"node_ids": ["480a10fd-d38f-4c31-958a-6a05a19e51bc", "b6f17db7-6d7f-4966-81bb-7387e5d8ddfe", "ebe138e7-ee4e-41fa-89ea-8fcf96c87ee5", "58e4417e-6083-4281-bd5c-792c4967f75c", "83dfb6cc-15c3-436c-b616-5aa4844810e0", "a176bd4a-dccc-49b2-90d7-77af1307d46c", "a51316ee-afd4-4c97-9127-fd185e62ea2f", "f3791155-b03a-464b-a923-3576cb065840", "bfc79314-0022-426a-a751-a8cd5ec99b6f", "8ee59b8d-0e48-408a-a68d-f7236dd14465", "739ef4bd-e0a2-40f5-a51b-e8866914f194", "24f0eba6-2651-4d71-a41b-b20f101fafc3", "70ca4295-a3e3-450c-a409-d369bfcd2700", "036d79ac-421b-4e50-aad8-d291a97ec81e", "aa74016a-c1cc-43e8-a990-9a5175ea5c10", "e877184e-774e-41dc-9b74-37c130fe384d", "54007c23-c45f-4466-8bc7-f953a6834970", "8e7e3cc4-ecc8-4c75-93ab-c685247cde45", "d59af89a-3ac0-4640-b800-151730ae6293", "1773b0b2-dc45-4d71-a349-0b08f8bb037f", "5ae16911-bd34-447f-a98a-380678742381", "997779ef-d58f-455d-97e5-fdbcc031581b", "dd31c989-69b2-414d-828b-05ce3e9eafb5", "e6700482-5e7f-4562-8a7e-e2b16fb8fa48", "08c0eabc-2e67-4b02-884c-6a70ef4ee5d5", "9471e6b6-6209-4ee6-90ec-a95e7a3bd296", "190df7a7-1eb4-49ab-a00d-d8ead5fba6e4", "4656f2cb-76ae-49f7-b586-ff186ec6bc92", "25357b59-6c6a-41e9-8512-4dda854d9736", "4344030d-cff4-474a-874f-e272f8724c6d", "5d8a9fee-9851-43bf-9b2c-1c93a40a3de0", "39b737cc-eaaf-4d3c-8a00-e9e448586ac4", "24ec2e1a-a02c-4b60-822a-98e277793e59", "3966f54e-52de-4176-9a44-0f2ea4a7067a", "e4565dff-8995-4f1a-8d43-45f846a41bef", "c5f13821-4092-4861-ad79-4aa9da46aecf", "852a04c8-2740-4d90-b425-d1e38ebcf3f8"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \ncommunities they serve as quickly a s they can.  But, as we pursue these discussions, we continue to invest in our \ndefense, and we think it's only prudent to do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question comes from the line of Brian Tanquilut of Jefferies. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "2ae4b0d0-1c08-4cd1-a0ba-3fc86acca790": {"node_ids": ["a0e3d11e-1cbe-4bb3-8825-185288c0b990", "a89d1093-94b3-4ece-b5b5-5a57983d77c5", "3df840a5-0618-456a-ab1f-dc71807663c9", "6fba2a9e-e649-4286-a695-d09eae1bd2e0", "f06db92b-aecd-425f-a9a9-d213a9a2062d", "9cb40e20-6651-42e0-9ba3-2ab0e3db08fc", "023a7b56-eb00-4dbd-b9ef-2f8445bc86f6", "564cba84-ef45-4e65-a2ba-d42e814c9b67", "b05d7ae8-2a31-4f15-a867-89e16ae45f3e", "e8ee2a13-c9e3-4753-8ff5-1f7f5035ffcb", "660b3754-f698-4007-81b7-ca29d6a3fec3", "0cc7f8dc-11f7-49c3-ab2f-9382c9222e54", "2331f3b9-e84c-4d80-bde4-7fec773ea4d4", "c0d58a80-22e6-4a77-a3f6-5aab2144aa6e", "bfc95602-dee1-49e6-afac-7d6029c3bc0b", "99d71e39-1a6f-42c3-9535-050260f0a1ba", "d2af3907-52e7-41f5-983f-5b8fcaa8d2f8", "cc0ea8f2-8efa-4473-bef4-66a1f16f94a7", "88ecdf42-27af-4e96-995f-413644de20ff", "4b805c01-232f-4f87-a051-c3a2e934594c", "dbc39247-f91c-4f64-9e19-4fdce88d60d7", "f7a0dc7f-96e9-436f-9e5a-ca90a04c4f26", "8fc6e1d5-4f82-4f64-93a0-19743da607bf", "9b8f25cd-4ed5-443b-91ce-f5409e97e877", "d2f7f4dc-bab3-4d9c-801a-2fd16359b0be", "d02cc29b-f017-453d-b039-c559c759d460", "6d0aea8f-24c4-4ab6-a931-1b4a70a9886b", "8768916f-34a6-4302-9b70-6ebec20925f1", "30cab0f2-623b-411c-9cdb-f8104d7a2520", "6a6b2756-ad05-4fd9-80f5-bdebe3917fed", "6da2b37b-45d7-47e8-93e2-5e856c717871", "a0404367-398d-4a00-bdf2-c333c2b534af", "d228fc14-38df-4eb6-9de7-3d84d9519855", "fa0dd67f-176e-4853-aef8-0dfba68c79e0"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for that question.  So let me just step back to the revenue g uidance. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "c30d9699-f1f8-4024-94ec-d0538a8d03e7": {"node_ids": ["f89c5a60-e684-4a72-b208-2d49ecab2ecb", "516d4a88-f647-4031-b462-2edd64e1d829", "bd7dfb22-a079-4194-be28-c1040338d97b", "bba9f927-ba48-44a8-9806-8b5b2536f396", "5ca1df4f-cded-42f5-bf35-378070226038", "22b98fbd-292f-4571-8bd3-937eecf1f6d3", "3122c6f1-7dba-4bba-a5db-930e86471dee", "4a31c7d5-6899-409f-a42d-76e7c46e525a", "1dad8d5a-8cd9-4b98-a16e-cdf8e783577a", "8e89e9e5-aa97-4e93-97fb-73e85a39cd3a", "decc5f2a-74fa-41f9-9217-aa7916ea660d", "db8eb874-f61d-4920-aad8-b53e37ed0ef9", "b1cc4963-a2ef-4b16-a8b9-6ded8b0ad0d2", "d865bd5c-b74e-41b9-ab05-0bd61035edd9", "9bde1ff7-83e9-429d-af93-689d880fb461", "b22c8212-3ba5-4a7d-8047-4b6d9d63b637", "2fe6d126-bd36-47e7-85f8-7d1eef2ac75f", "9478a0b3-3407-471c-8bdc-6940cc3d0805", "7b211f33-a6fb-45b6-b611-6fd8b0ee5c77", "bdb88d73-2103-43e6-9035-eb11f9f18fc5", "8078d93e-8a80-49e7-a6c2-0395e4c9abec", "18f44346-0449-43cc-a810-bc7286cd3f37", "7a7c4ff7-38da-49f8-b997-ca4b2b0705cc", "f97fe97b-34bd-489d-a9f9-9a5ef9aa31fa", "d83d35ad-65c0-4d84-866c-b07985bd7208", "01f0a8bd-4390-4105-9302-7c7ca7114bbc", "18d63caf-9e8a-4577-a21b-b42c9af1530f", "c04692eb-00df-4594-bf8a-62d26b49fb56", "5fcb0119-23a8-4276-b7fa-b9e4819fe79e", "019e5835-8e2d-461e-abc2-eb1398b410f0", "7de45917-80bb-4e1b-be9d-a1d2bea76a97", "20b9bac2-9b12-4a1f-9b35-49cd9e579169", "f3c11edc-88eb-4ec9-8252-c9b97c4a667e", "d27008b7-9325-49cc-824a-1dc9987c756a", "670439c4-3715-49ea-a581-80c3b84e2336", "100f4621-b3a9-494a-b2d9-8b7a35a1d780", "04963552-cfdd-4b81-8a5b-1b5648c26531", "1ef8834c-c5b4-4fa4-b00f-cdcd100c3655", "a309d6b6-7155-401c-9025-a55f953bc26e"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Of ficer & Director, McKesson Corp.   A \nYeah, sure.  Thank you for the question. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "03e78add-c0e1-4341-9187-cc01f92ed2b4": {"node_ids": ["5bba34f7-48b1-4bcb-9616-677856aa42f7", "c2055d9a-31d3-47df-ae3b-53b79bb4facf", "99915be1-8e04-4596-9eb3-99f94dfbab31", "13ad8f41-196e-44c7-aaf2-80ccd51f31ae", "54347623-4a44-4ddb-a4ab-4768d1b4d0d8", "34104dfa-1182-4efd-8c3c-ec990dc7c0c9", "cfdd9054-40fb-48e7-9e90-cd469ccc359f", "80718301-12c9-43f6-ac46-1fbb070d0ded", "b58e9d5c-f743-42c8-a87d-19715f4f413d", "09624e07-e5e9-49ae-8009-2e8ba09bfdbe", "03a2d54c-e670-42c4-bfa6-342b72f341c2", "46daac5b-d13d-4f83-82d6-e53abfc08ad0", "5954d1a5-5fbe-42e7-8893-9cd9b4f13f51", "a3e97f48-1bf4-42e7-8f28-efe234e82160", "527decb7-89d2-4d63-8fb3-fee312d66e78", "e89ab7b7-cc68-4187-8712-19ad586d650e", "a265481c-9d2b-4133-9ce4-5ff023e6f882", "8851f959-85e9-4013-95a3-41f43f79296f", "fc63b861-54ae-4994-aa8d-0705046842e9", "148c942a-ab40-4b88-8209-9322cf0ad1d6", "253d45c5-448f-492e-873c-135283d863a8", "00988ef4-2fe1-48d0-b551-cc37c13a9c4d", "ab3193a8-84f1-445a-b760-2f32146dc391", "94f15379-34e9-49d8-bf77-f4a48f7012c4", "2f0b6c60-72bb-47af-9842-a566d6dab5fd", "b41e8f56-d098-45de-a489-c37e7294a208", "a87c623e-b8fe-449f-8627-79006ecb3420", "3ba95780-2175-41c7-8fd4-799c086f6f17", "e90d7c71-6e3a-41a9-9810-bc2c45d683b1", "25d65221-bcf4-48f0-a4f9-6b5a4831bf50", "98cecef0-35dd-4584-93fe-954fc4c10914", "c8c729df-e092-4dc5-a7cb-cc29463071dc", "f3053796-dbc4-4247-a600-5380865e2433", "aa8db448-5c4f-490d-ba8f-fae3238eded5", "cc1bf378-cab2-4d24-9e45-ae7315fa73b7", "393a5c37-e3b0-4fe0-a3f1-2c02d91b1810", "53f6ce17-d066-44f6-bb90-c686d4020dcc", "7beded7b-b6be-479a-b097-7ed17dbf72c8", "fc7906bb-7338-4862-a5d2-8aa5d73db2b6", "942408f1-4240-4c83-a0bf-8424bbd11af9", "7aaf9043-188f-492b-aec7-a2ff6af49c93"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nYou were breaking up a little bit.  Let me \u2013 I think the question was coming back to the framework. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "652b9b03-6701-4e05-b5ec-91f83a9126b2": {"node_ids": ["55faefa0-d053-46c0-b39b-b742148ddecd", "dedba8dc-fc96-464e-b05f-7fc0086d3cf9", "bf5b1ce5-f64c-414c-9cdf-9b911b3a4e8a", "d0d78ab0-8c47-4ca8-9a0f-f9995e54d7ef", "dfc7f5d6-623e-4d0d-8ada-fa2262d3788a", "6f47966e-b2d3-4efa-8d34-cfae25675b25", "b25200ba-3318-4977-bf7d-89482eea3275", "f0171073-cd9c-4ed8-b1a0-6ecb25b8c979", "e8e1658a-12a8-4bb6-a120-3120b55b07ed", "a1d7e319-9257-4744-9286-7c0213ba0667", "97d37524-9901-4aa8-afb8-30648651d0e5", "1739dd3c-db8f-44b9-9a17-4bfe52aa6fc7", "18d089af-5cb2-4378-ac68-069541200a9f", "ccbc2dee-b693-44f8-b4ff-9c676df49640", "146293cb-f77d-4d4f-9cf9-c37fe3aa87d7", "87648df8-4091-477f-83d1-dee7f4fa08ba", "66f9f817-9493-4b39-8d0c-031065192948", "a5be56ab-676d-494b-9263-b1e5dc772920", "d67b0819-6262-4438-a997-feeddb812aae", "e8bdd93b-f25c-4eb8-bc08-1f1033e712cd", "c7fa67ef-6e05-4334-853d-7509ddbb04a4", "4704b8a0-17ff-460f-ae1b-9dee6c542e19", "205c5571-e7c6-4c6c-a069-75bb37bb78be", "1b20c5bd-6556-4f16-9e5e-63da996989d4", "c3453872-29db-4824-86a4-f3c4c1631b7c", "27dc5df4-3d11-4a67-98af-632629374ac5", "6449bfe2-fe34-42aa-b314-e2df073dc406", "e717e525-0c11-40db-a715-34661bd5bb35", "e032aa65-4c98-464a-aecb-e0d1bfd8cc5b", "65c4973a-8360-4bc0-b87e-b0988e0d1712", "e8e1f858-2679-4189-a58c-3f9d6639ab04", "26071d12-2810-4918-9ab6-385f91a42e10", "56eacc46-1598-4394-93c9-9d399818de69", "ef3d089d-2139-42bb-a147-90a18542b9f4", "88034bc9-4f52-4057-8a4a-28c9b495e433", "3722800f-64a8-4205-96b7-7b69638f9e49", "8907b920-8711-4188-8fd3-b9ba5fa8d954", "ed8b58fb-46e3-4f70-bf6e-c7743f32c0ca", "fa9dbfef-cdd5-436f-a382-fdc3fe000ec6", "30cf5c4f-791c-4382-8129-c6ccee4c7d3e", "d87de445-690e-4506-8acc-2dd1d2a0b55e", "38651076-8702-4bb1-ba4a-a63d0fa84fda"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question. ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "76a564a8-05aa-4e46-8113-1b328fb1f1f5": {"node_ids": ["202187bb-3bb1-4f4c-9529-52fb5100b9ba", "52f14eca-6e8d-4cd8-b906-0a8417eb0088", "6081764d-4cc0-4565-844f-21bc33228e2c", "27b1eee7-e7aa-4b2c-9ac5-96a2e7b027e3", "4ef16751-2ac7-4635-ae39-745866787c3b", "02ff784d-455e-4165-a4cd-6a8b7ae61d4d", "8775781e-ab0e-49a7-9e00-9c4df1a07797", "4f6149c4-7f97-41b9-8ef6-049423305406", "662c69bf-31ec-403f-a01e-b5ef7f321490", "c15150c9-cb32-411b-bc48-691b2fc2483c", "f1287af3-1dd4-44d4-a3d4-664784b45840", "5ac8c6e1-b193-4c5e-ad07-502c008c43c8", "cdf69789-398f-4645-87fc-d16a2c98046b", "b9abe786-4c53-436a-884b-f0619c6b0d41", "181cf335-fe3c-40ba-bfc3-830e91f0ca0f", "85b8ad1e-d651-4f98-b5d1-fcf5bf33d490", "3fa1634f-5a78-4847-a3e1-efb8c34d6500", "027f45b4-5f33-422b-b23a-4d38bd322a4c", "f7c5bfe2-9abf-44d1-a1bd-00aa0756c71e", "e1a35b43-5bfa-4a13-b5e6-4276c2b71088", "9da7bd18-44ec-4282-8044-ef95a24baa5d", "8d522bc7-3a05-42a9-a807-9267fbddc7c7", "9db6afb5-5f21-4aff-ae66-b396d12aabe9", "3f70cf69-1053-483a-9ea0-127f7b650b84", "0ef1a387-f7e6-4be3-b501-e8c0c7ec23d6", "ad11e4c1-c69f-45d7-ba44-3c6acde3660f", "a4c490ee-7adc-4199-a9ee-82562aab8abd", "822ee454-fa40-43cd-ac08-b2a33f61fd0b", "812fb29d-003f-4bda-b264-0c4619944556", "6b17f361-73ea-43fd-b4fd-12022c0351a3", "5df41663-18b2-4abd-b748-30d990bf2caa", "5bda5492-df9c-4226-a984-b01ebd1c7ec3", "a2a29478-410a-45eb-93cd-4d43bfdea142", "51e2288a-fd4c-4b96-9f3e-d77b371f916c", "2d97410f-6ebb-46f2-8ec7-5f4709f401db", "3016a943-b8ca-49c6-9b11-b27e8693ea6e"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nAnd then I guess just to f ollow up on that, maybe Britt.  I mean, just to maybe understand that a little bit better. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "16ba3c2d-0969-4a79-a29b-d1b45c44c5e4": {"node_ids": ["0e82f7ce-8f27-49af-8c5c-e129fc4729df", "e579cbed-d1fb-4d70-a8e8-c4f3bcaa5f6e", "75b242bc-7e65-47dd-b154-89dc415ad590", "000eab26-3f14-4ded-a2d3-ce4faa9b1ebd", "8e964af4-881a-4400-82c1-86b06ccd82d4", "427c8cbd-19d9-4ddb-83f3-2843c8d5ddbc", "f1f9a378-17ca-4d41-afcd-2324c5aabb09", "815e7dc3-8653-402f-9dfd-bc17d7ccd497", "0f17cc2c-15ed-4601-a7db-aab101475c1a", "7ed25b09-5306-48bc-9e19-e7997a094ba1", "9a0412e6-f6d1-465f-8ca4-50822fa7a374", "a02eb7b6-80ee-456e-95e4-5dc9210bc0c4", "058bc084-72dc-4890-adac-f14bb82a9fa3", "6e9ac47e-e717-4c64-8dc5-57b97d1dbb1b", "a6a631de-f313-4622-914f-f9bac98edb35", "68c0925d-7180-46ac-936a-d1dac01b0e00", "28771c67-effe-42f1-8c0e-a61cdb67f9de", "feccfd98-5f32-4248-8a71-11b26d277927", "731773ff-4856-4848-8d2c-a861dd05faa4", "573ad571-1b96-4ada-b237-e06a8de4a584", "76ac0899-877d-4fb8-bf9d-83681b20f56b", "4aac7526-7b37-401e-915d-cd3fd6b28c93", "d524ae9b-5ead-4de1-811b-fff811757d53", "77140513-2181-40f6-8b45-6d699368a32e", "20436f69-056d-47a6-bde7-5557f6591e83", "49fdec95-70e6-44d1-afcd-d788e7a92419", "f1d0a407-0e09-454a-841c-ef145343e342", "365200d9-022b-4499-9df7-9d82ce784cad"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nOne quick follow -up.  Can you talk about the performance and impact Northstar would have had in the quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "a5688580-d83a-42f1-8a16-47f74e44508d": {"node_ids": ["6a52e32e-53e0-4e68-8943-801c772ebaed", "755f3432-80df-463a-8024-6af242e5781c", "ff09d092-402e-4aa0-a729-b1d2e83f3bf5", "96d30d09-9439-4ff4-90f3-53bc018649a2", "4d9e9927-fc34-457b-9a38-13c8208439e3", "ec7cee9c-3f35-4ca5-9d9b-dc5afd7de27a", "dfcc7329-814d-4e0f-8fcd-6c49bda189ce", "67d4617b-a8a3-476f-85e3-f20265b8be80", "71efdae4-4a22-4c95-81e2-efcf0caebd99", "879371e0-82f5-44df-b57f-a2323f39418e", "19965a39-da82-4119-b6ef-69d0c3511a62", "8ca5f54b-c75e-424e-a560-0ae253726c2d", "c4551d03-72da-4a9f-8a43-43d1c66eb018", "f1c91e00-7642-4d49-88ae-b57a113b3aaf"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2020 Earnings Call  Corrected Transcript  \n30-Oct-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 355686, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}}}